COVANCE
THE DEVELOPMENT SERVICES COMPANY

Sponsor:

3M
St. Paul, Minnesota

FINAL REPORT

Study Title:

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Author:

Peter J. Thomford, PhD

Study Completion Date:

January 11, 2002

Testing Facility:

Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Laboratory Study Identification:

Covance 6329-223

Sponsor Study Identification:

3M Study No. T-6295.7

Volume I of II

Exhibit
1818
State of Minnesota v. 3M Co.,
Court File No. 27-CV-10-28862

3M_MN03278834

1818.0001

COMPLIANCE STATEMENT

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

All aspects of this study were in accordance with the Environmental Protection Agency Good Laboratory Practice Regulations, 40 CFR 792, with the exception that the analysis of fecal samples for urobilinogen at the Mayo Clinic were not done in compliance with Good Laboratory Practice Regulations.

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

11 Jan. 2002
Date

Andrew M. Seacat, PhD
Study Monitor
3M

Date

QUALITY ASSURANCE STATEMENT

This report has been reviewed by the Quality Assurance Unit of Covance Laboratories Inc., in accordance with the Environmental Protection Agency (EPA) Good Laboratory Practice Standards, 40 CFR 792. The following inspections were conducted and findings reported to the study director and study director management.

Inspection Dates			Date Reported to Study Director and
From	To	Phase	Study Director Management
08/06/98	08/06/98	Test Article Preparation	08/06/98
08/24/98	08/24/98	Protocol Review	08/24/98
11/25/98	11/25/98	Body Weight	11/25/98
03/03/99	03/03/99	Analytical Laboratory Inspection	03/03/99
04/09/99	04/12/99	Protocol Amendment Review	04/12/99
05/23/99	05/23/99	Protocol Amendment Review	05/23/99
09/27/99	09/27/99	Protocol Amendment Review	09/27/99
10/22/99	10/25/99	Data Review	10/27/99
10/20/99	10/27/99	Data Review	10/27/99
02/11/00	02/13/00	Protocol Amendment Review	02/13/00
03/16/00	03/16/00	Protocol Amendment Review	03/16/00
03/13/00	03/23/00	Data Review	03/23/00
04/04/00	04/04/00	Protocol Amendment Review	04/04/00
04/18/00	05/05/00	Report Review	05/09/00
05/31/00	05/31/00	Protocol Amendment Review	05/31/00
10/23/01	10/23/01	Protocol Amendment Review	10/23/01
12/18/01	12/18/01	Report Review	12/18/01

Harry Gilton
Representative
Quality Assurance Unit

11 Jan 2002
Date

3M_MN03278836

STUDY IDENTIFICATION

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Test Material	Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295)
Sponsor	3M Toxicology Services Building 220-2E-02, 3M Center St. Paul, Minnesota 55144-1000
Study Monitor	Andrew M. Seacat, PhD 3M 651.575.3161
Alternate Study Monitor	Marvin T. Case, DVM, PhD 3M Toxicology Services 651.733.5180
Study Location	Covance Laboratories Inc. 3301 Kinsman Boulevard Madison, Wisconsin 53704-2595
Study Director	Peter J. Thomford, PhD Covance Laboratories Inc. PO Box 7545 Madison, Wisconsin 53707-7545 608.241.7207
Study Timetable	
Study Initiation Date	August 20, 1998
In-Life (Experimental) Start Date	August 26, 1998
In-Life Termination Date	March 8, 2000
Experimental Termination Date	December 21, 2001

3M_MN03278837

1818.0004

KEY PERSONNEL

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Study Director	Peter J. Thomford, PhD
Study Toxicologist	Dale Aldridge, BS
Study Coordinator	Elizabeth A. Disch, BA
Manager, Large Animal Toxicology	Sharon Dunn, LATG, AT
Supervisor, Dose Formulation	Dixie Bushee, BS, LATG
Associate Director, Laboratory Animal Medicine	Donna J. Clemons, DVM, MS Diplomate, ACLAM
Clinical Pathologist	Robert L. Hall, DVM, PhD Diplomate, ACVP (Clinical Pathology)
Supervisor, Clinical Pathology	Ronald Markevitch, BS, MT (ASCP)
Anatomic Pathologist	Robert A. Leedle, DVM, PhD Diplomate, ACVP
Supervisor, Anatomic Pathology	Laurie J. Schuller, BA, LAT
Supervisor, Anatomic Pathology	Kimberly W. Durland, BS, HT
Consultant	Stephen I. Bistner, DVM Diplomate, ACVO Veterinary Ophthalmologist
Consultant	Dr. Saroj Das AniLytics Inc.
Consultant	Sandra R. Eldridge, PhD Pathology Associates North Carolina Division, A Charles River Company
Consultant	Sharon Ambrose Pathology Associates North Carolina Division, A Charles River Company
Consultant	Dr. Joe McConnell Mayo Clinic

3M_MN03278838

1818.0005

CONTENTS

VOLUME I OF II **Page**

ABSTRACT 11

PURPOSE 14

REGULATORY COMPLIANCE 14

TEST MATERIAL, VEHICLE, AND SOLVENT 14
- Test Material 14
- Vehicle 14
- Solvent 15
- Gelatin Capsules 15
- Reserve (Archive) Samples 15
- Disposition 15

TEST ANIMALS AND HUSBANDRY 15
- Animals 15
- Identification 16
- Justification 16
- Husbandry 16
- Acclimation 17

PROCEDURES 17
- Group Designations and Dosage Levels 17
- Dosing Procedures 18
- Dose Analyses 19
- Observation of Animals 19
- Clinical Pathology 20
- Blood Hormone Determination 21
- Serum PFOS Level Determination 21
- Additional Serum Collection 22
- Urine and Feces PFOS Level Determination 22
- Additional Fecal Samples 23
- Interim Liver Biopsy Samples 23
- Terminal Liver Biopsy Samples 23
- Anatomic Pathology - Terminal Sacrifice 24
- Anatomic Pathology - Recovery Sacrifice 26
- Statistical Analyses 27
- Record Retention 28

3M_MN03278839

CONTENTS (Continued)

VOLUME I OF II **Page**

RESULTS AND DISCUSSION 28
Observation of Animals 28
Clinical Pathology 30
Palmitoyl CoA Oxidase Determination 31
Blood Hormone Determination 31
Anatomic Pathology 31

CONCLUSION 33

SIGNATURES 34

REFERENCES 35

OPHTHALMOLOGY REPORT 36

PATHOLOGY REPORT 37

COMMENTS ON THE DATA 45

CODES, ABBREVIATIONS, AND UNITS 47
General Codes and Abbreviations 48
Codes for Clinical Pathology 49
Abbreviations and Units for Clinical Hematology 52
Abbreviations and Units for Clinical Chemistry 54
Abbreviations and Units for Clinical Urinalysis 56
Codes for Anatomic Pathology 57

FIGURES
1 Mean Body Weight Data (kg) - Males 59
2 Mean Body Weight Data (kg) - Females 60

TABLES
1 Summary of Clinical Observations - Treatment 61
2 Summary of Clinical Observations - Recovery (Days 186 through 365) 65
3 Summary of Clinical Observations - Recovery (Days 366 through 561) 66
4 Summary of Ophthalmic Observations - Treatment 68
5 Summary of Ophthalmic Observations - Recovery 70
6 Summary of Body Weight Data (kg) - Treatment 71
7 Summary of Body Weight Data (kg) - Recovery 76
8 Summary of Clinical Hematology Data - Day -27 84
9 Summary of Clinical Hematology Data - Day 37 88
10 Summary of Clinical Hematology Data - Day 62 92
11 Summary of Clinical Hematology Data - Day 91 96

3M_MN03278840

1818.0007

CONTENTS (Continued)

VOLUME I OF II **Page**

TABLES

12 Summary of Clinical Hematology Data - Day 153 100
13 Summary of Clinical Hematology Data - Day 182 104
14 Summary of Clinical Hematology Data - Day 217 108
15 Summary of Clinical Hematology Data - Day 245 112
16 Summary of Clinical Hematology Data - Day 274 116
17 Summary of Clinical Hematology Data - Day 322 120
18 Summary of Clinical Hematology Data - Day 364 124
19 Summary of Clinical Hematology Data - Day 456 128
20 Summary of Clinical Hematology Data - Day 546 132
21 Summary of Clinical Chemistry Data - Day -27 136
22 Summary of Clinical Chemistry Data - Day 37 142
23 Summary of Clinical Chemistry Data - Day 62 148
24 Summary of Clinical Chemistry Data - Day 91 154
25 Summary of Clinical Chemistry Data - Day 153 160
26 Summary of Clinical Chemistry Data - Day 182 166
27 Summary of Clinical Chemistry Data - Day 217 172
28 Summary of Clinical Chemistry Data - Day 245 178
29 Summary of Clinical Chemistry Data - Day 274 184
30 Summary of Clinical Chemistry Data - Day 322 190
31 Summary of Clinical Chemistry Data - Day 364 196
32 Summary of Clinical Chemistry Data - Day 456 202
33 Summary of Clinical Chemistry Data - Day 546 208
34 Summary of Clinical Urinalysis Data - Day -27 214
35 Summary of Clinical Urinalysis Data - Day 37 216
36 Summary of Clinical Urinalysis Data - Day 62 218
37 Summary of Clinical Urinalysis Data - Day 91 220
38 Summary of Clinical Urinalysis Data - Day 153 222
39 Summary of Clinical Urinalysis Data - Day 182 224
40 Summary of Clinical Urinalysis Data - Day 217 226
41 Summary of Clinical Urinalysis Data - Day 245 228
42 Summary of Clinical Urinalysis Data - Day 274 230
43 Summary of Clinical Urinalysis Data - Day 322 232
44 Summary of Clinical Urinalysis Data - Day 364 234
45 Summary of Clinical Urinalysis Data - Day 456 236
46 Summary of Clinical Urinalysis Data - Day 546 238
47 Summary of Palmitoyl CoA Oxidase Determinations - Terminal Sacrifice 240
48 Summary of Organ Weight Data - Terminal Sacrifice 242
49 Incidence of Macroscopic Observations - Terminal Sacrifice 272
50 Incidence of Macroscopic Observations - Recovery Sacrifice 275

3M_MN03278841

1818.0008

CONTENTS (Continued)

VOLUME I OF II **Page**

TABLES
51 Incidence of Microscopic Observations - Terminal Sacrifice 276
52 Incidence of Microscopic Observations - Recovery Sacrifice 286

APPENDIX 1 287
Protocol Deviations 288
Protocol 293
Protocol Amendment No. 1 311
Protocol Amendment No. 2 320
Protocol Amendment No. 3 328
Protocol Amendment No. 4 334

APPENDIX 2 336
Individual Animal Fate Data 337
Individual Clinical Observations 339
Individual Ophthalmic Observations 481

APPENDIX 3 496
Individual Body Weight Data (kg) 497

VOLUME II OF II

APPENDIX 4 511
Individual Clinical Hematology Data 512
Individual Clinical Chemistry Data 614
Individual Clinical Urinalysis Data 728

APPENDIX 5 818
Individual Palmitoyl CoA Oxidase Determinations 819
Individual Anatomic Pathology Data 823

APPENDIX 6 907
AniLytics Inc. Quality Assurance Statements 908
Summary and Individual Blood Hormone Determination 917

APPENDIX 7 963
Cell Proliferation Report 964

APPENDIX 8 977
Electron Microscopic Evaluation of Liver in Cynomolgus Monkeys 978

3M_MN03278842

1818.0009

CONTENTS (Continued)

VOLUME II OF II **Page**

APPENDIX 9 1069
Urobilinogen Analysis Report 1070

APPENDIX 10 1072
Dose Confirmation Analysis Report 1073
Compound Stability Report 1078
Analytical Laboratory Report 1080
Certificate of Analysis 1083
Quality Assurance Statement 1086

3M_MN03278843

1818.0010

ABSTRACT

The purpose of this study was to assess the effect of the test material, Perfluorooctane Sulfonic Acid Potassium Salt [PFOS; T-6295 (hereafter referred to as PFOS)] on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by oral capsule to cynomolgus monkeys for at least 26 weeks. The treatment period was followed by an approximate 52-week recovery period.

Male and female cynomolgus monkeys were assigned to four groups (six animals/sex in Groups 1, 3, and 4; four animals/sex in Group 2). Each group received dose preparations containing the vehicle, lactose, or 0.03, 0.15, or 0.75 mg of PFOS/kg of body weight/day (mg/kg/day). Two animals/group in Groups 1, 3, and 4 were in a recovery period and were not treated for at least 52 weeks following the 26 week treatment period.

Food was provided *ad libitum*, except when animals were fasted. Water was provided *ad libitum*. The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. At least once daily, animals were examined for abnormalities and signs of toxicity, and food consumption was assessed qualitatively. Ophthalmic examinations were done before initiation of treatment and during Weeks 26 and 52. Body weight data were recorded weekly before initiation of treatment, on Days -1 and 1, and weekly thereafter. Blood and urine samples were collected for clinical hematology, clinical chemistry, and urinalysis tests before initiation of treatment and at specified intervals during treatment and recovery. Blood was also collected for blood hormone and PFOS level determinations before, during, and after treatment at specified intervals. Feces and liver samples were also collected at specified intervals. On Day 155 (Week 23), one male given 0.75 mg/kg/day died, and on Day 179 (Week 26), one male given 0.75 mg/kg/day was sacrificed due to poor health. On Days 184 and 185 (Week 27), four animals/sex/group (Groups 1 through 3) and four females and two males (Group 4) were anesthetized, weighed, exsanguinated, and necropsied. At necropsy at the scheduled and unscheduled sacrifices, a serum sample was collected, macroscopic observations were recorded, selected organs were weighed, and selected tissues were collected and preserved. Microscopic examinations were done on tissues from each animal in the control and high-dose groups and selected tissues from animals in the low-and mid-dose groups. Tissues were also collected for palmitoyl CoA oxidase determination, cell proliferation evaluation, PFOS determination, and electron microscopy. Additionally, the bile was collected from the gallbladder, and the gallbladder was preserved. At the recovery sacrifice on Day 549, the remaining Group 4

3M_MN03278844

1818.0011

animals were anesthetized, weighed, exsanguinated, and necropsied. Macroscopic observations were recorded and specified tissues and serum were collected. Remaining animals in Groups 1 and 3 were transferred to Covance stock or transferred to a follow-up study, Covance 6329-268.

At all dose levels, clinical observations, ophthalmic observations, and palmitoyl CoA oxidase determinations do not appear to be affected by treatment with PFOS.

Two males given 0.75 mg/kg/day did not survive to scheduled termination. These deaths were preceded by some adverse clinical observations (constricted pupil, pale gums, abnormal feces, excessive salivation, labored respiration, dehydrated appearance, hypoactive, ataxic, recumbent, low food consumption) and appeared to be related to the administration of PFOS. When compared with animals given the control material, covariate adjusted mean body weights (CAM) for males given 0.75 mg/kg/day were slightly lower beginning at Week 21, and for females given 0.75 mg/kg/day CAM body weights were, in general, significantly lower beginning at Week 11. Similar decreases were not seen in the other treated groups; therefore, this finding is likely test material-related. Test material-related effects on body weights were not apparent during recovery. Low food consumption was noted sporadically for animals in the groups given the control material and 0.03 mg/kg/day throughout treatment. The incidence of low food consumption was generally higher in the groups given 0.15 or 0.75 mg/kg/day as compared to animals given the control material and appeared to be test material-related. During recovery, effects on food consumption were reversed.

Estradiol values were generally lower on Days 62, 91, and 182 in males given 0.75 mg/kg/day, although because of the variation in the data only the Day 182 value was significant. Estrone values were generally higher in all of the treated females on Days 37, 62, and 91, although because of the variation in the data none of these values were significantly different, and this difference was not apparent on Day 182. Triiodothyronine values were notably lower in both males and females given 0.15 and 0.75 mg/kg/day on Days 91 and 182. With the single exception of males given 0.15 mg/kg/day on Day 91, all values were significantly lower. During recovery were occasional instances in which the hormone values in treated groups differed slightly from those of controls, but those differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be clearly related to the administration of the test material. Apparent differences in the sexual maturity of both males and females used in this study complicates the interpretation of the hormone data.

3M_MN03278845

1818.0012

The only clinical pathology parameters considered related to the test material were lower total cholesterol for animals given 0.75 mg/kg/day and lower high density lipoprotein cholesterol for animals given 0.15 or 0.75 mg/kg/day. These effects were reversed within the first 5 and 9 weeks of recovery, respectively.

At the terminal sacrifice, increased liver weights, macroscopic observations of mottled liver, hepatocellular hypertrophy, and hepatocellular vacuolation in animals given 0.75 mg/kg/day were considered related to PFOS treatment. However, the microscopic examination liver biopsies taken during recovery did not indicate any test material-related findings and none of the macroscopic observations made at the recovery sacrifice were considered test material-related. There were no microscopic findings in the liver from the animals in the high-dose recovery group. This indicates that the hepatic test material-related effects were reversible.

Treatment with PFOS by oral capsule for at least 26 weeks is generally well-tolerated in male and female cynomolgus monkeys at doses up to 0.15 mg/kg/day. Clinical and pathological findings considered to be associated with the treatment of PFOS after at least 26 weeks of treatment were found to be reversible during a 52-week recovery period. Based on the data presented in this report, the no-observable-adverse-effect level is 0.15 mg/kg/day. Dose analyses (provided by the Sponsor), fecal analysis results (provided by the Mayo Clinic) and electron microscopy results (provided by Pathology Associates North Carolina Division, A Charles River Company), were provided for inclusion in the final report.

3M_MN03278846

1818.0013

PURPOSE

The purpose of this study was to assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The treatment period was followed by an approximate 52-week recovery period.

REGULATORY COMPLIANCE

All aspects of this study were done in accordance with the Environmental Protection Agency Good Laboratory Practice Regulations, 40 CFR 792, with the exception that the analysis of fecal samples for urobilinogen at the Mayo Clinic were not done in compliance with Good Laboratory Practice Regulations.

TEST MATERIAL, VEHICLE, AND SOLVENT

Test Material

The test material, Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295), Lot No. 217 (expiration date: August 31, 2001), is a white to off-white powder and is 86.9% pure. It was received at Covance on September 4, 1997. The test material was stored at room temperature.

Information on synthesis methods, composition, or other characteristics that define the test material is on file with the Sponsor.

Vehicle

The vehicle was lactose (Spectrum, New Brunswick, New Jersey), Lot No. NN0192 (expiration date February 13, 1999). It was received at Covance on March 30, 1998.

The vehicle was stored at room temperature.

Information on synthesis methods, purity, stability, composition, or other characteristics that define the vehicle is on file with the manufacturer.

3M_MN03278847

1818.0014

Solvent
The solvent was acetone (Spectrum, Gardena, California), Lot No. LH0253, (expiration date June 2000). It was received at Covance on June 23, 1997. The solvent was stored at room temperature.

Information on synthesis methods, composition, or other characteristics that define the solvent is on file with the manufacturer.

Gelatin Capsules
Gelatin capsules, Size Nos. 2 (Lot No. 122932, expiration date June 12, 2003) and 4 (Lot No. 544043, expiration date August 1, 2002) were manufactured by Torpac Inc., (Fairfield, New Jersey). Lot No. 122932 was received at Covance on June 12, 1998, and Lot No. 544043 was received on September 1 and November 10, 1998. The capsules were stored at room temperature. A copy of the Certificate of Analysis provided by the manufacturer is maintained in the data.

Reserve (Archive) Samples
A reserve sample (1 g) of each lot of the test material, vehicle, and each test material/lactose dilution was taken and stored at room temperature. These samples were transferred to the Sponsor after completion of the treatment phase (see Protocol Deviations).

Disposition
Remaining test material will be retained at Covance for use in possible future studies.

TEST ANIMALS AND HUSBANDRY

Animals
Young adult to adult cynomolgus monkeys were obtained from Covance Research Products Inc. (Denver, Pennsylvania) on June 30, 1998. The animals weighed 2.4 to 4.4 kg at initiation of treatment.

3M_MN03278848

1818.0015

Identification
Each animal was assigned a permanent number upon arrival and identified with a collar tag before initiation of treatment. All data for an animal are recorded under this number.

Justification
PFOS is a known hepatic peroxisome proliferator (PP) in the rat. When exposed to a PP, nonhuman primates (such as the cynomolgus monkey) respond similarly to humans (i.e., low to no hepatic response) and therefore are an appropriate human surrogate species.

Husbandry
Animal Rooms 251, 258, 259, and 527 were used for this study. Environmental controls for the animal rooms were set to maintain 18 to 29°C, a relative humidity of 30 to 70%, and a 12-hour light/12-hour dark cycle. Variations from these conditions are documented in the data and are considered to have had no effect on the outcome of the study.

The animals were housed individually in suspended, stainless-steel cages.

Certified primate diet (#8726C, Harlan Teklad) was provided once or twice daily, unless otherwise specified. The lot numbers are recorded in the data. The diet is routinely analyzed by the manufacturer for nutritional components and environmental contaminants. Results of specified nutrient and contaminant analyses are on file with Covance-Madison. Fruits or additional supplements were provided, but did not require analysis.

Water was provided *ad libitum*. Samples of the water are analyzed for specified microorganisms and environmental contaminants. The results are on file with Covance-Madison.

There were no known contaminants in the diet or water at levels that would have interfered with this study.

3M_MN03278849

1818.0016

Acclimation

Twenty-four males and 24 females were received on June 30, 1998, and acclimated in Animal Room 251 for 57 days before initiation of treatment. In general, animals in this shipment appeared healthy. During acclimation, the animals were examined for abnormalities indicative of health problems. In addition, three tuberculosis tests, a physical examination, and a fecal flotation for parasites were performed on each animal.

PROCEDURES

This study was conducted in accordance with the Protocol dated August 20, 1998, and Protocol Amendment Nos. 1, 2, 3, and 4. The protocol, protocol amendments, and protocol deviations are in Appendix 1.

Group Designations and Dosage Levels

Selection of animals for the study was based on data collected during acclimation. Animals were assigned to treatment groups using a computerized blocking procedure designed to achieve body weight balance with respect to treatment group.

Group	Dose Level (mg/kg/day)[a]	Total Material Dose Level (mg/kg/day)[b]	Number of Animals	
			Males	Females
1	0[a]	30[a]	6[d]	6[d]
2	0.03	15[b]	4	4
3	0.15	6[c]	6[d]	6[d]
4	0.75	30[c]	6[d]	6[d]

a The control group (Group 1) received the equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.

b The low-dose (Group 2) received the test material diluted with lactose (1:499, w:w).

c The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w:w).

d Two animals in Groups 1, 3, and 4 designated as recovery animals were treated for at least 26 weeks, then treatment was discontinued, and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

3M_MN03278850

1818.0017

Dosing Procedures

Vehicle. Dose levels were based on the vehicle as supplied for Group 1. For Group 1 dose preparations, the specified amount of lactose was weighed, transferred into gelatin capsules, and the top and bottom halves of each capsule were joined. Capsules were prepared at least once weekly.

Test Material. The test material/lactose preparations for Groups 2 through 4 were diluted once before initiation of treatment; capsules were prepared at least once weekly.

A specified amount of test material was weighed, placed into a labeled mixing container, and the appropriate volume of acetone was added. After stirring manually until the test material was dissolved, the required amount of lactose was weighed and transferred to the container. The components were mixed thoroughly using a spatula. The prepared test material dilution was stirred periodically while allowed to stand exposed to the air until the acetone had evaporated. Preparations were diluted to facilitate capsule preparation.

Samples of the finished mixture for dose analyses were taken directly from the container.

The dose preparations were stored at room temperature between capsule preparations. The appropriate amount of prepared test material was weighed and transferred into Size 2 (Days 1 through 8) or 4 (Days 9 through 184) gelatin capsules and the top and bottom halves of each capsule were joined. Size 4 capsules were used instead of Size 2 to better facilitate dose administration. Individual daily doses were based on the most recently recorded body weight, with the exception of doses given on days when body weight measurements were performed; on those days, the previous body weight was used.

All capsule preparations were stored at room temperature until used for dosing.

Method of Administration. Gelatin capsules were used to facilitate comparison with data from previous toxicology studies that used the oral route. Also, oral is the most likely route of exposure in humans. Partial or intact capsules were noted in the vomitus of several animals on occasion; however, this is not considered to have adversely affected the results of the study.

The dose preparations were administered orally in gelatin capsules once daily 7 days/week for at least 26 weeks (see Protocol Deviations for exceptions).

3M_MN03278851

1818.0018

Dose Analyses

Homogeneity and stability analyses were the responsibility of the Sponsor.

Samples (approximately 1 g each) were taken from the top, middle, and bottom of the test material/lactose preparations on Day -15 for homogeneity analysis. Samples collected from the middle of the preparations were also designated for prestudy stability analysis. A set of samples (approximately 1 g each) were taken from the low- and high-dose test material/lactose preparations at the end of the treatment phase for test material content analysis.

All samples were stored at room temperature until sent under ambient conditions to the Sponsor for analysis. Results of dose analyses were provided for inclusion in the final report.

Observation of Animals

Clinical Observations. The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. Animals were also observed at least once daily (a.m.) for signs of poor health or abnormal behavior, and food consumption was assessed qualitatively; only abnormal findings were recorded. Once weekly and on the day of scheduled sacrifice, each animal was observed; abnormal findings or an indication of normal was recorded (see Protocol Deviations for exceptions). Additionally, postdose observations were recorded during treatment approximately 30 to 90 minutes after the last dose administration; only abnormal findings were recorded.

Ophthalmology. Ophthalmic examinations were done on each animal before initiation of treatment, before the scheduled terminal sacrifice during Week 26, and during Week 52 (see Protocol Deviations). The pupils were dilated with 1% Mydriacyl® and the anterior portion of the eye, optic media, and ocular fundus were examined with an indirect ophthalmoscope by a board-certified ophthalmologist.

Body Weights. Individual body weight data were recorded weekly before initiation of treatment, on Day -1, on the first day of treatment, and weekly thereafter.

3M_MN03278852

1818.0019

Clinical Pathology

Blood and urine samples were collected from each animal once before initiation of treatment (Day -27); on Days 37, 62, 91, 153, and 182 of treatment; and on Days 217, 245, 274, 322, 364, 456, and 546 during recovery (see Protocol Deviations). Animals were fasted overnight, and urine was collected overnight on wet ice before blood sampling; water was provided *ad libitum*. Blood was collected from the femoral vein. Potassium EDTA was the anticoagulant used for hematology tests; no anticoagulant was used for the chemistry tests. Blood samples were collected from the animal that was sacrificed at an unscheduled interval. Animals were bled in sequential order on Days 37, 62, and 91 and in random order at all other scheduled collections; this is not expected to have an impact on the clinical pathology results. The following were evaluated (see Protocol Deviations for exceptions).

Hematology

- red blood cell (erythrocyte) count
- hemoglobin
- hematocrit
- mean corpuscular volume
- mean corpuscular hemoglobin
- mean corpuscular hemoglobin concentration
- platelet count
- white blood cell (leukocyte) count
- differential blood cell count
  - segmented neutrophil count
  - lymphocyte count
  - monocyte count
  - eosinophil count
  - basophil count
- blood cell morphology
- reticulocyte count

Clinical Chemistry

- glucose
- urea nitrogen
- creatinine
- total protein
- albumin
- globulin
- total bilirubin
- cholesterol
- triglycerides
- alanine aminotransferase
- alkaline phosphatase
- aspartate aminotransferase
- gamma glutamyltransferase
- sorbitol dehydrogenase
- creatine kinase
- calcium
- inorganic phosphorus
- sodium
- potassium
- chloride
- bile acids
- amylase
- lipase
- pancreatic-specific amylase
- high density lipoprotein (HDL) (effective with collection on Day 153)

3M_MN03278853

1818.0020

Urinalysis

volume (approximately 16 hours)	bilirubin
specific gravity	blood
pH	urobilinogen
protein	microscopic examination of sediment
glucose	appearance
ketones	

Blood Hormone Determination

Blood samples (approximately 5 mL) were collected from each animal three times before initiation of treatment (Days -50, -40, and -27); on Days 37, 62, 91, and 182 of treatment; and on Days 217, 245, 274, 322, 364, 456, and 546 during recovery (see Protocol Deviations). Animals were fasted overnight. Blood was collected from a femoral vein without using an anticoagulant. Samples were allowed to clot and centrifuged within 1 hour after collection; serum was harvested. The serum was divided into two approximately equal aliquots and stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to AniLytics Inc. for analysis of cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, total triiodothyronine, and total thyroxin. Beginning with the collection on Day 322 the samples were also analyzed for free triiodothyronine and free thyroxin.

Serum PFOS Level Determination

Blood samples (approximately 2 mL) were collected from each animal once before initiation of treatment (Day -27); during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, and 26, and 27 (Day 183) of treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 198), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, 53, 57, 61, 65, 69, 73, 77, and 79 (see Protocol Deviations). Animals were fasted overnight and water was provided *ad libitum*. Blood was collected from a femoral vein without using an anticoagulant. Samples were centrifuged within 1 hour after collection and serum was harvested. Serum samples were stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to the Sponsor for analysis. Results will reported separately.

3M_MN03278854

1818.0021

Additional Serum Collection

At the scheduled terminal necropsy and the necropsy of Animal No. I05506 (Group 4 male), blood samples (approximately 20 mL) were collected from the vena cava at the time of exsanguination. Samples were collected without using an anticoagulant and centrifuged within 1 hour of collection. Serum was harvested and stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to the Sponsor for possible future analysis.

An aliquot (0.8 ml) of the additional serum collection samples collected from all animals from Groups 1, 2, 3, and 4 sacrificed at the terminal necropsy were sent on dry ice by the Sponsor to AniLytics for total triiodothyronine, total thyroxin, free triiodothyronine, and free thyroxin determinations.

Additional serum samples collected at the terminal and recovery sacrifices were transferred by the Sponsor to Anilytics for analysis of estradiol, follicle stimulating hormone (FSH), and lutenizing hormone (LH) for females, and estradiol in males. Results were provided for inclusion in the final report.

Additionally, samples were transferred by the Sponsor to the Mayo Clinic for analysis of triiodothyronine (T3), total thyroxin (T4), free thyroxin (free T4), and thyroid stimulating hormone (TSH). Additional reserve samples of serum were transferred for possible future anlaysis for estradiol. Any unused serum will be returned to the Sponsor. Results were provided for inclusion in the final report.

Urine and Feces PFOS Level Determination

Urine [at least 2 mL (see Protocol Deviations)] and feces (at least 5 g) were collected overnight on the first day of recovery (Day 184) and on Days 189, 216, 275, 321, and 366 during recovery. In addition, a 24-hour sample of urine and feces was collected before the completion of 52 weeks of recovery. Except for the first day of recovery, animals were not fasted. Samples were stored in a freezer set to maintain -10 to -30°C, until they were packed on dry ice and shipped to the Sponsor. The samples will be analyzed for PFOS. Results will be reported separately.

3M_MN03278855

1818.0022

Additional Fecal Samples

During Week 23, a fresh fecal sample (up to 5 g) was collected from all animals in the control and high-dose groups. Samples were collected in white polypropylene containers after pans were cleaned in the morning to ensure that the fecal samples were not more than 6 hours old (see Protocol Deviations). Samples were packed on dry ice and shipped to the Mayo Clinic for analysis of urobilinogen using a routine, standardized, colormetric assay. Results were provided for inclusion in the final report.

Interim Liver Biopsy Samples

A sample of liver (approximately 1 to 2 g) was collected by biopsy from animals in Group 4 only during recovery [Week 57 (Day 393), on the same day as the serum PFOS blood collection]. This sample was divided into four portions as follows.
One subsample was preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides were prepared), and examined microscopically.

The second subsample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis (see Protocol Deviations). Results will be reported separately.

The third subsample was processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy were transferred to Pathology Associates. Tissues were processed and evaluated by electron microscopy by Pathology Associates. A report was provided by Pathology Assoicates for inclusion in the final report.

The fourth subsample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until transferred to the Sponsor for possible future analysis.

Terminal Liver Biopsy Samples

A sample of liver (approximately 1 g) was collected by biopsy from all animals in Group 3 during recovery [Week 80 (Day 554), one week after the serum PFOS blood collection (see Protocol Deviations)]. This sample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis. Results will be reported separately.

3M_MN03278856

1818.0023

Anatomic Pathology - Terminal Sacrifice

Necropsy. A necropsy was done on Animal No. I05509 (Group 4 male) that died on Day 155 (Week 23) and Animal No. I05506 (Group 4 male) that was sacrificed in a moribund condition on Day 179 (Week 26). During Week 27 (Days 184 and 185) four animals/sex/group (Groups 1 through 3) and four females and two males (Group 4) were fasted overnight, anesthetized with ketamine and xylazine, weighed, bled for required tests, exsanguinated, and necropsied. Animals were necropsied in random order.

The necropsy included a macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surface of the brain; the nasal cavity and paranasal sinuses; cervical tissues and organs; and the thoracic, abdominal, and pelvic cavities and viscera.

Organ Weights. At scheduled and unscheduled sacrifices, the following organs (when present) were weighed; paired organs were weighed separately.

adrenal (2)
brain
epididymis (2)
kidney (2)
liver
ovary (2)
pancreas
testis (2)
thyroid (2) with parathyroid

Organ-to-body weight percentages and organ-to-brain weight ratios were calculated.

Palmitoyl CoA Oxidase Determinations. Representative samples of the right lateral lobe of liver were collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until analyzed for palmitoyl CoA oxidase activity.

Cell Proliferation Evaluation. Representative samples of the left lateral lobe of the liver, left and right testes, and pancreas were collected and preserved in zinc formalin. A second set of tissues (representative samples of the left lateral lobe of the liver, left and right testes, and pancreas) preserved in formalin without zinc were also prepared. After fixation, samples were embedded in paraffin and shipped to Pathology Associates North Carolina Division, A Charles River Company (Pathology Associates) for proliferation cell nuclear antigen (PCNA) evaluation, including the examination of slides stained with

3M_MN03278857

1818.0024

hematoxylin and eosin (see Protocol Deviations). Results were provided by Pathology Associates for inclusion in the final report (Appendix 7).

Liver PFOS Determination. A section of liver (approximately 20 g) was collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped with plasma samples to the Sponsor. Results will be reported separately.

Gallbladder and Bile Collection. At the scheduled terminal sacrifice for each animal, bile was collected from the gallbladder, measured, transferred into a cryovial, and flash-frozen in liquid nitrogen. The gallbladder, once emptied, was weighed, and a section (approximately 4 to 5 mm) from the mid-portion was collected. The remaining gallbladder was placed in a cryovial and flash-frozen in liquid nitrogen. The bile and gallbladder samples were stored on dry ice until transferred to a freezer set to maintain -60 to -80°C. Samples were packed on dry ice and shipped to the Sponsor for possible future analysis.

Tissue Preservation. The following tissues (when present) or representative samples were collected and preserved in 10% neutral-buffered formalin, unless otherwise specified (see Protocol Deviations).

adrenal (2)
aorta
brain
cecum
cervix
colon
duodenum
epididymis (2)
esophagus
eyes [(2) preserved in Davidson's fixative for all sacrificed animals]
femur with bone marrow (articular surface of the distal end)
gallbladder
heart
ileum
jejunum
kidney (2)
lesions
liver
lung
mammary gland
mesenteric lymph node
ovary (2)
pancreas
pituitary
prostate
rectum
salivary gland [mandibular (2)]
sciatic nerve
seminal vesicle (2)
skeletal muscle (thigh)
skin
spinal cord (cervical, thoracic, and lumbar)
spleen

3M_MN03278858

1818.0025

sternum with bone marrow	thyroid (2) with parathyroid
stomach	trachea
testis [(2) preserved in Bouin's solution for all sacrificed animals]	urinary bladder
	uterus
thymus	vagina

Histopathology. Tissues (as appropriate) were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically from each animal in the control and high-dose groups (see Protocol Deviations for exceptions). In addition, liver and thymus for all animals in the low- and mid-dose groups and spinal cord gray matter from females in the low- and mid-dose groups were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Other tissues, as appropriate, will be retained for possible future examination.

Bone marrow smears from the sternum of each animal at scheduled and unscheduled sacrifices were prepared, stained with Wright's stain, and retained for possible examination.

Electron Microscopy. A sample of the liver was collected from each animal at the scheduled terminal sacrifice. Tissues were processed into blocks and, along with a hematoxylin and eosin-stained slide, were shipped to Pathology Associates for analysis. Results were provided for inclusion in the final report.

Anatomic Pathology - Recovery Sacrifice

Termination. Remaining animals in Group 1 were transferred to Covance stock on Day 549 and remaining animals in Group 3 were transferred to Covance 6329-268 on Day 561. On Day 549, remaining animals in Group 4 were fasted overnight, anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

The necropsy of the animals in Group 4 included a macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surface of the brain; the nasal cavity and paranasal sinuses; cervical tissues and organs; and the thoracic, abdominal, and pelvic cavities and viscera.

Liver Samples. Samples of liver were collected from animals in Group 4 as follows.

3M_MN03278859

1818.0026

One sample was preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides were prepared), and examined microscopically.

The second sample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis. Results will be reported separately.

The third sample was processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy were transferred to Pathology Associates. Tissues were processed and evaluated by electron microscopy by Pathology Associates. A report was provided by Pathology Associates for inclusion in the final report.

Additional Tissue and Serum Samples. Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, (approximately 3 g each, if possible), and bile and serum (each as much as possible) were collected. These samples were flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for possible future analysis.

Statistical Analyses

Levene's test (Levene, 1960) was done to test for variance homogeneity. In the case of heterogeneity of variance at $p \leq 0.05$, transformations were used to stabilize the variance. Comparison tests took variance heterogeneity into consideration.

One-way analysis of variance [ANOVA (Winer, 1971a)] was used (if applicable) to analyze initial body weights, organ weights, palmitoyl CoA oxidase activities, continuous clinical pathology values, and blood hormone determinations. If the ANOVA was significant, Dunnett's t-test (Dunnett, 1964) was used for control versus treated group comparisons.

One-way analysis of covariance [ANCOVA (Winer, 1971b)] was used to analyze body weights, with initial body weights as the covariate. If the ANCOVA was significant, covariate-adjusted means were used for control versus treated group comparisons.

3M_MN03278860

1818.0027

Group comparisons (Groups 2 through 4 versus Group 1) were evaluated at the 5.0%, two-tailed probability level. Only data collected on or after the first day of treatment were analyzed statistically. Statistical analyses were not performed on data collected during recovery.

Record Retention

All raw data, documentation, records, protocol, and specimens generated as a result of this study will be archived in the storage facilities of Covance-Madison for a period of at least 1 year. At least one year after the submission of the final report, the Sponsor will determine the final disposition of the materials. All raw data stored on magnetic media and the protocol, study correspondence, and an original copy of the final report will be retained by Covance-Madison.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (AniLytics Inc., 3M E. T. & S, Mayo Clinic, and Pathology Associates) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

RESULTS AND DISCUSSION

Observation of Animals

Clinical Observations. Clinical observations are summarized in Tables 1, 2, and 3; individual data are presented in Appendix 2. Individual animal fate data are also presented in Appendix 2.

Animal Nos. I05506 and I05509 given 0.75 mg/kg/day (Group 4 males) did not survive to the scheduled terminal sacrifice. All other animals survived to the scheduled study termination. No clinical observations noted in the animals that survived to the terminal sacrifice or recovery were attributable to the administration of PFOS.

Animal No. I05509 (Group 4 male) died after dosing on Day 155 (Week 23). On Day 154 (Week 22) observations of constricted pupil in both eyes and pale gums were noted. Observations noted on Day 155 prior to dosing included few, mucoid, liquid, and black-colored feces and low food consumption. Approximately 15 minutes after dosing, the animal was observed as hypoactive with labored respiration and pale gums. This

3M_MN03278861

1818.0028

animal also appeared dehydrated and was cold to the touch. These observations persisted until approximately 30 minutes postdose when the animal was also noted as recumbent. Shortly thereafter, the animal died during an examination by a laboratory animal veterinarian. An enlarged liver was detected by palpation. The cause of death was determined to be pulmonary necrosis with severe acute inflammation.

On Day 179 (Week 26), Animal No. I05506 (Group 4 male) was sacrificed in a moribund condition. Low food consumption was noted on Day 178 (Week 26) and at the a.m. observation interval on Day 179. Approximately 5 to 10 minutes postdose on Day 179, the animal had excessive salivation, labored respiration, and hypoactive and ataxic behavior. With the exception of excessive salivation, these findings continued to be observed approximately 3 hours postdose. The cause of the moribund condition was not determined.

Two additional animals had noteworthy observations during treatment. One female in the group given the control material, Animal No. I05529, was examined by a laboratory animal veterinarian on Day 5 (Week 1) due to observations of dehydration, thin appearance, clear oral and nasal discharge, excessive salivation, and audible respiration. This animal was diagnosed with pneumonia and treated with Lactated Ringer's solution and antibiotics. This animal had recovered by Day 14 (Week 2). Animal No. I05534 (Group 4 female) was diagnosed with a tapeworm infection during Week 23 and was treated with praziquantel. Neither infection was test material-related.

Clinical observations during recovery were typical of laboratory primates.

Ophthalmology. Ophthalmic observations are summarized in Tables 4 and 5; individual data are presented in Appendix 2.

There were no ophthalmic observations at the Week 26 or Week 52 examinations that were test material-related. Animal No. I05529 (Group 1 female) was noted as having increased myelination of the right optic nerve at the baseline and Week 52 ophthalmic examinations. Because this is a permanent, congenital condition, it was noted at the baseline and recovery examinations only and is not related to treatment with PFOS.

Body Weights. Body weight data are illustrated in Figures 1 and 2 and summarized in Tables 6 and 7; individual data are presented in Appendix 3.

3M_MN03278862

1818.0029

Covariate-adjusted mean (CAM) body weights were slightly lower in males given 0.75 mg/kg/day when compared with males given the control material beginning at Week 21; the difference was significant at Weeks 23 and 27. In females given 0.75 mg/kg/day, CAM body weights were significantly lower at Weeks 11 through 16, 19 through 23, and 25 through 27 when compared with females given the control material. These decreases were likely test material-related.

Differences in body weights were not apparent during the recovery period.

Food Consumption. Food consumption data are summarized in Tables 1, 2, and 3 (Summary of Clinical Observations); individual data are included in the individual clinical observations in Appendix 2.

Low food consumption was noted sporadically for animals in the groups given the control material and 0.03 mg/kg/day. The incidence of low food consumption was generally higher in the groups given 0.15 and 0.75 mg/kg/day as compared to animals given the control material and appeared to be test material-related. During recovery, instances of low food consumption were sporadic and were similar for animals in the control and treated groups.

Clinical Pathology

Hematology, clinical chemistry, and urinalysis data are summarized in Tables 8 through 46; individual data are presented in Appendix 4.

Administration of PFOS was associated with moderately to markedly lower total cholesterol for males and females given 0.75 mg/kg/day and high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. During the treatment period, the effect on total cholesterol became progressively worse over time. The effect on cholesterol was reversed within 5 weeks of the end of treatment, and the effect on high density lipoprotein cholesterol was reversed within 9 weeks of the end of treatment. Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day and higher serum bile acid concentration for males given 0.75 mg/kg/day. These potential effects of the test material were very mild, and neither was considered adverse.

3M_MN03278863

1818.0030

Palmitoyl CoA Oxidase Determination

Palmitoyl CoA oxidase determinations are summarized in Table 47; individual data are presented in Appendix 5.

Results of palmitoyl CoA oxidase determinations were not considered to be related to the test material.

Blood Hormone Determination

Summary and Individual Blood Hormone Data are presented in Appendix 6.

Estradiol values were generally lower on Days 62, 91, and 182 in males given 0.75 mg/kg/day, although because of the variation in the data only the Day 182 value was significant. Estrone values were generally higher in all of the treated females on Days 37, 62, and 91, although because of the variation in the data none of these values were significantly different, and this difference was not apparent on Day 182. Triiodothyronine values were notably lower on Days 91 and 182 in both males and females given 0.15 or 0.75 mg/kg/day. With the single exception on Day 91 of males given 0.15 mg/kg/day, all values were significantly lower. There were several other instances in which the hormone values in treated groups differed from those of controls, but these differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be related to the administration of the test material.

During recovery were occasional instances in which the hormone values in treated groups differed slightly from those of controls, but those differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be clearly related to the administration of the test material.

Apparent differences in the sexual maturity of both males and females used in this study complicates the interpretation of the hormone data.

Anatomic Pathology

Terminal body weights, absolute organ weights, organ-to-body weight percentages, and organ-to-brain weight ratios are summarized in Table 48; incidences of macroscopic and microscopic observations are summarized in Tables 49 through 52. Individual data are presented in Appendix 5.

3M_MN03278864

1818.0031

Two of four males receiving 0.75 mg/kg/day (high dose) did not survive to the scheduled terminal sacrifice at Week 27. At the terminal sacrifice, females in the group receiving 0.75 mg/kg/day had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. In males, liver-to-body weight percentages were increased in the high-dose group compared to the control group. Absolute and relative liver weight increases were regarded as test material-related. Among the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" livers were observed in the two high-dose males and in one high-dose female. Of the two males not surviving until the scheduled terminal sacrifice, one had "mottled" and "large" liver.

Microscopic examination of animals sacrificed at Week 27 and of the two males sacrificed at an unscheduled interval yielded test material-related observations in the liver. In four of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobullary or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was observed in all high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high-dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent because they were found in one of four low-dose males, and in a control and a low-dose female.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material-related findings.

At the recovery sacrifice, one of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related. Only livers were examined microscopically, and no test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

CONCLUSION

Treatment with PFOS by oral capsule for at least 26 weeks is generally well-tolerated in male and female cynomolgus monkeys at doses up to 0.15 mg/kg/day. Clinical and pathological findings considered to be associated with the treatment of PFOS after at least 26 weeks of treatment were found to be reversible during a 52-week recovery period. Based on the data presented in this report, the no-observable-adverse-effect level is 0.15 mg/kg/day. Dose analysis results (provided by the Sponsor), fecal analysis results (provided by the Mayo Clinic), and electron microscopy results (provided by Pathology Associates), were provided for inclusion in the final report.

3M_MN03278866

1818.0033

SIGNATURES

Elizabeth A. Disch, BA
Study Coordinator
Covance Laboratories Inc.

11 January 2002
Date

Peter J. Thornford, PhD
Study Director
Covance Laboratories Inc.

11 Jan 2002
Date

REFERENCES

Dunnett, C. W., "New Tables for Multiple Comparisons with a Control," Biometrics, 20:482-491 (1964).

Levene, H., "Robust Tests for Equality of Variances," Contributions to Probability and Statistics, (eds.) I. Olkin et al., Ch. 25, pp. 278-292, Stanford University Press: Stanford, California (1960).

Winer, B. J., "Design and Analysis of Single-Factor Experiments," Statistical Principles in Experimental Design, Second Ed., Ch. 3, pp. 149-260, McGraw-Hill: New York, New York (1971a).

Winer, B. J., "Analysis of Covariance," Statistical Principles in Experimental Design, Second Ed., Ch. 10, pp. 752-812, McGraw-Hill: New York, New York (1971b).

OPHTHALMOLOGY REPORT

Ophthalmic examinations were done before initiation of treatment and during Weeks 26 and 52. There were no ophthalmic observations at the Week 26 or Week 52 examinations that were test material-related. Animal No. I05529 (Group 1 female) was noted as having increased myelination of the right optic nerve at the baseline and Week 52 ophthalmic examinations. Because this is a permanent, congenital condition, it was noted at the baseline and recovery examinations only and is not related to treatment with PFOS. There were no test material-related observations at any of the examinations.

Stephen Bistner DVM, DACVO
Stephen I. Bistner, DVM
Diplomate, ACVO
Veterinary Ophthalmologist

December 18, 2001
Date

3M_MN03278869

1818.0036

PATHOLOGY REPORT

SUMMARY

The purpose of the study was to assess the effect of the test material, Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The test material was administered at dose levels of 0.03, 0.15, and 0.75 mg/kg/day. One male given 0.75 mg/kg/day died on Day 155 after dose administration and one male given 0.75 mg/kg/day was sacrificed on Day 179 due to poor health. The treatment period was followed by an approximate 52-week recovery period.

Administration of PFOS was associated with moderately to markedly lower total cholesterol for males and females given 0.75 mg/kg/day and high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. During the treatment period, the effect on total cholesterol became progressively worse over time. The effect on cholesterol was reversed within 5 weeks of the end of treatment, and the effect on high density lipoprotein cholesterol was reversed within 9 weeks of the end of treatment. Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day and higher serum bile acid concentration for males given 0.75 mg/kg/day. These potential effects of the test material were very mild, and neither was considered adverse.

Two of four males receiving 0.75 mg/kg/day did not survive to the scheduled terminal sacrifice at Week 27. At the terminal sacrifice, females in the group receiving 0.75 mg/kg/day had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. In males, liver-to-body weight percentages were increased in the high-dose group compared to controls. These absolute and relative liver weight increases were regarded as test material-related. Among the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" livers were observed in the two high-dose males and in one high-dose female. Of the two males not surviving until the scheduled terminal sacrifice, one had "mottled" and "large" liver.

3M_MN03278870

1818.0037

Microscopic examination of animals sacrificed at Week 27 and the two unscheduled sacrifice males yielded test material-related observations in the liver. In four of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobullary or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was also observed in four of four high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high-dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent because they were found in one of four low-dose males, and in a control and a low-dose female.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material-related findings.

For the recovery sacrifice at Week 79, only high-dose animals were necropsied. One of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related. Only livers were examined microscopically. No test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

METHODS

Four groups of male and female cynomolgus monkeys were administered the test material daily by capsule at a dose level of 0 (control group; received capsules containing lactose), 0.03, 0.15, or 0.75 mg/kg of body weight/day (mg/kg/day). There were six animals/sex in the control group and the groups given 0.15 or 0.75 mg/kg/day; two animals/sex in these groups were designated as recovery animals to be observed for approximately 26 weeks posttreatment. The recovery period was later extended an additional 26 weeks. There were four animals/sex in the group given 0.03 mg/kg/day.

3M_MN03278871

One male given 0.75 mg/kg/day died on Day 155 following dose administration, and one male given 0.75 mg/kg/day was sacrificed on Day 179 due to poor health.

Blood and urine were collected for hematology, clinical chemistry, and urinalysis tests once before initiation of treatment (Week -4), on Days 37, 62, 91, 153, and 182 and on Days 217, 245, 274, 322, 364, 456, and 546 (recovery animals). High density lipoprotein cholesterol was not measured at the clinical pathology intervals before Day 153.

The terminal sacrifice and necropsy occurred on Days 184/185; macroscopic observations were recorded, organ weights were obtained, and tissues were placed in fixative as specified by the protocol. Samples of the right lateral lobe of the liver from each animal were frozen for analysis of palmitoyl CoA oxidase activity. Sections of liver from each animal were processed to block for electron microscopy and shipped to the Sponsor's designee for ultrastructural evaluation. Samples of liver from each animal were frozen and shipped to the Sponsor for PFOS determination. The gallbladders and bile from each animal were collected, frozen, and shipped to the Sponsor. Samples of pancreas, left and right testes, and the left lateral lobe of the liver were preserved for cell proliferation evaluation by the Sponsor's designee using proliferation cell nuclear antigen. Light microscopic examinations were done on collected tissues from control animals and animals given 0.75 mg/kg/day. In addition, liver and thymus from all animals given 0.03 or 0.15 mg/kg/day and spinal cord gray matter from females given 0.03 or 0.15 mg/kg/day were examined by light microscopy.

During Week 57, liver biopsies were performed on the recovery animals that had been given 0.75 mg/kg/day. The tissue was divided into four samples. Three of the samples were used for light microscopic examination, ultrastructural examination by the Sponsor's designee, and PFOS analysis by the Sponsor, respectively. The fourth sample was frozen and shipped to the Sponsor for possible analysis. At the end of the recovery period (Week 79), the control animals were returned to the Covance stock colony, the animals that had been given 0.15 mg/kg/day were transferred to a subsequent study for the Sponsor (Covance 6329-268) following liver biopsy for PFOS analysis by the Sponsor, and the animals that had been given 0.75 mg/kg/day were sacrificed and necropsied. At this recovery necropsy, macroscopic observations were recorded, and three samples of liver were collected for light microscopic examination, ultrastructural examination by the Sponsor's designee, and PFOS analysis by the Sponsor, respectively.

3M_MN03278872

1818.0039

Statistically significant differences cited in the Results and Discussion are based on comparisons between the control and treated groups.

RESULTS AND DISCUSSION

Mortality

Two of four males receiving 0.75 mg/kg/day (high dose) of the test material did not survive to the scheduled terminal sacrifice at Week 27. One was found dead on Day 155. The other was sacrificed on Day 179 due to poor health. The cause of death in the animal found dead was judged to be pulmonary necrosis with severe acute inflammation. Microscopically, the pulmonary lesion appeared to be an acute exacerbation of a chronic lesion. The cause of death in the moribund animal was not determined. All other animals survived to their scheduled sacrifices.

Clinical Pathology

Week -4. Results of clinical pathology tests indicated no obvious group or individual health abnormalities. Several animals, however, had mildly elevated alanine aminotransferase activities at Week -4. These animals were primarily females and were dispersed among all of the groups. By Day 37, their alanine aminotransferase activities were no longer elevated. The transient increase in this liver enzyme was considered likely due to subclinical infection with Hepatitis A virus, a common infection in cynomolgus monkeys, and did not negatively impact evaluation of the test material.

Days 37, 62, 91, 153, and 182. Although there were several statistically significant or otherwise notable differences for clinical pathology test results between the control and treated animals, most of the differences were inconsistent over time or similar to differences present before initiation of treatment (i.e., Week -4). The only differences considered to represent effects of the test material were lower total cholesterol for males and females given 0.75 mg/kg/day and lower high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. The effect on total cholesterol became progressively worse over time. At Day 182, the mean total cholesterol concentrations for the males and females given 0.75 mg/kg/day were approximately 68% and 49% lower, respectively, than those for the control males and females. The effect on high density lipoprotein cholesterol, measured only at Days 153 and 182, was proportionately greater than that for total cholesterol. At Day 182, the mean high density lipoprotein cholesterol

3M_MN03278873

1818.0040

concentrations for the males and females given 0.75 mg/kg/day were approximately 79% and 62% lower, respectively, than those for the control males and females.

Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day (statistically lower on Days 91, 153, and 182) and higher serum bile acid concentration for males given 0.75 mg/kg/day (statistically higher on Day 182 only). These potential effects of the test material were very mild, and neither was considered adverse.

Statistically significant differences for other test results were considered incidental and unrelated to administration of the test material. These differences were inconsistent over time or were similar to differences that existed before the initiation of treatment.

Unscheduled sacrifice Animal No. I05506, a male given 0.75 mg/kg/day, was sacrificed on Day 179. The most notable findings for this animal were a moderate neutrophilic leukocytosis, mildly increased serum bile acid and globulin concentrations, and moderately to markedly decreased total cholesterol and high density lipoprotein cholesterol.

Days 217, 245, 274, 322, 364, 456, and 546 (Recovery animals). The effect on cholesterol was reversed by Day 217, and the effect on high density lipoprotein cholesterol was reversed by Day 245. There were no other findings considered to represent persistent or delayed occurrence of toxic effects.

Anatomic Pathology

Organ Weights. At the terminal sacrifice (Week 27) females in the group receiving 0.75 mg/kg/day (high-dose) had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. This increase was regarded as test material-related. In females the absolute pancreas weights were higher in animals receiving 0.03 mg/kg/day (low-dose) than in those receiving 0 mg/kg/day (control). Increased pancreatic weights were not regarded as test material-related.

In males, liver-to-body weight percentages were increased in the high-dose group compared to controls. The increase was regarded as test material-related. Left adrenal-to-body weight percentages were also increased in high dose males compared to controls. The significance of the increase left adrenal weight percentage was not known.

3M_MN03278874

1818.0041

Organ weights were not taken at the recovery sacrifice at Week 79.

Macroscopic Observations. Twenty one of 30 animals at the terminal sacrifice had at least one macroscopic observation. One of the observations was obesity; it was not regarded as pathologic. Thus, 20 animals had macroscopic observations. Of all the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" liver was observed in the two high-dose males and in one high-dose female.

The other observations included adhesions and dark or red foci in any of several organs. Among high-dose females, each had at least one observation of a dark or red focus. In addition, adrenal cortices of the two high-dose males and two of four high dose females were recorded as dark. In one high-dose female (Animal No. I05540), the red focus in the lung correlated microscopically with hemorrhage. There were no microscopic correlates for the other observations. Hence, dark or red foci were considered too non-specific to be considered test material-related. Additionally, dark and red foci were observed in animals in other dose groups. Dark adrenal cortices did not have a microscopic correlate; they, too, were not considered test material-related.

Of the two males not surviving until the scheduled terminal sacrifice, one did not have any macroscopic observations. The other (Animal No. I05509) had several observations. Of these observations, those in the liver were considered test material-related. The liver observations were "mottled" and "large".

For the recovery sacrifice at Week 79, only high dose animals were necropsied. One of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related.

Microscopic Observations. At the terminal sacrifice, all tissues from the control and high dose groups were examined. All tissues were examined on the two high-dose males not surviving until the terminal sacrifice; the microscopic data were grouped with that of the terminal sacrifice animals. Liver, thymus, and spinal cord (females only) were examined from animals in the low and intermediate dose groups. In four of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobullary or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was observed in four of four high-dose females. The microscopic observations of

3M_MN03278875

hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent. Multifocal hepatic vacuoles were found in one of four low dose males, and in a control and a low-dose female.

Two other observations were suggestive of possible test material effects upon examination of only control and high-dose animals. When tissues were examined from the low and intermediate dose groups as well, test material-dependency was not supported. In females, thymic atrophy was more pronounced in dosed animals than in controls. However, there is no clear dose-dependent pattern and thus, thymic atrophy cannot be considered test material-dependent. Intraneuronal pigment was observed in the spinal cord gray matter of two of four high dose, four of four mid-dose, three of four low-dose and one of four control females. And thus, spinal cord pigment was considered unrelated to the test material.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material related findings.

At the recovery sacrifice, livers were examined from high-dose animals. No test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

In those animals from which all tissues were examined, the width of the femoral growth plates were assessed as a general indication of the maturity of the animals. Based on this indicator, males were less mature than females.

3M_MN03278876

1818.0043

Robert L. Hall
Robert L. Hall, DVM, PhD
Diplomate, ACVP
(Clinical Pathology)

21 December 2001
Date

Robert A. Leedle
Robert A. Leedle, DVM, PhD
Diplomate, ACVP

21 December 2001
Date

3M_MN03278877

1818.0044

COMMENTS ON THE DATA

Various models of calculators, computers, and computer programs were used to analyze data in this study. Because different models round off or truncate numbers differently, values in some tables (e.g., means, standard deviations, or individual values) may differ slightly from those in other tables, from individually calculated data, or from statistical analysis data. Neither the integrity nor the interpretation of the data was affected by these differences.

Some tabular data were compiled using Excel® Version 7.0 software.

The units for the dose levels on the data collection system (PTS) summary tables are mg/kg/day.

The number of animals listed in the heading of the summary table for clinical observations reflects the number of animals assigned to each group at the start of the study.

The summary table for clinical observations indicates the number of animals for which a condition was observed without regard to the specific nature, severity, reversibility, number of incidences/animal, or the length of time the condition persisted.

Only observations other than normal are indicated on the summary of clinical observations table.

The specific details for comments in the individual clinical observations tables that are indicated with a "C" can be found at the end of each group for each sex.

The day of initiation of treatment is "Day 1, Week 1." Body weight data are entered at the start of a study week (e.g., a body weight recorded on Day 1 is considered a Week 1 body weight, a body weight recorded on Day 8 is considered a Week 2 body weight).

Differences in the population size (N) on the summary tables for clinical and anatomic pathology are explained on the individual data tables.

Results of clinical pathology samples collected for animals sacrificed at an unscheduled interval appear on the individual clinical pathology tables for the next scheduled interval. These results are not on the summary tables and are not included in the statistical analyses.

Statistical analyses were not done when there were two or fewer values for a parameter.

3M_MN03278878

1818.0045

COMMENTS ON THE DATA (continued)

Bile volume is located on the individual anatomic pathology table under the heading of "absolute organ weight (grams)". The value listed for bile is not a weight and is designated with a unit of mL.

Some clinical observations discussed in the report were documented on the Request for Veterinary Services form and will be archived with the raw data, but they do not appear on the individual clinical observations tables.

3M_MN03278879

1818.0046

CODES, ABBREVIATIONS, AND UNITS

General Codes and Abbreviations
Codes for Clinical Pathology
Abbreviations and Units for Clinical Hematology
Abbreviations and Units for Clinical Chemistry
Abbreviations and Units for Clinical Urinalysis
Codes for Anatomic Pathology

Note: The following lists of codes, abbreviations, and units are used by Covance. Some, but not necessarily all, of this information may be needed for this report.

3M_MN03278880

1818.0047

General Codes and Abbreviations

WK	Week
N	Number of measurements in a group
Mean; MEAN	Arithmetic mean
CAM	Covariate-adjusted mean
SD; S.D.; STAND DEV; STANDARD DEV; sd	Standard deviation
*	Group mean is significantly different from the mean of the control group (Group 1) at $p \leq 0.05$
-; NA	No value; not applicable; not present
P	Present
C	Comment found at the end of each group for each sex
UNSCHED	Unscheduled
DISPATCH	Observations transferred from the in-life module of the data collection system to the necropsy module for reference during necropsy. Observations are duplicates of the last in-life observations.
TBW	Terminal body weight
#	Number
VET EXAM	Veterinary examination
AM OBS	Observations recorded during the daily, morning observation interval.
30-90 OB	Observations recorded during the 30 to 90 minute postdose observation interval.
E2	Estradiol
FSH	Follicle stimulating hormone
LH	Lutenizing hormone
T3	Triiodothyronine
T4	Total thyroxin
FREE T4	Free thyroxin
TSH	Thyroid stimulating hormone

3M_MN03278881

1818.0048

Codes for Clinical Pathology

GENERAL CODES

NS	No sample
QS/QNS	Quantity not sufficient
NR	No repeat (sample volume not sufficient for repeat analysis)
FS	Fibrin strands
SC	Sample clotted
SH	Slightly hemolyzed
H	Hemolyzed
SL	Slightly lipemic
L	Lipemic
SI	Slightly icteric
I	Icteric
NF	Animal not fasted
U	Unscheduled/moribund bleed
DT/DOT	Animal died on test
DB	Died during bleeding
TJ	Technician judgment to repeat test
TE	Technical error (instrument or technician error that results in unacceptable data, e.g., unacceptable instrument output, sample spilled, entry of invalid data)
RE	Recording error (recorded incorrect data, e.g., wrong number, spelling error, incorrect date)
EE	Entry error (incorrect keyboard entry)
SE	Sampling error
PC	Platelets clumped
PD	Platelets decreased
PI	Platelets increased
PL	Platelets large
PA	Platelets appear adequate
CO	Color interferes with test
HB	Heinz bodies observed
PLASMO	Plasmodium
NO AGG	No aggregation
FR	Fractious
UTD	Unable to determine
NO COAG	No coagulation

3M_MN03278882

1818.0049

Codes for Clinical Pathology (Continued)

RESULTS NOT INCLUDED IN STATISTICAL ANALYSES

Hemolyzed clinical chemistry or coagulation samples
Samples from animals at unscheduled intervals
Prothrombin times (PT) greater than 50 seconds
Activated partial thromboplastin times (PTT) greater than 110 seconds
Bleed times (BLETIME) greater than 30 minutes

CODES FOR BLOOD CELL MORPHOLOGY

The following scale was used to measure the degree of anisocytosis (ANISO), poikilocytosis (POIK), polychromasia (POLY), hypochromasia (HYPO), and toxic neutrophils (TOXNEUT):

Scale	Degree	Presence
-	Normal for the species	Not present
1	Slight	Rare
2	Moderate	Few
3	Marked	Moderate
4	Not applicable	Many

URINE APPEARANCE

Color			Clarity	Miscellaneous
A Pale	E Amber	I Black	J Clear	M Debris
B Straw	F Brown	P Blue/green	K Hazy	O Feces
C Yellow	G Red	Q Blue	L Cloudy	
D Dark yellow	H Green	R Orange		

3M_MN03278883

1818.0050

Codes for Clinical Pathology (Continued)

URINE CHEMISTRY MULTISTIX® STRIP

Urine Glucose		Urine Ketone		Urine Blood	
-	Negative	-	Negative	-	Negative
+	100 mg/dL	+	5 mg/dL	+	Small
++	250 mg/dL	++	15 mg/dL	++	Moderate
+++	500 mg/dL	+++	40 mg/dL	+++	Large
++++	1,000 mg/dL	++++	80 mg/dL		
+++++	≥2,000 mg/dL	+++++	160 mg/dL		

Urine Urobilinogen		Urine Bilirubin	
-	0.2 mg/dL	-	Negative
+	1 mg/dL	+	Small
++	2 mg/dL	++	Moderate
+++	4 mg/dL	+++	Large
++++	8 mg/dL		

(1 mg = approximately 1 Ehrlich unit)

URINE SEDIMENT

Cells, Crystals, Casts, and Comments				Bacteria	
A	Amorphous urates	Q	Sperm	0	Not present
B	Amorphous phosphates	R	Fecal contamination	1	Few
C	Uric acid	S	Pinworm ova found	2	Moderate
D	Triple phosphates	T	Pinworm larvae found	3	Many
E	Calcium oxalate	U	Parasite ova found		
F	Calcium carbonate				
G	Granular casts	0	Not present		
H	Hyaline casts	1	1-5 per field		
I	Cellular casts	2	6-10 per field		
J	Waxy casts	3	11-20 per field		
K	Unknown crystal	4	>20 per field		
P	Mucous threads				

3M_MN03278884

Abbreviations and Units for Clinical Hematology

Test	Abbreviation (Units)
Red blood cell count	RBC (E6/UL or $X10^6$/mcL)
Hemoglobin	HGB (G/DL)
Hematocrit	HCT (%)
Mean corpuscular volume	MCV (FL)
Mean corpuscular hemoglobin	MCH (PG)
Mean corpuscular hemoglobin concentration	MCHC (%)
Platelet count	PLT (E3/UL or $X10^3$/mcL)
Mean platelet volume	MPV (FL)
Reticulocyte count	RETIC (%)
Absolute reticulocyte count	RETIC (E3/UL or $X10^3$/mcL)
Heinz body count	HEINZ (%)
Erythrocyte sedimentation rate	ESR (MM/HR)
Prothrombin time	PT (SEC)
Activated partial thromboplastin time	PTT (SEC)
Thrombin time	TT (SEC)
Activated coagulation time	ACT (SEC)
Fibrinogen	FBR (MG/DL)
Fibrin/fibrinogen degradation products	FDP (UG/ML)
Platelet aggregation	
Collagen	PAGG/COL (%)
Adenosine diphosphate	PAGG/ADP (%)
Alpha 2-antiplasmin	ANTIPLAS (%)
Bleeding time	BLE TIME (SEC)
Methemoglobin	METHGB (%)
Plasma hemoglobin	PLA HGB (MG/DL)
Myeloid/erythroid ratio	M/E RATIO
Estimated myeloid/erythroid ratio	EST M/E RATIO
White blood cell count	WBC (E3/UL or $X10^3$/mcL)
Differential blood cell count	
Nucleated red blood cell count	NRBC (/100 WBC)
Corrected white blood cell count	COR WBC (E3/UL or $X10^3$/mcL)
Segmented neutrophil count	N-SEG (E3/UL or $X10^3$/mcL) and %
Band neutrophil count	N-BAND (E3/UL or $X10^3$/mcL) and %
Lymphocyte count	LYMPH (E3/UL or $X10^3$/mcL) and %
Monocyte count	MONO (E3/UL or $X10^3$/mcL) and %
Eosinophil count	EOSIN (E3/UL or $X10^3$/mcL) and %
Basophil count	BASO (E3/UL or $X10^3$/mcL) and %
Anisocytosis	ANISO (-,1,2,3)
Polychromasia	POLY (-,1,2,3)
Poikilocytosis	POIK (-,1,2,3)

3M_MN03278885

1818.0052

Abbreviations and Units for Clinical Hematology (Continued)

Test	Abbreviation (Units)
Hypochromasia	HYPO (-,1,2,3)
Howell-Jolly bodies	HJBODY (-,1,2,3,4)
Basophilic stippling	BASTIP (-,1,2,3)
Toxic neutrophils	TOXNEUT (-,1,2,3,4)
Atypical lymphocytes	ATYPLYM (-,1,2,3,4)
Aqueous white blood cell count (right eye)	R EYE (WBC/UL)
Aqueous white blood cell count (left eye)	L EYE (WBC/UL)

3M_MN03278886

1818.0053

Abbreviations and Units for Clinical Chemistry

Test	Abbreviation (Units)
Glucose	GLU (MG/DL)
Urea nitrogen	UN (MG/DL)
Urea	UREA (MG/DL)
Creatinine	CREAT (MG/DL)
Total protein	T PRO (G/DL)
Albumin	ALB (G/DL)
Globulin	GLOB (G/DL)
Albumin/globulin ratio	A/G RATIO
Total bilirubin	T BILI (MG/DL)
Direct bilirubin	D BILI (MG/DL)
Indirect bilirubin	I BILI (MG/DL)
Cholesterol	CHOL (MG/DL)
Triglyceride	TRIG (MG/DL)
Urea nitrogen/creatinine ratio	UN/CREAT (RATIO)
Total lipids	T LIPIDS (MG/DL)
Phospholipids	P LIPIDS (MG/DL)
High-density lipoprotein cholesterol	HDL (MG/DL)
Low-density lipoprotein cholesterol	LDL (MG/DL)
Uric acid	UA (MG/DL)
Aspartate aminotransferase	AST/SGOT (IU/L)
Alanine aminotransferase	ALT/SGPT (IU/L)
Alkaline phosphatase	ALK PHOS (IU/L)
Gamma glutamyl transferase	GGT (IU/L)
Sorbitol dehydrogenase	SDH (IU/L)
Lactate dehydrogenase	LDH (IU/L)
Creatine kinase	CK (IU/L)
Amylase	AMYLASE (IU/L)
Lipase	LIPASE (IU/L)
Palmitoyl CoA oxidase	PCOAO (IU/G)
Calcium	CA (MG/DL)
Ionized calcium	ION CA (MG/DL)
Inorganic phosphorus	I PHOS (MG/DL)
Sodium	NA (MMOL/L)
Potassium	K (MMOL/L)
Chloride	CL (MMOL/L)
Magnesium	MG (MEQ/L or MG/DL)
Zinc	ZN (MG/L or PPM)
Strontium	SR (MG/L or PPM)
Iron	FE (UG/DL)

3M_MN03278887

1818.0054

Abbreviations and Units for Clinical Chemistry (Continued)

Test	Abbreviation (Units)
Excess iron	EX FE (UG/DL)
Total iron binding capacity	TIBC (UG/DL)
Unbound iron binding capacity	UIBC (UG/DL)
Percent iron saturation	FE %SAT (%)
Plasma cholinesterase	CHEP (MU/ML)
Red blood cell cholinesterase	CHER (MU/ML)
Brain cholinesterase	CHEB (MU/ML)
Caudate putamen	CAUD PUT (UMOL/G)
Hippocampus	HIPPOCAM (UMOL/G)
Frontal cortex	F CORTEX (UMOL/G)
Cerebellum	CEREBELL (UMOL/G)
Bicarbonate	BICARB (MMOL/L)
Serum hemoglobin	SER HGB (MG/DL)
Serum bile acids	SBA (UMOL/L or MG/DL)
Fecal bile acids	FBA (UG/ML)
Average fecal weight	FCC WGT (G)
Fecal bile acids (calculation)	FBA (MG/Day)
Osmolality	OSMO (MOSM/KG)
Electrophoresis	
Albumin	E ALB (G/DL)
Alpha-1-globulin	E A-1 (G/DL)
Alpha-2-globulin	E A-2 (G/DL)
Beta globulin	E BETA (G/DL)
Gamma globulin	E GAMMA (G/DL)
High-density lipoprotein	E-HDL (%)
Low-density lipoprotein	E-LDL (%)
Very-low-density lipoprotein	E-VLDL (%)
Insulin	INSULIN (UU/ML)
Adrenocorticotropic hormone	ACTH (PG/ML)
Cortisol	CORTISOL (UG/ML)
Glucagon	GLUCAGON (PG/ML)
Triiodothyronine	T3 (NG/DL)
Thyroxine	T4 (UG/DL)
Creatine kinase isoenzymes	
BB	CK-BB (U/L)
MB	CK-MB (U/L)
MM	CK-MM (U/L)

3M_MN03278888

1818.0055

Abbreviations and Units for Clinical Urinalysis

Test	Abbreviation (Units)
Urine volume	U VOL (ML)
8 hour urine volume	8 HR VOL (ML)
Specific gravity	SP GR
Urine osmolality	U OSMO (MOSM/KG)
Quantitative urinary/cerebrospinal fluid protein	QUAN PRO (MG/DL)
Urine protein excretion	PRO EXC (MG)
Urine chemistry Multistix® strip	
Urine pH	U PH
Urine protein	U PRO (MG/DL)
Urine glucose	U GLU
Urine ketones	U KET
Urine bilirubin	U BILI
Urine blood	U BLOOD
Urine urobilinogen	UROBILI
Urine reducing substances	U RE SUB
Microscopic examination of urine sediment	
Red blood cells per high-power field	RBC (PER HPF)
White blood cells per high-power field	WBC (PER HPF)
Epithelial cells per high-power field	EPITH (PER HPF)
Bacteria per high-power field	BACT (PER HPF)
Casts per low-power field	CASTS (PER LPF)
Crystals per low-power field	CRYSTALS (PER LPF1 or PER LPF2)
Urine appearance	URINE APP1 or URINE APP2
Comments	COMMENTS

Miscellaneous Codes and Abbreviations for Clinical Pathology

Fecal occult blood	Not applicable
Fecal parasite detection	Not applicable
Hemolytic potential	Not applicable

3M_MN03278889

1818.0056

Codes for Anatomic Pathology

Code	Definition
	ANIMAL DEATH CODES
T	Terminal sacrifice
U	Recovery sacrifice
D	Found dead
M	Moribund
P/O	Transferred to Covance stock
6	Transferred to Covance 6329-268
	MACROSCOPIC CODES
EX	Indicates that organ weight is excluded from calculations
NOT TAKEN	Organ weight not taken; explanation given in necropsy notes
MISSING	Organ missing or lost
UNSUITABLE	Organ technically unsuitable for weighing
AUTOLYTIC	Organ autolyzed and could not be weighed
EXCLUDE	Weight was taken, but was excluded from all calculations
	MICROSCOPIC CODES
Codes Prefacing Neoplastic Findings	
B-	Primary, benign neoplasm
M-	Primary, malignant neoplasm
N-	Metastatic neoplasm
I-	Locally invasive neoplasm
X-	Other neoplasm
Distribution of Findings	
Focal	
Diffuse	
Multifocal	

3M_MN03278890

1818.0057

Codes for Anatomic Pathology (Continued)

Code	Definition
Grades for Severity or Amount	
1	Minimal - the least amount of change that can be observed with the light microscope
2	Slight - less than average amount of change, but readily discernible as abnormal
3	Moderate - the average amount of change that is expected for a lesion
4	Moderately severe (marked) - a marked amount of change with possible loss of function of the affected cells or organs
5	Severe - a great amount of change with probable loss of function of the affected cell or organs and frequently involves large areas of the organ
Other Microscopic Codes	
TL	Total
P	Finding present
-	Finding not present

TISSUE ABBREVIATIONS

Abbreviation	Definition
LF	Left
RT	Right
LN	Lymph node
GL	Gland
STOMACH, GL	Glandular stomach
STOMACH, NONGL	Nonglandular
SALIV GL, MANDIB	Mandibular salivary gland
LN, ANT MES/PANC	Anterior mesenteric/pancreatic lymph node
AUDITORY SEB GL	Auditory sebaceous gland
LACRIMAL GLAND, EX	Exorbital lacrimal gland
HEMATO NEOPLASIA	Hematopoietic neoplasia
LACRIMAL GL, INT	Internal lacrimal gland
CAVITY, ABDOM	Abdominal cavity
SALIV GL,PAROTID	Parotid salivary gland
LN, TRACHEOBRON	Tracheobronchial lymph node
THYROID/PARA	Thyroid with parathyroid

3M_MN03278891

1818.0058

Figure 1

Mean Body Weight Data (kg) - Males

Covance 6329-223
3M T-6295.7



3M_MN03278892

Figure 2

Mean Body Weight Data (kg) - Females

Covance 6329-223
3M T-6295.7



3M_MN03278893

Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185

NUMBER OF ANIMALS AFFECTED

SEX:	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
CATEGORY DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD / QUALIFIER NUMBER:	6	4	6	6	6	4	6	6
*** TOP OF LIST ***								
APPEARANCE								
APPEARS DEHYDRATED	0	0	0	1	1	0	0	0
RECUMBENT	0	0	0	1	0	0	0	0
BEHAVIOR								
ATAXIC	0	0	0	1	0	0	0	0
HYPOACTIVE	0	0	0	2	1	0	0	0
DISCHARGE								
NASAL								
CLEAR	0	0	0	0	1	0	0	0
ORAL								
CLOUDY	0	0	0	0	1	0	0	0
VOMITUS								
WHITE IN COLOR	0	0	0	0	0	1	0	0
CONTAINING FOOD	1	1	3	1	2	0	2	1
INTACT CAPSULE	0	0	0	0	1	0	0	2
PARTIAL CAPSULE	0	1	0	3	3	0	0	3
EXCESSIVE SALIVATION	0	0	0	1	1	0	0	0
APPEARS TO BE MENSTRUATING	0	0	0	0	4	4	2	4
DISCHARGE UNKNOWN SOURCE								
FOUND IN PAN								
RED IN COLOR	1	0	0	0	1	0	0	0

3M_MN03278894

Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185

NUMBER OF ANIMALS AFFECTED

SEX:	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
CATEGORY / DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD / QUALIFIER / NUMBER:	6	4	6	6	6	4	6	6
EXCRETION								
DISCOLORED FECES								
BLACK IN COLOR	0	0	0	1	0	0	0	0
RED IN COLOR	0	0	0	0	1	0	0	3
YELLOW IN COLOR	0	0	0	0	0	0	0	1
DISCOLORED URINE								
GREEN IN COLOR	0	0	0	0	0	0	0	1
RED IN COLOR	0	0	1	0	0	0	0	0
FEW FECES	0	0	0	2	0	2	3	5
LIQUID FECES	1	1	0	1	2	0	0	2
MUCOID FECES	0	0	0	2	1	0	0	2
NO FECES	0	0	0	2	0	1	1	1
NON-FORMED FECES	3	2	1	1	2	1	0	2
SMALL FECES	0	0	0	0	0	0	0	1
EYES								
CONSTRICTED PUPIL								
EYES	0	0	0	1	0	0	0	0
RESPIRATION								
LABORED	0	0	0	2	0	0	0	0
SKIN & PELAGE								
ALOPECIA								
DORSAL	0	0	0	0	0	0	0	1
DORSAL-THORACIC	0	0	0	0	0	0	0	1

3M_MN03278895

Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185

NUMBER OF ANIMALS AFFECTED

SEX:	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
CATEGORY / DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD / QUALIFIER / NUMBER:	6	4	6	6	6	4	6	6
SKIN & PELAGE								
ALOPECIA								
DORSAL-THORACIC-LEFT	0	0	0	0	0	0	0	1
FEET	0	0	0	0	1	0	0	0
HEAD-ENTIRE	0	0	0	0	0	0	0	1
HEAD-CRANIAL	0	0	0	0	0	0	0	1
HEAD-MAXILLARY-LEFT	0	0	0	0	0	0	0	1
HEAD-MAXILLARY-RIGHT	0	0	0	0	0	0	0	1
LIMB-HIND-LEFT	0	0	0	0	0	0	0	1
LIMBS-ALL	0	0	0	0	0	0	0	2
LIMBS-FRONT	0	0	0	0	0	0	0	1
LIMBS-HIND	0	0	0	0	1	0	0	0
TAIL	0	0	0	0	1	0	0	1
BROKEN SKIN								
HAND-LEFT	1	0	0	0	0	0	0	0
DIGIT(S)-FRONT-LEFT	0	0	0	1	0	0	0	0
HEAD-CRANIAL	0	0	0	0	1	0	1	0
HEAD-MAXILLARY-LEFT	0	0	0	0	0	1	0	0
HEAD-MAXILLARY-RIGHT	0	0	0	0	0	1	0	0
MOUTH	0	0	0	0	1	0	0	0
PERI-ORBITAL-LEFT	0	0	0	0	1	1	0	1
PERI-ORBITAL-RIGHT	0	1	0	0	0	2	1	0
TAIL	1	0	1	0	0	0	0	0
TAIL-DISTAL	1	0	0	0	0	0	0	0
COLD TO TOUCH								
BODY-ENTIRE	0	0	0	1	0	0	0	0

3M_MN03278896

Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185

		NUMBER OF ANIMALS AFFECTED							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	1	2	3	4	1	2	3	4
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD									
QUALIFIER	NUMBER:	6	4	6	6	6	4	6	6
SKIN & PELAGE									
PALE SKIN									
HEAD-ENTIRE		0	0	0	0	0	0	0	1
GUMS		0	0	0	1	0	0	0	0
RED SKIN									
LIMB-FRONT-RIGHT		0	0	0	0	1	0	0	0
SCAB(S)									
HEAD-MAXILLARY-LEFT		0	0	0	0	0	1	0	0
LIMB-FRONT-LEFT		0	0	0	0	1	0	0	0
LIMB-FRONT-RIGHT		0	0	0	0	1	0	0	0
BRUISED SKIN									
PERI-ORBITAL-LEFT		0	0	0	0	0	0	0	1
QUALITATIVE FOOD CONSUMPTION									
LOW		3	3	6	6	5	3	6	6

*** END OF LIST ***

3M_MN03278897

Table 2

Summary of Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 186-365

NUMBER OF ANIMALS AFFECTED

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD									
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
*** TOP OF LIST ***									
DISCHARGE									
APPEARS TO BE MENSTRUATING		0	0	0	0	1	0	1	1
EXCRETION									
FEW FECES		0	0	0	0	0	0	1	0
LIQUID FECES		0	0	0	0	1	0	0	0
NON-FORMED FECES		0	0	1	0	0	0	0	1
SKIN & PELAGE									
ALOPECIA									
FEET		0	0	0	0	1	0	0	0
TAIL		0	0	0	0	1	0	0	0
BROKEN SKIN									
DIGIT(S)-FRONT-LEFT		1	0	0	0	0	0	0	0
QUALITATIVE FOOD CONSUMPTION									
LOW		1	0	2	1	2	0	2	2
*** END OF LIST ***									

3M_MN03278898

Table 3

Summary of Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 368-558

NUMBER OF ANIMALS AFFECTED

SEX:	MALE				FEMALE			
GROUP:	1	2	3	4	1	2	3	4
CATEGORY DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD / QUALIFIER NUMBER:	2	0	2	2	2	0	2	2
*** TOP OF LIST ***								
APPEARANCE								
SWOLLEN								
HEAD-MAXILLARY-RIGHT	0	0	1	0	0	0	0	0
DISCHARGE								
VOMITUS								
CONTAINING FOOD	1	0	2	0	1	0	1	0
APPEARS TO BE MENSTRUATING	0	0	0	0	1	0	0	1
DISCHARGE UNKNOWN SOURCE								
FOUND IN PAN								
RED IN COLOR	0	0	0	0	0	0	1	1
EXCRETION								
FEW FECES	0	0	1	0	0	0	2	0
LIQUID FECES	0	0	0	0	1	0	0	1
NO FECES	0	0	1	0	0	0	2	0
NON-FORMED FECES	1	0	1	1	1	0	0	1
SKIN & PELAGE								
ALOPECIA								
LIMB-HIND-RIGHT	0	0	0	0	1	0	0	0

3M_MN03278899

Table 3

Summary of Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 368-558

NUMBER OF ANIMALS AFFECTED

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD									
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
QUALITATIVE FOOD CONSUMPTION									
LOW		1	0	2	1	2	0	2	2
NONE		0	0	0	0	0	0	2	0

*** END OF LIST ***

3M_MN03278900

Table 4

Summary of Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

NUMBER OF ANIMALS AFFECTED

WEEK -4									
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	1	2	3	4	1	2	3	4
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD									
QUALIFIER	NUMBER:	6	4	6	6	6	4	6	6
*** TOP OF LIST ***									
NO VISIBLE LESIONS									
NO VISIBLE LESIONS									
EYE-LEFT		0	0	0	0	1	0	0	0
EYES		6	4	6	6	5	4	6	6
MISCELLANEOUS OPHTHALMICS									
INCREASED MYELINATION OF OPTIC NERVE									
EYE-RIGHT		0	0	0	0	1	0	0	0
*** END OF LIST ***									

3M_MN03278901

Table 4

Summary of Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

NUMBER OF ANIMALS AFFECTED

WEEK 26								
SEX:	-------MALE-------				------FEMALE------			
GROUP:	1	2	3	4	1	2	3	4
CATEGORY / DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD / QUALIFIER / NUMBER:	6	4	6	5	6	4	6	6
*** TOP OF LIST ***								
NO VISIBLE LESIONS								
NO VISIBLE LESIONS								
EYES	6	4	6	5	6	4	6	6
*** END OF LIST ***								

3M_MN03278902

Table 5

Summary of Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

NUMBER OF ANIMALS AFFECTED

WEEK 52

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
CATEGORY	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
KEYWORD									
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2
*** TOP OF LIST ***									
NO VISIBLE LESIONS									
NO VISIBLE LESIONS									
EYES		2	0	2	2	1	0	2	2
EYE-LEFT		0	0	0	0	1	0	0	0
MISCELLANEOUS OPHTHALMICS									
INCREASED MYELINATION OF OPTIC NERVE									
EYE-RIGHT		0	0	0	0	1	0	0	0
*** END OF LIST ***									

3M_MN03278903

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
-1[a]	N	6	4	6	6	6	4	6	6
	MEAN	3.2	3.4	3.0	3.3	2.8	3.0	3.0	2.9
	S.D.	0.43	0.73	0.33	0.59	0.33	0.55	0.38	0.54
-1[b]	N	6	4	6	6	6	4	6	6
	MEAN	3.3	3.4	3.1	3.4	2.8	3.0	3.0	2.9
	S.D.	0.45	0.65	0.34	0.55	0.29	0.55	0.41	0.52
1	N	6	4	6	6	6	4	6	6
	MEAN	3.3	3.4	3.1	3.4	2.8	3.1	3.0	2.9
	S.D.	0.45	0.70	0.35	0.55	0.29	0.60	0.41	0.52
2	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.2	3.3	3.2	2.9	3.0	3.0	2.9
	MEAN	3.3	3.4	3.1	3.4	2.8	3.1	3.0	2.9
	S.D.	0.44	0.64	0.34	0.62	0.26	0.59	0.43	0.49
3	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.3	3.3	3.3	2.9	3.0	2.9	2.9
	MEAN	3.3	3.4	3.2	3.4	2.8	3.1	3.0	2.9
	S.D.	0.41	0.68	0.32	0.59	0.38	0.59	0.43	0.49
4	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	3.0	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.9	3.1	3.0	2.9
	S.D.	0.38	0.64	0.34	0.58	0.34	0.65	0.43	0.52
5	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	2.9	2.9	2.9	2.8
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.8
	S.D.	0.39	0.64	0.34	0.60	0.35	0.60	0.44	0.55

a Day -7.
b Day -1.

3M_MN03278904

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
6	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	2.9	3.0	2.9	2.8
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.8
	S.D.	0.41	0.63	0.34	0.60	0.36	0.57	0.48	0.55
7	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	3.0	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.9
	S.D.	0.42	0.64	0.33	0.63	0.38	0.61	0.47	0.48
8	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.3	3.4	2.9	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.9
	S.D.	0.39	0.64	0.30	0.65	0.39	0.61	0.47	0.50
9	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.4	3.4	3.5	3.0	3.0	3.0	2.9
	MEAN	3.4	3.6	3.2	3.5	2.9	3.2	3.0	2.9
	S.D.	0.43	0.60	0.29	0.65	0.40	0.66	0.46	0.55
10	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.4	3.3	3.4	3.0	3.0	3.0	2.9
	MEAN	3.4	3.6	3.2	3.5	2.9	3.1	3.0	2.9
	S.D.	0.43	0.60	0.33	0.65	0.36	0.62	0.44	0.55
11	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.5	3.4	3.5	3.0	3.0	3.0	2.8*
	MEAN	3.4	3.7	3.2	3.6	2.9	3.1	3.0	2.8
	S.D.	0.46	0.68	0.33	0.66	0.35	0.60	0.46	0.51
12	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.5	3.4	3.4	3.1	3.0	3.0	2.9*
	MEAN	3.4	3.7	3.2	3.5	3.0	3.2	3.0	2.9
	S.D.	0.47	0.68	0.29	0.65	0.37	0.59	0.48	0.50

3M_MN03278905

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
13	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.5	3.1	3.1	3.0	2.8*
	MEAN	3.5	3.7	3.3	3.6	3.0	3.2	3.1	2.8
	S.D.	0.46	0.65	0.27	0.66	0.36	0.62	0.47	0.46
14	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.5	3.4	3.4	3.0	3.1	3.0	2.8*
	MEAN	3.5	3.7	3.2	3.5	2.9	3.2	3.1	2.8
	S.D.	0.44	0.57	0.31	0.67	0.37	0.62	0.48	0.44
15	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.4	3.0	3.1	3.1	2.8*
	MEAN	3.5	3.7	3.3	3.5	2.9	3.2	3.1	2.8
	S.D.	0.46	0.61	0.30	0.68	0.38	0.63	0.49	0.38
16	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.6	3.4	3.3	3.0	3.1	3.0	2.8*
	MEAN	3.4	3.8	3.3	3.4	2.9	3.2	3.1	2.8
	S.D.	0.48	0.60	0.27	0.71	0.34	0.63	0.45	0.38
17	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.7	3.4	3.4	3.1	3.1	3.1	2.9
	MEAN	3.5	3.8	3.3	3.5	3.0	3.2	3.1	2.9
	S.D.	0.49	0.56	0.26	0.75	0.37	0.70	0.45	0.44
18	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.4	3.1	3.1	3.0	2.9
	MEAN	3.5	3.7	3.3	3.5	2.9	3.2	3.1	2.9
	S.D.	0.50	0.56	0.23	0.69	0.38	0.68	0.48	0.45
19	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.4	3.1	3.1	3.1	2.9*
	MEAN	3.6	3.8	3.3	3.5	3.0	3.3	3.1	2.9
	S.D.	0.50	0.59	0.19	0.73	0.34	0.66	0.50	0.39

3M_MN03278906

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
20	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.7	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.5	3.8	3.3	3.4	3.0	3.2	3.2	2.8
	S.D.	0.53	0.59	0.22	0.73	0.34	0.67	0.48	0.38
21	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.6	3.4	3.2	3.0	3.1	3.0	2.8*
	MEAN	3.6	3.8	3.2	3.3	2.9	3.2	3.0	2.8
	S.D.	0.55	0.64	0.26	0.72	0.34	0.70	0.46	0.33
22	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.6	3.8	3.3	3.4	3.0	3.2	3.1	2.8
	S.D.	0.56	0.56	0.25	0.62	0.37	0.68	0.44	0.31
23	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.2*	3.0	3.1	3.1	2.8*
	MEAN	3.6	3.8	3.3	3.3	2.9	3.2	3.1	2.8
	S.D.	0.58	0.55	0.25	0.67	0.31	0.68	0.46	0.35
24	N	6	4	6	5	6	4	6	6
	CAM	3.6	3.7	3.5	3.3	3.0	3.1	3.1	2.8
	MEAN	3.6	3.9	3.3	3.4	2.9	3.2	3.1	2.8
	S.D.	0.63	0.60	0.26	0.69	0.32	0.76	0.46	0.32
25	N	6	4	6	5	6	4	6	6
	CAM	3.7	3.8	3.6	3.3	3.1	3.2	3.1	2.8*
	MEAN	3.7	3.9	3.4	3.5	3.0	3.3	3.2	2.8
	S.D.	0.61	0.55	0.20	0.72	0.37	0.76	0.46	0.31
26	N	6	4	6	5	6	4	6	6
	CAM	3.7	3.8	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.7	3.9	3.3	3.4	3.0	3.2	3.1	2.8
	S.D.	0.67	0.55	0.20	0.73	0.37	0.79	0.46	0.35

3M_MN03278907

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
27	N	6	4	6	4	6	4	6	6
	CAM	3.7	3.8	3.5	3.0*	3.1	3.1	3.0	2.8*
	MEAN	3.7	3.9	3.3	3.2	3.0	3.2	3.1	2.8
	S.D.	0.68	0.56	0.26	0.83	0.35	0.72	0.51	0.37

3M_MN03278908

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
28	N	2	2	2	2	2	2
	MEAN	3.5	3.1	3.1	2.7	3.3	2.6
	S.D.	0.42	0.21	0.57	0.35	0.71	0.14
29	N	2	2	2	2	2	2
	MEAN	3.6	3.1	3.3	2.7	3.4	2.7
	S.D.	0.42	0.28	0.64	0.42	0.71	0.14
30	N	2	2	2	2	2	2
	MEAN	3.6	3.0	3.3	2.7	3.3	2.7
	S.D.	0.42	0.28	0.57	0.35	0.71	0.14
31	N	2	2	2	2	2	2
	MEAN	3.7	3.1	3.5	2.7	3.4	2.8
	S.D.	0.42	0.35	0.71	0.42	0.78	0.21
32	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.6	2.8	3.5	2.9
	S.D.	0.42	0.35	0.85	0.35	0.78	0.35
33	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.7	2.8	3.5	3.0
	S.D.	0.42	0.28	0.78	0.42	0.78	0.28
34	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.8	2.8	3.4	3.0
	S.D.	0.42	0.21	0.99	0.35	0.85	0.28

3M_MN03278909

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
35	N	2	2	2	2	2	2
	MEAN	3.8	3.1	3.7	2.8	3.5	3.0
	S.D.	0.35	0.28	0.99	0.35	0.92	0.21
36	N	2	2	2	2	2	2
	MEAN	3.8	3.3	3.9	2.8	3.6	3.1
	S.D.	0.42	0.21	1.06	0.35	0.92	0.35
37	N	2	2	2	2	2	2
	MEAN	3.9	3.2	3.9	2.8	3.6	3.1
	S.D.	0.42	0.28	1.06	0.42	0.78	0.35
38	N	2	2	2	2	2	2
	MEAN	3.9	3.2	3.8	2.8	3.5	3.0
	S.D.	0.42	0.21	0.99	0.35	0.85	0.42
39	N	2	2	2	2	2	2
	MEAN	3.9	3.1	3.7	2.7	3.5	2.9
	S.D.	0.35	0.28	0.99	0.42	0.85	0.35
40	N	2	2	2	2	2	2
	MEAN	3.9	3.1	3.7	2.6	3.4	3.0
	S.D.	0.35	0.28	1.06	0.42	0.85	0.21
41	N	2	2	2	2	2	2
	MEAN	4.0	3.3	3.8	2.8	3.6	3.1
	S.D.	0.42	0.21	0.99	0.42	0.85	0.35

3M_MN03278910

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
42	N	2	2	2	2	2	2
	MEAN	4.0	3.2	3.8	2.7	3.6	2.9
	S.D.	0.28	0.21	1.06	0.42	0.78	0.35
43	N	2	2	2	2	2	2
	MEAN	4.0	3.2	3.8	2.7	3.6	3.0
	S.D.	0.28	0.21	0.99	0.42	0.78	0.42
44	N	2	2	2	2	2	2
	MEAN	4.2	3.3	3.8	2.8	3.7	3.1
	S.D.	0.28	0.21	0.92	0.35	0.92	0.35
45	N	2	2	2	2	2	2
	MEAN	4.3	3.3	3.8	2.8	3.7	3.1
	S.D.	0.21	0.28	0.92	0.42	0.78	0.35
46	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.0	2.8	3.6	3.1
	S.D.	0.21	0.28	0.92	0.42	0.85	0.42
47	N	2	2	2	2	2	2
	MEAN	4.2	3.2	3.8	2.7	3.6	3.1
	S.D.	0.14	0.28	0.85	0.42	0.92	0.49
48	N	2	2	2	2	2	2
	MEAN	4.2	3.2	3.9	2.6	3.6	3.1
	S.D.	0.18	0.25	0.78	0.35	0.94	0.49

3M_MN03278911

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
49	N	2	2	2	2	2	2
	MEAN	4.3	3.3	4.1	2.8	3.7	3.2
	S.D.	0.21	0.21	0.78	0.35	0.92	0.35
50	N	2	2	2	2	2	2
	MEAN	4.3	3.2	4.0	2.7	3.6	3.1
	S.D.	0.21	0.28	0.71	0.35	0.92	0.35
51	N	2	2	2	2	2	2
	MEAN	4.3	3.3	4.1	2.7	3.7	3.1
	S.D.	0.21	0.21	0.64	0.42	0.92	0.35
52	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.7	3.1
	S.D.	0.21	0.21	0.57	0.28	0.92	0.42
53	N	2	2	2	2	2	2
	MEAN	4.4	3.2	4.1	2.6	3.6	3.1
	S.D.	0.21	0.28	0.49	0.28	0.99	0.49
54	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.2	2.6	3.6	3.1
	S.D.	0.28	0.21	0.49	0.28	0.92	0.49
55	N	2	2	2	2	2	2
	MEAN	4.5	3.3	4.1	2.7	3.5	3.1
	S.D.	0.28	0.21	0.42	0.35	0.99	0.64

3M_MN03278912

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
56	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.6	3.1
	S.D.	0.35	0.14	0.35	0.35	0.92	0.57
57	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.0	2.6	3.6	3.0
	S.D.	0.35	0.21	0.28	0.35	0.92	0.57
58	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.6	3.0
	S.D.	0.35	0.14	0.35	0.28	0.78	0.57
59	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.5	3.0
	S.D.	0.42	0.14	0.42	0.35	0.71	0.57
60	N	2	2	2	2	2	2
	MEAN	4.6	3.4	4.3	2.8	3.6	3.2
	S.D.	0.49	0.14	0.42	0.35	0.85	0.49
61	N	2	2	2	2	2	2
	MEAN	4.6	3.4	4.3	2.7	3.6	3.2
	S.D.	0.49	0.14	0.42	0.28	0.78	0.49
62	N	2	2	2	2	2	2
	MEAN	4.5	3.5	4.4	2.7	3.6	3.2
	S.D.	0.49	0.21	0.49	0.42	0.78	0.57

3M_MN03278913

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
63	N	2	2	2	2	2	2
	MEAN	4.5	3.4	4.4	2.8	3.6	3.2
	S.D.	0.57	0.14	0.42	0.35	0.71	0.57
64	N	2	2	2	2	2	2
	MEAN	4.4	3.4	4.5	2.7	3.6	3.2
	S.D.	0.64	0.14	0.21	0.35	0.78	0.64
65	N	2	2	2	2	2	2
	MEAN	4.4	3.4	4.4	2.7	3.5	3.1
	S.D.	0.57	0.07	0.21	0.35	0.78	0.57
66	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.3	2.6	3.5	3.1
	S.D.	0.64	0.14	0.28	0.28	0.78	0.57
67	N	2	2	2	2	2	2
	MEAN	4.5	3.4	4.4	2.7	3.6	3.2
	S.D.	0.57	0.14	0.21	0.35	0.71	0.57
68	N	2	2	2	2	2	2
	MEAN	4.6	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.21	0.21	0.35	0.78	0.64
69	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.14	0.28	0.28	0.85	0.71

3M_MN03278914

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
70	N	2	2	2	2	2	2
	MEAN	4.6	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.07	0.21	0.35	0.78	0.71
71	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.2
	S.D.	0.64	0.07	0.28	0.35	0.85	0.71
72	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.71	0.07	0.21	0.35	0.78	0.78
73	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.2
	S.D.	0.71	0.07	0.21	0.35	0.85	0.78
74	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.85	0.07	0.21	0.42	0.78	0.78
75	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.78	0.07	0.21	0.28	0.78	0.78
76	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.4
	S.D.	0.85	0.07	0.21	0.28	0.71	0.78

3M_MN03278915

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	SEX:	MALE			FEMALE		
	GROUP:	1	3	4	1	3	4
	DOSE:	0	0.15	0.75	0	0.15	0.75
WEEK	UNITS:	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
77	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.7	3.3
	S.D.	0.85	0.07	0.14	0.35	0.78	0.78
78	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.6	3.5	3.2
	S.D.	0.92	0.07	0.14	0.28	0.85	0.85
79	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.3
	S.D.	0.92	0.00	0.07	0.35	0.85	0.85
80	N	0	2	0	0	2	0
	MEAN		3.3			3.4	
	S.D.		0.21			0.85	

3M_MN03278916

Table 8

Summary of Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.45	12.2	41.2	63.9	19.0	29.8	530	.3	20
	S.D.	.275	.36	1.30	2.32	.87	.56	125.0	.19	12.6
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.99	12.4	42.9	61.5	17.8	29.0	574	.4	24
	S.D.	.688	.46	2.95	2.51	1.13	1.34	210.3	.24	14.9
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.76	12.6	42.9	63.5	18.7	29.5	493	.5	32
	S.D.	.315	.41	1.88	2.38	.76	.41	109.0	.53	34.5
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.88	12.5	43.1	62.8	18.2	29.0	415	.5	33
	S.D.	.575	.82	2.06	3.44	1.01	.61	202.6	.47	27.8
	N	6	6	6	6	6	6	6	6	6

3M_MN03278917

Table 8

Summary of Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	8.6	3.9	4.0	.6	.1	.0	44	47	7	1	0
	S.D.	1.76	1.28	.90	.24	.08	.05	8.9	9.2	2.4	.8	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	11.0	5.2	4.6	.8	.2	.0	47	43	8	2	0
	S.D.	1.00	1.88	1.05	.48	.17	.00	15.2	9.4	4.4	1.3	.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	11.9	6.6	4.1	.9	.2	.0	54	36	8	2	0
	S.D.	1.95	2.42	1.14	.25	.31	.04	13.4	10.9	3.3	2.1	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.4	3.7	4.3	1.1	.2	.1	39	46	12	2	1
	S.D.	2.53	1.40	1.25	.53	.25	.08	10.9	9.5	3.3	3.3	.8
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278918

Table 8

Summary of Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.09	12.0	39.3	64.7	19.7	30.4	539	.6	35
	S.D.	.681	.97	3.93	4.51	1.81	.87	79.5	.46	24.2
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.31	11.5	39.5	62.7	18.3	29.2	482	.4	27
	S.D.	.522	1.06	3.26	4.49	1.73	.71	72.4	.31	17.1
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.54	12.0	40.1	61.4	18.3	29.8	481	.4	29
	S.D.	.320	.49	1.97	2.79	.50	.68	100.9	.26	16.2
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.50	12.1	41.5	63.9	18.7	29.2	435	.2	16
	S.D.	.195	.50	1.68	1.14	.50	.52	108.9	.18	11.4
	N	6	6	6	6	6	6	6	6	6

3M_MN03278919

Table 8

Summary of Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	10.2	4.6	4.5	.8	.3	.0	45	44	7	3	0
	S.D.	2.52	1.14	1.36	.24	.28	.05	8.3	7.6	1.2	2.1	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	8.7	5.0	2.9	.6	.1	.0	55	35	8	2	0
	S.D.	2.41	2.52	.79	.17	.05	.05	14.3	11.6	2.8	.6	.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	10.1	5.1	3.8	.8	.3	.0	48	40	9	3	0
	S.D.	2.94	2.81	.40	.20	.27	.04	13.0	8.4	3.8	3.0	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.0	4.8	3.2	.8	.1	.0	54	35	9	1	0
	S.D.	3.08	1.70	1.66	.32	.18	.04	10.7	9.7	4.2	1.4	.4
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278920

Table 9

Summary of Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.45	12.4	40.6	63.0	19.1	30.4	486	.2	14
	S.D.	.221	.55	1.44	2.74	.97	.58	117.8	.16	10.4
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.86	12.5	42.4	61.9	18.2	29.5	532	.4	29
	S.D.	.501	.38	3.93	4.61	1.17	1.69	146.1	.35	23.8
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.66	12.5	41.2	62.0	18.8	30.3	476	.4	25
	S.D.	.385	.27	.76	2.96	1.06	.53	59.6	.14	10.5
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.53	11.8	40.2	61.7	18.1	29.4	383	.4	25
	S.D.	.431	.57	1.74	2.63	.85	.57	164.3	.10	5.9
	N	6	6	6	6	6	6	6	6	6

3M_MN03278921

Table 9

Summary of Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	7.6	3.9	3.1	.5	.0	.0	50	43	7	1	0
	S.D.	1.98	2.01	.67	.31	.08	.08	14.4	12.8	3.4	1.2	.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	10.8	6.3	3.7	.5	.2	.0	58	36	5	2	0
	S.D.	1.89	2.40	1.26	.17	.05	.00	15.9	14.2	1.7	.5	.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	10.0	6.0	3.2	.6	.2	.0	58	33	6	2	0
	S.D.	2.06	2.23	.91	.24	.32	.05	12.5	10.4	3.6	2.3	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	10.3	6.6	2.9	.6	.1	.0	62	30	7	1	1
	S.D.	4.16	3.69	.52	.18	.11	.05	9.8	7.5	2.7	1.2	.4
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278922

Table 9

Summary of Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^5$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.41	12.2	40.5	63.1	19.0	30.2	538	.3	22
	S.D.	.351	.69	2.42	2.31	.83	.29	84.2	.16	10.8
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.60	11.8	40.6	61.8	18.1	29.2	417	.3	18
	S.D.	.664	.97	2.92	6.28	1.80	.48	23.6	.28	15.6
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.55	11.8	39.7	60.7	18.1	29.7	431	.3	19
	S.D.	.343	.41	1.06	2.68	.75	.29	85.3	.12	8.0
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.21	11.6	39.1	63.0	18.6	29.6	469	.3	20
	S.D.	.280	.38	1.96	1.48	.44	.89	95.4	.23	13.1
	N	6	6	6	6	6	6	6	6	6

3M_MN03278923

Table 9

Summary of Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	12.7	7.8	3.6	1.1	.3	.0	59	30	8	2	0
	S.D.	4.75	3.77	1.59	.67	.26	.08	18.2	16.2	2.3	1.7	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	9.6	5.7	2.8	.8	.2	.0	60	29	8	3	0
	S.D.	2.37	1.90	.82	.24	.17	.05	10.6	6.0	2.1	2.2	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	9.1	5.5	2.9	.5	.2	.0	56	35	6	3	0
	S.D.	2.66	2.48	.72	.13	.18	.00	17.0	15.7	1.6	1.2	.0
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	8.9	5.3	2.9	.6	.1	.0	56	35	7	1	0
	S.D.	2.85	3.19	1.06	.20	.08	.00	15.1	13.7	2.7	1.2	.4
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278924

Table 10

Summary of Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.49	12.5	41.1	63.3	19.2	30.4	522	.3	18
	S.D.	.292	.53	1.78	3.03	.95	.84	126.9	.27	17.3
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.84	12.4	41.4	60.7	18.2	29.9	536	.4	25
	S.D.	.437	.33	1.36	2.92	.91	.62	152.1	.45	29.6
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.60	12.5	40.7	61.7	18.9	30.6	504	.3	21
	S.D.	.315	.52	1.42	2.56	.87	.50	97.3	.25	17.3
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.73	12.3	41.2	61.3	18.3	29.8	437	.3	19
	S.D.	.516	.75	2.31	3.02	.72	.52	217.8	.19	12.6
	N	6	6	6	6	6	6	6	6	6

3M_MN03278925

Table 10

Summary of Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	7.3	3.0	3.5	.6	.1	.0	42	48	8	2	0
	S.D.	.81	.68	.87	.26	.08	.05	10.5	8.2	3.2	.8	.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	10.5	6.1 *	3.4	.8	.2	.0	58	32	8	2	0
	S.D.	1.79	1.51	.82	.38	.05	.00	9.5	6.5	3.5	.5	.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	11.8 *	7.0 *	3.9	.7	.2	.0	56	35	7	2	0
	S.D.	3.02	3.16	1.18	.40	.13	.05	16.3	14.6	4.0	.8	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.6	5.3	3.4	.6	.2	.0	52	38	6	2	0
	S.D.	2.97	2.52	.52	.23	.21	.08	10.0	11.2	1.0	2.1	.5
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278926

Table 10

Summary of Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.23	12.3	40.2	64.9	19.9	30.6	572	.4	27
	S.D.	.766	.66	3.27	4.33	1.87	1.01	74.6	.22	11.2
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.48	12.0	40.2	62.4	18.5	29.7	462	.4	28
	S.D.	.593	.83	2.39	6.25	2.02	.67	83.8	.37	24.1
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	7.00	12.8	42.3	60.5	18.3	30.3	436	.4	24
	S.D.	1.068	2.17	6.70	2.31	.76	.57	133.5	.28	18.2
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.28	11.8	40.2	64.0	18.9	29.5	504	.3	17
	S.D.	.397	.29	1.96	1.27	.72	.70	148.3	.25	14.9
	N	6	6	6	6	6	6	6	6	6

3M_MN03278927

Table 10

Summary of Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	11.1	5.8	4.3	.6	.3	.0	50	40	6	2	0
	S.D.	2.93	3.08	1.73	.48	.18	.08	17.6	15.9	4.6	2.0	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	8.7	4.4	3.4	.6	.2	.0	50	40	8	2	0
	S.D.	1.42	1.59	1.16	.13	.17	.06	14.5	14.9	.5	1.7	.6
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	8.8	4.3	3.6	.5	.3	.0	48	42	6	3	0
	S.D.	1.78	1.75	.93	.16	.15	.05	13.1	11.2	2.9	1.6	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.3	5.6	3.0	.6	.1	.0	56	36	7	1	0
	S.D.	4.59	3.89	1.07	.40	.08	.05	13.2	14.2	2.7	1.0	.4
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278928

Table 11

Summary of Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.43	12.4	40.3	62.8	19.3	30.7	490	.3	21
	S.D.	.314	.53	2.17	3.11	1.06	1.00	124.3	.26	16.4
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	7.00	12.7	42.5	61.0	18.2	29.8	512	.7	47
	S.D.	.628	.55	1.78	3.13	1.02	.43	208.8	.54	33.7
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.50	12.3	40.4	62.1	19.0	30.6	496	.5	33
	S.D.	.295	.16	.93	2.53	.76	.49	82.6	.54	32.0
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.66	12.2	41.0	61.6	18.2	29.6 *	431	.4	26
	S.D.	.488	.81	2.23	2.47	.77	.65	198.6	.19	11.8
	N	6	6	6	6	6	6	6	6	6

3M_MN03278929

Table 11

Summary of Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	6.7	2.4	3.7	.4	.1	.0	37	55	6	2	0
	S.D.	1.99	.64	1.24	.16	.08	.04	4.1	2.8	2.1	1.3	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	8.5	4.4	3.3	.6	.2	.0	50	40 *	7	2	0
	S.D.	1.60	1.79	.88	.00	.10	.00	13.9	12.6	1.0	1.4	.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	10.3	5.7 *	3.7	.6	.2	.0	56 *	36 *	7	2	0
	S.D.	3.21	1.85	1.61	.27	.18	.05	9.3	8.4	2.6	1.8	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.4	5.1 *	3.5	.6	.2	.0	52 *	38 *	6	2	0
	S.D.	2.56	2.06	.71	.28	.16	.05	9.8	7.8	3.2	1.6	.5
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278930

Table 11

Summary of Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.31	12.3	40.3	64.1	19.5	30.4	562	.3	20
	S.D.	.565	.77	2.79	3.90	1.21	.33	83.6	.08	5.7
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.20	11.7	39.2	63.6	19.0	29.9	467	.5	30
	S.D.	.472	.97	2.18	7.19	2.78	1.21	33.4	.13	7.9
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.50	12.0	39.4	60.7	18.6	30.6	442	.2	14
	S.D.	.298	.42	1.44	2.35	.78	.57	78.9	.10	6.6
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.32	11.9	40.3	63.8	18.8	29.4	504	.2	12
	S.D.	.210	.36	1.54	1.37	.51	.54	124.1	.15	9.4
	N	6	6	6	6	6	6	6	6	6

3M_MN03278931

Table 11

Summary of Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	9.4	4.0	4.3	.6	.4	.0	44	46	7	4	0
	S.D.	1.89	1.31	1.59	.10	.27	.04	12.5	10.3	1.0	2.4	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	8.7	4.4	3.2	.8	.2	.0	48	39	9	2	0
	S.D.	3.42	2.74	1.22	.41	.10	.10	13.2	11.2	3.9	1.0	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	8.7	4.4	3.4	.6	.2	.0	51	39	7	2	0
	S.D.	1.25	.82	.69	.18	.12	.00	6.4	6.6	1.5	1.0	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	8.1	4.6	2.9	.6	.1	.0	56	36	7	2	0
	S.D.	1.91	1.75	1.02	.26	.08	.05	13.1	10.4	3.5	1.2	.5
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278932

Table 12

Summary of Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.68	12.5	40.9	61.4	18.7	30.6	464	.2	17
	S.D.	.421	.54	2.28	2.74	.88	.62	131.6	.26	18.7
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	7.08	12.6	41.7	59.0	17.8	30.2	483	.2	14
	S.D.	.513	.46	1.91	2.70	.90	.82	167.0	.16	10.7
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.78	12.6	41.3	61.1	18.7	30.6	519	.4	30
	S.D.	.479	.38	1.47	2.82	.95	.40	146.4	.15	9.6
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.65	11.8	40.0	60.3	17.7	29.4 *	398	.6	39
	S.D.	.641	1.04	3.32	2.43	.87	.50	199.1	.48	30.3
	N	6	6	6	6	6	6	6	6	6

3M_MN03278933

Table 12

Summary of Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	7.3	2.7	3.9	.5	.2	.0	35	54	7	2	0
	S.D.	2.62	1.64	.91	.29	.15	.08	8.6	8.3	2.9	2.7	.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	9.9	5.6	3.5	.6	.2	.0	56	36	6	2	0
	S.D.	1.04	1.70	1.08	.22	.08	.00	15.0	13.5	1.8	1.0	.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	10.1	5.2	4.0	.7	.3	.0	49	42	7	2	0
	S.D.	2.44	2.81	1.17	.12	.21	.05	18.2	16.4	2.5	2.0	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.0	4.3	3.6	.8	.2	.0	45	44	9	2	0
	S.D.	2.87	3.02	1.08	.44	.18	.04	16.3	16.1	3.7	1.5	.4
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278934

Table 12

Summary of Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.60	12.4	40.6	61.7	18.8	30.6	520	.4	24
	S.D.	.559	.85	2.96	2.45	.77	.46	73.1	.31	20.5
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.66	12.0	40.4	61.1	18.1	29.6 *	387	.6	39
	S.D.	.641	.92	2.44	6.52	2.23	.82	52.3	.61	33.6
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.66	12.1	39.9	59.8	18.2	30.4	460	.3	20
	S.D.	.257	.45	1.31	2.12	.64	.18	83.7	.24	16.1
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.33	11.7	39.5	62.4	18.5	29.7 *	492	.2	11
	S.D.	.288	.44	1.98	2.21	.70	.65	144.0	.12	7.9
	N	6	6	6	6	6	6	6	6	6

3M_MN03278935

Table 12

Summary of Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	9.7	4.6	4.1	.8	.2	.0	44	44	9	3	0
	S.D.	2.44	2.98	1.08	.30	.18	.05	18.7	15.9	3.9	2.3	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	9.3	5.0	2.9	1.1	.2	.1	50	36	11	2	1
	S.D.	4.49	3.55	.62	1.00	.14	.08	12.6	15.6	3.6	1.4	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	8.1	3.7	3.4	.6	.3	.0	44	44	8	3	0
	S.D.	2.23	1.98	.96	.14	.15	.00	14.5	14.4	2.2	1.9	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.5	4.4	4.0	.8	.2	.0	46	43	9	2	1
	S.D.	2.99	2.33	2.19	.35	.13	.05	17.4	16.5	4.3	.9	.5
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278936

Table 13

Summary of Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.60	12.5	41.1	62.3	18.9	30.3	467	.2	11
	S.D.	.354	.50	2.07	2.53	.78	.79	90.4	.08	5.8
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.96	12.5	42.1	60.7	18.0	29.6	466	.2	12
	S.D.	.627	.45	1.79	2.81	1.05	.88	183.0	.17	11.8
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.65	12.5	41.0	61.8	18.8	30.4	470	.3	19
	S.D.	.372	.31	1.15	2.76	.80	.30	63.1	.04	3.2
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.32	11.4 *	38.8	61.5	17.9	29.2 *	401	.2	12
	S.D.	.387	.83	2.45	2.72	1.08	.48	228.0	.24	14.6
	N	4	4	4	4	4	4	4	4	4

3M_MN03278937

Table 13

Summary of Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	9.7	4.2	4.4	.7	.2	.0	45	46	7	2	0
	S.D.	1.76	1.66	1.46	.46	.18	.05	16.1	12.4	4.1	2.0	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	8.4	4.8	2.8	.6	.2	.0	57	34	6	2	0
	S.D.	.74	1.46	.74	.26	.06	.00	15.1	10.6	3.8	1.0	.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	10.0	5.2	4.1	.5	.2	.0	50	42	5	2	0
	S.D.	2.44	2.10	1.39	.14	.20	.00	15.2	13.6	2.4	2.1	.0
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	7.6	2.9	4.0	.5	.1	.0	38	53	7	2	0
	S.D.	2.09	1.13	1.16	.12	.10	.06	6.9	9.1	2.9	1.7	.6
	N	4	4	4	4	4	4	4	4	4	4	4

3M_MN03278938

Table 13

Summary of Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^2$/mcL	RETIC %	RETIC $X10^5$/mcL
0										
	MEAN	6.40	12.1	40.8	63.8	19.0	29.7	484	.4	27
	S.D.	.461	.64	2.67	2.49	.70	.65	100.1	.24	15.1
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	6.15	11.2	38.3	62.3	18.2	29.3	429	.2	13
	S.D.	.798	1.66	5.67	6.23	2.09	.94	54.7	.13	5.8
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	6.57	11.9	39.9	60.8	18.2	29.9	412	.2	12
	S.D.	.256	.62	1.78	2.50	.73	.35	74.4	.12	7.5
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	6.09	11.3	39.2	64.3	18.6	29.0	490	.2	12
	S.D.	.360	.37	2.17	1.46	.71	1.09	166.0	.21	12.7
	N	6	6	6	6	6	6	6	6	6

3M_MN03278939

Table 13

Summary of Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^2$/mcL	MONO $X10^2$/mcL	EOSIN $X10^2$/mcL	BASO $X10^2$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	10.4	5.0	4.3	.7	.2	.0	46	44	8	3	0
	S.D.	3.59	3.41	1.96	.15	.19	.05	17.5	15.1	3.4	1.8	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	8.5	4.3	3.2	.7	.3	.0	50	38	8	3	0
	S.D.	2.05	1.45	.57	.32	.15	.10	9.3	10.1	2.2	1.4	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	9.2	4.5	3.8	.6	.3	.0	48	43	6	3	0
	S.D.	1.61	1.73	.61	.18	.24	.04	13.0	11.7	2.1	2.0	.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	9.7	4.2	4.6	.7	.2	.1	46	45	8	2	0
	S.D.	2.73	1.10	2.70	.32	.08	.05	14.6	14.8	3.4	.8	.5
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278940

Table 14

Summary of Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.26	12.0	38.1	60.8	19.1	31.5	483	.4	22
	S.D.	.007	.21	.28	.35	.28	.35	193.7	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.49	12.7	40.7	62.8	19.6	31.2	488	.3	20
	S.D.	.057	.42	1.27	1.34	.42	.07	118.8	.14	9.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	5.90	11.6	37.8	64.0	19.5	30.6	469	.4	26
	S.D.	.042	.07	.64	.71	.07	.42	22.6	.21	12.0
	N	2	2	2	2	2	2	2	2	2

3M_MN03278941

Table 14

Summary of Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	7.3	2.4	4.0	.6	.2	.0	34	54	9	3	1
	S.D.	1.70	.14	1.63	.14	.07	.00	4.9	9.9	4.2	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	11.5	6.2	4.5	.6	.3	.0	53	38	6	3	0
	S.D.	3.82	2.05	2.12	.21	.14	.00	.0	5.7	3.5	2.8	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	11.8	6.0	4.4	.9	.4	.0	50	39	7	4	0
	S.D.	4.10	2.69	.78	.57	.07	.00	5.7	7.1	2.8	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278942

Table 14

Summary of Clinical Hematology Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	5.94	11.8	36.9	62.0	19.8	32.0	468	.3	18
	S.D.	.714	1.20	4.81	.64	.35	.99	111.0	.28	19.1
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.14	11.9	37.6	61.4	19.5	31.7	408	.4	22
	S.D.	.092	.14	.57	.07	.07	.14	37.5	.21	13.4
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.42	12.0	40.2	62.6	18.7	29.8	444	.5	32
	S.D.	.417	.28	2.90	.57	.71	1.34	160.5	.28	20.5
	N	2	2	2	2	2	2	2	2	2

3M_MN03278943

Table 14

Summary of Clinical Hematology Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	8.2	4.6	2.8	.6	.1	.0	55	36	8	2	0
	S.D.	2.76	2.12	.35	.28	.00	.00	7.1	7.8	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	7.6	2.6	4.0	.6	.4	.0	34	53	8	4	1
	S.D.	1.06	1.20	.35	.14	.21	.07	10.6	11.3	2.8	2.1	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	9.3	2.6	5.8	.6	.2	.0	28	64	6	3	0
	S.D.	2.26	.64	1.20	.35	.07	.07	.7	2.1	2.8	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278944

Table 15

Summary of Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.52	12.6	39.2	60.2	19.4	32.1	556	.2	13
	S.D.	.332	.57	1.91	.07	.07	.00	181.7	.14	8.5
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.78	13.3	42.2	62.1	19.6	31.6	493	.2	10
	S.D.	.049	.00	.49	1.13	.28	.21	36.8	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.20	11.9	39.5	63.7	19.2	30.1	532	.6	36
	S.D.	.191	.71	.64	.99	.49	1.27	43.1	.28	16.3
	N	2	2	2	2	2	2	2	2	2

3M_MN03278945

Table 15

Summary of Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	10.0	3.2	6.1	.4	.3	.0	32	60	4	3	0
	S.D.	2.90	.78	2.12	.07	.00	.00	1.4	3.5	.7	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	11.4	5.5	4.8	.6	.4	.0	48	42	6	3	0
	S.D.	1.13	.42	1.06	.28	.07	.00	.7	4.9	3.5	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	13.4	5.6	6.2	1.0	.5	.1	41	47	8	4	1
	S.D.	5.52	2.83	1.77	.64	.14	.00	4.2	5.7	2.1	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278946

Table 15

Summary of Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.22	12.3	38.4	61.6	19.8	32.1	519	.2	16
	S.D.	.735	1.41	4.95	.71	.07	.49	82.0	.07	6.4
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.74	12.7	40.7	60.3	18.8	31.2	425	.2	10
	S.D.	.191	.28	.35	1.27	.14	.28	48.1	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.70	12.5	42.0	62.7	18.7	29.8	440	.2	17
	S.D.	.453	.42	2.97	.21	.71	1.20	149.2	.21	15.6
	N	2	2	2	2	2	2	2	2	2

3M_MN03278947

Table 15

Summary of Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	11.4	7.1	3.4	.7	.2	.0	62	30	6	2	0
	S.D.	1.56	2.83	.85	.28	.14	.00	16.3	12.0	2.8	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	9.4	3.0	5.0	1.0	.4	.0	28	56	11	4	0
	S.D.	2.76	2.97	.49	.00	.28	.07	23.3	21.9	2.8	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	11.0	3.6	6.2	.9	.2	.1	32	56	8	2	1
	S.D.	.21	1.34	1.77	.28	.07	.00	12.7	14.8	2.8	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278948

Table 16

Summary of Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.72	12.6	40.1	59.6	18.8	31.6	504	.2	17
	S.D.	.198	.49	2.12	1.34	.21	.42	228.4	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.78	13.1	41.8	61.5	19.3	31.4	496	.4	27
	S.D.	.106	.42	2.05	1.98	.28	.49	105.4	.28	19.8
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.45	12.3	41.0	63.6	19.1	29.9	519	.3	19
	S.D.	.495	1.13	2.40	1.13	.21	.92	60.8	.14	7.1
	N	2	2	2	2	2	2	2	2	2

3M_MN03278949

Table 16

Summary of Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	7.3	2.6	3.7	.8	.1	.0	36	51	10	2	1
	S.D.	.42	.28	.42	.35	.00	.07	6.4	2.8	4.2	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	11.5	6.6	4.1	.4	.2	.0	58	36	4	2	0
	S.D.	2.26	2.05	.14	.21	.14	.00	6.4	8.5	1.4	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	11.6	5.0	5.4	.8	.4	.0	40	49	7	2	1
	S.D.	6.22	3.54	1.91	.49	.21	.07	9.2	9.9	.0	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278950

Table 16

Summary of Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.32	12.3	39.0	61.7	19.5	31.6	510	.4	25
	S.D.	1.082	1.70	7.57	1.41	.71	1.91	135.8	.00	4.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.64	12.6	40.1	60.3	18.8	31.2	423	.4	23
	S.D.	.071	.07	.57	.21	.35	.64	5.7	.21	14.1
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.78	12.5	40.8	60.2	18.4	30.5	440	.4	30
	S.D.	.410	.35	1.56	1.34	.64	.35	137.9	.35	21.9
	N	2	2	2	2	2	2	2	2	2

3M_MN03278951

Table 16

Summary of Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	8.8	5.4	2.8	.5	.0	.0	60	33	6	1	0
	S.D.	1.13	2.40	.99	.14	.07	.00	19.1	15.6	2.8	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	7.8	2.9	3.8	.6	.4	.0	34	53	8	5	1
	S.D.	2.26	2.55	.64	.07	.28	.07	22.6	22.6	.7	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	9.2	4.4	4.1	.6	.1	.0	48	44	6	0	0
	S.D.	2.26	.92	.85	.49	.00	.07	2.1	2.1	3.5	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278952

Table 17

Summary of Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.72	12.6	40.2	59.8	18.8	31.5	544	.3	20
	S.D.	.078	.35	.57	.07	.28	.42	209.3	.28	19.1
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.80	13.2	41.9	61.5	19.4	31.5	491	.2	10
	S.D.	.127	.57	1.84	1.48	.49	.07	80.6	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.22	11.8	38.1	61.1	19.0	31.0	572	.6	34
	S.D.	.198	.42	.35	1.34	.07	.71	43.1	.35	21.2
	N	2	2	2	2	2	2	2	2	2

3M_MN03278953

Table 17

Summary of Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	8.6	4.2	3.8	.6	.1	.0	48	42	8	1	0
	S.D.	1.20	.21	1.06	.07	.00	.00	4.9	6.4	1.4	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	12.8	8.2	3.7	.8	.2	.0	64	30	6	1	0
	S.D.	1.34	2.05	.99	.21	.07	.00	9.2	10.6	1.4	.0	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	9.0	4.0	3.9	.8	.2	.0	43	44	10	2	0
	S.D.	3.75	2.55	1.13	.07	.07	.07	9.9	6.4	2.8	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278954

Table 17

Summary of Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.32	12.3	38.4	60.8	19.6	32.1	546	.2	13
	S.D.	.403	.64	2.12	.49	.21	.07	140.0	.14	9.9
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.76	12.5	40.1	59.4	18.4	31.0	472	.4	24
	S.D.	.071	.00	.78	1.77	.21	.64	103.9	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.50	11.9	39.5	60.8	18.4	30.2	424	.3	20
	S.D.	.431	.42	2.19	.64	.64	.71	155.6	.28	19.8
	N	2	2	2	2	2	2	2	2	2

3M_MN03278955

Table 17

Summary of Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	11.8	7.2	3.2	1.0	.2	.0	59	30	8	2	0
	S.D.	4.38	3.96	.07	.57	.07	.00	11.3	11.3	2.1	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	9.4	4.2	4.2	.6	.4	.0	42	48	7	4	0
	S.D.	2.83	3.18	.42	.21	.28	.00	21.2	19.1	4.2	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	8.9	2.7	5.6	.6	.2	.0	30	62	6	2	0
	S.D.	1.56	.57	.78	.07	.07	.00	1.4	1.4	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278956

Table 18

Summary of Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.53	12.4	39.5	60.5	19.2	31.6	514	.1	6
	S.D.	.042	.07	.07	.49	.21	.07	179.6	.14	9.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.72	13.0	41.2	61.3	19.4	31.7	448	.1	7
	S.D.	.283	.64	2.97	1.91	.28	.57	68.6	.14	9.9
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.23	12.2	38.9	62.5	19.5	31.2	508	.8	46
	S.D.	.198	.21	.28	2.40	.28	.85	17.7	1.06	64.3
	N	2	2	2	2	2	2	2	2	2

3M_MN03278957

Table 18

Summary of Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	10.8	6.6	3.4	.7	.0	.0	61	32	6	0	0
	S.D.	.14	.99	.92	.14	.07	.07	8.5	9.2	.7	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	12.5	8.2	3.5	.8	.1	.0	64	28	6	0	0
	S.D.	1.84	1.98	.71	.49	.14	.00	6.4	10.6	2.8	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	12.2	6.4	4.2	1.1	.4	.0	52	36	9	3	0
	S.D.	3.96	2.69	.78	.42	.07	.07	4.9	5.7	.0	.0	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278958

Table 18

Summary of Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.28	12.4	38.1	60.8	19.8	32.6	534	.2	10
	S.D.	.453	.78	2.90	.35	.14	.42	142.8	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.77	12.6	40.8	60.2	18.6	31.0	456	.2	10
	S.D.	.113	.14	1.34	.92	.07	.64	67.9	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.54	12.2	40.1	61.3	18.6	30.4	448	.2	10
	S.D.	.028	.07	.57	1.13	.14	.78	181.7	.07	4.2
	N	2	2	2	2	2	2	2	2	2

3M_MN03278959

Table 18

Summary of Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	7.4	3.4	2.8	1.0	.2	.0	46	37	14	3	0
	S.D.	1.48	1.13	.42	.28	.14	.00	6.4	1.4	6.4	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	8.1	3.0	3.7	.9	.4	.0	38	46	11	5	0
	S.D.	.57	.71	.99	.42	.14	.07	10.6	9.2	4.2	2.8	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	10.8	4.7	5.2	.8	.1	.0	43	48	8	1	0
	S.D.	.78	.57	.21	.42	.14	.00	1.4	4.9	3.5	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278960

Table 19

Summary of Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.63	12.9	40.2	60.7	19.4	32.0	460	.3	20
	S.D.	.269	.57	1.34	.42	.00	.28	174.7	.14	9.9
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	7.16	14.0	45.6	63.7	19.5	30.6	490	.3	22
	S.D.	.049	.21	.99	.92	.14	.21	106.8	.28	20.5
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.30	12.6	40.6	64.5	19.9	31.0	510	.7	42
	S.D.	.530	.92	2.69	1.13	.21	.14	92.6	.99	58.7
	N	2	2	2	2	2	2	2	2	2

3M_MN03278961

Table 19

Summary of Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	11.6	6.4	4.4	.6	.1	.0	55	38	6	1	0
	S.D.	.57	1.48	.78	.07	.00	.07	9.9	8.5	.7	.0	.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	11.6	4.9	5.9	.6	.2	.0	42	50	6	2	0
	S.D.	1.27	1.13	.42	.21	.00	.00	4.9	2.1	2.1	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	16.6	10.3	4.8	1.2	.4	.1	62	28	6	2	0
	S.D.	6.51	3.96	1.77	.64	.21	.00	.7	.7	.7	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278962

Table 19

Summary of Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.26	12.4	38.5	61.6	19.8	32.2	494	.5	31
	S.D.	.884	1.56	5.23	.35	.35	.49	122.3	.14	4.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.66	12.7	40.8	61.4	19.2	31.2	451	.3	20
	S.D.	.064	.00	.85	.71	.21	.78	14.1	.14	9.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	7.06	13.1	42.9	60.8	18.5	30.6	446	.2	12
	S.D.	.629	.57	3.18	.92	.78	.92	215.7	.21	16.3
	N	2	2	2	2	2	2	2	2	2

3M_MN03278963

Table 19

Summary of Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	8.8	4.4	3.4	.7	.3	.0	50	38	8	3	0
	S.D.	.78	.14	.64	.14	.14	.00	6.4	3.5	.7	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	9.9	3.8	4.6	.9	.6	.0	37	48	9	6	0
	S.D.	1.70	1.70	.07	.14	.28	.00	11.3	6.4	.0	4.2	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	10.6	3.0	6.2	1.0	.3	.2	29	58	9	3	2
	S.D.	.92	.71	1.56	.07	.14	.07	9.9	9.9	1.4	1.4	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278964

Table 20

Summary of Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.56	12.6	40.7	61.9	19.2	31.0	434	.5	33
	S.D.	.035	.00	1.06	1.27	.07	.71	96.9	.28	18.4
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.90	13.6	43.9	63.6	19.8	31.1	373	.7	48
	S.D.	.141	.21	.42	.71	.00	.28	5.7	.00	.7
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.42	12.6	42.4	66.0	19.6	29.8	520	.6	38
	S.D.	.000	.14	1.56	2.33	.14	.78	59.4	.42	27.6
	N	2	2	2	2	2	2	2	2	2

3M_MN03278965

Table 20

Summary of Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	8.4	3.1	4.2	.8	.1	.2	36	52	9	1	2
	S.D.	1.77	1.56	.14	.42	.00	.21	11.3	12.0	2.8	.0	2.1
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	10.9	5.0	4.7	.8	.4	.1	46	42	8	2	1
	S.D.	3.96	1.70	2.12	.14	.21	.00	1.4	4.2	4.2	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	16.0	9.8	4.4	1.2	.2	.2	62	28	8	2	2
	S.D.	.35	1.48	1.41	.07	.21	.14	11.3	7.8	.7	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278966

Table 20

Summary of Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
0										
	MEAN	6.02	11.8	37.5	62.5	19.8	31.6	508	.4	26
	S.D.	.700	1.06	4.17	.21	.49	.71	35.4	.21	9.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.46	12.3	40.2	62.2	19.0	30.6	406	.4	29
	S.D.	.191	.42	1.34	.21	.14	.14	2.1	.21	12.7
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.72	12.4	40.8	60.8	18.5	30.4	396	.3	20
	S.D.	.134	.14	.28	1.56	.57	.14	146.4	.14	9.9
	N	2	2	2	2	2	2	2	2	2

3M_MN03278967

Table 20

Summary of Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0												
	MEAN	11.2	7.0	2.8	1.0	.3	.2	58	28	10	2	1
	S.D.	6.15	4.95	.49	.42	.14	.07	12.0	11.3	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	11.5	5.4	4.2	1.0	.6	.2	46	37	10	5	2
	S.D.	3.25	2.33	1.20	.07	.21	.00	7.1	.0	2.8	2.8	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	10.4	3.1	6.4	.5	.2	.2	30	61	5	2	2
	S.D.	.85	.14	.92	.00	.14	.07	3.5	4.2	.0	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03278968

Table 21

Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	76	20	1.2	9.0	4.9	4.1	.6	9	138	70
	S.D.	12.5	3.8	.10	.32	.21	.26	.45	2.0	33.7	13.3
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	70	20	1.2	9.6	5.2	4.4	.4	9	110	61
	S.D.	8.3	6.2	.17	.58	.46	.48	.18	1.4	20.1	35.0
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	82	21	1.2	9.5	5.1	4.4	.6	10	151	56
	S.D.	30.4	3.3	.22	.44	.34	.26	.37	2.2	26.1	4.9
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	73	20	1.3	9.4	5.2	4.3	.5	9	138	67
	S.D.	15.4	2.0	.11	.38	.28	.37	.29	1.3	29.3	11.0
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278969

Table 21

Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	56	32	711	134	7	1133	395	55	247
	S.D.	16.5	9.7	252.6	42.8	1.9	535.3	93.4	84.4	54.0
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	44	36	700	141	3	936	476	35	302
	S.D.	6.3	11.2	265.6	34.5	1.0	709.0	164.6	20.6	107.4
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	72	69	770	160	8	1087	386	51	242
	S.D.	23.5	35.7	210.3	68.4	5.4	322.3	94.5	42.4	62.4
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	68	80	840	171	6	1094	529	41	324
	S.D.	11.7	54.2	360.9	53.3	1.5	497.4	135.6	31.8	72.2
	N	6	6	6	6	6	6	6	6	6

3M_MN03278970

Table 21

Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.8	6.2	159	5.4	109
	S.D.	.60	.84	4.6	.58	2.9
	N	6	6	6	6	6
0.03						
	MEAN	11.6	6.6	164	5.9	111
	S.D.	.53	.44	6.0	.32	2.2
	N	4	4	4	4	4
0.15						
	MEAN	11.5	7.1	163	6.4	112
	S.D.	.62	.99	5.3	.60	2.7
	N	6	6	6	6	6
0.75						
	MEAN	11.3	6.9	161	5.8	108
	S.D.	.54	1.06	4.8	.62	2.9
	N	6	6	6	6	6

3M_MN03278971

Table 21

Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	76	22	1.2	9.6	4.9	4.7	.5	7	149	73
	S.D.	22.2	1.6	.08	.78	.35	.83	.34	1.9	37.2	32.4
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	73	22	1.2	9.3	4.7	4.6	.5	6	130	62
	S.D.	10.7	1.3	.08	.50	.18	.41	.17	1.7	12.4	7.5
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	76	23	1.1	9.6	4.7	4.9	.6	12	144	58
	S.D.	12.0	3.9	.10	.62	.57	.38	.21	12.1	14.0	11.7
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	78	24	1.2	9.4	4.8	4.6	.6	9	154	61
	S.D.	16.3	3.9	.18	.78	.40	.65	.37	1.4	10.1	16.6
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278972

Table 21

Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	64	140	291	123	4	979	374	28	220
	S.D.	6.7	76.9	130.1	54.0	1.6	384.3	121.9	12.5	73.1
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	54	103	201	94	3	484	378	26	237
	S.D.	10.2	29.4	12.5	48.5	.8	156.7	153.7	15.9	79.9
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	74	110	257	87	4	844	416	35	244
	S.D.	35.5	41.0	118.5	32.9	2.4	306.4	121.0	21.2	81.3
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	72	123	310	75	4	1624	384	19	247
	S.D.	15.4	54.2	141.4	24.3	2.0	1251.5	88.6	15.4	54.1
	N	6	6	6	6	6	6	6	6	6

3M_MN03278973

Table 21

Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	11.4	6.2	163	6.2	114
	S.D.	1.10	.63	7.1	.96	5.0
	N	6	6	6	6	6
0.03						
	MEAN	10.9	4.7	163	5.9	115
	S.D.	.58	.99	3.4	.70	3.3
	N	4	4	4	4	4
0.15						
	MEAN	11.0	5.9	162	6.1	115
	S.D.	.59	.78	6.1	.63	3.1
	N	6	6	6	6	6
0.75						
	MEAN	11.3	5.5	163	6.1	114
	S.D.	.59	.50	4.9	.80	1.5
	N	6	6	6	6	6

3M_MN03278974

Table 22

Summary of Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	60	20	1.1	8.9	4.7	4.2	.8	9	140	69
	S.D.	5.9	3.3	.12	.56	.13	.49	.43	1.5	22.1	18.7
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	62	18	1.2	9.3	5.0	4.3	.4	8	118	47
	S.D.	8.3	3.9	.18	1.02	.46	.85	.16	1.3	28.4	4.6
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	61	21	1.2	9.2	4.8	4.4	.6	8	146	58
	S.D.	9.8	4.9	.23	.33	.25	.32	.27	.8	21.5	5.3
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	65	21	1.3	9.3	5.1	4.2	.4	7	130	91
	S.D.	7.8	2.3	.12	.37	.36	.40	.17	1.5	18.0	27.3
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278975

Table 22

Summary of Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	45	39	888	134	7	354	374	22	222
	S.D.	15.9	19.5	339.5	42.9	2.6	461.0	106.3	12.5	58.4
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	37	40	876	120	3	191	459	24	282
	S.D.	6.3	13.0	384.3	35.4	1.5	58.2	149.3	13.6	93.3
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	48	50	896	136	5	184	369	40	221
	S.D.	15.9	23.8	267.3	57.3	3.2	59.7	78.9	21.7	55.5
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	43	46	996	142	2 *	283	522	26	307
	S.D.	10.0	23.0	417.0	39.9	.4	149.7	124.7	10.9	55.9
	N	6	6	6	6	6	6	6	6	6

3M_MN03278976

Table 22

Summary of Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.6	6.7	160	5.4	115
	S.D.	.25	.80	3.6	.28	3.4
	N	6	6	6	6	6
0.03						
	MEAN	11.2	6.9	165	5.8	116
	S.D.	1.12	1.58	10.1	.74	4.2
	N	4	4	4	4	4
0.15						
	MEAN	11.0	6.8	160	5.6	115
	S.D.	.39	1.00	3.1	.38	.9
	N	6	6	6	6	6
0.75						
	MEAN	10.9	6.6	162	5.4	114
	S.D.	.43	1.29	3.4	.29	2.7
	N	6	6	6	6	6

3M_MN03278977

Table 22

Summary of Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	58	22	1.1	9.3	4.4	4.9	.6	8	147	71
	S.D.	14.7	4.4	.16	.71	.26	.80	.34	.5	26.9	25.7
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	67	21	1.1	9.0	4.5	4.5	.5	9	124	64
	S.D.	15.2	3.0	.05	.41	.15	.39	.25	2.5	11.1	12.0
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	60	20	1.0	9.2	4.3	4.9	.6	8	133	57
	S.D.	8.4	3.6	.04	.26	.37	.40	.14	3.2	22.4	11.3
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	70	22	1.1	9.1	4.4	4.7	.4	7	123	66
	S.D.	11.5	5.4	.14	.31	.10	.38	.15	1.2	14.1	23.0
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278978

Table 22

Summary of Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	44	59	362	102	5	240	339	18	194
	S.D.	12.1	30.2	125.6	42.9	2.4	146.6	89.9	13.2	58.2
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	49	70	240	88	3	378	384	28	237
	S.D.	15.9	13.3	48.7	54.7	1.3	262.2	110.9	15.2	55.5
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	36	68	319	76	3	198	414	34	230
	S.D.	6.6	30.9	129.0	20.3	1.5	101.3	115.1	17.4	70.7
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	36	46	415	58	2 *	331	373	23	230
	S.D.	8.0	7.5	188.9	20.0	.9	242.1	83.3	5.9	66.0
	N	6	6	6	6	6	6	6	6	6

3M_MN03278979

Table 22

Summary of Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.4	5.7	161	5.7	115
	S.D.	.39	.73	4.9	.38	4.4
	N	6	6	6	6	6
0.03						
	MEAN	10.2	4.2 *	161	5.2	116
	S.D.	.42	.37	5.4	.92	4.3
	N	4	4	4	4	4
0.15						
	MEAN	9.7	5.1	157	5.2	114
	S.D.	.73	.65	2.5	.39	1.1
	N	6	6	6	6	6
0.75						
	MEAN	10.4	5.0	160	5.9	116
	S.D.	.25	.48	5.3	.42	3.0
	N	6	6	6	6	6

3M_MN03278980

Table 23

Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	59	20	1.1	8.6	4.6	4.0	.7	9	153	62
	S.D.	9.1	3.9	.08	.50	.17	.42	.42	1.5	23.0	19.0
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	59	20	1.2	9.0	4.7	4.3	.4	10	114 *	60
	S.D.	2.9	3.7	.14	.69	.36	.58	.10	2.2	25.1	14.8
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	67	18	1.2	8.8	4.6	4.1	.5	10	144	57
	S.D.	13.3	3.9	.19	.42	.48	.44	.23	1.7	19.7	13.4
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	74	19	1.3	8.8	4.8	4.0	.3	10	125	76
	S.D.	10.6	2.6	.12	.41	.53	.59	.06	2.7	20.6	16.6
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278981

Table 23

Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	36	34	839	130	7	132	371	22	224
	S.D.	7.9	15.2	321.9	46.2	2.3	27.8	115.8	13.9	64.2
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	35	35	750	116	4	149	428	21	270
	S.D.	7.2	17.5	369.9	25.0	1.5	47.7	143.3	13.8	92.9
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	40	37	806	128	5	153	344	20	213
	S.D.	9.4	11.7	237.8	39.4	3.8	19.9	89.3	11.3	61.7
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	34	43	823	125	3	203 *	499	22	301
	S.D.	6.3	16.2	367.0	29.9	.8	57.2	119.4	13.4	53.4
	N	6	6	6	6	6	6	6	6	6

3M_MN03278982

Table 23

Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.4	7.1	160	5.4	120
	S.D.	.39	.66	2.9	.44	2.5
	N	6	6	6	6	6
0.03						
	MEAN	10.5	6.8	166	5.6	122
	S.D.	.44	.88	12.5	.92	9.3
	N	4	4	4	4	4
0.15						
	MEAN	10.4	6.6	160	5.4	120
	S.D.	.26	1.08	3.5	.50	3.5
	N	6	6	6	6	6
0.75						
	MEAN	10.5	6.8	159	5.6	120
	S.D.	.60	1.31	6.4	.63	2.8
	N	6	6	6	6	6

3M_MN03278983

Table 23

Summary of Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	57	21	1.1	9.0	4.4	4.7	.5	9	155	86
	S.D.	10.2	3.5	.13	.57	.21	.75	.24	.8	45.4	49.4
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	66	22	1.1	8.8	4.3	4.5	.6	10	127	76
	S.D.	17.3	3.4	.05	.44	.10	.46	.26	3.7	11.2	21.5
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	62	20	1.0	9.0	4.3	4.7	.6	10	137	64
	S.D.	12.6	2.7	.10	.15	.33	.24	.18	3.2	19.5	18.0
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	74	20	1.2	9.0	4.4	4.6	.4	9	127	61
	S.D.	7.2	5.0	.13	.44	.17	.39	.10	1.9	18.9	10.5
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278984

Table 23

Summary of Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	38	53	360	106	4	262	342	14	198
	S.D.	3.4	16.7	152.5	47.7	1.8	123.6	86.9	14.7	55.5
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	45	77	241	84	4	276	358	19	228
	S.D.	9.9	15.8	45.3	44.5	2.2	67.9	108.3	16.7	55.8
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	37	60	305	75	4	194	410	28	234
	S.D.	7.8	29.3	134.0	20.8	1.0	76.1	129.7	19.6	82.3
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	31	42	398	58	2 *	243	385	27	246
	S.D.	7.8	6.2	200.5	20.0	.4	130.1	89.4	9.9	56.7
	N	6	6	6	6	6	6	6	6	6

3M_MN03278985

Table 23

Summary of Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.0	6.0	162	5.8	120
	S.D.	.34	.36	6.5	.59	5.1
	N	6	6	6	6	6
0.03						
	MEAN	9.9	4.6 *	160	5.2	120
	S.D.	.22	.30	2.9	.43	2.2
	N	4	4	4	4	4
0.15						
	MEAN	9.6	5.1 *	160	5.5	123
	S.D.	.48	.51	3.6	.60	3.0
	N	6	6	6	6	6
0.75						
	MEAN	10.2	5.0 *	161	5.8	120
	S.D.	.60	.30	3.5	.67	1.8
	N	6	6	6	6	6

3M_MN03278986

Table 24

Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	60	20	1.1	8.7	4.8	3.9	.7	8	154	68
	S.D.	8.0	4.3	.14	.40	.12	.33	.38	1.2	24.6	20.4
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	64	20	1.3	9.6	5.3 *	4.2	.4	8	126	54
	S.D.	7.6	4.9	.22	.98	.39	.75	.13	.6	14.9	9.8
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	75	19	1.2	9.0	5.0	4.0	.4	9	150	50
	S.D.	18.5	4.6	.16	.19	.14	.21	.22	2.7	18.8	10.4
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	73	19	1.4	9.4	5.2 *	4.2	.3 *	10	112 *	73
	S.D.	19.1	1.3	.19	.36	.31	.35	.05	3.6	27.0	21.0
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278987

Table 24

Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	39	35	866	136	7	168	392	33	265
	S.D.	7.7	15.8	296.2	50.1	2.6	32.4	111.8	30.3	71.2
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	35	60	789	131	4	175	465	48	318
	S.D.	7.0	55.8	401.7	34.5	1.4	42.5	185.6	57.9	125.4
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	42	45	851	140	6	164	377	27	258
	S.D.	12.2	22.4	265.3	58.6	4.3	36.2	94.9	18.3	70.1
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	36	44	807	127	2 *	214	468	32	350
	S.D.	6.3	21.0	428.6	27.4	.6	75.7	149.1	17.5	70.4
	N	6	6	6	6	6	6	6	6	6

3M_MN03278988

Table 24

Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.3	6.8	160	5.1	117
	S.D.	.77	.37	7.1	.56	5.3
	N	6	6	6	6	6
0.03						
	MEAN	10.5	6.7	167	5.7	120
	S.D.	.79	.70	4.9	1.04	4.1
	N	4	4	4	4	4
0.15						
	MEAN	10.6	6.8	161	5.4	118
	S.D.	.51	1.05	4.6	.35	7.0
	N	6	6	6	6	6
0.75						
	MEAN	10.8	6.4	163	5.4	117
	S.D.	.41	.94	5.0	.45	4.2
	N	6	6	6	6	6

3M_MN03278989

Table 24

Summary of Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0											
	MEAN	66	20	1.2	9.2	4.7	4.6	.4	8	166	67
	S.D.	20.5	2.7	.10	.51	.38	.51	.16	1.5	42.0	10.9
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	68	22	1.1	9.0	4.6	4.4	.5	8	134	61
	S.D.	14.7	3.3	.08	.69	.19	.54	.27	1.4	15.6	14.0
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	60	20	1.0	9.1	4.4	4.6	.4	10	140	56
	S.D.	12.4	4.2	.05	.24	.41	.32	.10	5.8	13.1	18.0
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	79	22	1.2	9.5	4.8	4.7	.3	11	111 *	60
	S.D.	15.5	6.3	.19	.45	.29	.33	.08	7.0	26.6	14.4
	N	6	6	6	6	6	6	6	6	6	6

3M_MN03278990

Table 24

Summary of Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	44	54	329	110	6	786	370	15	236
	S.D.	9.1	17.9	128.7	46.5	2.2	947.2	87.4	17.5	62.7
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	43	79	233	103	4	220	390	18	269
	S.D.	14.6	26.6	57.5	78.3	4.4	39.4	99.8	10.9	62.5
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	37	67	324	74	4	209	442	40	282
	S.D.	11.1	42.8	140.3	19.2	2.5	81.8	127.6	46.1	87.7
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	34	45	388	63	2 *	416	379	19	263
	S.D.	9.8	13.0	150.1	22.3	.5	377.0	96.5	13.6	59.4
	N	6	6	6	6	6	6	6	6	6

3M_MN03278991

Table 24

Summary of Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	5.7	161	5.6	118
	S.D.	1.11	.66	5.9	.74	6.1
	N	6	6	6	6	6
0.03						
	MEAN	10.2	4.2 *	161	5.2	117
	S.D.	1.21	.44	7.5	.93	6.8
	N	4	4	4	4	4
0.15						
	MEAN	10.0	5.2	160	5.7	120
	S.D.	.53	.63	3.4	.45	4.2
	N	6	6	6	6	6
0.75						
	MEAN	10.6	5.1	162	5.8	118
	S.D.	.58	.53	4.7	.54	3.9
	N	6	6	6	6	6

3M_MN03278992

Table 25

Summary of Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	60	20	1.1	8.2	4.8	3.4	.7	10	154	60	69
	S.D.	8.0	3.0	.12	.45	.19	.34	.41	1.5	29.9	18.3	10.6
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	61	19	1.2	8.8	5.2	3.6	.4	7	120	60	46 *
	S.D.	4.3	2.2	.19	.83	.24	.66	.08	1.0	16.3	24.9	4.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	63	22	1.2	8.8	5.0	3.8	.5	10	149	65	55 *
	S.D.	9.4	4.5	.18	.55	.31	.61	.20	2.3	22.8	9.5	12.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	76	20	1.3	9.0	4.9	4.1	.2 *	14	65 *	60	19 *
	S.D.	17.0	2.2	.20	.23	.48	.43	.05	5.5	20.3	26.3	6.5
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278993

Table 25

Summary of Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	31	43	792	142	3	165	392	23	276
	S.D.	4.9	27.3	305.3	53.1	2.6	28.5	112.8	10.5	74.9
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	30	36	684	123	2	133	470	41	339
	S.D.	6.3	19.8	348.2	32.2	1.5	42.6	165.2	40.0	123.2
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	40	55	853	148	4	193	429	166	312
	S.D.	15.7	17.2	207.5	63.8	3.1	38.4	69.9	339.9	67.7
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	39	52	646	112	2	352 *	517	32	364
	S.D.	8.8	26.6	384.1	36.1	1.2	297.5	124.5	17.2	59.9
	N	6	6	6	6	6	6	6	6	6

3M_MN03278994

Table 25

Summary of Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.1	6.6	157	5.4	116
	S.D.	.73	.31	6.1	.48	4.1
	N	6	6	6	6	6
0.03						
	MEAN	10.8	6.3	159	5.5	117
	S.D.	.56	1.09	3.9	.67	4.1
	N	4	4	4	4	4
0.15						
	MEAN	10.4	6.8	158	5.5	115
	S.D.	.64	1.01	3.2	.43	4.2
	N	6	6	6	6	6
0.75						
	MEAN	10.8	6.8	158	5.8	113
	S.D.	.76	1.66	7.9	.73	7.8
	N	6	6	6	6	6

3M_MN03278995

Table 25

Summary of Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	58	20	1.1	8.9	4.7	4.2	.5	9	163	80	59
	S.D.	9.9	4.0	.14	.80	.47	.63	.27	1.3	48.5	47.1	16.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	64	20	1.1	8.6	4.4	4.2	.5	8	110 *	82	47
	S.D.	12.1	6.0	.17	.25	.40	.29	.34	1.7	22.1	28.5	9.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	57	22	1.1	8.8	4.5	4.2	.5	10	130	69	41 *
	S.D.	4.9	3.1	.08	.33	.37	.48	.12	3.1	23.2	13.7	9.2
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	70	18	1.2	8.9	4.5	4.4	.3	15	91 *	64	23 *
	S.D.	14.6	5.3	.14	.43	.41	.40	.08	13.8	23.1	13.5	4.3
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03278996

Table 25

Summary of Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	36	77	315	112	2	235	373	18	256
	S.D.	8.2	43.3	143.3	51.2	.8	105.0	74.3	17.7	55.7
	N	6	6	6	6	6	6	6	5	6
0.03										
	MEAN	38	80	262	108	2	255	378	18	275
	S.D.	16.2	52.8	42.2	97.8	.8	131.7	108.8	13.5	67.7
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	36	66	308	72	3	242	432	25	293
	S.D.	13.4	34.1	120.9	20.3	2.5	116.5	165.5	15.2	129.4
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	40	48	336	61	2	695	380	26	281
	S.D.	18.1	10.0	146.9	24.2	2.3	1217.1	104.1	10.9	76.1
	N	6	6	6	6	6	6	6	6	6

3M_MN03278997

Table 25

Summary of Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	5.6	158	6.0	119
	S.D.	.87	.34	8.5	.81	7.2
	N	6	6	6	6	6
0.03						
	MEAN	9.8	4.1 *	155	5.6	116
	S.D.	1.04	.84	6.9	.46	6.8
	N	4	4	4	4	4
0.15						
	MEAN	9.8	5.0	154	5.4	116
	S.D.	.42	.96	2.2	.52	3.6
	N	6	6	6	6	6
0.75						
	MEAN	10.5	4.9	158	6.3	116
	S.D.	.67	.71	5.0	.75	4.4
	N	6	6	6	6	6

3M_MN03278998

Table 26

Summary of Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	60	18	1.1	8.2	4.8	3.5	.6	6	152	45	63
	S.D.	6.1	3.9	.16	.54	.23	.40	.23	.8	27.5	8.7	11.1
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	64	18	1.2	8.8	5.0	3.8	.3 *	5 *	110 *	33	42 *
	S.D.	9.1	6.3	.16	.65	.34	.47	.08	.5	17.0	6.6	3.7
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	70	17	1.1	8.5	4.9	3.6	.4	6	147	36	48
	S.D.	8.3	2.6	.17	.30	.31	.17	.10	1.3	24.0	10.4	14.3
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	76	22	1.2	9.0	4.9	4.1	.2 *	18 *	48 *	30	13 *
	S.D.	12.6	4.5	.24	.77	.53	.44	.05	8.6	18.8	11.8	5.4
	N	4	4	4	4	4	4	4	4	4	4	4

3M_MN03278999

Table 26

Summary of Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	32	39	735	150	6	210	393	29	280
	S.D.	6.2	17.9	318.7	65.6	3.7	158.7	102.8	13.4	68.5
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	27	29	604	126	4	138	442	24	314
	S.D.	6.2	8.8	353.5	42.6	1.9	58.8	136.5	10.6	96.4
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	36	47	688	148	6	174	381	30	270
	S.D.	13.3	16.9	178.3	55.8	3.8	101.5	82.3	11.8	59.0
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	34	47	389	104	3	182	446	36	320
	S.D.	5.3	19.7	155.7	25.3	1.0	64.5	65.3	22.2	25.2
	N	4	4	4	4	4	4	4	4	4

3M_MN03279000

Table 26

Summary of Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	6.4	154	5.1	111
	S.D.	.43	.82	4.8	.23	1.5
	N	6	6	6	6	6
0.03						
	MEAN	10.0	5.8	156	5.0	109
	S.D.	.20	.96	1.5	.32	2.2
	N	4	4	4	4	4
0.15						
	MEAN	10.1	6.2	154	5.0	110
	S.D.	.41	.82	4.7	.25	2.9
	N	6	6	6	6	6
0.75						
	MEAN	10.3	6.1	153	5.4	106
	S.D.	.62	1.22	6.4	.17	5.3
	N	4	4	4	4	4

3M_MN03279001

Table 26

Summary of Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	58	20	1.1	8.9	4.7	4.2	.4	6	160	56	56
	S.D.	15.2	3.7	.18	.66	.42	.55	.25	.6	46.5	13.3	16.0
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	54	20	1.0	8.6	4.4	4.2	.5	5	122	49	42
	S.D.	7.8	3.4	.17	.76	.47	.38	.24	1.5	21.6	14.7	9.1
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	64	19	1.0	8.9	4.5	4.4	.4	8	129	49	36 *
	S.D.	9.0	3.1	.09	.47	.35	.67	.08	2.0	22.3	15.8	12.1
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	73	20	1.2	9.2	4.6	4.7	.2	7	82 *	53	21 *
	S.D.	11.0	4.7	.16	.37	.31	.63	.08	3.4	14.7	15.8	7.2
	N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279002

Table 26

Summary of Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	41	87	283	114	5	212	378	32	258
	S.D.	25.0	85.9	137.1	53.3	3.1	123.4	84.6	37.1	64.1
	N	6	6	6	6	6	6	6	6	6
0.03										
	MEAN	42	72	239	111	6	823	358	19	260
	S.D.	14.6	26.3	39.7	99.5	6.0	1281.8	100.7	15.0	64.4
	N	4	4	4	4	4	4	4	4	4
0.15										
	MEAN	37	53	254	71	7	182	439	33	294
	S.D.	13.0	36.1	85.3	19.7	5.2	84.7	140.9	21.6	111.7
	N	6	6	6	6	6	6	6	6	6
0.75										
	MEAN	33	44	316	64	3	284	375	31	273
	S.D.	6.2	9.9	172.4	22.7	1.5	119.3	64.9	21.2	43.1
	N	6	6	6	6	6	6	6	6	6

3M_MN03279003

Table 26

Summary of Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	5.3	156	5.3	111
	S.D.	.68	.84	6.8	.56	5.0
	N	6	6	6	6	6
0.03						
	MEAN	9.6	4.4	152	4.8	109
	S.D.	.84	.39	7.2	.94	3.6
	N	4	4	4	4	4
0.15						
	MEAN	9.8	4.8	154	5.0	110
	S.D.	.16	1.10	3.3	.37	1.8
	N	6	6	6	6	6
0.75						
	MEAN	10.3	5.2	156	5.4	110
	S.D.	.69	.76	4.9	.82	3.1
	N	6	6	6	6	6

3M_MN03279004

Table 27

Summary of Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	57	16	1.0	8.0	4.6	3.4	.5	12	132	44	58
	S.D.	2.8	4.9	.07	.21	.07	.14	.14	1.4	28.3	.7	12.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	70	17	.9	9.0	5.1	3.9	.6	16	158	39	61
	S.D.	12.0	.0	.14	.42	.00	.42	.21	.0	37.5	2.8	19.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	73	14	1.0	8.7	4.6	4.2	.6	14	137	69	28
	S.D.	4.2	2.1	.07	.00	.35	.35	.00	3.5	4.2	32.5	7.8
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279005

Table 27

Summary of Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	22	26	932	150	4	139	338	36	250
	S.D.	3.5	3.5	316.1	123.7	.7	77.8	87.7	7.8	58.7
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	37	44	793	138	12	162	454	46	288
	S.D.	8.5	2.1	175.4	68.6	1.4	21.9	42.4	2.1	62.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	32	48	518	143	2	200	505	38	346
	S.D.	4.9	28.3	27.6	22.6	.7	32.5	53.7	21.2	23.3
	N	2	2	2	2	2	2	2	2	2

3M_MN03279006

Table 27

Summary of Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.0	6.3	152	5.0	111
	S.D.	.57	1.13	2.8	.49	1.4
	N	2	2	2	2	2
0.15						
	MEAN	11.0	6.6	155	5.3	108
	S.D.	.78	.00	1.4	.28	2.8
	N	2	2	2	2	2
0.75						
	MEAN	10.8	6.2	159	5.4	111
	S.D.	.21	1.13	2.8	.07	1.4
	N	2	2	2	2	2

3M_MN03279007

Table 27

Summary of Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	59	16	.8	8.6	4.6	4.0	.4	14	119	72	54
	S.D.	11.3	4.9	.14	.42	.21	.21	.42	1.4	46.7	50.2	29.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	76	18	1.0	8.7	4.0	4.6	.6	14	145	56	44
	S.D.	.7	2.1	.00	.14	.07	.21	.00	.7	4.2	4.9	24.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	75	23	1.0	9.3	4.6	4.7	.6	19	133	78	34
	S.D.	9.9	2.8	.21	.42	.57	.14	.07	7.1	2.8	21.9	12.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279008

Table 27

Summary of Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	34	103	184	61	4	137	343	13	244
	S.D.	.7	24.0	33.2	28.3	.7	28.3	48.1	18.4	17.7
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	26	48	182	70	4	657	486	32	350
	S.D.	9.9	7.8	97.6	2.1	4.2	763.7	244.0	21.9	163.3
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	23	50	220	94	4	165	345	38	256
	S.D.	.0	16.3	29.0	37.5	2.1	29.7	69.3	4.2	47.4
	N	2	2	2	2	2	2	2	2	2

3M_MN03279009

Table 27

Summary of Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	9.8	4.8	148	5.4	108
	S.D.	.14	1.56	4.9	.64	6.4
	N	2	2	2	2	2
0.15						
	MEAN	9.8	5.5	152	5.5	110
	S.D.	.14	.28	3.5	.00	2.1
	N	2	2	2	2	2
0.75						
	MEAN	10.3	5.8	152	5.0	110
	S.D.	.14	.64	.0	.21	2.1
	N	2	2	2	2	2

3M_MN03279010

Table 28

Summary of Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	101	16	1.1	8.7	4.8	3.8	.4	8	134	33	77
	S.D.	21.2	1.4	.14	.14	.07	.07	.07	.7	29.0	7.1	5.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	81	17	1.1	9.0	5.2	3.8	.6	8	160	48	84
	S.D.	2.8	.0	.14	.14	.07	.07	.28	4.2	46.0	5.7	26.9
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	72	17	1.0	8.8	4.6	4.2	.4	11	136	64	52
	S.D.	16.3	1.4	.00	.35	.35	.00	.00	5.7	4.9	10.6	2.1
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279011

Table 28

Summary of Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	27	28	900	144	4	177	358	42	270
	S.D.	4.2	.7	334.5	107.5	2.8	45.3	72.1	13.4	50.9
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	34	40	838	142	4	156	462	37	297
	S.D.	21.2	.0	62.9	62.2	3.5	46.0	57.3	21.2	79.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	46	53	680	166	4	257	544	32	372
	S.D.	4.9	28.3	78.5	14.1	3.5	111.7	118.8	21.9	54.4
	N	2	2	2	2	2	2	2	2	2

3M_MN03279012

Table 28

Summary of Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	6.6	154	5.0	117
	S.D.	.35	.64	3.5	.00	.0
	N	2	2	2	2	2
0.15						
	MEAN	10.9	6.6	160	5.2	117
	S.D.	.57	.21	.7	.07	1.4
	N	2	2	2	2	2
0.75						
	MEAN	10.8	7.0	162	5.2	116
	S.D.	.64	1.13	3.5	.28	2.8
	N	2	2	2	2	2

3M_MN03279013

Table 28

Summary of Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	58	18	1.0	9.0	4.6	4.4	.6	9	131	57	70
	S.D.	14.1	3.5	.35	.64	.14	.49	.35	1.4	52.3	5.7	25.5
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	87	20	1.0	9.0	4.1	4.9	.4	11	150	71	72
	S.D.	5.7	1.4	.14	.28	.14	.14	.14	1.4	17.7	1.4	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	92	22	1.2	9.4	4.7	4.7	.2	15	149	95	64
	S.D.	.7	.0	.07	.57	.42	.14	.07	5.7	2.8	48.1	13.4
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279014

Table 28

Summary of Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	36	116	182	58	2	168	329	10	242
	S.D.	9.2	59.4	30.4	20.5	.7	50.9	48.1	14.8	27.6
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	30	66	188	80	3	392	482	34	346
	S.D.	9.2	7.1	105.4	4.2	2.8	384.0	242.5	17.7	157.7
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	25	40	236	98	2	148	331	66	250
	S.D.	4.2	1.4	17.7	33.2	.7	27.6	76.4	66.5	54.4
	N	2	2	2	2	2	2	2	2	2

3M_MN03279015

Table 28

Summary of Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	9.7	4.6	150	4.6	114
	S.D.	.14	.28	4.2	.21	4.9
	N	2	2	2	2	2
0.15						
	MEAN	9.8	5.4	152	5.4	118
	S.D.	.49	.28	4.9	.71	2.1
	N	2	2	2	2	2
0.75						
	MEAN	10.6	5.4	160	5.5	120
	S.D.	.57	.71	7.8	.99	6.4
	N	2	2	2	2	2

3M_MN03279016

Table 29

Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	67	16	1.2	8.5	4.7	3.8	.4	2	130	36	64
	S.D.	18.4	3.5	.14	.42	.14	.28	.42	.7	26.2	15.6	14.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	74	19	1.0	8.8	5.0	3.8	.4	9	168	48	76
	S.D.	2.8	1.4	.14	.21	.21	.00	.14	2.8	50.2	13.4	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	70	18	1.2	8.8	4.8	4.0	.3	8	139	74	40
	S.D.	9.2	3.5	.21	.07	.42	.35	.14	3.5	5.7	23.3	7.1
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279017

Table 29

Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	28	35	842	124	7	176	318	36	239
	S.D.	12.7	5.7	409.4	90.5	4.2	35.4	71.4	7.1	53.7
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	26	39	850	146	4	141	444	39	285
	S.D.	6.4	4.2	105.4	70.0	2.8	22.6	43.1	2.8	75.0
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	38	54	689	164	4	230	512	35	354
	S.D.	3.5	21.2	186.7	7.8	.7	89.8	84.1	24.0	32.5
	N	2	2	2	2	2	2	2	2	2

3M_MN03279018

Table 29

Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	6.0	154	5.8	116
	S.D.	.21	1.13	4.9	.21	.7
	N	2	2	2	2	2
0.15						
	MEAN	11.2	6.4	159	5.6	118
	S.D.	1.20	.21	7.1	.35	6.4
	N	2	2	2	2	2
0.75						
	MEAN	11.2	6.4	160	5.6	114
	S.D.	.57	.92	3.5	.35	2.1
	N	2	2	2	2	2

3M_MN03279019

Table 29

Summary of Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	56	20	.8	8.7	4.4	4.3	.6	8	129	48	62
	S.D.	15.6	4.9	.00	.85	.28	.57	.57	2.1	58.0	7.8	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	74	21	.9	8.9	4.0	4.9	.4	5	144	59	52
	S.D.	4.9	2.8	.14	.28	.00	.28	.21	.0	6.4	11.3	22.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	92	23	1.0	9.0	4.4	4.6	.1	6	144	70	56
	S.D.	3.5	4.2	.14	.35	.42	.07	.00	2.1	.7	31.8	4.2
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279020

Table 29

Summary of Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	40	104	163	58	3	301	309	9	225
	S.D.	9.9	34.6	35.4	17.7	1.4	189.5	26.9	12.7	9.9
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	37	58	172	76	9	1214	468	74	340
	S.D.	14.1	2.1	94.0	.7	7.1	1557.8	256.0	33.9	177.5
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	29	44	226	87	5	142	316	32	236
	S.D.	18.4	10.6	25.5	29.7	1.4	31.8	113.8	2.1	83.4
	N	2	2	2	2	2	2	2	2	2

3M_MN03279021

Table 29

Summary of Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	9.8	4.4	150	5.0	110
	S.D.	.78	.28	7.8	.92	4.9
	N	2	2	2	2	2
0.15						
	MEAN	9.5	5.2	150	4.8	111
	S.D.	.00	.07	2.8	.92	5.7
	N	2	2	2	2	2
0.75						
	MEAN	10.4	5.2	156	6.0	119
	S.D.	.00	.85	2.1	.07	2.8
	N	2	2	2	2	2

3M_MN03279022

Table 30

Summary of Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	71	18	1.2	8.6	4.8	3.8	.4	6	134	52	69
	S.D.	4.2	2.1	.07	.07	.14	.07	.57	.7	34.6	21.9	17.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	62	28	1.4	8.7	5.1	3.6	.7	7	163	61	72
	S.D.	23.3	2.8	.21	.42	.14	.28	.71	1.4	65.1	18.4	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	66	18	1.4	8.6	4.7	3.8	.4	8	136	90	39
	S.D.	14.8	.7	.35	.49	.42	.07	.28	2.1	.7	51.6	7.1
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279023

Table 30

Summary of Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	38	38	772	124	4	966	487	94	366
	S.D.	5.7	6.4	386.8	105.4	1.4	149.2	35.4	5.7	19.8
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	53	68	882	140	6	570	1297	710	962
	S.D.	9.9	7.1	159.1	68.6	.0	77.1	454.0	227.7	326.7
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	61	76	708	157	2	1048	625	30	442
	S.D.	21.2	23.3	191.6	1.4	1.4	368.4	144.2	7.8	85.6
	N	2	2	2	2	2	2	2	2	2

3M_MN03279024

Table 30

Summary of Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.4	5.4	150	5.0	106
	S.D.	.49	.57	3.5	.14	.7
	N	2	2	2	2	2
0.15						
	MEAN	11.0	5.8	154	5.0	106
	S.D.	.92	.64	.0	.07	2.8
	N	2	2	2	2	2
0.75						
	MEAN	10.6	5.8	154	5.4	108
	S.D.	.92	1.13	4.9	.35	.0
	N	2	2	2	2	2

3M_MN03279025

Table 30

Summary of Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	54	15	1.2	8.4	4.4	4.1	.5	10	118	42	58
	S.D.	14.1	1.4	.21	.07	.07	.14	.57	4.9	41.7	8.5	23.3
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	64	28	1.3	8.8	3.9	4.8	.5	8	148	86	60
	S.D.	7.8	.7	.14	.78	.14	.64	.00	3.5	9.2	23.3	19.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	85	18	1.5	8.7	4.3	4.4	.0	6	129	74	60
	S.D.	1.4	9.2	.14	.64	.42	.21	.07	2.1	14.1	9.2	.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279026

Table 30

Summary of Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	56	87	156	60	4	1118	366	0	268
	S.D.	14.1	14.1	18.4	30.4	2.1	132.9	33.9	.0	12.0
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	48	78	160	73	6	1058	554	73	406
	S.D.	17.0	9.9	64.3	8.5	3.5	644.2	237.6	14.1	166.9
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	44	112	235	80	2	1065	449	64	338
	S.D.	2.1	60.1	21.2	35.4	.7	574.2	1.4	43.1	1.4
	N	2	2	2	2	2	2	2	2	2

3M_MN03279027

Table 30

Summary of Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	9.7	4.7	147	5.0	104
	S.D.	.14	.42	1.4	.21	4.9
	N	2	2	2	2	2
0.15						
	MEAN	9.8	5.2	151	5.2	108
	S.D.	.57	.49	4.2	.07	1.4
	N	2	2	2	2	2
0.75						
	MEAN	10.3	4.2	156	5.5	110
	S.D.	.00	.21	2.8	.42	1.4
	N	2	2	2	2	2

3M_MN03279028

Table 31

Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	72	20	1.3	8.9	5.2	3.8	.5	6	126	40	61
	S.D.	2.1	4.9	.00	.00	.21	.21	.28	.7	30.4	7.8	14.1
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	74	26	1.2	8.6	5.2	3.4	.8	6	166	48	74
	S.D.	2.1	3.5	.07	.64	.35	.28	.42	.7	55.9	21.9	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	70	18	1.2	8.4	4.8	3.6	.4	4	119	51	38
	S.D.	9.2	1.4	.14	.14	.35	.21	.21	2.1	4.2	21.2	4.9
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279029

Table 31

Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	50	42	714	138	6	2137	376	38	272
	S.D.	4.9	4.9	461.7	119.5	3.5	19.8	17.7	.7	36.8
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	60	66	820	143	8	1495	1294	579	958
	S.D.	6.4	4.9	134.4	63.6	.7	356.4	489.3	302.6	351.4
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	60	66	622	155	4	1310	516	33	358
	S.D.	2.8	25.5	202.2	1.4	2.8	980.8	142.1	2.8	79.2
	N	2	2	2	2	2	2	2	2	2

3M_MN03279030

Table 31

Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.6	4.7	156	5.4	111
	S.D.	.49	.71	2.1	.14	.0
	N	2	2	2	2	2
0.15						
	MEAN	10.9	5.6	155	5.4	111
	S.D.	1.41	.14	7.1	.49	2.8
	N	2	2	2	2	2
0.75						
	MEAN	10.6	4.9	154	5.4	110
	S.D.	.49	.42	2.1	.64	3.5
	N	2	2	2	2	2

3M_MN03279031

Table 31

Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	55	20	1.0	9.0	4.7	4.2	.8	6	137	49	60
	S.D.	1.4	2.1	.14	.07	.00	.07	.49	.7	35.4	9.9	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	73	24	1.0	8.7	3.9	4.8	.8	6	137	54	54
	S.D.	9.9	2.8	.07	.57	.14	.42	.07	.0	1.4	16.3	24.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	88	23	1.2	8.7	4.4	4.2	.4	9	142	75	60
	S.D.	4.2	2.8	.07	.78	.64	.14	.07	5.7	14.8	28.3	7.8
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279032

Table 31

Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	86	202	162	77	6	2408	398	16	300
	S.D.	34.6	135.1	7.1	45.3	1.4	806.1	85.6	23.3	50.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	50	78	148	79	12	871	467	47	345
	S.D.	17.7	24.0	55.9	1.4	4.9	195.2	230.5	7.1	161.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	56	80	228	86	4	1797	479	47	370
	S.D.	15.6	3.5	21.2	43.1	1.4	786.3	67.9	.0	58.7
	N	2	2	2	2	2	2	2	2	2

3M_MN03279033

Table 31

Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	9.9	4.9	148	5.0	106
	S.D.	.28	.99	4.9	.92	4.2
	N	2	2	2	2	2
0.15						
	MEAN	9.4	4.8	148	5.4	110
	S.D.	.64	.07	3.5	.71	2.1
	N	2	2	2	2	2
0.75						
	MEAN	10.2	4.4	155	5.4	112
	S.D.	.35	.21	2.8	.21	1.4
	N	2	2	2	2	2

3M_MN03279034

Table 32

Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	74	14	1.2	8.7	5.0	3.6	.6	3	132	32	58
	S.D.	8.5	2.8	.00	.28	.21	.07	.35	.0	14.1	.7	3.5
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	91	16	1.2	9.1	5.4	3.6	.4	6	178	41	80
	S.D.	4.2	1.4	.07	.28	.07	.35	.21	.7	54.4	2.8	36.1
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	70	14	1.2	8.9	5.0	4.0	.6	4	118	59	35
	S.D.	7.8	.7	.21	.57	.64	.07	.35	.7	5.7	31.1	12.7
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279035

Table 32

Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	24	24	620	124	6	102	298	16	233
	S.D.	7.1	3.5	320.3	91.9	5.7	34.6	30.4	7.1	18.4
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	25	46	871	150	2	141	450	16	294
	S.D.	5.7	.7	141.4	68.6	.7	31.1	52.3	2.1	83.4
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	34	41	418	138	0	202	422	16	294
	S.D.	4.9	12.7	55.9	13.4	.7	32.5	82.0	4.9	44.5
	N	2	2	2	2	2	2	2	2	2

3M_MN03279036

Table 32

Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.2	6.0	153	5.4	111
	S.D.	.21	.49	4.2	.42	2.8
	N	2	2	2	2	2
0.15						
	MEAN	11.8	6.9	164	6.0	116
	S.D.	1.20	.42	4.2	.49	3.5
	N	2	2	2	2	2
0.75						
	MEAN	10.6	5.3	155	5.0	111
	S.D.	.78	1.98	4.2	.57	2.8
	N	2	2	2	2	2

3M_MN03279037

Table 32

Summary of Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	64	17	1.0	8.5	4.6	3.9	.6	6	120	56	50
	S.D.	21.9	.0	.07	.28	.00	.28	.49	2.1	30.4	5.7	23.3
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	78	17	1.0	8.7	4.1	4.6	.6	5	144	71	47
	S.D.	.7	1.4	.07	.42	.00	.42	.07	1.4	.0	17.0	15.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	100	19	1.0	8.7	4.5	4.2	.2	4	138	78	64
	S.D.	2.1	2.8	.07	.64	.57	.07	.07	1.4	1.4	50.9	12.0
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279038

Table 32

Summary of Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	43	134	156	72	4	222	268	10	204
	S.D.	18.4	69.3	24.7	33.2	2.1	31.1	34.6	2.1	17.0
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	32	50	140	78	7	183	339	13	250
	S.D.	10.6	22.6	65.1	3.5	4.2	100.4	137.2	2.8	87.0
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	25	54	232	94	2	124	296	18	230
	S.D.	.0	14.8	22.6	43.1	2.1	14.1	89.8	7.1	66.5
	N	2	2	2	2	2	2	2	2	2

3M_MN03279039

Table 32

Summary of Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	9.9	5.2	148	5.0	108
	S.D.	.42	.35	5.7	.14	3.5
	N	2	2	2	2	2
0.15						
	MEAN	9.8	5.2	152	5.6	112
	S.D.	.42	.21	1.4	.35	.7
	N	2	2	2	2	2
0.75						
	MEAN	10.4	5.4	154	6.2	116
	S.D.	.14	.35	.7	.85	2.8
	N	2	2	2	2	2

3M_MN03279040

Table 33

Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	82	16	1.2	8.8	4.7	4.1	.4	6	134	31	70
	S.D.	4.9	2.8	.07	.14	.14	.00	.21	.7	21.9	1.4	9.9
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	79	19	1.2	8.8	5.1	3.7	.4	4	166	36	92
	S.D.	2.8	.0	.07	.28	.28	.00	.21	1.4	48.1	6.4	31.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	79	16	1.4	9.4	5.1	4.3	.6	7	138	44	57
	S.D.	5.7	.0	.00	.14	.14	.28	.35	4.2	9.2	10.6	14.1
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279041

Table 33

Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	24	25	505	116	10	111	262	14	202
	S.D.	6.4	7.1	277.2	94.8	12.7	46.7	4.2	4.9	1.4
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	30	34	754	136	3	171	402	12	264
	S.D.	.7	2.1	130.1	60.1	2.8	58.0	62.9	.7	81.3
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	36	40	404	148	0	165	440	16	297
	S.D.	12.7	3.5	88.4	1.4	.0	.0	111.0	7.8	52.3
	N	2	2	2	2	2	2	2	2	2

3M_MN03279042

Table 33

Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.6	6.6	160	6.0	116
	S.D.	.21	.07	3.5	.57	6.4
	N	2	2	2	2	2
0.15						
	MEAN	11.2	7.0	166	6.4	120
	S.D.	.28	.92	3.5	.78	3.5
	N	2	2	2	2	2
0.75						
	MEAN	11.9	5.8	172	6.1	118
	S.D.	.14	.57	3.5	.14	3.5
	N	2	2	2	2	2

3M_MN03279043

Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0												
	MEAN	60	16	1.0	8.5	4.4	4.1	.6	6	124	53	64
	S.D.	9.9	.7	.07	.42	.00	.42	.35	.7	39.6	2.8	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	72	18	1.0	8.4	3.8	4.6	.6	5	138	60	62
	S.D.	2.1	1.4	.21	.21	.21	.00	.07	.0	12.7	19.1	34.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	96	19	1.2	8.4	4.3	4.2	.3	5	146	76	74
	S.D.	4.9	.0	.00	.78	.42	.35	.00	1.4	1.4	50.9	7.8
	N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279044

Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0										
	MEAN	42	120	151	69	0	154	280	12	212
	S.D.	16.3	100.4	28.3	33.9	.0	87.0	50.2	.7	28.3
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	26	34	146	79	2	94	353	11	261
	S.D.	.7	4.2	70.0	4.2	.7	20.5	142.8	4.2	93.3
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	28	59	213	89	2	130	311	15	240
	S.D.	12.0	28.3	38.2	39.6	2.1	47.4	86.3	4.2	64.3
	N	2	2	2	2	2	2	2	2	2

3M_MN03279045

Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0						
	MEAN	10.1	5.4	151	5.2	110
	S.D.	.00	.28	1.4	.14	2.1
	N	2	2	2	2	2
0.15						
	MEAN	10.0	5.2	156	5.8	114
	S.D.	.28	.35	1.4	.49	3.5
	N	2	2	2	2	2
0.75						
	MEAN	10.5	5.6	162	6.2	120
	S.D.	.28	.35	4.2	.78	6.4
	N	2	2	2	2	2

3M_MN03279046

Table 34

Summary of Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	41.5	1.026	7.3
	S.D.	17.76	.0050	.75
	N	6	6	6
0.03				
	MEAN	52.5	1.021	7.4
	S.D.	10.15	.0021	.48
	N	4	4	4
0.15				
	MEAN	97.8	1.019	7.1
	S.D.	71.41	.0078	.20
	N	6	6	6
0.75				
	MEAN	83.5	1.018	7.2
	S.D.	46.63	.0066	.26
	N	6	6	6

3M_MN03279047

Table 34

Summary of Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	90.7	1.018	7.3
	S.D.	75.84	.0060	.41
	N	6	6	6
0.03				
	MEAN	92.5	1.019	7.1
	S.D.	88.38	.0082	.25
	N	4	4	4
0.15				
	MEAN	71.8	1.021	7.8
	S.D.	33.80	.0052	.42
	N	6	6	6
0.75				
	MEAN	88.0	1.020	7.3
	S.D.	78.91	.0068	.41
	N	6	6	6

3M_MN03279048

Table 35

Summary of Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	50.2	1.018	7.5
	S.D.	13.75	.0071	.45
	N	6	6	6
0.03				
	MEAN	72.5	1.021	7.5
	S.D.	29.73	.0048	.41
	N	4	4	4
0.15				
	MEAN	94.3	1.019	7.2
	S.D.	105.16	.0092	.27
	N	6	6	6
0.75				
	MEAN	79.0	1.018	7.3
	S.D.	42.12	.0082	.75
	N	6	6	6

3M_MN03279049

Table 35

Summary of Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	118.5	1.014	8.0
	S.D.	218.53	.0103	.32
	N	6	6	6
0.03				
	MEAN	86.8	1.018	7.8
	S.D.	56.91	.0056	.29
	N	4	4	4
0.15				
	MEAN	83.7	1.017	7.5
	S.D.	53.05	.0076	.32
	N	6	6	6
0.75				
	MEAN	100.2	1.022	7.8
	S.D.	155.27	.0094	.61
	N	6	6	6

3M_MN03279050

Table 36

Summary of Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	77.5	1.018	8.0
	S.D.	50.66	.0054	.32
	N	6	6	6
0.03				
	MEAN	62.2	1.018	8.0
	S.D.	34.86	.0076	.41
	N	4	4	4
0.15				
	MEAN	94.5	1.015	7.8
	S.D.	59.43	.0095	.42
	N	6	6	6
0.75				
	MEAN	68.0	1.017	7.9
	S.D.	26.39	.0051	.38
	N	6	6	6

3M_MN03279051

Table 36

Summary of Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	74.3	1.019	8.2
	S.D.	61.32	.0076	.26
	N	6	6	6
0.03				
	MEAN	53.5	1.020	7.6
	S.D.	32.58	.0056	.48
	N	4	4	4
0.15				
	MEAN	62.3	1.020	7.8
	S.D.	28.86	.0061	.26
	N	6	6	6
0.75				
	MEAN	81.0	1.017	7.6 *
	S.D.	51.27	.0091	.38
	N	6	6	6

3M_MN03279052

Table 37

Summary of Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	47.5	1.024	7.5
	S.D.	7.31	.0046	.77
	N	6	6	6
0.03				
	MEAN	65.8	1.018	7.8
	S.D.	40.43	.0062	.29
	N	4	4	4
0.15				
	MEAN	101.2	1.014 *	7.4
	S.D.	73.16	.0061	.49
	N	6	6	6
0.75				
	MEAN	54.0	1.020	7.2
	S.D.	19.47	.0066	.88
	N	6	6	6

3M_MN03279053

Table 37

Summary of Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	93.3	1.015	8.0
	S.D.	68.15	.0053	.00
	N	6	6	6
0.03				
	MEAN	64.8	1.018	7.4
	S.D.	30.02	.0034	.48
	N	4	4	4
0.15				
	MEAN	63.2	1.018	7.5
	S.D.	22.56	.0073	.63
	N	6	6	6
0.75				
	MEAN	120.5	1.017	7.8
	S.D.	125.14	.0096	.42
	N	6	6	6

3M_MN03279054

Table 38

Summary of Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	131.3	1.013	7.1
	S.D.	110.42	.0072	.49
	N	6	6	6
0.03				
	MEAN	55.0	1.020	7.4
	S.D.	21.32	.0052	.48
	N	4	4	4
0.15				
	MEAN	137.8	1.011	7.1
	S.D.	114.54	.0062	.20
	N	6	6	6
0.75				
	MEAN	180.0	1.011	7.1
	S.D.	136.48	.0082	.58
	N	6	6	6

3M_MN03279055

Table 38

Summary of Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	85.2	1.016	7.5
	S.D.	53.91	.0084	.32
	N	6	6	6
0.03				
	MEAN	60.5	1.016	7.0
	S.D.	36.93	.0029	.41
	N	4	4	4
0.15				
	MEAN	40.7	1.022	7.1
	S.D.	11.15	.0040	.20
	N	6	6	6
0.75				
	MEAN	89.0	1.017	7.1
	S.D.	93.46	.0085	.66
	N	6	6	6

3M_MN03279056

Table 39

Summary of Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	116.2	1.014	7.9
	S.D.	79.33	.0072	.20
	N	6	6	6
0.03				
	MEAN	75.5	1.017	7.9
	S.D.	26.20	.0022	.25
	N	4	4	4
0.15				
	MEAN	122.3	1.013	7.5
	S.D.	125.43	.0053	1.00
	N	6	6	6
0.75				
	MEAN	121.0	1.013	7.2
	S.D.	108.83	.0059	.65
	N	4	4	4

3M_MN03279057

Table 39

Summary of Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	85.7	1.016	8.1
	S.D.	40.59	.0050	.20
	N	6	6	6
0.03				
	MEAN	76.2	1.016	7.6
	S.D.	31.48	.0054	.48
	N	4	4	4
0.15				
	MEAN	73.3	1.017	7.9
	S.D.	25.33	.0055	.20
	N	6	6	6
0.75				
	MEAN	131.8	1.014	7.8
	S.D.	156.54	.0058	.26
	N	6	6	6

3M_MN03279058

Table 40

Summary of Clinical Urinalysis Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	179.5	1.010	7.2
	S.D.	24.75	.0000	.35
	N	2	2	2
0.15				
	MEAN	239.5	1.007	7.5
	S.D.	79.90	.0028	.00
	N	2	2	2
0.75				
	MEAN	87.5	1.013	7.0
	S.D.	36.06	.0028	.71
	N	2	2	2

3M_MN03279059

Table 40

Summary of Clinical Urinalysis Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	143.0	1.014	7.8
	S.D.	77.78	.0078	.35
	N	2	2	2
0.15				
	MEAN	121.0	1.015	7.2
	S.D.	80.61	.0000	.35
	N	2	2	2
0.75				
	MEAN	89.0	1.015	7.5
	S.D.	36.77	.0000	.71
	N	2	2	2

3M_MN03279060

Table 41

Summary of Clinical Urinalysis Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	195.5	1.009	7.8
	S.D.	9.19	.0014	.35
	N	2	2	2
0.15				
	MEAN	196.0	1.010	7.5
	S.D.	132.94	.0064	.00
	N	2	2	2
0.75				
	MEAN	83.0	1.017	7.8
	S.D.	29.70	.0042	.35
	N	2	2	2

3M_MN03279061

Table 41

Summary of Clinical Urinalysis Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	117.0	1.018	8.0
	S.D.	100.41	.0113	.00
	N	2	2	2
0.15				
	MEAN	131.5	1.016	7.2
	S.D.	62.93	.0021	.35
	N	2	2	2
0.75				
	MEAN	91.5	1.016	7.8
	S.D.	48.79	.0035	.35
	N	2	2	2

3M_MN03279062

Table 42

Summary of Clinical Urinalysis Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	284.0	1.004	6.8
	S.D.	50.91	.0007	.35
	N	2	2	2
0.15				
	MEAN	234.0	1.007	7.2
	S.D.	169.71	.0042	.35
	N	2	2	2
0.75				
	MEAN	67.5	1.018	7.0
	S.D.	50.20	.0106	.71
	N	2	2	2

3M_MN03279063

Table 42

Summary of Clinical Urinalysis Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	141.5	1.006	7.8
	S.D.	33.23	.0014	.35
	N	2	2	2
0.15				
	MEAN	63.5	1.020	7.5
	S.D.	37.48	.0050	.00
	N	2	2	2
0.75				
	MEAN	64.5	1.010	7.2
	S.D.	58.69	.0007	1.06
	N	2	2	2

3M_MN03279064

Table 43

Summary of Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	296.0	1.008	6.8
	S.D.	254.56	.0092	.35
	N	2	2	2
0.15				
	MEAN	99.5	1.016	6.5
	S.D.	94.05	.0099	.71
	N	2	2	2
0.75				
	MEAN	47.5	1.020	6.0
	S.D.	4.95	.0092	.00
	N	2	2	2

3M_MN03279065

Table 43

Summary of Clinical Urinalysis Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	220.5	1.006	8.0
	S.D.	188.80	.0050	.00
	N	2	2	2
0.15				
	MEAN	59.0	1.018	6.5
	S.D.	24.04	.0042	.71
	N	2	2	2
0.75				
	MEAN	92.0	1.014	6.8
	S.D.	29.70	.0035	.35
	N	2	2	2

3M_MN03279066

Table 44

Summary of Clinical Urinalysis Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	206.5	1.017	7.8
	S.D.	81.32	.0028	.35
	N	2	2	2
0.15				
	MEAN	74.5	1.018	7.5
	S.D.	10.61	.0000	.71
	N	2	2	2
0.75				
	MEAN	90.0	1.018	6.8
	S.D.	14.14	.0050	1.06
	N	2	2	2

3M_MN03279067

Table 44

Summary of Clinical Urinalysis Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	158.0	1.011	8.0
	S.D.	11.31	.0000	.00
	N	2	2	2
0.15				
	MEAN	68.5	1.021	7.0
	S.D.	13.44	.0014	.00
	N	2	2	2
0.75				
	MEAN	76.0	1.018	7.0
	S.D.	46.67	.0007	.71
	N	2	2	2

3M_MN03279068

Table 45

Summary of Clinical Urinalysis Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	185.0	1.010	8.0
	S.D.	120.21	.0028	.00
	N	2	2	2
0.15				
	MEAN	182.0	1.008	8.0
	S.D.	147.08	.0050	.00
	N	2	2	2
0.75				
	MEAN	84.0	1.012	8.0
	S.D.	8.49	.0050	.00
	N	2	2	2

3M_MN03279069

Table 45

Summary of Clinical Urinalysis Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	214.0	1.009	8.0
	S.D.	164.05	.0057	.00
	N	2	2	2
0.15				
	MEAN	145.0	1.011	7.8
	S.D.	74.95	.0042	.35
	N	2	2	2
0.75				
	MEAN	118.0	1.005	8.0
	S.D.	82.02	.0042	.00
	N	2	2	2

3M_MN03279070

Table 46

Summary of Clinical Urinalysis Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	430.0	1.005	8.0
	S.D.	70.71	.0000	.00
	N	2	2	2
0.15				
	MEAN	300.0	1.006	7.8
	S.D.	148.49	.0028	.35
	N	2	2	2
0.75				
	MEAN	222.5	1.010	8.0
	S.D.	173.24	.0071	.00
	N	2	2	2

3M_MN03279071

Table 46

Summary of Clinical Urinalysis Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	132.5	1.011	8.0
	S.D.	38.89	.0057	.00
	N	2	2	2
0.15				
	MEAN	67.5	1.018	8.0
	S.D.	24.75	.0014	.00
	N	2	2	2
0.75				
	MEAN	99.0	1.014	8.0
	S.D.	80.61	.0050	.00
	N	2	2	2

3M_MN03279072

Table 47

Summary of Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		PCOAO IU/G
0		
	MEAN	5
	S.D.	1.5
	N	4
0.03		
	MEAN	5
	S.D.	1.0
	N	4
0.15		
	MEAN	6
	S.D.	.6
	N	4
0.75		
	MEAN	7
	S.D.	1.4
	N	2

3M_MN03279073

Table 47

Summary of Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		PCOAO IU/G
0		
	MEAN	4
	S.D.	.8
	N	4
0.03		
	MEAN	4
	S.D.	1.3
	N	4
0.15		
	MEAN	6
	S.D.	1.0
	N	4
0.75		
	MEAN	6 *
	S.D.	.8
	N	4

3M_MN03279074

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LEFT ADRENAL

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.2858	0.0083	0.0045
STANDARD DEV:		765.9	0.0195	0.0012	0.0002
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.3105	0.0087	0.0051
STANDARD DEV:		524.0	0.0367	0.0015	0.0008
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2692	0.0084	0.0043
STANDARD DEV:		199.8	0.0298	0.0006	0.0003
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	0.2933	0.0103	0.0052
STANDARD DEV:		304.9	0.0650	0.0016	0.0014
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	0.3815	0.0132	0.0063
STANDARD DEV:		723.4	0.0508	0.0033	0.0010
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	0.3400	0.0122	0.0058
STANDARD DEV:		335.9	0.0589	0.0012	0.0010

3M_MN03279075

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LEFT ADRENAL

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4					
		NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	0.3665	0.0120*	0.0055
		STANDARD DEV:	1120.8	0.1237	0.0003	0.0012
F	4					
		NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	0.3468	0.0134	0.0061
		STANDARD DEV:	403.1	0.0265	0.0029	0.0004

3M_MN03279076

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RIGHT ADRENAL

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.2093	0.0059	0.0033
STANDARD DEV:		765.9	0.0503	0.0011	0.0008
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.2240	0.0063	0.0036
STANDARD DEV:		524.0	0.0243	0.0012	0.0005
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2135	0.0067	0.0033
STANDARD DEV:		199.8	0.0484	0.0014	0.0006
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	0.2178	0.0076	0.0039
STANDARD DEV:		304.9	0.0772	0.0021	0.0016
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	0.2768	0.0095	0.0046
STANDARD DEV:		723.4	0.0356	0.0020	0.0005
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	0.2425	0.0088	0.0042
STANDARD DEV:		335.9	0.0377	0.0008	0.0006

3M_MN03279077

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RIGHT ADRENAL

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4					
		NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	0.2725	0.0090	0.0041
		STANDARD DEV:	1120.8	0.0686	0.0011	0.0006
F	4					
		NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	0.2535	0.0098	0.0044
		STANDARD DEV:	403.1	0.0306	0.0025	0.0004

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

BRAIN

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M 1	NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	63.1425	1.8330	1.0000
	STANDARD DEV:	765.9	1.1363	0.3051	0.0000
M 2	NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	61.7943	1.7415	1.0000
	STANDARD DEV:	524.0	5.5692	0.3701	0.0000
M 3	NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	63.3520	1.9873	1.0000
	STANDARD DEV:	199.8	5.3720	0.1406	0.0000
F 1	NUMBER IN GROUP:	4	4	4	4
	MEAN:	2821.3	56.6408	2.0307	1.0000
	STANDARD DEV:	304.9	4.1710	0.3056	0.0000
F 2	NUMBER IN GROUP:	4	4	4	4
	MEAN:	2988.8	60.6083	2.1053	1.0000
	STANDARD DEV:	723.4	2.6726	0.4471	0.0000
F 3	NUMBER IN GROUP:	4	4	4	4
	MEAN:	2768.8	58.3910	2.1321	1.0000
	STANDARD DEV:	335.9	3.2163	0.2735	0.0000

3M_MN03279079

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

BRAIN

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4					
		NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	66.2635	2.2566	1.0000
		STANDARD DEV:	1120.8	7.8154	0.5678	0.0000
F	4					
		NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	57.0957	2.1883	1.0000
		STANDARD DEV:	403.1	2.2179	0.3459	0.0000

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF EPIDIDYMIS

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	1.1407	0.0314	0.0180
STANDARD DEV:		765.9	0.5031	0.0076	0.0076
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	1.4208	0.0371	0.0243
STANDARD DEV:		524.0	0.9897	0.0196	0.0197
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.9760	0.0306	0.0155
STANDARD DEV:		199.8	0.0910	0.0027	0.0025
F	1				
NUMBER IN GROUP:		4			
MEAN:		2821.3			
STANDARD DEV:		304.9			
F	2				
NUMBER IN GROUP:		4			
MEAN:		2988.8			
STANDARD DEV:		723.4			
F	3				
NUMBER IN GROUP:		4			
MEAN:		2768.8			
STANDARD DEV:		335.9			

3M_MN03279081

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF EPIDIDYMIS

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	1.3095	0.0387	0.0189
		STANDARD DEV:	1120.8	1.0812	0.0210	0.0141
F	4	NUMBER IN GROUP:	4			
		MEAN:	2653.8			
		STANDARD DEV:	403.1			

3M_MN03279082

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT EPIDIDYMIS

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	1.2160	0.0340	0.0192
STANDARD DEV:		765.9	0.4066	0.0063	0.0061
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	1.3563	0.0353	0.0232
STANDARD DEV:		524.0	0.9663	0.0191	0.0192
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	1.0213	0.0322	0.0163
STANDARD DEV:		199.8	0.0786	0.0039	0.0025
F	1				
NUMBER IN GROUP:		4			
MEAN:		2821.3			
STANDARD DEV:		304.9			
F	2				
NUMBER IN GROUP:		4			
MEAN:		2988.8			
STANDARD DEV:		723.4			
F	3				
NUMBER IN GROUP:		4			
MEAN:		2768.8			
STANDARD DEV:		335.9			

3M_MN03279083

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT EPIDIDYMIS

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	1.3805	0.0396	0.0198
		STANDARD DEV:	1120.8	1.3371	0.0290	0.0178
F	4	NUMBER IN GROUP:	4			
		MEAN:	2653.8			
		STANDARD DEV:	403.1			

3M_MN03279084

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF KIDNEY

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	6.2305	0.1780	0.0985
STANDARD DEV:		765.9	0.8729	0.0147	0.0120
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	6.6015	0.1838	0.1078
STANDARD DEV:		524.0	0.4812	0.0231	0.0163
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	5.8875	0.1844	0.0936
STANDARD DEV:		199.8	0.6683	0.0157	0.0150

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	5.5023	0.1943	0.0978
STANDARD DEV:		304.9	0.9665	0.0191	0.0214
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	5.8693	0.1993	0.0972
STANDARD DEV:		723.4	0.9019	0.0191	0.0166
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	5.5955	0.2033	0.0960
STANDARD DEV:		335.9	0.4375	0.0174	0.0090

3M_MN03279085

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF KIDNEY

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	5.5310	0.1837	0.0828
		STANDARD DEV:	1120.8	1.3916	0.0217	0.0112
F	4	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	5.7638	0.2190	0.1007
		STANDARD DEV:	403.1	0.9586	0.0364	0.0138

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT KIDNEY

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	6.0052	0.1712	0.0949
STANDARD DEV:		765.9	0.9353	0.0127	0.0130
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	6.7495	0.1875	0.1104
STANDARD DEV:		524.0	0.6929	0.0228	0.0206
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	5.7358	0.1795	0.0910
STANDARD DEV:		199.8	0.6730	0.0140	0.0131

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	5.2995	0.1876	0.0941
STANDARD DEV:		304.9	0.7814	0.0168	0.0173
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	5.7718	0.1966	0.0956
STANDARD DEV:		723.4	0.8467	0.0260	0.0163
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	5.4028	0.1965	0.0926
STANDARD DEV:		335.9	0.4663	0.0210	0.0067

3M_MN03279087

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT KIDNEY

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4					
		NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	5.4045	0.1801	0.0810
		STANDARD DEV:	1120.8	1.2594	0.0247	0.0095
F	4					
		NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	5.7878	0.2191	0.1011
		STANDARD DEV:	403.1	1.1793	0.0375	0.0181

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LIVER

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	54.9200	1.5733	0.8689
STANDARD DEV:		765.9	8.1496	0.2144	0.1203
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	62.0868	1.7413	1.0090
STANDARD DEV:		524.0	5.2757	0.3311	0.0994
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	57.3325	1.7955	0.9059
STANDARD DEV:		199.8	5.5102	0.0901	0.0581

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	51.0925	1.8015	0.9104
STANDARD DEV:		304.9	9.4330	0.1518	0.2199
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	56.8278	1.9074	0.9392
STANDARD DEV:		723.4	12.5811	0.0398	0.2089
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	57.0393	2.0747	0.9783
STANDARD DEV:		335.9	3.1240	0.1801	0.0629

3M_MN03279089

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LIVER

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	85.2815	2.7247*	1.2616
		STANDARD DEV:	1120.8	38.3782	0.2548	0.4304
F	4	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	75.2997*	2.8466*	1.3189*
		STANDARD DEV:	403.1	13.3835	0.3447	0.2262

3M_MN03279090

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF OVARY

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1	NUMBER IN GROUP:	4			
		MEAN:	3540.0			
		STANDARD DEV:	765.9			
M	2	NUMBER IN GROUP:	4			
		MEAN:	3631.3			
		STANDARD DEV:	524.0			
M	3	NUMBER IN GROUP:	4			
		MEAN:	3190.0			
		STANDARD DEV:	199.8			
F	1	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2821.3	0.1688	0.0059	0.0030
		STANDARD DEV:	304.9	0.0679	0.0022	0.0013
F	2	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2988.8	0.1723	0.0056	0.0028
		STANDARD DEV:	723.4	0.0729	0.0011	0.0012
F	3	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2768.8	0.1873	0.0067	0.0032
		STANDARD DEV:	335.9	0.0847	0.0028	0.0015

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4				
NUMBER IN GROUP:		2			
MEAN:		3077.5			
STANDARD DEV:		1120.8			
F	4				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2653.8	0.1590	0.0063	0.0028
STANDARD DEV:		403.1	0.0563	0.0031	0.0009

3M_MN03279092

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT OVARY

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4			
MEAN:		3540.0			
STANDARD DEV:		765.9			
M	2				
NUMBER IN GROUP:		4			
MEAN:		3631.3			
STANDARD DEV:		524.0			
M	3				
NUMBER IN GROUP:		4			
MEAN:		3190.0			
STANDARD DEV:		199.8			
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	0.1423	0.0050	0.0025
STANDARD DEV:		304.9	0.0491	0.0012	0.0010
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	0.1788	0.0061	0.0029
STANDARD DEV:		723.4	0.0453	0.0014	0.0007
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	0.1367	0.0049	0.0024
STANDARD DEV:		335.9	0.0353	0.0010	0.0007

3M_MN03279093

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4				
NUMBER IN GROUP:		2			
MEAN:		3077.5			
STANDARD DEV:		1120.8			
F	4				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2653.8	0.1498	0.0058	0.0026
STANDARD DEV:		403.1	0.0169	0.0015	0.0003

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF TESTIS

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	6.9795	0.1918	0.1100
STANDARD DEV:		765.9	3.7391	0.0803	0.0572
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	7.8848	0.2009	0.1369
STANDARD DEV:		524.0	7.4545	0.1587	0.1434
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	5.0977	0.1600	0.0814
STANDARD DEV:		199.8	0.6925	0.0215	0.0173

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	1				
NUMBER IN GROUP:		4			
MEAN:		2821.3			
STANDARD DEV:		304.9			
F	2				
NUMBER IN GROUP:		4			
MEAN:		2988.8			
STANDARD DEV:		723.4			
F	3				
NUMBER IN GROUP:		4			
MEAN:		2768.8			
STANDARD DEV:		335.9			

3M_MN03279095

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF TESTIS

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4					
		NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	7.0340	0.1946	0.0998
		STANDARD DEV:	1120.8	7.9238	0.1866	0.1078
F	4					
		NUMBER IN GROUP:	4			
		MEAN:	2653.8			
		STANDARD DEV:	403.1			

3M_MN03279096

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT TESTIS

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	6.7453	0.1868	0.1064
STANDARD DEV:		765.9	3.3813	0.0764	0.0518
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	8.1230	0.2089	0.1403
STANDARD DEV:		524.0	7.2175	0.1504	0.1403
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	5.0045	0.1568	0.0798
STANDARD DEV:		199.8	0.7091	0.0194	0.0163
F	1				
NUMBER IN GROUP:		4			
MEAN:		2821.3			
STANDARD DEV:		304.9			
F	2				
NUMBER IN GROUP:		4			
MEAN:		2988.8			
STANDARD DEV:		723.4			
F	3				
NUMBER IN GROUP:		4			
MEAN:		2768.8			
STANDARD DEV:		335.9			

3M_MN03279097

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4				
NUMBER IN GROUP:		2	2	2	2
MEAN:		3077.5	6.9155	0.1906	0.0980
STANDARD DEV:		1120.8	7.8977	0.1872	0.1076

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	4				
NUMBER IN GROUP:		4			
MEAN:		2653.8			
STANDARD DEV:		403.1			

3M_MN03279098

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

PANCREAS

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	5.4570	0.1576	0.0863
STANDARD DEV:		765.9	0.8021	0.0319	0.0119
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	4.8133	0.1309	0.0799
STANDARD DEV:		524.0	1.3674	0.0234	0.0298
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	4.3790	0.1365	0.0687
STANDARD DEV:		199.8	1.1403	0.0294	0.0138

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	4.4270	0.1571	0.0787
STANDARD DEV:		304.9	0.4797	0.0097	0.0125
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	5.9108*	0.2030	0.0982
STANDARD DEV:		723.4	1.0351	0.0437	0.0216
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	4.6248	0.1678	0.0792
STANDARD DEV:		335.9	0.4099	0.0126	0.0059

3M_MN03279099

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

PANCREAS

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	4.1355	0.1341	0.0615
		STANDARD DEV:	1120.8	1.5450	0.0014	0.0161
F	4	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	4.3725	0.1659	0.0768
		STANDARD DEV:	403.1	0.4273	0.0119	0.0089

3M_MN03279100

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF THYROID/PARA

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.1675	0.0047	0.0026
STANDARD DEV:		765.9	0.0479	0.0004	0.0007
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.2750	0.0074	0.0046
STANDARD DEV:		524.0	0.1374	0.0028	0.0027
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2075	0.0064	0.0032
STANDARD DEV:		199.8	0.0792	0.0022	0.0011
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	0.2567	0.0088	0.0047
STANDARD DEV:		304.9	0.1415	0.0037	0.0029
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	0.2138	0.0071	0.0035
STANDARD DEV:		723.4	0.0751	0.0013	0.0012
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	0.1542	0.0057	0.0027
STANDARD DEV:		335.9	0.0382	0.0018	0.0007

3M_MN03279101

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF THYROID/PARA

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	0.2020	0.0063	0.0030
		STANDARD DEV:	1120.8	0.1174	0.0015	0.0014
F	4	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	0.1872	0.0071	0.0033
		STANDARD DEV:	403.1	0.0463	0.0017	0.0008

3M_MN03279102

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT THYROID/PARA

SEX DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	0.1690	0.0046	0.0027
STANDARD DEV:		765.9	0.0711	0.0009	0.0011
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	0.2632	0.0070	0.0045
STANDARD DEV:		524.0	0.1614	0.0035	0.0031
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	0.2575	0.0080	0.0040
STANDARD DEV:		199.8	0.1150	0.0032	0.0016
F	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2821.3	0.2455	0.0084	0.0044
STANDARD DEV:		304.9	0.1300	0.0034	0.0027
F	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2988.8	0.2350	0.0078	0.0039
STANDARD DEV:		723.4	0.0815	0.0016	0.0013
F	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		2768.8	0.1332	0.0048	0.0023
STANDARD DEV:		335.9	0.0279	0.0007	0.0005

3M_MN03279103

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT THYROID/PARA

SEX	DOSE GROUP		TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	4	NUMBER IN GROUP:	2	2	2	2
		MEAN:	3077.5	0.2360	0.0072	0.0034
		STANDARD DEV:	1120.8	0.1556	0.0024	0.0019
F	4	NUMBER IN GROUP:	4	4	4	4
		MEAN:	2653.8	0.1945	0.0073	0.0034
		STANDARD DEV:	403.1	0.0633	0.0019	0.0011

Incidence of Macroscopic Observations

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
** TOP OF LIST **									
GENERAL COMMENT (GC)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
BONE MARROW SMEAR TAKEN		4	4	4	2	4	4	4	4
EYES - DAVIDSONS		4	4	4	2	4	4	4	4
NO MACROSCOPIC LESIONS		2	2	3	0	1	0	1	0
ANIMAL OBESE		0	0	0	0	0	1	0	0
LUNG (LU)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	3	2	2	1	1	0
ADHESION(S)		0	1	1	0	2	3	1	0
RED FOCUS(I)/AREA(S)		1	0	0	0	0	0	1	2
DARK FOCUS(I)/AREA(S)		0	0	0	0	0	2	1	2
LIGHT FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1
LIVER (LI)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	0	3	3	4	3
MOTTLED		0	0	0	2	0	0	0	1
ADHESION(S)		0	0	0	0	0	1	0	0
LIGHT FOCUS(I)/AREA(S)		0	0	0	0	1	0	0	0
SPLEEN (SP)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	4	2	4	4	3	4
LARGE		1	1	0	0	0	0	0	0

** CONTINUED ON NEXT PAGE **

3M_MN03279105

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
** FROM PREVIOUS PAGE **									
SPLEEN (SP)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	4	2	4	4	3	4
LIGHT FOCUS(I)/AREA(S)		0	0	0	0	0	0	1	0
LN, MESENTERIC (MS)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	1	4	4	4	4
DIFFUSELY RED		0	0	0	1	0	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	0	4	4	4	2
DIFFUSELY DARK		0	0	0	2	0	0	0	2
STOMACH, GL (ST)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	3	4	4	4
RED FOCUS(I)/AREA(S)		0	0	0	0	1	0	0	0
CECUM (CE)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	4	4	2	3
RED FOCUS(I)/AREA(S)		0	0	0	0	0	0	2	0
DARK FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1

3M_MN03279106

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

ORGAN AND KEYWORD(S) OR PHRASE		--- NUMBER-OF-ANIMALS-AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		4	4	4	2	4	4	4	4
COLON (CO)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	4	4	4	3
DARK FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1
SKIN (SK)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	4	4	2	4	4	4	2
ABRASION(S)/ULCERATION(S)		1	0	0	0	0	0	0	0
ALOPECIA-DIFFUSE		0	0	0	0	0	0	0	1
ALOPECIA-FOCAL		0	0	0	0	0	0	0	1
TESTIS (TE)	NUMBER EXAMINED:	4	4	4	2	0	0	0	0
	NOT REMARKABLE:	4	3	4	2	0	0	0	0
LARGE		0	1	0	0	0	0	0	0
ADIPOSE TISSUE (AT)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	3	2	4	4	4	3
RAISED FOCUS(I)/AREA(S)		0	0	1	0	0	0	0	1

** END OF LIST **

3M_MN03279107

Incidence of Macroscopic Observations

Recovery Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=4;WEEKS=ALL
DEATH=U;SUBSET=ALL

ORGAN AND KEYWORD(S) OR PHRASE	NUMBER:	--- NUMBER OF ANIMALS AFFECTED --- SEX: MALE	FEMALE
	GROUP:	-4-	-4-
** TOP OF LIST **			
GENERAL COMMENT (GC)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	1
NO MACROSCOPIC LESIONS		1	1
LUNG (LU)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	2
ADHESION(S)		1	0
LIVER (LI)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	2	1
ADHESION(S)		0	1
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	2
NODULE(S)		1	0
** END OF LIST **			

3M_MN03279108

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	NUMBER:	--- NUMBER OF ANIMALS AFFECTED ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
** TOP OF LIST **									
BONE, FEMUR (FE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	3	0	0	3
--GROWTH PLATE OPEN		4	0	0	2	1	0	0	1
MARROW, FEMUR (FM)	NUMBER EXAMINED:	1	0	0	0	2	0	0	1
	NOT REMARKABLE:	1	0	0	0	2	0	0	1
MARROW, STERNUM (SE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	4
--HYPOCELLULAR, MARROW		0	0	0	0	1	0	0	0
BONE, STERNUM (SB)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
EYE (EY)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
BRAIN (BR)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	0	1	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR		0	0	0	1	0	0	0	0
--INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR		2	0	0	2	3	0	0	2
--INFLAMMATION, LYMPHOHISTIOCYTIC		0	0	0	0	0	0	0	1

3M_MN03279109

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	NUMBER:	--- NUMBER OF ANIMALS AFFECTED ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
KIDNEY (KD)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		2	0	0	1	1	0	0	0
--GLOMERULOSCLEROSIS		1	0	0	0	1	0	0	0
--MINERALIZATION, CORTEX		0	0	0	1	0	0	0	0
--MINERALIZATION, MEDULLA		0	0	0	0	0	0	0	2
LUNG (LU)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	2	2	0	0	2
--HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR		4	0	0	0	1	0	0	1
--FIBROSIS, PLEURAL/SUBPLEURAL		0	0	0	0	2	0	0	0
--FIBROSIS, INTERSTITIAL		0	0	0	0	1	0	0	0
--INFILTRATE, MACROPHAGE, ALVEOLAR		0	0	0	0	0	0	0	1
--HEMORRHAGE		0	0	0	0	0	0	0	1
HEART (HT)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
LIVER (LI)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	0	1	3	0	0	0	1	0
--INFILTRATE, LYMPHOHISTIOCYTIC		4	3	1	0	4	4	3	3
--GRANULOMA		1	0	0	0	0	0	0	0
--HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR		0	0	0	1	0	0	0	3
--HYPERTROPHY, HEPATOCELLULAR		0	0	1	1	0	0	0	1

** CONTINUED ON NEXT PAGE **

3M_MN03279110

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		4	4	4	2	4	4	4	4
** FROM PREVIOUS PAGE **									
LIVER (LI)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	0	1	3	0	0	0	1	0
--VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR		0	0	0	1	0	0	0	1
--VACUOLATION, HEPATOCELLULAR		0	1	0	0	1	1	0	1
--STASIS, BILE		0	1	0	0	0	0	0	0
--DEGENERATION/NECROSIS, HEPATOCELLULAR		0	0	0	0	0	0	1	0
GALLBLADDER (GB)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	1	3	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	1	1	0	0	2
SPLEEN (SP)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
THYMUS (TH)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	1	1	0	4	0	0	1
--CYST		0	1	0	1	0	1	1	2
--ATROPHY		1	2	3	2	0	4	4	3
LN, MESENTERIC (MS)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	3	0	0	4
--HEMORRHAGE		1	0	0	1	0	0	0	0
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	1	0	0	0

3M_MN03279111

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		4	4	4	2	4	4	4	4
TRACHEA (TR)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	1	0	0	0	2	0	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		3	0	0	2	2	0	0	4
--INFLAMMATION, ACUTE		0	0	0	1	0	0	0	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	4
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	0
THYROID (TY)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	1
--CYST, ULTIMOBRANCHIAL		0	0	0	0	0	0	0	2
PARATHYROID (PT)	NUMBER EXAMINED:	4	0	0	2	3	0	0	4
	NOT REMARKABLE:	3	0	0	2	3	0	0	4
--CYST		1	0	0	0	0	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	2	3	0	0	3
--HYPERTROPHY, CORTICAL CELL		1	0	0	0	1	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	0
--PIGMENT		0	0	0	0	0	0	0	1

3M_MN03279112

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		4	4	4	2	4	4	4	4
ADRENAL, MEDULLA (MA)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
AORTA (AO)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	3
--PROLIFERATION, INTIMAL		0	0	0	0	0	0	0	1
PITUITARY (PI)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
SALIV GL, MANDIB (SG)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	1	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		4	0	0	1	2	0	0	2
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	1
--DEGENERATION		0	0	0	0	1	0	0	0
--INFLAMMATION, GRANULOMATOUS		0	0	0	0	1	0	0	0
--REGENERATION, MYOFIBER		0	0	0	0	1	0	0	0
--PARASITES, CYST		0	0	0	0	1	0	0	1

3M_MN03279113

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		4	4	4	2	4	4	4	4
SPINAL CORD (SC)	NUMBER EXAMINED:	4	0	0	2	4	4	4	4
	NOT REMARKABLE:	4	0	0	2	3	1	0	2
--PIGMENT, NEURONAL		0	0	0	0	1	3	4	2
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
STOMACH, GL (ST)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
DUODENUM (DU)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	2	0	0	1
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	2	0	0	3
PANCREAS (PA)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	4	0	0	4
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	0	1	0	0	1
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	2	3	0	0	3

3M_MN03279114

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	NUMBER:	--- NUMBER OF ANIMALS AFFECTED ---							
	SEX:	-------MALE-------				------FEMALE------			
	GROUP:	-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
ILEUM (IL)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	1	0	0	2
--INFILTRATE, MACROPHAGE, PIGMENTED		2	0	0	1	3	0	0	2
CECUM (CE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	3	0	0	2
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	1	0	0	1
--PARASITISM		0	0	0	0	0	0	0	1
COLON (CO)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	2	4	0	0	3
--INFILTRATE, EOSINOPHILIC		1	0	0	0	0	0	0	0
--PARASITISM, INTRAMUSCULAR		1	0	0	0	0	0	0	1
RECTUM (RE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
SKIN (SK)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	4	0	0	2
--HYPERPLASIA, EPIDERMAL (ACANTHOSIS)		1	0	0	0	0	0	0	0
--INFLAMMATION, CHRONIC-ACTIVE		1	0	0	0	0	0	0	0
--ULCERATION		1	0	0	0	0	0	0	0
--HAIR FOLLICLES, DECREASED		0	0	0	0	0	0	0	2

3M_MN03279115

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	2	0	0	4
--INFLAMMATION, ACUTE		0	0	0	0	1	0	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	2	0	0	1	0	0	0	0
	NOT REMARKABLE:	2	0	0	1	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	1	0	0	3
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	3	0	0	1
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	2	0	0	3
--AMYLOID		0	0	0	0	2	0	0	1
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	3	0	0	2
--MINERALIZATION		0	0	0	0	1	0	0	1
--AMYLOID		0	0	0	0	0	0	0	1
--ONE EXAMINED		0	0	0	0	0	0	0	1

3M_MN03279116

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- NUMBER OF ANIMALS AFFECTED ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
	NUMBER:	4	4	4	2	4	4	4	4
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	4	0	0	4
CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	4	0	0	4
PROSTATE (PR)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	2	0	0	0	0	0	0	0
--INFLAMMATION, LYMPHOHISTIOCYTIC		2	0	0	2	0	0	0	0
SEMINAL VESICLES (SV)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	4	0	0	2	0	0	0	0
EPIDIDYMIDES (EP)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0
--HYPOSPERMIA		1	0	0	1	0	0	0	0
TESTIS (TE)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0
--IMMATURE		1	0	0	1	0	0	0	0

3M_MN03279117

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
SEX:		-------MALE-------				------FEMALE------			
GROUP:		-1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
NUMBER:		4	4	4	2	4	4	4	4
ADIPOSE TISSUE (AT)	NUMBER EXAMINED:	0	0	0	0	0	0	0	1
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
--LYMPHOID TISSUE		0	0	0	0	0	0	0	1
CAUSE OF DEATH (CD)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0
LN, TRACHEOBRON (TB)	NUMBER EXAMINED:	0	0	0	0	0	0	0	0
	NOT REMARKABLE:	0	0	0	0	0	0	0	0

** END OF LIST **

3M_MN03279118

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=4;WEEKS=ALL
DEATH=U;FIND=ALL;SUBSET=ALL

ORGAN AND FINDING DESCRIPTION	NUMBER:	--- NUMBER OF ANIMALS AFFECTED --- SEX: MALE	FEMALE
		GROUP: -4-	-4-
** TOP OF LIST **			
LIVER, BIOPSY[a] (LI0)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	2
--PIGMENT, HEPATOCELLULAR		1	0
LIVER (LI)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		2	1
--PIGMENT, HEPATOCELLULAR		1	0
--HYPERPLASIA, BILE DUCT		1	0
--INFLAMMATION, EOSINOPHILIC, PERI-BILE DUCT		1	0
--FIBROSIS, CAPSULAR		0	1
** END OF LIST **			

a The liver biopsy was taken during Week 57 of recovery.

3M_MN03279119

APPENDIX 1

Protocol Deviations
Protocol
Protocol Amendment No. 1
Protocol Amendment No. 2
Protocol Amendment No. 3
Protocol Amendment No. 4

3M_MN03279120

Protocol Deviations

Protocol. Reserve (Archive) Samples. "These samples will be transferred to the Sponsor after completion of the in-life phase."

Actual Procedure. These samples were shipped to the Sponsor after the dosing phase was competed, which was prior to the end of the in-life phase.

Protocol. Dosing Procedures. Method of Administration. "Orally by gelatin capsules, daily (7 days/week) for at least 26 weeks."

Actual Procedure. On Day 3, Animal Nos. I05520 (Group 1 male) and I05529 (Group 1 female) did not receive a dose administration due to bleeding and irritation in the throat. Dosing was discontinued for Animal No. I05530 (Group 1 female) from Days 10 through 14 due to a sore inside its mouth.

Protocol. Observation of Animals. Clinical Observations. "Once weekly, each animal will be observed; abnormal findings or an indication that the animal was normal will be recorded."

Actual Procedure. During the course of the study, several animals did not have a weekly observation of normal of abnormal recorded on various scheduled days.

Protocol. Observation of Animals. Ophthalmic Examinations. Before initiation of treatment and before each scheduled sacrifice; the anterior portion of the eye, optic media, and ocular fundus will be examined using an indirect ophthalmoscope by a board-certified ophthalmologist.

Actual Procedure. An ophthalmic examination was completed during Week 52 instead of prior to the recovery sacrifice during Week 79.

3M_MN03279121

Protocol Deviations (Continued)

Protocol. Clinical Pathology. Frequency. Scheduled Collections. "Once before initiation of treatment; after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery"

Actual Procedure. On Day 184, urine samples were collected for several animals; however, these samples were not required by the protocol and were discarded.

Samples were collected on Days 273 and 363 of recovery.

Protocol. Clinical Pathology. Tests. Hematology. Eleven hematological parameters were to be tested at all intervals.

Actual Procedure. In addition to the required hematology tests at the pretreatment interval, mean platelet volume, red blood cell distribution width, platelet distribution width, and plateletcrit were also inadvertently tested for.

Protocol. Blood Hormone Determination. Frequency. "Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery."

Actual Procedure. Samples were collected on Days 273 and 363 of recovery.

Protocol. Serum PFOS Level Determination. Method of Collection. "Animals will be fasted overnight; blood (approximately 2 mL) will be collected from a femoral vein without an anticoagulant."

Actual Procedure. Animals were not fasted overnight for the scheduled collection on Day 197; however, animals were fasted the following night and collection was done on Day 198.

3M_MN03279122

Protocol Deviations (Continued)

Protocol. Urine and Feces PFOS Level Determination. Method of Collection. "Animals will not be fasted (except for the first day of recovery); urine (at least 2 mL) and feces (at least 5 g) will be collected overnight."

Actual Procedure. The amount of urine collected was not documented at the time of each collection and therefore cannot be verified.

Protocol. Additional Fecal Samples. "The samples will be collected in the early afternoon after pans are cleaned in the morning to ensure that they are no more than 6 hours old."

Actual Procedure. On Day 160, some fecal samples were collected in the late morning rather than the early afternoon.

Protocol. Interim Liver Biopsy Samples. "Kris J. Hansen or her alternate will be notified regarding the shipment of the samples."

Actual Procedure. The phone call made to notify Kris J. Hansen prior to shipment of these samples was not documented and therefore cannot be verified.

Protocol. Terminal Liver Biopsy Samples. "A sample of liver (approximately 1 g) will be collected by biopsy from all animals in Groups 3 during recovery (Week 79, within 1 day of the serum PFOS blood collection)."

Actual Procedure. These samples were collected during Week 80, and were not collected within one day of the serum PFOS blood collection.

Protocol. Postmortem Procedures. Cell Proliferation Evaluation. "After fixation, samples for proliferation cell nuclear antigen (PCNA) evaluation will be embedded in paraffin and shipped to:"

3M_MN03279123

Protocol Deviations (Continued)

Actual Procedure. PCNA analysis was not done for Animal No. I05509 (Group 4 male).

Protocol. Termination. Postmortem Procedures. Additional Lung Tissue Samples. "At the terminal necropsy, a sample of lung (approximately 5 g) will be collected from an animal in the high-dose group. This sample will be weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped. This frozen sample, and a sample of lung (approximately 1 g, stored in formalin) from Animal No. I05509 (Group 4 male, died January 27, 1999) will be sent separately under appropriate conditions (ambient or packed on dry ice) to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples."

Actual Procedure. This procedure was inadvertently not done at the terminal sacrifice; thus no samples were available for shipment to Kris J. Hansen, PhD.

Protocol. Termination. Postmortem Procedures. Tissue Preservation. "The following tissues (when present) from each animal will be preserved in 10% neutral-buffered formalin, unless otherwise specified, for possible future microscopic examination."

3M_MN03279124

Protocol Deviations (Continued)

Actual Procedure. Femoral bone marrow from Animal Nos. I05517, I05519, I05527 (Group 1 males), I05507, I05509, I05512 (Group 4 males), I05531, I05535 (Group 1 females), I05536, I05540, and I05551 (Group 4 females); mammary gland from Animal Nos. I05508, I05519 (Group 1 males), and I05512 (Group 4 male); and parathyroid from Animal No. I05544 (Group 1 female) were insufficient. These tissues, therefore, were not examined microscopically. Additionally, one ovary of a possible two was examined from Animal No. I05536 (Group 4 female). Missing tissues are listed with appropriate comments in the pathology data sheets for individual animals. Summary tables do not include them as having been examined.

These deviations are not expected to have affected the results of the study.

3M_MN03279125

COVANCE
THE DEVELOPMENT SERVICES COMPANY

Sponsor:

3M
St. Paul, Minnesota

PROTOCOL

Study Title:

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Date:

August 20, 1998

Performing Laboratory:

Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Laboratory Study Identification:

Proposal No. 90545B

Covance 6329-223

Sponsor Project Identification:

3M Study No. T-6295.7

3M_MN03279126

Study
26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Purpose
To assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks

Sponsor
3M
Toxicology Services
Building 220-2E-02, 3M Center
St. Paul, Minnesota 55144-1000

Study Monitor
Andrew M. Seacat, PhD
3M
Telephone No.: 651.575.3161
Facsimile No.: 651.733.1773

Alternate Study Monitor
Marvin T. Case, DVM, PhD
3M Toxicology Services
Telephone No.: 651.733.5180
Facsimile No.: 651.733.1773

Study Location
Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Mailing Address: PO Box 7545
Madison, Wisconsin 53707-7545

3M_MN03279127

Study Director
Peter J. Thomford, PhD
Covance Laboratories Inc.
Telephone No.: 608.241.7207
Facsimile No.: 608.242.2736

Study Toxicologist
Dale Aldridge, BS
Covance Laboratories Inc.

Proposed Study Timetable
Experimental Start Date: August 26, 1998
In-life Start Date: August 26, 1998
In-life Termination Date: To be determined
Audited Draft Report Date: To be determined
Experimental Termination Date: To be determined

Regulatory Compliance
This study will be conducted in compliance with the Environmental Protection Agency Good Laboratory Practice Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments.

Animal Care and Use Statement
All procedures in this protocol are in compliance with the Animal Welfare Act Regulations, 9 CFR 1-4. In the opinion of the Sponsor and study director, the study does not unnecessarily duplicate any previous work.

Quality Assurance
The protocol, study conduct, and final report will be audited by the Covance Quality Assurance Unit (QAU). The proliferation cell nuclear antigen evaluation data and report will be audited by the QAU of Pathology Associates International. The dose analysis and serum and liver PFOS analysis and report will be audited by the QAU of 3M Environmental Laboratories. The blood hormone determinations and report will be audited by the QAU of Ani Lytics Inc.

3M_MN03279128

1818.0295

Test Material

Identification
Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295)

Lot Number
The lot number will be maintained in the raw data.

Purity
Responsibility of the Sponsor

Stability
Responsibility of the Sponsor

Storage Conditions
At room temperature

Characteristics
Information on synthesis methods, composition, or other characteristics that define the test material is on file with the Sponsor.

Vehicle

Identification
Lactose

Lot Number
The lot number will be maintained in the raw data.

Purity
On file with the manufacturer

Stability
On file with the manufacturer

Storage Conditions
At room temperature

3M_MN03279129

1818.0296

Gelatin Capsules
Capsules (Size No. 2) obtained from Torpac, Inc. (Fairfield, New Jersey); lot number will be supplied by the manufacturer. Gelatin capsules will be stored at room temperature. A copy of the Certificate of Analysis provided by the manufacturer will be maintained in the data.

Reserve (Archive) Samples
A reserve sample of each lot of test material, vehicle, and each test material/lactose dilution (1 g each) will be taken and stored at room temperature. These samples will be transferred to the Sponsor after completion of the in-life phase.

Disposition of Test Material
Any remaining test material will be retained at Covance for use in possible future studies.

Animals

Species
Cynomolgus monkey

Source
Covance Research Products Inc.

Age at Initiation of Treatment
Young adult/adult

Weight at Initiation of Treatment
Approximately 2 to 5 kg

Number and Sex
22 males and 22 females

Identification
Collar tag

Husbandry

Housing
Individual; animals will be housed in suspended, stainless steel cages.

3M_MN03279130

1818.0297

Diet
Certified primate diet (#8726C, Harlan Teklad) once or twice daily. The diet is routinely analyzed by the manufacturer for nutritional components and environmental contaminants. Results of specified nutrient and contaminant analyses are on file at Covance-Madison. Fruit, vegetables, or other supplements may be provided but will not require analysis.

Water
Ad libitum. Samples of the water are routinely analyzed for specified microorganisms and environmental contaminants. The results are on file at Covance-Madison.

Contaminants
There are no known contaminants in the diet or water at levels that might interfere with this study.

Environment
Environmental controls for the animal room will be set to maintain 18 to 29°C, a relative humidity of 30 to 70%, and a 12-hour light/12-hour dark cycle. The dark cycle may be interrupted to accommodate in-life procedures.

Acclimation
Minimum of 4 weeks

Randomization
Animals will be weighed, stratified by body weight, and allocated to the number of blocks equal to the number of animals to be selected for each group. Animals in each block will then be assigned to groups using computer-generated random numbers.

Justification
PFOS is a known hepatic peroxisome proliferator (PP) in the rat. When exposed to PP, nonhuman primates (such as the cynomolgus monkey) respond similarly to humans (i.e., low to no hepatic response) and therefore are an appropriate human surrogate species.

3M_MN03279131

1818.0298

Group Designations and Dosage Levels

Group	Dose Level (mg/kg/day)[a]	Total Material Dose Level (mg/kg/day)[b]	Number of Animals Males	Females
1	0[a]	30[a]	6[d]	6[d]
2	0.03	15[b]	4	4
3	0.15	6[c]	6[d]	6[d]
4	0.75	30[c]	6[d]	6[d]

a Dose levels will be provided. The control group (Group 1) will receive an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.

b The low-dose (Group 2) will receive the test material diluted with lactose (1:499, w:w).

c The mid-dose (Group 3) and high-dose (Group 4) groups will receive the test material diluted with lactose (1:39, w:w).

d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 13 weeks posttreatment. Based on plasma test material levels and clinical pathology findings, the recovery may be reduced or extended, at the discretion of the study director and after consultation with the Sponsor.

Dosing Procedures

Method of Administration
Orally by gelatin capsules, daily (7 days/week) for at least 26 weeks

Reason for Dosing Route
To compare with data from previous toxicology studies using the oral route, which is the most likely route of exposure

Dose Preparation
Capsules will be prepared at least weekly. The size and number of capsules will depend on the physical characteristics of the test material, the dose level, and the weight of the monkey. Individual daily doses will be based on the most recent individual body weights, with the exception of body weight collection days when the previous body weight will be used. Dose levels will be based on the vehicle as supplied for Group 1.

3M_MN03279132

For the Groups 2 through 4 dose preparations, the test material will be dissolved in acetone and diluted with lactose (1:499, 1:39, and 1:39, w:w, respectively) once before initiation of treatment. Dilution with lactose is necessary to facilitate capsule preparation. All dose preparations will be stored at room temperature until dosed.

Dose Analyses
Dose analyses will be done by the Sponsor.

Homogeneity
Samples (approximately 1 g each) will be collected from the top, middle, and bottom of the test material/lactose preparations for the low- and high-dose groups and analyzed for test material content. All samples will be stored at room temperature until analyzed.

Stability
Homogeneity samples collected from the middle of the preparations will be used for the prestudy stability analysis. One set of samples (approximately 1 g each) will be taken from the low- and high-dose test material/lactose preparations at the end of the in-life phase and analyzed for test material content.

Sample Shipping
Samples will be shipped under ambient conditions to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of for test material content will be done on the samples. Results will be provided for inclusion in the final report.

Observation of Animals

Clinical Observations
Each animal will be observed twice daily (a.m. and p.m.) for mortality and moribundity; findings will be recorded as they are observed.

3M_MN03279133

Each animal will be observed daily and food consumption will be assessed qualitatively; abnormal findings will be recorded. Once weekly, each animal will be observed; abnormal findings, or an indication that the animal is normal will be recorded. During treatment, each animal will be observed for signs of poor health or abnormal behavior approximately 30 to 90 minutes after the last animal on test has been dosed; abnormal findings will be recorded.

Additional findings will be recorded as they are observed.

Body Weights
Weekly before initiation of treatment, on the first day of treatment, and weekly thereafter. An additional body weight will be recorded on Day -1 for the Day 1 dose calculations.

Ophthalmic Examinations
Before initiation of treatment and before each scheduled sacrifice; the anterior portion of the eye, optic media, and ocular fundus will be examined using an indirect ophthalmoscope by a board-certified ophthalmologist.

Clinical Pathology

Frequency

Unscheduled Collections
When possible, blood will be collected for clinical pathology tests from animals sacrificed at unscheduled intervals

Scheduled Collections
Once before initiation of treatment; and (before the daily dose) after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, and 90 days of recovery

Method of Collection
Animals will be fasted overnight; blood will be collected from a femoral vein. Anticoagulant will be potassium EDTA for hematology tests. No anticoagulant is required for clinical chemistry tests. Urine will be collected overnight on wet ice:

3M_MN03279134

Tests

Hematology

red blood cell (erythrocyte) count	platelet count
hemoglobin	white blood cell (leukocyte) count
hematocrit	differential blood cell count
mean corpuscular volume	blood cell morphology
mean corpuscular hemoglobin	reticulocyte count
mean corpuscular hemoglobin concentration	

Clinical Chemistry

glucose	aspartate aminotransferase gamma
urea nitrogen	glutamyltransferase
creatinine	sorbitol dehydrogenase
total protein	creatine kinase
albumin	calcium
globulin	inorganic phosphorus
total bilirubin	sodium
direct bilirubin (if total bilirubin is greater than 2.0 mg/dL)	potassium
	chloride
cholesterol	bile acids
triglycerides	amylase
alanine aminotransferase	lipase
alkaline phosphatase	pancreatic-specific amylase

Urinalysis

appearance	glucose
volume (approximately 16 hours)	ketones
specific gravity	bilirubin
pH	blood
protein	microscopic examination of sediment
urobilinogen	

Blood Hormone Determination

Frequency

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, and 90 days of recovery

3M_MN03279135

1818.0302

Number of Animals
All

Method of Collection
Animals will be fasted overnight; blood will be collected from a femoral vein. Approximately 5 mL of blood will be collected without anticoagulant and allowed to clot for serum samples.

Sample Handling
Samples for serum will be centrifuged within 1 hour after collection, and serum will be harvested. Serum will be divided into two approximately equal aliquots and stored in a freezer set to maintain -60 to -80°C until packed on dry ice and shipped to:

Dr. Saroj Das
Ani Lytics Inc.
200 Girard Street, Suite 200
Gaithersburg, Maryland 20877
Telephone No.: 301.921.0168
Facsimile No.: 301.977.0433

Ani Lytics Inc. will be notified regarding shipment of samples.

Tests
Samples will be analyzed by Ani Lytics Inc., for cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, triiodothyronine (T3), and thyroxin (T4).

Serum PFOS Level Determination

Frequency
Before initaition of treatment, and during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, 28, 30, 32, 34, and 39.

Number of Animals
All

Method of Collection
Animals will be fasted overnight; blood (approximately 2 mL) will be collected from a femoral vein without an anticoagulant.

3M_MN03279136

1818.0303

Sample Handling
Samples will be centrifuged within 1 hour after collection, and serum will be harvested. Serum samples will be stored in a freezer set to maintain -60 to -80°C.

Sample Shipping
Serum samples will be packed on dry ice and shipped to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of serum for PFOS will be done on the samples. Results will be provided for inclusion in the final report.

Additional Serum Collection
At scheduled and unscheduled necropsies, blood (as much as possible, up to 20 mL) will be collected from the vena cava without an anticoagulant from animals at the time of exsanguination. Samples will be centrifuged within 1 hour after collection, and serum will be harvested. Serum from each animal will be transferred into an appropriate container and stored in a freezer set to maintain -60 to -80°C until shipped to the Sponsor (Kris J. Hansen) for possible future analysis.

Urine and Feces PFOS Level Determination

Frequency
On the first day of recovery and after at least 6, 30, and 90 days of recovery

Number of Animals
All

Method of Collection
Animals will not be fasted; urine (approximately 2 mL) and feces (approximately 5 grams) will be collected overnight.

3M_MN03279137

Sample Handling
Samples will be stored in a freezer set to maintain -10 to -30°C.

Sample Shipping
Samples will be packed on dry ice and shipped to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of urine and feces for PFOS will be done on the samples. Results will be provided for inclusion in the final report.

Termination

Unscheduled Sacrifices and Deaths
Necropsies will be done. Animals to be sacrificed will be anesthetized with ketamine and xylazine, weighed, bled for required tests, and exsanguinated.

Scheduled Sacrifices
After at least 26 weeks of treatment, four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

After at least 26 weeks of treatment and at least 13 weeks without treatment, the remaining animals will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

Postmortem Procedures

Necropsy
The necropsy will include examination of:

all orifices
cranial cavity
external surface of the brain; the external surface of the spinal cord and cut surfaces of the brain and spinal cord will be examined when tissue trimming is performed.
cervical tissues and organs

3M_MN03279138

thoracic, abdominal, and pelvic cavities and viscera
external surface of the body
nasal cavity and paranasal sinuses

Organ Weights
From each animal at scheduled and unscheduled sacrifices, the following organs (when present) will be weighed; paired organs will be weighed separately:

adrenal (2)
brain
epididymis (2)
kidney (2)
liver
ovary (2)
pancreas
testis (2)
thyroid (2) with parathyroid

Organ-to-body weight percentages and organ-to-brain weight ratios will be calculated.

Palmitoyl CoA Oxidase Determinations
Representative samples of the right lateral lobe of liver will be collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer set to maintain -60 to -80°C until analyzed for palmitoyl CoA oxidase activity.

Cell Proliferation Evaluation
Representative samples of the left lateral lobe of the liver, left and right testes, and pancreas will be collected and preserved in zinc formalin.

After fixation, samples for proliferation cell nuclear antigen (PCNA) evaluation will be embedded in paraffin and shipped to:

Sandra R. Eldridge, PhD
Pathology Associates International
15 Worman's Mill Court
Suite I
Frederick, Maryland 21701
Telephone: 301.663.1644 ext. 2036
Facsimile: 301.663.8994

Pathology Associates International will be notified regarding shipment of samples. PCNA evaluation will be done on the samples. Results will be provided for inclusion in the final report.

3M_MN03279139

Liver PFOS Determination
A section (approximately 20 g) of liver will be collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer set to maintain -60 to -80°C until shipped with plasma samples to 3M (Kris Hansen) for analysis. Results will be provided for inclusion in the final report.

Tissue Preservation
The following tissues (when present) from each animal will be preserved in 10% neutral-buffered formalin, unless otherwise specified, for possible future microscopic examination:

adrenal (2)
aorta
brain
cecum
cervix
colon
duodenum
epididymis (2)
esophagus
eye [(2) to be preserved in Davidson's fixative for sacrificed animals only]
femur with bone marrow (articular surface of the distal end)
gallbladder
heart
ileum
jejunum
kidney (2)
lesions
liver
lung
mammary gland
ovary (2)
mesenteric lymph node
pancreas
pituitary
prostate
rectum
salivary gland [mandibular (2)]
sciatic nerve
seminal vesicle (2)
skeletal muscle (thigh)
skin
spinal cord (cervical, thoracic, and lumbar)
spleen
sternum with bone marrow
stomach
testis [(2) to be preserved in Bouins' solution for sacrificed animals only]
thymus
thyroid (2) with parathyroid
trachea
urinary bladder
uterus
vagina

Bone Marrow Smear
From the sternum of each animal at unscheduled and scheduled sacrifices (made and held for possible future examination).

3M_MN03279140

Histopathology
Tissues from each animal in the control and high-dose groups will be embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Tissues from all other animals will be retained for possible future examination.

Reports

Letter Report
A letter report will be prepared following the terminal sacrifice.

Final Report
A draft report that includes the following information will be prepared and submitted:

Experimental Design and Methods

Results
mortality
clinical observations
body weights
food consumption
ophthalmic examinations
clinical pathology results
palmitoyl CoA oxidase activities
hormone analyses (provided by Ani Lytics)
serum, urine, feces, and liver PFOS levels (provided by 3M)
cell proliferation evaluations (provided by Pathology Associates International)
dose analyses (provided by 3M)
organ weights
organ-to-body weight percentages
organ-to-brain weight ratios
macroscopic observations
microscopic observations

Statistical Evaluation
Levene's test will be done to test for variance homogeneity. In the case of heterogeneity of variance at $p \leq 0.05$, transformations will be used to stabilize the variance. Comparison tests will take variance heterogeneity into consideration.

3M_MN03279141

1818.0308

One-way analysis of variance (ANOVA) will be used (if applicable) to analyze initial body weights, palmitoyl CoA oxidase activities, and continuous clinical pathology values. If the ANOVA is significant, Dunnett's t-test will be used for control versus treated group comparisons.

One-way analysis of covariance (ANCOVA) will be used to analyze body weights, with initial body weights as the covariate. If the ANCOVA is significant, covariate-adjusted means will be used for control versus treated group comparisons.

Group comparisons (Groups 2 through 4 versus Group 1) will be evaluated at the 5.0% two-tailed probability level. Only data collected on or after the first day of treatment will be analyzed statistically.

At the end of 1 year after issuance of the audited draft report, if no requested revisions or instructions to finalize have been communicated by the Sponsor, then the audited draft report will be considered 'final' and issued as the final report, signed by the study director, and submitted to the Sponsor.

Any modifications or changes to the audited draft report requested 1 year after issuance will be performed at additional cost to the Sponsor.

Record Retention

All raw data, documentation, records, protocol, specimens, and final report generated as a result of this study generated by Covance will be archived in the storage facilities of Covance for a period of 1 year following submission of the final report to the Sponsor. One year after submission of the final report, all of the aforementioned materials will be sent to the Sponsor, and a return fee will be charged. The Sponsor may elect to have the materials retained in the Covance archives for an additional period of time, and Covance will charge a storage fee. If the Sponsor chooses to have Covance dispose of the materials, a disposal fee will be charged. All raw data stored on magnetic media will be retained by Covance.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

3M_MN03279142

1818.0309

PROTOCOL APPROVAL

Andrew M. Seacat

8/24/98

Andrew M. Seacat, PhD
Study Monitor
3M

Date

Peter J. Thomford

8/20/98

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

Date

3M_MN03279143

1818.0310

COVANCE
THE DEVELOPMENT SERVICES COMPANY

PROTOCOL AMENDMENT NO. 1

Covance 6329-223
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective August 20, 1998

1. **Page 4, Vehicle, Storage Conditions.** To include the solvent used to dissolve the test material before mixing with the lactose, add the following after this section.

Solvent

Identification
Acetone

Lot Numbers
The lot numbers will be maintained in the raw data.

Purity
On file with the manufacturer

Stability
On file with the manufacturer

Storage Conditions
At room temperature

3M_MN03279144

Characteristics
Information on synthesis methods, composition, or other characteristics that define the solvent is on file with the manufacturer.

2. **Page 7, Group Designations and Dosage Levels, Footnote a, Sentence 1.** To correct an error, delete this sentence.

Effective September 2, 1998

3. **Page 5, Gelatin Capsules, Sentence 1.** To change the size of the gelatin capsules, delete this sentence and replace with the following.

Capsules (Size Nos. 2 or 4) obtained from Torpac, Inc. (Fairfield, New Jersey); lot number will be supplied by the manufacturer.

Effective December 15, 1998

4. **Page 14, Postmortem Procedures, Cell Proliferation Evaluation, Paragraph 3, Sentence 2.** To include evaluation of slides stained with hematoxylin and eosin in the PCNA evaluation, delete this sentence and replace with the following.

PCNA evaluation (including examination of slides stained with hematoxylin and eosin) will be done on the samples.

Effective January 21, 1999

5. **Page 10, Clinical Pathology, Tests, Clinical Chemistry.** To include an additional clinical chemistry test, add the following.

High density lipoprotein (HDL)

Effective January 21 and 28 and February 2, 1999

6. **Page 12, Urine and Feces PFOS Level Determination, Sample Shipping.** At the request of the Sponsor to collect additional fecal samples (effective January 21, 1999) and to clarify the sample collection requirements (effective January 28 and February 2, 1999), add the following after this section.

3M_MN03279145

Additional Fecal Samples
During Week 23, a fresh fecal sample of at least 5 g, if possible, will be collected from 6 males and 6 females each in the control and high-dose groups, survival permitting. The samples will be collected in the early afternoon after pans are cleaned in the morning to ensure that they are no more than 6 hours old. The samples will be collected in white polypropylene containers and sent on dry ice to:

Joe McConnell
Porphyrins and Nutritional Chemistry Group
Mayo Clinic
200 First Street SW
Rochester, Minnesota 55905
Telephone: 507.284.2150
Lab Telephone: 507.284.3232

Dr. McConnell will be contacted before shipping the samples.

Effective January 21 and February 12 and 16, 1999

7. **Page 9, Clinical Pathology, Frequency, Scheduled Collections.** To reflect the decision of the Sponsor and the Study Director to add a collection interval after 150 days of treatment (effective January 21, 1999), to extend the length of recovery (effective February 12, 1999), and to clarify the collection requirement (effective February 12, 1999), delete the text in this section and replace with the following.

Once before initiation of treatment; and after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, and 180 days of recovery

Effective February 10 and 16, 1999

8. **Page 12, Urine and Feces PFOS Level Determination, Method of Collection.** To modify the amount of sample to be collected (effective February 10, 1999) and to permit collection of samples from fasted animals on the first day of recovery (effective February 16, 1999), delete the text in this section and replace with the following.

Animals will not be fasted (except for the first day of recovery); urine (at least 2 mL) and feces (at least 5 g) will be collected overnight.

3M_MN03279146

Effective February 12, 1999

9. **Page 7, Group Designations and Dosage Levels, Footnote d.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this footnote and replace with the following.

   d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 26 weeks posttreatment.

Effective February 12 and 15, 1999

10. **Page 11, Serum PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to revise the requirements for these collections during recovery (effective February 15, 1999), delete the text in this section and replace with the following.

    Before initiation of treatment; during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, and 27 (Day 183) during treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 197), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, and 53.

11. **Page 13, Termination, Scheduled Sacrifices.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to prioritize the number of animals designated for recovery (effective February 15, 1999), delete the text in this section and replace with the following.

    After at least 26 weeks of treatment, up to four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

    After at least 26 weeks of treatment and at least 26 weeks without treatment, two animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

3M_MN03279147

Effective February 12 and 16, 1999

12. **Page 10, Blood Hormone Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to clarify the requirements (effective February 16, 1999), delete the text in this section and replace with the following.

    Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, and 180 days of recovery

13. **Page 12, Urine and Feces PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to clarify the requirements (effective February 16, 1999), delete the text in this section and replace with the following.

    On the first day of recovery and after at least 6, 30, 90, 135, and 180 days of recovery

Effective February 15, 17, and 18, 1999

14. **Page 13, Postmortem Procedures.** To facilitate a request by the Sponsor to transfer samples of lung tissue (effective February 15 and 18, 1999) and gallbladder and bile (effective February 17, 1999), add the following.

    Additional Lung Tissue Samples
    At the terminal necropsy, a sample of lung (approximately 5g) will be collected from an animal in the high-dose group. This sample will be weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped. This frozen sample and a sample of lung (approximately 1 g, stored in formalin) from Animal No. I05509 (Group 4 male, died January 27, 1999) will be sent separately under appropriate conditions (ambient or packed on dry ice) to:

    Kris J. Hansen, PhD
    3M E. T. & S.
    Bldg. 2-3E-09
    935 Bush Avenue
    St. Paul, Minnesota 55106
    Telephone: 651.778.6018
    Facsimile: 651.778.6176

3M_MN03279148

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Additional Gallbladder and Bile Samples
At the scheduled necropsies, the gallbladder and bile will be collected and stored according to a special collection and fixation procedure. Frozen gallbladder and bile samples will be packed on dry ice and transferred to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Effective February 24 and March 9, 1999

15. **Page 13, Postmortem Procedures.** To facilitate a request by the Sponsor to prepare (effective February 24, 1999) and transfer (effective March 9, 1999) samples of liver for electron microscopy and to prepare and transfer hematoxylin and eosin-stained slides for light microscopy (effective March 9, 1999), add the following.

Electron Microscopy
At the terminal necropsy, samples of liver will be collected and processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone: 919.544.5257
Facsimile: 919.544.3218

3M_MN03279149

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. PAI is responsible for the quality assurance auditing and maintenance of any raw data or specimens produced by PAI.

Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

Effective April 22, 1999

16. **Page 16, Reports, Statistical Evaluation, Paragraph 2, Sentence 1.** To add statistical analysis of organ weight and hormone values, delete this sentence and replace with the following.

One-way analysis of variance (ANOVA) will be used (if applicable) to analyze initial body weights, palmitoyl CoA oxidase activities, continuous clinical pathology values, hormone values, and organ weight data.

Effective April 26, 1999

17. **Page 14, Postmortem Procedures, Cell Proliferation Evaluation, Paragraph 1.** To add a second set of tissues for cell proliferation evaluation, add the following to this paragraph.

A second set of tissues (representative samples of the left lateral lobe of the liver, left and right testes, and pancreas) preserved in formalin without zinc will also be prepared.

Effective April 28, 1999

18. **Page 8, Dose Analyses, Stability, Sentence 2.** To change the schedule for the return of the samples, delete this sentence and replace with the following.

One set of samples (approximately 1 g each) will be taken from the low- and high-dose test material/lactose preparations at the end of the treatment phase and will be analyzed for test material content.

3M_MN03279150

Effective May 6, 1999

19. **Page 16, Reports, Letter Report.** To change the letter report to an interim report, delete the text in this section and replace with the following.

Interim Report
An interim report, including all items from the final report as appropriate, will be prepared following the terminal sacrifice.

Effective May 17, 1999

20. **Page 16, Postmortem Procedures, Histopathology, Sentence 2.** To include target organs for animals in the low- and mid-dose groups, delete this sentence and replace with the following.

In addition, liver and thymus for all animals in the low- and mid-dose groups and spinal cord gray matter from females in the low- and mid-dose groups will be embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Other tissues, as appropriate, will be retained for possible future examination.

Effective May 18, 1999

21. **Page 3, Proposed Study Timetable.** To include proposed dates for in-life termination, the unaudited draft interim report, and the audited draft report, delete the text in this section and replace with the following.

Experimental Start Date: August 26, 1998
In-life Start Date: August 26, 1998
In-life Termination Date: August 27, 1999
Unaudited Draft Interim Report Date: May 11, 1999
Audited Draft Report Date: December 28, 1999
Experimental Termination Date: To be determined

3M_MN03279151

AMENDMENT APPROVAL

Andrew M. Seacat

Andrew M. Seacat, PhD
Study Monitor
3M

6/10/99
Date

Peter J. Thomford

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

03 June 1999
Date

3M_MN03279152

COVANCE
THE DEVELOPMENT SERVICES COMPANY

PROTOCOL AMENDMENT NO. 2

Covance 6329-223
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective February 19, 1999

1. **Page 9, Observation of Animals, Clinical Observations, Paragraph 2, Sentence 2.** To add an observation on the day of scheduled sacrifice, delete this sentence and replace with the following.

   Once weekly and on the day of scheduled sacrifice, each animal will be observed; abnormal findings or an indication that the animal is normal will be recorded.

Effective June 11, 1999

2. **Page 11, Blood Hormone Determination, Tests.** To add free triiodothyronine (T3) and free thyroxin (T4) tests, delete the text in this section and replace with the following.

   Samples will be analyzed by Ani Lytics Inc. for cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, total and free triiodothyronine (T3), and total and free thyroxin (T4).

3M_MN03279153

3. **Page 16, Reports, Final Report, Statistical Evaluation.** To add repeated measure statistical analysis of cholesterol and total and free triiodothyronine (T3), add the following to the end of the section.

   Cholesterol and total and free triiodothyronine (T3) will be analyzed by repeated measures analysis of covariance (ANCOVA) procedure with average pretreatment measurements for the parameters as covariates. Treatment effects under ANOVA or ANCOVA procedures will be evaluated at $p = 0.05$ level. All post-hoc control-versus-treated-group mean comparisons (including values during recovery) will be conducted using Dunnett's many-on-one t procedure.

   Analyses will be carried out with SAS procedure PROC MIXED or BMDP, or both.

Effective August 24, 1999

4. **Page 7, Group Designations and Dosage Levels, Footnote d.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this footnote and replace with the following.

   d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

5. **Page 9, Clinical Pathology, Frequency, Scheduled Collections.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

   Once before initiation of treatment; after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery

6. **Page 10, Blood Hormone Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

   Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery

3M_MN03279154

7. **Page 11, Serum PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Before initiation of treatment; during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, and 27 (Day 183) during treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 197), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, 53, 57, 61, 65, 69, 73, 77, and 79

Effective August 24, 1999, and January 12 and 21, 2000

8. **Page 13, Termination, Scheduled Sacrifices.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective August 24, 1999), to reflect the decision of the Sponsor to cancel the recovery necropsy (effective January 12, 2000), and to subsequently clarify the requirement (effective January 21, 2000), delete the text in this section and replace with the following.

After at least 26 weeks of treatment, up to four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

After at least 26 weeks of treatment and at least 52 weeks without treatment, the remaining animals will be removed from the study as follows.

Two animals/sex in Group 1 will be returned to the Covance stock.

Two animals/sex in Group 3 will be transferred to a subsequent study (Covance 6329-268).

Two animals/sex in Group 4 will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

Effective August 24 and September 22, 1999

9. **Page 12, Additional Fecal Samples.** At the request of the Sponsor to collect liver samples by biopsy (effective August 24, 1999) and to modify the procedures (effective September 22, 1999), add the following after this section.

3M_MN03279155

1818.0322

Interim Liver Biopsy Samples
A sample of liver (approximately 1 to 2 g) will be collected by biopsy from animals in Group 4 only during recovery (Week 57, within 1 day of the serum PFOS blood collection). This sample will be divided into four portions as follows.

One subsample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second subsample will be flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

The third subsample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone No.: 919.544.5257
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

3M_MN03279156

The fourth subsample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, and transferred to the Sponsor for possible future analysis.

Effective January 12 and 21, 2000

10. **Page 12, Interim Liver Biopsy Samples.** At the request of the Sponsor to collect liver samples by biopsy, then terminate the study and transfer the animals to a subsequent study (effective January 12, 2000) and to modify the requirement (effective January 21, 2000), add the following after this section.

Terminal Liver Biopsy Samples
A sample of liver (approximately 1 g) will be collected by biopsy from all animals in Groups 3 during recovery (Week 79, within 1 day of the serum PFOS blood collection). This sample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

Effective January 21, 2000

11. **Page 12, Additional Serum Collection.** To reflect the decision of the Sponsor to analyze additional serum samples for specified thyroid hormones, add following to the end of this section.

An aliquot (0.8 ml) of the additional serum collection samples collected from all animals from Groups 1, 2, 3 and 4 sacrificed at the terminal necropsy will be sent on dry ice by the Sponsor to Dr. Saroj Das, Ani Lytics, for free T3, free T4, total T3, and total T4 determinations.

3M_MN03279157

12. **Page 12, Urine and Feces PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor to collect a 24-hour urine and fecal sample after one year of recovery, delete the text in this section and replace with the following.

On the first day of recovery and after at least 6, 30, 90, 135, and 180 days of recovery. In addition, a 24-hour sample of urine and feces will be collected before the completion of 52 weeks of recovery.

13. **Page 16, Postmortem Procedures, Histopathology.** To define the postmortem procedures for recovery animals in the high-dose group, add the following after this section.

Postmortem Procedures for Recovery Animals in the High-Dose Group
At necropsy of the recovery animals in the high-dose group, procedures (including organ weights and collection of tissues for histopathological examination) described previously are not required. The following procedures will be done.

Necropsy
The necropsy will include examination of:

all orifices
cranial cavity
external surface of the brain; the external surface of the spinal cord and cut surfaces of the brain and spinal cord will be examined when tissue trimming is performed
cervical tissues and organs
thoracic, abdominal, and pelvic cavities and viscera
external surface of the body
nasal cavity and paranasal sinuses

Liver Samples
A sample of liver (approximately 1 to 2 g) will be collected. This sample will be divided into three portions as follows.

One subsample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second subsample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

3M_MN03279158

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

The third subsample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone No.: 919.544.5257
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

Additional Tissue and Serum Samples
Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, bile, (approximately 3 g each), and serum (as much as possible) will be collected. These samples will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for possible future analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

3M_MN03279159

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Effective February 11 and 15, 2000

14. **Page 3, Proposed Study Timetable.** To change proposed dates for in-life termination (effective February 11, 2000) and the audited draft report (effective February 15, 2000), delete the text in this section and replace with the following.

Experimental Start Date: August 26, 1998
In-life Start Date: August 26, 1998
In-life Termination Date: March 7, 2000
Unaudited Draft Interim Report Date: May 11, 1999
Audited Draft Report Date: May 29, 2000
Experimental Termination Date: To be determined

AMENDMENT APPROVAL

Andrew M. Seacat

3/30/2000

Andrew M. Seacat, PhD
Study Monitor
3M

Date

Peter J. Thornford, PhD
Study Director
Covance Laboratories Inc.

16 Feb 2000

Date

3M_MN03279160

COVANCE
THE DEVELOPMENT SERVICES COMPANY

PROTOCOL AMENDMENT NO. 3

Covance 6329-223
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective August 20, 1998

1. **Page 16, Reports, Final Report, Statistical Evaluation, Paragraph 4.** To correct an omission, add the following to the end of the section.

   Data collected during recovery will not be analyzed statistically due to the small sample size.

Effective January 21, 2000

2. **Protocol Amendment No. 2, Item 13.** To correct a typographical error, change the font to bold on the following heading.

   Postmortem Procedures for Recovery Animals in the High-Dose Group

Effective February 18, 2000

3. **Page 12, Serum PFOS Level Determinations, Sample Shipping, Paragraph 3, Sentence 3.** To indicate that the results of the Sponsor's analysis of serum samples for PFOS will be reported separately, delete this sentence and replace with the following.

   Results will be reported separately.

3M_MN03279161

4. **Page 12, Interim Liver Biopsy Samples, Paragraph 3, Sentence 2.** To indicate that the results of the Sponsor's analysis of the interim liver biopsy samples will be reported separately, delete this sentence and replace with the following.

   Results will be reported separately.

5. **Page 12, Terminal Liver Biopsy Samples, Paragraph 2, Sentence 2.** To indicate that the results of the Sponsor's analysis of the terminal liver biopsy samples will be reported separately, delete this sentence and replace with the following.

   Results will be reported separately.

6. **Page 15, Postmortem Procedures, Liver PFOS Determinations, Sentence 2.** To indicate that the results of the Sponsor's analysis of the liver samples will be reported separately, delete this sentence and replace with the following.

   Results will be reported separately.

7. **Page 16, Reports, Final Report, Statistical Evaluation, Paragraph 4.** To remove repeated measure statistical analysis of cholesterol and total and free triiodothyronine (T3) at the request of the Sponsor, delete the following.

   Cholesterol and total and free triiodothyronine (T3) will be analyzed by repeated measures analysis of covariance (ANCOVA) procedure with average pretreatment measurements for the parameters as covariates. Treatment effects under ANOVA or ANCOVA procedures will be evaluated at $p = 0.05$ level. All post-hoc control-versus-treated-group mean comparisons (including values during recovery) will be conducted using Dunnett's many-on-one t procedure.

   Analyses will be carried out with SAS procedure PROC MIXED or BMDP, or both.

Effective February 18 and 22, 2000

8. **Page 16, Reports, Final Report, Results.** To indicate that the results of the Sponsor's analysis of the serum and liver samples (effective February 18, 2000) and urine and feces samples (effective February 22, 2000) will be reported separately, delete the following.

   serum, urine, feces, and liver PFOS levels (provided by 3M)

3M_MN03279162

9. **Page 16, Postmortem Procedures for Recovery Animals in the High-Dose Group, Liver Samples.** To indicate that the results of the Sponsor's analysis of the liver samples will be reported separately (effective February 18, 2000) and to modify the amount of liver collected at necropsy (effective February 22, 2000), delete the text in this section and replace with the following.

Samples of liver will be collected as follows.

One sample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second sample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be reported separately.

The third sample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone No.: 919.544.5257
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

3M_MN03279163

Effective February 22, 2000

10. **Page 13, Urine and Feces PFOS Determination, Sample Shipping, Paragraph 2, Sentence 3.** To indicate that the results of the Sponsor's analysis of the urine and feces samples will be reported separately, delete this sentence and replace with the following.

    Results will be reported separately.

11. **Page 16, Postmortem Procedures for Recovery Animals in the High-Dose Group, Additional Tissue and Serum Samples, Paragraph 1.** To modify the amount of tissue collected at necropsy, delete this paragraph and replace with the following.

    Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, (approximately 3 g each, if possible), and bile and serum (each as much as possible) will be collected. These samples will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for possible future analysis to:

    Kris J. Hansen, PhD
    3M E. T. & S.
    Bldg. 2-3E-09
    935 Bush Avenue
    St. Paul, Minnesota 55106
    Telephone No.: 651.778.6018
    Facsimile No.: 651.778.6176

    Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Effective April 6, 2000

12. **Page 3, Regulatory Compliance.** To include a compliance exception for the fecal analysis done at the Mayo Clinic, delete the text in this section and replace with the following.

3M_MN03279164

This study will be conducted in compliance with the Environmental Protection Agency Good Laboratory Practice Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments with the following exception. Analysis of fecal samples for urobilinogen at the Mayo Clinic will not be done in compliance with GLPs.

13. **Page 3, Quality Assurance.** To include an exception for the fecal analysis done at the Mayo Clinic, add the following to the end of the section.

    Analysis of fecal samples for urobilinogen at the Mayo Clinic will not be done in compliance with GLPs and will not be audited by a Quality Assurance Unit.

14. **Page 12, Additional Fecal Samples.** To clarify analysis and reporting requirements for fecal analysis, add the following to the end of this section.

    The samples will be analyzed for urobilinogen using a routine standardized colormetric assay. The results of these analyses will be provided for inclusion in the final report.

15. **Page 17, Record Retention, Paragraph 2.** To include the record retention requirements for fecal analysis, delete this paragraph and replace with the following.

    Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, Mayo Clinic, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

Effective April 7, 2000

16. **Page 2, Purpose.** To modify the purpose of the study, delete the text in this section and replace with the following.

    To assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The treatment period will be followed by an approximate 52-week recovery period.

3M_MN03279165

Effective April 17, 2000

17. **Page 12, Additional Serum Collection.** To reflect the decision of the Sponsor to analyze additional serum samples for specified thyroid hormones and lipoproteins, add following to the end of this section.

An additional aliquot (1.0 ml) of the additional serum collection samples collected from specified animals sacrificed at the terminal and recovery necropsies will be sent on dry ice by the Sponsor to Dr. Saroj Das, Ani Lytics, for thyroid stimulating hormone (TSH), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total lipoprotein, and calculated very low-density lipoprotein determinations. Results of these analyses will be provided for inclusion in the final report.

AMENDMENT APPROVAL

Andrew M. Seacat, PhD
Study Monitor
3M

5/9/2000
Date

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

01 May 2000
Date

3M_MN03279166

COVANCE
THE DEVELOPMENT SERVICES COMPANY

PROTOCOL AMENDMENT NO. 4

Covance 6329-223
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective 24 May 2001

1. **Page 13, Postmortem Procedures, Electron Microscopy, and all other occurrences of "Pathology Associates International."** To reflect a change in the name of the subcontractor, delete all occurrences of "Pathology Associates International" in the protocol and replace with the following.

   Pathology Associates North Carolina Division, A Charles River Company

Effective 27 August 2001

2. **Page 12, Additional Serum Collection** To reflect the Sponsor's decision to do additional hormone analyses at Ani Lytics, Inc. on serum samples, add the following to the end of the section.

   At the request of the sponsor, serum samples collected at the terminal and recovery sacrifices will be transferred by the sponsor to Ani Lytics, Inc. for analysis of estradiol, follicle stimulating hormone (FSH), and lutenizing hormone (LH) for females, and estradiol in males. Results of these analyses will be provided for inclusion in the final report.

3M_MN03279167

Effective 17 September 2001

3. **Page 12, Additional Serum Collection** To reflect the Sponsor's decision to do additional analyses at Mayo Clinic on serum samples, add the following to the end of the section.

   At the request of the sponsor, specified serum samples will be transferred by the sponsor to R. Singh, PhD, Hilton 730, Mayo Clinic, Rochester, MN for analysis of triiodothyronine (T3), total thyroxin (T4), free thyroxin (free T4), and thyroid stimulating hormone (TSH). Additional reserve samples of serum will be transferred for possible future analysis for estradiol. Any unused serum will be returned to the sponsor. Results of these analyses will be provided for inclusion in the final report.

AMENDMENT APPROVAL

Andrew M. Seacat

Andrew M. Seacat, PhD
Study Monitor
3M

10/17/2001
Date

Peter J. Thomford

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

15 Oct 2001
Date

3M_MN03279168

1818.0335

APPENDIX 2

Individual Animal Fate Data
Individual Clinical Observations
Individual Ophthalmic Observations

3M_MN03279169

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DOSE GROUP	SEX	DEATH CODE	TYPE OF DEATH	DESCRIPTION OF DEATH	DATE OF DEATH	DAY OF STUDY	WEEK OF STUDY
I05508	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05517	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05519	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05520	1	MALE	O	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05526	1	MALE	O	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05527	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05514	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05515	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05516	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05521	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05505	3	MALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05510	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05518	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05523	3	MALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05524	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05528	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05506	4	MALE	M	UNSCHEDULED	UNSCHEDULED DEATH	02/20/99	179	26
I05507	4	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05509	4	MALE	D	UNSCHEDULED	UNSCHEDULED DEATH	01/27/99	155	23
I05511	4	MALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05512	4	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05522	4	MALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05529	1	FEMALE	P	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05530	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05531	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05535	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05544	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05549	1	FEMALE	P	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05537	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05541	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05547	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05550	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05532	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05538	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27

3M_MN03279170

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DOSE GROUP	SEX	DEATH CODE	TYPE OF DEATH	DESCRIPTION OF DEATH	DATE OF DEATH	DAY OF STUDY	WEEK OF STUDY
I05539	3	FEMALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05545	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05548	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05552	3	FEMALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05533	4	FEMALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05534	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05536	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05540	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05542	4	FEMALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05551	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27

3M_MN03279171

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05508	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P

3M_MN03279172

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05517	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		102	P	-	-	-

3M_MN03279173

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05517	T	27	QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
					176	P	-	-	-
					177	P	-	-	-
					179	P	-	-	-
I05519	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-

3M_MN03279174

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05519	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
I05520	O	79	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		141	P	-	-	-
			EXCRETION						
			LIQUID FECES		29	-	-	P	-
			NON-FORMED FECES		29	P	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-

3M_MN03279175

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05520	O	79	NORMAL					
			NO REMARKABLE OBSERVATIONS	134	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	122	P	-	-	-
I05526	O	79	EXCRETION					
			NON-FORMED FECES	179	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-

3M_MN03279176

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05526	O	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
I05527	T	27	DISCHARGE UNKNOWN SOURCE						
			FOUND IN PAN						
			RED IN COLOR		144	P	-	-	-
			EXCRETION						
			NON-FORMED FECES		2	P	-	-	-
			SKIN & PELAGE						
			BROKEN SKIN						
			HAND-LEFT		37	P	-	-	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					43	P	-	-	-
			TAIL		168	-	-	P	-
					169	P	-	-	-
					170	-	-	P	-
					176	P	-	-	-
					177	-	-	P	-

3M_MN03279177

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05527	T	27	SKIN & PELAGE						
			BROKEN SKIN						
			TAIL		178	P	-	P	-
					179	P	-	-	-
					180	P	-	-	-
					181	-	-	P	-
					183	P	-	-	-
					184	P	-	-	P
			TAIL-DISTAL		145	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-

3M_MN03279178

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M1 DOSE: 0 MG/KG/DAY) DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05527	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	155	P	-	-	-
				162	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	43	P	-	-	-

3M_MN03279179

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M2 DOSE: 0.03 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05514	T	27	EXCRETION					
			LIQUID FECES	91	P	-	-	-
			NON-FORMED FECES	105	-	-	P	-
				132	-	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-

3M_MN03279180

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	GROUP: M2 DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05514	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	183	P	-	-	-
				184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	102	P	-	-	-
				179	P	-	-	-
I05515	T	27	EXCRETION					
			NON-FORMED FECES	69	-	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-

3M_MN03279181

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DOSE: 0.03 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05515	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
					162	P	-	-	-
I05516	T	27	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		179	P	-	-	-
			PARTIAL CAPSULE		85	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-

3M_MN03279182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05516	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-
				185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	179	P	-	-	-
I05521	T	27	SKIN & PELAGE					
			BROKEN SKIN					
			PERI-ORBITAL-RIGHT	20	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DOSE: 0.03 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05521	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P

3M_MN03279184

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05505	6	81	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	141	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-

3M_MN03279185

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05505	6	81						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	80	P	-	-	-
				141	P	-	-	-
				180	P	-	-	-
I05510	T	27	EXCRETION					
			DISCOLORED URINE					
			RED IN COLOR	97	-	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-

3M_MN03279186

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05510	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-
				185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	67	P	-	-	-
				73	P	-	-	-
				109	P	-	-	-
				127	P	-	-	-
				141	P	-	-	-
				142	P	-	-	-
				148	P	-	-	-
				154	P	-	-	-
				180	P	-	-	-
				183	P	-	-	-
I05518	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	179	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-

3M_MN03279187

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05518	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
					179	P	-	-	-

3M_MN03279188

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05523	6	81	SKIN & PELAGE						
			BROKEN SKIN						
			TAIL		149	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-

3M_MN03279189

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY / KEYWORD / QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY; DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05523	6	81						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	6	P	-	-	-
				141	P	-	-	-
				179	P	-	-	-
I05524	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	141	P	-	-	-
			EXCRETION					
			NON-FORMED FECES	179	P	-	-	-
				180	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-

3M_MN03279190

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05524	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		43	P	-	-	-
					65	P	-	-	-
					141	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-
I05528	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					85	P	-	-	-

3M_MN03279191

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD / QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY, DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05528	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				120	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-
				185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	78	P	-	-	-
				113	P	-	-	-
				116	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				162	P	-	-	-
				176	P	-	-	-
				179	P	-	-	-

3M_MN03279192

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05506	M	26	BEHAVIOR					
			ATAXIC					
			<UNSPECIFIED>	179	-	P	-	P
			HYPOACTIVE					
			<UNSPECIFIED>	179	-	P	-	P
			DISCHARGE					
			EXCESSIVE SALIVATION	179	-	P	-	-
			RESPIRATION					
			LABORED	179	-	P	-	P
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-

3M_MN03279193

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05506	M	26	NORMAL						
			NO REMARKABLE OBSERVATIONS		134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		3	P	-	-	-
					141	P	-	-	-
					178	P	-	-	-
					179	P	-	-	-
I05507	T	27	DISCHARGE						
			VOMITUS						
			PARTIAL CAPSULE		11	-	-	P	-
					111	-	-	P	-
					178	-	-	P	-
			SKIN & PELAGE						
			BROKEN SKIN						
			DIGIT(S)-FRONT-LEFT		97	-	-	P	-
					98	P	-	P	-
					99	P	-	P	-
					100	P	-	-	-
					101	-	-	P	-
					102	P	-	-	-
					104	P	-	P	-
					106	P	-	P	-
					107	P	-	P	-

3M_MN03279194

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05507	T	27	SKIN & PELAGE					
			BROKEN SKIN					
			DIGIT(S)-FRONT-LEFT	108	P	-	-	-
				111	-	-	P	-
				112	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-

3M_MN03279195

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05507	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
I05509	D	23	APPEARANCE						
			APPEARS DEHYDRATED		155	-	P	-	P
			OTHER		155	-	-	-	PC
			BEHAVIOR						
			HYPOACTIVE						
			<UNSPECIFIED>		155	-	P	-	P
			EXCRETION						
			DISCOLORED FECES						
			BLACK IN COLOR		155	P	-	-	-
			FEW FECES		152	P	-	-	-
					155	P	-	-	-
			LIQUID FECES		155	P	-	-	-
			MUCOID FECES		155	P	-	-	-
			NO FECES		154	P	-	-	-
			EYES						
			CONSTRICTED PUPIL						
			EYES		154	-	-	P	-
			RESPIRATION						
			LABORED		155	-	P	-	P

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05509	D	23						
			SKIN & PELAGE					
			COLD TO TOUCH					
			BODY-ENTIRE	155	-	P	-	P
			PALE SKIN					
			GUMS	154	-	-	P	-
				155	-	P	-	P
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-

3M_MN03279197

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05509	D	23						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	141	P	-	-	-
				152	P	-	-	-
				154	P	-	-	-
				155	P	-	-	-
I05511	U	79	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	100	P	-	-	-
			PARTIAL CAPSULE	155	-	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-

3M_MN03279198

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05511	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		57	P	-	-	-
					60	P	-	-	-
					100	P	-	-	-
					102	P	-	-	-
					141	P	-	-	-
					145	P	-	-	-
					148	P	-	-	-
					154	P	-	-	-
					155	P	-	-	-
					170	P	-	-	-
					171	P	-	-	-
					172	P	-	-	-
					173	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					177	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-

3M_MN03279199

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY / KEYWORD / QUALIFIER (GROUP: M4 DOSE: 0.75 MG/KG/DAY; DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
I05512	T	27	DISCHARGE					
			VOMITUS					
			PARTIAL CAPSULE	32	-	-	P	-
				37	-	-	P	-
			EXCRETION					
			FEW FECES	100	P	-	-	-
				102	P	-	-	-
				105	P	-	-	-
				106	P	-	-	-
				110	P	-	-	-
				125	P	-	-	-
				126	P	-	-	-
				127	P	-	-	-
				128	P	-	-	-
				129	P	-	-	-
				130	P	-	-	-
				133	P	-	-	-
				134	P	-	-	-
				155	P	-	-	-
				156	P	-	-	-
				157	P	-	-	-
				158	P	-	-	-
				159	P	-	-	-
				161	P	-	-	-
				181	P	-	-	-
				183	P	-	-	-
				184	P	-	-	-
			NO FECES	99	P	-	-	-
				131	P	-	-	-
				132	P	-	-	-
			NON-FORMED FECES	130	P	-	-	-

3M_MN03279200

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05512	T	27	EXCRETION					
			NON-FORMED FECES	133	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				184	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	17	P	-	-	-
				98	P	-	-	-
				99	P	-	-	-
				100	P	-	-	-

3M_MN03279201

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05512	T	27	QUALITATIVE FOOD CONSUMPTION LOW		102	P	-	-	-
					105	P	-	-	-
					110	P	-	-	-
					116	P	-	-	-
					125	P	-	-	-
					126	P	-	-	-
					127	P	-	-	-
					128	P	-	-	-
					129	P	-	-	-
					130	P	-	-	-
					131	P	-	-	-
					132	P	-	-	-
					133	P	-	-	-
					134	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	-	-
					158	P	-	-	-
					159	P	-	-	-
					160	P	-	-	-
					161	P	-	-	-
					162	P	-	-	-
					164	P	-	-	-
					168	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					178	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-
					181	P	-	-	-

3M_MN03279202

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05512	T	27	QUALITATIVE FOOD CONSUMPTION						
			LOW		183	P	-	-	-
I05522	U	79	EXCRETION						
			MUCOID FECES		179	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-

3M_MN03279203

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05522	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		102	P	-	-	-
					180	P	-	-	-

3M_MN03279204

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL	GROUP	STUDY DAY	WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05509	M4	155	23	APPEARANCE OTHER	AFTER DOSING ANIMAL BECAME RECUMBENT. VET WAS CALLED. ANIMAL DIED PRIOR TO VET EXAM.

3M_MN03279205

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY / KEYWORD / QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY; DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
I05529	P	79	APPEARANCE					
			APPEARS DEHYDRATED	5	-	-	P	-
				6	P	-	-	-
				7	P	-	-	-
			BEHAVIOR					
			HYPOACTIVE					
			<UNSPECIFIED>	6	-	-	P	-
				7	P	-	-	-
				8	P	-	P	-
			DISCHARGE					
			NASAL					
			CLEAR	5	-	-	P	-
				6	P	-	P	-
				7	P	-	-	-
				8	P	-	P	-
				9	P	-	-	-
			ORAL					
			CLOUDY	6	-	-	P	-
				7	P	-	-	-
				8	P	-	-	-
			EXCESSIVE SALIVATION	5	-	-	P	-
				6	P	-	P	-
				7	P	-	-	-
				8	P	-	-	-
			EXCRETION					
			LIQUID FECES	29	P	-	-	-
				30	P	-	-	-
				38	P	-	P	-
				39	P	-	-	-

3M_MN03279206

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05529	P	79	EXCRETION					
			LIQUID FECES	40	-	-	P	-
				41	P	-	-	-
				42	P	-	P	-
				43	P	-	-	-
				44	P	-	-	-
				65	-	-	P	-
				66	P	-	-	-
				67	P	-	-	-
				68	P	-	-	-
				69	P	-	-	-
				70	P	-	-	-
				99	-	-	P	-
				100	P	-	P	-
				101	P	-	-	-
				102	P	-	-	-
				115	-	-	P	-
			NON-FORMED FECES	71	P	-	-	-
				73	P	-	-	-
				77	P	-	-	-
				103	P	-	-	-
				115	P	-	-	-
			SKIN & PELAGE					
			ALOPECIA					
			FEET	105	P	-	P	-
				106	P	-	P	-
				107	P	-	P	-
				108	P	-	P	-
				109	P	-	P	-
				110	P	-	P	-
				111	P	-	P	-

3M_MN03279207

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			FEET		112	P	-	P	-
					113	P	-	P	-
					114	P	-	P	-
					115	P	-	P	-
					117	P	-	P	-
					118	P	-	P	-
					119	P	-	P	-
					120	P	-	P	-
					121	P	-	P	-
					122	-	-	P	-
					124	-	-	P	-
					125	P	-	P	-
					126	P	-	P	-
					127	P	-	P	-
					128	P	-	P	-
					129	-	-	P	-
					130	P	-	P	-
					131	P	-	P	-
					132	P	-	P	-
					133	P	-	P	-
					134	P	-	P	-
					135	P	-	P	-
					136	P	-	P	-
					137	P	-	P	-
					138	P	-	-	-
					139	P	-	P	-
					140	P	-	P	-
					142	P	-	P	-
					143	P	-	P	-
					146	P	-	P	-

3M_MN03279208

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05529	P	79	SKIN & PELAGE					
			ALOPECIA					
			FEET	147	P	-	P	-
				148	P	-	-	-
				149	P	-	P	-
				150	P	-	P	-
				151	P	-	P	-
				152	P	-	P	-
				153	P	-	P	-
				154	P	-	-	-
				155	P	-	-	-
				156	P	-	-	-
				157	P	-	P	-
				158	-	-	P	-
				162	P	-	P	-
				163	P	-	P	-
				164	P	-	P	-
				165	P	-	P	-
				166	P	-	P	-
				167	P	-	P	-
				168	P	-	P	-
				169	P	-	P	-
				170	P	-	P	-
				171	P	-	P	-
				172	P	-	P	-
				173	P	-	P	-
				174	P	-	P	-
				175	P	-	P	-
				176	P	-	P	-
				177	P	-	P	-
				178	P	-	P	-
				179	P	-	P	-

3M_MN03279209

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			FEET		180	P	-	P	-
					181	-	-	P	-
					182	P	-	P	-
					183	P	-	P	-
					184	P	-	-	-
					185	P	-	-	-
			LIMBS-HIND		92	-	-	P	-
					93	-	-	P	-
					94	P	-	P	-
					95	P	-	P	-
					96	P	-	P	-
					98	P	-	P	-
					99	P	-	P	-
					100	P	-	P	-
					101	P	-	-	-
					102	P	-	P	-
					142	-	-	P	-
					144	-	-	P	-
			TAIL		134	P	-	P	-
					135	P	-	P	-
					136	P	-	P	-
					137	P	-	P	-
					138	P	-	-	-
					139	P	-	P	-
					140	P	-	P	-
					142	P	-	P	-
					143	P	-	P	-
					146	P	-	P	-
					147	P	-	P	-
					148	P	-	-	-

3M_MN03279210

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05529	P	79	SKIN & PELAGE					
			ALOPECIA					
			TAIL	149	P	-	P	-
				150	P	-	P	-
				151	P	-	P	-
				152	P	-	P	-
				153	P	-	P	-
				154	P	-	-	-
				155	P	-	-	-
				156	P	-	-	-
				157	P	-	P	-
				158	-	-	P	-
				162	P	-	P	-
				163	P	-	P	-
				164	P	-	P	-
				165	P	-	P	-
				166	P	-	P	-
				167	P	-	P	-
				168	P	-	P	-
				169	P	-	P	-
				170	P	-	P	-
				171	P	-	P	-
				172	P	-	P	-
				173	P	-	P	-
				174	P	-	P	-
				175	P	-	P	-
				176	P	-	P	-
				177	P	-	P	-
				178	P	-	P	-
				179	P	-	P	-
				180	P	-	P	-
				181	-	-	P	-

3M_MN03279211

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05529	P	79	SKIN & PELAGE					
			ALOPECIA					
			TAIL	182	P	-	P	-
				183	P	-	P	-
				184	P	-	-	-
				185	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				141	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	5	P	-	-	-
				8	P	-	-	-
				41	P	-	-	-
				42	P	-	-	-
				69	P	-	-	-
				72	P	-	-	-
				73	P	-	-	-
				75	P	-	-	-
				102	P	-	-	-
				174	P	-	-	-
				179	P	-	-	-

3M_MN03279212

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY / KEYWORD / QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY; DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
I05530	T	27	DISCHARGE					
			VOMITUS					
			PARTIAL CAPSULE	97	-	-	P	-
			APPEARS TO BE MENSTRUATING	39	-	-	P	-
				40	P	-	-	-
				92	P	-	-	-
				176	P	-	-	-
				180	P	-	-	-
			EXCRETION					
			DISCOLORED FECES					
			RED IN COLOR	28	P	-	-	-
			LIQUID FECES	27	P	-	-	-
				28	P	-	P	-
				29	P	-	-	-
				31	-	-	P	-
				32	P	-	-	-
				33	P	-	-	-
				34	P	-	P	-
				35	P	-	-	-
				36	P	-	-	-
				37	P	-	-	-
				38	P	-	P	-
				39	-	-	P	-
				40	P	-	-	-
				49	P	-	-	-
				50	P	-	-	-
				51	P	-	P	-
				55	P	-	-	-
			MUCOID FECES	28	P	-	-	-
			NON-FORMED FECES	12	P	-	-	-
				31	P	-	-	-

3M_MN03279213

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05530	T	27	EXCRETION					
			NON-FORMED FECES	41	P	-	-	-
				54	P	-	-	-
				55	P	-	-	-
				57	P	-	-	-
			SKIN & PELAGE					
			BROKEN SKIN					
			MOUTH	10	-	-	P	-
				12	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				23	P	-	-	-
				25	P	-	P	-
				26	P	-	P	-
				27	P	-	P	-
				28	P	-	P	-
				29	P	-	P	-
				30	P	-	P	-
				31	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				43	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-

3M_MN03279214

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05530	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				183	P	-	-	-
				184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	26	P	-	-	-
				27	P	-	-	-
				29	P	-	-	-
				141	P	-	-	-
I05531	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	179	P	-	-	-
			APPEARS TO BE MENSTRUATING	176	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-

3M_MN03279215

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05531	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
					179	P	-	-	-

3M_MN03279216

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
GROUP: F1 DOSE: 0 MG/KG/DAY								
I05535	T	27	DISCHARGE					
			APPEARS TO BE MENSTRUATING	37	-	-	P	-
				38	P	-	-	-
				108	P	-	P	-
				137	P	-	P	-
				138	P	-	-	-
				166	P	-	P	-
				167	P	-	P	-
			SKIN & PELAGE					
			RED SKIN					
			LIMB-FRONT-RIGHT	22	-	-	P	-
				23	-	-	P	-
				24	P	-	P	-
			SCAB(S)					
			LIMB-FRONT-LEFT	183	P	-	-	-
			LIMB-FRONT-RIGHT	22	-	-	P	-
				23	-	-	P	-
				24	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-

3M_MN03279217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05535	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					185	P	-	-	P
I05544	T	27	DISCHARGE						
			VOMITUS						
			CONTAINING FOOD		141	P	-	-	-
			PARTIAL CAPSULE		29	-	-	P	-
					33	-	-	P	-
					34	-	-	P	-
					66	-	-	P	-
					117	-	-	P	-
					141	-	-	P	-
			DISCHARGE UNKNOWN SOURCE						
			FOUND IN PAN						
			RED IN COLOR		112	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05544	T	27							
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		6	P	-	-	-
					36	P	-	-	-
					38	P	-	-	-

3M_MN03279219

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY / KEYWORD / QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY; DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05544	T	27	QUALITATIVE FOOD CONSUMPTION					
			LOW	42	P	-	-	-
				43	P	-	-	-
				127	P	-	-	-
				171	P	-	-	-
				174	P	-	-	-
				176	P	-	-	-
I05549	P	79	DISCHARGE					
			VOMITUS					
			INTACT CAPSULE	111	-	-	P	-
			PARTIAL CAPSULE	97	-	-	P	-
			APPEARS TO BE MENSTRUATING	175	P	-	-	-
			SKIN & PELAGE					
			BROKEN SKIN					
			HEAD-CRANIAL	3	-	-	P	-
			PERI-ORBITAL-LEFT	7	-	-	P	-
				8	P	-	P	-
				15	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-

3M_MN03279220

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05549	P	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		141	P	-	-	-
					175	P	-	-	-

3M_MN03279221

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	GROUP: F2 DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05537	T	27	DISCHARGE					
			VOMITUS					
			WHITE IN COLOR	1	-	-	P	-
			APPEARS TO BE MENSTRUATING	45	-	-	P	-
				46	-	-	P	-
				47	P	-	-	-
				48	P	-	-	-
				49	-	-	P	-
				72	P	-	P	-
				73	P	-	P	-
				74	P	-	P	-
				75	P	-	-	-
				104	P	-	-	-
				105	P	-	P	-
				106	P	-	P	-
				107	P	-	-	-
				168	P	-	P	-
				169	P	-	P	-
			SKIN & PELAGE					
			BROKEN SKIN					
			HEAD-MAXILLARY-RIGHT	50	-	-	P	-
				52	-	-	P	-
			PERI-ORBITAL-LEFT	8	P	-	P	-
				9	P	-	P	-
				10	P	-	P	-
			PERI-ORBITAL-RIGHT	3	P	-	P	-
				4	P	-	-	-
				6	P	-	P	-
				7	-	-	P	-

3M_MN03279222

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2 DOSE: 0.03 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05537	T	27							
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P

3M_MN03279223

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	GROUP: F2 DOSE: 0.03 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05541	T	27	DISCHARGE					
			APPEARS TO BE MENSTRUATING	99	-	-	P	-
				102	P	-	-	-
				152	-	-	P	-
				154	-	-	P	-
			EXCRETION					
			FEW FECES	141	P	-	-	-
			SKIN & PELAGE					
			BROKEN SKIN					
			PERI-ORBITAL-RIGHT	98	-	-	P	-
				99	P	-	P	-
				102	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				106	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				148	P	-	-	-

3M_MN03279224

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2 DOSE: 0.03 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05541	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		3	P	-	-	-
					22	P	-	-	-
					28	P	-	-	-
					29	P	-	-	-
					43	P	-	-	-
					55	P	-	-	-
					57	P	-	-	-
					76	P	-	-	-
					87	P	-	-	-
					113	P	-	-	-
					140	P	-	-	-
					169	P	-	-	-
					174	P	-	-	-
					179	P	-	-	-
I05547	T	27	DISCHARGE						
			APPEARS TO BE MENSTRUATING		129	P	-	-	-
					164	-	-	P	-
					165	P	-	-	-
					167	P	-	-	-
			EXCRETION						
			FEW FECES		150	P	-	-	-

3M_MN03279225

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F2 DOSE: 0.03 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05547	T	27	EXCRETION					
			FEW FECES	151	P	-	-	-
				152	P	-	-	-
				156	P	-	-	-
				168	P	-	-	-
			NO FECES	154	P	-	-	-
				155	P	-	-	-
			NON-FORMED FECES	178	P	-	-	-
				181	-	-	P	-
			SKIN & PELAGE					
			BROKEN SKIN					
			HEAD-MAXILLARY-LEFT	170	P	-	P	-
				171	P	-	P	-
				172	P	-	P	-
				173	-	-	P	-
				174	P	-	P	-
				175	P	-	-	-
			SCAB(S)					
			HEAD-MAXILLARY-LEFT	176	P	-	-	-
				178	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-

3M_MN03279226

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD / QUALIFIER (GROUP: F2 DOSE: 0.03 MG/KG/DAY, DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05547	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				183	P	-	-	-
				185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	17	P	-	-	-
				41	P	-	-	-
				43	P	-	-	-
				55	P	-	-	-
				57	P	-	-	-
				66	P	-	-	-
				99	P	-	-	-
				120	P	-	-	-
				121	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				150	P	-	-	-
				151	P	-	-	-
				152	P	-	-	-

3M_MN03279227

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05547	T	27	QUALITATIVE FOOD CONSUMPTION					
			LOW	154	P	-	-	-
				155	P	-	-	-
				156	P	-	-	-
				160	P	-	-	-
				161	P	-	-	-
				162	P	-	-	-
				165	P	-	-	-
				167	P	-	-	-
				168	P	-	-	-
				169	P	-	-	-
				170	P	-	-	-
				171	P	-	-	-
				174	P	-	-	-
				175	P	-	-	-
				179	P	-	-	-
				184	P	-	-	-
I05550	T	27	DISCHARGE					
			APPEARS TO BE MENSTRUATING	91	-	-	P	-
				92	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-

3M_MN03279228

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2 DOSE: 0.03 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05550	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		3	P	-	-	-
					141	P	-	-	-
					179	P	-	-	-

3M_MN03279229

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05532	T	27	SKIN & PELAGE					
			BROKEN SKIN					
			HEAD-CRANIAL	2	P	-	P	-
			PERI-ORBITAL-RIGHT	3	P	-	P	-
				31	-	-	P	-
				32	P	-	P	-
				33	-	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-

3M_MN03279230

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05532	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		26	P	-	-	-
					29	P	-	-	-
					32	P	-	-	-
					41	P	-	-	-
					55	P	-	-	-
					57	P	-	-	-
					58	P	-	-	-
					65	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					115	P	-	-	-
					116	P	-	-	-
					120	P	-	-	-
					126	P	-	-	-
					141	P	-	-	-
					143	P	-	-	-
					147	P	-	-	-
					150	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					164	P	-	-	-
					169	P	-	-	-
					170	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					179	P	-	-	-
					183	P	-	-	-

3M_MN03279231

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05538	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	141	P	-	-	-
				179	P	-	-	-
			EXCRETION					
			FEW FECES	43	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-

3M_MN03279232

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05538	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		27	P	-	-	-
					41	P	-	-	-
					42	P	-	-	-
					43	P	-	-	-
					141	P	-	-	-
					160	P	-	-	-
					167	P	-	-	-
					174	P	-	-	-
					178	P	-	-	-
					179	P	-	-	-
I05539	6	81	DISCHARGE						
			APPEARS TO BE MENSTRUATING		71	P	-	P	-
			EXCRETION						
			FEW FECES		141	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05539	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		57	P	-	-	-
					64	P	-	-	-
					78	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					120	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		17	P	-	-	-
					18	P	-	-	-
					24	P	-	-	-
					57	P	-	-	-
					60	P	-	-	-
					70	P	-	-	-
					85	P	-	-	-
					109	P	-	-	-
					113	P	-	-	-
					116	P	-	-	-
					127	P	-	-	-
					132	P	-	-	-
					133	P	-	-	-
					138	P	-	-	-
					139	P	-	-	-

3M_MN03279234

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05539	6	81	QUALITATIVE FOOD CONSUMPTION					
			LOW	150	P	-	-	-
				155	P	-	-	-
				158	P	-	-	-
				159	P	-	-	-
				162	P	-	-	-
				171	P	-	-	-
				174	P	-	-	-
				179	P	-	-	-
I05545	T	27	DISCHARGE					
			APPEARS TO BE MENSTRUATING	136	P	-	P	-
			EXCRETION					
			NO FECES	51	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				127	P	-	-	-

3M_MN03279235

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05545	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		25	P	-	-	-
					30	P	-	-	-
					35	P	-	-	-
					43	P	-	-	-
					74	P	-	-	-
					78	P	-	-	-
					86	P	-	-	-
					113	P	-	-	-
					116	P	-	-	-
					120	P	-	-	-
					141	P	-	-	-
					149	P	-	-	-
					150	P	-	-	-
					155	P	-	-	-
					161	P	-	-	-
					169	P	-	-	-
					171	P	-	-	-
					174	P	-	-	-
					175	P	-	-	-
					176	P	-	-	-
					179	P	-	-	-

3M_MN03279236

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05545	T	27	QUALITATIVE FOOD CONSUMPTION					
			LOW	180	P	-	-	-
				183	P	-	-	-
I05548	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	141	P	-	-	-
			EXCRETION					
			FEW FECES	178	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-

3M_MN03279237

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05548	T	27	NORMAL						
			NO REMARKABLE OBSERVATIONS		148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		18	P	-	-	-
					28	P	-	-	-
					58	P	-	-	-
					141	P	-	-	-
					142	P	-	-	-
					174	P	-	-	-
I05552	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-

3M_MN03279238

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05552	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		20	P	-	-	-
					141	P	-	-	-
					156	P	-	-	-

3M_MN03279239

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05533	U	79	DISCHARGE						
			APPEARS TO BE MENSTRUATING		39	P	-	P	-
					40	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			HEAD-CRANIAL		22	-	-	P	-
					24	-	-	P	-
					27	P	-	P	-
					28	-	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	-	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	-	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-
					42	P	-	P	-
					43	P	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					48	-	-	P	-
					49	-	-	P	-
					50	P	-	P	-
					51	P	-	P	-
					52	P	-	P	-

3M_MN03279240

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05533	U	79	SKIN & PELAGE						
			ALOPECIA						
			HEAD-CRANIAL		53	P	-	P	-
					54	P	-	P	-
					55	P	-	P	-
					56	P	-	P	-
					57	P	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	-	-	P	-
					61	-	-	P	-
					62	P	-	-	-
			HEAD-MAXILLARY-LEFT		27	-	-	P	-
					28	-	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	-	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	-	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-
					42	P	-	P	-
					43	P	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					48	-	-	P	-

3M_MN03279241

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05533	U	79	SKIN & PELAGE						
			ALOPECIA						
			HEAD-MAXILLARY-LEFT		49	-	-	P	-
					50	P	-	P	-
					51	P	-	P	-
					52	P	-	P	-
					53	P	-	P	-
					54	P	-	P	-
					55	P	-	P	-
					56	P	-	P	-
					57	P	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	-	-	P	-
					61	-	-	P	-
					62	P	-	P	-
					63	P	-	P	-
			HEAD-MAXILLARY-RIGHT		27	-	-	P	-
					28	-	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	-	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	-	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-

3M_MN03279242

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05533	U	79	SKIN & PELAGE					
			ALOPECIA					
			HEAD-MAXILLARY-RIGHT	42	P	-	P	-
				43	P	-	P	-
				44	-	-	P	-
				45	-	-	P	-
				48	-	-	P	-
				49	-	-	P	-
				50	P	-	P	-
				51	P	-	P	-
				52	P	-	P	-
				53	P	-	P	-
				54	P	-	P	-
				55	P	-	P	-
				56	P	-	P	-
				57	P	-	P	-
				58	P	-	P	-
				59	P	-	P	-
				60	-	-	P	-
				61	-	-	P	-
				62	P	-	P	-
				63	P	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-

3M_MN03279243

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05533	U	79	NORMAL					
			NO REMARKABLE OBSERVATIONS	92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	141	P	-	-	-
I05534	T	27	DISCHARGE					
			VOMITUS					
			PARTIAL CAPSULE	6	-	-	P	-
				10	-	-	P	-
				72	-	-	P	-
			APPEARS TO BE MENSTRUATING	59	P	-	-	-
				98	P	-	-	-
				133	P	-	-	-
				134	P	-	-	-
			EXCRETION					
			DISCOLORED FECES					
			RED IN COLOR	149	P	-	-	-

3M_MN03279244

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05534	T	27	EXCRETION					
			DISCOLORED FECES					
			RED IN COLOR	150	P	-	-	-
			YELLOW IN COLOR	156	P	-	-	-
			FEW FECES	102	P	-	-	-
				105	P	-	-	-
				107	P	-	-	-
				109	P	-	-	-
				113	P	-	-	-
				127	P	-	-	-
				163	P	-	-	-
			LIQUID FECES	92	P	-	-	-
				93	P	-	-	-
				136	P	-	-	-
				137	P	-	P	-
				138	P	-	-	-
				139	P	-	-	-
				141	P	-	P	-
				142	P	-	-	-
				143	P	-	-	-
				144	P	-	-	-
				156	P	-	-	-
				185	P	-	-	-
			MUCOID FECES	150	P	-	-	-
			NO FECES	49	P	-	-	-
			NON-FORMED FECES	110	P	-	-	-
				113	P	-	-	-
				127	P	-	-	-
				137	P	-	-	-
				140	P	-	-	-
				144	P	-	-	-
				145	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05534	T	27	EXCRETION					
			NON-FORMED FECES	146	P	-	-	-
				147	P	-	-	-
				148	P	-	-	-
				149	P	-	-	-
				150	P	-	-	-
			SKIN & PELAGE					
			BROKEN SKIN					
			PERI-ORBITAL-LEFT	70	-	-	P	-
				71	P	-	P	-
			OTHER	9	PC	-	PC	-
				10	PC	-	PC	-
				12	PC	-	-	-
				15	PC	-	PC	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				85	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				183	P	-	-	-
				185	-	-	-	P

3M_MN03279246

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05534	T	27							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		2	P	-	-	-
					3	P	-	-	-
					8	P	-	-	-
					10	P	-	-	-
					22	P	-	-	-
					24	P	-	-	-
					38	P	-	-	-
					43	P	-	-	-
					49	P	-	-	-
					60	P	-	-	-
					63	P	-	-	-
					66	P	-	-	-
					78	P	-	-	-
					80	P	-	-	-
					81	P	-	-	-
					92	P	-	-	-
					93	P	-	-	-
					98	P	-	-	-
					100	P	-	-	-
					102	P	-	-	-
					105	P	-	-	-
					109	P	-	-	-
					113	P	-	-	-
					116	P	-	-	-
					120	P	-	-	-
					122	P	-	-	-
					125	P	-	-	-
					127	P	-	-	-
					128	P	-	-	-

3M_MN03279247

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05534	T	27	QUALITATIVE FOOD CONSUMPTION					
			LOW	129	P	-	-	-
				133	P	-	-	-
				134	P	-	-	-
				137	P	-	-	-
				138	P	-	-	-
				141	P	-	-	-
				148	P	-	-	-
				149	P	-	-	-
				150	P	-	-	-
				154	P	-	-	-
				155	P	-	-	-
				156	P	-	-	-
				157	P	-	-	-
				162	P	-	-	-
				164	P	-	-	-
				167	P	-	-	-
				170	P	-	-	-
				174	P	-	-	-
				175	P	-	-	-
				176	P	-	-	-
				180	P	-	-	-
				184	P	-	-	-
I05536	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	141	P	-	-	-
			PARTIAL CAPSULE	30	-	-	P	-
			EXCRETION					
			DISCOLORED FECES					
			RED IN COLOR	69	-	-	P	-

3M_MN03279248

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05536	T	27	EXCRETION					
			FEW FECES	88	P	-	-	-
			LIQUID FECES	88	P	-	-	-
			NON-FORMED FECES	179	P	-	-	-
				183	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				134	P	-	-	-
				148	P	-	-	-
				155	P	-	-	-
				162	P	-	-	-
				169	P	-	-	-
				176	P	-	-	-
				184	P	-	-	P

3M_MN03279249

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05536	T	27							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		3	P	-	-	-
					65	P	-	-	-
					72	P	-	-	-
					81	P	-	-	-
					88	P	-	-	-
					114	P	-	-	-
					117	P	-	-	-
					126	P	-	-	-
					127	P	-	-	-
					129	P	-	-	-
					130	P	-	-	-
					141	P	-	-	-
					149	P	-	-	-
					156	P	-	-	-
					157	P	-	-	-
					160	P	-	-	-
					180	P	-	-	-
					181	P	-	-	-
I05540	T	27	DISCHARGE						
			VOMITUS						
			INTACT CAPSULE		99	-	-	P	-
			EXCRETION						
			DISCOLORED FECES						
			RED IN COLOR		27	P	-	P	-
					28	P	-	P	-
			DISCOLORED URINE						
			GREEN IN COLOR		71	P	-	-	-

3M_MN03279250

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	EXCRETION						
			DISCOLORED URINE						
			GREEN IN COLOR		72	P	-	-	-
			FEW FECES		28	P	-	-	-
					29	P	-	-	-
			MUCOID FECES		28	-	-	P	-
					29	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			DORSAL		1	P	-	-	-
					141	-	-	P	-
			DORSAL-THORACIC		1	-	-	P	-
					2	P	-	P	-
					3	-	-	P	-
					5	-	-	P	-
					6	P	-	P	-
					7	P	-	P	-
					8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
					11	P	-	P	-
					12	P	-	P	-
					13	P	-	P	-
					14	P	-	P	-
					15	P	-	P	-
					16	P	-	P	-
					17	P	-	P	-
					18	P	-	P	-
					19	P	-	P	-
					20	P	-	P	-
					21	P	-	P	-

3M_MN03279251

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			DORSAL-THORACIC		22	P	-	P	-
					23	P	-	P	-
					24	P	-	P	-
					25	P	-	P	-
					26	P	-	P	-
					27	P	-	P	-
					28	P	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	P	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	P	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-
					42	P	-	P	-
					43	P	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					46	P	-	P	-
					47	P	-	P	-
					48	-	-	P	-
					49	-	-	P	-
					50	P	-	P	-
					51	P	-	-	-

3M_MN03279252

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			DORSAL-THORACIC		142	P	-	P	-
					143	P	-	P	-
					146	P	-	P	-
					147	P	-	P	-
					148	P	-	P	-
					149	P	-	P	-
					150	P	-	P	-
					151	P	-	P	-
					152	P	-	P	-
					153	P	-	P	-
					154	P	-	P	-
					155	P	-	P	-
					156	P	-	P	-
					157	P	-	P	-
					158	P	-	P	-
					159	P	-	P	-
					160	P	-	P	-
					161	P	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-

3M_MN03279253

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			DORSAL-THORACIC		174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-
					180	P	-	P	-
					181	P	-	P	-
					182	P	-	P	-
					183	P	-	P	-
					184	P	-	P	-
					185	P	-	-	P
			DORSAL-THORACIC-LEFT		57	-	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	P	-	P	-
					61	P	-	P	-
					62	P	-	P	-
					63	P	-	P	-
					64	P	-	P	-
					65	P	-	P	-
					66	P	-	P	-
					67	P	-	P	-
					68	P	-	P	-
					69	P	-	P	-
					70	P	-	P	-
					71	P	-	P	-
					72	P	-	P	-
					73	P	-	P	-
					74	P	-	P	-

3M_MN03279254

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			DORSAL-THORACIC-LEFT		76	P	-	P	-
					77	P	-	P	-
					78	P	-	-	-
					79	P	-	P	-
					80	P	-	P	-
					81	P	-	P	-
					82	P	-	P	-
					83	P	-	P	-
					84	P	-	P	-
					85	P	-	P	-
					86	P	-	P	-
					87	P	-	P	-
					88	P	-	-	-
					89	P	-	P	-
					90	P	-	P	-
					91	P	-	P	-
					92	P	-	P	-
					93	P	-	P	-
					94	P	-	P	-
					95	P	-	P	-
					96	P	-	P	-
					97	P	-	P	-
					98	P	-	P	-
					99	P	-	P	-
					100	P	-	P	-
					101	-	-	P	-
					102	P	-	P	-
					103	P	-	P	-
					104	P	-	P	-
					105	P	-	P	-

3M_MN03279255

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			DORSAL-THORACIC-LEFT		106	P	-	P	-
					107	P	-	P	-
					108	P	-	P	-
					109	P	-	P	-
					110	P	-	P	-
					111	P	-	P	-
					112	P	-	P	-
					113	P	-	P	-
					114	P	-	P	-
					115	P	-	P	-
					117	P	-	P	-
					118	P	-	P	-
					119	P	-	P	-
					120	P	-	P	-
					121	P	-	P	-
					122	P	-	P	-
					123	P	-	P	-
					124	P	-	P	-
					125	P	-	P	-
					126	P	-	P	-
					127	P	-	P	-
					128	P	-	P	-
					129	-	-	P	-
					130	-	-	P	-
					131	-	-	P	-
					132	P	-	P	-
					133	P	-	P	-
					134	P	-	P	-
					135	P	-	P	-
					136	P	-	P	-

3M_MN03279256

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			DORSAL-THORACIC-LEFT		137	P	-	P	-
					138	P	-	P	-
					139	P	-	P	-
					140	P	-	P	-
			HEAD-ENTIRE		1	P	-	P	-
					2	P	-	P	-
					3	-	-	P	-
					5	-	-	P	-
					6	P	-	P	-
					7	P	-	P	-
					8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
					11	P	-	P	-
					12	P	-	P	-
					13	P	-	P	-
					14	P	-	P	-
					15	P	-	P	-
					16	P	-	P	-
					17	P	-	P	-
					18	P	-	P	-
					19	P	-	P	-
					20	P	-	P	-
					21	P	-	P	-
					22	P	-	P	-
					23	P	-	P	-
					24	P	-	P	-
					25	P	-	P	-
					26	P	-	P	-
					27	P	-	P	-

3M_MN03279257

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			HEAD-ENTIRE		28	P	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	P	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	P	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-
			LIMB-HIND-LEFT		57	-	-	P	-
					58	P	-	P	-
					59	P	-	P	-
					60	P	-	P	-
					61	P	-	P	-
					62	P	-	P	-
					63	P	-	P	-
					64	P	-	P	-
					65	P	-	P	-
					66	P	-	P	-
					67	P	-	P	-
					68	P	-	P	-
					69	P	-	P	-
					70	P	-	P	-
					71	P	-	P	-
					72	P	-	P	-

3M_MN03279258

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMB-HIND-LEFT		73	P	-	P	-
					74	P	-	P	-
					76	P	-	P	-
					77	P	-	P	-
					78	P	-	-	-
					79	P	-	P	-
					80	P	-	P	-
					81	P	-	P	-
					82	P	-	P	-
					83	P	-	P	-
					84	P	-	P	-
					85	P	-	P	-
					86	P	-	P	-
					87	P	-	P	-
					88	P	-	-	-
					89	P	-	P	-
					90	P	-	P	-
					91	P	-	P	-
					92	P	-	P	-
					93	P	-	P	-
					94	P	-	P	-
					95	P	-	P	-
					96	P	-	P	-
					97	P	-	P	-
					98	P	-	P	-
					99	P	-	P	-
					100	P	-	P	-
					101	-	-	P	-
					102	P	-	P	-
					103	P	-	P	-

3M_MN03279259

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMB-HIND-LEFT		104	P	-	-	-
			LIMBS-ALL		42	P	-	P	-
					43	P	-	P	-
					44	-	-	P	-
					45	-	-	P	-
					46	P	-	P	-
					47	P	-	P	-
					48	-	-	P	-
					49	-	-	P	-
					50	P	-	P	-
					51	P	-	P	-
					52	P	-	P	-
					53	P	-	P	-
					54	P	-	P	-
					55	P	-	P	-
					56	P	-	-	-
					57	P	-	-	-
			LIMBS-FRONT		1	P	-	P	-
					2	P	-	P	-
					3	-	-	P	-
					5	-	-	P	-
					6	P	-	P	-
					7	P	-	P	-
					8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
					11	P	-	P	-
					12	P	-	P	-
					13	P	-	P	-
					14	P	-	P	-

3M_MN03279260

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMBS-FRONT		15	P	-	P	-
					16	P	-	P	-
					17	P	-	P	-
					18	P	-	P	-
					19	P	-	P	-
					20	P	-	P	-
					21	P	-	P	-
					22	P	-	P	-
					23	P	-	P	-
					24	P	-	P	-
					25	P	-	P	-
					26	P	-	P	-
					27	P	-	P	-
					28	P	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-
					32	P	-	P	-
					33	P	-	P	-
					34	P	-	P	-
					35	P	-	P	-
					36	P	-	P	-
					37	P	-	P	-
					38	P	-	P	-
					39	P	-	P	-
					40	P	-	-	-
					41	P	-	P	-
			TAIL		145	-	-	P	-
					146	P	-	P	-
					147	P	-	P	-

3M_MN03279261

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			TAIL		148	P	-	P	-
					149	P	-	P	-
					150	P	-	P	-
					151	P	-	P	-
					152	P	-	P	-
					153	P	-	P	-
					154	P	-	P	-
					155	P	-	P	-
					156	P	-	P	-
					157	P	-	P	-
					158	P	-	P	-
					159	P	-	P	-
					160	P	-	P	-
					161	P	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-
					174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-

3M_MN03279262

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05540	T	27	SKIN & PELAGE						
			ALOPECIA						
			TAIL		178	P	-	P	-
					179	P	-	P	-
					180	P	-	P	-
					181	P	-	P	-
					182	P	-	P	-
					183	P	-	P	-
					184	P	-	P	-
					185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION						
			LOW		17	P	-	-	-
					20	P	-	-	-
					25	P	-	-	-
					27	P	-	-	-
					69	P	-	-	-
					71	P	-	-	-
					73	P	-	-	-
					74	P	-	-	-
					78	P	-	-	-
					80	P	-	-	-
					85	P	-	-	-
					87	P	-	-	-
					120	P	-	-	-
					132	P	-	-	-
					137	P	-	-	-
					141	P	-	-	-
					155	P	-	-	-
					179	P	-	-	-

3M_MN03279263

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY / KEYWORD / QUALIFIER (GROUP: F4 DOSE: 0.75 MG/KG/DAY; DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCHED	30-90 OB	DISPATCH
I05542	U	79	DISCHARGE					
			VOMITUS					
			INTACT CAPSULE	136	P	-	P	-
			PARTIAL CAPSULE	65	-	-	P	-
				78	-	-	P	-
				126	-	-	P	-
				131	-	-	P	-
			APPEARS TO BE MENSTRUATING	71	P	-	P	-
				115	P	-	-	-
				161	P	-	-	-
			EXCRETION					
			PEW FECES	155	P	-	-	-
				161	P	-	-	-
				162	P	-	-	-
			SKIN & PELAGE					
			PALE SKIN					
			HEAD-ENTIRE	182	-	-	P	-
				183	P	-	-	-
				184	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				85	P	-	-	-

3M_MN03279264

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05542	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		14	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					49	P	-	-	-
					57	P	-	-	-
					59	P	-	-	-
					60	P	-	-	-
					65	P	-	-	-
					78	P	-	-	-
					92	P	-	-	-
					98	P	-	-	-
					125	P	-	-	-
					134	P	-	-	-
					139	P	-	-	-
					141	P	-	-	-
					142	P	-	-	-
					143	P	-	-	-
					154	P	-	-	-
					155	P	-	-	-

3M_MN03279265

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05542	U	79	QUALITATIVE FOOD CONSUMPTION					
			LOW	161	P	-	-	-
				162	P	-	-	-
				175	P	-	-	-
I05551	T	27	DISCHARGE					
			APPEARS TO BE MENSTRUATING	43	-	-	P	-
				44	-	-	P	-
				45	-	-	P	-
				73	P	-	P	-
				74	P	-	P	-
				75	P	-	P	-
				76	P	-	P	-
				80	P	-	-	-
				112	P	-	P	-
				113	P	-	P	-
				137	-	-	P	-
				138	P	-	P	-
				139	P	-	P	-
				140	P	-	P	-
				141	P	-	P	-
				166	P	-	P	-
				167	P	-	P	-
				168	P	-	-	-
			EXCRETION					
			FEW FECES	161	P	-	-	-
			SMALL FECES	49	P	-	P	-
			SKIN & PELAGE					
			ALOPECIA					
			LIMBS-ALL	1	P	-	P	-

3M_MN03279266

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05551	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMBS-ALL		2	P	-	P	-
					3	-	-	P	-
					4	-	-	P	-
					5	-	-	P	-
					6	P	-	P	-
					7	P	-	P	-
					8	P	-	P	-
					9	P	-	P	-
					10	P	-	P	-
					11	P	-	P	-
					12	P	-	P	-
					13	P	-	P	-
					14	P	-	P	-
					15	P	-	P	-
					16	P	-	P	-
					17	P	-	P	-
					18	P	-	P	-
					19	P	-	P	-
					20	P	-	P	-
					21	P	-	P	-
					22	P	-	P	-
					23	P	-	P	-
					24	P	-	P	-
					25	P	-	P	-
					26	P	-	P	-
					27	P	-	P	-
					28	P	-	P	-
					29	P	-	P	-
					30	P	-	P	-
					31	P	-	P	-

3M_MN03279267

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL	32	P	-	P	-
				33	P	-	P	-
				34	P	-	P	-
				35	P	-	P	-
				36	P	-	P	-
				37	P	-	P	-
				38	P	-	P	-
				39	P	-	P	-
				40	P	-	P	-
				41	P	-	P	-
				42	P	-	P	-
				43	P	-	P	-
				44	-	-	P	-
				45	-	-	P	-
				46	P	-	P	-
				47	P	-	P	-
				48	-	-	P	-
				49	P	-	P	-
				50	P	-	P	-
				51	P	-	P	-
				52	P	-	P	-
				53	P	-	P	-
				54	P	-	P	-
				55	P	-	P	-
				56	P	-	P	-
				57	P	-	P	-
				58	P	-	P	-
				59	P	-	P	-
				60	P	-	P	-
				61	P	-	P	-

3M_MN03279268

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL		62	P	-	P	-
					63	P	-	P	-
					64	P	-	P	-
					65	P	-	P	-
					66	P	-	P	-
					67	P	-	P	-
					68	P	-	P	-
					69	P	-	P	-
					70	P	-	P	-
					71	P	-	P	-
					72	P	-	P	-
					73	P	-	P	-
					74	P	-	P	-
					75	P	-	P	-
					76	P	-	P	-
					77	P	-	P	-
					78	P	-	P	-
					79	P	-	P	-
					80	P	-	P	-
					81	P	-	P	-
					82	P	-	P	-
					83	P	-	P	-
					84	P	-	P	-
					85	P	-	P	-
					86	P	-	P	-
					87	P	-	P	-
					88	P	-	P	-
					89	P	-	P	-
					90	P	-	P	-
					91	P	-	P	-

3M_MN03279269

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05551	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMBS-ALL		92	P	-	P	-
					93	P	-	P	-
					94	P	-	P	-
					95	P	-	P	-
					96	P	-	P	-
					97	P	-	P	-
					98	P	-	P	-
					99	P	-	P	-
					100	P	-	P	-
					101	-	-	P	-
					102	P	-	P	-
					103	P	-	P	-
					104	P	-	P	-
					105	P	-	P	-
					106	P	-	P	-
					107	P	-	P	-
					108	P	-	P	-
					109	P	-	P	-
					110	P	-	P	-
					111	P	-	P	-
					112	P	-	P	-
					113	P	-	P	-
					114	P	-	P	-
					115	P	-	P	-
					116	-	-	P	-
					117	P	-	P	-
					118	P	-	P	-
					119	P	-	P	-
					120	P	-	P	-
					121	P	-	P	-

3M_MN03279270

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05551	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMBS-ALL		122	P	-	P	-
					123	P	-	P	-
					124	P	-	P	-
					125	P	-	P	-
					126	P	-	P	-
					127	P	-	P	-
					128	P	-	P	-
					129	-	-	P	-
					130	-	-	P	-
					131	-	-	P	-
					132	P	-	P	-
					133	P	-	P	-
					134	P	-	P	-
					135	P	-	P	-
					136	P	-	P	-
					137	P	-	P	-
					138	P	-	P	-
					139	P	-	P	-
					140	P	-	P	-
					141	-	-	P	-
					142	P	-	P	-
					143	P	-	P	-
					144	-	-	P	-
					145	-	-	P	-
					146	P	-	P	-
					147	P	-	P	-
					148	P	-	P	-
					149	P	-	P	-
					150	P	-	P	-
					151	P	-	P	-

3M_MN03279271

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05551	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMBS-ALL		152	P	-	P	-
					153	P	-	P	-
					154	P	-	P	-
					155	P	-	P	-
					156	P	-	P	-
					157	P	-	P	-
					158	P	-	P	-
					159	P	-	P	-
					160	P	-	P	-
					161	P	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-
					174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-
					180	P	-	P	-
					181	P	-	P	-

3M_MN03279272

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 1-185)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05551	T	27	SKIN & PELAGE					
			ALOPECIA					
			LIMBS-ALL	182	P	-	P	-
				183	P	-	P	-
				184	P	-	P	-
				185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	72	P	-	-	-
				85	P	-	-	-
				102	P	-	-	-
				146	P	-	-	-
				162	P	-	-	-

3M_MN03279273

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL	GROUP	STUDY DAY	WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05534	F4	9	2	SKIN & PELAGE	BRUISED SKIN PERI-ORBITAL LEFT EYE.
		TO 15	3	OTHER	

3M_MN03279274

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05520	O	79	SKIN & PELAGE						
			BROKEN SKIN						
			DIGIT(S)-FRONT-LEFT		361	P	-	-	-
					362	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

3M_MN03279275

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 186-365)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05520	O	79						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	273	P	-	-	-
I05526	O	79	NORMAL					
			NO REMARKABLE OBSERVATIONS	190	P	-	-	-
				197	P	-	-	-
				204	P	-	-	-
				211	P	-	-	-
				218	P	-	-	-
				225	P	-	-	-
				232	P	-	-	-
				239	P	-	-	-
				246	P	-	-	-
				253	P	-	-	-
				260	P	-	-	-
				267	P	-	-	-
				274	P	-	-	-
				281	P	-	-	-
				288	P	-	-	-
				295	P	-	-	-
				302	P	-	-	-
				309	P	-	-	-
				316	P	-	-	-
				323	P	-	-	-
				330	P	-	-	-
				337	P	-	-	-
				344	P	-	-	-
				351	P	-	-	-
				358	P	-	-	-
				365	P	-	-	-

3M_MN03279276

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05505	6	81	EXCRETION						
			NON-FORMED FECES		191	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

3M_MN03279277

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05505	6	81							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		240	P	-	-	-
I05523	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

3M_MN03279278

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05523	6	81							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		247	P	-	-	-

3M_MN03279279

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05511	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		255	P	-	-	-

3M_MN03279280

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05522	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

3M_MN03279281

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05529	P	79	EXCRETION						
			LIQUID FECES		277	P	-	-	-
					278	P	-	-	-
					306	P	-	-	-
					308	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			FEET		186	P	-	-	-
					187	P	-	-	-
					188	P	-	-	-
					189	P	-	-	-
					190	P	-	-	-
					191	P	-	-	-
					192	P	-	-	-
					193	P	-	-	-
					194	P	-	-	-
					195	P	-	-	-
					197	P	-	-	-
					200	P	-	-	-
					201	P	-	-	-
					203	P	-	-	-
					204	P	-	-	-
					206	P	-	-	-
					210	P	-	-	-
					211	P	-	-	-
					213	P	-	-	-
					216	P	-	-	-
					217	P	-	-	-
					218	P	-	-	-
					219	P	-	-	-
					220	P	-	-	-

3M_MN03279282

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE ALOPECIA FEET		221	P	-	-	-
					222	P	-	-	-
					223	P	-	-	-
					225	P	-	-	-
					226	P	-	-	-
					229	P	-	-	-
					230	P	-	-	-
					231	P	-	-	-
					232	P	-	-	-
					233	P	-	-	-
					234	P	-	-	-
					235	P	-	-	-
					236	P	-	-	-
					237	P	-	-	-
					238	P	-	-	-
					239	P	-	-	-
					240	P	-	-	-
					241	P	-	-	-
					244	P	-	-	-
					245	P	-	-	-
					246	P	-	-	-
					247	P	-	-	-
					248	P	-	-	-
					251	P	-	-	-
					252	P	-	-	-
					253	P	-	-	-
					254	P	-	-	-
					255	P	-	-	-
					257	P	-	-	-
					258	P	-	-	-

3M_MN03279283

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			FEET		259	P	-	-	-
					260	P	-	-	-
					261	P	-	-	-
					263	P	-	-	-
					264	P	-	-	-
					265	P	-	-	-
					266	P	-	-	-
					267	P	-	-	-
					268	P	-	-	-
					269	P	-	-	-
					272	P	-	-	-
					273	P	-	-	-
					274	P	-	-	-
					275	P	-	-	-
					276	P	-	-	-
					277	P	-	-	-
					278	P	-	-	-
					279	P	-	-	-
					280	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					289	P	-	-	-
					294	P	-	-	-
					295	P	-	-	-
					298	P	-	-	-
					301	P	-	-	-
					302	P	-	-	-
					305	P	-	-	-
					306	P	-	-	-
					308	P	-	-	-

3M_MN03279284

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			FEET		309	P	-	-	-
					310	P	-	-	-
					311	P	-	-	-
					314	P	-	-	-
			TAIL		186	P	-	-	-
					187	P	-	-	-
					188	P	-	-	-
					189	P	-	-	-
					190	P	-	-	-
					191	P	-	-	-
					192	P	-	-	-
					193	P	-	-	-
					194	P	-	-	-
					195	P	-	-	-
					197	P	-	-	-
					200	P	-	-	-
					201	P	-	-	-
					203	P	-	-	-
					204	P	-	-	-
					206	P	-	-	-
					210	P	-	-	-
					211	P	-	-	-
					213	P	-	-	-
					216	P	-	-	-
					217	P	-	-	-
					218	P	-	-	-
					219	P	-	-	-
					220	P	-	-	-
					221	P	-	-	-
					222	P	-	-	-

3M_MN03279285

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			TAIL		223	P	-	-	-
					225	P	-	-	-
					226	P	-	-	-
					229	P	-	-	-
					230	P	-	-	-
					231	P	-	-	-
					232	P	-	-	-
					233	P	-	-	-
					234	P	-	-	-
					235	P	-	-	-
					236	P	-	-	-
					237	P	-	-	-
					238	P	-	-	-
					239	P	-	-	-
					240	P	-	-	-
					241	P	-	-	-
					244	P	-	-	-
					245	P	-	-	-
					246	P	-	-	-
					247	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

3M_MN03279286

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		195	P	-	-	-
					210	P	-	-	-
					247	P	-	-	-
					248	P	-	-	-
					260	P	-	-	-
					272	P	-	-	-
					273	P	-	-	-
					294	P	-	-	-
I05549	P	79	DISCHARGE						
			APPEARS TO BE MENSTRUATING		261	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-

3M_MN03279287

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05549	P	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		195	P	-	-	-
					231	P	-	-	-
					248	P	-	-	-
					272	P	-	-	-

3M_MN03279288

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 186-365)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05539	6	81	DISCHARGE					
			APPEARS TO BE MENSTRUATING	216	P	-	-	-
				217	P	-	-	-
				246	P	-	-	-
				275	P	-	-	-
			EXCRETION					
			FEW FECES	191	P	-	-	-
				195	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	190	P	-	-	-
				197	P	-	-	-
				204	P	-	-	-
				211	P	-	-	-
				218	P	-	-	-
				225	P	-	-	-
				232	P	-	-	-
				239	P	-	-	-
				253	P	-	-	-
				260	P	-	-	-
				267	P	-	-	-
				274	P	-	-	-
				281	P	-	-	-
				288	P	-	-	-
				295	P	-	-	-
				302	P	-	-	-
				309	P	-	-	-
				316	P	-	-	-
				323	P	-	-	-
				330	P	-	-	-
				337	P	-	-	-

3M_MN03279289

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05539	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		191	P	-	-	-
					195	P	-	-	-
					213	P	-	-	-
					218	P	-	-	-
					251	P	-	-	-
					254	P	-	-	-
					259	P	-	-	-
					269	P	-	-	-
					316	P	-	-	-
					346	P	-	-	-
I05552	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-

3M_MN03279290

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05552	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		220	P	-	-	-
					343	P	-	-	-
					344	P	-	-	-
					346	P	-	-	-

3M_MN03279291

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 186-365)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05533	U	79	EXCRETION					
			NON-FORMED FECES	245	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	190	P	-	-	-
				197	P	-	-	-
				204	P	-	-	-
				211	P	-	-	-
				218	P	-	-	-
				225	P	-	-	-
				232	P	-	-	-
				239	P	-	-	-
				246	P	-	-	-
				253	P	-	-	-
				260	P	-	-	-
				267	P	-	-	-
				274	P	-	-	-
				281	P	-	-	-
				288	P	-	-	-
				295	P	-	-	-
				302	P	-	-	-
				309	P	-	-	-
				316	P	-	-	-
				323	P	-	-	-
				330	P	-	-	-
				337	P	-	-	-
				344	P	-	-	-
				351	P	-	-	-
				358	P	-	-	-
				365	P	-	-	-

3M_MN03279292

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 186-365)	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05533	U	79						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	241	P	-	-	-
				244	P	-	-	-
				343	P	-	-	-
I05542	U	79	DISCHARGE					
			APPEARS TO BE MENSTRUATING	260	P	-	-	-
				299	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	190	P	-	-	-
				197	P	-	-	-
				204	P	-	-	-
				211	P	-	-	-
				218	P	-	-	-
				225	P	-	-	-
				232	P	-	-	-
				239	P	-	-	-
				246	P	-	-	-
				253	P	-	-	-
				267	P	-	-	-
				274	P	-	-	-
				288	P	-	-	-
				295	P	-	-	-
				302	P	-	-	-
				309	P	-	-	-
				316	P	-	-	-
				323	P	-	-	-
				330	P	-	-	-
				337	P	-	-	-

3M_MN03279293

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD / QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05542	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		269	P	-	-	-
					273	P	-	-	-
					275	P	-	-	-
					281	P	-	-	-
					302	P	-	-	-
					343	P	-	-	-
					344	P	-	-	-

3M_MN03279294

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

GROUP: M1 DOSE: 0 MG/KG/DAY

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
I05520	O	79	EXCRETION						
			NON-FORMED FECES		533	P	-	-	-
					534	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-

3M_MN03279295

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05520	O	79						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	541	P	-	-	-
I05526	O	79	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	535	P	-	-	-
				541	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	-
				379	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				400	P	-	-	-
				407	P	-	-	-
				414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				456	P	-	-	-
				463	P	-	-	-
				470	P	-	-	-
				477	P	-	-	-
				484	P	-	-	-
				491	P	-	-	-
				498	P	-	-	-
				505	P	-	-	-
				512	P	-	-	-

3M_MN03279296

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05526	O	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-

3M_MN03279297

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD / QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY; DAYS 368-558)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP: AM OBS	UNSCH	EXTRA	DISPATCH
I05505	6	81	APPEARANCE					
			SWOLLEN					
			HEAD-MAXILLARY-RIGHT	390	P	-	-	-
				391	P	-	-	-
				393	P	-	-	-
				394	P	-	-	-
				395	P	-	-	-
				397	P	-	-	-
				400	P	-	-	-
			DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	535	P	-	-	-
			EXCRETION					
			FEW FECES	555	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	-
				379	P	-	-	-
				386	P	-	-	-
				407	P	-	-	-
				414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				456	P	-	-	-
				463	P	-	-	-
				470	P	-	-	-
				477	P	-	-	-

3M_MN03279298

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 368-558)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05505	6	81	NORMAL					
			NO REMARKABLE OBSERVATIONS	484	P	-	-	-
				491	P	-	-	-
				498	P	-	-	-
				505	P	-	-	-
				512	P	-	-	-
				519	P	-	-	-
				526	P	-	-	-
				533	P	-	-	-
				540	P	-	-	-
				547	P	-	-	-
				554	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	375	P	-	-	-
				376	P	-	-	-
				555	P	-	-	-
I05523	6	81	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	535	P	-	-	-
			EXCRETION					
			NO FECES	555	P	-	-	-
				556	P	-	-	-
			NON-FORMED FECES	557	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				400	P	-	-	-

3M_MN03279299

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05523	6	81	NORMAL						
			NO REMARKABLE OBSERVATIONS		407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					554	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		375	P	-	-	-
					379	P	-	-	-
					553	P	P	-	-
					555	P	-	-	-
					558	P	-	-	-

3M_MN03279300

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
I05511	U	79	NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					549	P	-	-	P

3M_MN03279301

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
I05522	U	79	EXCRETION					
			NON-FORMED FECES	402	P	-	-	-
				403	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	-
				379	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				400	P	-	-	-
				407	P	-	-	-
				414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				456	P	-	-	-
				463	P	-	-	-
				470	P	-	-	-
				477	P	-	-	-
				484	P	-	-	-
				491	P	-	-	-
				498	P	-	-	-
				505	P	-	-	-
				512	P	-	-	-
				519	P	-	-	-
				526	P	-	-	-
				533	P	-	-	-
				540	P	-	-	-
				547	P	-	-	-
				549	P	-	-	P

3M_MN03279302

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY DAYS 368-558	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP DAY	AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05522	U	79							
			QUALITATIVE FOOD CONSUMPTION						
			LOW		394	P	-	-	-

3M_MN03279303

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
I05529	P	79	EXCRETION					
			LIQUID FECES	489	P	-	-	-
				491	P	-	-	-
				492	P	-	-	-
				493	P	-	-	-
				494	P	-	-	-
			NON-FORMED FECES	496	P	-	-	-
			SKIN & PELAGE					
			ALOPECIA					
			LIMB-HIND-RIGHT	368	P	-	-	-
				369	P	-	-	-
				372	P	-	-	-
				376	P	-	-	-
				377	P	-	-	-
				378	P	-	-	-
				549	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	379	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				400	P	-	-	-
				407	P	-	-	-
				414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				456	P	-	-	-
				463	P	-	-	-

3M_MN03279304

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05529	P	79	NORMAL					
			NO REMARKABLE OBSERVATIONS	470	P	-	-	-
				477	P	-	-	-
				484	P	-	-	-
				498	P	-	-	-
				505	P	-	-	-
				512	P	-	-	-
				519	P	-	-	-
				526	P	-	-	-
				533	P	-	-	-
				540	P	-	-	-
				547	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	372	P	-	-	-
				376	P	-	-	-
				452	P	-	-	-
I05549	P	79	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	535	P	-	-	-
			APPEARS TO BE MENSTRUATING	372	P	-	-	-
				400	P	-	-	-
				456	P	-	-	-
				484	P	-	-	-
				541	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	379	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				407	P	-	-	-

3M_MN03279305

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05549	P	79	NORMAL					
			NO REMARKABLE OBSERVATIONS	414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				463	P	-	-	-
				470	P	-	-	-
				477	P	-	-	-
				491	P	-	-	-
				498	P	-	-	-
				505	P	-	-	-
				512	P	-	-	-
				519	P	-	-	-
				526	P	-	-	-
				533	P	-	-	-
				540	P	-	-	-
				547	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	372	P	-	-	-
				452	P	-	-	-

3M_MN03279306

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (DAYS 368-558)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
I05539	6	81	GROUP: F3 DOSE: 0.15 MG/KG/DAY					
			DISCHARGE UNKNOWN SOURCE					
			FOUND IN PAN					
			RED IN COLOR	555	P	-	-	-
				556	P	-	-	-
			EXCRETION					
			FEW FECES	404	P	-	-	-
				558	P	-	-	-
			NO FECES	555	P	-	-	-
				556	P	-	-	-
				557	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	-
				379	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				400	P	-	-	-
				407	P	-	-	-
				414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				456	P	-	-	-
				463	P	-	-	-
				470	P	-	-	-
				477	P	-	-	-
				484	P	-	-	-
				491	P	-	-	-
				498	P	-	-	-

3M_MN03279307

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 368-558)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05539	6	81	NORMAL					
			NO REMARKABLE OBSERVATIONS	505	P	-	-	-
				512	P	-	-	-
				519	P	-	-	-
				526	P	-	-	-
				533	P	-	-	-
				540	P	-	-	-
				547	P	-	-	-
				554	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION					
			LOW	375	P	-	-	-
				376	P	-	-	-
				399	P	-	-	-
				404	P	-	-	-
				407	P	-	-	-
				553	-	P	-	-
				556	P	-	-	-
				557	P	-	-	-
				558	P	-	-	-
			NONE	555	P	-	-	-
I05552	6	81	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	535	P	-	-	-
			EXCRETION					
			FEW FECES	555	P	-	-	-
				557	P	-	-	-
				558	P	-	-	-
			NO FECES	556	P	-	-	-

3M_MN03279308

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05552	6	81							
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					554	P	-	-	-

3M_MN03279309

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05552	6	81						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	372	P	-	-	-
				557	P	-	-	-
				558	P	-	-	-
			NONE	555	P	-	-	-
				556	P	-	-	-

3M_MN03279310

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 368-558	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
I05533	U	79	EXCRETION						
			LIQUID FECES		399	P	-	-	-
					400	P	-	-	-
			NON-FORMED FECES		402	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					549	P	-	-	P

3M_MN03279311

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 368-558)	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05533	U	79						
			QUALITATIVE FOOD CONSUMPTION					
			LOW	394	P	-	-	-
I05542	U	79	DISCHARGE					
			APPEARS TO BE MENSTRUATING	496	P	-	-	-
			DISCHARGE UNKNOWN SOURCE					
			FOUND IN PAN					
			RED IN COLOR	375	P	-	-	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	-
				379	P	-	-	-
				386	P	-	-	-
				393	P	-	-	-
				400	P	-	-	-
				407	P	-	-	-
				414	P	-	-	-
				421	P	-	-	-
				428	P	-	-	-
				435	P	-	-	-
				442	P	-	-	-
				449	P	-	-	-
				456	P	-	-	-
				463	P	-	-	-
				470	P	-	-	-
				477	P	-	-	-
				484	P	-	-	-
				491	P	-	-	-
				498	P	-	-	-

3M_MN03279312

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD / QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY DAYS 368-558 DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCH	EXTRA	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05542	U	79	NORMAL					
			NO REMARKABLE OBSERVATIONS	505	P	-	-	-
				512	P	-	-	-
				519	P	-	-	-
				526	P	-	-	-
				533	P	-	-	-
				540	P	-	-	-
				547	P	-	-	-
				549	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	375	P	-	-	-
				394	P	-	-	-
				395	P	-	-	-

3M_MN03279313

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05508	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05517	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05519	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05520	O	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05526	O	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05527	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279314

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2 DOSE: 0.03 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05514	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05515	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05516	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05521	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279315

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05505	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05510	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05518	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05523	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05524	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05528	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279316

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05506	M	26	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05507	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05509	D	23	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4
I05511	U	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05512	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05522	U	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279317

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DOSE: 0 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05529	P	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYE-LEFT	-4
			EYES	26
			MISCELLANEOUS OPHTHALMICS	
			INCREASED MYELINATION OF OPTIC NERVE	
			EYE-RIGHT	-4
I05530	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05531	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05535	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05544	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05549	P	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279318

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2 DOSE: 0.03 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05537	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05541	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05547	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05550	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279319

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05532	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05538	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05539	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05545	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05548	T	27	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26
I05552	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	-4, 26

3M_MN03279320

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05533	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	-4, 26
I05534	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	-4, 26
I05536	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	-4, 26
I05540	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	-4, 26
I05542	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	-4, 26
I05551	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	-4, 26

3M_MN03279321

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05520	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	52
I05526	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES	52

3M_MN03279322

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: M3 DOSE: 0.15 MG/KG/DAY)	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05505	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52
I05523	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52

3M_MN03279323

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DOSE: 0.75 MG/KG/DAY WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05511	U	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52
I05522	U	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52

3M_MN03279324

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER (GROUP: F1 DOSE: 0 MG/KG/DAY)	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05529	P	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYE-LEFT	52
			MISCELLANEOUS OPHTHALMICS	
			OTHER	
			EYE-RIGHT	52C
I05549	P	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52

3M_MN03279325

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL	GROUP	STUDY DAY	WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05529	F1	363	52	MISCELLANEOUS OPHTHALMICS OTHER EYE-RIGHT	INCREASED MYELINATION OF OPTIC NERVE HEAD THAT MAY BE ASSOCIATED WITH OPTIC NEURITIS. MACULA NORMAL.

3M_MN03279326

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DOSE: 0.15 MG/KG/DAY WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05539	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52
I05552	6	81	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52

3M_MN03279327

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DOSE: 0.75 MG/KG/DAY WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05533	U	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52
I05542	U	79	NO VISIBLE LESIONS	
			NO VISIBLE LESIONS	
			EYES	52

3M_MN03279328

APPENDIX 3

Individual Body Weight Data (kg)

3M_MN03279329

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK[a] -1	WEEK[b] -1	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8
GROUP: MALE 1 - 0 MG/KG/DAY										
I05508	3.0	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2
I05517	3.4	3.4	3.4	3.3	3.2	3.2	3.3	3.3	3.3	3.3
I05519	2.9	3.0	3.0	3.0	3.0	3.1	3.1	3.0	3.0	3.1
I05520	2.9	2.9	2.9	2.9	3.0	3.1	3.0	3.0	2.9	3.0
I05526	3.0	3.0	3.0	3.1	3.2	3.3	3.3	3.3	3.3	3.3
I05527	4.0	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1
GROUP: MALE 2 - 0.03 MG/KG/DAY										
I05514	3.1	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3
I05515	3.3	3.3	3.3	3.2	3.3	3.4	3.4	3.5	3.4	3.4
I05516	2.7	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9
I05521	4.4	4.3	4.4	4.3	4.4	4.4	4.4	4.4	4.4	4.4
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.1	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.2
I05510	2.9	3.0	2.9	2.9	2.9	3.0	3.0	3.0	3.1	3.1
I05518	3.0	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2
I05523	2.6	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
I05524	2.9	2.9	2.9	3.0	3.1	3.1	3.1	3.1	3.1	3.0
I05528	3.6	3.7	3.7	3.7	3.7	3.8	3.8	3.8	3.8	3.7
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05506	3.3	3.4	3.4	3.4	3.5	3.5	3.6	3.7	3.7	3.7
I05507	4.4	4.4	4.4	4.5	4.5	4.5	4.5	4.5	4.6	4.6
I05509	3.1	3.2	3.2	3.1	3.2	3.2	3.3	3.3	3.2	3.2
I05511	2.8	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.8
I05512	2.8	2.9	2.9	2.8	2.9	3.0	3.0	3.0	3.1	3.0
I05522	3.4	3.4	3.4	3.4	3.5	3.6	3.6	3.6	3.6	3.6

a Day -7.
b Day -1.

3M_MN03279330

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK[a] -1	WEEK[b] -1	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8
GROUP:	FEMALE 1 - 0 MG/KG/DAY									
I05529	2.5	2.5	2.5	2.7	2.3	2.4	2.4	2.4	2.4	2.4
I05530	2.9	2.9	2.9	2.8	2.9	2.9	2.7	2.7	2.8	2.8
I05531	2.6	2.6	2.6	2.6	2.6	2.7	2.6	2.6	2.7	2.6
I05535	3.4	3.3	3.3	3.3	3.4	3.4	3.4	3.4	3.5	3.5
I05544	2.6	2.7	2.7	2.6	2.6	2.7	2.7	2.6	2.6	2.6
I05549	2.9	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0
GROUP:	FEMALE 2 - 0.03 MG/KG/DAY									
I05537	3.8	3.8	3.9	3.9	3.9	4.0	3.9	3.9	4.0	4.0
I05541	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6
I05547	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
I05550	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.9	2.9
GROUP:	FEMALE 3 - 0.15 MG/KG/DAY									
I05532	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
I05538	3.2	3.2	3.2	3.1	3.1	3.0	3.0	3.0	3.0	3.0
I05539	3.6	3.7	3.7	3.8	3.8	3.8	3.8	3.9	3.9	3.9
I05545	2.6	2.6	2.6	2.7	2.7	2.7	2.6	2.6	2.6	2.6
I05548	2.8	2.9	2.9	3.0	2.9	3.0	3.0	3.0	3.0	3.0
I05552	2.8	2.8	2.8	2.7	2.7	2.7	2.7	2.7	2.7	2.7
GROUP:	FEMALE 4 - 0.75 MG/KG/DAY									
I05533	2.6	2.6	2.6	2.6	2.6	2.6	2.5	2.6	2.6	2.5
I05534	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
I05536	3.9	3.9	3.9	3.8	3.8	3.9	3.9	3.9	3.8	3.8
I05540	2.9	3.0	3.0	3.1	3.1	2.8	2.6	2.6	2.8	2.9
I05542	2.8	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
I05551	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.3	2.4	2.4

a Day -7.
b Day -1.

3M_MN03279331

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14	WEEK 15	WEEK 16	WEEK 17	WEEK 18
GROUP: MALE 1 - 0 MG/KG/DAY										
I05508	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.4	3.4	
I05517	3.4	3.3	3.3	3.3	3.3	3.3	3.3	3.1	3.3	3.3
I05519	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.3	3.2
I05520	3.0	3.0	3.1	3.0	3.0	3.1	3.0	3.0	3.0	3.0
I05526	3.4	3.4	3.5	3.5	3.6	3.5	3.6	3.6	3.7	3.7
I05527	4.2	4.2	4.3	4.3	4.3	4.3	4.3	4.3	4.4	4.4
GROUP: MALE 2 - 0.03 MG/KG/DAY										
I05514	3.3	3.3	3.4	3.4	3.4	3.4	3.5	3.5	3.6	3.5
I05515	3.5	3.5	3.6	3.7	3.7	3.6	3.6	3.7	3.8	3.7
I05516	3.0	3.0	3.0	3.0	3.1	3.2	3.2	3.2	3.3	3.2
I05521	4.4	4.4	4.6	4.6	4.6	4.5	4.6	4.6	4.6	4.5
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.3	3.2	3.3	3.3	3.3	3.2	3.3	3.3	3.3	3.3
I05510	3.1	3.1	3.2	3.2	3.3	3.1	3.2	3.2	3.3	3.3
I05518	3.3	3.2	3.2	3.3	3.3	3.2	3.2	3.3	3.3	3.3
I05523	2.8	2.7	2.8	2.8	2.9	2.9	2.9	2.9	3.0	2.9
I05524	3.2	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.0	3.2
I05528	3.7	3.7	3.8	3.7	3.7	3.8	3.8	3.7	3.7	3.6
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05506	3.8	3.7	3.9	3.8	3.9	3.8	3.9	3.9	4.0	3.9
I05507	4.7	4.6	4.7	4.7	4.7	4.6	4.6	4.5	4.6	4.5
I05509	3.2	3.2	3.2	3.2	3.2	3.1	3.1	3.0	3.1	3.0
I05511	2.9	2.8	2.9	2.9	2.9	2.9	2.9	2.8	2.7	2.8
I05512	3.1	3.0	3.1	3.1	3.1	2.9	2.9	2.7	2.8	2.8
I05522	3.6	3.6	3.7	3.6	3.7	3.7	3.7	3.6	3.7	3.7

3M_MN03279332

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14	WEEK 15	WEEK 16	WEEK 17	WEEK 18
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.5	2.5	2.6	2.6	2.6	2.4	2.5	2.5	2.5
I05530	2.9	2.9	3.0	3.1	3.0	3.0	3.0	3.0	3.0	3.0
I05531	2.7	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
I05535	3.6	3.5	3.5	3.6	3.6	3.6	3.5	3.5	3.6	3.6
I05544	2.6	2.7	2.7	2.7	2.8	2.7	2.7	2.8	2.8	2.7
I05549	3.0	3.0	2.9	3.0	3.0	3.0	3.0	3.0	3.1	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY										
I05537	4.1	4.0	4.0	4.0	4.1	4.1	4.1	4.1	4.2	4.2
I05541	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.6	2.7
I05547	3.0	3.0	3.0	3.1	3.1	3.1	3.0	3.0	3.0	3.0
I05550	2.9	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05532	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.8
I05538	3.0	3.0	3.2	3.2	3.3	3.2	3.3	3.3	3.4	3.4
I05539	3.9	3.9	3.9	3.9	3.9	4.0	4.0	3.9	3.9	3.9
I05545	2.6	2.7	2.7	2.6	2.6	2.7	2.7	2.7	2.7	2.6
I05548	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.0	3.1	3.0
I05552	2.8	2.8	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.6	2.6	2.6	2.7	2.7	2.6	2.6	2.6	2.7	2.6
I05534	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
I05536	3.9	3.9	3.8	3.8	3.7	3.6	3.5	3.4	3.7	3.6
I05540	3.1	3.0	2.8	2.8	2.8	2.7	2.9	3.0	3.1	3.1
I05542	2.8	2.7	2.7	2.7	2.7	2.7	2.6	2.6	2.8	2.7
I05551	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.3	2.4	2.3

3M_MN03279333

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 19	WEEK 20	WEEK 21	WEEK 22	WEEK 23	WEEK 24	WEEK 25	WEEK 26	WEEK 27
GROUP: MALE 1 - 0 MG/KG/DAY									
I05508	3.4	3.4	3.4	3.4	3.4	3.4	3.6	3.6	3.6
I05517	3.4	3.4	3.3	3.3	3.3	3.4	3.4	3.3	3.3
I05519	3.3	3.2	3.2	3.2	3.3	3.3	3.4	3.4	3.4
I05520	3.1	3.0	3.1	3.1	3.1	3.0	3.2	3.2	3.1
I05526	3.7	3.7	3.7	3.8	3.7	3.7	3.8	3.9	3.8
I05527	4.5	4.5	4.6	4.6	4.7	4.8	4.9	5.0	5.0
GROUP: MALE 2 - 0.03 MG/KG/DAY									
I05514	3.6	3.6	3.6	3.6	3.7	3.7	3.8	3.8	3.8
I05515	3.8	3.8	3.6	3.7	3.7	3.7	3.8	3.8	3.7
I05516	3.2	3.2	3.2	3.3	3.3	3.3	3.4	3.4	3.4
I05521	4.6	4.6	4.7	4.6	4.6	4.7	4.7	4.7	4.7
GROUP: MALE 3 - 0.15 MG/KG/DAY									
I05505	3.3	3.3	3.2	3.3	3.3	3.3	3.4	3.3	3.2
I05510	3.3	3.3	3.2	3.3	3.3	3.4	3.5	3.4	3.4
I05518	3.3	3.3	3.2	3.3	3.3	3.3	3.3	3.4	3.3
I05523	3.0	3.0	2.9	2.9	2.9	2.9	3.1	3.0	2.9
I05524	3.3	3.3	3.2	3.3	3.3	3.3	3.4	3.4	3.3
I05528	3.6	3.7	3.7	3.7	3.7	3.7	3.7	3.6	3.7
GROUP: MALE 4 - 0.75 MG/KG/DAY									
I05506	4.0	4.0	3.9	3.9	3.9	4.0	4.0	3.9	
I05507	4.5	4.4	4.3	4.2	4.2	4.1	4.2	4.2	4.2
I05509	3.0	3.1	2.9	3.0	2.8				
I05511	2.9	2.8	2.6	2.7	2.7	2.8	2.7	2.6	2.5
I05512	2.6	2.5	2.6	2.8	2.7	2.6	2.7	2.7	2.5
I05522	3.7	3.6	3.6	3.6	3.6	3.6	3.7	3.7	3.5

3M_MN03279334

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 19	WEEK 20	WEEK 21	WEEK 22	WEEK 23	WEEK 24	WEEK 25	WEEK 26	WEEK 27
GROUP: FEMALE 1 - 0 MG/KG/DAY									
I05529	2.5	2.5	2.5	2.5	2.5	2.6	2.5	2.5	2.4
I05530	3.0	3.0	2.9	3.0	3.0	3.0	3.1	3.0	3.0
I05531	2.8	2.8	2.7	2.8	2.7	2.7	2.8	2.8	2.9
I05535	3.5	3.5	3.5	3.6	3.4	3.5	3.6	3.6	3.5
I05544	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9
I05549	3.1	3.1	3.0	3.1	3.0	3.0	3.0	3.1	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY									
I05537	4.2	4.2	4.2	4.2	4.2	4.3	4.4	4.4	4.3
I05541	2.7	2.7	2.6	2.7	2.8	2.7	2.8	2.8	2.8
I05547	3.1	3.0	3.0	2.9	2.8	2.7	2.8	2.7	2.8
I05550	3.0	3.0	2.9	3.0	2.9	3.0	3.1	3.0	3.0
GROUP: FEMALE 3 - 0.15 MG/KG/DAY									
I05532	2.8	2.8	2.7	2.8	2.8	2.8	2.8	2.8	2.7
I05538	3.4	3.4	3.3	3.5	3.5	3.4	3.5	3.4	3.5
I05539	4.0	4.0	3.8	3.8	3.8	3.9	3.9	3.9	3.9
I05545	2.7	2.8	2.6	2.7	2.6	2.7	2.7	2.7	2.7
I05548	3.1	3.1	3.0	3.1	3.1	3.1	3.1	3.1	3.1
I05552	2.8	2.8	2.7	2.8	2.8	2.8	2.9	2.8	2.7
GROUP: FEMALE 4 - 0.75 MG/KG/DAY									
I05533	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.5
I05534	2.9	2.8	2.7	2.9	2.8	2.9	2.8	2.7	2.8
I05536	3.5	3.5	3.3	3.3	3.4	3.3	3.3	3.4	3.4
I05540	3.1	3.0	3.0	2.9	2.9	3.0	3.0	3.0	3.0
I05542	2.7	2.7	2.6	2.7	2.6	2.6	2.7	2.6	2.6
I05551	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4

3M_MN03279335

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 28	WEEK 29	WEEK 30	WEEK 31	WEEK 32	WEEK 33	WEEK 34	WEEK 35	WEEK 36	WEEK 37
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	3.2	3.3	3.3	3.4	3.5	3.5	3.5	3.5	3.5	3.6
I05526	3.8	3.9	3.9	4.0	4.1	4.1	4.1	4.0	4.1	4.2
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.2	3.3	3.2	3.3	3.4	3.4	3.3	3.3	3.4	3.4
I05523	2.9	2.9	2.8	2.8	2.9	3.0	3.0	2.9	3.1	3.0
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05511	2.7	2.8	2.9	3.0	3.0	3.1	3.1	3.0	3.1	3.1
I05522	3.5	3.7	3.7	4.0	4.2	4.2	4.5	4.4	4.6	4.6
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
I05549	2.9	3.0	2.9	3.0	3.0	3.1	3.0	3.0	3.0	3.1
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05539	3.8	3.9	3.8	3.9	4.0	4.0	4.0	4.1	4.2	4.1
I05552	2.8	2.9	2.8	2.8	2.9	2.9	2.8	2.8	2.9	3.0
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.5	2.6	2.6	2.6	2.7	2.8	2.8	2.8	2.8	2.8
I05542	2.7	2.8	2.8	2.9	3.2	3.2	3.2	3.1	3.3	3.3

3M_MN03279336

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 38	WEEK 39	WEEK 40	WEEK 41	WEEK 42	WEEK 43	WEEK 44	WEEK 45	WEEK 46	WEEK 47
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	3.6	3.6	3.6	3.7	3.8	3.8	4.0	4.1	4.2	4.1
I05526	4.2	4.1	4.1	4.3	4.2	4.2	4.4	4.4	4.5	4.3
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.3	3.3	3.3	3.4	3.3	3.3	3.4	3.5	3.5	3.4
I05523	3.0	2.9	2.9	3.1	3.0	3.0	3.1	3.1	3.1	3.0
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05511	3.1	3.0	2.9	3.1	3.0	3.1	3.2	3.2	3.3	3.2
I05522	4.5	4.4	4.4	4.5	4.5	4.5	4.5	4.5	4.6	4.4
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.4	2.3	2.5	2.4	2.4	2.5	2.5	2.5	2.4
I05549	3.0	3.0	2.9	3.1	3.0	3.0	3.0	3.1	3.1	3.0
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05539	4.1	4.1	4.0	4.2	4.1	4.1	4.3	4.2	4.2	4.2
I05552	2.9	2.9	2.8	3.0	3.0	3.0	3.0	3.1	3.0	2.9
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.7	2.7	2.8	2.8	2.7	2.7	2.8	2.8	2.8	2.7
I05542	3.3	3.2	3.1	3.3	3.2	3.3	3.3	3.3	3.4	3.4

3M_MN03279337

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 48	WEEK 49	WEEK 50	WEEK 51	WEEK 52	WEEK 53	WEEK 54	WEEK 55	WEEK 56	WEEK 57
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.1	4.1	4.1	4.1	4.2	4.2	4.2	4.3	4.2	4.1
I05526	4.3	4.4	4.4	4.4	4.5	4.5	4.6	4.7	4.7	4.6
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4
I05523	3.0	3.1	3.0	3.1	3.1	3.0	3.1	3.1	3.2	3.1
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	3.3	3.5	3.5	3.6	3.7	3.7	3.8	3.8	3.9	3.8
I05522	4.4	4.6	4.5	4.5	4.5	4.4	4.5	4.4	4.4	4.2
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.3	2.5	2.4	2.4	2.5	2.4	2.4	2.4	2.4	2.3
I05549	2.8	3.0	2.9	3.0	2.9	2.8	2.8	2.9	2.9	2.8
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.3	4.3	4.2	4.3	4.3	4.3	4.2	4.2	4.2	4.2
I05552	2.9	3.0	2.9	3.0	3.0	2.9	2.9	2.8	2.9	2.9
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.7	2.9	2.8	2.8	2.8	2.7	2.7	2.6	2.7	2.6
I05542	3.4	3.4	3.3	3.3	3.4	3.4	3.4	3.5	3.5	3.4

3M_MN03279338

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 58	WEEK 59	WEEK 60	WEEK 61	WEEK 62	WEEK 63	WEEK 64	WEEK 65	WEEK 66	WEEK 67
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.2	4.1	4.2	4.2	4.1	4.1	4.0	4.0	4.0	4.1
I05526	4.7	4.7	4.9	4.9	4.8	4.9	4.9	4.8	4.9	4.9
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.4	3.4	3.5	3.5	3.6	3.5	3.5	3.4	3.4	3.5
I05523	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.3	3.2	3.3
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	3.9	3.8	4.0	4.0	4.0	4.1	4.3	4.2	4.1	4.2
I05522	4.4	4.4	4.6	4.6	4.7	4.7	4.6	4.5	4.5	4.5
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.5	2.4	2.5	2.5	2.4	2.5	2.4	2.4	2.4	2.4
I05549	2.9	2.9	3.0	2.9	3.0	3.0	2.9	2.9	2.8	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.1	4.0	4.2	4.1	4.1	4.1	4.1	4.0	4.0	4.1
I05552	3.0	3.0	3.0	3.0	3.0	3.1	3.0	2.9	2.9	3.1
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.6	2.6	2.8	2.8	2.8	2.8	2.7	2.7	2.7	2.8
I05542	3.4	3.4	3.5	3.5	3.6	3.6	3.6	3.5	3.5	3.6

3M_MN03279339

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 68	WEEK 69	WEEK 70	WEEK 71	WEEK 72	WEEK 73	WEEK 74	WEEK 75	WEEK 76	WEEK 77
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.2	4.3	4.2	4.2	4.3	4.2	4.2	4.2	4.2	4.1
I05526	5.0	5.1	5.0	5.1	5.3	5.2	5.4	5.3	5.4	5.3
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.6	3.6	3.5	3.5	3.6	3.5	3.6	3.6	3.6	3.5
I05523	3.3	3.4	3.4	3.4	3.5	3.4	3.5	3.5	3.5	3.4
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	4.3	4.3	4.3	4.2	4.3	4.2	4.3	4.3	4.3	4.3
I05522	4.6	4.7	4.6	4.6	4.6	4.5	4.6	4.6	4.6	4.5
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.4	2.5	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.4
I05549	2.9	2.9	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.1	4.2	4.1	4.2	4.2	4.2	4.2	4.2	4.2	4.2
I05552	3.0	3.0	3.0	3.0	3.1	3.0	3.1	3.1	3.2	3.1
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.7	2.7	2.7	2.7	2.7	2.6	2.7	2.7	2.8	2.7
I05542	3.6	3.7	3.7	3.7	3.8	3.7	3.8	3.8	3.9	3.8

3M_MN03279340

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WEEK 78	WEEK 79	WEEK 80
GROUP: MALE 1 - 0 MG/KG/DAY			
I05520	4.0	4.0	
I05526	5.3	5.3	
GROUP: MALE 3 - 0.15 MG/KG/DAY			
I05505	3.5	3.5	3.5
I05523	3.4	3.5	3.2
GROUP: MALE 4 - 0.75 MG/KG/DAY			
I05511	4.3	4.4	
I05522	4.5	4.5	
GROUP: FEMALE 1 - 0 MG/KG/DAY			
I05529	2.4	2.4	
I05549	2.8	2.9	
GROUP: FEMALE 3 - 0.15 MG/KG/DAY			
I05539	4.1	4.2	4.0
I05552	2.9	3.0	2.8
GROUP: FEMALE 4 - 0.75 MG/KG/DAY			
I05533	2.6	2.7	
I05542	3.8	3.9	

3M_MN03279341

COVANCE
THE DEVELOPMENT SERVICES COMPANY

Sponsor:

3M
St. Paul, Minnesota

FINAL REPORT

Study Title:

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Author:

Peter J. Thomford, PhD

Study Completion Date:

January 11, 2002

Testing Facility:

Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Laboratory Study Identification:

Covance 6329-223

Sponsor Study Identification:

3M Study No. T-6295.7

Volume II of II

3M_MN03279342

CONTENTS

VOLUME II OF II **Page**

APPENDIX 4 511
Individual Clinical Hematology Data 512
Individual Clinical Chemistry Data 614
Individual Clinical Urinalysis Data 728

APPENDIX 5 818
Individual Palmitoyl CoA Oxidase Determinations 819
Individual Anatomic Pathology Data 823

APPENDIX 6 907
AniLytics Inc. Quality Assurance Statements 908
Summary and Individual Blood Hormone Determination 917

APPENDIX 7 963
Cell Proliferation Report 964

APPENDIX 8 977
Electron Microscopic Evaluation of Liver in Cynomolgus Monkeys 978

APPENDIX 9 1069
Urobilinogen Analysis Report 1070

APPENDIX 10 1072
Dose Confirmation Analysis Report 1073
Compound Stability Report 1078
Analytical Laboratory Report 1080
Certificate of Analysis 1083
Quality Assurance Statement 1086

3M_MN03279343

1818.0510

APPENDIX 4

Individual Clinical Hematology Data
Individual Clinical Chemistry Data
Individual Clinical Urinalysis Data

3M_MN03279344

Appendix 4

Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.48	12.3	40.3	62.2	19.0	30.5	419	.3	19
I05517	6.25	12.8	42.4	67.8	20.5	30.2	380	.5	31
I05519	6.97	12.5	42.9	61.5	17.9	29.0	577	.5	35
I05520	6.27	11.8	39.4	62.9	18.8	29.9	681	.0	0
I05526	6.48	12.0	41.1	63.5	18.6	29.3	472	.2	13
I05527	6.27	12.1	40.9	65.3	19.3	29.6	652	.3	19
MEAN	6.45	12.2	41.2	63.9	19.0	29.8	530	.3	20
S.D.	.275	.36	1.30	2.32	.87	.56	125.0	.19	12.6
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	7.28	12.5	45.5	62.5	17.2	27.5	469	.5	36
I05515	6.22	11.8	39.8	64.0	18.9	29.6	675	.6	37
I05516	6.67	12.5	40.9	61.3	18.7	30.6	341	.1	7
I05521	7.79	12.9	45.3	58.1	16.6	28.5	813	.2	16
MEAN	6.99	12.4	42.9	61.5	17.8	29.0	574	.4	24
S.D.	.688	.46	2.95	2.51	1.13	1.34	210.3	.24	14.9
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.45	12.6	42.0	65.2	19.6	30.0	469	1.4	90
I05510	6.58	11.9	39.7	60.3	18.1	29.9	546	.5	33
I05518	7.36	13.0	44.8	60.9	17.6	29.0	375	.7	52
I05523	6.73	12.8	43.1	64.1	19.0	29.7	569	.0	0
I05524	6.76	13.0	44.6	66.1	19.3	29.2	635	.0	0
I05528	6.67	12.6	43.1	64.6	18.9	29.3	366	.3	20
MEAN	6.76	12.6	42.9	63.5	18.7	29.5	493	.5	32
S.D.	.315	.41	1.88	2.38	.76	.41	109.0	.53	34.5
N	6	6	6	6	6	6	6	6	6

3M_MN03279345

Appendix 4

Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.63	13.4	45.8	60.0	17.6	29.3	519	.6	46
I05507	6.94	12.0	41.5	59.7	17.3	28.9	58	.3	21
I05509	6.89	11.9	42.3	61.4	17.3	28.1	409	.4	28
I05511	5.90	11.4	40.3	68.4	19.4	28.4	528	1.4	83
I05512	7.20	13.1	44.5	61.8	18.1	29.3	342	.2	14
I05522	6.73	13.1	44.1	65.5	19.5	29.7	636	.1	7
MEAN	6.88	12.5	43.1	62.8	18.2	29.0	415	.5	33
S.D.	.575	.82	2.06	3.44	1.01	.61	202.6	.47	27.8
N	6	6	6	6	6	6	6	6	6

3M_MN03279346

Appendix 4

Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	6.6	2.1	4.0	.4	.0	.0	32	61	6	0	0
I05517	9.2	3.3	4.7	1.0	.1	.1	36	52	11	1	1
I05519	6.7	3.1	3.1	.4	.2	.0	46	46	5	2	0
I05520	9.0	5.1	3.0	.8	.0	.1	56	34	9	0	1
I05526	11.3	5.4	5.3	.5	.1	.0	48	47	5	1	0
I05527	8.9	4.4	3.7	.7	.1	.0	49	41	8	1	0
MEAN	8.6	3.9	4.0	.6	.1	.0	44	47	7	1	0
S.D.	1.76	1.28	.90	.24	.08	.05	8.9	9.2	2.4	.8	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	11.7	7.2	4.0	.4	.2	.0	62	34	3	2	0
I05515	11.5	3.2	6.2	1.5	.5	.0	28	54	13	4	0
I05516	9.5	4.0	4.4	.9	.1	.0	42	47	10	1	0
I05521	11.1	6.3	4.0	.6	.2	.0	56	36	6	2	0
MEAN	11.0	5.2	4.6	.8	.2	.0	47	43	8	2	0
S.D.	1.00	1.88	1.05	.48	.17	.00	15.2	9.4	4.4	1.3	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	12.5	9.4	2.4	.6	.1	.0	75	19	5	1	0
I05510	11.1	5.8	4.2	1.0	.1	.0	52	38	9	1	0
I05518	10.7	4.8	4.6	1.3	.0	.0	45	43	12	0	0
I05523	15.0	9.8	3.7	.8	.6	.0	66	25	5	4	0
I05524	9.4	4.2	4.0	1.1	.0	.1	45	42	12	0	1
I05528	12.7	5.3	5.9	.8	.7	.0	42	46	6	5	0
MEAN	11.9	6.6	4.1	.9	.2	.0	54	36	8	2	0
S.D.	1.95	2.42	1.14	.25	.31	.04	13.4	10.9	3.3	2.1	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279347

Appendix 4

Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	9.3	3.0	5.0	1.1	.2	.1	32	54	12	2	1
I05507	13.7	4.9	6.3	2.1	.1	.2	36	46	15	1	2
I05509	7.5	3.3	2.8	.7	.7	.0	44	37	9	9	0
I05511	8.0	3.9	3.3	.6	.1	.0	49	41	8	1	0
I05512	7.1	1.6	4.3	1.2	.0	.0	22	60	16	0	1
I05522	11.0	5.5	4.1	1.1	.2	.1	50	37	10	2	1
MEAN	9.4	3.7	4.3	1.1	.2	.1	39	46	12	2	1
S.D.	2.53	1.40	1.25	.53	.25	.08	10.9	9.5	3.3	3.3	.8
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279348

Appendix 4

Individual Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03			Dosage Unit: mg/kg/day	
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279349

Appendix 4

Individual Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.96	11.5	37.1	62.2	19.3	31.0	631	.4	24
I05530	6.78	13.3	45.0	66.4	19.6	29.5	552	.3	20
I05531	5.72	10.5	34.7	60.6	18.3	30.2	584	.1	6
I05535	6.66	12.2	40.8	61.3	18.3	29.9	577	.5	33
I05544	4.98	11.6	36.2	72.7	23.2	31.9	471	1.3	65
I05549	6.45	12.6	41.9	65.0	19.5	30.1	417	1.0	64
MEAN	6.09	12.0	39.3	64.7	19.7	30.4	539	.6	35
S.D.	.681	.97	3.93	4.51	1.81	.87	79.5	.46	24.2
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.13	10.6	36.7	59.9	17.3	28.8	529	.3	18
I05541	5.78	12.0	40.0	69.1	20.8	30.2	426	.9	52
I05547	6.30	10.7	37.4	59.3	17.0	28.6	558	.4	25
I05550	7.02	12.8	43.9	62.5	18.2	29.1	414	.2	14
MEAN	6.31	11.5	39.5	62.7	18.3	29.2	482	.4	27
S.D.	.522	1.06	3.26	4.49	1.73	.71	72.4	.31	17.1
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.95	12.7	43.2	62.2	18.2	29.3	433	.4	28
I05538	6.16	11.3	38.3	62.1	18.4	29.6	475	.3	18
I05539	6.23	11.7	39.2	62.9	18.8	29.9	477	.8	50
I05545	6.72	12.3	40.7	60.6	18.3	30.1	325	.1	7
I05548	6.76	11.8	38.0	56.2	17.4	31.0	615	.4	27
I05552	6.39	12.0	41.1	64.2	18.7	29.1	560	.7	45
MEAN	6.54	12.0	40.1	61.4	18.3	29.8	481	.4	29
S.D.	.320	.49	1.97	2.79	.50	.68	100.9	.26	16.2
N	6	6	6	6	6	6	6	6	6

3M_MN03279350

Appendix 4

Individual Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.46	12.1	41.2	63.8	18.7	29.3	337	.2	13
I05534	6.72	13.1	44.2	65.8	19.5	29.6	438	.4	27
I05536	6.67	12.1	41.7	62.6	18.2	29.1	606	.1	7
I05540	6.21	11.8	39.6	63.8	19.0	29.8	433	.0	0
I05542	6.57	12.0	42.4	64.5	18.2	28.3	492	.4	26
I05551	6.35	11.7	40.0	63.0	18.5	29.4	304	.4	25
MEAN	6.50	12.1	41.5	63.9	18.7	29.2	435	.2	16
S.D.	.195	.50	1.68	1.14	.50	.52	108.9	.18	11.4
N	6	6	6	6	6	6	6	6	6

3M_MN03279351

Appendix 4

Individual Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	7.4	3.4	3.3	.6	.2	.0	45	45	8	2	0
I05530	11.7	6.0	4.9	.7	.1	.0	51	42	6	1	0
I05531	8.4	5.0	2.6	.7	.1	.1	59	31	8	1	1
I05535	12.6	5.0	6.0	.8	.6	.1	39	48	7	5	1
I05544	13.0	5.3	5.8	1.2	.7	.0	40	44	9	6	0
I05549	8.0	3.1	4.3	.5	.1	.0	38	54	6	2	0
MEAN	10.2	4.6	4.5	.8	.3	.0	45	44	7	3	0
S.D.	2.52	1.14	1.36	.24	.28	.05	8.3	7.6	1.2	2.1	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	12.2	8.6	2.7	.6	.2	.0	70	22	5	2	0
I05541	8.1	3.0	4.1	.9	.1	.1	36	50	11	1	1
I05547	6.8	3.6	2.5	.6	.1	.0	53	36	9	2	0
I05550	7.6	4.6	2.4	.5	.1	.0	60	32	6	1	0
MEAN	8.7	5.0	2.9	.6	.1	.0	55	35	8	2	0
S.D.	2.41	2.52	.79	.17	.05	.05	14.3	11.6	2.8	.6	.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	7.6	2.6	3.6	1.2	.2	.0	35	48	15	2	0
I05538	12.0	7.4	3.7	.7	.2	.0	62	31	6	2	0
I05539	7.1	2.6	3.5	.9	.2	.0	36	49	12	2	0
I05545	14.4	9.4	4.2	.7	.0	.0	65	29	5	0	0
I05548	11.3	5.4	4.4	.8	.7	.0	48	39	7	6	0
I05552	8.0	3.3	3.4	.7	.6	.1	41	42	9	8	1
MEAN	10.1	5.1	3.8	.8	.3	.0	48	40	9	3	0
S.D.	2.94	2.81	.40	.20	.27	.04	13.0	8.4	3.8	3.0	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279352

Appendix 4

Individual Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	10.0	4.1	5.1	.7	.0	.0	41	51	7	0	0
I05534	13.3	6.9	5.2	.7	.4	.0	52	39	6	3	0
I05536	9.6	4.4	3.5	1.3	.3	.1	46	36	14	3	1
I05540	8.9	5.4	2.4	.9	.1	.0	61	27	10	1	0
I05542	8.3	5.9	2.0	.4	.0	.0	71	24	4	0	0
I05551	3.8	2.0	1.2	.5	.0	.0	53	32	14	1	0
MEAN	9.0	4.8	3.2	.8	.1	.0	54	35	9	1	0
S.D.	3.08	1.70	1.66	.32	.18	.04	10.7	9.7	4.2	1.4	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279353

Appendix 4

Individual Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

3M_MN03279354

Appendix 4

Individual Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.53	13.0	41.4	63.4	19.9	31.4	369	.1	7
I05517	6.32	13.0	42.7	67.5	20.5	30.4	443	.2	13
I05519	6.83	12.2	40.9	59.8	17.8	29.8	474	.3	20
I05520	6.50	12.1	39.5	60.7	18.6	30.7	644	.1	6
I05526	6.20	11.6	38.6	62.3	18.7	30.0	375	.1	6
I05527	6.34	12.2	40.6	64.0	19.3	30.1	614	.5	32
MEAN	6.45	12.4	40.6	63.0	19.1	30.4	486	.2	14
S.D.	.221	.55	1.44	2.74	.97	.58	117.8	.16	10.4
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	7.32	13.0	47.9	65.5	17.8	27.2	492	.6	44
I05515	6.51	12.5	42.5	65.2	19.2	29.4	629	.8	52
I05516	6.35	12.2	39.0	61.4	19.2	31.2	344	.3	19
I05521	7.26	12.2	40.3	55.6	16.8	30.1	665	.0	0
MEAN	6.86	12.5	42.4	61.9	18.2	29.5	532	.4	29
S.D.	.501	.38	3.93	4.61	1.17	1.69	146.1	.35	23.8
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.34	12.8	41.3	65.1	20.3	31.1	421	.3	19
I05510	6.99	12.3	41.5	59.3	17.6	29.7	483	.4	28
I05518	7.20	12.7	42.1	58.5	17.7	30.2	498	.6	43
I05523	6.78	12.6	41.3	60.9	18.5	30.5	544	.4	27
I05524	6.31	12.3	41.4	65.6	19.5	29.7	519	.2	13
I05528	6.34	12.1	39.8	62.7	19.1	30.4	388	.3	19
MEAN	6.66	12.5	41.2	62.0	18.8	30.3	476	.4	25
S.D.	.385	.27	.76	2.96	1.06	.53	59.6	.14	10.5
N	6	6	6	6	6	6	6	6	6

3M_MN03279355

Appendix 4

Individual Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.03	12.3	41.0	58.3	17.4	29.9	459	.3	21
I05507	6.57	11.4	39.6	60.2	17.3	28.7	69 PA	.3	20
I05509	6.84	12.1	41.9	61.3	17.6	28.8	399	.3	21
I05511	5.80	10.9	37.1	63.9	18.8	29.5	490	.4	23
I05512	6.60	12.1	40.3	61.0	18.3	30.1	362	.5	33
I05522	6.32	12.3	41.5	65.6	19.4	29.6	519	.5	32
MEAN	6.53	11.8	40.2	61.7	18.1	29.4	383	.4	25
S.D.	.431	.57	1.74	2.63	.85	.57	164.3	.10	5.9
N	6	6	6	6	6	6	6	6	6

3M_MN03279356

Appendix 4

Individual Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	5.2	1.8	2.9	.4	.0	.0	34	57	9	1	0
I05517	7.8	2.5	4.2	.9	.0	.2	32	53	12	0	2
I05519	7.1	3.5	3.4	.2	.1	.0	49	48	3	1	0
I05520	6.8	3.5	2.9	.4	.0	.0	52	43	5	0	0
I05526	7.5	4.7	2.2	.3	.2	.0	63	30	4	3	0
I05527	11.2	7.5	2.8	.9	.0	.0	67	25	8	0	0
MEAN	7.6	3.9	3.1	.5	.0	.0	50	43	7	1	0
S.D.	1.98	2.01	.67	.31	.08	.08	14.4	12.8	3.4	1.2	.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	11.9	5.9	5.3	.5	.2	.0	50	44	4	2	0
I05515	8.0	3.1	4.1	.6	.2	.0	39	51	7	2	0
I05516	12.1	8.2	3.1	.7	.2	.0	67	25	5	2	0
I05521	11.0	8.1	2.4	.3	.1	.0	74	22	3	1	0
MEAN	10.8	6.3	3.7	.5	.2	.0	58	36	5	2	0
S.D.	1.89	2.40	1.26	.17	.05	.00	15.9	14.2	1.7	.5	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	11.7	9.3	2.0	.2	.3	.0	79	17	2	2	0
I05510	8.8	5.1	2.9	.7	.0	.0	58	32	8	1	0
I05518	9.4	3.9	4.6	.8	.0	.0	42	49	8	0	0
I05523	11.1	7.0	3.6	.4	.1	.0	63	32	4	1	0
I05524	6.9	3.5	2.6	.8	.0	.1	50	37	12	0	1
I05528	12.4	7.2	3.6	.7	.8	.1	58	30	5	6	0
MEAN	10.0	6.0	3.2	.6	.2	.0	58	33	6	2	0
S.D.	2.06	2.23	.91	.24	.32	.05	12.5	10.4	3.6	2.3	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279357

Appendix 4

Individual Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	7.1	3.4	2.9	.7	.1	.0	48	41	9	1	1
I05507	17.9	13.3	3.8	.7	.1	.1	74	21	4	0	1
I05509	11.6	8.0	2.8	.4	.3	.0	69	24	4	3	0
I05511	8.5	5.5	2.4	.5	.1	.1	65	28	6	1	1
I05512	6.6	3.5	2.4	.7	.0	.0	53	36	10	0	1
I05522	10.2	6.2	3.0	.9	.0	.1	61	30	9	0	1
MEAN	10.3	6.6	2.9	.6	.1	.0	62	30	7	1	1
S.D.	4.16	3.69	.52	.18	.11	.05	9.8	7.5	2.7	1.2	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279358

Appendix 4

Individual Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03			Dosage Unit: mg/kg/day	
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279359

Appendix 4

Individual Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	6.43	12.3	40.4	62.8	19.1	30.5	647	.3	19
I05530	6.51	12.7	42.1	64.7	19.6	30.2	629	.5	33
I05531	6.37	11.6	38.8	60.8	18.1	29.8	439	.2	13
I05535	6.52	11.8	39.1	60.0	18.0	30.0	538	.1	7
I05544	5.78	11.6	37.9	65.6	20.0	30.5	499	.4	23
I05549	6.85	13.3	44.4	64.8	19.5	30.0	475	.5	34
MEAN	6.41	12.2	40.5	63.1	19.0	30.2	538	.3	22
S.D.	.351	.69	2.42	2.31	.83	.29	84.2	.16	10.8
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.60	10.9	38.1	57.8	16.6	28.7	448	.3	20
I05541	5.70	11.7	40.5	70.9	20.6	29.0	391	.7	40
I05547	6.79	11.6	39.0	57.4	17.0	29.7	417	.1	7
I05550	7.29	13.2	44.7	61.3	18.1	29.6	411	.1	7
MEAN	6.60	11.8	40.6	61.8	18.1	29.2	417	.3	18
S.D.	.664	.97	2.92	6.28	1.80	.48	23.6	.28	15.6
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.43	11.9	39.5	61.3	18.5	30.1	451	.4	26
I05538	6.40	11.3	38.4	60.1	17.7	29.5	398	.4	26
I05539	6.35	12.0	40.6	63.8	18.9	29.5	406	.1	6
I05545	6.85	12.4	41.2	60.1	18.1	30.1	300	.3	21
I05548	7.09	11.9	39.8	56.1	16.8	29.8	553	.3	21
I05552	6.19	11.4	38.8	62.7	18.5	29.5	478	.2	12
MEAN	6.55	11.8	39.7	60.7	18.1	29.7	431	.3	19
S.D.	.343	.41	1.06	2.68	.75	.29	85.3	.12	8.0
N	6	6	6	6	6	6	6	6	6

3M_MN03279360

Appendix 4

Individual Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.04	11.6	38.0	62.8	19.1	30.5	345	.3	18
I05534	5.91	11.3	38.4	65.0	19.2	29.5	532	.7	41
I05536	6.43	11.7	41.3	64.2	18.3	28.4	531	.2	13
I05540	6.09	11.4	37.1	60.9	18.7	30.8	501	.1	6
I05542	6.66	12.2	41.8	62.8	18.3	29.2	555	.2	13
I05551	6.12	11.1	37.9	62.0	18.2	29.3	351	.5	31
MEAN	6.21	11.6	39.1	63.0	18.6	29.6	469	.3	20
S.D.	.280	.38	1.96	1.48	.44	.89	95.4	.23	13.1
N	6	6	6	6	6	6	6	6	6

3M_MN03279361

Appendix 4

Individual Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	9.6	6.2	2.8	.5	.1	.0	65	30	5	1	0
I05530	12.1	8.3	2.8	1.0	.0	.0	68	23	8	0	0
I05531	14.6	11.7	1.9	.9	.1	.1	80	13	6	1	0
I05535	21.4	12.2	5.9	2.4	.7	.2	57	28	11	3	1
I05544	8.6	2.3	5.2	.7	.3	.0	26	61	8	4	1
I05549	10.1	5.9	2.8	1.0	.4	.0	58	28	10	4	0
MEAN	12.7	7.8	3.6	1.1	.3	.0	59	30	8	2	0
S.D.	4.75	3.77	1.59	.67	.26	.08	18.2	16.2	2.3	1.7	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	7.7	3.5	2.8	.8	.5	.1	46	36	10	6	2
I05541	11.5	6.5	3.7	1.1	.2	.0	56	32	10	2	0
I05547	7.3	5.0	1.7	.5	.1	.0	68	24	7	1	0
I05550	11.7	7.9	2.8	.8	.2	.0	68	24	6	2	0
MEAN	9.6	5.7	2.8	.8	.2	.0	60	29	8	3	0
S.D.	2.37	1.90	.82	.24	.17	.05	10.6	6.0	2.1	2.2	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	8.0	5.4	2.0	.4	.1	.0	68	25	5	2	0
I05538	9.4	5.1	3.4	.6	.3	.0	54	36	6	3	0
I05539	4.4	1.2	2.8	.4	.1	.0	26	63	8	2	0
I05545	10.0	5.2	3.9	.7	.1	.0	52	39	7	1	0
I05548	11.7	7.7	3.0	.5	.4	.0	66	26	4	4	0
I05552	11.2	8.2	2.2	.4	.5	.0	73	19	4	4	0
MEAN	9.1	5.5	2.9	.5	.2	.0	56	35	6	3	0
S.D.	2.66	2.48	.72	.13	.18	.00	17.0	15.7	1.6	1.2	.0
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279362

Appendix 4

Individual Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.8	3.9	4.4	.4	.0	.0	45	50	5	0	0
I05534	8.8	4.6	3.0	.9	.2	.0	52	34	11	3	1
I05536	7.6	4.8	2.0	.6	.1	.0	63	27	8	2	0
I05540	9.7	5.0	3.9	.6	.1	.0	51	40	7	1	0
I05542	13.7	11.5	1.8	.4	.0	.0	84	13	3	0	0
I05551	5.0	2.2	2.3	.4	.1	.0	44	47	7	2	0
MEAN	8.9	5.3	2.9	.6	.1	.0	56	35	7	1	0
S.D.	2.85	3.19	1.06	.20	.08	.00	15.1	13.7	2.7	1.2	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279363

Appendix 4

Individual Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

3M_MN03279364

Appendix 4

Individual Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.68	13.2	42.0	62.8	19.8	31.5	463	.1	7
I05517	6.29	12.9	42.8	68.0	20.4	30.1	423	.5	31
I05519	6.93	12.2	41.6	59.9	17.6	29.4	524	.3	21
I05520	6.53	12.4	39.9	61.1	18.9	31.0	699	.0	0
I05526	6.10	11.7	38.1	62.4	19.1	30.7	377	.1	6
I05527	6.43	12.5	42.3	65.8	19.4	29.5	644	.7	45
MEAN	6.49	12.5	41.1	63.3	19.2	30.4	522	.3	18
S.D.	.292	.53	1.78	3.03	.95	.84	126.9	.27	17.3
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	6.86	12.2	41.7	60.9	17.7	29.1	438	.1	7
I05515	6.61	12.6	42.3	63.9	19.1	29.9	647	1.0	66
I05516	6.44	12.0	39.4	61.1	18.7	30.6	376	.4	26
I05521	7.44	12.7	42.2	56.8	17.1	30.0	684	.0	0
MEAN	6.84	12.4	41.4	60.7	18.2	29.9	536	.4	25
S.D.	.437	.33	1.36	2.92	.91	.62	152.1	.45	29.6
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.47	13.0	41.6	64.2	20.1	31.3	450	.5	32
I05510	6.82	12.4	40.1	58.8	18.2	30.9	499	.5	34
I05518	7.10	12.7	41.5	58.5	17.8	30.5	578	.6	43
I05523	6.51	12.7	40.9	62.8	19.5	31.0	625	.1	7
I05524	6.54	12.6	42.1	64.3	19.3	30.0	520	.0	0
I05528	6.19	11.5	38.2	61.8	18.6	30.2	349	.2	12
MEAN	6.60	12.5	40.7	61.7	18.9	30.6	504	.3	21
S.D.	.315	.52	1.42	2.56	.87	.50	97.3	.25	17.3
N	6	6	6	6	6	6	6	6	6

3M_MN03279365

Appendix 4

Individual Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.46	13.1	43.4	58.2	17.6	30.2	534	.3	22
I05507	6.81	12.1	40.5	59.4	17.7	29.8	36	.1	7
I05509	6.69	11.9	40.0	59.8	17.7	29.6	480	.5	33
I05511	5.86	11.1	37.6	64.1	18.9	29.5	629	.4	23
I05512	6.90	12.8	41.6	60.3	18.5	30.7	359	.0	0
I05522	6.65	12.8	43.8	65.9	19.3	29.3	586	.4	27
MEAN	6.73	12.3	41.2	61.3	18.3	29.8	437	.3	19
S.D.	.516	.75	2.31	3.02	.72	.52	217.8	.19	12.6
N	6	6	6	6	6	6	6	6	6

3M_MN03279366

Appendix 4

Individual Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	7.4	3.7	3.3	.4	.0	.0	49	45	5	1	0
I05517	8.0	2.1	4.7	1.0	.1	.1	27	59	12	1	2
I05519	6.7	3.1	3.2	.4	.0	.0	46	48	5	1	0
I05520	8.0	3.8	3.4	.6	.1	.1	48	43	7	1	1
I05526	6.0	3.2	2.2	.5	.1	.0	52	36	9	2	0
I05527	7.8	2.4	4.2	.9	.2	.0	31	54	12	3	0
MEAN	7.3	3.0	3.5	.6	.1	.0	42	48	8	2	0
S.D.	.81	.68	.87	.26	.08	.05	10.5	8.2	3.2	.8	.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	8.1	5.0	2.3	.5	.2	.0	62	29	6	2	0
I05515	10.3	4.6	4.3	1.2	.2	.0	44	42	12	2	0
I05516	12.1	7.3	3.5	1.1	.1	.0	61	29	9	1	0
I05521	11.6	7.5	3.4	.5	.2	.0	65	29	4	2	0
MEAN	10.5	6.1	3.4	.8	.2	.0	58	32	8	2	0
S.D.	1.79	1.51	.82	.38	.05	.00	9.5	6.5	3.5	.5	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	10.8	8.0	2.3	.2	.3	.0	73	21	2	3	0
I05510	13.3	8.7	3.7	.7	.1	.0	65	28	6	1	0
I05518	9.9	3.2	5.8	.8	.1	.0	32	59	8	1	0
I05523	12.7	7.7	4.5	.4	.1	.0	60	36	3	1	0
I05524	7.7	3.2	3.4	1.0	.1	.1	41	44	13	1	1
I05528	16.4	11.1	3.6	1.3	.4	.1	68	22	8	2	0
MEAN	11.8	7.0	3.9	.7	.2	.0	56	35	7	2	0
S.D.	3.02	3.16	1.18	.40	.13	.05	16.3	14.6	4.0	.8	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279367

Appendix 4

Individual Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	6.5	2.5	3.5	.4	.1	.0	38	54	6	1	0
I05507	14.6	9.6	3.6	1.0	.2	.2	66	24	7	2	1
I05509	10.6	6.4	2.8	.7	.6	.1	60	27	7	6	1
I05511	7.7	4.2	3.0	.4	.1	.0	54	39	5	1	0
I05512	7.7	3.6	3.5	.6	.0	.0	46	45	8	0	0
I05522	10.7	5.5	4.3	.7	.2	.0	51	40	6	2	0
MEAN	9.6	5.3	3.4	.6	.2	.0	52	38	6	2	0
S.D.	2.97	2.52	.52	.23	.21	.08	10.0	11.2	1.0	2.1	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279368

Appendix 4

Individual Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279369

Appendix 4

Individual Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	6.15	12.0	38.4	62.4	19.5	31.3	668	.5	31
I05530	5.93	12.1	39.7	66.8	20.3	30.4	515	.6	36
I05531	6.56	12.1	40.5	61.6	18.5	30.0	644	.1	7
I05535	7.02	12.7	42.4	60.4	18.2	30.0	600	.3	21
I05544	4.91	11.5	35.4	72.1	23.4	32.4	506	.7	34
I05549	6.83	13.4	44.9	65.8	19.6	29.8	501	.5	34
MEAN	6.23	12.3	40.2	64.9	19.9	30.6	572	.4	27
S.D.	.766	.66	3.27	4.33	1.87	1.01	74.6	.22	11.2
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.44	10.9	37.8	58.8	16.9	28.8	357	.3	19
I05541	5.67	12.2	40.5	71.3	21.4	30.1	507	.7	40
I05547	6.82	11.9	39.2	57.4	17.4	30.3	548	.8	55
I05550	7.01	12.9	43.4	62.0	18.4	29.7	437	.0	0
MEAN	6.48	12.0	40.2	62.4	18.5	29.7	462	.4	28
S.D.	.593	.83	2.39	6.25	2.02	.67	83.8	.37	24.1
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	9.13	17.2	55.9	61.2	18.8	30.8	306	.1	9
I05538	6.64	11.8	40.0	60.3	17.8	29.5	456	.6	40
I05539	6.45	12.5	40.4	62.6	19.3	30.9	374	.0	0
I05545	6.74	12.2	40.3	59.8	18.0	30.2	326	.7	47
I05548	6.80	11.7	38.4	56.4	17.2	30.4	667	.3	20
I05552	6.21	11.6	38.9	62.6	18.6	29.7	486	.5	31
MEAN	7.00	12.8	42.3	60.5	18.3	30.3	436	.4	24
S.D.	1.068	2.17	6.70	2.31	.76	.57	133.5	.28	18.2
N	6	6	6	6	6	6	6	6	6

3M_MN03279370

Appendix 4

Individual Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.04	11.7	39.0	64.6	19.3	29.9	355	.4	24
I05534	5.74	11.4	37.9	66.0	19.8	30.0	620	.5	29
I05536	6.72	12.2	42.6	63.5	18.2	28.7	622	.1	7
I05540	6.13	11.9	39.5	64.5	19.4	30.1	432	.6	37
I05542	6.75	12.1	42.6	63.0	18.0	28.5	665	.0	0
I05551	6.32	11.7	39.5	62.5	18.6	29.7	333	.1	6
MEAN	6.28	11.8	40.2	64.0	18.9	29.5	504	.3	17
S.D.	.397	.29	1.96	1.27	.72	.70	148.3	.25	14.9
N	6	6	6	6	6	6	6	6	6

3M_MN03279371

Appendix 4

Individual Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	5.8	2.9	2.2	.5	.1	.0	50	38	9	1	1
I05530	13.0	7.8	4.5	.5	.1	.0	60	35	4	1	0
I05531	14.1	9.9	3.0	.9	.2	.1	70	22	6	1	1
I05535	10.9	3.5	5.4	1.4	.5	.2	32	49	13	5	1
I05544	10.5	2.9	7.0	.0	.5	.0	27	67	0	5	0
I05549	12.4	7.9	3.7	.4	.3	.0	64	30	3	2	0
MEAN	11.1	5.8	4.3	.6	.3	.0	50	40	6	2	0
S.D.	2.93	3.08	1.73	.48	.18	.08	17.6	15.9	4.6	2.0	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	10.6	5.7	3.4	.8	.5	.1	54	33	8	5	1
I05541	8.3	2.4	5.0	.6	.2	.1	29	61	8	2	1
I05547	7.2	3.7	2.7	.5	.2	.0	52	38	7	2	0
I05550	8.8	5.6	2.4	.7	.1	.0	63	27	8	1	0
MEAN	8.7	4.4	3.4	.6	.2	.0	50	40	8	2	0
S.D.	1.42	1.59	1.16	.13	.17	.06	14.5	14.9	.5	1.7	.6
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	8.9	5.7	2.3	.7	.1	.0	64	26	8	1	0
I05538	10.6	5.7	4.1	.4	.4	.0	54	39	4	4	0
I05539	6.1	2.2	3.1	.5	.2	.1	37	51	9	3	1
I05545	9.7	4.0	5.0	.5	.2	.0	41	51	5	2	0
I05548	7.1	2.3	3.7	.7	.3	.1	32	52	10	5	1
I05552	10.1	6.0	3.2	.3	.5	.0	60	32	3	5	0
MEAN	8.8	4.3	3.6	.5	.3	.0	48	42	6	3	0
S.D.	1.78	1.75	.93	.16	.15	.05	13.1	11.2	2.9	1.6	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279372

Appendix 4

Individual Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.4	3.2	4.8	.4	.0	.0	38	57	4	0	0
I05534	18.0	12.8	3.6	1.4	.2	.1	71	20	8	1	0
I05536	6.7	3.9	1.8	.7	.2	.1	58	27	11	3	1
I05540	8.1	4.5	2.9	.6	.1	.0	55	36	7	1	0
I05542	10.0	6.9	2.6	.4	.1	.0	69	27	4	1	0
I05551	4.8	2.1	2.3	.3	.1	.0	44	48	6	1	0
MEAN	9.3	5.6	3.0	.6	.1	.0	56	36	7	1	0
S.D.	4.59	3.89	1.07	.40	.08	.05	13.2	14.2	2.7	1.0	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279373

Appendix 4

Individual Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

3M_MN03279374

Appendix 4

Individual Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.39	12.8	39.6	62.0	20.0	32.2	387	.3	19
I05517	6.21	12.8	41.3	66.6	20.7	31.1	406	.7	43
I05519	6.92	12.2	40.7	58.8	17.6	29.9	475	.1	7
I05520	6.45	12.1	39.2	60.8	18.8	30.8	671	.1	6
I05526	6.01	11.5	37.4	62.3	19.2	30.8	384	.2	12
I05527	6.59	12.8	43.8	66.4	19.4	29.3	614	.6	40
MEAN	6.43	12.4	40.3	62.8	19.3	30.7	490	.3	21
S.D.	.314	.53	2.17	3.11	1.06	1.00	124.3	.26	16.4
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	6.96	12.3	42.2	60.6	17.7	29.2	389	.3	21
I05515	6.71	12.8	42.9	63.9	19.1	29.8	630	1.0	67
I05516	6.43	12.2	40.4	62.8	19.0	30.2	290	1.3	84
I05521	7.88	13.4	44.7	56.8	17.0	30.0	741	.2	16
MEAN	7.00	12.7	42.5	61.0	18.2	29.8	512	.7	47
S.D.	.628	.55	1.78	3.13	1.02	.43	208.8	.54	33.7
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.07	12.1	39.4	64.8	19.9	30.7	505	1.6	97
I05510	6.64	12.2	39.6	59.6	18.3	30.7	487	.4	27
I05518	6.95	12.5	40.9	58.8	18.0	30.5	501	.2	14
I05523	6.33	12.5	40.0	63.2	19.7	31.2	585	.4	25
I05524	6.48	12.4	41.9	64.6	19.2	29.7	555	.2	13
I05528	6.51	12.3	40.3	61.8	18.8	30.5	346	.3	20
MEAN	6.50	12.3	40.4	62.1	19.0	30.6	496	.5	33
S.D.	.295	.16	.93	2.53	.76	.49	82.6	.54	32.0
N	6	6	6	6	6	6	6	6	6

3M_MN03279375

Appendix 4

Individual Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.22	13.0	42.6	59.0	18.0	30.5	522	.3	22
I05507	6.81	11.9	41.5	61.0	17.4	28.6	50	.4	27
I05509	6.37	11.3	38.3	60.2	17.7	29.4	475	.6	38
I05511	5.94	11.2	38.0	64.0	18.8	29.4	552	.4	24
I05512	7.13	12.9	43.0	60.2	18.1	30.0	396	.1	7
I05522	6.48	12.7	42.3	65.3	19.5	29.9	592	.6	39
MEAN	6.66	12.2	41.0	61.6	18.2	29.6	431	.4	26
S.D.	.488	.81	2.23	2.47	.77	.65	198.6	.19	11.8
N	6	6	6	6	6	6	6	6	6

3M_MN03279376

Appendix 4

Individual Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	6.1	2.3	3.2	.3	.2	.0	38	52	5	4	1
I05517	7.8	2.9	4.2	.6	.1	.1	37	54	8	1	1
I05519	5.8	2.5	3.0	.2	.0	.0	44	52	3	1	0
I05520	5.1	1.7	2.9	.4	.1	.0	34	57	8	1	1
I05526	5.1	1.7	2.8	.4	.1	.0	34	56	8	3	0
I05527	10.2	3.3	6.0	.6	.2	.0	33	59	6	2	0
MEAN	6.7	2.4	3.7	.4	.1	.0	37	55	6	2	0
S.D.	1.99	.64	1.24	.16	.08	.04	4.1	2.8	2.1	1.3	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	6.9	3.5	2.6	.6	.3	.0	50	38	8	4	0
I05515	7.7	2.4	4.5	.6	.2	.0	31	58	8	2	0
I05516	10.6	6.4	3.4	.6	.1	.0	60	32	6	1	0
I05521	8.7	5.3	2.7	.6	.1	.0	61	31	7	1	0
MEAN	8.5	4.4	3.3	.6	.2	.0	50	40	7	2	0
S.D.	1.60	1.79	.88	.00	.10	.00	13.9	12.6	1.0	1.4	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	8.9	6.2	2.2	.3	.1	.0	70	25	4	1	0
I05510	10.7	6.4	3.2	.9	.1	.1	60	30	9	1	1
I05518	15.8	7.9	6.8	1.0	.1	.1	50	43	6	1	1
I05523	8.6	4.3	3.7	.4	.1	.0	50	43	5	1	0
I05524	6.4	2.8	2.8	.7	.0	.1	44	44	11	0	1
I05528	11.4	6.8	3.4	.6	.5	.0	59	30	6	5	0
MEAN	10.3	5.7	3.7	.6	.2	.0	56	36	7	2	0
S.D.	3.21	1.85	1.61	.27	.18	.05	9.3	8.4	2.6	1.8	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279377

Appendix 4

Individual Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	7.9	3.6	3.5	.6	.1	.0	46	45	7	1	1
I05507	10.3	5.0	3.9	1.1	.2	.1	48	38	10	2	1
I05509	9.1	5.3	2.8	.5	.4	.0	58	31	6	5	0
I05511	11.5	7.5	3.4	.4	.2	.0	65	30	4	1	0
I05512	5.3	2.0	2.7	.5	.0	.1	38	50	10	1	1
I05522	12.3	7.0	4.6	.3	.4	.0	57	37	2	3	0
MEAN	9.4	5.1	3.5	.6	.2	.0	52	38	6	2	0
S.D.	2.56	2.06	.71	.28	.16	.05	9.8	7.8	3.2	1.6	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279378

Appendix 4

Individual Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279379

Appendix 4

Individual Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	6.13	11.9	38.3	62.5	19.4	31.0	682	.2	12
I05530	6.50	13.0	43.2	66.5	20.0	30.1	556	.3	20
I05531	6.44	12.0	39.2	60.9	18.6	30.5	629	.4	26
I05535	6.71	12.1	40.1	59.9	18.0	30.1	515	.4	27
I05544	5.26	11.3	37.0	70.4	21.5	30.5	446	.3	16
I05549	6.81	13.4	44.1	64.7	19.7	30.4	544	.3	20
MEAN	6.31	12.3	40.3	64.1	19.5	30.4	562	.3	20
S.D.	.565	.77	2.79	3.90	1.21	.33	83.6	.08	5.7
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.22	10.6	37.1	59.7	17.0	28.4	492	.5	31
I05541	5.52	12.8	40.8	73.9	23.1	31.3	462	.5	28
I05547	6.49	11.3	37.5	57.8	17.5	30.2	493	.6	39
I05550	6.55	12.2	41.3	63.0	18.6	29.6	422	.3	20
MEAN	6.20	11.7	39.2	63.6	19.0	29.9	467	.5	30
S.D.	.472	.97	2.18	7.19	2.78	1.21	33.4	.13	7.9
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.49	12.2	40.0	61.6	18.8	30.6	423	.2	13
I05538	6.70	12.0	40.8	61.0	18.0	29.5	432	.1	7
I05539	6.16	12.1	39.3	63.8	19.7	30.8	394	.3	18
I05545	6.89	12.7	40.9	59.3	18.4	31.1	355	.3	21
I05548	6.59	11.5	37.6	56.9	17.5	30.7	585	.3	20
I05552	6.14	11.7	37.8	61.6	19.0	30.9	461	.1	6
MEAN	6.50	12.0	39.4	60.7	18.6	30.6	442	.2	14
S.D.	.298	.42	1.44	2.35	.78	.57	78.9	.10	6.6
N	6	6	6	6	6	6	6	6	6

3M_MN03279380

Appendix 4

Individual Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.39	11.9	40.1	62.7	18.7	29.8	328	.1	6
I05534	6.06	11.8	39.8	65.7	19.5	29.7	520	.4	24
I05536	6.35	11.7	40.4	63.6	18.4	28.9	568	.1	6
I05540	6.47	12.5	42.2	65.2	19.3	29.5	597	.3	19
I05542	6.57	11.9	41.6	63.3	18.2	28.7	635	.0	0
I05551	6.07	11.4	37.8	62.3	18.7	30.1	378	.3	18
MEAN	6.32	11.9	40.3	63.8	18.8	29.4	504	.2	12
S.D.	.210	.36	1.54	1.37	.51	.54	124.1	.15	9.4
N	6	6	6	6	6	6	6	6	6

3M_MN03279381

Appendix 4

Individual Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	6.4	3.2	2.6	.5	.1	.0	50	41	8	1	1
I05530	11.1	6.2	4.1	.6	.2	.0	56	37	5	2	0
I05531	9.1	4.7	3.5	.6	.3	.0	51	38	7	3	0
I05535	11.7	3.0	7.1	.8	.7	.1	26	61	7	6	1
I05544	9.1	2.8	5.1	.6	.7	.0	30	56	6	7	0
I05549	8.7	4.4	3.5	.6	.2	.0	50	40	7	2	0
MEAN	9.4	4.0	4.3	.6	.4	.0	44	46	7	4	0
S.D.	1.89	1.31	1.59	.10	.27	.04	12.5	10.3	1.0	2.4	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	8.3	3.5	3.0	1.3	.3	.2	42	37	15	3	2
I05541	10.4	4.4	4.9	.8	.2	.0	42	47	8	2	0
I05547	4.1	1.7	2.0	.3	.1	.0	41	48	8	3	0
I05550	12.0	8.2	2.9	.8	.1	.0	68	24	6	1	0
MEAN	8.7	4.4	3.2	.8	.2	.0	48	39	9	2	0
S.D.	3.42	2.74	1.22	.41	.10	.10	13.2	11.2	3.9	1.0	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	6.5	3.6	2.4	.3	.1	.0	56	37	5	2	0
I05538	9.5	5.2	3.2	.8	.2	.0	55	34	9	2	0
I05539	8.5	3.3	4.4	.5	.2	.0	39	52	6	2	1
I05545	8.8	4.4	3.5	.7	.1	.0	50	40	8	1	0
I05548	10.2	5.2	3.9	.7	.3	.0	51	38	7	3	0
I05552	8.9	4.9	3.1	.5	.4	.0	55	35	6	4	0
MEAN	8.7	4.4	3.4	.6	.2	.0	51	39	7	2	0
S.D.	1.25	.82	.69	.18	.12	.00	6.4	6.6	1.5	1.0	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279382

Appendix 4

Individual Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.2	3.1	4.3	.7	.1	.1	38	53	8	1	1
I05534	8.5	4.1	3.1	1.0	.2	.1	48	37	12	3	1
I05536	5.7	2.8	2.2	.6	.2	.0	50	38	10	3	0
I05540	10.7	6.5	3.8	.4	.1	.0	60	35	4	1	0
I05542	9.5	7.0	2.2	.3	.0	.0	74	23	3	0	0
I05551	6.2	4.1	1.7	.4	.1	.0	66	27	6	1	0
MEAN	8.1	4.6	2.9	.6	.1	.0	56	36	7	2	0
S.D.	1.91	1.75	1.02	.26	.08	.05	13.1	10.4	3.5	1.2	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279383

Appendix 4

Individual Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

3M_MN03279384

Appendix 4

Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.44	12.3	39.3	61.0	19.1	31.4	351	.1	6
I05517	6.54	13.1	43.3	66.3	20.0	30.2	379	.2	13
I05519	7.40	12.8	42.9	58.0	17.3	29.9	447	.4	30
I05520	6.44	12.1	38.7	60.1	18.8	31.2	643	.0	0
I05526	6.28	11.7	38.6	61.3	18.7	30.5	354	.1	6
I05527	6.95	12.9	42.8	61.6	18.5	30.1	613	.7	49
MEAN	6.68	12.5	40.9	61.4	18.7	30.6	464	.2	17
S.D.	.421	.54	2.28	2.74	.88	.62	131.6	.26	18.7
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	6.80	12.0	40.8	59.9	17.7	29.5	389	.2	14
I05515	7.26	13.0	44.0	60.7	17.9	29.5	618	.2	15
I05516	6.55	12.4	39.6	60.5	18.9	31.2	296	.4	26
I05521	7.71	12.9	42.4	55.0	16.7	30.4	630	.0	0
MEAN	7.08	12.6	41.7	59.0	17.8	30.2	483	.2	14
S.D.	.513	.46	1.91	2.70	.90	.82	167.0	.16	10.7
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.35	12.6	40.5	63.7	19.9	31.2	406	.5	32
I05510	7.19	12.6	41.3	57.5	17.5	30.5	496	.2	14
I05518	7.53	13.2	43.4	57.6	17.6	30.5	546	.4	30
I05523	6.39	12.2	39.8	62.3	19.2	30.8	783	.4	26
I05524	6.74	12.8	42.8	63.5	19.1	30.0	515	.6	40
I05528	6.50	12.2	40.2	61.9	18.8	30.4	366	.6	39
MEAN	6.78	12.6	41.3	61.1	18.7	30.6	519	.4	30
S.D.	.479	.38	1.47	2.82	.95	.40	146.4	.15	9.6
N	6	6	6	6	6	6	6	6	6

3M_MN03279385

Appendix 4

Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	7.78	13.4	45.8	59.0	17.3	29.3	486	.4	31
I05507	6.93	11.7	39.3	56.7	16.8	29.7	21	.1	7
I05509	6.08	10.3	36.1	59.4	16.9	28.5	373	.7	43
I05511	6.10	11.1	37.7	61.8	18.2	29.5	553	1.1	67
I05512	6.61	12.0	40.4	61.2	18.2	29.7	405	1.2	79
I05522	6.38	12.1	40.5	63.6	19.0	29.9	552	.1	6
MEAN	6.65	11.8	40.0	60.3	17.7	29.4	398	.6	39
S.D.	.641	1.04	3.32	2.43	.87	.50	199.1	.48	30.3
N	6	6	6	6	6	6	6	6	6

3M_MN03279386

Appendix 4

Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	5.3	1.8	2.9	.3	.4	.0	34	54	5	7	0
I05517	6.7	1.7	4.5	.4	.0	.0	25	68	6	0	0
I05519	6.7	2.9	3.5	.2	.1	.0	43	52	3	1	0
I05520	7.8	2.3	4.3	.7	.3	.2	30	55	9	4	2
I05526	5.2	1.6	2.9	.6	.1	.0	32	56	11	1	0
I05527	12.3	5.9	5.1	1.0	.1	.0	48	42	8	1	0
MEAN	7.3	2.7	3.9	.5	.2	.0	35	54	7	2	0
S.D.	2.62	1.64	.91	.29	.15	.08	8.6	8.3	2.9	2.7	.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	10.0	6.2	3.0	.4	.3	.0	62	30	4	3	0
I05515	8.8	3.1	4.8	.6	.2	.0	35	55	7	3	0
I05516	11.3	6.4	3.8	.9	.2	.0	56	34	8	2	0
I05521	9.6	6.8	2.3	.5	.1	.0	70	24	5	1	0
MEAN	9.9	5.6	3.5	.6	.2	.0	56	36	6	2	0
S.D.	1.04	1.70	1.08	.22	.08	.00	15.0	13.5	1.8	1.0	.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	11.8	8.6	2.5	.5	.3	.0	73	21	4	2	0
I05510	9.3	5.5	3.1	.6	.1	.0	59	33	7	1	0
I05518	9.7	2.9	5.9	.8	.1	.1	30	61	9	1	1
I05523	13.8	8.3	4.4	.6	.4	.0	60	32	4	3	0
I05524	6.7	1.9	4.1	.7	.1	.1	28	61	10	1	1
I05528	9.2	3.8	3.9	.8	.6	.1	42	43	8	6	1
MEAN	10.1	5.2	4.0	.7	.3	.0	49	42	7	2	0
S.D.	2.44	2.81	1.17	.12	.21	.05	18.2	16.4	2.5	2.0	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279387

Appendix 4

Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	6.7	2.5	3.6	.5	.1	.0	38	54	7	1	0
I05507	8.9	3.9	4.4	.5	.1	.0	44	50	5	1	0
I05509	13.2	10.0	1.8	1.4	.0	.0	76	13	11	0	0
I05511	5.9	2.2	3.2	.3	.2	.0	37	55	6	3	0
I05512	7.6	2.2	4.0	1.2	.1	.0	29	53	15	2	0
I05522	11.6	5.2	4.9	.9	.5	.1	45	42	8	4	1
MEAN	9.0	4.3	3.6	.8	.2	.0	45	44	9	2	0
S.D.	2.87	3.02	1.08	.44	.18	.04	16.3	16.1	3.7	1.5	.4
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279388

Appendix 4

Individual Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	-	-	-	-	-
I05507	-	-	-	-	-
I05509	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279389

Appendix 4

Individual Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.82	11.3	36.1	61.9	19.3	31.2	609	.2	12
I05530	6.31	12.5	41.0	65.1	19.8	30.4	544	.5	32
I05531	6.88	12.6	40.7	59.1	18.3	31.0	586	.1	7
I05535	7.30	12.9	42.9	58.7	17.7	30.2	469	.0	0
I05544	6.25	11.6	38.7	62.0	18.6	30.0	498	.7	44
I05549	7.02	13.6	44.4	63.3	19.3	30.5	416	.7	49
MEAN	6.60	12.4	40.6	61.7	18.8	30.6	520	.4	24
S.D.	.559	.85	2.96	2.45	.77	.46	73.1	.31	20.5
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.74	10.9	38.5	57.0	16.2	28.4	322	.4	27
I05541	5.74	12.2	40.3	70.3	21.2	30.2	385	1.5	86
I05547	6.96	11.7	39.0	56.0	16.8	30.0	450	.1	7
I05550	7.20	13.1	43.9	61.0	18.2	29.8	391	.5	36
MEAN	6.66	12.0	40.4	61.1	18.1	29.6	387	.6	39
S.D.	.641	.92	2.44	6.52	2.23	.82	52.3	.61	33.6
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.80	12.5	40.8	60.0	18.4	30.7	424	.7	48
I05538	6.37	11.7	38.5	60.5	18.4	30.4	425	.4	25
I05539	6.59	12.3	40.6	61.6	18.7	30.3	506	.3	20
I05545	7.00	12.7	41.5	59.3	18.1	30.6	326	.0	0
I05548	6.84	11.6	38.3	55.9	17.0	30.3	545	.2	14
I05552	6.39	11.9	39.4	61.6	18.7	30.3	532	.2	13
MEAN	6.66	12.1	39.9	59.8	18.2	30.4	460	.3	20
S.D.	.257	.45	1.31	2.12	.64	.18	83.7	.24	16.1
N	6	6	6	6	6	6	6	6	6

3M_MN03279390

Appendix 4

Individual Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.67	12.2	41.2	61.7	18.4	29.8	320	.3	20
I05534	6.20	12.1	41.4	66.7	19.5	29.3	582	.3	19
I05536	6.07	11.0	36.8	60.7	18.2	30.0	563	.1	6
I05540	5.97	11.5	37.3	62.4	19.2	30.8	491	.0	0
I05542	6.56	11.6	40.0	60.9	17.6	28.9	671	.1	7
I05551	6.51	11.9	40.3	61.9	18.3	29.6	322	.2	13
MEAN	6.33	11.7	39.5	62.4	18.5	29.7	492	.2	11
S.D.	.288	.44	1.98	2.21	.70	.65	144.0	.12	7.9
N	6	6	6	6	6	6	6	6	6

3M_MN03279391

Appendix 4

Individual Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	8.4	5.1	2.6	.6	.1	.0	60	31	7	1	0
I05530	8.3	1.8	5.9	.5	.1	.0	22	70	6	2	0
I05531	14.5	9.9	3.8	.7	.1	.0	68	26	5	1	0
I05535	8.3	2.4	4.4	1.0	.5	.1	28	52	12	6	1
I05544	8.7	2.9	3.9	1.3	.4	.1	34	45	15	5	1
I05549	10.0	5.3	3.8	.7	.1	.1	53	38	7	1	1
MEAN	9.7	4.6	4.1	.8	.2	.0	44	44	9	3	0
S.D.	2.44	2.98	1.08	.30	.18	.05	18.7	15.9	3.9	2.3	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	8.5	4.2	3.0	.9	.4	.2	49	35	10	4	2
I05541	6.5	2.2	3.6	.5	.1	.1	34	56	8	1	1
I05547	15.9	10.2	2.8	2.6	.1	.1	64	18	16	1	0
I05550	6.4	3.5	2.1	.5	.2	.0	55	34	9	2	0
MEAN	9.3	5.0	2.9	1.1	.2	.1	50	36	11	2	1
S.D.	4.49	3.55	.62	1.00	.14	.08	12.6	15.6	3.6	1.4	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	5.6	2.5	2.4	.6	.1	.0	45	43	10	1	1
I05538	10.6	6.6	2.9	.8	.3	.0	63	27	7	3	0
I05539	6.3	1.1	4.5	.5	.2	.0	18	71	8	3	0
I05545	11.0	5.3	4.8	.6	.2	.0	48	44	5	2	0
I05548	7.6	3.2	3.1	.8	.4	.0	42	41	11	5	0
I05552	7.5	3.4	3.0	.5	.5	.0	45	40	7	6	1
MEAN	8.1	3.7	3.4	.6	.3	.0	44	44	8	3	0
S.D.	2.23	1.98	.96	.14	.15	.00	14.5	14.4	2.2	1.9	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279392

Appendix 4

Individual Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	8.2	2.1	4.9	.9	.2	.1	26	60	11	3	1
I05534	13.2	3.8	7.9	1.0	.4	.1	29	60	7	3	1
I05536	10.1	6.6	1.9	1.3	.2	.1	65	19	13	2	1
I05540	11.7	7.4	3.5	.6	.1	.0	64	30	5	1	0
I05542	9.0	5.0	3.6	.3	.2	.0	55	39	3	2	0
I05551	4.6	1.7	2.2	.6	.0	.0	38	48	13	1	1
MEAN	9.5	4.4	4.0	.8	.2	.0	46	43	9	2	1
S.D.	2.99	2.33	2.19	.35	.13	.05	17.4	16.5	4.3	.9	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279393

Appendix 4

Individual Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

3M_MN03279394

Appendix 4

Individual Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	6.43	12.8	40.3	62.7	19.9	31.7	404	.1	6
I05517	6.72	13.1	44.2	65.8	19.5	29.6	399	.2	13
I05519	7.22	12.7	42.0	58.1	17.6	30.2	445	.2	14
I05520	6.17	11.7	38.0	61.6	18.9	30.7	591	.1	6
I05526	6.48	12.2	40.4	62.3	18.8	30.2	392	.1	6
I05527	6.57	12.3	41.7	63.5	18.8	29.6	571	.3	20
MEAN	6.60	12.5	41.1	62.3	18.9	30.3	467	.2	11
S.D.	.354	.50	2.07	2.53	.78	.79	90.4	.08	5.8
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	6.88	12.1	42.5	61.7	17.6	28.5	398	.4	28
I05515	6.47	12.2	40.7	62.9	18.8	29.9	559	.2	13
I05516	6.61	12.5	40.8	61.7	18.9	30.6	246	.0	0
I05521	7.86	13.1	44.5	56.6	16.7	29.5	663	.1	8
MEAN	6.96	12.5	42.1	60.7	18.0	29.6	466	.2	12
S.D.	.627	.45	1.79	2.81	1.05	.88	183.0	.17	11.8
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.43	12.5	41.8	65.0	19.5	30.0	411	.3	19
I05510	6.98	12.4	40.8	58.4	17.8	30.4	464	.3	21
I05518	7.21	12.8	42.1	58.4	17.7	30.4	514	.3	22
I05523	6.50	12.6	40.7	62.6	19.3	30.9	526	.3	20
I05524	6.57	12.6	41.8	63.5	19.2	30.2	527	.2	13
I05528	6.21	11.9	39.0	62.9	19.1	30.4	380	.3	19
MEAN	6.65	12.5	41.0	61.8	18.8	30.4	470	.3	19
S.D.	.372	.31	1.15	2.76	.80	.30	63.1	.04	3.2
N	6	6	6	6	6	6	6	6	6

3M_MN03279395

Appendix 4

Individual Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^5$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506 a	7.69	13.3	44.3	57.7	17.2	29.9	560	.2	15
I05507	6.64	11.0	38.4	57.9	16.5	28.5	78 PA	.3	20
I05511	5.76	10.4	35.7	62.0	18.1	29.2	486	.5	29
I05512	6.46	11.7	39.8	61.6	18.1	29.4	429	.0	0
I05522	6.44	12.3	41.5	64.5	19.1	29.6	610	.0	0
MEAN	6.32	11.4	38.8	61.5	17.9	29.2	401	.2	12
S.D.	.387	.83	2.45	2.72	1.08	.48	228.0	.24	14.6
N	4	4	4	4	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

3M_MN03279396

Appendix 4

Individual Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	9.5	3.6	4.8	.6	.5	.0	38	50	6	6	0
I05517	9.0	2.6	5.6	.6	.1	.1	30	62	7	1	1
I05519	6.8	4.0	2.5	.3	.1	.0	58	37	4	1	0
I05520	12.0	5.8	5.0	.7	.4	.1	49	42	6	3	1
I05526	10.0	6.7	2.8	.4	.1	.0	67	28	4	1	0
I05527	10.8	2.8	6.0	1.6	.3	.1	26	55	15	3	1
MEAN	9.7	4.2	4.4	.7	.2	.0	45	46	7	2	0
S.D.	1.76	1.66	1.46	.46	.18	.05	16.1	12.4	4.1	2.0	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	8.9	5.7	2.6	.4	.2	.0	64	30	4	2	0
I05515	7.5	2.7	3.6	.9	.2	.0	36	48	12	3	1
I05516	8.1	5.8	1.9	.3	.1	.0	71	23	4	1	0
I05521	9.1	5.2	3.2	.6	.1	.0	58	35	6	1	0
MEAN	8.4	4.8	2.8	.6	.2	.0	57	34	6	2	0
S.D.	.74	1.46	.74	.26	.06	.00	15.1	10.6	3.8	1.0	.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	10.3	7.5	2.3	.4	.2	.0	72	22	4	2	0
I05510	9.1	4.6	3.9	.4	.1	.0	51	43	5	1	0
I05518	13.6	6.6	6.6	.3	.1	.0	48	48	2	0	0
I05523	10.8	6.3	3.8	.5	.1	.0	59	35	5	1	0
I05524	6.1	1.6	3.8	.5	.1	.0	26	63	9	1	0
I05528	10.0	4.6	4.1	.7	.6	.0	46	41	7	6	0
MEAN	10.0	5.2	4.1	.5	.2	.0	50	42	5	2	0
S.D.	2.44	2.10	1.39	.14	.20	.00	15.2	13.6	2.4	2.1	.0
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279397

Appendix 4

Individual Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506 a	19.7	14.7	4.0	1.0	.0	.0	74	20	5	0	0
I05507	9.4	3.9	4.9	.4	.1	.0	42	52	5	1	0
I05511	5.1	2.0	2.3	.6	.2	.1	39	45	11	4	1
I05512	6.6	1.9	4.3	.4	.0	.0	28	66	5	0	0
I05522	9.2	3.9	4.5	.6	.2	.1	43	49	6	2	1
MEAN	7.6	2.9	4.0	.5	.1	.0	38	53	7	2	0
S.D.	2.09	1.13	1.16	.12	.10	.06	6.9	9.1	2.9	1.7	.6
N	4	4	4	4	4	4	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

3M_MN03279398

Appendix 4

Individual Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	-	-	-	-	-
I05517	-	-	-	-	-
I05519	-	-	-	-	-
I05520	-	-	-	-	-
I05526	-	-	-	-	-
I05527	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	-	-	-	-	-
I05515	-	-	-	-	-
I05516 b	-	-	-	-	-
I05521	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05510	-	-	-	-	-
I05518	-	-	-	-	-
I05523	-	-	-	-	-
I05524	-	-	-	-	-
I05528	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506 a	-	-	-	-	-
I05507	-	-	-	-	-
I05511	-	-	-	-	-
I05512	-	-	-	-	-
I05522	-	-	-	-	-

a Unscheduled sacrifice on Day 179.
b Plasmodium was observed.

3M_MN03279399

Appendix 4

Individual Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.66	11.0	35.7	63.0	19.5	31.0	595	.2	11
I05530	6.38	12.6	42.6	66.8	19.7	29.6	583	.4	26
I05531	6.63	12.0	40.5	61.2	18.1	29.5	534	.3	20
I05535	7.04	12.7	42.8	60.8	18.1	29.7	369	.2	14
I05544	6.20	11.9	40.9	65.9	19.2	29.1	439	.8	50
I05549	6.52	12.5	42.3	64.9	19.2	29.6	383	.6	39
MEAN	6.40	12.1	40.8	63.8	19.0	29.7	484	.4	27
S.D.	.461	.64	2.67	2.49	.70	.65	100.1	.24	15.1
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	6.69	10.8	38.9	58.2	16.2	27.9	442	.2	13
I05541	5.80	12.2	41.4	71.3	21.1	29.5	380	.2	12
I05547	5.20	9.0	30.1	58.0	17.4	30.0	501	.4	21
I05550	6.92	12.7	42.7	61.8	18.3	29.7	394	.1	7
MEAN	6.15	11.2	38.3	62.3	18.2	29.3	429	.2	13
S.D.	.798	1.66	5.67	6.23	2.09	.94	54.7	.13	5.8
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	6.65	12.3	40.8	61.3	18.4	30.1	373	.3	20
I05538	6.14	11.0	37.6	61.2	17.9	29.3	381	.3	18
I05539	6.67	12.5	41.9	62.7	18.8	29.9	400	.2	13
I05545	6.81	12.4	41.0	60.3	18.3	30.3	318	.0	0
I05548	6.75	11.3	37.8	56.1	16.8	30.0	484	.2	14
I05552	6.38	11.9	40.2	63.0	18.7	29.7	517	.1	6
MEAN	6.57	11.9	39.9	60.8	18.2	29.9	412	.2	12
S.D.	.256	.62	1.78	2.50	.73	.35	74.4	.12	7.5
N	6	6	6	6	6	6	6	6	6

3M_MN03279400

Appendix 4

Individual Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.00	11.3	37.6	62.6	18.9	30.1	288	.2	12
I05534	5.65	11.0	37.7	66.8	19.4	29.1	587	.5	28
I05536	6.08	10.9	39.3	64.6	17.9	27.8	559	.0	0
I05540	5.99	11.6	38.6	64.5	19.3	29.9	454	.0	0
I05542	6.75	11.9	43.4	64.3	17.7	27.5	725	.4	27
I05551	6.09	11.3	38.4	63.1	18.6	29.5	328	.1	6
MEAN	6.09	11.3	39.2	64.3	18.6	29.0	490	.2	12
S.D.	.360	.37	2.17	1.46	.71	1.09	166.0	.21	12.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279401

Appendix 4

Individual Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	14.6	11.4	2.5	.6	.1	.1	78	17	4	1	1
I05530	7.3	2.6	3.9	.6	.2	.0	35	54	8	3	0
I05531	10.5	5.2	4.3	.7	.2	.1	50	41	7	2	1
I05535	13.9	5.5	7.0	1.0	.3	.1	39	50	7	2	1
I05544	10.4	2.9	6.2	.6	.6	.0	28	60	6	6	0
I05549	5.4	2.4	2.1	.7	.1	.0	44	40	14	2	0
MEAN	10.4	5.0	4.3	.7	.2	.0	46	44	8	3	0
S.D.	3.59	3.41	1.96	.15	.19	.05	17.5	15.1	3.4	1.8	.5
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	10.1	5.4	3.1	1.1	.4	.2	54	30	11	4	2
I05541	6.6	2.4	3.5	.5	.2	.0	37	53	7	3	0
I05547	6.8	4.0	2.4	.4	.1	.0	58	35	6	1	0
I05550	10.4	5.5	3.7	.8	.4	.0	53	35	7	4	0
MEAN	8.5	4.3	3.2	.7	.3	.0	50	38	8	3	0
S.D.	2.05	1.45	.57	.32	.15	.10	9.3	10.1	2.2	1.4	1.0
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	8.2	3.9	3.8	.4	.1	.0	48	46	5	1	0
I05538	9.2	4.5	3.8	.6	.3	.0	49	41	6	4	0
I05539	7.5	1.6	4.9	.8	.1	.1	22	65	10	2	2
I05545	11.0	6.3	3.9	.6	.1	.0	57	36	6	1	0
I05548	11.3	6.2	3.7	.6	.7	.0	55	33	5	6	0
I05552	8.0	4.3	3.0	.3	.4	.0	54	37	4	4	0
MEAN	9.2	4.5	3.8	.6	.3	.0	48	43	6	3	0
S.D.	1.61	1.73	.61	.18	.24	.04	13.0	11.7	2.1	2.0	.8
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279402

Appendix 4

Individual Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	7.5	3.2	3.8	.4	.1	.1	42	51	5	1	1
I05534	12.1	5.0	6.0	1.0	.2	.1	41	49	8	1	1
I05536	8.4	4.1	2.8	1.2	.2	.1	49	34	14	2	1
I05540	10.3	5.9	3.8	.5	.1	.0	58	37	5	1	0
I05542	13.4	3.0	9.3	.8	.3	.1	22	69	6	3	0
I05551	6.4	4.0	1.8	.5	.1	.0	63	28	8	1	0
MEAN	9.7	4.2	4.6	.7	.2	.1	46	45	8	2	0
S.D.	2.73	1.10	2.70	.32	.08	.05	14.6	14.8	3.4	.8	.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279403

Appendix 4

Individual Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05529	-	-	-	-	-
I05530	-	-	-	-	-
I05531	-	-	-	-	-
I05535	-	-	-	-	-
I05544	-	-	-	-	-
I05549	-	-	-	-	-
Group: 2	Dose Level: 0.03			Dosage Unit: mg/kg/day	
I05537	-	-	-	-	-
I05541	-	-	-	-	-
I05547	-	-	-	-	-
I05550	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05532	-	-	-	-	-
I05538	-	-	-	-	-
I05539	-	-	-	-	-
I05545	-	-	-	-	-
I05548	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05533	-	-	-	-	-
I05534	-	-	-	-	-
I05536	-	-	-	-	-
I05540	-	-	-	-	-
I05542	-	-	-	-	-
I05551	-	-	-	-	-

3M_MN03279404

APPENDIX 4

Individual Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.27	12.1	38.3	61.0	19.3	31.7	620	.3	19
I05526	6.26	11.8	37.9	60.5	18.9	31.2	346	.4	25
MEAN	6.26	12.0	38.1	60.8	19.1	31.5	483	.4	22
S.D.	.007	.21	.28	.35	.28	.35	193.7	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.53	13.0	41.6	63.7	19.9	31.3	404	.4	26
I05523	6.45	12.4	39.8	61.8	19.3	31.2	572	.2	13
MEAN	6.49	12.7	40.7	62.8	19.6	31.2	488	.3	20
S.D.	.057	.42	1.27	1.34	.42	.07	118.8	.14	9.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	5.93	11.6	38.2	64.5	19.5	30.3	485	.3	18
I05522	5.87	11.5	37.3	63.5	19.6	30.9	453	.6	35
MEAN	5.90	11.6	37.8	64.0	19.5	30.6	469	.4	26
S.D.	.042	.07	.64	.71	.07	.42	22.6	.21	12.0
N	2	2	2	2	2	2	2	2	2

3M_MN03279405

APPENDIX 4

Individual Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	8.5	2.5	5.2	.5	.3	.0	30	61	6	3	1
I05526	6.1	2.3	2.9	.7	.2	.0	37	47	12	3	1
MEAN	7.3	2.4	4.0	.6	.2	.0	34	54	9	3	1
S.D.	1.70	.14	1.63	.14	.07	.00	4.9	9.9	4.2	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	8.8	4.7	3.0	.7	.4	.0	53	34	8	5	0
I05523	14.2	7.6	6.0	.4	.2	.0	53	42	3	1	0
MEAN	11.5	6.2	4.5	.6	.3	.0	53	38	6	3	0
S.D.	3.82	2.05	2.12	.21	.14	.00	.0	5.7	3.5	2.8	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	8.9	4.1	3.9	.5	.4	.0	46	44	5	4	0
I05522	14.7	7.9	5.0	1.3	.5	.0	54	34	9	4	0
MEAN	11.8	6.0	4.4	.9	.4	.0	50	39	7	4	0
S.D.	4.10	2.69	.78	.57	.07	.00	5.7	7.1	2.8	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279406

APPENDIX 4

Individual Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279407

APPENDIX 4

Individual Clinical Hematology Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.44	10.9	33.5	61.5	20.1	32.7	547	.1	5
I05549	6.45	12.6	40.3	62.4	19.6	31.3	390	.5	32
MEAN	5.94	11.8	36.9	62.0	19.8	32.0	468	.3	18
S.D.	.714	1.20	4.81	.64	.35	.99	111.0	.28	19.1
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.07	11.8	37.2	61.4	19.5	31.8	382	.2	12
I05552	6.20	12.0	38.0	61.3	19.4	31.6	435	.5	31
MEAN	6.14	11.9	37.6	61.4	19.5	31.7	408	.4	22
S.D.	.092	.14	.57	.07	.07	.14	37.5	.21	13.4
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.13	11.8	38.2	62.2	19.2	30.8	330	.3	18
I05542	6.72	12.2	42.3	63.0	18.2	28.9	557	.7	47
MEAN	6.42	12.0	40.2	62.6	18.7	29.8	444	.5	32
S.D.	.417	.28	2.90	.57	.71	1.34	160.5	.28	20.5
N	2	2	2	2	2	2	2	2	2

3M_MN03279408

APPENDIX 4

Individual Clinical Hematology Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	10.1	6.1	3.0	.8	.1	.0	60	30	8	1	0
I05549	6.2	3.1	2.5	.4	.1	.0	50	41	7	2	0
MEAN	8.2	4.6	2.8	.6	.1	.0	55	36	8	2	0
S.D.	2.76	2.12	.35	.28	.00	.00	7.1	7.8	.7	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	6.9	1.8	4.3	.7	.2	.1	26	61	10	3	1
I05552	8.4	3.5	3.8	.5	.5	.0	41	45	6	6	1
MEAN	7.6	2.6	4.0	.6	.4	.0	34	53	8	4	1
S.D.	1.06	1.20	.35	.14	.21	.07	10.6	11.3	2.8	2.1	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	7.7	2.1	5.0	.3	.3	.0	27	65	4	4	0
I05542	10.9	3.0	6.7	.8	.2	.1	28	62	8	2	1
MEAN	9.3	2.6	5.8	.6	.2	.0	28	64	6	3	0
S.D.	2.26	.64	1.20	.35	.07	.07	.7	2.1	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279409

APPENDIX 4

Individual Clinical Hematology Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

3M_MN03279410

APPENDIX 4

Individual Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.75	13.0	40.6	60.2	19.3	32.1	685	.1	7
I05526	6.28	12.2	37.9	60.3	19.4	32.1	428	.3	19
MEAN	6.52	12.6	39.2	60.2	19.4	32.1	556	.2	13
S.D.	.332	.57	1.91	.07	.07	.00	181.7	.14	8.5
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.75	13.3	42.5	62.9	19.8	31.4	467	.1	7
I05523	6.82	13.3	41.8	61.3	19.4	31.7	519	.2	14
MEAN	6.78	13.3	42.2	62.1	19.6	31.6	493	.2	10
S.D.	.049	.00	.49	1.13	.28	.21	36.8	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.06	11.4	39.0	64.4	18.8	29.2	501	.8	48
I05522	6.33	12.4	39.9	63.0	19.5	31.0	562	.4	25
MEAN	6.20	11.9	39.5	63.7	19.2	30.1	532	.6	36
S.D.	.191	.71	.64	.99	.49	1.27	43.1	.28	16.3
N	2	2	2	2	2	2	2	2	2

3M_MN03279411

APPENDIX 4

Individual Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	12.1	3.8	7.6	.5	.3	.0	31	63	4	2	0
I05526	8.0	2.7	4.6	.4	.3	.0	33	58	5	4	0
MEAN	10.0	3.2	6.1	.4	.3	.0	32	60	4	3	0
S.D.	2.90	.78	2.12	.07	.00	.00	1.4	3.5	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	10.6	5.2	4.1	.8	.4	.0	49	39	8	4	0
I05523	12.2	5.8	5.6	.4	.3	.0	48	46	3	2	0
MEAN	11.4	5.5	4.8	.6	.4	.0	48	42	6	3	0
S.D.	1.13	.42	1.06	.28	.07	.00	.7	4.9	3.5	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	9.5	3.6	4.9	.6	.4	.1	38	51	6	4	1
I05522	17.3	7.6	7.4	1.5	.6	.1	44	43	9	4	1
MEAN	13.4	5.6	6.2	1.0	.5	.1	41	47	8	4	1
S.D.	5.52	2.83	1.77	.64	.14	.00	4.2	5.7	2.1	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279412

APPENDIX 4

Individual Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279413

APPENDIX 4

Individual Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.70	11.3	34.9	61.1	19.8	32.4	577	.2	11
I05549	6.74	13.3	41.9	62.1	19.7	31.7	461	.3	20
MEAN	6.22	12.3	38.4	61.6	19.8	32.1	519	.2	16
S.D.	.735	1.41	4.95	.71	.07	.49	82.0	.07	6.4
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.88	12.9	40.9	59.4	18.7	31.4	391	.1	7
I05552	6.61	12.5	40.4	61.2	18.9	31.0	459	.2	13
MEAN	6.74	12.7	40.7	60.3	18.8	31.2	425	.2	10
S.D.	.191	.28	.35	1.27	.14	.28	48.1	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.38	12.2	39.9	62.5	19.2	30.7	335	.1	6
I05542	7.02	12.8	44.1	62.8	18.2	29.0	546	.4	28
MEAN	6.70	12.5	42.0	62.7	18.7	29.8	440	.2	17
S.D.	.453	.42	2.97	.21	.71	1.20	149.2	.21	15.6
N	2	2	2	2	2	2	2	2	2

3M_MN03279414

APPENDIX 4

Individual Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	12.5	9.1	2.8	.5	.1	.0	73	22	4	1	0
I05549	10.3	5.1	4.0	.9	.3	.0	50	39	8	3	0
MEAN	11.4	7.1	3.4	.7	.2	.0	62	30	6	2	0
S.D.	1.56	2.83	.85	.28	.14	.00	16.3	12.0	2.8	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	7.5	.9	5.3	1.0	.2	.1	12	71	13	3	1
I05552	11.4	5.1	4.6	1.0	.6	.0	45	40	9	5	0
MEAN	9.4	3.0	5.0	1.0	.4	.0	28	56	11	4	0
S.D.	2.76	2.97	.49	.00	.28	.07	23.3	21.9	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	10.8	4.5	5.0	1.1	.2	.1	41	46	10	1	1
I05542	11.1	2.6	7.5	.7	.3	.1	23	67	6	3	1
MEAN	11.0	3.6	6.2	.9	.2	.1	32	56	8	2	1
S.D.	.21	1.34	1.77	.28	.07	.00	12.7	14.8	2.8	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279415

APPENDIX 4

Individual Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549 a	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

a Plasmodium was observed.

3M_MN03279416

APPENDIX 4

Individual Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.86	13.0	41.6	60.6	19.0	31.3	666	.2	14
I05526	6.58	12.3	38.6	58.7	18.7	31.9	343	.3	20
MEAN	6.72	12.6	40.1	59.6	18.8	31.6	504	.2	17
S.D.	.198	.49	2.12	1.34	.21	.42	228.4	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.86	13.4	43.2	62.9	19.5	31.0	421	.6	41
I05523	6.71	12.8	40.3	60.1	19.1	31.7	570	.2	13
MEAN	6.78	13.1	41.8	61.5	19.3	31.4	496	.4	27
S.D.	.106	.42	2.05	1.98	.28	.49	105.4	.28	19.8
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.10	11.5	39.3	64.4	18.9	29.3	476	.4	24
I05522	6.80	13.1	42.7	62.8	19.2	30.6	562	.2	14
MEAN	6.45	12.3	41.0	63.6	19.1	29.9	519	.3	19
S.D.	.495	1.13	2.40	1.13	.21	.92	60.8	.14	7.1
N	2	2	2	2	2	2	2	2	2

3M_MN03279417

APPENDIX 4

Individual Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	7.6	2.4	4.0	1.0	.1	.0	32	53	13	2	1
I05526	7.0	2.8	3.4	.5	.1	.1	41	49	7	2	1
MEAN	7.3	2.6	3.7	.8	.1	.0	36	51	10	2	1
S.D.	.42	.28	.42	.35	.00	.07	6.4	2.8	4.2	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	13.1	8.1	4.0	.6	.3	.0	62	30	5	3	0
I05523	9.9	5.2	4.2	.3	.1	.0	53	42	3	1	0
MEAN	11.5	6.6	4.1	.4	.2	.0	58	36	4	2	0
S.D.	2.26	2.05	.14	.21	.14	.00	6.4	8.5	1.4	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	7.2	2.5	4.0	.5	.2	.0	34	56	7	2	1
I05522	16.0	7.5	6.7	1.2	.5	.1	47	42	7	3	1
MEAN	11.6	5.0	5.4	.8	.4	.0	40	49	7	2	1
S.D.	6.22	3.54	1.91	.49	.21	.07	9.2	9.9	.0	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279418

APPENDIX 4

Individual Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279419

APPENDIX 4

Individual Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.55	11.1	33.7	60.7	20.0	33.0	606	.4	22
I05549	7.08	13.5	44.4	62.7	19.0	30.3	414	.4	28
MEAN	6.32	12.3	39.0	61.7	19.5	31.6	510	.4	25
S.D.	1.082	1.70	7.57	1.41	.71	1.91	135.8	.00	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.59	12.6	39.7	60.2	19.1	31.7	419	.5	33
I05552	6.69	12.5	40.5	60.5	18.6	30.8	427	.2	13
MEAN	6.64	12.6	40.1	60.3	18.8	31.2	423	.4	23
S.D.	.071	.07	.57	.21	.35	.64	5.7	.21	14.1
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.49	12.2	39.7	61.2	18.8	30.7	343	.7	45
I05542	7.07	12.7	41.9	59.3	17.9	30.2	538	.2	14
MEAN	6.78	12.5	40.8	60.2	18.4	30.5	440	.4	30
S.D.	.410	.35	1.56	1.34	.64	.35	137.9	.35	21.9
N	2	2	2	2	2	2	2	2	2

3M_MN03279420

APPENDIX 4

Individual Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	9.6	7.1	2.1	.4	.0	.0	73	22	4	0	0
I05549	8.0	3.7	3.5	.6	.1	.0	46	44	8	2	1
MEAN	8.8	5.4	2.8	.5	.0	.0	60	33	6	1	0
S.D.	1.13	2.40	.99	.14	.07	.00	19.1	15.6	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	6.2	1.1	4.3	.5	.2	.0	18	69	8	4	1
I05552	9.4	4.7	3.4	.6	.6	.1	50	37	7	6	1
MEAN	7.8	2.9	3.8	.6	.4	.0	34	53	8	5	1
S.D.	2.26	2.55	.64	.07	.28	.07	22.6	22.6	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	10.8	5.0	4.7	1.0	.1	.1	46	43	9	0	1
I05542	7.6	3.7	3.5	.3	.1	.0	49	46	4	1	0
MEAN	9.2	4.4	4.1	.6	.1	.0	48	44	6	0	0
S.D.	2.26	.92	.85	.49	.00	.07	2.1	2.1	3.5	.7	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279421

APPENDIX 4

Individual Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

3M_MN03279422

APPENDIX 4

Individual Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.78	12.9	40.6	59.8	19.0	31.8	692	.5	34
I05526	6.67	12.4	39.8	59.7	18.6	31.2	396	.1	7
MEAN	6.72	12.6	40.2	59.8	18.8	31.5	544	.3	20
S.D.	.078	.35	.57	.07	.28	.42	209.3	.28	19.1
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.89	13.6	43.2	62.6	19.8	31.6	434	.2	14
I05523	6.71	12.8	40.6	60.5	19.1	31.5	548	.1	7
MEAN	6.80	13.2	41.9	61.5	19.4	31.5	491	.2	10
S.D.	.127	.57	1.84	1.48	.49	.07	80.6	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.08	11.5	37.8	62.1	18.9	30.5	542	.8	49
I05522	6.36	12.1	38.3	60.2	19.0	31.5	603	.3	19
MEAN	6.22	11.8	38.1	61.1	19.0	31.0	572	.6	34
S.D.	.198	.42	.35	1.34	.07	.71	43.1	.35	21.2
N	2	2	2	2	2	2	2	2	2

3M_MN03279423

APPENDIX 4

Individual Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	9.5	4.3	4.5	.6	.1	.0	45	47	7	1	0
I05526	7.8	4.0	3.0	.7	.1	.0	52	38	9	1	0
MEAN	8.6	4.2	3.8	.6	.1	.0	48	42	8	1	0
S.D.	1.20	.21	1.06	.07	.00	.00	4.9	6.4	1.4	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	13.7	9.6	3.0	.9	.2	.0	70	22	7	1	0
I05523	11.8	6.7	4.4	.6	.1	.0	57	37	5	1	0
MEAN	12.8	8.2	3.7	.8	.2	.0	64	30	6	1	0
S.D.	1.34	2.05	.99	.21	.07	.00	9.2	10.6	1.4	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	6.3	2.2	3.1	.8	.2	.1	36	49	12	3	1
I05522	11.6	5.8	4.7	.9	.1	.0	50	40	8	1	0
MEAN	9.0	4.0	3.9	.8	.2	.0	43	44	10	2	0
S.D.	3.75	2.55	1.13	.07	.07	.07	9.9	6.4	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279424

APPENDIX 4

Individual Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279425

APPENDIX 4

Individual Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^6$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	6.04	11.9	36.9	61.1	19.7	32.2	645	.1	6
I05549	6.61	12.8	39.9	60.4	19.4	32.1	447	.3	20
MEAN	6.32	12.3	38.4	60.8	19.6	32.1	546	.2	13
S.D.	.403	.64	2.12	.49	.21	.07	140.0	.14	9.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.81	12.5	39.6	58.2	18.3	31.5	399	.4	27
I05552	6.71	12.5	40.7	60.7	18.6	30.6	546	.3	20
MEAN	6.76	12.5	40.1	59.4	18.4	31.0	472	.4	24
S.D.	.071	.00	.78	1.77	.21	.64	103.9	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.20	11.6	37.9	61.2	18.8	30.7	314	.1	6
I05542	6.81	12.2	41.0	60.3	17.9	29.7	534	.5	34
MEAN	6.50	11.9	39.5	60.8	18.4	30.2	424	.3	20
S.D.	.431	.42	2.19	.64	.64	.71	155.6	.28	19.8
N	2	2	2	2	2	2	2	2	2

3M_MN03279426

APPENDIX 4

Individual Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	14.9	10.0	3.2	1.4	.2	.0	67	22	10	1	0
I05549	8.7	4.4	3.3	.6	.3	.0	51	38	7	3	0
MEAN	11.8	7.2	3.2	1.0	.2	.0	59	30	8	2	0
S.D.	4.38	3.96	.07	.57	.07	.00	11.3	11.3	2.1	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	7.4	2.0	4.5	.7	.2	.0	27	61	10	3	0
I05552	11.4	6.5	3.9	.4	.6	.0	57	34	4	5	0
MEAN	9.4	4.2	4.2	.6	.4	.0	42	48	7	4	0
S.D.	2.83	3.18	.42	.21	.28	.00	21.2	19.1	4.2	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	7.8	2.3	5.0	.5	.1	.0	29	63	7	1	0
I05542	10.0	3.1	6.1	.6	.2	.0	31	61	6	2	0
MEAN	8.9	2.7	5.6	.6	.2	.0	30	62	6	2	0
S.D.	1.56	.57	.78	.07	.07	.00	1.4	1.4	.7	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279427

APPENDIX 4

Individual Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	-	-	-	-	-
I05542	-	-	-	-	-

3M_MN03279428

APPENDIX 4

Individual Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10³/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10³/mcL	RETIC %	RETIC X10³/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.50	12.5	39.5	60.8	19.3	31.7	641	.2	13
I05526	6.56	12.4	39.4	60.1	19.0	31.6	387	.0	0
MEAN	6.53	12.4	39.5	60.5	19.2	31.6	514	.1	6
S.D.	.042	.07	.07	.49	.21	.07	179.6	.14	9.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.92	13.5	43.3	62.7	19.6	31.3	399	.2	14
I05523	6.52	12.6	39.1	60.0	19.2	32.1	496	.0	0
MEAN	6.72	13.0	41.2	61.3	19.4	31.7	448	.1	7
S.D.	.283	.64	2.97	1.91	.28	.57	68.6	.14	9.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.09	12.0	39.1	64.2	19.7	30.6	520	1.5	91
I05522	6.37	12.3	38.7	60.8	19.3	31.8	495	.0	0
MEAN	6.23	12.2	38.9	62.5	19.5	31.2	508	.8	46
S.D.	.198	.21	.28	2.40	.28	.85	17.7	1.06	64.3
N	2	2	2	2	2	2	2	2	2

3M_MN03279429

APPENDIX 4

Individual Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	10.7	5.9	4.1	.6	.0	.1	55	38	6	0	1
I05526	10.9	7.3	2.8	.8	.1	.0	67	25	7	1	0
MEAN	10.8	6.6	3.4	.7	.0	.0	61	32	6	0	0
S.D.	.14	.99	.92	.14	.07	.07	8.5	9.2	.7	.7	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	13.8	9.6	3.0	1.1	.2	.0	69	21	8	1	0
I05523	11.2	6.8	4.0	.4	.0	.0	60	36	4	0	0
MEAN	12.5	8.2	3.5	.8	.1	.0	64	28	6	0	0
S.D.	1.84	1.98	.71	.49	.14	.00	6.4	10.6	2.8	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	9.4	4.5	3.7	.8	.3	.0	48	40	9	3	0
I05522	15.0	8.3	4.8	1.4	.4	.1	55	32	9	3	1
MEAN	12.2	6.4	4.2	1.1	.4	.0	52	36	9	3	0
S.D.	3.96	2.69	.78	.42	.07	.07	4.9	5.7	.0	.0	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279430

APPENDIX 4

Individual Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279431

APPENDIX 4

Individual Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10^3/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10^3/mcL	RETIC %	RETIC X10^3/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.96	11.9	36.1	60.5	19.9	32.9	635	.1	6
I05549	6.60	13.0	40.2	61.0	19.7	32.3	433	.2	13
MEAN	6.28	12.4	38.1	60.8	19.8	32.6	534	.2	10
S.D.	.453	.78	2.90	.35	.14	.42	142.8	.07	4.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.69	12.5	39.8	59.5	18.7	31.4	408	.2	13
I05552	6.85	12.7	41.7	60.8	18.6	30.5	504	.1	7
MEAN	6.77	12.6	40.8	60.2	18.6	31.0	456	.2	10
S.D.	.113	.14	1.34	.92	.07	.64	67.9	.07	4.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.56	12.2	39.7	60.5	18.7	30.9	320	.1	7
I05542	6.52	12.1	40.5	62.1	18.5	29.8	577	.2	13
MEAN	6.54	12.2	40.1	61.3	18.6	30.4	448	.2	10
S.D.	.028	.07	.57	1.13	.14	.78	181.7	.07	4.2
N	2	2	2	2	2	2	2	2	2

3M_MN03279432

APPENDIX 4

Individual Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	8.5	4.2	3.1	.8	.3	.0	50	36	10	4	0
I05549	6.4	2.6	2.5	1.2	.1	.0	41	38	19	2	0
MEAN	7.4	3.4	2.8	1.0	.2	.0	46	37	14	3	0
S.D.	1.48	1.13	.42	.28	.14	.00	6.4	1.4	6.4	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	8.5	2.5	4.4	1.2	.3	.1	30	52	14	3	1
I05552	7.7	3.5	3.0	.6	.5	.0	45	39	8	7	0
MEAN	8.1	3.0	3.7	.9	.4	.0	38	46	11	5	0
S.D.	.57	.71	.99	.42	.14	.07	10.6	9.2	4.2	2.8	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	11.4	5.1	5.1	1.1	.0	.0	44	45	10	0	0
I05542	10.3	4.3	5.4	.5	.2	.0	42	52	5	2	0
MEAN	10.8	4.7	5.2	.8	.1	.0	43	48	8	1	0
S.D.	.78	.57	.21	.42	.14	.00	1.4	4.9	3.5	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279433

APPENDIX 4

Individual Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05533	-	-	-	-	-
I05542	-	-	-	-	-

3M_MN03279434

APPENDIX 4

Individual Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10^3/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10^3/mcL	RETIC %	RETIC X10^3/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.82	13.3	41.2	60.4	19.4	32.2	584	.4	27
I05526	6.44	12.5	39.3	61.0	19.4	31.8	337	.2	13
MEAN	6.63	12.9	40.2	60.7	19.4	32.0	460	.3	20
S.D.	.269	.57	1.34	.42	.00	.28	174.7	.14	9.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	7.19	14.1	46.3	64.3	19.6	30.5	415	.5	36
I05523	7.12	13.8	44.9	63.0	19.4	30.8	566	.1	7
MEAN	7.16	14.0	45.6	63.7	19.5	30.6	490	.3	22
S.D.	.049	.21	.99	.92	.14	.21	106.8	.28	20.5
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	5.93	11.9	38.7	65.3	20.1	30.9	445	1.4	83
I05522	6.68	13.2	42.5	63.7	19.8	31.1	576	.0	0
MEAN	6.30	12.6	40.6	64.5	19.9	31.0	510	.7	42
S.D.	.530	.92	2.69	1.13	.21	.14	92.6	.99	58.7
N	2	2	2	2	2	2	2	2	2

3M_MN03279435

APPENDIX 4

Individual Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	11.2	5.4	4.9	.7	.1	.1	48	44	6	1	1
I05526	12.0	7.5	3.8	.6	.1	.0	62	32	5	1	0
MEAN	11.6	6.4	4.4	.6	.1	.0	55	38	6	1	0
S.D.	.57	1.48	.78	.07	.00	.07	9.9	8.5	.7	.0	.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	10.7	4.1	5.6	.8	.2	.0	38	52	7	2	0
I05523	12.5	5.7	6.2	.5	.2	.0	45	49	4	1	0
MEAN	11.6	4.9	5.9	.6	.2	.0	42	50	6	2	0
S.D.	1.27	1.13	.42	.21	.00	.00	4.9	2.1	2.1	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	12.0	7.5	3.5	.7	.2	.1	63	29	6	1	1
I05522	21.2	13.1	6.0	1.6	.5	.1	62	28	7	3	0
MEAN	16.6	10.3	4.8	1.2	.4	.1	62	28	6	2	0
S.D.	6.51	3.96	1.77	.64	.21	.00	.7	.7	.7	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279436

APPENDIX 4

Individual Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279437

APPENDIX 4

Individual Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10³/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10³/mcL	RETIC %	RETIC X10³/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.63	11.3	34.8	61.8	20.1	32.6	580	.6	34
I05549	6.88	13.5	42.2	61.3	19.6	31.9	407	.4	28
MEAN	6.26	12.4	38.5	61.6	19.8	32.2	494	.5	31
S.D.	.884	1.56	5.23	.35	.35	.49	122.3	.14	4.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.61	12.7	40.2	60.9	19.3	31.7	441	.4	26
I05552	6.70	12.7	41.4	61.9	19.0	30.6	461	.2	13
MEAN	6.66	12.7	40.8	61.4	19.2	31.2	451	.3	20
S.D.	.064	.00	.85	.71	.21	.78	14.1	.14	9.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.62	12.7	40.7	61.4	19.1	31.2	293	.0	0
I05542	7.51	13.5	45.2	60.1	18.0	29.9	598	.3	23
MEAN	7.06	13.1	42.9	60.8	18.5	30.6	446	.2	12
S.D.	.629	.57	3.18	.92	.78	.92	215.7	.21	16.3
N	2	2	2	2	2	2	2	2	2

3M_MN03279438

APPENDIX 4

Individual Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	8.2	4.5	2.9	.6	.2	.0	55	36	7	2	0
I05549	9.3	4.3	3.8	.8	.4	.0	46	41	8	4	0
MEAN	8.8	4.4	3.4	.7	.3	.0	50	38	8	3	0
S.D.	.78	.14	.64	.14	.14	.00	6.4	3.5	.7	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	11.1	5.0	4.7	1.0	.4	.0	45	43	9	3	0
I05552	8.7	2.6	4.6	.8	.8	.0	29	52	9	9	0
MEAN	9.9	3.8	4.6	.9	.6	.0	37	48	9	6	0
S.D.	1.70	1.70	.07	.14	.28	.00	11.3	6.4	.0	4.2	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	9.9	3.5	5.1	1.0	.2	.1	36	51	10	2	1
I05542	11.2	2.5	7.3	.9	.4	.2	22	65	8	4	2
MEAN	10.6	3.0	6.2	1.0	.3	.2	29	58	9	3	2
S.D.	.92	.71	1.56	.07	.14	.07	9.9	9.9	1.4	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279439

APPENDIX 4

Individual Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05533	-	-	-	-	-
I05542	-	-	-	-	-

3M_MN03279440

APPENDIX 4

Individual Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC X10^3/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10^3/mcL	RETIC %	RETIC X10^3/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	6.54	12.6	39.9	61.0	19.2	31.5	503	.7	46
I05526	6.59	12.6	41.4	62.8	19.1	30.5	366	.3	20
MEAN	6.56	12.6	40.7	61.9	19.2	31.0	434	.5	33
S.D.	.035	.00	1.06	1.27	.07	.71	96.9	.28	18.4
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	6.80	13.5	43.6	64.1	19.8	30.9	377	.7	48
I05523	7.00	13.8	44.2	63.1	19.8	31.3	369	.7	49
MEAN	6.90	13.6	43.9	63.6	19.8	31.1	373	.7	48
S.D.	.141	.21	.42	.71	.00	.28	5.7	.00	.7
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	6.42	12.7	43.5	67.6	19.7	29.2	478	.9	58
I05522	6.42	12.5	41.3	64.3	19.5	30.3	562	.3	19
MEAN	6.42	12.6	42.4	66.0	19.6	29.8	520	.6	38
S.D.	.000	.14	1.56	2.33	.14	.78	59.4	.42	27.6
N	2	2	2	2	2	2	2	2	2

3M_MN03279441

APPENDIX 4

Individual Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	7.1	2.0	4.3	.5	.1	.3	28	60	7	1	4
I05526	9.6	4.2	4.1	1.1	.1	.0	44	43	11	1	1
MEAN	8.4	3.1	4.2	.8	.1	.2	36	52	9	1	2
S.D.	1.77	1.56	.14	.42	.00	.21	11.3	12.0	2.8	.0	2.1
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	8.1	3.8	3.2	.9	.2	.1	47	39	11	2	1
I05523	13.7	6.2	6.2	.7	.5	.1	45	45	5	3	1
MEAN	10.9	5.0	4.7	.8	.4	.1	46	42	8	2	1
S.D.	3.96	1.70	2.12	.14	.21	.00	1.4	4.2	4.2	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	15.7	10.9	3.4	1.2	.1	.1	70	22	7	1	1
I05522	16.2	8.8	5.4	1.3	.4	.3	54	33	8	2	2
MEAN	16.0	9.8	4.4	1.2	.2	.2	62	28	8	2	2
S.D.	.35	1.48	1.41	.07	.21	.14	11.3	7.8	.7	.7	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279442

APPENDIX 4

Individual Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05520	-	-	-	-	-
I05526	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05505	-	-	-	-	-
I05523	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05511	-	-	-	-	-
I05522	-	-	-	-	-

3M_MN03279443

APPENDIX 4

Individual Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC $X10^3$/mcL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $X10^3$/mcL	RETIC %	RETIC $X10^3$/mcL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	5.52	11.1	34.6	62.6	20.1	32.1	533	.6	33
I05549	6.51	12.6	40.5	62.3	19.4	31.1	483	.3	20
MEAN	6.02	11.8	37.5	62.5	19.8	31.6	508	.4	26
S.D.	.700	1.06	4.17	.21	.49	.71	35.4	.21	9.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	6.60	12.6	41.2	62.4	19.1	30.7	405	.3	20
I05552	6.33	12.0	39.3	62.1	18.9	30.5	408	.6	38
MEAN	6.46	12.3	40.2	62.2	19.0	30.6	406	.4	29
S.D.	.191	.42	1.34	.21	.14	.14	2.1	.21	12.7
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	6.62	12.5	41.0	61.9	18.9	30.5	293	.2	13
I05542	6.81	12.3	40.6	59.7	18.1	30.3	500	.4	27
MEAN	6.72	12.4	40.8	60.8	18.5	30.4	396	.3	20
S.D.	.134	.14	.28	1.56	.57	.14	146.4	.14	9.9
N	2	2	2	2	2	2	2	2	2

3M_MN03279444

APPENDIX 4

Individual Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	WBC $X10^3$/mcL	N-SEG $X10^3$/mcL	LYMPH $X10^3$/mcL	MONO $X10^3$/mcL	EOSIN $X10^3$/mcL	BASO $X10^3$/mcL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	6.9	3.5	2.5	.7	.2	.1	50	36	10	2	1
I05549	15.6	10.5	3.2	1.3	.4	.2	67	20	9	3	1
MEAN	11.2	7.0	2.8	1.0	.3	.2	58	28	10	2	1
S.D.	6.15	4.95	.49	.42	.14	.07	12.0	11.3	.7	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	13.8	7.1	5.1	1.0	.4	.2	51	37	8	3	2
I05552	9.2	3.8	3.4	1.1	.7	.2	41	37	12	7	2
MEAN	11.5	5.4	4.2	1.0	.6	.2	46	37	10	5	2
S.D.	3.25	2.33	1.20	.07	.21	.00	7.1	.0	2.8	2.8	.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	9.8	3.2	5.7	.5	.1	.2	33	58	5	1	2
I05542	11.0	3.0	7.0	.5	.3	.1	28	64	5	2	1
MEAN	10.4	3.1	6.4	.5	.2	.2	30	61	5	2	2
S.D.	.85	.14	.92	.00	.14	.07	3.5	4.2	.0	.7	.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279445

APPENDIX 4

Individual Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	ANISO	POLY	POIK	HYPO	TOXNEUT
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day	
I05529	-	-	-	-	-
I05549	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day	
I05539	-	-	-	-	-
I05552	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day	
I05533	-	-	-	-	-
I05542	-	-	-	-	-

3M_MN03279446

Appendix 4

Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05508	62	22	1.0	8.7	4.6	4.1	1.3	5	88	71
I05517	76	21	1.3	9.2	4.7	4.5	1.0	11	137	92
I05519	74	27	1.2	9.3	5.0	4.3	.3	10	174	58
I05520	69	17	1.1	8.7	4.9	3.8	.7	9	111	78
I05526	75	19	1.1	9.4	5.2	4.2	.3	9	150	63
I05527	99	17	1.2	8.8	4.9	3.9	.2	9	170	58
MEAN	76	20	1.2	9.0	4.9	4.1	.6	9	138	70
S.D.	12.5	3.8	.10	.32	.21	.26	.45	2.0	33.7	13.3
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05514	76	17	1.2	9.7	5.5	4.2	.5	9	138	41
I05515	69	17	1.0	9.5	4.6	4.9	.2	8	111	48
I05516	58	29	1.1	8.8	5.0	3.8	.6	11	98	113
I05521	75	16	1.4	10.2	5.6	4.6	.3	8	93	41
MEAN	70	20	1.2	9.6	5.2	4.4	.4	9	110	61
S.D.	8.3	6.2	.17	.58	.46	.48	.18	1.4	20.1	35.0
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05505	59	20	1.2	9.3	5.2	4.1	1.3	14	186	48
I05510	138	16	.9	8.8	4.4	4.4	.3	10	157	59
I05518	95	22	1.5	10.1	5.3	4.8	.5	9	124	55
I05523	76	20	1.1	9.3	5.2	4.1	.3	8	124	53
I05524	69	25	1.4	9.6	5.2	4.4	.7	10	141	62
I05528	58	24	1.3	9.7	5.2	4.5	.7	8	175	57
MEAN	82	21	1.2	9.5	5.1	4.4	.6	10	151	56
S.D.	30.4	3.3	.22	.44	.34	.26	.37	2.2	26.1	4.9
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279447

Appendix 4

Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05506	67	18	1.3	9.6	5.1	4.5	.4	10	129	68
I05507	102	22	1.4	9.9	5.0	4.9	.4	7	121	58
I05509	71	22	1.4	9.5	5.3	4.2	.8	10	117	62
I05511	58	21	1.1	8.8	4.7	4.1	1.0	8	115	55
I05512	75	22	1.3	9.2	5.3	3.9	.3	10	188	77
I05522	64	18	1.3	9.5	5.5	4.0	.3	9	159	83
MEAN	73	20	1.3	9.4	5.2	4.3	.5	9	138	67
S.D.	15.4	2.0	.11	.38	.28	.37	.29	1.3	29.3	11.0
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279448

Appendix 4

Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	58	24	546	152	8	1086	451	12	284
I05517	84	51	628	125	9	1908	508	226	325
I05519	58	33	514	117	9	783	448	12	249
I05520	36	26	866	88	4	660	336	17	220
I05526	58	31	1156	211	7	1671	250	25	168
I05527	43	29	556	113	6	692	376	37	235
MEAN	56	32	711	134	7	1133	395	55	247
S.D.	16.5	9.7	252.6	42.8	1.9	535.3	93.4	84.4	54.0
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	53	27	642	155	4	1955	413	19	243
I05515	38	43	787	125	4	348	715	43	441
I05516	43	48	1002	182	2	848	435	60	326
I05521	43	26	369	103	3	595	340	17	196
MEAN	44	36	700	141	3	936	476	35	302
S.D.	6.3	11.2	265.6	34.5	1.0	709.0	164.6	20.6	107.4
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	66	99	720	194	12	670	367	133	190
I05510	39	29	814	130	4	1109	450	15	301
I05518	54	34	579	124	2	1047	326	33	218
I05523	99	78	716	82	16	1549	471	29	291
I05524	84	118	1165	154	10	820	469	56	296
I05528	93	56	624	278	5	1329	236	39	156
MEAN	72	69	770	160	8	1087	386	51	242
S.D.	23.5	35.7	210.3	68.4	5.4	322.3	94.5	42.4	62.4
N	6	6	6	6	6	6	6	6	6

3M_MN03279449

Appendix 4

Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	54	49	1443	167	6	1602	653	52	359
I05507	54	94	447	138	9	575	515	19	326
I05509	80	181	585	156	6	1265	704	39	435
I05511	71	32	927	199	6	540	543	99	325
I05512	69	48	646	105	5	907	396	15	274
I05522	80	78	992	259	5	1676	362	21	224
MEAN	68	80	840	171	6	1094	529	41	324
S.D.	11.7	54.2	360.9	53.3	1.5	497.4	135.6	31.8	72.2
N	6	6	6	6	6	6	6	6	6

3M_MN03279450

Appendix 4

Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	10.2	6.5	154	4.9	106
I05517	10.3	5.8	154	4.8	106
I05519	11.1	6.6	161	5.9	113
I05520	10.5	6.1	158	5.7	111
I05526	11.8	7.5	166	6.1	111
I05527	10.7	5.0	160	4.9	109
MEAN	10.8	6.2	159	5.4	109
S.D.	.60	.84	4.6	.58	2.9
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	12.2	6.5	171	6.2	114
I05515	11.3	6.9	159	5.8	110
I05516	11.1	7.1	159	5.5	109
I05521	12.0	6.1	167	6.1	112
MEAN	11.6	6.6	164	5.9	111
S.D.	.53	.44	6.0	.32	2.2
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.9	5.9	161	5.8	112
I05510	10.7	7.5	156	5.8	111
I05518	12.2	6.9	169	7.2	113
I05523	11.2	6.6	164	6.1	116
I05524	11.9	8.8	168	7.0	110
I05528	10.9	6.7	158	6.3	108
MEAN	11.5	7.1	163	6.4	112
S.D.	.62	.99	5.3	.60	2.7
N	6	6	6	6	6

3M_MN03279451

Appendix 4

Individual Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	11.8	8.0	165	6.1	112
I05507	11.3	6.0	157	6.5	108
I05509	10.9	5.9	158	5.5	104
I05511	10.5	6.1	156	4.8	106
I05512	11.8	7.0	162	5.8	109
I05522	11.7	8.3	168	6.3	110
MEAN	11.3	6.9	161	5.8	108
S.D.	.54	1.06	4.8	.62	2.9
N	6	6	6	6	6

3M_MN03279452

Appendix 4

Individual Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05529	54	23	1.2	9.4	5.1	4.3	1.2	7	93	56
I05530	108	23	1.3	9.9	5.5	4.4	.3	10	168	91
I05531	70	23	1.3	8.6	4.6	4.0	.5	7	137	54
I05535	51	19	1.3	9.9	4.6	5.3	.5	4	203	131
I05544	82	22	1.2	10.8	4.7	6.1	.4	7	133	56
I05549	92	21	1.1	9.0	4.9	4.1	.3	7	159	48
MEAN	76	22	1.2	9.6	4.9	4.7	.5	7	149	73
S.D.	22.2	1.6	.08	.78	.35	.83	.34	1.9	37.2	32.4
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05537	71	21	1.3	10.0	4.9	5.1	.5	5	120	68
I05541	66	23	1.2	9.2	4.5	4.7	.7	6	133	69
I05547	89	22	1.2	8.9	4.6	4.3	.3	9	146	55
I05550	67	24	1.1	9.0	4.8	4.2	.6	6	120	56
MEAN	73	22	1.2	9.3	4.7	4.6	.5	6	130	62
S.D.	10.7	1.3	.08	.50	.18	.41	.17	1.7	12.4	7.5
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05532	86	20	1.2	10.7	5.5	5.2	.8	7	162	50
I05538	87	21	1.1	9.8	5.2	4.6	.3	7	142	42
I05539	82	29	1.3	9.2	3.9	5.3	.6	7	141	66
I05545	72	20	1.1	9.1	4.7	4.4	.9	37	156	74
I05548	55	21	1.0	9.1	4.4	4.7	.5	11	122	63
I05552	74	27	1.1	9.8	4.6	5.2	.6	6	140	53
MEAN	76	23	1.1	9.6	4.7	4.9	.6	12	144	58
S.D.	12.0	3.9	.10	.62	.57	.38	.21	12.1	14.0	11.7
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279453

Appendix 4

Individual Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05533	106	27	1.3	9.4	4.9	4.5	.4	11	163	69
I05534	71	21	1.4	10.1	5.5	4.6	.4	8	149	65
I05536	88	17	1.2	10.5	4.6	5.9	.3	9	137	53
I05540	74	26	1.1	8.6	4.4	4.2	.4	8	164	37
I05542	71	25	1.3	8.8	4.6	4.2	.5	9	152	86
I05551	60	26	.9	8.8	4.5	4.3	1.3	7	158	56
MEAN	78	24	1.2	9.4	4.8	4.6	.6	9	154	61
S.D.	16.3	3.9	.18	.78	.40	.65	.37	1.4	10.1	16.6
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279454

Appendix 4

Individual Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	66	202	195	101	3	484	425	27	265
I05530	65	211	274	121	5	1588	281	39	135
I05531	75	215	217	98	7	792	360	46	211
I05535	61	48	550	163	5	872	314	12	184
I05544	61	82	256	204	3	896	595	27	342
I05549	55	83	254	50	3	1242	272	19	185
MEAN	64	140	291	123	4	979	374	28	220
S.D.	6.7	76.9	130.1	54.0	1.6	384.3	121.9	12.5	73.1
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	68	89	200	166	2	706	219	25	152
I05541	54	146	184	72	3	395	293	12	189
I05547	44	80	210	62	3	477	433	17	286
I05550	50	98	211	75	4	356	566	48	322
MEAN	54	103	201	94	3	484	378	26	237
S.D.	10.2	29.4	12.5	48.5	.8	156.7	153.7	15.9	79.9
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	77	76	201	127	2	1192	366	35	177
I05538	68	135	454	120	4	1003	411	46	230
I05539	39	65	122	64	2	362	269	44	179
I05545	140	160	198	41	8	663	484	25	272
I05548	74	143	334	80	6	1073	352	0	210
I05552	48	78	232	91	3	769	617	62	393
MEAN	74	110	257	87	4	844	416	35	244
S.D.	35.5	41.0	118.5	32.9	2.4	306.4	121.0	21.2	81.3
N	6	6	6	6	6	6	6	6	6

3M_MN03279455

Appendix 4

Individual Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	101	216	301	121	5	3858	411	25	269
I05534	63	88	329	64	3	902	545	0	343
I05536	68	148	575	63	7	2229	336	15	205
I05540	57	126	182	52	4	417	380	39	223
I05542	74	99	204	79	3	1377	294	31	196
I05551	67	63	269	70	1	964	337	4	246
MEAN	72	123	310	75	4	1624	384	19	247
S.D.	15.4	54.2	141.4	24.3	2.0	1251.5	88.6	15.4	54.1
N	6	6	6	6	6	6	6	6	6

3M_MN03279456

Appendix 4

Individual Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	10.9	5.8	155	5.6	106
I05530	13.0	6.5	173	8.0	119
I05531	10.4	5.6	159	5.4	110
I05535	12.4	7.1	166	6.4	116
I05544	11.5	6.8	167	6.0	118
I05549	10.3	5.7	156	5.7	112
MEAN	11.4	6.2	163	6.2	114
S.D.	1.10	.63	7.1	.96	5.0
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	10.9	4.4	165	5.2	113
I05541	11.7	3.8	164	6.5	117
I05547	10.3	4.4	158	5.4	112
I05550	10.8	6.1	165	6.5	119
MEAN	10.9	4.7	163	5.9	115
S.D.	.58	.99	3.4	.70	3.3
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	11.5	6.2	167	6.4	113
I05538	11.5	5.6	164	6.3	116
I05539	10.5	6.1	164	6.3	118
I05545	10.3	4.9	156	5.3	111
I05548	10.6	5.3	152	5.5	112
I05552	11.6	7.1	166	7.0	118
MEAN	11.0	5.9	162	6.1	115
S.D.	.59	.78	6.1	.63	3.1
N	6	6	6	6	6

3M_MN03279457

Appendix 4

Individual Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.9	5.1	163	5.1	114
I05534	11.6	5.7	164	6.3	112
I05536	12.1	5.7	168	6.0	115
I05540	10.7	6.1	159	6.8	116
I05542	11.7	4.7	167	7.1	115
I05551	10.7	5.6	155	5.3	113
MEAN	11.3	5.5	163	6.1	114
S.D.	.59	.50	4.9	.80	1.5
N	6	6	6	6	6

3M_MN03279458

Appendix 4

Individual Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05508	54	20	1.1	9.2	4.8	4.4	1.4	8	118	70
I05517	68	19	1.2	9.9	4.8	5.1	1.1	11	171	85
I05519	57	26	1.1	8.5	4.5	4.0	.4	9	161	45
I05520	62	19	1.0	8.7	4.8	3.9	.9	7	117	90
I05526	54	19	.9	8.4	4.6	3.8	.4	10	134	48
I05527	65	16	1.2	8.8	4.8	4.0	.4	8	139	74
MEAN	60	20	1.1	8.9	4.7	4.2	.8	9	140	69
S.D.	5.9	3.3	.12	.56	.13	.49	.43	1.5	22.1	18.7
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05514	65	22	1.4	10.0	5.7	4.3	.6	9	148	51
I05515	72	14	1.1	9.9	4.8	5.1	.2	7	132	45
I05516	58	21	1.0	7.8	4.7	3.1	.4	8	108	50
I05521	53	16	1.3	9.5	4.9	4.6	.4	6	83	41
MEAN	62	18	1.2	9.3	5.0	4.3	.4	8	118	47
S.D.	8.3	3.9	.18	1.02	.46	.85	.16	1.3	28.4	4.6
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05505	52	17	1.1	9.0	5.0	4.0	1.0	7	176	50
I05510	62	17	.8	9.0	4.7	4.3	.3	7	159	54
I05518	71	19	1.4	9.7	4.9	4.8	.4	8	135	61
I05523	68	18	1.1	9.3	5.2	4.1	.3	8	116	65
I05524	68	26	1.4	8.8	4.5	4.3	.6	7	134	59
I05528	47	28	1.1	9.4	4.7	4.7	.7	9	155	56
MEAN	61	21	1.2	9.2	4.8	4.4	.6	8	146	58
S.D.	9.8	4.9	.23	.33	.25	.32	.27	.8	21.5	5.3
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279459

Appendix 4

Individual Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05506	58	20	1.4	9.1	4.9	4.2	.5	8	112	109
I05507	75	24	1.4	9.4	5.0	4.4	.3	6	109	72
I05509	66	19	1.3	9.9	5.4	4.5	.4	6	127	68
I05511	54	21	1.1	9.3	4.5	4.8	.7	5	130	62
I05512	64	23	1.2	8.8	5.1	3.7	.2	8	156	108
I05522	71	18	1.3	9.4	5.5	3.9	.4	9	143	128
MEAN	65	21	1.3	9.3	5.1	4.2	.4	7	130	91
S.D.	7.8	2.3	.12	.37	.36	.40	.17	1.5	18.0	27.3
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279460

Appendix 4

Individual Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	37	30	776	159	4	173	482	21	288
I05517	53	59	605	130	7	170	268	23	155
I05519	46	28	690	112	11	231	451	12	235
I05520	26	23	876	77	5	99	349	11	223
I05526	35	27	1552	203	9	160	235	17	152
I05527	71	69	830	126	7	1291	462	45	278
MEAN	45	39	888	134	7	354	374	22	222
S.D.	15.9	19.5	339.5	42.9	2.6	461.0	106.3	12.5	58.4
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	30	23	855	144	2	169	440	14	252
I05515	38	53	999	104	4	137	666	44	391
I05516	35	36	1284	153	2	186	421	18	314
I05521	45	46	365	77	5	273	310	20	171
MEAN	37	40	876	120	3	191	459	24	282
S.D.	6.3	13.0	384.3	35.4	1.5	58.2	149.3	13.6	93.3
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	55	58	721	154	10	176	339	29	163
I05510	25	20	1042	127	1	138	451	6	295
I05518	46	38	733	117	3	140	339	61	212
I05523	35	45	878	73	6	143	436	39	264
I05524	54	91	1359	103	6	222	407	42	238
I05528	70	45	643	239	3	287	240	65	155
MEAN	48	50	896	136	5	184	369	40	221
S.D.	15.9	23.8	267.3	57.3	3.2	59.7	78.9	21.7	55.5
N	6	6	6	6	6	6	6	6	6

3M_MN03279461

Appendix 4

Individual Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	29	20	1772	149	3	154	675	38	341
I05507	33	35	564	112	2	164	536	9	329
I05509	54	87	967	169	2	436	626	21	380
I05511	46	36	798	138	2	143	539	35	311
I05512	50	43	808	85	2	329	348	20	236
I05522	48	54	1069	197	2	473	409	30	247
MEAN	43	46	996	142	2	283	522	26	307
S.D.	10.0	23.0	417.0	39.9	.4	149.7	124.7	10.9	55.9
N	6	6	6	6	6	6	6	6	6

3M_MN03279462

Appendix 4

Individual Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	10.3	7.0	161	5.4	114
I05517	11.0	6.7	163	5.8	115
I05519	10.6	7.0	155	5.3	112
I05520	10.5	6.8	158	5.2	115
I05526	10.4	7.4	159	5.2	114
I05527	10.7	5.1	165	5.8	122
MEAN	10.6	6.7	160	5.4	115
S.D.	.25	.80	3.6	.28	3.4
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	12.9	9.0	180	6.6	121
I05515	10.8	6.8	162	6.2	114
I05516	10.5	6.5	160	5.1	116
I05521	10.7	5.2	158	5.2	111
MEAN	11.2	6.9	165	5.8	116
S.D.	1.12	1.58	10.1	.74	4.2
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.2	5.4	159	5.1	114
I05510	11.2	7.4	161	5.3	116
I05518	11.4	6.4	162	5.6	114
I05523	10.9	6.9	163	6.1	116
I05524	10.4	8.3	163	5.8	115
I05528	10.6	6.3	155	5.9	115
MEAN	11.0	6.8	160	5.6	115
S.D.	.39	1.00	3.1	.38	.9
N	6	6	6	6	6

3M_MN03279463

Appendix 4

Individual Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	10.6	7.8	164	5.1	119
I05507	10.6	5.1	158	5.1	111
I05509	10.9	6.1	162	5.4	115
I05511	10.6	5.2	157	5.8	114
I05512	11.3	7.8	162	5.5	114
I05522	11.6	7.6	166	5.7	113
MEAN	10.9	6.6	162	5.4	114
S.D.	.43	1.29	3.4	.29	2.7
N	6	6	6	6	6

3M_MN03279464

Appendix 4

Individual Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05529	50	21	.9	9.2	4.5	4.7	1.1	8	106	64
I05530	86	25	1.3	9.0	4.8	4.2	.4	8	154	56
I05531	57	25	1.2	8.5	4.4	4.1	.8	7	160	65
I05535	43	16	1.1	9.6	4.0	5.6	.3	7	183	123
I05544	59	27	1.1	10.6	4.5	6.1	.6	8	127	63
I05549	55	18	.9	9.1	4.5	4.6	.2	8	151	56
MEAN	58	22	1.1	9.3	4.4	4.9	.6	8	147	71
S.D.	14.7	4.4	.16	.71	.26	.80	.34	.5	26.9	25.7
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05537	87	20	1.1	9.1	4.4	4.7	.4	5	114	60
I05541	65	22	1.1	9.3	4.4	4.9	.8	10	130	78
I05547	65	18	1.0	8.4	4.4	4.0	.2	10	137	50
I05550	50	25	1.1	9.2	4.7	4.5	.5	10	116	69
MEAN	67	21	1.1	9.0	4.5	4.5	.5	9	124	64
S.D.	15.2	3.0	.05	.41	.15	.39	.25	2.5	11.1	12.0
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05532	53	22	1.0	9.4	4.4	5.0	.7	8	146	60
I05538	60	21	1.0	9.0	4.7	4.3	.4	7	105	36
I05539	72	15	1.1	9.0	3.9	5.1	.7	7	149	65
I05545	64	17	1.0	9.4	4.7	4.7	.6	15	162	66
I05548	48	20	1.0	8.9	4.0	4.9	.4	7	114	54
I05552	60	25	1.0	9.5	4.0	5.5	.5	7	123	63
MEAN	60	20	1.0	9.2	4.3	4.9	.6	8	133	57
S.D.	8.4	3.6	.04	.26	.37	.40	.14	3.2	22.4	11.3
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279465

Appendix 4

Individual Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05533	86	27	1.1	9.2	4.3	4.9	.3	9	136	68
I05534	70	19	1.3	9.1	4.3	4.8	.3	6	130	59
I05536	77	15	1.1	9.6	4.3	5.3	.3	7	102	51
I05540	58	21	1.0	9.0	4.5	4.5	.4	6	121	61
I05542	74	30	1.2	8.7	4.5	4.2	.4	7	138	110
I05551	56	22	.9	8.9	4.4	4.5	.7	6	113	46
MEAN	70	22	1.1	9.1	4.4	4.7	.4	7	123	66
S.D.	11.5	5.4	.14	.31	.10	.38	.15	1.2	14.1	23.0
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279466

Appendix 4

Individual Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	28	36	209	88	3	109	376	14	232
I05530	54	108	400	98	9	205	244	27	107
I05531	33	51	330	80	4	156	326	38	188
I05535	44	38	583	138	7	180	332	11	186
I05544	44	38	351	164	3	274	494	18	279
I05549	60	85	298	44	5	518	263	0	169
MEAN	44	59	362	102	5	240	339	18	194
S.D.	12.1	30.2	125.6	42.9	2.4	146.6	89.9	13.2	58.2
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	49	73	210	170	3	287	254	24	168
I05541	68	81	257	65	2	761	344	15	218
I05547	29	51	193	54	3	165	423	23	273
I05550	49	76	301	64	5	301	514	50	290
MEAN	49	70	240	88	3	378	384	28	237
S.D.	15.9	13.3	48.7	54.7	1.3	262.2	110.9	15.2	55.5
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	33	35	286	103	1	206	364	41	172
I05538	41	69	459	90	4	121	387	50	200
I05539	26	49	130	73	2	110	305	36	198
I05545	45	125	219	43	2	267	533	41	282
I05548	35	70	423	70	5	123	317	0	179
I05552	38	60	396	76	4	363	580	36	350
MEAN	36	68	319	76	3	198	414	34	230
S.D.	6.6	30.9	129.0	20.3	1.5	101.3	115.1	17.4	70.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279467

Appendix 4

Individual Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	34	56	305	95	1	153	404	32	261
I05534	37	35	543	37	2	766	485	15	298
I05536	42	49	743	52	2	352	341	20	203
I05540	37	50	269	46	3	413	394	27	215
I05542	22	40	296	61	3	130	233	24	119
I05551	45	46	332	60	1	174	383	21	284
MEAN	36	46	415	58	2	331	373	23	230
S.D.	8.0	7.5	188.9	20.0	.9	242.1	83.3	5.9	66.0
N	6	6	6	6	6	6	6	6	6

3M_MN03279468

Appendix 4

Individual Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	10.5	6.8	151	5.3	108
I05530	10.8	5.6	163	6.0	111
I05531	9.7	5.0	165	6.2	120
I05535	10.6	5.6	161	5.9	117
I05544	10.6	6.4	162	5.4	115
I05549	10.2	5.0	162	5.4	117
MEAN	10.4	5.7	161	5.7	115
S.D.	.39	.73	4.9	.38	4.4
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	9.9	4.7	154	4.0	110
I05541	10.7	4.3	166	6.2	118
I05547	9.8	3.8	159	5.1	117
I05550	10.4	4.2	164	5.5	120
MEAN	10.2	4.2	161	5.2	116
S.D.	.42	.37	5.4	.92	4.3
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	9.2	5.5	159	5.0	113
I05538	10.0	4.9	154	5.3	114
I05539	8.5	5.2	156	5.3	114
I05545	10.5	4.0	160	5.0	116
I05548	9.7	4.9	155	4.8	113
I05552	10.2	5.9	159	5.9	114
MEAN	9.7	5.1	157	5.2	114
S.D.	.73	.65	2.5	.39	1.1
N	6	6	6	6	6

3M_MN03279469

Appendix 4

Individual Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.0	5.4	152	5.6	114
I05534	10.5	4.1	162	5.9	117
I05536	10.6	4.9	161	5.9	117
I05540	10.5	5.1	158	6.3	115
I05542	10.7	5.4	168	6.3	122
I05551	10.3	4.9	158	5.2	114
MEAN	10.4	5.0	160	5.9	116
S.D.	.25	.48	5.3	.42	3.0
N	6	6	6	6	6

3M_MN03279470

Appendix 4

Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05508	51	21	1.1	9.1	4.7	4.4	1.3	8	132	67
I05517	71	17	1.2	9.3	4.8	4.5	1.0	11	179	97
I05519	54	26	1.1	8.4	4.7	3.7	.4	11	178	44
I05520	56	16	1.0	8.3	4.4	3.9	.8	8	124	63
I05526	52	22	1.0	8.1	4.7	3.4	.3	8	147	48
I05527	70	17	1.1	8.2	4.4	3.8	.3	10	158	56
MEAN	59	20	1.1	8.6	4.6	4.0	.7	9	153	62
S.D.	9.1	3.9	.08	.50	.17	.42	.42	1.5	23.0	19.0
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05514	56	18	1.2	8.6	4.9	3.7	.5	13	142	57
I05515	62	17	1.3	9.9	4.8	5.1	.4	8	129	73
I05516	61	25	1.0	8.4	4.2	4.2	.3	10	98	71
I05521	57	18	1.3	9.3	5.0	4.3	.3	9	89	41
MEAN	59	20	1.2	9.0	4.7	4.3	.4	10	114	60
S.D.	2.9	3.7	.14	.69	.36	.58	.10	2.2	25.1	14.8
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05505	58	16	1.1	8.8	4.9	3.9	.9	9	183	53
I05510	59	14	.8	8.1	4.1	4.0	.3	8	145	57
I05518	83	16	1.3	9.0	4.8	4.2	.3	10	142	48
I05523	84	19	1.2	9.0	5.4	3.6	.3	13	130	55
I05524	62	22	1.3	8.4	4.4	4.0	.5	10	135	46
I05528	54	24	1.2	9.2	4.3	4.9	.5	9	132	83
MEAN	67	18	1.2	8.8	4.6	4.1	.5	10	144	57
S.D.	13.3	3.9	.19	.42	.48	.44	.23	1.7	19.7	13.4
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279471

Appendix 4

Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05506	68	18	1.3	8.2	4.4	3.8	.3	10	106	70
I05507	95	23	1.4	9.1	4.5	4.6	.3	8	104	81
I05509	71	18	1.2	9.3	5.1	4.2	.3	14	117	62
I05511	67	17	1.1	8.8	4.3	4.5	.4	6	125	56
I05512	71	22	1.4	8.4	4.9	3.5	.2	11	144	96
I05522	70	17	1.2	8.8	5.7	3.1	.3	9	155	94
MEAN	74	19	1.3	8.8	4.8	4.0	.3	10	125	76
S.D.	10.6	2.6	.12	.41	.53	.59	.06	2.7	20.6	16.6
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279472

Appendix 4

Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	34	24	709	154	4	116	510	18	312
I05517	44	47	512	102	8	144	280	47	168
I05519	45	27	742	125	9	148	448	9	235
I05520	24	21	848	77	5	82	365	11	241
I05526	33	27	1455	209	9	143	197	20	133
I05527	33	59	767	114	5	156	428	27	256
MEAN	36	34	839	130	7	132	371	22	224
S.D.	7.9	15.2	321.9	46.2	2.3	27.8	115.8	13.9	64.2
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	26	16	634	121	5	93	359	11	214
I05515	43	57	955	109	5	173	641	38	390
I05516	38	40	1125	147	2	201	383	9	295
I05521	34	28	287	87	5	129	331	27	182
MEAN	35	35	750	116	4	149	428	21	270
S.D.	7.2	17.5	369.9	25.0	1.5	47.7	143.3	13.8	92.9
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	44	41	643	143	10	127	305	14	155
I05510	23	20	980	134	1	157	442	0	294
I05518	38	31	698	109	3	133	327	32	216
I05523	41	40	798	80	6	175	436	24	268
I05524	49	55	1181	106	9	152	354	23	212
I05528	47	33	535	194	2	173	203	26	135
MEAN	40	37	806	128	5	153	344	20	213
S.D.	9.4	11.7	237.8	39.4	3.8	19.9	89.3	11.3	61.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279473

Appendix 4

Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	26	28	1502	139	4	155	657	38	349
I05507	27	31	462	96	2	163	496	14	312
I05509	36	64	626	127	2	300	593	15	367
I05511	43	38	683	127	2	169	516	20	299
I05512	34	34	725	89	3	189	340	8	237
I05522	35	63	941	171	3	244	390	40	243
MEAN	34	43	823	125	3	203	499	22	301
S.D.	6.3	16.2	367.0	29.9	.8	57.2	119.4	13.4	53.4
N	6	6	6	6	6	6	6	6	6

3M_MN03279474

Appendix 4

Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	10.0	6.8	159	4.7	116
I05517	10.8	6.9	161	5.7	118
I05519	10.6	7.6	157	5.7	121
I05520	10.0	6.4	158	5.4	120
I05526	10.9	8.2	159	5.0	121
I05527	10.3	6.8	165	5.8	123
MEAN	10.4	7.1	160	5.4	120
S.D.	.39	.66	2.9	.44	2.5
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	10.0	6.8	160	5.1	117
I05515	11.0	7.2	185	7.0	136
I05516	10.3	7.5	159	5.2	116
I05521	10.7	5.5	161	5.2	120
MEAN	10.5	6.8	166	5.6	122
S.D.	.44	.88	12.5	.92	9.3
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	10.6	5.3	158	4.9	121
I05510	10.1	7.4	154	4.9	115
I05518	10.7	6.6	161	6.1	120
I05523	10.4	7.2	162	5.1	121
I05524	10.2	7.8	161	5.8	120
I05528	10.1	5.3	164	5.3	126
MEAN	10.4	6.6	160	5.4	120
S.D.	.26	1.08	3.5	.50	3.5
N	6	6	6	6	6

3M_MN03279475

Appendix 4

Individual Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	10.0	7.6	159	5.3	121
I05507	10.3	6.2	153	5.6	118
I05509	10.1	5.9	158	5.3	121
I05511	10.1	5.1	152	4.7	115
I05512	11.1	8.7	163	6.5	123
I05522	11.4	7.3	169	6.0	120
MEAN	10.5	6.8	159	5.6	120
S.D.	.60	1.31	6.4	.63	2.8
N	6	6	6	6	6

3M_MN03279476

Appendix 4

Individual Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05529	51	18	.9	8.5	4.4	4.1	.9	8	93	59
I05530	69	22	1.2	8.6	4.5	4.1	.3	9	152	59
I05531	61	25	1.2	8.5	4.5	4.0	.7	8	176	61
I05535	47	16	1.2	9.5	4.2	5.3	.4	9	227	185
I05544	67	24	1.2	9.8	4.0	5.8	.6	9	126	79
I05549	46	22	1.0	9.3	4.5	4.8	.3	10	156	70
MEAN	57	21	1.1	9.0	4.4	4.7	.5	9	155	86
S.D.	10.2	3.5	.13	.57	.21	.75	.24	.8	45.4	49.4
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05537	92	19	1.1	9.2	4.4	4.8	.4	7	126	87
I05541	62	23	1.1	9.2	4.2	5.0	.8	8	130	99
I05547	58	19	1.0	8.3	4.3	4.0	.3	15	140	50
I05550	54	26	1.1	8.7	4.4	4.3	.8	12	113	68
MEAN	66	22	1.1	8.8	4.3	4.5	.6	10	127	76
S.D.	17.3	3.4	.05	.44	.10	.46	.26	3.7	11.2	21.5
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05532	53	20	1.2	9.2	4.7	4.5	.8	10	148	58
I05538	60	20	1.0	9.1	4.6	4.5	.4	9	113	33
I05539	76	18	1.1	8.9	4.0	4.9	.8	6	153	86
I05545	79	16	.9	9.0	4.4	4.6	.4	15	153	62
I05548	48	20	1.0	8.8	4.0	4.8	.5	13	112	75
I05552	57	24	1.0	9.1	4.0	5.1	.6	9	145	68
MEAN	62	20	1.0	9.0	4.3	4.7	.6	10	137	64
S.D.	12.6	2.7	.10	.15	.33	.24	.18	3.2	19.5	18.0
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279477

Appendix 4

Individual Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05533	88	19	1.2	8.8	4.4	4.4	.3	9	139	53
I05534	73	20	1.4	9.5	4.7	4.8	.5	9	142	63
I05536	75	14	1.2	9.6	4.3	5.3	.2	9	101	56
I05540	68	18	1.1	9.0	4.5	4.5	.4	12	148	78
I05542	74	19	1.2	8.5	4.2	4.3	.3	6	120	68
I05551	69	29	1.0	8.7	4.4	4.3	.4	8	111	50
MEAN	74	20	1.2	9.0	4.4	4.6	.4	9	127	61
S.D.	7.2	5.0	.13	.44	.17	.39	.10	1.9	18.9	10.5
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279478

Appendix 4

Individual Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	35	49	245	86	2	182	352	11	219
I05530	38	49	331	92	6	226	272	5	118
I05531	32	45	321	83	5	490	346	38	201
I05535	39	39	665	170	6	294	330	5	191
I05544	41	49	290	159	2	245	498	26	286
I05549	40	86	308	48	4	138	251	0	170
MEAN	38	53	360	106	4	262	342	14	198
S.D.	3.4	16.7	152.5	47.7	1.8	123.6	86.9	14.7	55.5
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	55	77	241	150	3	316	244	27	166
I05541	41	98	239	67	2	334	296	0	196
I05547	33	60	186	53	4	182	410	12	270
I05550	51	73	297	66	7	270	483	38	280
MEAN	45	77	241	84	4	276	358	19	228
S.D.	9.9	15.8	45.3	44.5	2.2	67.9	108.3	16.7	55.8
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	35	31	233	99	2	302	365	41	172
I05538	46	87	451	89	5	124	381	35	208
I05539	29	43	129	72	3	121	271	30	180
I05545	48	105	202	39	4	253	528	11	283
I05548	33	41	428	68	4	142	310	0	182
I05552	33	54	386	81	4	224	605	53	380
MEAN	37	60	305	75	4	194	410	28	234
S.D.	7.8	29.3	134.0	20.8	1.0	76.1	129.7	19.6	82.3
N	6	6	6	6	6	6	6	6	6

3M_MN03279479

Appendix 4

Individual Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	29	39	285	96	2	172	414	30	271
I05534	35	41	506	39	2	285	503	41	317
I05536	31	44	755	52	1	204	340	23	204
I05540	31	52	240	48	2	483	434	34	240
I05542	19	33	250	52	2	113	241	18	161
I05551	43	42	351	62	2	200	377	15	283
MEAN	31	42	398	58	2	243	385	27	246
S.D.	7.8	6.2	200.5	20.0	.4	130.1	89.4	9.9	56.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279480

Appendix 4

Individual Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.7	5.9	151	4.7	114
I05530	9.6	6.2	159	6.3	114
I05531	10.4	5.9	166	6.0	123
I05535	10.3	6.5	167	6.1	125
I05544	9.9	5.7	160	5.5	119
I05549	10.3	5.5	168	6.0	125
MEAN	10.0	6.0	162	5.8	120
S.D.	.34	.36	6.5	.59	5.1
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	9.7	4.8	159	4.9	120
I05541	10.2	4.2	163	5.6	119
I05547	10.0	4.4	156	4.8	118
I05550	9.8	4.8	160	5.6	123
MEAN	9.9	4.6	160	5.2	120
S.D.	.22	.30	2.9	.43	2.2
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	9.7	5.2	166	6.5	127
I05538	10.0	4.8	156	5.4	121
I05539	8.8	5.3	160	5.6	127
I05545	10.1	4.3	158	5.5	121
I05548	9.9	5.2	158	4.7	122
I05552	9.4	5.8	162	5.1	121
MEAN	9.6	5.1	160	5.5	123
S.D.	.48	.51	3.6	.60	3.0
N	6	6	6	6	6

3M_MN03279481

Appendix 4

Individual Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	9.9	5.0	157	5.4	118
I05534	10.8	4.6	163	6.9	121
I05536	11.0	5.1	160	6.2	119
I05540	9.4	5.2	157	5.8	121
I05542	10.4	4.7	164	5.1	119
I05551	10.0	5.4	165	5.3	123
MEAN	10.2	5.0	161	5.8	120
S.D.	.60	.30	3.5	.67	1.8
N	6	6	6	6	6

3M_MN03279482

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05508	53	19	1.0	8.7	4.7	4.0	1.2	6	119	61
I05517	64	19	1.3	9.1	4.8	4.3	1.1	8	177	101
I05519	57	29	1.1	8.3	4.7	3.6	.5	9	170	56
I05520	54	19	1.0	8.4	4.7	3.7	.8	8	132	81
I05526	56	17	1.1	8.3	4.8	3.5	.3	7	151	43
I05527	74	20	1.3	9.2	5.0	4.2	.4	9	177	66
MEAN	60	20	1.1	8.7	4.8	3.9	.7	8	154	68
S.D.	8.0	4.3	.14	.40	.12	.33	.38	1.2	24.6	20.4
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05514	57	19	1.2	9.0	5.1	3.9	.6	7	143	51
I05515	74	14	1.2	10.3	5.2	5.1	.3	8	132	60
I05516	64	26	1.1	8.5	5.1	3.4	.4	7	109	64
I05521	59	19	1.6	10.5	5.9	4.6	.4	8	119	42
MEAN	64	20	1.3	9.6	5.3	4.2	.4	8	126	54
S.D.	7.6	4.9	.22	.98	.39	.75	.13	.6	14.9	9.8
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05505	65	15	1.2	8.7	5.1	3.6	.8	8	173	49
I05510	70	14	1.0	9.0	4.9	4.1	.3	6	163	56
I05518	108	19	1.3	9.0	5.0	4.0	.2	8	125	38
I05523	78	16	1.0	9.1	5.2	3.9	.3	9	139	48
I05524	75	26	1.4	8.8	4.8	4.0	.5	14	136	68
I05528	53	22	1.2	9.2	5.0	4.2	.5	8	161	44
MEAN	75	19	1.2	9.0	5.0	4.0	.4	9	150	50
S.D.	18.5	4.6	.16	.19	.14	.21	.22	2.7	18.8	10.4
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279483

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05506	63	20	1.6	9.5	5.5	4.0	.3	9	107	88
I05507	111	21	1.6	9.8	5.1	4.7	.2	8	80	57
I05509	75	18	1.3	9.8	5.4	4.4	.3	17	90	59
I05511	62	18	1.1	9.0	4.7	4.3	.3	9	105	56
I05512	63	20	1.4	9.0	5.3	3.7	.2	10	147	68
I05522	65	18	1.3	9.5	5.5	4.0	.3	7	141	108
MEAN	73	19	1.4	9.4	5.2	4.2	.3	10	112	73
S.D.	19.1	1.3	.19	.36	.31	.35	.05	3.6	27.0	21.0
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279484

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	41	25	706	152	4	222	525	18	359
I05517	48	45	533	102	6	164	275	23	184
I05519	46	31	782	130	11	166	437	0	261
I05520	27	24	901	82	7	120	377	20	275
I05526	36	24	1408	226	9	167	251	53	186
I05527	36	63	863	126	5	168	487	84	325
MEAN	39	35	866	136	7	168	392	33	265
S.D.	7.7	15.8	296.2	50.1	2.6	32.4	111.8	30.3	71.2
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	26	16	692	127	5	130	386	10	254
I05515	35	38	824	113	4	153	741	134	492
I05516	37	46	1306	181	2	189	396	30	322
I05521	43	142	335	104	5	227	338	18	205
MEAN	35	60	789	131	4	175	465	48	318
S.D.	7.0	55.8	401.7	34.5	1.4	42.5	185.6	57.9	125.4
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	46	39	710	143	11	164	356	38	200
I05510	25	21	1097	160	1	137	501	5	365
I05518	41	37	645	111	4	140	324	25	240
I05523	34	38	724	76	11	129	454	25	306
I05524	45	87	1271	108	4	194	394	12	266
I05528	61	49	660	244	3	220	235	56	174
MEAN	42	45	851	140	6	164	377	27	258
S.D.	12.2	22.4	265.3	58.6	4.3	36.2	94.9	18.3	70.1
N	6	6	6	6	6	6	6	6	6

3M_MN03279485

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	29	21	1624	154	3	133	730	63	433
I05507	30	34	463	108	2	174	556	18	381
I05509	40	75	563	122	2	305	409	26	417
I05511	43	35	566	118	1	204	345	35	320
I05512	31	34	726	95	2	157	353	15	263
I05522	41	65	900	166	2	308	414	38	287
MEAN	36	44	807	127	2	214	468	32	350
S.D.	6.3	21.0	428.6	27.4	.6	75.7	149.1	17.5	70.4
N	6	6	6	6	6	6	6	6	6

3M_MN03279486

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	9.7	6.9	158	4.7	115
I05517	11.0	6.3	160	5.1	117
I05519	9.8	6.6	154	4.7	112
I05520	10.2	6.7	156	5.2	114
I05526	9.5	6.9	159	4.9	119
I05527	11.4	7.4	174	6.2	127
MEAN	10.3	6.8	160	5.1	117
S.D.	.77	.37	7.1	.56	5.3
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	9.8	6.9	163	4.6	117
I05515	10.1	6.7	173	6.8	125
I05516	10.6	7.5	163	5.1	117
I05521	11.6	5.8	169	6.4	123
MEAN	10.5	6.7	167	5.7	120
S.D.	.79	.70	4.9	1.04	4.1
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.0	5.8	160	4.8	117
I05510	11.4	8.2	169	5.6	129
I05518	10.0	6.6	159	5.3	115
I05523	10.7	6.5	160	5.7	122
I05524	10.4	8.0	162	5.7	110
I05528	10.3	5.8	155	5.3	112
MEAN	10.6	6.8	161	5.4	118
S.D.	.51	1.05	4.6	.35	7.0
N	6	6	6	6	6

3M_MN03279487

Appendix 4

Individual Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	10.7	7.1	170	5.1	125
I05507	11.2	6.7	160	5.8	114
I05509	10.4	5.6	158	5.1	117
I05511	10.3	5.0	158	5.0	116
I05512	11.2	6.6	163	5.2	115
I05522	11.1	7.5	167	6.1	114
MEAN	10.8	6.4	163	5.4	117
S.D.	.41	.94	5.0	.45	4.2
N	6	6	6	6	6

3M_MN03279488

Appendix 4

Individual Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05529	48	20	1.0	8.8	4.7	4.1	.7	8	99	65
I05530	78	22	1.3	9.8	5.4	4.4	.3	6	189	65
I05531	95	21	1.2	8.5	4.5	4.0	.4	10	182	61
I05535	58	15	1.2	9.4	4.4	5.0	.3	7	217	88
I05544	78	22	1.1	9.7	4.4	5.3	.5	9	136	57
I05549	42	18	1.1	9.3	4.7	4.6	.3	9	171	65
MEAN	66	20	1.2	9.2	4.7	4.6	.4	8	166	67
S.D.	20.5	2.7	.10	.51	.38	.51	.16	1.5	42.0	10.9
N	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day							
I05537	81	18	1.1	9.0	4.7	4.3	.3	7	114	53
I05541	51	22	1.2	9.8	4.7	5.1	.9	7	143	81
I05547	61	22	1.0	8.1	4.3	3.8	.4	8	149	50
I05550	80	26	1.1	9.0	4.6	4.4	.4	10	129	60
MEAN	68	22	1.1	9.0	4.6	4.4	.5	8	134	61
S.D.	14.7	3.3	.08	.69	.19	.54	.27	1.4	15.6	14.0
N	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05532	62	15	1.1	9.2	4.8	4.4	.6	7	153	42
I05538	55	20	1.1	9.3	4.9	4.4	.3	7	122	35
I05539	74	18	1.0	8.7	3.8	4.9	.4	8	143	77
I05545	49	24	1.0	8.9	4.6	4.3	.5	22	151	67
I05548	45	17	1.0	9.0	4.3	4.7	.4	10	125	43
I05552	74	26	1.0	9.3	4.2	5.1	.4	8	143	72
MEAN	60	20	1.0	9.1	4.4	4.6	.4	10	140	56
S.D.	12.4	4.2	.05	.24	.41	.32	.10	5.8	13.1	18.0
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279489

Appendix 4

Individual Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05533	84	22	1.2	9.8	4.8	5.0	.3	9	142	62
I05534	89	18	1.4	9.5	5.0	4.5	.3	6	131	76
I05536	89	14	1.2	9.6	4.5	5.1	.3	6	65	51
I05540	63	20	1.4	10.0	5.2	4.8	.3	13	105	53
I05542	93	32	1.3	9.1	4.5	4.6	.3	7	115	78
I05551	56	26	.9	8.8	4.6	4.2	.5	24	109	42
MEAN	79	22	1.2	9.5	4.8	4.7	.3	11	111	60
S.D.	15.5	6.3	.19	.45	.29	.33	.08	7.0	26.6	14.4
N	6	6	6	6	6	6	6	6	6	6

3M_MN03279490

Appendix 4

Individual Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	36	55	220	81	3	188	387	8	264
I05530	57	78	322	123	9	1481	292	0	144
I05531	35	43	292	84	6	128	410	45	259
I05535	53	38	583	161	7	2407	350	10	224
I05544	40	38	274	164	5	146	510	25	327
I05549	44	74	284	50	4	368	269	0	198
MEAN	44	54	329	110	6	786	370	15	236
S.D.	9.1	17.9	128.7	46.5	2.2	947.2	87.4	17.5	62.7
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	39	72	219	220	2	247	269	23	190
I05541	39	80	238	73	2	250	348	2	249
I05547	30	50	168	53	3	165	454	23	330
I05550	64	114	307	67	11	217	487	25	306
MEAN	43	79	233	103	4	220	390	18	269
S.D.	14.6	26.6	57.5	78.3	4.4	39.4	99.8	10.9	62.5
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	30	34	235	98	1	196	447	130	245
I05538	37	57	531	85	4	149	426	41	261
I05539	23	52	157	69	3	107	290	26	213
I05545	56	153	229	42	2	345	520	25	319
I05548	38	54	404	68	7	230	329	0	214
I05552	40	54	390	82	7	227	640	18	443
MEAN	37	67	324	74	4	209	442	40	282
S.D.	11.1	42.8	140.3	19.2	2.5	81.8	127.6	46.1	87.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279491

Appendix 4

Individual Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	35	43	296	106	1	1132	389	35	281
I05534	38	34	447	43	1	476	482	0	338
I05536	33	42	668	54	2	367	343	18	221
I05540	31	41	294	52	2	141	480	35	292
I05542	20	40	280	58	2	105	225	16	169
I05551	50	71	346	63	2	276	353	12	279
MEAN	34	45	388	63	2	416	379	19	263
S.D.	9.8	13.0	150.1	22.3	.5	377.0	96.5	13.6	59.4
N	6	6	6	6	6	6	6	6	6

3M_MN03279492

Appendix 4

Individual Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	10.2	5.5	151	5.0	109
I05530	11.1	6.0	168	6.7	125
I05531	10.3	4.8	160	5.1	116
I05535	11.0	6.8	166	5.7	125
I05544	8.1	5.6	160	4.8	118
I05549	10.7	5.5	162	6.1	117
MEAN	10.2	5.7	161	5.6	118
S.D.	1.11	.66	5.9	.74	6.1
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	9.7	4.5	156	4.6	110
I05541	11.5	3.6	170	6.5	122
I05547	8.8	4.5	154	4.5	113
I05550	10.9	4.0	165	5.4	124
MEAN	10.2	4.2	161	5.2	117
S.D.	1.21	.44	7.5	.93	6.8
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	9.7	5.4	160	5.2	116
I05538	10.7	5.0	161	6.2	121
I05539	9.2	5.4	156	5.3	116
I05545	10.1	4.1	156	5.6	118
I05548	10.4	5.2	160	5.7	125
I05552	9.9	6.0	165	6.3	125
MEAN	10.0	5.2	160	5.7	120
S.D.	.53	.63	3.4	.45	4.2
N	6	6	6	6	6

3M_MN03279493

Appendix 4

Individual Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.4	4.9	159	5.4	122
I05534	10.5	4.2	165	6.2	124
I05536	10.7	5.0	160	5.9	114
I05540	11.5	5.8	170	6.6	117
I05542	10.6	5.3	163	5.8	118
I05551	9.7	5.2	157	5.1	115
MEAN	10.6	5.1	162	5.8	118
S.D.	.58	.53	4.7	.54	3.9
N	6	6	6	6	6

3M_MN03279494

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	57	22	1.0	7.7	4.6	3.1	1.2	8	115	68	58
I05517	74	16	1.2	8.9	5.0	3.9	1.2	11	178	82	77
I05519	52	25	1.1	7.9	4.7	3.2	.4	12	183	39	84
I05520	55	19	1.0	8.2	4.6	3.6	.6	11	124	78	57
I05526	60	20	1.2	8.1	5.0	3.1	.4	9	147	42	70
I05527	65	20	1.3	8.6	4.9	3.7	.3	10	178	54	67
MEAN	60	20	1.1	8.2	4.8	3.4	.7	10	154	60	69
S.D.	8.0	3.0	.12	.45	.19	.34	.41	1.5	29.9	18.3	10.6
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	56	18	1.1	8.3	5.0	3.3	.5	7	136	49	52
I05515	63	19	1.3	9.6	5.2	4.4	.3	8	127	97	45
I05516	60	22	1.1	7.9	5.0	2.9	.4	8	117	49	42
I05521	66	17	1.5	9.4	5.5	3.9	.4	6	98	44	43
MEAN	61	19	1.2	8.8	5.2	3.6	.4	7	120	60	46
S.D.	4.3	2.2	.19	.83	.24	.66	.08	1.0	16.3	24.9	4.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	58	21	1.1	8.4	5.3	3.1	.7	11	191	49	74
I05510	62	16	.9	8.2	4.7	3.5	.3	7	135	69	60
I05518	71	24	1.3	9.3	5.4	3.9	.4	10	145	73	56
I05523	74	17	1.1	9.6	4.7	4.9	.2	9	129	74	49
I05524	65	27	1.4	8.5	5.0	3.5	.6	11	136	64	53
I05528	48	25	1.1	8.6	4.8	3.8	.6	14	157	59	36
MEAN	63	22	1.2	8.8	5.0	3.8	.5	10	149	65	55
S.D.	9.4	4.5	.18	.55	.31	.61	.20	2.3	22.8	9.5	12.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279495

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506	80	22	1.6	9.4	5.4	4.0	.2	11	57	51	16
I05507	98	23	1.4	9.0	4.8	4.2	.2	14	29	29	9
I05509	60	21	1.2	9.0	4.2	4.8	.3	17	65	89	18
I05511	55	17	1.0	9.0	4.6	4.4	.3	8	75	41	25
I05512	91	19	1.2	8.7	5.1	3.6	.2	24	76	58	27
I05522	72	19	1.3	9.2	5.4	3.8	.2	13	87	95	20
MEAN	76	20	1.3	9.0	4.9	4.1	.2	14	65	60	19
S.D.	17.0	2.2	.20	.23	.48	.43	.05	5.5	20.3	26.3	6.5
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279496

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	29	31	723	156	2	157	527	28	377
I05517	34	51	490	125	2	130	290	27	203
I05519	37	29	666	128	8	194	457	12	285
I05520	23	22	842	79	3	135	408	20	307
I05526	30	30	1370	238	1	184	226	12	174
I05527	33	95	659	126	1	191	446	39	309
MEAN	31	43	792	142	3	165	392	23	276
S.D.	4.9	27.3	305.3	53.1	2.6	28.5	112.8	10.5	74.9
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	22	13	606	132	4	92	403	14	273
I05515	35	59	778	109	3	144	713	100	502
I05516	35	43	1093	163	1	188	420	19	360
I05521	28	28	258	88	1	108	344	31	220
MEAN	30	36	684	123	2	133	470	41	339
S.D.	6.3	19.8	348.2	32.2	1.5	42.6	165.2	40.0	123.2
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	43	72	740	160	4	218	348	30	211
I05510	28	43	848	143	1	178	514	9	392
I05518	33	40	720	129	2	201	356	36	274
I05523	20	36	897	70	1	122	479	28	346
I05524	50	75	1241	121	7	213	402	36	282
I05528	63	63	673	262	8	225	475	860	365
MEAN	40	55	853	148	4	193	429	166	312
S.D.	15.7	17.2	207.5	63.8	3.1	38.4	69.9	339.9	67.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279497

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	28	24	1262	168	2	180	758	61	475
I05507	31	39	239	109	2	219	499	9	359
I05509	52	85	902	88	5	954	504	25	371
I05511	44	33	415	98	2	207	494	33	340
I05512	40	46	377	70	2	267	439	25	346
I05522	37	85	683	141	2	285	406	36	296
MEAN	39	52	646	112	2	352	517	32	364
S.D.	8.8	26.6	384.1	36.1	1.2	297.5	124.5	17.2	59.9
N	6	6	6	6	6	6	6	6	6

3M_MN03279498

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	9.0	6.6	154	4.7	116
I05517	11.0	6.2	160	5.4	116
I05519	10.3	6.8	150	5.3	110
I05520	9.8	6.9	151	5.3	112
I05526	9.9	6.9	163	5.8	121
I05527	10.8	6.3	164	6.1	119
MEAN	10.1	6.6	157	5.4	116
S.D.	.73	.31	6.1	.48	4.1
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	10.2	6.6	154	5.0	113
I05515	11.3	6.6	163	6.1	114
I05516	10.4	7.2	159	4.9	118
I05521	11.2	4.7	161	6.1	122
MEAN	10.8	6.3	159	5.5	117
S.D.	.56	1.09	3.9	.67	4.1
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	9.6	5.7	161	5.7	120
I05510	10.1	7.2	154	4.8	119
I05518	11.3	6.9	159	6.0	114
I05523	10.9	6.2	158	5.3	116
I05524	9.9	8.6	161	5.6	109
I05528	10.3	6.5	154	5.8	112
MEAN	10.4	6.8	158	5.5	115
S.D.	.64	1.01	3.2	.43	4.2
N	6	6	6	6	6

3M_MN03279499

Appendix 4

Individual Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506	11.4	7.9	171	6.6	128
I05507	10.4	6.7	156	6.4	111
I05509	9.5	4.3	153	4.8	107
I05511	10.5	5.9	153	5.8	108
I05512	11.4	9.1	160	5.1	109
I05522	11.3	7.2	163	6.2	114
MEAN	10.8	6.8	158	5.8	113
S.D.	.76	1.66	7.9	.73	7.8
N	6	6	6	6	6

3M_MN03279500

Appendix 4

Individual Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	48	21	.9	7.6	4.3	3.3	1.0	7	80	53	39
I05530	74	22	1.3	9.6	5.6	4.0	.3	9	175	65	73
I05531	62	25	1.2	8.2	4.6	3.6	.6	9	177	70	64
I05535	57	16	1.2	9.2	4.4	4.8	.4	9	226	175	56
I05544	57	23	1.1	9.4	4.6	4.8	.6	9	143	59	42
I05549	47	15	1.1	9.3	4.8	4.5	.3	11	175	56	81
MEAN	58	20	1.1	8.9	4.7	4.2	.5	9	163	80	59
S.D.	9.9	4.0	.14	.80	.47	.63	.27	1.3	48.5	47.1	16.8
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	46	18	1.0	8.6	4.4	4.2	.4	6	102	61	43
I05541	70	25	1.3	8.9	4.6	4.3	1.0	9	128	123	61
I05547	72	12	.9	8.3	3.8	4.5	.2	10	82	65	41
I05550	68	24	1.1	8.5	4.7	3.8	.5	9	127	77	42
MEAN	64	20	1.1	8.6	4.4	4.2	.5	8	110	82	47
S.D.	12.1	6.0	.17	.25	.40	.29	.34	1.7	22.1	28.5	9.5
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	49	20	1.1	9.2	5.1	4.1	.6	8	133	54	33
I05538	53	23	1.0	8.5	4.6	3.9	.3	7	100	57	37
I05539	62	18	1.2	8.8	4.2	4.6	.4	9	144	72	56
I05545	59	24	1.0	8.3	4.7	3.6	.5	12	136	83	37
I05548	58	23	1.1	8.7	4.3	4.4	.4	15	107	86	48
I05552	60	27	1.0	9.0	4.1	4.9	.6	8	162	60	34
MEAN	57	22	1.1	8.8	4.5	4.2	.5	10	130	69	41
S.D.	4.9	3.1	.08	.33	.37	.48	.12	3.1	23.2	13.7	9.2
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279501

Appendix 4

Individual Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	81	21	1.2	9.6	5.1	4.5	.3	15	100	62	25
I05534	74	12	1.4	9.1	4.6	4.5	.3	9	128	69	23
I05536	70	13	1.1	9.0	3.9	5.1	.2	8	62	44	20
I05540	62	15	1.1	8.7	4.6	4.1	.3	8	80	67	16
I05542	87	18	1.1	8.4	4.2	4.2	.4	9	77	84	25
I05551	46	26	1.0	8.6	4.6	4.0	.4	43	99	55	28
MEAN	70	18	1.2	8.9	4.5	4.4	.3	15	91	64	23
S.D.	14.6	5.3	.14	.43	.41	.40	.08	13.8	23.1	13.5	4.3
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279502

Appendix 4

Individual Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	52	159	175	78	3	192	395	11	285
I05530 QS	33	82	305	115	1	377	296	-	175
I05531	30	51	277	82	2	156	383	45	255
I05535	31	48	593	171	2	362	361	8	244
I05544	37	44	266	176	1	155	499	25	342
I05549	33	79	272	53	2	169	302	0	232
MEAN	36	77	315	112	2	235	373	18	256
S.D.	8.2	43.3	143.3	51.2	.8	105.0	74.3	17.7	55.7
N	6	6	6	6	6	6	6	5	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	54	88	221	254	3	395	249	25	182
I05541	33	70	233	70	2	293	358	3	276
I05547	17	18	280	42	2	79	394	11	302
I05550	46	146	312	68	1	253	513	33	341
MEAN	38	80	262	108	2	255	378	18	275
S.D.	16.2	52.8	42.2	97.8	.8	131.7	108.8	13.5	67.7
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	36	47	259	100	2	268	371	23	212
I05538	31	53	498	78	3	118	405	45	264
I05539	24	38	169	68	3	201	280	34	211
I05545	61	131	228	38	2	330	494	28	322
I05548	26	75	401	67	1	126	310	0	208
I05552	38	52	292	78	8	412	733	19	541
MEAN	36	66	308	72	3	242	432	25	293
S.D.	13.4	34.1	120.9	20.3	2.5	116.5	165.5	15.2	129.4
N	6	6	6	6	6	6	6	5	6

3M_MN03279503

Appendix 4

Individual Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	33	45	285	107	1	297	374	33	284
I05534	73	42	359	44	2	3173	554	6	406
I05536	34	41	616	47	7	99	344	23	238
I05540	30	40	230	44	2	139	404	36	270
I05542	22	62	216	57	1	154	232	31	178
I05551	46	60	310	66	1	306	373	30	308
MEAN	40	48	336	61	2	695	380	26	281
S.D.	18.1	10.0	146.9	24.2	2.3	1217.1	104.1	10.9	76.1
N	6	6	6	6	6	6	6	6	6

3M_MN03279504

Appendix 4

Individual Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.4	5.2	144	4.7	107
I05530	11.7	6.0	169	6.6	124
I05531	10.1	5.8	155	5.8	116
I05535	10.7	5.8	163	6.9	125
I05544	10.1	5.2	159	5.6	125
I05549	9.4	5.8	161	6.5	116
MEAN	10.2	5.6	158	6.0	119
S.D.	.87	.34	8.5	.81	7.2
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	8.4	4.0	148	5.1	108
I05541	10.9	4.9	163	6.1	118
I05547	10.0	3.0	151	5.3	113
I05550	10.0	4.6	159	5.8	124
MEAN	9.8	4.1	155	5.6	116
S.D.	1.04	.84	6.9	.46	6.8
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	9.5	5.0	153	4.7	110
I05538	9.3	3.8	152	5.3	118
I05539	9.7	5.7	154	5.8	115
I05545	9.9	4.0	152	5.7	114
I05548	10.4	5.1	158	4.8	120
I05552	10.2	6.3	154	5.9	118
MEAN	9.8	5.0	154	5.4	116
S.D.	.42	.96	2.2	.52	3.6
N	6	6	6	6	6

3M_MN03279505

Appendix 4

Individual Clinical Chemistry Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.6	5.0	158	5.3	116
I05534	11.7	6.0	166	7.1	114
I05536	10.5	5.0	153	7.1	116
I05540	10.1	4.0	153	5.9	111
I05542	10.6	4.3	161	6.5	124
I05551	9.7	5.3	156	5.7	114
MEAN	10.5	4.9	158	6.3	116
S.D.	.67	.71	5.0	.75	4.4
N	6	6	6	6	6

3M_MN03279506

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05508	64	18	1.1	8.5	4.9	3.6	.9	5	127	45	56
I05517	68	14	1.2	9.1	4.9	4.2	.8	7	166	55	66
I05519	51	25	1.0	7.7	4.6	3.1	.5	5	186	37	82
I05520	59	16	.8	7.7	4.5	3.2	.5	6	112	35	53
I05526	57	21	1.2	8.4	5.1	3.3	.3	6	165	41	67
I05527	64	17	1.2	8.1	4.6	3.5	.4	6	158	55	54
MEAN	60	18	1.1	8.2	4.8	3.5	.6	6	152	45	63
S.D.	6.1	3.9	.16	.54	.23	.40	.23	.8	27.5	8.7	11.1
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05514	62	18	1.2	8.6	4.9	3.7	.3	5	135	28	47
I05515	77	12	1.2	9.1	4.8	4.3	.2	4	104	35	42
I05516	59	27	1.0	8.0	4.8	3.2	.4	5	98	41	38
I05521	57	16	1.4	9.5	5.5	4.0	.3	5	102	27	41
MEAN	64	18	1.2	8.8	5.0	3.8	.3	5	110	33	42
S.D.	9.1	6.3	.16	.65	.34	.47	.08	.5	17.0	6.6	3.7
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	70	15	1.1	8.6	5.2	3.4	.5	8	190	22	73
I05510	71	13	.8	8.2	4.4	3.8	.2	5	136	51	53
I05518	83	18	1.2	8.5	5.0	3.5	.3	7	119	31	48
I05523	68	16	1.1	9.0	5.2	3.8	.3	5	137	45	39
I05524	72	19	1.3	8.4	4.8	3.6	.4	5	151	32	42
I05528	57	20	1.1	8.2	4.7	3.5	.4	5	149	35	32
MEAN	70	17	1.1	8.5	4.9	3.6	.4	6	147	36	48
S.D.	8.3	2.6	.17	.30	.31	.17	.10	1.3	24.0	10.4	14.3
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279507

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05506 a	107	28	1.8	9.2	4.4	4.8	.2	58	67	75	11
I05507	93	22	1.4	9.3	4.8	4.5	.2	28	28	22	8
I05511	66	23	.9	8.0	4.2	3.8	.2	18	59	36	20
I05512	78	27	1.3	8.8	5.2	3.6	.2	7	38	19	10
I05522	67	16	1.4	9.8	5.4	4.4	.3	19	69	44	15
MEAN	76	22	1.2	9.0	4.9	4.1	.2	18	48	30	13
S.D.	12.6	4.5	.24	.77	.53	.44	.05	8.6	18.8	11.8	5.4
N	4	4	4	4	4	4	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

3M_MN03279508

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	28	32	756	169	2	122	524	15	373
I05517	35	52	420	126	5	106	308	37	210
I05519	41	27	628	149	10	526	440	19	281
I05520	23	26	776	72	3	207	388	30	298
I05526	30	26	1322	266	7	159	243	22	194
I05527	33	69	510	118	11	140	454	51	327
MEAN	32	39	735	150	6	210	393	29	280
S.D.	6.2	17.9	318.7	65.6	3.7	158.7	102.8	13.4	68.5
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	19	16	548	136	2	93	379	15	260
I05515	34	35	552	100	6	219	646	37	443
I05516	29	34	1085	182	2	143	391	15	329
I05521	27	31	233	87	4	96	354	27	224
MEAN	27	29	604	126	4	138	442	24	314
S.D.	6.2	8.8	353.5	42.6	1.9	58.8	136.5	10.6	96.4
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	30	39	650	171	4	118	412	36	234
I05510	21	20	634	133	3	102	431	7	333
I05518	39	51	558	115	7	116	336	36	256
I05523	22	58	697	95	3	101	472	36	337
I05524	50	69	1035	125	13	296	397	37	277
I05528	51	43	557	250	5	314	240	27	184
MEAN	36	47	688	148	6	174	381	30	270
S.D.	13.3	16.9	178.3	55.8	3.8	101.5	82.3	11.8	59.0
N	6	6	6	6	6	6	6	6	6

3M_MN03279509

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506 a	73	29	876	134	10	4040	738	67	432
I05507	30	46	208	110	2	182	474	17	344
I05511	41	25	344	101	4	101	524	27	339
I05512	36	44	422	71	3	175	379	32	297
I05522	30	73	581	132	2	258	408	68	299
MEAN	34	47	389	104	3	182	446	36	320
S.D.	5.3	19.7	155.7	25.3	1.0	64.5	65.3	22.2	25.2
N	4	4	4	4	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

3M_MN03279510

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05508	10.1	6.8	156	4.7	111
I05517	10.9	5.5	160	5.3	113
I05519	10.2	6.5	149	5.2	112
I05520	9.7	6.2	151	5.2	109
I05526	10.5	7.7	159	5.2	112
I05527	9.9	5.6	150	4.9	110
MEAN	10.2	6.4	154	5.1	111
S.D.	.43	.82	4.8	.23	1.5
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05514	9.9	5.7	157	5.1	112
I05515	9.9	5.3	155	4.8	107
I05516	9.9	7.1	154	4.7	109
I05521	10.3	4.9	157	5.4	108
MEAN	10.0	5.8	156	5.0	109
S.D.	.20	.96	1.5	.32	2.2
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	10.8	5.0	157	4.8	112
I05510	9.7	6.5	152	4.9	113
I05518	10.2	6.1	147	5.4	107
I05523	10.2	6.3	158	5.2	112
I05524	10.1	7.5	158	5.2	110
I05528	9.7	5.8	150	4.8	106
MEAN	10.1	6.2	154	5.0	110
S.D.	.41	.82	4.7	.25	2.9
N	6	6	6	6	6

3M_MN03279511

Appendix 4

Individual Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05506 a	10.6	6.9	157	7.5	111
I05507	10.1	7.2	144	5.5	99
I05511	9.6	4.4	152	5.2	111
I05512	10.3	6.1	157	5.6	109
I05522	11.1	6.7	158	5.4	106
MEAN	10.3	6.1	153	5.4	106
S.D.	.62	1.22	6.4	.17	5.3
N	4	4	4	4	4

a Unscheduled sacrifice on Day 179.

3M_MN03279512

Appendix 4

Individual Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	35	23	.8	8.0	4.4	3.6	.9	5	87	46	32
I05530	58	21	1.3	9.6	5.5	4.1	.3	6	181	48	71
I05531	68	22	1.2	8.4	4.5	3.9	.4	6	176	74	59
I05535	44	16	1.2	9.4	4.7	4.7	.3	6	226	72	60
I05544	75	22	1.2	9.5	4.4	5.1	.4	7	143	55	43
I05549	65	14	1.0	8.7	4.6	4.1	.2	6	149	44	73
MEAN	58	20	1.1	8.9	4.7	4.2	.4	6	160	56	56
S.D.	15.2	3.7	.18	.66	.42	.55	.25	.6	46.5	13.3	16.0
N	6	6	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day								
I05537	62	18	1.1	9.1	4.6	4.5	.5	4	99	53	33
I05541	58	18	1.2	9.3	4.7	4.6	.8	6	143	66	54
I05547	53	19	.8	7.6	3.7	3.9	.2	4	109	31	42
I05550	44	25	1.0	8.5	4.6	3.9	.5	7	138	45	37
MEAN	54	20	1.0	8.6	4.4	4.2	.5	5	122	49	42
S.D.	7.8	3.4	.17	.76	.47	.38	.24	1.5	21.6	14.7	9.1
N	4	4	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05532	80	17	1.1	9.2	5.0	4.2	.4	10	130	44	25
I05538	63	17	.9	8.6	4.6	4.0	.3	7	98	26	34
I05539	66	18	1.1	9.0	4.3	4.7	.4	6	154	68	58
I05545	56	21	1.0	8.4	4.7	3.7	.5	11	137	56	38
I05548	55	16	.9	8.5	4.3	4.2	.3	7	108	37	38
I05552	66	24	1.0	9.6	4.0	5.6	.3	7	149	61	25
MEAN	64	19	1.0	8.9	4.5	4.4	.4	8	129	49	36
S.D.	9.0	3.1	.09	.47	.35	.67	.08	2.0	22.3	15.8	12.1
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279513

Appendix 4

Individual Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	78	23	1.2	9.1	4.8	4.3	.2	5	88	46	22
I05534	74	22	1.4	9.4	4.8	4.6	.2	6	93	77	15
I05536	86	12	1.2	9.9	4.0	5.9	.2	5	67	34	21
I05540	67	18	1.1	9.1	4.7	4.4	.3	12	76	45	11
I05542	80	22	1.1	9.2	4.4	4.8	.2	4	66	67	26
I05551	55	25	.9	8.8	4.6	4.2	.4	11	102	50	31
MEAN	73	20	1.2	9.2	4.6	4.7	.2	7	82	53	21
S.D.	11.0	4.7	.16	.37	.31	.63	.08	3.4	14.7	15.8	7.2
N	6	6	6	6	6	6	6	6	6	6	6

3M_MN03279514

Appendix 4

Individual Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	91	262	169	86	10	151	350	19	252
I05530	30	55	274	113	2	197	282	16	158
I05531	25	42	243	81	4	84	407	103	274
I05535	37	56	554	172	5	287	351	14	234
I05544	39	61	237	182	7	134	530	41	355
I05549	26	47	222	48	2	422	345	0	275
MEAN	41	87	283	114	5	212	378	32	258
S.D.	25.0	85.9	137.1	53.3	3.1	123.4	84.6	37.1	64.1
N	6	6	6	6	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	58	61	207	260	3	2745	254	14	184
I05541	34	60	218	70	2	209	337	12	252
I05547	26	55	296	50	5	147	347	8	265
I05550	50	111	236	65	15	190	496	41	341
MEAN	42	72	239	111	6	823	358	19	260
S.D.	14.6	26.3	39.7	99.5	6.0	1281.8	100.7	15.0	64.4
N	4	4	4	4	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	34	38	228	102	5	167	372	56	204
I05538	29	32	363	69	5	95	430	52	272
I05539	21	43	118	74	2	238	302	42	232
I05545	59	126	219	41	3	321	514	29	323
I05548	42	35	303	65	14	109	335	0	226
I05552	35	43	295	76	13	164	683	17	505
MEAN	37	53	254	71	7	182	439	33	294
S.D.	13.0	36.1	85.3	19.7	5.2	84.7	140.9	21.6	111.7
N	6	6	6	6	6	6	6	6	6

3M_MN03279515

Appendix 4

Individual Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	33	43	243	107	4	253	337	29	256
I05534	33	34	245	43	1	203	467	9	338
I05536	31	38	659	58	4	189	408	19	277
I05540	25	37	217	48	2	296	399	68	252
I05542	32	59	212	63	5	515	279	42	213
I05551	44	53	320	65	4	251	358	20	300
MEAN	33	44	316	64	3	284	375	31	273
S.D.	6.2	9.9	172.4	22.7	1.5	119.3	64.9	21.2	43.1
N	6	6	6	6	6	6	6	6	6

3M_MN03279516

Appendix 4

Individual Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.1	4.5	142	4.5	102
I05530	11.1	6.1	159	6.1	112
I05531	9.8	5.2	155	5.1	108
I05535	10.6	6.1	159	5.0	112
I05544	10.2	5.7	160	5.4	115
I05549	10.1	4.1	158	5.7	115
MEAN	10.2	5.3	156	5.3	111
S.D.	.68	.84	6.8	.56	5.0
N	6	6	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day		
I05537	9.2	4.2	148	3.9	106
I05541	10.9	4.2	163	6.1	114
I05547	9.1	5.0	149	4.5	110
I05550	9.4	4.3	149	4.5	107
MEAN	9.6	4.4	152	4.8	109
S.D.	.84	.39	7.2	.94	3.6
N	4	4	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05532	9.7	5.4	155	4.8	110
I05538	9.6	3.3	149	4.4	108
I05539	9.8	5.8	155	5.1	110
I05545	9.9	3.7	156	5.1	112
I05548	9.6	4.6	151	5.0	113
I05552	10.0	5.9	158	5.5	110
MEAN	9.8	4.8	154	5.0	110
S.D.	.16	1.10	3.3	.37	1.8
N	6	6	6	6	6

3M_MN03279517

Appendix 4

Individual Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	9.3	4.7	148	4.3	109
I05534	10.8	5.3	160	6.6	113
I05536	10.9	5.3	162	5.9	112
I05540	9.9	4.4	155	5.0	106
I05542	11.0	6.6	158	5.7	107
I05551	10.0	5.0	155	4.9	113
MEAN	10.3	5.2	156	5.4	110
S.D.	.69	.76	4.9	.82	3.1
N	6	6	6	6	6

3M_MN03279518

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	59	12	1.1	7.9	4.6	3.3	.6	11	112	43	49
I05526	55	19	1.0	8.2	4.7	3.5	.4	13	152	44	67
MEAN	57	16	1.0	8.0	4.6	3.4	.5	12	132	44	58
S.D.	2.8	4.9	.07	.21	.07	.14	.14	1.4	28.3	.7	12.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	61	17	.8	8.7	5.1	3.6	.8	16	184	37	75
I05523	78	17	1.0	9.3	5.1	4.2	.5	16	131	41	47
MEAN	70	17	.9	9.0	5.1	3.9	.6	16	158	39	61
S.D.	12.0	.0	.14	.42	.00	.42	.21	.0	37.5	2.8	19.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	70	13	1.0	8.7	4.3	4.4	.6	12	140	46	33
I05522	76	16	1.1	8.7	4.8	3.9	.6	17	134	92	22
MEAN	73	14	1.0	8.7	4.6	4.2	.6	14	137	69	28
S.D.	4.2	2.1	.07	.00	.35	.35	.00	3.5	4.2	32.5	7.8
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279519

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	19	23	709	62	3	84	400	30	292
I05526	24	28	1156	237	4	194	276	41	209
MEAN	22	26	932	150	4	139	338	36	250
S.D.	3.5	3.5	316.1	123.7	.7	77.8	87.7	7.8	58.7
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	43	45	917	186	11	177	424	48	244
I05523	31	42	669	89	13	146	484	45	332
MEAN	37	44	793	138	12	162	454	46	288
S.D.	8.5	2.1	175.4	68.6	1.4	21.9	42.4	2.1	62.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	36	28	538	127	1	177	543	23	362
I05522	29	68	499	159	2	223	467	53	329
MEAN	32	48	518	143	2	200	505	38	346
S.D.	4.9	28.3	27.6	22.6	.7	32.5	53.7	21.2	23.3
N	2	2	2	2	2	2	2	2	2

3M_MN03279520

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	9.6	5.5	150	4.6	112
I05526	10.4	7.1	154	5.3	110
MEAN	10.0	6.3	152	5.0	111
S.D.	.57	1.13	2.8	.49	1.4
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.5	6.6	156	5.5	110
I05523	10.4	6.6	154	5.1	106
MEAN	11.0	6.6	155	5.3	108
S.D.	.78	.00	1.4	.28	2.8
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	10.6	5.4	157	5.4	112
I05522	10.9	7.0	161	5.5	110
MEAN	10.8	6.2	159	5.4	111
S.D.	.21	1.13	2.8	.07	1.4
N	2	2	2	2	2

3M_MN03279521

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	51	19	.7	8.3	4.4	3.9	.7	13	86	108	33
I05549	67	12	.9	8.9	4.7	4.2	.1	15	152	37	74
MEAN	59	16	.8	8.6	4.6	4.0	.4	14	119	72	54
S.D.	11.3	4.9	.14	.42	.21	.21	.42	1.4	46.7	50.2	29.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	76	19	1.0	8.6	4.1	4.5	.6	14	142	59	61
I05552	77	16	1.0	8.8	4.0	4.8	.6	13	148	52	26
MEAN	76	18	1.0	8.7	4.0	4.6	.6	14	145	56	44
S.D.	.7	2.1	.00	.14	.07	.21	.00	.7	4.2	4.9	24.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	82	21	1.1	9.6	5.0	4.6	.6	14	135	62	25
I05542	68	25	.8	9.0	4.2	4.8	.5	24	131	93	42
MEAN	75	23	1.0	9.3	4.6	4.7	.6	19	133	78	34
S.D.	9.9	2.8	.21	.42	.57	.14	.07	7.1	2.8	21.9	12.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279522

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	35	120	161	81	4	157	377	26	257
I05549	34	86	208	41	5	117	309	0	232
MEAN	34	103	184	61	4	137	343	13	244
S.D.	.7	24.0	33.2	28.3	.7	28.3	48.1	18.4	17.7
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	19	43	113	69	1	117	313	48	235
I05552	33	54	251	72	7	1197	658	17	466
MEAN	26	48	182	70	4	657	486	32	350
S.D.	9.9	7.8	97.6	2.1	4.2	763.7	244.0	21.9	163.3
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	23	38	241	121	2	144	394	35	289
I05542	23	61	200	68	5	186	296	41	222
MEAN	23	50	220	94	4	165	345	38	256
S.D.	.0	16.3	29.0	37.5	2.1	29.7	69.3	4.2	47.4
N	2	2	2	2	2	2	2	2	2

3M_MN03279523

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.7	5.9	145	5.0	103
I05549	9.9	3.7	152	5.9	112
MEAN	9.8	4.8	148	5.4	108
S.D.	.14	1.56	4.9	.64	6.4
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.9	5.7	155	5.5	112
I05552	9.7	5.3	150	5.5	109
MEAN	9.8	5.5	152	5.5	110
S.D.	.14	.28	3.5	.00	2.1
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.4	5.4	152	5.2	111
I05542	10.2	6.3	152	4.9	108
MEAN	10.3	5.8	152	5.0	110
S.D.	.14	.64	.0	.21	2.1
N	2	2	2	2	2

3M_MN03279524

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	116	15	1.2	8.8	4.9	3.9	.5	8	114	28	73
I05526	86	17	1.0	8.6	4.8	3.8	.4	9	155	38	81
MEAN	101	16	1.1	8.7	4.8	3.8	.4	8	134	33	77
S.D.	21.2	1.4	.14	.14	.07	.07	.07	.7	29.0	7.1	5.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	79	17	1.2	9.1	5.3	3.8	.8	5	193	44	103
I05523	83	17	1.0	8.9	5.2	3.7	.4	11	128	52	65
MEAN	81	17	1.1	9.0	5.2	3.8	.6	8	160	48	84
S.D.	2.8	.0	.14	.14	.07	.07	.28	4.2	46.0	5.7	26.9
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	61	16	1.0	8.6	4.4	4.2	.4	7	132	56	54
I05522	84	18	1.0	9.1	4.9	4.2	.4	15	139	71	51
MEAN	72	17	1.0	8.8	4.6	4.2	.4	11	136	64	52
S.D.	16.3	1.4	.00	.35	.35	.00	.00	5.7	4.9	10.6	2.1
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279525

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	24	27	664	68	2	145	409	33	306
I05526	30	28	1137	220	6	209	307	52	234
MEAN	27	28	900	144	4	177	358	42	270
S.D.	4.2	.7	334.5	107.5	2.8	45.3	72.1	13.4	50.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	49	40	882	186	6	189	422	22	241
I05523	19	40	793	98	1	124	503	52	353
MEAN	34	40	838	142	4	156	462	37	297
S.D.	21.2	.0	62.9	62.2	3.5	46.0	57.3	21.2	79.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	42	33	736	156	1	178	628	17	410
I05522	49	73	625	176	6	336	460	48	333
MEAN	46	53	680	166	4	257	544	32	372
S.D.	4.9	28.3	78.5	14.1	3.5	111.7	118.8	21.9	54.4
N	2	2	2	2	2	2	2	2	2

3M_MN03279526

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	9.9	6.2	152	5.0	117
I05526	10.4	7.1	157	5.0	117
MEAN	10.2	6.6	154	5.0	117
S.D.	.35	.64	3.5	.00	.0
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.3	6.5	160	5.2	118
I05523	10.5	6.8	159	5.1	116
MEAN	10.9	6.6	160	5.2	117
S.D.	.57	.21	.7	.07	1.4
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	10.4	6.2	159	5.0	118
I05522	11.3	7.8	164	5.4	114
MEAN	10.8	7.0	162	5.2	116
S.D.	.64	1.13	3.5	.28	2.8
N	2	2	2	2	2

3M_MN03279527

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	48	20	.7	8.5	4.5	4.0	.8	8	94	61	52
I05549	68	15	1.2	9.4	4.7	4.7	.3	10	168	53	88
MEAN	58	18	1.0	9.0	4.6	4.4	.6	9	131	57	70
S.D.	14.1	3.5	.35	.64	.14	.49	.35	1.4	52.3	5.7	25.5
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	83	19	1.1	8.8	4.0	4.8	.5	12	163	72	91
I05552	91	21	.9	9.2	4.2	5.0	.3	10	138	70	52
MEAN	87	20	1.0	9.0	4.1	4.9	.4	11	150	71	72
S.D.	5.7	1.4	.14	.28	.14	.14	.14	1.4	17.7	1.4	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	92	22	1.3	9.8	5.0	4.8	.2	19	151	61	54
I05542	91	22	1.2	9.0	4.4	4.6	.3	11	147	129	73
MEAN	92	22	1.2	9.4	4.7	4.7	.2	15	149	95	64
S.D.	.7	.0	.07	.57	.42	.14	.07	5.7	2.8	48.1	13.4
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279528

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	42	158	160	73	2	204	363	21	261
I05549	29	74	203	44	3	132	295	0	222
MEAN	36	116	182	58	2	168	329	10	242
S.D.	9.2	59.4	30.4	20.5	.7	50.9	48.1	14.8	27.6
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	24	61	113	77	1	120	311	46	235
I05552	37	71	262	83	5	663	654	21	458
MEAN	30	66	188	80	3	392	482	34	346
S.D.	9.2	7.1	105.4	4.2	2.8	384.0	242.5	17.7	157.7
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	28	41	249	121	2	168	385	113	289
I05542	22	39	224	74	1	129	277	19	212
MEAN	25	40	236	98	2	148	331	66	250
S.D.	4.2	1.4	17.7	33.2	.7	27.6	76.4	66.5	54.4
N	2	2	2	2	2	2	2	2	2

3M_MN03279529

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.6	4.8	147	4.5	111
I05549	9.8	4.4	153	4.8	118
MEAN	9.7	4.6	150	4.6	114
S.D.	.14	.28	4.2	.21	4.9
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.5	5.6	148	4.9	117
I05552	10.2	5.2	155	5.9	120
MEAN	9.8	5.4	152	5.4	118
S.D.	.49	.28	4.9	.71	2.1
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.2	4.9	155	4.8	116
I05542	11.0	5.9	166	6.2	125
MEAN	10.6	5.4	160	5.5	120
S.D.	.57	.71	7.8	.99	6.4
N	2	2	2	2	2

3M_MN03279530

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	80	13	1.3	8.8	4.8	4.0	.7	3	112	25	54
I05526	54	18	1.1	8.2	4.6	3.6	.1	2	149	47	75
MEAN	67	16	1.2	8.5	4.7	3.8	.4	2	130	36	64
S.D.	18.4	3.5	.14	.42	.14	.28	.42	.7	26.2	15.6	14.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	76	18	.9	9.0	5.2	3.8	.5	11	203	38	94
I05523	72	20	1.1	8.7	4.9	3.8	.3	7	132	57	57
MEAN	74	19	1.0	8.8	5.0	3.8	.4	9	168	48	76
S.D.	2.8	1.4	.14	.21	.21	.00	.14	2.8	50.2	13.4	26.2
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	63	20	1.0	8.8	4.5	4.3	.4	5	135	58	45
I05522	76	15	1.3	8.9	5.1	3.8	.2	10	143	91	35
MEAN	70	18	1.2	8.8	4.8	4.0	.3	8	139	74	40
S.D.	9.2	3.5	.21	.07	.42	.35	.14	3.5	5.7	23.3	7.1
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279531

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	19	31	552	60	4	151	368	31	277
I05526	37	39	1131	188	10	201	267	41	201
MEAN	28	35	842	124	7	176	318	36	239
S.D.	12.7	5.7	409.4	90.5	4.2	35.4	71.4	7.1	53.7
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	31	42	925	195	2	157	414	41	232
I05523	22	36	776	96	6	125	475	37	338
MEAN	26	39	850	146	4	141	444	39	285
S.D.	6.4	4.2	105.4	70.0	2.8	22.6	43.1	2.8	75.0
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	41	39	821	158	3	167	572	18	377
I05522	36	69	557	169	4	294	453	52	331
MEAN	38	54	689	164	4	230	512	35	354
S.D.	3.5	21.2	186.7	7.8	.7	89.8	84.1	24.0	32.5
N	2	2	2	2	2	2	2	2	2

3M_MN03279532

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	10.3	5.2	157	5.9	116
I05526	10.0	6.8	150	5.6	115
MEAN	10.2	6.0	154	5.8	116
S.D.	.21	1.13	4.9	.21	.7
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	12.0	6.2	164	5.9	123
I05523	10.3	6.5	154	5.4	114
MEAN	11.2	6.4	159	5.6	118
S.D.	1.20	.21	7.1	.35	6.4
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	10.8	5.7	158	5.4	115
I05522	11.6	7.0	163	5.9	112
MEAN	11.2	6.4	160	5.6	114
S.D.	.57	.92	3.5	.35	2.1
N	2	2	2	2	2

3M_MN03279533

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	45	23	.8	8.1	4.2	3.9	1.0	7	88	42	43
I05549	67	16	.8	9.3	4.6	4.7	.2	10	170	53	80
MEAN	56	20	.8	8.7	4.4	4.3	.6	8	129	48	62
S.D.	15.6	4.9	.00	.85	.28	.57	.57	2.1	58.0	7.8	26.2
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	78	19	.8	8.7	4.0	4.7	.5	5	148	67	68
I05552	71	23	1.0	9.1	4.0	5.1	.2	5	139	51	36
MEAN	74	21	.9	8.9	4.0	4.9	.4	5	144	59	52
S.D.	4.9	2.8	.14	.28	.00	.28	.21	.0	6.4	11.3	22.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	95	20	.9	9.2	4.7	4.5	.1	4	145	47	53
I05542	90	26	1.1	8.7	4.1	4.6	.1	7	144	92	59
MEAN	92	23	1.0	9.0	4.4	4.6	.1	6	144	70	56
S.D.	3.5	4.2	.14	.35	.42	.07	.00	2.1	.7	31.8	4.2
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279534

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	47	128	138	70	2	167	328	18	232
I05549	33	79	188	45	4	435	290	0	218
MEAN	40	104	163	58	3	301	309	9	225
S.D.	9.9	34.6	35.4	17.7	1.4	189.5	26.9	12.7	9.9
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	27	60	105	77	4	113	287	50	214
I05552	47	57	238	76	14	2316	649	98	465
MEAN	37	58	172	76	9	1214	468	74	340
S.D.	14.1	2.1	94.0	.7	7.1	1557.8	256.0	33.9	177.5
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	42	51	244	108	6	165	396	34	295
I05542	16	36	208	66	4	120	235	31	177
MEAN	29	44	226	87	5	142	316	32	236
S.D.	18.4	10.6	25.5	29.7	1.4	31.8	113.8	2.1	83.4
N	2	2	2	2	2	2	2	2	2

3M_MN03279535

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.3	4.6	144	4.3	107
I05549	10.4	4.2	155	5.6	114
MEAN	9.8	4.4	150	5.0	110
S.D.	.78	.28	7.8	.92	4.9
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.5	5.3	152	5.4	115
I05552	9.5	5.2	148	4.1	107
MEAN	9.5	5.2	150	4.8	111
S.D.	.00	.07	2.8	.92	5.7
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.4	5.8	154	6.1	121
I05542	10.4	4.6	157	6.0	117
MEAN	10.4	5.2	156	6.0	119
S.D.	.00	.85	2.1	.07	2.8
N	2	2	2	2	2

3M_MN03279536

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	74	19	1.3	8.5	4.7	3.8	.8	5	109	67	57
I05526	68	16	1.2	8.6	4.9	3.7	.0	6	158	36	81
MEAN	71	18	1.2	8.6	4.8	3.8	.4	6	134	52	69
S.D.	4.2	2.1	.07	.07	.14	.07	.57	.7	34.6	21.9	17.0
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	45	26	1.3	9.0	5.2	3.8	1.2	8	209	48	91
I05523	78	30	1.6	8.4	5.0	3.4	.2	6	117	74	54
MEAN	62	28	1.4	8.7	5.1	3.6	.7	7	163	61	72
S.D.	23.3	2.8	.21	.42	.14	.28	.71	1.4	65.1	18.4	26.2
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	55	18	1.2	8.2	4.4	3.8	.6	6	137	54	44
I05522	76	19	1.7	8.9	5.0	3.9	.2	9	136	127	34
MEAN	66	18	1.4	8.6	4.7	3.8	.4	8	136	90	39
S.D.	14.8	.7	.35	.49	.42	.07	.28	2.1	.7	51.6	7.1
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279537

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	34	34	499	50	3	860	512	90	380
I05526	42	43	1046	199	5	1071	462	98	352
MEAN	38	38	772	124	4	966	487	94	366
S.D.	5.7	6.4	386.8	105.4	1.4	149.2	35.4	5.7	19.8
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	60	63	995	189	6	515	1618	871	1193
I05523	46	73	770	92	6	624	976	549	731
MEAN	53	68	882	140	6	570	1297	710	962
S.D.	9.9	7.1	159.1	68.6	.0	77.1	454.0	227.7	326.7
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	76	59	844	156	3	787	727	36	503
I05522	46	92	573	158	1	1308	523	25	382
MEAN	61	76	708	157	2	1048	625	30	442
S.D.	21.2	23.3	191.6	1.4	1.4	368.4	144.2	7.8	85.6
N	2	2	2	2	2	2	2	2	2

3M_MN03279538

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	10.1	5.0	148	4.9	107
I05526	10.8	5.8	153	5.1	106
MEAN	10.4	5.4	150	5.0	106
S.D.	.49	.57	3.5	.14	.7
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.6	6.3	154	5.1	104
I05523	10.3	5.4	154	5.0	108
MEAN	11.0	5.8	154	5.0	106
S.D.	.92	.64	.0	.07	2.8
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	9.9	5.0	151	5.1	108
I05522	11.2	6.6	158	5.6	108
MEAN	10.6	5.8	154	5.4	108
S.D.	.92	1.13	4.9	.35	.0
N	2	2	2	2	2

3M_MN03279539

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	44	16	1.4	8.4	4.4	4.0	.9	6	89	48	41
I05549	64	14	1.1	8.5	4.3	4.2	.1	13	148	36	74
MEAN	54	15	1.2	8.4	4.4	4.1	.5	10	118	42	58
S.D.	14.1	1.4	.21	.07	.07	.14	.57	4.9	41.7	8.5	23.3
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	69	27	1.4	8.2	3.8	4.4	.5	11	141	102	74
I05552	58	28	1.2	9.3	4.0	5.3	.5	6	154	69	46
MEAN	64	28	1.3	8.8	3.9	4.8	.5	8	148	86	60
S.D.	7.8	.7	.14	.78	.14	.64	.00	3.5	9.2	23.3	19.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	86	25	1.6	9.1	4.6	4.5	.1	8	139	68	60
I05542	84	12	1.4	8.2	4.0	4.2	.0	5	119	81	60
MEAN	85	18	1.5	8.7	4.3	4.4	.0	6	129	74	60
S.D.	1.4	9.2	.14	.64	.42	.21	.07	2.1	14.1	9.2	.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279540

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	66	97	143	82	2	1212	390	0	277
I05549	46	77	169	39	5	1024	342	0	260
MEAN	56	87	156	60	4	1118	366	0	268
S.D.	14.1	14.1	18.4	30.4	2.1	132.9	33.9	.0	12.0
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	36	71	114	67	4	602	386	63	288
I05552	60	85	205	79	9	1513	722	83	524
MEAN	48	78	160	73	6	1058	554	73	406
S.D.	17.0	9.9	64.3	8.5	3.5	644.2	237.6	14.1	166.9
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	43	70	250	105	2	1471	448	33	337
I05542	46	155	220	55	1	659	450	94	339
MEAN	44	112	235	80	2	1065	449	64	338
S.D.	2.1	60.1	21.2	35.4	.7	574.2	1.4	43.1	1.4
N	2	2	2	2	2	2	2	2	2

3M_MN03279541

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.8	5.0	146	5.1	100
I05549	9.6	4.4	148	4.8	107
MEAN	9.7	4.7	147	5.0	104
S.D.	.14	.42	1.4	.21	4.9
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.4	4.8	148	5.2	107
I05552	10.2	5.5	154	5.1	109
MEAN	9.8	5.2	151	5.2	108
S.D.	.57	.49	4.2	.07	1.4
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.3	4.4	154	5.2	109
I05542	10.3	4.1	158	5.8	111
MEAN	10.3	4.2	156	5.5	110
S.D.	.00	.21	2.8	.42	1.4
N	2	2	2	2	2

3M_MN03279542

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	74	17	1.3	8.9	5.0	3.9	.7	5	105	35	51
I05526	71	24	1.3	8.9	5.3	3.6	.3	6	148	46	71
MEAN	72	20	1.3	8.9	5.2	3.8	.5	6	126	40	61
S.D.	2.1	4.9	.00	.00	.21	.21	.28	.7	30.4	7.8	14.1
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	73	23	1.2	9.0	5.4	3.6	1.1	7	206	33	93
I05523	76	28	1.1	8.1	4.9	3.2	.5	6	127	64	54
MEAN	74	26	1.2	8.6	5.2	3.4	.8	6	166	48	74
S.D.	2.1	3.5	.07	.64	.35	.28	.42	.7	55.9	21.9	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	63	19	1.1	8.3	4.5	3.8	.6	6	116	36	41
I05522	76	17	1.3	8.5	5.0	3.5	.3	3	122	66	34
MEAN	70	18	1.2	8.4	4.8	3.6	.4	4	119	51	38
S.D.	9.2	1.4	.14	.14	.35	.21	.21	2.1	4.2	21.2	4.9
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279543

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	46	45	387	53	3	2123	388	38	298
I05526	53	38	1040	222	8	2151	363	37	246
MEAN	50	42	714	138	6	2137	376	38	272
S.D.	4.9	4.9	461.7	119.5	3.5	19.8	17.7	.7	36.8
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	64	63	915	188	9	1243	1640	793	1207
I05523	55	70	725	98	8	1747	948	365	710
MEAN	60	66	820	143	8	1495	1294	579	958
S.D.	6.4	4.9	134.4	63.6	.7	356.4	489.3	302.6	351.4
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	62	48	765	154	6	617	616	35	414
I05522	58	84	479	156	2	2004	415	31	302
MEAN	60	66	622	155	4	1310	516	33	358
S.D.	2.8	25.5	202.2	1.4	2.8	980.8	142.1	2.8	79.2
N	2	2	2	2	2	2	2	2	2

3M_MN03279544

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	10.3	4.2	154	5.3	111
I05526	11.0	5.2	157	5.5	111
MEAN	10.6	4.7	156	5.4	111
S.D.	.49	.71	2.1	.14	.0
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.9	5.7	160	5.8	113
I05523	9.9	5.5	150	5.1	109
MEAN	10.9	5.6	155	5.4	111
S.D.	1.41	.14	7.1	.49	2.8
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	10.2	5.2	153	5.9	113
I05522	10.9	4.6	156	5.0	108
MEAN	10.6	4.9	154	5.4	110
S.D.	.49	.42	2.1	.64	3.5
N	2	2	2	2	2

3M_MN03279545

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	54	21	.9	8.9	4.7	4.2	1.1	5	112	56	40
I05549	56	18	1.1	9.0	4.7	4.3	.4	6	162	42	79
MEAN	55	20	1.0	9.0	4.7	4.2	.8	6	137	49	60
S.D.	1.4	2.1	.14	.07	.00	.07	.49	.7	35.4	9.9	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	66	22	1.1	8.3	3.8	4.5	.8	6	136	66	71
I05552	80	26	1.0	9.1	4.0	5.1	.7	6	138	43	36
MEAN	73	24	1.0	8.7	3.9	4.8	.8	6	137	54	54
S.D.	9.9	2.8	.07	.57	.14	.42	.07	.0	1.4	16.3	24.7
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	91	21	1.2	9.2	4.9	4.3	.3	13	152	55	55
I05542	85	25	1.1	8.1	4.0	4.1	.4	5	131	95	66
MEAN	88	23	1.2	8.7	4.4	4.2	.4	9	142	75	60
S.D.	4.2	2.8	.07	.78	.64	.14	.07	5.7	14.8	28.3	7.8
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279546

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	110	297	157	109	7	2978	459	33	336
I05549	61	106	167	45	5	1838	338	0	265
MEAN	86	202	162	77	6	2408	398	16	300
S.D.	34.6	135.1	7.1	45.3	1.4	806.1	85.6	23.3	50.2
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	37	61	109	78	8	733	304	42	231
I05552	62	95	188	80	15	1009	630	52	459
MEAN	50	78	148	79	12	871	467	47	345
S.D.	17.7	24.0	55.9	1.4	4.9	195.2	230.5	7.1	161.2
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	67	78	243	117	5	2353	527	47	412
I05542	45	83	213	56	3	1241	431	47	329
MEAN	56	80	228	86	4	1797	479	47	370
S.D.	15.6	3.5	21.2	43.1	1.4	786.3	67.9	.0	58.7
N	2	2	2	2	2	2	2	2	2

3M_MN03279547

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.7	5.6	144	4.3	103
I05549	10.1	4.2	151	5.6	109
MEAN	9.9	4.9	148	5.0	106
S.D.	.28	.99	4.9	.92	4.2
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.0	4.8	146	4.9	108
I05552	9.9	4.7	151	5.9	111
MEAN	9.4	4.8	148	5.4	110
S.D.	.64	.07	3.5	.71	2.1
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.5	4.6	153	5.3	111
I05542	10.0	4.3	157	5.6	113
MEAN	10.2	4.4	155	5.4	112
S.D.	.35	.21	2.8	.21	1.4
N	2	2	2	2	2

3M_MN03279548

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	80	12	1.2	8.9	5.2	3.7	.8	3	122	31	56
I05526	68	16	1.2	8.5	4.9	3.6	.3	3	142	32	61
MEAN	74	14	1.2	8.7	5.0	3.6	.6	3	132	32	58
S.D.	8.5	2.8	.00	.28	.21	.07	.35	.0	14.1	.7	3.5
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	88	15	1.2	9.3	5.4	3.9	.6	5	216	39	106
I05523	94	17	1.1	8.9	5.5	3.4	.3	6	139	43	55
MEAN	91	16	1.2	9.1	5.4	3.6	.4	6	178	41	80
S.D.	4.2	1.4	.07	.28	.07	.35	.21	.7	54.4	2.8	36.1
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	64	13	1.0	8.5	4.5	4.0	.8	4	122	37	44
I05522	75	14	1.3	9.3	5.4	3.9	.3	3	114	81	26
MEAN	70	14	1.2	8.9	5.0	4.0	.6	4	118	59	35
S.D.	7.8	.7	.21	.57	.64	.07	.35	.7	5.7	31.1	12.7
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279549

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	19	21	394	59	2	77	319	11	246
I05526	29	26	847	189	10	126	276	21	220
MEAN	24	24	620	124	6	102	298	16	233
S.D.	7.1	3.5	320.3	91.9	5.7	34.6	30.4	7.1	18.4
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	29	46	971	198	2	163	413	14	235
I05523	21	45	771	101	1	119	487	17	353
MEAN	25	46	871	150	2	141	450	16	294
S.D.	5.7	.7	141.4	68.6	.7	31.1	52.3	2.1	83.4
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	37	32	458	129	1	179	480	20	326
I05522	30	50	379	148	0	225	364	13	263
MEAN	34	41	418	138	0	202	422	16	294
S.D.	4.9	12.7	55.9	13.4	.7	32.5	82.0	4.9	44.5
N	2	2	2	2	2	2	2	2	2

3M_MN03279550

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	10.4	5.7	156	5.7	113
I05526	10.1	6.4	150	5.1	109
MEAN	10.2	6.0	153	5.4	111
S.D.	.21	.49	4.2	.42	2.8
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	12.6	6.6	167	6.3	118
I05523	10.9	7.2	161	5.6	113
MEAN	11.8	6.9	164	6.0	116
S.D.	1.20	.42	4.2	.49	3.5
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	10.0	3.9	152	4.6	113
I05522	11.1	6.7	158	5.4	109
MEAN	10.6	5.3	155	5.0	111
S.D.	.78	1.98	4.2	.57	2.8
N	2	2	2	2	2

3M_MN03279551

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	48	17	.9	8.3	4.6	3.7	1.0	7	99	60	34
I05549	79	17	1.0	8.7	4.6	4.1	.3	4	142	52	67
MEAN	64	17	1.0	8.5	4.6	3.9	.6	6	120	56	50
S.D.	21.9	.0	.07	.28	.00	.28	.49	2.1	30.4	5.7	23.3
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	79	16	1.0	8.4	4.1	4.3	.6	4	144	83	58
I05552	78	18	.9	9.0	4.1	4.9	.5	6	144	59	36
MEAN	78	17	1.0	8.7	4.1	4.6	.6	5	144	71	47
S.D.	.7	1.4	.07	.42	.00	.42	.07	1.4	.0	17.0	15.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	98	17	1.1	9.1	4.9	4.2	.2	5	137	42	55
I05542	101	21	1.0	8.2	4.1	4.1	.3	3	139	114	72
MEAN	100	19	1.0	8.7	4.5	4.2	.2	4	138	78	64
S.D.	2.1	2.8	.07	.64	.57	.07	.07	1.4	1.4	50.9	12.0
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279552

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	56	183	139	96	6	200	293	9	216
I05549	30	85	174	49	3	244	244	12	192
MEAN	43	134	156	72	4	222	268	10	204
S.D.	18.4	69.3	24.7	33.2	2.1	31.1	34.6	2.1	17.0
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	25	34	94	76	4	112	242	15	189
I05552	40	66	186	81	10	254	436	11	312
MEAN	32	50	140	78	7	183	339	13	250
S.D.	10.6	22.6	65.1	3.5	4.2	100.4	137.2	2.8	87.0
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	25	64	248	124	0	134	360	13	277
I05542	25	43	216	63	3	114	233	23	183
MEAN	25	54	232	94	2	124	296	18	230
S.D.	.0	14.8	22.6	43.1	2.1	14.1	89.8	7.1	66.5
N	2	2	2	2	2	2	2	2	2

3M_MN03279553

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	9.6	4.9	144	4.9	105
I05549	10.2	5.4	152	5.1	110
MEAN	9.9	5.2	148	5.0	108
S.D.	.42	.35	5.7	.14	3.5
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.5	5.3	151	5.4	111
I05552	10.1	5.0	153	5.9	112
MEAN	9.8	5.2	152	5.6	112
S.D.	.42	.21	1.4	.35	.7
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.3	5.1	155	5.6	114
I05542	10.5	5.6	154	6.8	118
MEAN	10.4	5.4	154	6.2	116
S.D.	.14	.35	.7	.85	2.8
N	2	2	2	2	2

3M_MN03279554

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05520	79	14	1.2	8.7	4.6	4.1	.5	6	119	30	63
I05526	86	18	1.3	8.9	4.8	4.1	.2	5	150	32	77
MEAN	82	16	1.2	8.8	4.7	4.1	.4	6	134	31	70
S.D.	4.9	2.8	.07	.14	.14	.00	.21	.7	21.9	1.4	9.9
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05505	77	19	1.2	8.6	4.9	3.7	.6	5	200	31	114
I05523	81	19	1.1	9.0	5.3	3.7	.3	3	132	40	69
MEAN	79	19	1.2	8.8	5.1	3.7	.4	4	166	36	92
S.D.	2.8	.0	.07	.28	.28	.00	.21	1.4	48.1	6.4	31.8
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05511	75	16	1.4	9.5	5.0	4.5	.8	4	145	37	67
I05522	83	16	1.4	9.3	5.2	4.1	.3	10	132	52	47
MEAN	79	16	1.4	9.4	5.1	4.3	.6	7	138	44	57
S.D.	5.7	.0	.00	.14	.14	.28	.35	4.2	9.2	10.6	14.1
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279555

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	19	20	309	49	1	78	265	10	203
I05526	28	30	701	183	19	144	259	17	201
MEAN	24	25	505	116	10	111	262	14	202
S.D.	6.4	7.1	277.2	94.8	12.7	46.7	4.2	4.9	1.4
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	31	36	846	178	1	130	357	12	206
I05523	30	33	662	93	5	212	446	13	321
MEAN	30	34	754	136	3	171	402	12	264
S.D.	.7	2.1	130.1	60.1	2.8	58.0	62.9	.7	81.3
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	45	37	467	149	0	165	519	22	334
I05522	27	42	342	147	0	165	362	11	260
MEAN	36	40	404	148	0	165	440	16	297
S.D.	12.7	3.5	88.4	1.4	.0	.0	111.0	7.8	52.3
N	2	2	2	2	2	2	2	2	2

3M_MN03279556

APPENDIX 4

Individual Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05520	10.8	6.5	162	6.4	120
I05526	10.5	6.6	157	5.6	111
MEAN	10.6	6.6	160	6.0	116
S.D.	.21	.07	3.5	.57	6.4
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05505	11.4	6.3	164	5.8	117
I05523	11.0	7.6	169	6.9	122
MEAN	11.2	7.0	166	6.4	120
S.D.	.28	.92	3.5	.78	3.5
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05511	12.0	5.4	174	6.0	121
I05522	11.8	6.2	169	6.2	116
MEAN	11.9	5.8	172	6.1	118
S.D.	.14	.57	3.5	.14	3.5
N	2	2	2	2	2

3M_MN03279557

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day								
I05529	67	17	.9	8.2	4.4	3.8	.8	6	96	55	44
I05549	53	16	1.0	8.8	4.4	4.4	.3	5	152	51	83
MEAN	60	16	1.0	8.5	4.4	4.1	.6	6	124	53	64
S.D.	9.9	.7	.07	.42	.00	.42	.35	.7	39.6	2.8	27.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day								
I05539	71	19	1.1	8.5	3.9	4.6	.5	5	147	73	86
I05552	74	17	.8	8.2	3.6	4.6	.6	5	129	46	37
MEAN	72	18	1.0	8.4	3.8	4.6	.6	5	138	60	62
S.D.	2.1	1.4	.21	.21	.21	.00	.07	.0	12.7	19.1	34.6
N	2	2	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day								
I05533	100	19	1.2	9.0	4.6	4.4	.3	6	145	40	68
I05542	93	19	1.2	7.9	4.0	3.9	.3	4	147	112	79
MEAN	96	19	1.2	8.4	4.3	4.2	.3	5	146	76	74
S.D.	4.9	.0	.00	.78	.42	.35	.00	1.4	1.4	50.9	7.8
N	2	2	2	2	2	2	2	2	2	2	2

3M_MN03279558

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	53	191	131	93	0	216	316	11	232
I05549	30	49	171	45	0	93	245	12	192
MEAN	42	120	151	69	0	154	280	12	212
S.D.	16.3	100.4	28.3	33.9	.0	87.0	50.2	.7	28.3
N	2	2	2	2	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05539	27	31	96	76	2	80	252	14	195
I05552	26	37	195	82	1	109	454	8	327
MEAN	26	34	146	79	2	94	353	11	261
S.D.	.7	4.2	70.0	4.2	.7	20.5	142.8	4.2	93.3
N	2	2	2	2	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	36	79	240	117	3	164	372	12	286
I05542	19	39	186	61	0	97	250	18	195
MEAN	28	59	213	89	2	130	311	15	240
S.D.	12.0	28.3	38.2	39.6	2.1	47.4	86.3	4.2	64.3
N	2	2	2	2	2	2	2	2	2

3M_MN03279559

APPENDIX 4

Individual Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day		
I05529	10.1	5.2	150	5.1	108
I05549	10.1	5.6	152	5.3	111
MEAN	10.1	5.4	151	5.2	110
S.D.	.00	.28	1.4	.14	2.1
N	2	2	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day		
I05539	9.8	5.4	155	5.4	112
I05552	10.2	4.9	157	6.1	117
MEAN	10.0	5.2	156	5.8	114
S.D.	.28	.35	1.4	.49	3.5
N	2	2	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day		
I05533	10.3	5.9	159	5.6	115
I05542	10.7	5.4	165	6.7	124
MEAN	10.5	5.6	162	6.2	120
S.D.	.28	.35	4.2	.78	6.4
N	2	2	2	2	2

3M_MN03279560

Appendix 4

Individual Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	37.0	1.025	8.0
I05517	28.0	1.032	7.0
I05519	47.0	1.025	8.0
I05520	75.0	1.018	7.5
I05526	32.0	1.030	7.5
I05527	30.0	1.023	6.0
MEAN	41.5	1.026	7.3
S.D.	17.76	.0050	.75
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	67.0	1.019	7.0
I05515	46.0	1.023	7.5
I05516	52.0	1.020	7.0
I05521	45.0	1.023	8.0
MEAN	52.5	1.021	7.4
S.D.	10.15	.0021	.48
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	228.0	1.007	7.0
I05510	52.0	1.025	7.0
I05518	93.0	1.020	7.0
I05523	43.0	1.026	7.0
I05524	46.0	1.025	7.5
I05528	125.0	1.013	7.0
MEAN	97.8	1.019	7.1
S.D.	71.41	.0078	.20
N	6	6	6

3M_MN03279561

Appendix 4

Individual Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	43.0	1.026	7.0
I05507	59.0	1.022	7.5
I05509	68.0	1.018	7.0
I05511	173.0	1.008	7.0
I05512	92.0	1.013	7.5
I05522	66.0	1.022	7.0
MEAN	83.5	1.018	7.2
S.D.	46.63	.0066	.26
N	6	6	6

3M_MN03279562

Appendix 4

Individual Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	0	-	+++	-	+++	-
I05517	10	-	+++	-	-	-
I05519	0	-	-	-	-	-
I05520	0	+	+++	-	-	-
I05526	10	+	+	-	-	-
I05527	0	-	++	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	0	-	-	-	-	-
I05516	10	-	++	-	+	-
I05521	10	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	10	-	-	-	-	-
I05518	30	+	-	-	+++	-
I05523	10	-	-	-	-	-
I05524	10	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	10	-	++	-	+	-
I05507	0	-	-	-	++	-
I05509	10	-	-	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	+	-	+	-
I05522	10	-	-	-	-	-

3M_MN03279563

Appendix 4

Individual Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	0	0	0	3	0	2B4D	0	DK	-
I05517	0	0	2	3	0	2B4D	0	DK	PQ
I05519	0	0	0	3	0	4B4E	0	CL	-
I05520	0	0	1	2	0	4B4D	0	BK	-
I05526	0	0	1	2	0	4B3D	0	CK	-
I05527	0	0	0	1	0	4B3E	0	BK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	0	0	1	3	0	4B2E	0	CK	-
I05515	0	0	0	3	0	4B4D	4E	CL	-
I05516	0	0	0	3	0	4B2D	0	CK	-
I05521	0	0	0	3	0	4B4D	0	BL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	1	2	0	3B	0	BK	-
I05510	0	0	0	3	0	4B4D	4E	BL	-
I05518	0	0	4	3	0	4B	0	DL	-
I05523	0	0	0	3	0	4B2D	0	BL	-
I05524	0	0	0	3	0	3B4D	0	CK	-
I05528	0	0	1	3	0	4B	0	BK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	2	0	1	3	0	2B2D	0	CK	-
I05507	0	1	0	3	0	4B4D	0	CL	Q
I05509	0	1	4	3	0	4B1E	0	BK	Q
I05511	0	0	1	3	0	4B	0	BK	Q
I05512	0	0	1	3	0	2B	0	BK	-
I05522	0	1	1	2	0	2B	0	BJ	-

3M_MN03279564

Appendix 4

Individual Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	52.0	1.017	7.0
I05530	100.0	1.020	7.0
I05531	57.0	1.020	7.5
I05535	45.0	1.023	7.0
I05544	240.0	1.007	7.5
I05549	50.0	1.023	8.0
MEAN	90.7	1.018	7.3
S.D.	75.84	.0060	.41
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	225.0	1.007	7.5
I05541	48.0	1.023	7.0
I05547	45.0	1.024	7.0
I05550	52.0	1.023	7.0
MEAN	92.5	1.019	7.1
S.D.	88.38	.0082	.25
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	140.0	1.012	8.0
I05538	61.0	1.023	7.5
I05539	53.0	1.026	8.0
I05545	62.0	1.018	7.0
I05548	64.0	1.020	8.0
I05552	51.0	1.025	8.0
MEAN	71.8	1.021	7.8
S.D.	33.80	.0052	.42
N	6	6	6

3M_MN03279565

Appendix 4

Individual Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	35.0	1.026	7.5
I05534	59.0	1.024	8.0
I05536	64.0	1.023	7.5
I05540	247.0	1.007	7.0
I05542	72.0	1.019	7.0
I05551	51.0	1.021	7.0
MEAN	88.0	1.020	7.3
S.D.	78.91	.0068	.41
N	6	6	6

3M_MN03279566

Appendix 4

Individual Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	++	-	-	-
I05530	10	-	-	-	+	-
I05531	0	-	-	-	-	-
I05535	0	-	++	-	-	-
I05544	0	-	-	-	+	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	-	-	+++	-
I05541	0	-	+	-	-	-
I05547	10	-	-	-	++	-
I05550	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	0	-	-	-	-	-
I05538	0	-	+	-	-	-
I05539	10	-	-	-	++	-
I05545	0	-	++	-	-	-
I05548	0	-	+	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+++	-	-	-
I05534	0	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	-	-	-	-
I05542	0	-	-	-	-	-
I05551	0	-	+	-	-	-

3M_MN03279567

Appendix 4

Individual Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	1	1	3	1H	3B4D	0	BK	P
I05530	0	0	0	3	0	4B	0	DL	-
I05531	0	0	1	3	0	4B4D	0	CK	-
I05535	0	0	0	3	0	2B2D	0	CL	-
I05544	0	0	2	3	0	4B	0	AK	-
I05549	0	0	0	1	0	4B1D	1E	BK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	0	0	1	3	0	4B4D	0	BK	-
I05541	0	1	1	3	0	4B2D	0	DL	-
I05547	0	0	0	3	0	2B	0	DL	-
I05550	0	0	1	2	0	4B1E	0	CK	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	0	0	2	2	0	1D4F	0	BJ	-
I05538	0	0	1	2	0	1B1E	1F	CK	-
I05539	0	0	1	3	0	4B	0	CK	-
I05545	0	0	1	2	0	4B	0	CK	P
I05548	0	0	0	3	0	2B	0	CL	-
I05552	0	0	2	3	0	4B	0	CL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	1	2	3	0	2B4D	0	DK	-
I05534	0	0	1	2	0	4B4D	0	CL	-
I05536	0	0	1	3	0	3B3D	0	CL	-
I05540	0	0	4	3	0	0	0	AK	-
I05542	0	1	1	3	0	4B1E	0	CK	-
I05551	0	0	1	3	0	4B1D	0	CK	-

3M_MN03279568

Appendix 4

Individual Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	56.0	1.023	8.0
I05517	47.0	1.025	7.0
I05519	48.0	1.021	8.0
I05520	66.0	1.013	7.0
I05526	26.0	1.006	7.5
I05527	58.0	1.017	7.5
MEAN	50.2	1.018	7.5
S.D.	13.75	.0071	.45
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	62.0	1.020	7.0
I05515	108.0	1.017	7.5
I05516	38.0	1.028	8.0
I05521	82.0	1.019	7.5
MEAN	72.5	1.021	7.5
S.D.	29.73	.0048	.41
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	307.0	1.002	7.0
I05510	34.0	1.023	7.5
I05518	70.0	1.017	7.5
I05523	54.0	1.019	7.5
I05524	37.0	1.028	7.0
I05528	64.0	1.025	7.0
MEAN	94.3	1.019	7.2
S.D.	105.16	.0092	.27
N	6	6	6

3M_MN03279569

Appendix 4

Individual Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	50.0	1.023	8.0
I05507	52.0	1.026	8.0
I05509	36.0	1.023	8.0
I05511	110.0	1.008	6.5
I05512	146.0	1.007	7.0
I05522	80.0	1.018	6.5
MEAN	79.0	1.018	7.3
S.D.	42.12	.0082	.75
N	6	6	6

3M_MN03279570

Appendix 4

Individual Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	0	-	+	-	-	-
I05517	0	-	++	-	-	-
I05519	0	-	-	-	-	-
I05520	0	-	+++	-	-	-
I05526	0	-	+	-	-	-
I05527	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	0	-	-	-	-	-
I05516	0	-	-	-	-	-
I05521	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	+	-	-	-
I05523	0	-	-	-	-	-
I05524	0	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	0	-	++	-	-	-
I05507	0	-	-	-	-	-
I05509	0	-	-	-	-	-
I05511	0	-	+	-	-	-
I05512	0	-	+	-	-	-
I05522	0	-	+++	-	-	-

3M_MN03279571

Appendix 4

Individual Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	0	0	1	2	0	4D	0	BK	-
I05517	0	0	1	2	0	1D	0	CK	-
I05519	0	0	0	2	0	3E3F	0	BK	-
I05520	0	0	1	1	0	0	0	BJ	P
I05526	0	0	0	1	0	1B1D	0	BJ	-
I05527	0	0	0	1	0	4D	0	BJ	P
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	1	0	1	2	0	2E	0	BK	PQ
I05515	0	0	0	3	0	4B4D	0	BK	P
I05516	0	0	1	2	0	4B1D	0	CK	-
I05521	0	0	0	2	0	4B2D	1E	BL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	0	0	0	1B	0	AJ	Q
I05510	0	0	0	3	0	4D	0	BK	-
I05518	0	0	0	1	0	3D	0	BK	PQ
I05523	0	0	1	2	0	2D3E	0	BK	Q
I05524	0	1	1	1	0	0	0	CK	-
I05528	0	0	0	2	0	4B1E	0	BK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	0	0	1	2	0	0	0	BK	P
I05507	0	0	0	1	0	3B4D	0	BK	Q
I05509	0	0	1	1	0	0	0	BK	Q
I05511	0	0	0	3	0	1B	0	BJ	Q
I05512	0	0	0	3	0	2B	0	BJ	-
I05522	0	0	0	2	0	0	0	BK	PQ

3M_MN03279572

Appendix 4

Individual Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	14.0	1.010	8.5
I05530	20.0	1.003	8.0
I05531	31.0	1.026	8.0
I05535	564.0	1.001	7.5
I05544	38.0	1.020	8.0
I05549	44.0	1.021	8.0
MEAN	118.5	1.014	8.0
S.D.	218.53	.0103	.32
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	170.0	1.011	7.5
I05541	46.0	1.020	8.0
I05547	76.0	1.016	8.0
I05550	55.0	1.024	7.5
MEAN	86.8	1.018	7.8
S.D.	56.91	.0056	.29
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	78.0	1.014	7.5
I05538	186.0	1.006	7.5
I05539	66.0	1.019	7.0
I05545	85.0	1.012	7.5
I05548	47.0	1.024	8.0
I05552	40.0	1.026	7.5
MEAN	83.7	1.017	7.5
S.D.	53.05	.0076	.32
N	6	6	6

3M_MN03279573

Appendix 4

Individual Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	38.0	1.024	8.0
I05534	32.0	1.026	8.5
I05536	44.0	1.028	8.0
I05540	417.0	1.003	8.0
I05542	34.0	1.025	7.0
I05551	36.0	1.026	7.0
MEAN	100.2	1.022	7.8
S.D.	155.27	.0094	.61
N	6	6	6

3M_MN03279574

Appendix 4

Individual Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05530	10	-	-	-	++	-
I05531	0	-	-	-	-	-
I05535	0	-	-	-	+++	-
I05544	0	-	+	-	-	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	-	-	-	-
I05541	0	-	+	-	-	-
I05547	0	-	-	-	-	-
I05550	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	0	-	-	-	-	-
I05538	0	-	-	-	-	-
I05539	0	-	-	-	-	-
I05545	0	-	-	-	-	-
I05548	0	-	+	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	+	-	+	-
I05534	10	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	-	-	-	-
I05542	0	-	+++	-	-	-
I05551	0	-	-	-	-	-

3M_MN03279575

Appendix 4

Individual Clinical Urinalysis Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	2	1	0	1E2F	0	BJ	P
I05530	0	0	0	3	0	4B	0	BLM	-
I05531	0	1	0	2	0	3B4D	0	CL	-
I05535	0	0	1	1	0	0	0	AK	-
I05544	0	0	0	2	0	3B3D	0	BK	-
I05549	0	1	0	3	0	1E1F	0	BK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	0	0	1	2	0	4B	0	BK	-
I05541	0	0	1	2	0	4B4D	0	BK	-
I05547	0	0	0	1	0	2D	0	BK	P
I05550	0	0	0	1	0	1B	0	BK	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	0	1	1	2	0	4B2E	0	BK	-
I05538	0	0	2	1	0	3B	0	BK	-
I05539	0	0	0	3	0	4B3E	0	BK	-
I05545	0	0	1	3	0	4B4D	0	BL	-
I05548	0	0	0	3	0	3B1D	0	BK	-
I05552	0	0	1	1	0	3B1D	1E	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	1	1	3	0	3B3D	1E	BK	-
I05534	0	0	1	1	0	2B4D	0	BK	P
I05536	0	0	0	1	0	4B1D	3E	BL	-
I05540	0	0	1	2	0	0	0	AK	-
I05542	0	1	1	1	0	3D	0	BK	P
I05551	0	1	1	2	0	4B1D	0	BK	-

3M_MN03279576

Appendix 4

Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	40.0	1.025	8.0
I05517	67.0	1.017	8.0
I05519	54.0	1.017	8.0
I05520	65.0	1.014	7.5
I05526	179.0	1.010	8.0
I05527	60.0	1.022	8.5
MEAN	77.5	1.018	8.0
S.D.	50.66	.0054	.32
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	44.0	1.010	8.5
I05515	69.0	1.020	8.0
I05516	28.0	1.028	7.5
I05521	108.0	1.016	8.0
MEAN	62.2	1.018	8.0
S.D.	34.86	.0076	.41
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	192.0	1.006	8.0
I05510	53.0	1.021	8.0
I05518	82.0	1.014	8.0
I05523	131.0	1.006	7.5
I05524	25.0	1.031	8.0
I05528	84.0	1.014	7.0
MEAN	94.5	1.015	7.8
S.D.	59.43	.0095	.42
N	6	6	6

3M_MN03279577

Appendix 4

Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	50.0	1.020	7.5
I05507	66.0	1.018	8.0
I05509	34.0	1.023	8.0
I05511	107.0	1.009	8.0
I05512	89.0	1.013	7.5
I05522	62.0	1.019	8.5
MEAN	68.0	1.017	7.9
S.D.	26.39	.0051	.38
N	6	6	6

3M_MN03279578

Appendix 4

Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	10	-	++	-	-	-
I05517	10	-	+	-	-	-
I05519	0	-	-	-	-	-
I05520	0	-	+++	-	-	-
I05526	0	-	+	-	-	-
I05527	10	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	10	-	++	-	-	-
I05516	10	-	++	-	-	-
I05521	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	-	-	-	-
I05523	0	-	+	-	+++	-
I05524	10	-	+++	-	-	-
I05528	0	-	+	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	10	-	+++	-	-	-
I05507	10	-	-	-	-	-
I05509	10	-	-	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	+++	-	-	-
I05522	10	-	-	-	+++	-

3M_MN03279579

Appendix 4

Individual Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	0	0	0	3	0	2B3D	0	CK	Q
I05517	0	1	1	2	0	2B2D	0	CK	-
I05519	0	0	1	1	0	2E	0	CK	-
I05520	0	0	1	2	0	2B3D	0	BK	-
I05526	0	0	1	2	0	2B	0	BJ	-
I05527	0	0	1	3	0	2B4D	0	CK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	0	0	1	2	0	2B1E	0	AJ	Q
I05515	0	0	1	3	0	2B4D	0	CK	-
I05516	0	0	1	2	0	4D	0	CK	P
I05521	0	0	0	3	0	3B1D	0	BK	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	1	0	3	0	4B1D	0	AK	Q
I05510	0	0	0	1	0	3B4D	1E	CK	-
I05518	0	0	1	3	0	4B3D	0	BK	-
I05523	0	1	1	2	0	2B	0	AK	-
I05524	0	0	1	2	0	2B4D	0	CK	P
I05528	0	0	1	2	0	3B1E	0	BK	P
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	0	0	1	1	0	4D	0	CK	Q
I05507	0	0	1	2	0	4D	0	CK	PQ
I05509	0	1	1	1	0	0	0	CK	P
I05511	0	0	1	1	0	2B1D	0	BK	Q
I05512	0	0	1	2	0	1D	0	BJ	-
I05522	0	1	0	3	0	1B3D	0	BK	-

3M_MN03279580

Appendix 4

Individual Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	62.0	1.020	8.0
I05530	68.0	1.022	8.5
I05531	31.0	1.024	8.0
I05535	195.0	1.005	8.0
I05544	60.0	1.016	8.0
I05549	30.0	1.026	8.5
MEAN	74.3	1.019	8.2
S.D.	61.32	.0076	.26
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	97.0	1.015	8.0
I05541	18.0	1.028	8.0
I05547	50.0	1.018	7.5
I05550	49.0	1.021	7.0
MEAN	53.5	1.020	7.6
S.D.	32.58	.0056	.48
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	98.0	1.010	7.5
I05538	56.0	1.022	8.0
I05539	47.0	1.022	8.0
I05545	98.0	1.016	8.0
I05548	30.0	1.028	7.5
I05552	45.0	1.020	8.0
MEAN	62.3	1.020	7.8
S.D.	28.86	.0061	.26
N	6	6	6

3M_MN03279581

Appendix 4

Individual Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	45.0	1.020	7.5
I05534	115.0	1.011	8.0
I05536	42.0	1.024	7.5
I05540	158.0	1.010	8.0
I05542	99.0	1.007	7.5
I05551	27.0	1.030	7.0
MEAN	81.0	1.017	7.6
S.D.	51.27	.0091	.38
N	6	6	6

3M_MN03279582

Appendix 4

Individual Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	++++	-	-	-
I05530	10	-	-	-	+++	-
I05531	0	-	+	-	-	-
I05535	0	-	-	-	-	-
I05544	0	-	++	-	-	-
I05549	10	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	10	-	-	-	-	-
I05541	10	-	++++	-	-	-
I05547	10	-	-	-	-	-
I05550	10	-	++++	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	10	-	+	-	-	-
I05538	10	-	-	-	-	-
I05539	10	-	+++	-	-	-
I05545	0	-	-	-	-	-
I05548	10	-	++++	-	-	-
I05552	10	-	+++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+	-	-	-
I05534	0	-	-	-	-	-
I05536	10	-	+	-	-	-
I05540	0	-	-	-	-	-
I05542	0	-	-	-	-	-
I05551	10	-	+++	-	-	-

3M_MN03279583

Appendix 4

Individual Clinical Urinalysis Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	1	2	0	4D	0	CK	P
I05530	1	0	1	3	0	4B	0	CK	-
I05531	0	1	1	2	0	2B3D	0	CK	-
I05535	0	0	1	2	0	0	0	BJ	P
I05544	0	0	1	1	0	4D1E	0	BK	-
I05549	0	0	1	3	0	2B1D	0	CK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	0	0	1	2	0	2B4D	0	BK	P
I05541	0	1	1	3	0	4B4D	0	CK	P
I05547	0	1	1	1	0	4B2D	0	CK	P
I05550	0	1	2	1	0	2D	0	CK	P
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	0	4	2	1	0	0	0	BJ	P
I05538	0	0	1	2	0	3B3D	0	CK	-
I05539	0	1	2	1	0	4D	0	CK	P
I05545	0	0	1	1	0	4B1D	0	BK	-
I05548	0	1	1	3	0	4D	0	CK	P
I05552	0	1	0	2	0	2B2D	0	CK	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	1	1	1	2	0	4B2D	0	CK	-
I05534	0	0	2	3	0	4D	0	BK	P
I05536	0	1	1	1	0	3D1E	0	CK	P
I05540	0	1	1	3	0	1B	0	BK	-
I05542	0	1	1	3	0	2B3D	0	AJ	P
I05551	0	1	1	3	0	2B4D	0	CK	P

3M_MN03279584

Appendix 4

Individual Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	46.0	1.023	8.0
I05517	40.0	1.026	6.0
I05519	60.0	1.017	8.0
I05520	43.0	1.023	7.5
I05526	52.0	1.026	7.5
I05527	44.0	1.031	8.0
MEAN	47.5	1.024	7.5
S.D.	7.31	.0046	.77
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	29.0	1.010	8.0
I05515	66.0	1.017	8.0
I05516	46.0	1.025	7.5
I05521 a	122.0	1.019	7.5
MEAN	65.8	1.018	7.8
S.D.	40.43	.0062	.29
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	241.0	1.005	7.0
I05510	48.0	1.010	7.0
I05518	106.0	1.017	8.0
I05523	72.0	1.010	7.0
I05524	42.0	1.021	7.5
I05528	98.0	1.018	8.0
MEAN	101.2	1.014	7.4
S.D.	73.16	.0061	.49
N	6	6	6

a Sample collected on Day 92.

3M_MN03279585

Appendix 4

Individual Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	42.0	1.021	6.5
I05507	28.0	1.030	8.0
I05509	48.0	1.021	8.0
I05511	70.0	1.017	8.0
I05512	82.0	1.010	6.0
I05522	54.0	1.023	7.0
MEAN	54.0	1.020	7.2
S.D.	19.47	.0066	.88
N	6	6	6

3M_MN03279586

Appendix 4

Individual Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	10	-	-	-	-	-
I05517	10	-	++++	-	-	-
I05519	10	-	+	-	-	-
I05520	10	-	++++	-	-	-
I05526	10	-	+	-	-	-
I05527	10	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	-	-	-	-
I05515	10	-	-	-	-	-
I05516	10	-	-	-	-	-
I05521 a	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	-	-	-	-
I05523	0	-	-	-	-	-
I05524	10	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	10	-	++++	-	-	-
I05507	10	-	-	-	-	-
I05509	0	-	-	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	++	-	-	-
I05522	10	-	-	-	-	-

a Sample collected on Day 92.

3M_MN03279587

Appendix 4

Individual Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	0	0	0	3	0	3D2F	0	CK	-
I05517	0	0	2	3	0	4B	0	CK	P
I05519	0	0	0	3	0	3B1D	1F	BK	-
I05520	0	0	0	3	0	4B4D	1E	BK	-
I05526	0	0	0	2	0	1B4D	0	CK	-
I05527	0	0	0	2	0	4B4D	3E	CL	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	0	0	0	3	0	4B2E	0	BK	Q
I05515	0	0	0	3	0	4B1D	0	BK	-
I05516	0	0	1	3	0	1D	0	CK	-
I05521 a	0	0	0	1	0	4B2E	0	CK	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	1	2	0	0	0	AJ	PQ
I05510	0	1	0	3	0	3B	0	BK	PQ
I05518	0	0	0	3	0	2B1E	0	BL	-
I05523	0	1	0	3	0	4B	0	AK	PQ
I05524	0	0	1	2	0	0	0	CK	P
I05528	0	0	0	2	0	3B2E	1F	BK	Q
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	0	1	1	2	0	0	0	CK	PQ
I05507	0	0	0	1	0	4B4D	1E	CL	-
I05509	0	0	0	3	0	1B	0	BJ	-
I05511	0	0	0	2	0	3B1E	0	BL	Q
I05512	0	0	1	2	0	0	0	BJ	P
I05522	0	0	1	1	0	4D	0	BJ	Q

a Sample collected on Day 92.

3M_MN03279588

Appendix 4

Individual Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	45.0	1.016	8.0
I05530	67.0	1.020	8.0
I05531	62.0	1.019	8.0
I05535	229.0	1.006	8.0
I05544	65.0	1.018	8.0
I05549	92.0	1.012	8.0
MEAN	93.3	1.015	8.0
S.D.	68.15	.0053	.00
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	104.0	1.017	7.0
I05541	31.0	1.021	7.5
I05547	60.0	1.014	7.0
I05550	64.0	1.021	8.0
MEAN	64.8	1.018	7.4
S.D.	30.02	.0034	.48
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	102.0	1.011	8.0
I05538	74.0	1.012	7.0
I05539	56.0	1.026	7.5
I05545	48.0	1.014	6.5
I05548	61.0	1.020	8.0
I05552	38.0	1.028	8.0
MEAN	63.2	1.018	7.5
S.D.	22.56	.0073	.63
N	6	6	6

3M_MN03279589

Appendix 4

Individual Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	30.0	1.025	8.0
I05534	46.0	1.023	8.0
I05536	268.0	1.005	8.0
I05540	295.0	1.005	8.0
I05542	38.0	1.022	7.0
I05551	46.0	1.024	7.5
MEAN	120.5	1.017	7.8
S.D.	125.14	.0096	.42
N	6	6	6

3M_MN03279590

Appendix 4

Individual Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	-	-	-	-
I05530	10	-	-	-	+++	-
I05531	10	-	-	-	-	-
I05535	10	-	-	-	-	-
I05544	10	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	-	-	-	-
I05541	10	-	+	-	-	-
I05547	0	-	-	-	-	-
I05550	30	-	-	-	+++	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	10	-	-	-	-	-
I05538	0	-	+	-	+	-
I05539	10	-	-	-	-	-
I05545	0	-	+	-	-	-
I05548	10	-	+	-	-	-
I05552	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+	-	-	-
I05534	10	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	-	-	-	-
I05542	10	-	++	-	-	-
I05551	10	-	-	-	-	-

3M_MN03279591

Appendix 4

Individual Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	0	3	0	3B4D	0	BK	-
I05530	4	0	0	3	0	3B4D	0	BL	-
I05531	0	0	0	3	0	4B2E	0	BL	-
I05535	0	0	1	3	0	2B1F	0	BJ	-
I05544	0	0	0	3	0	2B	0	BL	-
I05549	0	0	1	3	0	2B1D	1E	BK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	0	0	1	2	0	3B1D	1E	BK	-
I05541	0	0	1	3	0	4B4D	1E1F	BL	-
I05547	0	0	0	3	0	3B1D	0	BL	P
I05550	4	0	1	3	0	3B	0	CL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	0	1	4	3	0	1B4D	0	BK	P
I05538	0	0	2	3	0	3D	0	BK	-
I05539	0	0	0	2	0	4B2E	0	BL	-
I05545	0	0	1	1	0	0	0	BK	-
I05548	0	0	1	1	0	4B4D	0	BL	-
I05552	0	0	1	1	0	4B1D	1E	CL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	3	1	3	0	4D	0	CK	P
I05534	0	0	0	2	0	4B4D	0	BL	-
I05536	0	0	1	2	0	3D	0	AJ	-
I05540	0	0	2	3	0	0	0	AK	-
I05542	0	2	1	3	0	2B2D	0	BK	P
I05551	0	0	1	3	0	3B1D	0	BL	-

3M_MN03279592

Appendix 4

Individual Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	68.0	1.017	7.5
I05517	76.0	1.013	7.0
I05519	210.0	1.004	7.5
I05520	34.0	1.019	6.5
I05526	320.0	1.005	6.5
I05527	80.0	1.021	7.5
MEAN	131.3	1.013	7.1
S.D.	110.42	.0072	.49
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	56.0	1.017	7.5
I05515	46.0	1.020	7.0
I05516	34.0	1.028	7.0
I05521	84.0	1.017	8.0
MEAN	55.0	1.020	7.4
S.D.	21.32	.0052	.48
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	360.0	1.004	7.5
I05510	92.0	1.009	7.0
I05518	66.0	1.014	7.0
I05523	140.0	1.008	7.0
I05524	44.0	1.022	7.0
I05528	125.0	1.011	7.0
MEAN	137.8	1.011	7.1
S.D.	114.54	.0062	.20
N	6	6	6

3M_MN03279593

Appendix 4

Individual Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05506	80.0	1.012	7.0
I05507	200.0	1.008	7.5
I05509	32.0	1.026	6.0
I05511	390.0	1.003	7.0
I05512	280.0	1.005	7.5
I05522	98.0	1.013	7.5
MEAN	180.0	1.011	7.1
S.D.	136.48	.0082	.58
N	6	6	6

3M_MN03279594

Appendix 4

Individual Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	0	-	-	-	-	-
I05517	0	-	++	-	-	-
I05519	0	-	-	-	-	-
I05520	0	-	++++	-	-	-
I05526	0	-	+	-	-	-
I05527	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	0	-	++	-	+	-
I05515	0	-	++	-	-	-
I05516	0	-	-	-	-	-
I05521	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05510	0	-	-	-	-	-
I05518	0	-	+	-	-	-
I05523	0	-	-	-	-	-
I05524	0	-	++	-	-	-
I05528	0	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05506	0	-	+++	-	-	-
I05507	0	-	-	-	-	-
I05509	10	-	++	-	-	-
I05511	0	-	-	-	-	-
I05512	0	-	-	-	-	-
I05522	0	-	-	-	-	-

3M_MN03279595

Appendix 4

Individual Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	0	0	1	3	0	4B	0	BK	Q
I05517	0	0	1	2	0	0	0	BK	P
I05519	0	0	0	2	0	0	0	AJ	-
I05520	0	0	1	3	0	0	0	BK	-
I05526	0	0	1	3	0	0	0	AK	-
I05527	0	0	0	3	0	4B4D	0	BL	Q
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	0	0	0	3	0	3B1D	1E	BK	PQ
I05515	0	0	1	3	0	1B1D	1E	BK	PQ
I05516	0	0	1	3	0	4B1D	0	BK	PQ
I05521	0	0	1	3	0	4B4D	0	BL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	1	3	0	0	0	AK	-
I05510	0	0	1	3	0	0	0	BK	-
I05518	0	0	0	3	0	4B	0	BK	-
I05523	0	1	1	3	0	0	0	BK	Q
I05524	0	0	1	2	0	0	0	BK	-
I05528	0	1	1	3	0	0	0	BK	Q
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05506	0	0	1	3	0	2B	0	BK	Q
I05507	0	0	0	2	0	0	0	AK	-
I05509	0	1	1	3	0	0	0	BK	P
I05511	0	0	0	2	0	0	0	AK	-
I05512	0	0	1	2	0	0	0	AK	-
I05522	0	0	1	3	0	0	0	BK	-

3M_MN03279596

Appendix 4

Individual Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	44.0	1.022	7.5
I05530	36.0	1.024	8.0
I05531	36.0	1.023	7.5
I05535	145.0	1.006	7.0
I05544	100.0	1.011	7.5
I05549	150.0	1.007	7.5
MEAN	85.2	1.016	7.5
S.D.	53.91	.0084	.32
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	110.0	1.013	7.0
I05541	40.0	1.020	7.0
I05547	26.0	1.017	6.5
I05550	66.0	1.016	7.5
MEAN	60.5	1.016	7.0
S.D.	36.93	.0029	.41
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	44.0	1.023	7.0
I05538	46.0	1.027	7.0
I05539	54.0	1.018	7.0
I05545	46.0	1.018	7.0
I05548	28.0	1.022	7.5
I05552	26.0	1.027	7.0
MEAN	40.7	1.022	7.1
S.D.	11.15	.0040	.20
N	6	6	6

3M_MN03279597

Appendix 4

Individual Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	30.0	1.025	7.0
I05534	52.0	1.011	8.0
I05536	110.0	1.012	7.5
I05540	270.0	1.005	6.0
I05542	36.0	1.021	7.0
I05551	36.0	1.026	7.0
MEAN	89.0	1.017	7.1
S.D.	93.46	.0085	.66
N	6	6	6

3M_MN03279598

Appendix 4

Individual Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	+	-	+++	-
I05530	10	-	-	-	-	-
I05531	0	-	+	-	-	-
I05535	0	-	+	-	-	-
I05544	0	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	0	-	+	-	-	-
I05541	30	-	++	-	+++	-
I05547	10	-	++++	-	-	-
I05550	0	-	+	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	0	-	+	-	-	-
I05538	0	-	+++	-	-	-
I05539	0	-	+	-	-	-
I05545	0	-	++	-	-	-
I05548	10	-	+++	-	-	-
I05552	0	-	+++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	0	-	+++	-	-	-
I05534	0	-	-	-	-	-
I05536	0	-	-	-	-	-
I05540	0	-	+	-	-	-
I05542	0	-	++	-	-	-
I05551	0	-	++	-	-	-

3M_MN03279599

Appendix 4

Individual Clinical Urinalysis Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	2	1	0	3	0	3B1D	0	BL	-
I05530	0	1	0	3	0	4B4D	0	BL	-
I05531	0	0	0	2	0	4B4D	2E4F	BL	P
I05535	0	0	1	2	0	0	0	BK	-
I05544	0	0	1	3	0	4B	0	BL	-
I05549	0	0	2	3	0	0	0	BK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	0	0	1	3	0	2B4D	0	BK	-
I05541	4	1	1	3	0	0	0	CK	P
I05547	0	1	1	3	0	3B2E	0	BL	P
I05550	0	0	2	3	0	0	0	BK	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	0	4	2	2	0	0	0	BK	P
I05538	0	0	1	1	0	1D	0	CK	-
I05539	0	1	3	3	0	1D	0	BK	P
I05545	0	0	2	3	0	4D	0	BK	P
I05548	0	1	1	3	0	4B4D	0	BL	-
I05552	0	0	1	3	0	4D	0	CK	P
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	0	1	1	3	0	2B2D	0	BK	-
I05534	0	0	1	3	0	2B4D	0	BK	-
I05536	0	1	1	2	0	4B3D	1E	BL	-
I05540	0	1	2	1	0	0	0	AK	-
I05542	0	2	1	3	0	2B4D	0	BK	-
I05551	0	1	1	3	0	3B4D	0	CK	-

3M_MN03279600

Appendix 4

Individual Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05508	184.0	1.006	8.0
I05517	49.0	1.021	7.5
I05519	62.0	1.012	8.0
I05520	102.0	1.013	8.0
I05526	242.0	1.006	8.0
I05527	58.0	1.023	8.0
MEAN	116.2	1.014	7.9
S.D.	79.33	.0072	.20
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05514	94.0	1.014	8.0
I05515	52.0	1.019	7.5
I05516	54.0	1.018	8.0
I05521	102.0	1.016	8.0
MEAN	75.5	1.017	7.9
S.D.	26.20	.0022	.25
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	368.0	1.003	8.0
I05510	122.0	1.012	8.0
I05518	78.0	1.016	8.5
I05523	21.0	1.017	6.0
I05524	49.0	1.015	6.5
I05528	96.0	1.016	8.0
MEAN	122.3	1.013	7.5
S.D.	125.43	.0053	1.00
N	6	6	6

3M_MN03279601

Appendix 4

Individual Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05507	280.0	1.005	7.5
I05511	96.0	1.017	8.0
I05512	36.0	1.018	6.5
I05522	72.0	1.012	7.0
MEAN	121.0	1.013	7.2
S.D.	108.83	.0059	.65
N	4	4	4

3M_MN03279602

Appendix 4

Individual Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05508	10	-	-	-	-	-
I05517	10	-	-	-	-	-
I05519	10	-	-	-	-	-
I05520	10	-	-	-	-	-
I05526	10	-	-	-	-	-
I05527	10	-	+	-	-	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05514	10	-	-	-	-	-
I05515	10	-	-	-	-	-
I05516	10	-	-	-	-	-
I05521	10	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	10	-	-	-	-	-
I05510	10	-	-	-	-	-
I05518	10	-	-	-	-	-
I05523	10	-	++	-	-	-
I05524	10	-	-	-	-	-
I05528	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05507	10	-	-	-	-	-
I05511	10	-	-	-	-	-
I05512	10	-	-	-	-	-
I05522	10	-	-	-	-	-

3M_MN03279603

Appendix 4

Individual Clinical Urinalysis Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05508	0	0	0	3	0	2B1E	0	BK	-
I05517	0	0	0	2	0	3B3D	0	BL	-
I05519	0	0	0	3	0	4B	0	BK	-
I05520	0	0	0	3	0	3B1D	0	BL	-
I05526	0	1	0	3	0	2B	0	AK	-
I05527	0	0	0	3	0	4B4D	0	BL	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05514	0	0	0	2	0	2B2E	0	BK	Q
I05515	0	0	0	3	0	4B1E	0	BK	-
I05516	0	0	1	3	0	2B	0	BK	-
I05521	0	0	0	3	0	4B	0	BL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	0	3	0	2B	0	AK	-
I05510	0	0	1	3	0	2B1E	0	BK	-
I05518	0	0	0	3	0	4B4D	0	BK	-
I05523	0	0	0	1	0	1B	0	BJ	P
I05524	0	0	0	3	0	0	0	BK	-
I05528	0	0	0	1	0	4B1E	0	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05507	0	0	0	1	0	0	0	AJ	Q
I05511	0	0	1	2	0	4B	0	BK	Q
I05512	0	0	0	2	0	0	0	BJ	P
I05522	0	0	1	2	0	2D	0	BK	PQ

3M_MN03279604

Appendix 4

Individual Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	50.0	1.020	8.0
I05530	62.0	1.015	8.0
I05531	57.0	1.023	8.5
I05535	159.0	1.009	8.0
I05544	86.0	1.017	8.0
I05549	100.0	1.013	8.0
MEAN	85.7	1.016	8.1
S.D.	40.59	.0050	.20
N	6	6	6
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day
I05537	108.0	1.013	7.0
I05541	38.0	1.020	7.5
I05547	95.0	1.009	8.0
I05550	64.0	1.020	8.0
MEAN	76.2	1.016	7.6
S.D.	31.48	.0054	.48
N	4	4	4
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05532	118.0	1.010	8.0
I05538	61.0	1.021	8.0
I05539	70.0	1.022	8.0
I05545	66.0	1.013	7.5
I05548	82.0	1.014	8.0
I05552	43.0	1.023	8.0
MEAN	73.3	1.017	7.9
S.D.	25.33	.0055	.20
N	6	6	6

3M_MN03279605

Appendix 4

Individual Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	47.0	1.016	7.5
I05534	82.0	1.015	8.0
I05536	72.0	1.017	8.0
I05540	450.0	1.003	7.5
I05542	84.0	1.018	8.0
I05551	56.0	1.018	8.0
MEAN	131.8	1.014	7.8
S.D.	156.54	.0058	.26
N	6	6	6

3M_MN03279606

Appendix 4

Individual Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	10	-	-	-	-	-
I05530	10	-	-	-	-	-
I05531	10	-	-	-	-	-
I05535	10	-	-	-	-	-
I05544	10	-	-	-	-	-
I05549	10	-	-	-	+	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day			
I05537	10	-	++	-	-	-
I05541	10	-	++	-	-	-
I05547	10	-	-	-	-	-
I05550	10	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05532	10	-	-	-	-	-
I05538	10	-	-	-	-	-
I05539	10	-	-	-	-	-
I05545	10	-	-	-	-	-
I05548	10	-	-	-	-	-
I05552	10	-	-	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	30	-	+++	-	+++	-
I05534	10	-	-	-	+	-
I05536	10	-	-	-	-	-
I05540	10	-	-	-	-	-
I05542	10	-	-	-	-	-
I05551	10	-	-	-	-	-

3M_MN03279607

Appendix 4

Individual Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05529	0	0	1	3	0	4B1D	0	BL	-
I05530	0	0	0	3	0	4B2D	0	BL	-
I05531	0	0	1	3	1G	4B1E	0	BK	-
I05535	0	0	1	3	0	4D	0	BK	-
I05544	0	0	1	3	0	4B	0	BL	-
I05549	0	1	1	3	0	2B1D	0	BK	-
Group: 2	Dose Level: 0.03		Dosage Unit: mg/kg/day						
I05537	0	1	1	3	0	3B2E	0	BK	-
I05541	0	1	1	3	0	3B1E	0	BL	-
I05547	0	0	1	3	0	4B	0	BK	P
I05550	0	0	1	3	0	4B1E	0	BL	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05532	0	3	0	3	0	2B2E	0	BK	-
I05538	0	0	1	2	0	4B2E	1F	BL	-
I05539	0	0	0	1	0	3B1E	0	BL	-
I05545	0	0	1	2	0	2B2D	0	BK	-
I05548	0	0	1	3	0	3B	0	BK	-
I05552	0	1	1	3	0	3B3D	0	BL	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05533	2	0	1	3	0	0	0	BK	-
I05534	0	1	1	3	0	3B	0	BL	-
I05536	0	0	2	2	0	4B3D	0	BL	-
I05540	0	0	1	2	0	1B	0	AK	-
I05542	0	0	0	3	0	4B	0	BK	-
I05551	0	1	1	3	0	3B3D	0	BL	-

3M_MN03279608

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	162.0	1.010	7.5
I05526	197.0	1.010	7.0
MEAN	179.5	1.010	7.2
S.D.	24.75	.0000	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	296.0	1.005	7.5
I05523	183.0	1.009	7.5
MEAN	239.5	1.007	7.5
S.D.	79.90	.0028	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	62.0	1.011	6.5
I05522	113.0	1.015	7.5
MEAN	87.5	1.013	7.0
S.D.	36.06	.0028	.71
N	2	2	2

3M_MN03279609

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05505	0	-	-	-	-	-
I05523	0	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05511	0	-	-	-	+	-
I05522	0	-	-	-	-	-

3M_MN03279610

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05520	0	1	0	1	0	4B	BK	-
I05526	0	0	1	2	0	4B	BJ	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05505	0	0	0	2	0	2B	AJ	-
I05523	0	0	0	2	0	2B	AK	Q
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05511	0	0	1	3	0	3B	BK	-
I05522	0	0	0	3	0	3B	BK	-

3M_MN03279611

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	88.0	1.020	8.0
I05549	198.0	1.009	7.5
MEAN	143.0	1.014	7.8
S.D.	77.78	.0078	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	178.0	1.015	7.5
I05552	64.0	1.015	7.0
MEAN	121.0	1.015	7.2
S.D.	80.61	.0000	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	63.0	1.015	7.0
I05542	115.0	1.015	8.0
MEAN	89.0	1.015	7.5
S.D.	36.77	.0000	.71
N	2	2	2

3M_MN03279612

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05529	0	-	-	-	-	-
I05549	0	-	-	-	+	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05539	10	-	-	-	+++	-
I05552	10	-	+	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05533	0	-	+	-	-	-
I05542	0	-	-	-	-	-

3M_MN03279613

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	URINE APP1	COMMENTS
Group: 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	0	0	1	3	0	4B	CK	-
I05549	0	0	0	3	0	3B	AK	-
Group: 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05539	4	0	1	3	0	4B3E	BK	-
I05552	0	0	1	3	0	4B	BK	-
Group: 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	0	0	1	3	0	4B	BK	P
I05542	0	0	0	3	0	3B	BK	-

3M_MN03279614

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	202.0	1.008	7.5
I05526	189.0	1.010	8.0
MEAN	195.5	1.009	7.8
S.D.	9.19	.0014	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	290.0	1.005	7.5
I05523	102.0	1.014	7.5
MEAN	196.0	1.010	7.5
S.D.	132.94	.0064	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	62.0	1.014	7.5
I05522	104.0	1.020	8.0
MEAN	83.0	1.017	7.8
S.D.	29.70	.0042	.35
N	2	2	2

3M_MN03279615

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05505	0	-	-	-	-	-
I05523	0	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05511	0	-	-	-	-	-
I05522	10	-	-	-	-	-

3M_MN03279616

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day						
I05520	0	0	1	3	0	0	0	AJ	Q
I05526	0	0	0	3	0	1D	0	AJ	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day						
I05505	0	0	0	3	0	0	0	AJ	-
I05523	0	1	1	2	1H	2B2F	0	AJ	PQ
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day						
I05511	0	0	1	2	0	3D	0	BJ	-
I05522	0	0	0	3	0	4B	0	BL	-

3M_MN03279617

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	46.0	1.026	8.0
I05549	188.0	1.010	8.0
MEAN	117.0	1.018	8.0
S.D.	100.41	.0113	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	176.0	1.015	7.0
I05552	87.0	1.018	7.5
MEAN	131.5	1.016	7.2
S.D.	62.93	.0021	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	57.0	1.014	7.5
I05542	126.0	1.019	8.0
MEAN	91.5	1.016	7.8
S.D.	48.79	.0035	.35
N	2	2	2

3M_MN03279618

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05529	10	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05539	0	-	-	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05533	10	-	+	-	-	-
I05542	0	-	-	-	-	-

3M_MN03279619

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0			Dosage Unit: mg/kg/day						
I05529	0	0	0	3	0	3B1D	1E	BK	-
I05549	0	0	1	3	0	2B	0	BJ	-
Group: 3 Dose Level: 0.15			Dosage Unit: mg/kg/day						
I05539	0	0	1	3	0	1B	0	BJ	-
I05552	0	0	1	1	0	4B1E	0	BL	-
Group: 4 Dose Level: 0.75			Dosage Unit: mg/kg/day						
I05533	0	1	1	3	0	2B1D	0	BK	-
I05542	0	0	1	2	0	3B2E	2F	BL	-

3M_MN03279620

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	248.0	1.004	6.5
I05526	320.0	1.003	7.0
MEAN	284.0	1.004	6.8
S.D.	50.91	.0007	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	354.0	1.004	7.5
I05523	114.0	1.010	7.0
MEAN	234.0	1.007	7.2
S.D.	169.71	.0042	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	32.0	1.026	6.5
I05522	103.0	1.011	7.5
MEAN	67.5	1.018	7.0
S.D.	50.20	.0106	.71
N	2	2	2

3M_MN03279621

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05505	0	-	-	-	-	-
I05523	10	-	-	-	+++	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05511	10	-	+	-	-	-
I05522	0	-	-	-	-	-

3M_MN03279622

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05520	0	0	0	3	0	0	AJ	-
I05526	0	0	1	2	0	0	AJ	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	0	0	0	3	0	0	AJ	-
I05523	0	0	0	3	0	0	BJ	PQ
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05511	0	0	0	2	0	1B4E	BJ	-
I05522	0	0	0	3	0	1B	BJ	-

3M_MN03279623

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	118.0	1.007	7.5
I05549	165.0	1.005	8.0
MEAN	141.5	1.006	7.8
S.D.	33.23	.0014	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	90.0	1.016	7.5
I05552	37.0	1.023	7.5
MEAN	63.5	1.020	7.5
S.D.	37.48	.0050	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	23.0	1.011	8.0
I05542	106.0	1.010	6.5
MEAN	64.5	1.010	7.2
S.D.	58.69	.0007	1.06
N	2	2	2

3M_MN03279624

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05529	0	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05539	10	-	-	-	-	-
I05552	10	-	++	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05533	10	-	-	-	-	-
I05542	0	-	++	-	-	-

3M_MN03279625

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	URINE APP1	COMMENTS
Group: 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	0	0	1	3	0	0	AJ	P
I05549	0	0	1	3	0	1D	AJ	-
Group: 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05539	0	1	1	3	0	1B2E	BJ	-
I05552	0	0	1	3	0	4B	BL	-
Group: 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	0	0	0	3	0	4B	BL	-
I05542	0	0	1	3	0	1B	BJ	P

3M_MN03279626

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	116.0	1.015	6.5
I05526	476.0	1.002	7.0
MEAN	296.0	1.008	6.8
S.D.	254.56	.0092	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	166.0	1.009	7.0
I05523	33.0	1.023	6.0
MEAN	99.5	1.016	6.5
S.D.	94.05	.0099	.71
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	51.0	1.013	6.0
I05522	44.0	1.026	6.0
MEAN	47.5	1.020	6.0
S.D.	4.95	.0092	.00
N	2	2	2

3M_MN03279627

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	0	-	+++	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	-	-	-	-	-
I05523	0	-	+++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	0	-	++++	-	-	-
I05522	0	-	++++	-	-	-

3M_MN03279628

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	URINE APP1	COMMENTS
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day					
I05520	0	0	1	1	0	1B	BJ	-
I05526	0	0	1	1	0	0	AJ	Q
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day					
I05505	0	1	1	3	0	3B	BJ	-
I05523	0	0	1	3	0	2B	BJ	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day					
I05511	0	1	1	2	0	2B	BJ	Q
I05522	0	0	0	2	0	0	BJ	Q

3M_MN03279629

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	87.0	1.010	8.0
I05549	354.0	1.003	8.0
MEAN	220.5	1.006	8.0
S.D.	188.80	.0050	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	76.0	1.015	7.0
I05552	42.0	1.021	6.0
MEAN	59.0	1.018	6.5
S.D.	24.04	.0042	.71
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	71.0	1.017	6.5
I05542	113.0	1.012	7.0
MEAN	92.0	1.014	6.8
S.D.	29.70	.0035	.35
N	2	2	2

3M_MN03279630

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	-	-	-	-	-
I05549	10	-	-	-	++	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	0	-	++	-	-	-
I05552	0	-	+++++	-	-	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	+++	-	++	-
I05542	0	-	-	-	-	-

3M_MN03279631

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	0	1	1	2	0	2B	BJ	-
I05549	0	0	1	3	0	0	AJ	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05539	0	1	1	3	0	1D	BK	-
I05552	0	0	1	3	0	1B	CJ	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05533	0	1	1	2	0	0	BJ	-
I05542	0	1	1	1	0	0	BJ	-

3M_MN03279632

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	149.0	1.019	8.0
I05526	264.0	1.015	7.5
MEAN	206.5	1.017	7.8
S.D.	81.32	.0028	.35
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	82.0	1.018	8.0
I05523	67.0	1.018	7.0
MEAN	74.5	1.018	7.5
S.D.	10.61	.0000	.71
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	100.0	1.015	7.5
I05522	80.0	1.022	6.0
MEAN	90.0	1.018	6.8
S.D.	14.14	.0050	1.06
N	2	2	2

3M_MN03279633

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05520	10	++++	-	-	+	-
I05526	10	+	-	-	+	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05505	0	+	-	-	+	-
I05523	10	-	++	-	+++	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05511	10	-	-	-	++	-
I05522	10	+	-	-	+++	-

3M_MN03279634

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	0	1	1	3	0	3B1E	1K	BL	-
I05526	0	0	1	3	0	3B1K	0	BL	Q
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	1	2	0	3B3D	0	BL	-
I05523	0	1	1	3	0	3B3D	0	CK	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	0	0	0	3	0	4B3D	0	BK	-
I05522	0	0	1	3	0	3B	0	BL	-

3M_MN03279635

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	166.0	1.011	8.0
I05549	150.0	1.011	8.0
MEAN	158.0	1.011	8.0
S.D.	11.31	.0000	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	78.0	1.020	7.0
I05552	59.0	1.022	7.0
MEAN	68.5	1.021	7.0
S.D.	13.44	.0014	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	43.0	1.018	6.5
I05542	109.0	1.019	7.5
MEAN	76.0	1.018	7.0
S.D.	46.67	.0007	.71
N	2	2	2

3M_MN03279636

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day			
I05529	0	+	-	-	+	-
I05549	0	+	-	-	+	-
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day			
I05539	10	-	+	-	+++	-
I05552	10	+	++	-	++	-
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day			
I05533	10	-	++	-	++	-
I05542	10	+	+	-	+	-

3M_MN03279637

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	0	0	3	0	4B2D	3K	BL	-
I05549	0	0	1	3	0	4B1D	0	BL	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	0	0	1	3	0	4K	0	BK	-
I05552	0	0	1	3	0	3B1D	0	BL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	1	1	3	0	2B	0	BK	-
I05542	0	0	0	3	0	3B3K	0	BL	-

3M_MN03279638

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	100.0	1.012	8.0
I05526	270.0	1.008	8.0
MEAN	185.0	1.010	8.0
S.D.	120.21	.0028	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	286.0	1.004	8.0
I05523	78.0	1.011	8.0
MEAN	182.0	1.008	8.0
S.D.	147.08	.0050	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	90.0	1.008	8.0
I05522	78.0	1.015	8.0
MEAN	84.0	1.012	8.0
S.D.	8.49	.0050	.00
N	2	2	2

3M_MN03279639

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05505	0	-	-	-	-	-
I05523	10	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05511	0	-	-	-	-	-
I05522	0	-	-	-	-	-

3M_MN03279640

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	0	0	0	3	0	1B1D	0	BK	-
I05526	0	0	1	3	0	0	0	AJ	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	0	2	0	0	0	AJ	Q
I05523	0	0	0	3	0	4B1D	0	BK	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	0	0	1	3	0	0	0	BJ	Q
I05522	0	0	0	3	0	2B4D	0	BJ	-

3M_MN03279641

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	98.0	1.013	8.0
I05549	330.0	1.005	8.0
MEAN	214.0	1.009	8.0
S.D.	164.05	.0057	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	198.0	1.008	7.5
I05552	92.0	1.014	8.0
MEAN	145.0	1.011	7.8
S.D.	74.95	.0042	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	60.0	1.002	8.0
I05542	176.0	1.008	8.0
MEAN	118.0	1.005	8.0
S.D.	82.02	.0042	.00
N	2	2	2

3M_MN03279642

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05529	0	-	-	-	-	-
I05549	10	-	-	-	+++	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05539	0	-	-	-	-	-
I05552	0	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05533	0	-	-	-	-	-
I05542	0	-	-	-	+	-

3M_MN03279643

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	0	1	3	0	2B4D	0	BK	-
I05549	0	1	1	3	0	0	0	AJ	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	0	1	1	3	0	0	0	AJ	-
I05552	0	0	1	3	0	3B	0	BK	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	0	1	3	0	2B	0	AK	-
I05542	0	0	0	3	0	4B	0	AL	-

3M_MN03279644

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05520	480.0	1.005	8.0
I05526	380.0	1.005	8.0
MEAN	430.0	1.005	8.0
S.D.	70.71	.0000	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05505	405.0	1.004	7.5
I05523	195.0	1.008	8.0
MEAN	300.0	1.006	7.8
S.D.	148.49	.0028	.35
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05511	345.0	1.005	8.0
I05522	100.0	1.015	8.0
MEAN	222.5	1.010	8.0
S.D.	173.24	.0071	.00
N	2	2	2

3M_MN03279645

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05520	0	-	-	-	-	-
I05526	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05505	0	-	-	-	-	-
I05523	0	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05511	0	-	-	-	-	-
I05522	0	-	-	-	-	-

3M_MN03279646

APPENDIX 4

Individual Clinical Urinalysis Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05520	0	0	1	1	0	1B	0	AJ	-
I05526	0	0	0	3	0	1B	0	AJ	Q
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05505	0	0	0	2	0	0	0	AJ	-
I05523	0	0	0	1	0	2B	0	AJ	Q
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05511	0	0	0	1	0	1B	0	AJ	Q
I05522	0	0	0	1	0	2B1D	2E	BK	-

3M_MN03279647

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U VOL ML	SP GR	U PH
Group: 1	Dose Level: 0		Dosage Unit: mg/kg/day
I05529	105.0	1.015	8.0
I05549	160.0	1.007	8.0
MEAN	132.5	1.011	8.0
S.D.	38.89	.0057	.00
N	2	2	2
Group: 3	Dose Level: 0.15		Dosage Unit: mg/kg/day
I05539	85.0	1.017	8.0
I05552	50.0	1.019	8.0
MEAN	67.5	1.018	8.0
S.D.	24.75	.0014	.00
N	2	2	2
Group: 4	Dose Level: 0.75		Dosage Unit: mg/kg/day
I05533	42.0	1.017	8.0
I05542	156.0	1.010	8.0
MEAN	99.0	1.014	8.0
S.D.	80.61	.0050	.00
N	2	2	2

3M_MN03279648

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	U PRO MG/DL	U GLU	U KET	U BILI	U BLOOD	UROBILI
Group: 1	Dose Level: 0			Dosage Unit: mg/kg/day		
I05529	0	-	-	-	-	-
I05549	0	-	-	-	-	-
Group: 3	Dose Level: 0.15			Dosage Unit: mg/kg/day		
I05539	10	-	-	-	-	-
I05552	10	-	-	-	-	-
Group: 4	Dose Level: 0.75			Dosage Unit: mg/kg/day		
I05533	0	-	-	-	-	-
I05542	0	-	-	-	+++	-

3M_MN03279649

APPENDIX 4

Individual Clinical Urinalysis Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

ANIMAL NUMBER	RBC PER HPF	WBC PER HPF	EPITH PER HPF	BACT PER HPF	CASTS PER LPF	CRYSTALS PER LPF1	CRYSTALS PER LPF2	URINE APP1	COMMENTS
Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day									
I05529	0	1	0	2	0	2B2D	1F	BJ	-
I05549	0	0	0	2	0	2B	0	BJ	-
Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day									
I05539	0	0	0	2	0	3B1E	0	BK	-
I05552	0	0	0	2	0	2B2E	0	BL	-
Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day									
I05533	0	0	0	2	0	3B3D	0	BL	-
I05542	0	1	1	1	0	3B	0	AL	-

3M_MN03279650

APPENDIX 5

Individual Palmitoyl CoA Oxidase Determinations
Individual Anatomic Pathology Data

3M_MN03279651

Appendix 5

Individual Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	PCOAO IU/G
Group: 1	Dose Level: 0 Dosage Unit: mg/kg/day
I05508	4
I05517	4
I05519	6
I05527	7
MEAN	5
S.D.	1.5
N	4
Group: 2	Dose Level: 0.03 Dosage Unit: mg/kg/day
I05514	4
I05515	5
I05516	4
I05521	6
MEAN	5
S.D.	1.0
N	4
Group: 3	Dose Level: 0.15 Dosage Unit: mg/kg/day
I05510	6
I05518	6
I05524	5
I05528	5
MEAN	6
S.D.	.6
N	4

3M_MN03279652

Appendix 5

Individual Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	PCOAO IU/G
Group: 4	Dose Level: 0.75 Dosage Unit: mg/kg/day
I05507	8
I05512	6
MEAN	7
S.D.	1.4
N	2

3M_MN03279653

Appendix 5

Individual Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	PCOAO IU/G
Group: 1	Dose Level: 0 Dosage Unit: mg/kg/day
I05530	3
I05531	4
I05535	4
I05544	5
MEAN	4
S.D.	.8
N	4
Group: 2	Dose Level: 0.03 Dosage Unit: mg/kg/day
I05537	4
I05541	4
I05547	2
I05550	5
MEAN	4
S.D.	1.3
N	4
Group: 3	Dose Level: 0.15 Dosage Unit: mg/kg/day
I05532	5
I05538	5
I05545	6
I05548	7
MEAN	6
S.D.	1.0
N	4

3M_MN03279654

Appendix 5

Individual Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	PCOAO IU/G
Group: 4	Dose Level: 0.75 Dosage Unit: mg/kg/day
I05534	6
I05536	7
I05540	6
I05551	5
MEAN	6
S.D.	.8
N	4

3M_MN03279655

Individual Anatomic Pathology Data

Unscheduled Deaths

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M)
DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.4730	.0130 %	.0072	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3840	.0106 %	.0058	WEIGHT TAKEN
BRAIN (BR)	65.9350	1.8189 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	1.2760	.0352 %	.0194	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.2520	.0345 %	.0190	WEIGHT TAKEN
LF KIDNEY (KD0)	6.1230	.1689 %	.0929	WEIGHT TAKEN
RT KIDNEY (KD1)	5.9240	.1634 %	.0898	WEIGHT TAKEN
LIVER (LI)	88.6340	2.4451 %	1.3443	WEIGHT TAKEN
LF TESTIS (TE0)	7.0730	.1951 %	.1073	WEIGHT TAKEN
RT TESTIS (TE1)	7.0020	.1932 %	.1062	WEIGHT TAKEN
PANCREAS (PA)	6.7010	.1849 %	.1016	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1980	.0055 %	.0030	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2070	.0057 %	.0031	WEIGHT TAKEN
GALLBLADDER (GB)	--------	--------	--------	NOT SCHEDULED
BILE(VOLUME) (BI)	--------	--------	--------	NOT SCHEDULED

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MODERATELY SEVERE
BRAIN (BR) :
-INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR,-MINIMAL
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL
-INFILTRATE, LYMPHOHISTIOCYTIC, MENINGEAL,-SLIGHT
KIDNEY (KD) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
-CAST, PROTEINACEOUS,-SLIGHT

3M_MN03279656

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M)
DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR,-MODERATE, DIFFUSE -STASIS, BILE,-SLIGHT, MULTI-FOCAL THYMUS (TH) : -CYST,-PRESENT -ATROPHY,-MODERATELY SEVERE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL ESOPHAGUS (ES) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT THYROID (TY) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -CYST, ULTIMOBRANCHIAL,-PRESENT ADRENAL, CORTEX (AC) : -MINERALIZATION, VASCULAR,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT SPINAL CORD (SC) : -INFILTRATION, LYMPHOHISTIOCYTIC MENINGEAL/PERIVASCULAR,-SLIGHT DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT

3M_MN03279657

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M)
DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY

CAUSE OF DEATH (CD) :
-UNDETERMINED,-PRESENT

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

3M_MN03279658

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05509 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (D)
DATE OF DEATH: 01/27/99 STUDY DAY OF DEATH: 155 STUDY WEEK OF DEATH: 23 TERMINAL BODY WEIGHT: NOT ENTERED
DATE AND TIME OF NECROPSY: 01/27/99 10:21 PROSECTOR: NANCY DIEDRICH RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NOT AVAILABLE

*** ORGAN WEIGHTS WERE NOT RECORDED ***

O B S E R V A T I O N S

NECROPSY	HISTOPATHOLOGY
	BONE, FEMUR (PE) : -GROWTH PLATE OPEN,-MODERATELY SEVERE
	MARROW, FEMUR (PM) : >SECTION EXAMINED; TISSUE NOT PRESENT
	KIDNEY (KD) : -MINERALIZATION, PAPILLARY,-MODERATE
LUNG (LU) : -ADHESION(S); ALL LOBES TO EACH OTHER AND PLEURA: MULTIPLE INDISTINCT ADHESIONS; CANNOT DISTINGUISH LOBES FROM ONE ANOTHER; COLLECTED -MOTTLED; ALL RIGHT LOBES: RED, DARK RED, AND TAN; LOBES APPEAR FIRM -EROSION(S)/ULCERATION(S); APPEARS TO BE RIGHT CAUDAL LOBE: SINGLE ULCERATED AREA, 2.5 X 1.5 CM; ULCERATED AREA EXTENDS DEEP INTO LUNG TISSUE; WALLS OF ULCERATION APPEAR GREEN, TAN, GRAY AND MOIST; COLLECTED INTACT	LUNG (LU) : -FIBROSIS, PLEURAL/SUBPLEURAL,-MODERATE -INFILTRATE, MACROPHAGE, ALVEOLAR,-MODERATE -NECROSIS,-SEVERE -INFLAMMATION, ACUTE,-SEVERE -FIBRIN, PLEURAL,-MODERATELY SEVERE
LIVER (LI) : -MOTTLED; ALL LOBES: DARK BROWN AND TAN -LARGE; ALL LOBES: THICKENED	LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE -VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATE
	THYMUS (TH) : -ATROPHY,-MODERATE
	TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL

3M_MN03279659

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05509 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (D)
DATE OF DEATH: 01/27/99 STUDY DAY OF DEATH: 155 STUDY WEEK OF DEATH: 23 TERMINAL BODY WEIGHT: NOT ENTERED
DATE AND TIME OF NECROPSY: 01/27/99 10:21 PROSECTOR: NANCY DIEDRICH RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NOT AVAILABLE

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
COLON (CO) : -DARK FOCUS(I)/AREA(S); WITHIN MUCOSA: SINGLE DARK BROWN AREA, 0.3 X 0.2 CM; COLLECTED ON ROUTINE SECTION	COLON (CO) : >UNREMARKABLE
	CAUSE OF DEATH (CD) : -NECROSIS, PULMONARY,-PRESENT
LN, TRACHEOBRON (TB) : -LARGE; UP TO 1.0 X 0.9 X 0.5 CM (CAP 29)	LN, TRACHEOBRON (TB) : -INFLAMMATION, ACUTE,-MODERATE

3M_MN03279660

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05509 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (D)
DATE OF DEATH: 01/27/99 STUDY DAY OF DEATH: 155 STUDY WEEK OF DEATH: 23 TERMINAL BODY WEIGHT: NOT ENTERED
DATE AND TIME OF NECROPSY: 01/27/99 10:21 PROSECTOR: NANCY DIEDRICH RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NOT AVAILABLE

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), GENERAL COMMENT (GC), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

3M_MN03279661

Individual Anatomic Pathology Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05508 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3285.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 10:24 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2650	.0081 %	.0042	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2010	.0061 %	.0032	WEIGHT TAKEN
BRAIN (BR)	62.3670	1.8985 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.8310	.0253 %	.0133	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0370	.0316 %	.0166	WEIGHT TAKEN
LF KIDNEY (KD0)	5.8660	.1786 %	.0941	WEIGHT TAKEN
RT KIDNEY (KD1)	5.4930	.1672 %	.0881	WEIGHT TAKEN
LIVER (LI)	59.3880	1.8079 %	.9522	WEIGHT TAKEN
LF TESTIS (TE0)	5.5360	.1685 %	.0888	WEIGHT TAKEN
RT TESTIS (TE1)	5.1190	.1558 %	.0821	WEIGHT TAKEN
PANCREAS (PA)	4.3000	.1309 %	.0689	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1520	.0046 %	.0024	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1390	.0042 %	.0022	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-RED FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK RED PINPOINT FOCI

SPLEEN (SP) :
-LARGE; 7.0 X 4.0 X 3.0 CM

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MODERATELY SEVERE
KIDNEY (KD) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
-GLOMERULOSCLEROSIS,-MINIMAL
LUNG (LU) :
-HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-SLIGHT
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
SPLEEN (SP) :
>UNREMARKABLE

3M_MN03279662

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05508 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3285.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 10:24 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	LN, MESENTERIC (MS) : -HEMORRHAGE,-SLIGHT TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT COLON (CO) : -INFILTRATE, EOSINOPHILIC,-SLIGHT MAMMARY, MALE (MM) : >SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.4890 GRAMS BILE VOLUME IS 1.6000 ML	

3M_MN03279663

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05508 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3285.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 10:24 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), HEART (HT), GALLBLADDER (GB), THYMUS (TH), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), RECTUM (RE), SKIN (SK), URINARY BLADDER (UB), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

3M_MN03279664

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2840	.0093 %	.0045	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1430	.0047 %	.0023	WEIGHT TAKEN
BRAIN (BR)	62.4920	2.0456 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	1.0930	.0358 %	.0175	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.2250	.0401 %	.0196	WEIGHT TAKEN
LF KIDNEY (KD0)	5.9980	.1963 %	.0960	WEIGHT TAKEN
RT KIDNEY (KD1)	5.7530	.1883 %	.0921	WEIGHT TAKEN
LIVER (LI)	44.2710	1.4491 %	.7084	WEIGHT TAKEN
LF TESTIS (TE0)	8.0310	.2629 %	.1285	WEIGHT TAKEN
RT TESTIS (TE1)	8.1690	.2674 %	.1307	WEIGHT TAKEN
PANCREAS (PA)	5.8790	.1924 %	.0941	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1490	.0049 %	.0024	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1400	.0046 %	.0022	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MODERATE
MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
LUNG (LU) :
-HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-MINIMAL
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
LN, MESENTERIC (MS) :
-INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE

3M_MN03279665

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT ADRENAL, CORTEX (AC) : -HYPERTROPHY, CORTICAL CELL,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL PANCREAS (PA) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL COLON (CO) : -PARASITISM, INTRAMUSCULAR,-PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.6330 GRAMS BILE VOLUME IS 1.6000 ML	

3M_MN03279666

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), JEJUNUM (JE), ILEUM (IL), CECUM (CE), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

3M_MN03279667

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2820	.0090 %	.0045	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2330	.0074 %	.0037	WEIGHT TAKEN
BRAIN (BR)	62.8980	2.0031 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.7730	.0246 %	.0123	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.8270	.0263 %	.0131	WEIGHT TAKEN
LF KIDNEY (KD0)	5.5490	.1767 %	.0882	WEIGHT TAKEN
RT KIDNEY (KD1)	5.3860	.1715 %	.0856	WEIGHT TAKEN
LIVER (LI)	53.1740	1.6934 %	.8454	WEIGHT TAKEN
LF TESTIS (TE0)	2.7780	.0885 %	.0442	WEIGHT TAKEN
RT TESTIS (TE1)	2.9990	.0955 %	.0477	WEIGHT TAKEN
PANCREAS (PA)	5.5570	.1770 %	.0883	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1310	.0042 %	.0021	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1220	.0039 %	.0019	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MODERATELY SEVERE
MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL
KIDNEY (KD) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
LUNG (LU) :
-HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-SLIGHT

3M_MN03279668

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT PARATHYROID (PT) : -CYST,-PRESENT ADRENAL, CORTEX (AC) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE CECUM (CE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE MAMMARY, MALE (MM) : >SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL EPIDIDYMIDES (EP) : -HYPOSPERMIA,-MODERATE TESTIS (TE) : -IMMATURE,-PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS	

3M_MN03279669

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY

GENERAL COMMENT (GC) :
-NO MACROSCOPIC LESIONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.7260 GRAMS BILE VOLUME IS 1.2000 ML

THE POLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), HEART (HT), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), ESOPHAGUS (ES), THYROID (TY), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK), URINARY BLADDER (UB), SEMINAL VESICLES (SV)

HISTOPATHOLOGY

3M_MN03279670

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3120	.0067 %	.0048	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2600	.0056 %	.0040	WEIGHT TAKEN
BRAIN (BR)	64.8130	1.3849 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	1.8660	.0399 %	.0288	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.7750	.0379 %	.0274	WEIGHT TAKEN
LF KIDNEY (KD0)	7.5090	.1604 %	.1159	WEIGHT TAKEN
RT KIDNEY (KD1)	7.3890	.1579 %	.1140	WEIGHT TAKEN
LIVER (LI)	62.8470	1.3429 %	.9697	WEIGHT TAKEN
LF TESTIS (TE0)	11.5730	.2473 %	.1786	WEIGHT TAKEN
RT TESTIS (TE1)	10.6940	.2285 %	.1650	WEIGHT TAKEN
PANCREAS (PA)	6.0920	.1302 %	.0940	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2380	.0051 %	.0037	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2750	.0059 %	.0042	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-SLIGHT
MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL
LUNG (LU) :
-HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-SLIGHT
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-GRANULOMA,-MINIMAL, FOCAL

3M_MN03279671

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	THYMUS (TH) : -ATROPHY,-SEVERE SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL MUSCLE, SKELETAL (SM) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
SKIN (SK) : -ABRASION(S)/ULCERATION(S); 2.0 CM FROM TIP OF TAIL: SINGLE RED, MOIST ABRADED AREA, 0.8 CM IN DIAMETER; COLLECTED	SKIN (SK) : -HYPERPLASIA, EPIDERMAL (ACANTHOSIS),-MODERATE -INFLAMMATION, CHRONIC-ACTIVE,-SLIGHT -ULCERATION,-MODERATELY SEVERE URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.6430 GRAMS BILE VOLUME IS 2.4000 ML	

3M_MN03279672

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), JEJUNUM (JE), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, MALE (MM), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

3M_MN03279673

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05514 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3495.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3620	.0104 %	.0058	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2420	.0069 %	.0039	WEIGHT TAKEN
BRAIN (BR)	62.4280	1.7862 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	1.1580	.0331 %	.0185	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0010	.0286 %	.0160	WEIGHT TAKEN
LF KIDNEY (KD0)	6.0230	.1723 %	.0965	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1700	.1765 %	.0988	WEIGHT TAKEN
LIVER (LI)	64.2170	1.8374 %	1.0287	WEIGHT TAKEN
LF TESTIS (TE0)	6.7090	.1920 %	.1075	WEIGHT TAKEN
RT TESTIS (TE1)	5.1600	.1476 %	.0827	WEIGHT TAKEN
PANCREAS (PA)	4.7970	.1373 %	.0768	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.3130	.0090 %	.0050	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3200	.0092 %	.0051	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
THYMUS (TH) :
-ATROPHY,-MODERATE

3M_MN03279674

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05514 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3495.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.7220 GRAMS BILE VOLUME IS 1.4000 ML	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	

3M_MN03279675

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05515 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 6:45 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2770	.0080 %	.0043	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1900	.0055 %	.0030	WEIGHT TAKEN
BRAIN (BR)	63.7670	1.8350 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.7590	.0218 %	.0119	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.8690	.0250 %	.0136	WEIGHT TAKEN
LF KIDNEY (KD0)	6.4220	.1848 %	.1007	WEIGHT TAKEN
RT KIDNEY (KD1)	6.2010	.1784 %	.0972	WEIGHT TAKEN
LIVER (LI)	55.8260	1.6065 %	.8755	WEIGHT TAKEN
LF TESTIS (TE0)	2.7190	.0782 %	.0426	WEIGHT TAKEN
RT TESTIS (TE1)	3.3300	.0958 %	.0522	WEIGHT TAKEN
PANCREAS (PA)	5.0260	.1446 %	.0788	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1340	.0039 %	.0021	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1240	.0036 %	.0019	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.4620 GRAMS BILE VOLUME IS 1.2000 ML

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL

3M_MN03279676

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05515 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 6:45 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
THYMUS (TH)

3M_MN03279677

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05516 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3170.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2940	.0093 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2410	.0076 %	.0036	WEIGHT TAKEN
BRAIN (BR)	67.0240	2.1143 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.8820	.0278 %	.0132	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.7570	.0239 %	.0113	WEIGHT TAKEN
LF KIDNEY (KD0)	6.8380	.2157 %	.1020	WEIGHT TAKEN
RT KIDNEY (KD1)	7.0240	.2216 %	.1048	WEIGHT TAKEN
LIVER (LI)	68.1040	2.1484 %	1.0161	WEIGHT TAKEN
LF TESTIS (TE0)	3.3570	.1059 %	.0501	WEIGHT TAKEN
RT TESTIS (TE1)	5.1290	.1618 %	.0765	WEIGHT TAKEN
PANCREAS (PA)	3.0500	.0962 %	.0455	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2040	.0064 %	.0030	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1430	.0045 %	.0021	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

SPLEEN (SP) :
-LARGE; 7.0 X 5.0 X 3.0 CM

TESTIS (TE) :
-LARGE; RIGHT: 2.5 X 1.5 X 1.4 CM (FOR COMPARISON, LEFT IS 2.0 X 1.5 X 1.0 CM)
GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS

HISTOPATHOLOGY

SPLEEN (SP) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL
THYMUS (TH) :
-CYST,-PRESENT
TESTIS (TE) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

3M_MN03279678

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05516 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3170.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY

GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.6300 GRAMS BILE VOLUME IS 1.4000 ML

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER (LI)

3M_MN03279679

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05521 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4385.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3090	.0070 %	.0057	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2230	.0051 %	.0041	WEIGHT TAKEN
BRAIN (BR)	53.9580	1.2305 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	2.8840	.0658 %	.0534	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	2.7980	.0638 %	.0519	WEIGHT TAKEN
LF KIDNEY (KD0)	7.1230	.1624 %	.1320	WEIGHT TAKEN
RT KIDNEY (KD1)	7.6030	.1734 %	.1409	WEIGHT TAKEN
LIVER (LI)	60.2000	1.3729 %	1.1157	WEIGHT TAKEN
LF TESTIS (TE0)	18.7540	.4277 %	.3476	WEIGHT TAKEN
RT TESTIS (TE1)	18.8730	.4304 %	.3498	WEIGHT TAKEN
PANCREAS (PA)	6.3800	.1455 %	.1182	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.4490	.0102 %	.0083	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.4660	.0106 %	.0086	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-VACUOLATION, HEPATOCELLULAR,-MINIMAL, MULTI-FOCAL
-STASIS, BILE,-MODERATE, MULTI-FOCAL
THYMUS (TH) :
-ATROPHY,-MODERATELY SEVERE

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS

3M_MN03279680

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05521 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4385.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
GENERAL INFORMATION (XX) :	
>NOTE:>GALLBLADDER WEIGHT IS 0.4810 GRAMS BILE VOLUME IS 1.4000 ML	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	

3M_MN03279681

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05510 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3180.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2490	.0078 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1600	.0050 %	.0028	WEIGHT TAKEN
BRAIN (BR)	56.7600	1.7849 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	1.0910	.0343 %	.0192	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0750	.0338 %	.0189	WEIGHT TAKEN
LF KIDNEY (KD0)	6.4950	.2042 %	.1144	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1190	.1924 %	.1078	WEIGHT TAKEN
LIVER (LI)	54.2060	1.7046 %	.9550	WEIGHT TAKEN
LF TESTIS (TE0)	6.0950	.1917 %	.1074	WEIGHT TAKEN
RT TESTIS (TE1)	5.8860	.1851 %	.1037	WEIGHT TAKEN
PANCREAS (PA)	3.8800	.1220 %	.0684	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1660	.0052 %	.0029	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1960	.0062 %	.0035	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); BILATERAL CAUDAL LOBES TO PLEURA AND DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT
ADIPOSE TISSUE (AT) :
-RAISED FOCUS(I)/AREA(S); DIFFUSE, THROUGHOUT MESENTERY AND THORACIC CAVITY: MULTIPLE, TAN, FIRM NODULES, UP TO 0.6 CM IN DIAMETER WITHIN MESENTERY (CAP 29), UP TO 0.3 CM IN DIAMETER WITHIN THORACIC CAVITY (CAP 30) AND COLLECTED INTACT WITH LUNG ADHESIONS
GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

ADIPOSE TISSUE (AT) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

3M_MN03279682

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05510 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3180.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY

GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.6690 GRAMS BILE VOLUME IS 2.4000 ML

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER (LI), THYMUS (TH)

3M_MN03279683

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05518 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3070.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2790	.0091 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2460	.0080 %	.0039	WEIGHT TAKEN
BRAIN (BR)	62.8420	2.0470 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.8790	.0286 %	.0140	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	1.0970	.0357 %	.0175	WEIGHT TAKEN
LF KIDNEY (KD0)	5.6790	.1850 %	.0904	WEIGHT TAKEN
RT KIDNEY (KD1)	5.6110	.1828 %	.0893	WEIGHT TAKEN
LIVER (LI)	57.5930	1.8760 %	.9165	WEIGHT TAKEN
LF TESTIS (TE0)	4.5720	.1489 %	.0728	WEIGHT TAKEN
RT TESTIS (TE1)	4.6220	.1506 %	.0735	WEIGHT TAKEN
PANCREAS (PA)	3.1580	.1029 %	.0503	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2450	.0080 %	.0039	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3110	.0101 %	.0049	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

THYMUS (TH) :
-ATROPHY,-MINIMAL

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.5320 GRAMS BILE VOLUME IS 1.3000 ML

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05518 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3070.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER (LI)

3M_MN03279685

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05524 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3035.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:42 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2420	.0080 %	.0038	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1860	.0061 %	.0029	WEIGHT TAKEN
BRAIN (BR)	63.9330	2.1065 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.9350	.0308 %	.0146	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.9840	.0324 %	.0154	WEIGHT TAKEN
LF KIDNEY (KD0)	5.0370	.1660 %	.0788	WEIGHT TAKEN
RT KIDNEY (KD1)	4.8440	.1596 %	.0758	WEIGHT TAKEN
LIVER (LI)	52.5550	1.7316 %	.8220	WEIGHT TAKEN
LF TESTIS (TE0)	4.6940	.1547 %	.0734	WEIGHT TAKEN
RT TESTIS (TE1)	4.2750	.1409 %	.0669	WEIGHT TAKEN
PANCREAS (PA)	4.6550	.1534 %	.0728	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1210	.0040 %	.0019	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1330	.0044 %	.0021	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

THYMUS (TH) :
-ATROPHY,-MINIMAL

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.9610 GRAMS BILE VOLUME IS 0.8000 ML

3M_MN03279686

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05524 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3035.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:42 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER (LI)

3M_MN03279687

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05528 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:19 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3070	.0088 %	.0044	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2620	.0075 %	.0037	WEIGHT TAKEN
BRAIN (BR)	69.8730	2.0107 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.9990	.0287 %	.0143	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.9290	.0267 %	.0133	WEIGHT TAKEN
LF KIDNEY (KD0)	6.3390	.1824 %	.0907	WEIGHT TAKEN
RT KIDNEY (KD1)	6.3690	.1833 %	.0912	WEIGHT TAKEN
LIVER (LI)	64.9760	1.8698 %	.9299	WEIGHT TAKEN
LF TESTIS (TE0)	5.0300	.1447 %	.0720	WEIGHT TAKEN
RT TESTIS (TE1)	5.2350	.1506 %	.0749	WEIGHT TAKEN
PANCREAS (PA)	5.8230	.1676 %	.0833	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2980	.0086 %	.0043	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3900	.0112 %	.0056	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE
THYMUS (TH) :
-ATROPHY,-SLIGHT

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.5220 GRAMS BILE VOLUME IS 1.8000 ML

3M_MN03279688

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05528 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:19 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

3M_MN03279689

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.4540	.0117 %	.0063	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3210	.0083 %	.0045	WEIGHT TAKEN
BRAIN (BR)	71.7900	1.8550 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	2.0740	.0536 %	.0289	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	2.3260	.0601 %	.0324	WEIGHT TAKEN
LF KIDNEY (KD0)	6.5150	.1683 %	.0908	WEIGHT TAKEN
RT KIDNEY (KD1)	6.2950	.1627 %	.0877	WEIGHT TAKEN
LIVER (LI)	112.4190	2.9049 %	1.5659	WEIGHT TAKEN
LF TESTIS (TE0)	12.6370	.3265 %	.1760	WEIGHT TAKEN
RT TESTIS (TE1)	12.5000	.3230 %	.1741	WEIGHT TAKEN
PANCREAS (PA)	5.2280	.1351 %	.0728	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2850	.0074 %	.0040	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3460	.0089 %	.0048	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LIVER (LI) :
-MOTTLED; ALL LOBES: BROWN AND TAN

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-SLIGHT
MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR,-MINIMAL
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT
KIDNEY (KD) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
-MINERALIZATION, CORTEX,-MINIMAL
LIVER (LI) :
-HYPERTROPHY, HEPATOCELLULAR,-MODERATE, DIFFUSE

3M_MN03279690

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	LIVER (LI) : -VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATELY SEVERE
	THYMUS (TH) : -CYST,-PRESENT -ATROPHY,-MODERATELY SEVERE
LN, MESENTERIC (MS) : -DIFFUSELY RED; DARK RED	LN, MESENTERIC (MS) : >UNREMARKABLE
	TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: DARK BROWN	ADRENAL, CORTEX (AC) : >UNREMARKABLE
	JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS	
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5330 GRAMS BILE VOLUME IS 2.0000 ML	

3M_MN03279691

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE)

3M_MN03279692

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05512 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2285.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2790	.0122 %	.0046	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2240	.0098 %	.0037	WEIGHT TAKEN
BRAIN (BR)	60.7370	2.6581 %	1.0000	WEIGHT TAKEN
LF EPIDIDYMIS (EP0)	.5450	.0239 %	.0090	WEIGHT TAKEN
RT EPIDIDYMIS (EP1)	.4350	.0190 %	.0072	WEIGHT TAKEN
LF KIDNEY (KD0)	4.5470	.1990 %	.0749	WEIGHT TAKEN
RT KIDNEY (KD1)	4.5140	.1975 %	.0743	WEIGHT TAKEN
LIVER (LI)	58.1440	2.5446 %	.9573	WEIGHT TAKEN
LF TESTIS (TE0)	1.4310	.0626 %	.0236	WEIGHT TAKEN
RT TESTIS (TE1)	1.3310	.0582 %	.0219	WEIGHT TAKEN
PANCREAS (PA)	3.0430	.1332 %	.0501	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1190	.0052 %	.0020	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1260	.0055 %	.0021	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LIVER (LI) :
-MOTTLED; ALL LOBES: BROWN AND TAN

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MODERATE
MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL
LIVER (LI) :
-HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-SLIGHT
GALLBLADDER (GB) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
THYMUS (TH) :
-ATROPHY,-MODERATELY SEVERE

3M_MN03279693

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05512 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2285.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	LN, MESENTERIC (MS) : -HEMORRHAGE,-MINIMAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -INFLAMMATION, ACUTE,-MINIMAL
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN	ADRENAL, CORTEX (AC) : >UNREMARKABLE SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT MAMMARY, MALE (MM) : >SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL EPIDIDYMIDES (EP) : -HYPOSPERMIA,-SEVERE TESTIS (TE) : -IMMATURE,-PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.3100 GRAMS BILE VOLUME IS 1.2000 ML	

3M_MN03279694

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05512 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2285.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), LUNG (LU), HEART (HT), SPLEEN (SP), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), URINARY BLADDER (UB), SEMINAL VESICLES (SV)

3M_MN03279695

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2755.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2480	.0090 %	.0041	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1640	.0060 %	.0027	WEIGHT TAKEN
BRAIN (BR)	60.5500	2.1978 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.6520	.2052 %	.0933	WEIGHT TAKEN
RT KIDNEY (KD1)	5.4770	.1988 %	.0905	WEIGHT TAKEN
LIVER (LI)	49.1800	1.7851 %	.8122	WEIGHT TAKEN
LF OVARY (OV0)	.1220	.0044 %	.0020	WEIGHT TAKEN
RT OVARY (OV1)	.1280	.0046 %	.0021	WEIGHT TAKEN
PANCREAS (PA)	4.2470	.1542 %	.0701	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2100	.0076 %	.0035	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2150	.0078 %	.0036	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MINIMAL
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MODERATE
KIDNEY (KD) :
-GLOMERULOSCLEROSIS,-MINIMAL
LUNG (LU) :
-HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-MINIMAL
-FIBROSIS, PLEURAL/SUBPLEURAL,-SLIGHT
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
TRACHEA (TR) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL

3M_MN03279696

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2755.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	THYROID (TY) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL MUSCLE, SKELETAL (SM) : -DEGENERATION,-SLIGHT -INFLAMMATION, GRANULOMATOUS,-MODERATE -REGENERATION, MYOFIBER,-MODERATELY SEVERE URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5970 GRAMS BILE VOLUME IS 1.2000 ML	

3M_MN03279697

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2755.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV)

3M_MN03279698

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05531 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2360	.0090 %	.0043	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.1480	.0056 %	.0027	WEIGHT TAKEN
BRAIN (BR)	54.3050	2.0688 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	4.3520	.1658 %	.0801	WEIGHT TAKEN
RT KIDNEY (KD1)	4.2910	.1635 %	.0790	WEIGHT TAKEN
LIVER (LI)	42.1310	1.6050 %	.7758	WEIGHT TAKEN
LF OVARY (OV0)	.0990	.0038 %	.0018	WEIGHT TAKEN
RT OVARY (OV1)	.0930	.0035 %	.0017	WEIGHT TAKEN
PANCREAS (PA)	3.9080	.1489 %	.0720	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1970	.0075 %	.0036	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1740	.0066 %	.0032	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT
KIDNEY (KD) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
ADRENAL, CORTEX (AC) :
-HYPERTROPHY, CORTICAL CELL,-MINIMAL
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-SLIGHT
JEJUNUM (JE) :
-INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE

3M_MN03279699

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05531 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MINIMAL UTERUS (UT) : -AMYLOID,-SLIGHT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.7250 GRAMS BILE VOLUME IS 1.8000 ML	

3M_MN03279700

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05531 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2625.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), OVARY (OV), VAGINA (VA), CERVIX (CV)

3M_MN03279701

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05535 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3270.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 8:13 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3770	.0115 %	.0073	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3150	.0096 %	.0061	WEIGHT TAKEN
BRAIN (BR)	51.9670	1.5892 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	6.6940	.2047 %	.1288	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1830	.1891 %	.1190	WEIGHT TAKEN
LIVER (LI)	64.3990	1.9694 %	1.2392	WEIGHT TAKEN
LF OVARY (OV0)	.2280	.0070 %	.0044	WEIGHT TAKEN
RT OVARY (OV1)	.2100	.0064 %	.0040	WEIGHT TAKEN
PANCREAS (PA)	5.0450	.1543 %	.0971	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.4660	.0143 %	.0090	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.4370	.0134 %	.0084	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, AND PERICARDIAL SAC: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT

STOMACH, GL (ST) :
-RED FOCUS(I)/AREA(S); MUCOSA, FUNDIC: SINGLE RED FOCUS, 0.3 MM IN DIAMETER; FOCUS HAS A STELLATE PATTERN

HISTOPATHOLOGY

MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
LUNG (LU) :
-FIBROSIS, PLEURAL/SUBPLEURAL,-SEVERE
-FIBROSIS, INTERSTITIAL,-MODERATELY SEVERE

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-VACUOLATION, HEPATOCELLULAR,-MINIMAL, MULTI-FOCAL
SALIV GL, MANDIB (SG) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
STOMACH, GL (ST) :
>UNREMARKABLE

3M_MN03279702

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05535 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3270.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 8:13 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
STOMACH, GL (ST) :	
>NOTE:>FUNDIC MUCOSA, ALONG GREATER CURVATURE: SINGLE APPARENT HOOK WORM EMBEDDED INTO MUCOSA, 3.0 X 0.1 X 0.1 CM	
	DUODENUM (DU) :
	-INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	JEJUNUM (JE) :
	-INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	ILEUM (IL) :
	-INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	CECUM (CE) :
	-INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
	MAMMARY, FEMALE (MF) :
	-INFLAMMATION, ACUTE,-MINIMAL
	URINARY BLADDER (UB) :
	-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	UTERUS (UT) :
	-AMYLOID,-SLIGHT
GENERAL COMMENT (GC) :	
-BONE MARROW SMEAR TAKEN	
-EYES - DAVIDSONS	
GENERAL INFORMATION (XX) :	
>NOTE:>ANIMAL APPEARS TO BE IN ESTROUS GALLBLADDER WEIGHT IS 0.6970 GRAMS BILE VOLUME IS 2.6000 ML	

3M_MN03279703

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05535 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3270.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 8:13 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK), OVARY (OV), VAGINA (VA), CERVIX (CV)

3M_MN03279704

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2635.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3120	.0118 %	.0052	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2440	.0093 %	.0041	WEIGHT TAKEN
BRAIN (BR)	59.7410	2.2672 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.3110	.2016 %	.0889	WEIGHT TAKEN
RT KIDNEY (KD1)	5.2470	.1991 %	.0878	WEIGHT TAKEN
LIVER (LI)	48.6600	1.8467 %	.8145	WEIGHT TAKEN
LF OVARY (OV0)	.2260	.0086 %	.0038	WEIGHT TAKEN
RT OVARY (OV1)	.1380	.0052 %	.0023	WEIGHT TAKEN
PANCREAS (PA)	4.5080	.1711 %	.0755	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1540	.0058 %	.0026	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1560	.0059 %	.0026	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LIVER (LI) :
-LIGHT FOCUS(I)/AREA(S); TRIM COMMENT: DIAPHRAGMATIC SURFACE OF LEFT LATERAL LOBE: SINGLE TAN AREA, 1.0 CM IN DIAMETER; SUBMITTED ON ROUTINE SECTION

HISTOPATHOLOGY

MARROW, STERNUM (SE) :
-HYPOCELLULAR, MARROW,-SLIGHT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MODERATE
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL

GALLBLADDER (GB) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
LN, MESENTERIC (MS) :
-INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
TRACHEA (TR) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2635.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	ESOPHAGUS (ES) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL PARATHYROID (PT) : >SECTION EXAMINED; TISSUE NOT PRESENT MUSCLE, SKELETAL (SM) : -PARASITES, CYST,-PRESENT >NOTE:>HEAVY BURDEN, SARCOCYST-LIKE. DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT MAMMARY, FEMALE (MF) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT OVARY (OV) : -MINERALIZATION,-MODERATE
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.3810 GRAMS BILE VOLUME IS 2.2000 ML	

3M_MN03279706

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2635.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
BONE, FEMUR (FE), MARROW, FEMUR (FM), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), LUNG (LU), HEART (HT), SPLEEN (SP), THYMUS (TH), THYROID (TY), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), UTERUS (UT), VAGINA (VA), CERVIX (CV)

3M_MN03279707

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05537 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4055.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3730	.0092 %	.0061	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3030	.0075 %	.0049	WEIGHT TAKEN
BRAIN (BR)	61.3750	1.5136 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	7.0240	.1732 %	.1144	WEIGHT TAKEN
RT KIDNEY (KD1)	6.6650	.1644 %	.1086	WEIGHT TAKEN
LIVER (LI)	75.2140	1.8548 %	1.2255	WEIGHT TAKEN
LF OVARY (OV0)	.2790	.0069 %	.0045	WEIGHT TAKEN
RT OVARY (OV1)	.2280	.0056 %	.0037	WEIGHT TAKEN
PANCREAS (PA)	6.1370	.1513 %	.1000	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.3200	.0079 %	.0052	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.3400	.0084 %	.0055	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
THYMUS (TH) :
-ATROPHY,-MINIMAL
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-SLIGHT

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-ANIMAL OBESE
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.5100 GRAMS BILE VOLUME IS
3.0000 ML

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05537 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4055.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

3M_MN03279709

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05541 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2510.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:47 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.4170	.0166 %	.0066	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.3060	.0122 %	.0048	WEIGHT TAKEN
BRAIN (BR)	63.2760	2.5210 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	4.9450	.1970 %	.0781	WEIGHT TAKEN
RT KIDNEY (KD1)	4.6880	.1868 %	.0741	WEIGHT TAKEN
LIVER (LI)	47.6610	1.8988 %	.7532	WEIGHT TAKEN
LF OVARY (OV0)	.1240	.0049 %	.0020	WEIGHT TAKEN
RT OVARY (OV1)	.1570	.0063 %	.0025	WEIGHT TAKEN
PANCREAS (PA)	5.0750	.2022 %	.0802	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2130	.0085 %	.0034	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2300	.0092 %	.0036	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); RIGHT AND LEFT CAUDAL LOBES AND LEFT INTERMEDIATE LOBE TO DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT
-DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN AREAS, PINPOINT AND UP TO 0.7 X 0.4 CM
LIVER (LI) :
-ADHESION(S); DIAPHRAGMATIC SURFACE OF RIGHT LATERAL LOBE TO SURROUNDING MESENTERY, ALONG MARGIN: MULTIPLE TAN, FIBROUS ADHESIONS (CAP 29)

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL

THYMUS (TH) :
-ATROPHY,-MODERATE
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-MODERATE

3M_MN03279710

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05541 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2510.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:47 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.5260 GRAMS BILE VOLUME IS
1.0000 ML

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

3M_MN03279711

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05547 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2570.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3130	.0122 %	.0051	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2300	.0089 %	.0038	WEIGHT TAKEN
BRAIN (BR)	60.8690	2.3684 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.4180	.2108 %	.0890	WEIGHT TAKEN
RT KIDNEY (KD1)	5.5840	.2173 %	.0917	WEIGHT TAKEN
LIVER (LI)	49.9520	1.9437 %	.8206	WEIGHT TAKEN
LF OVARY (OV0)	.1590	.0062 %	.0026	WEIGHT TAKEN
RT OVARY (OV1)	.2030	.0079 %	.0033	WEIGHT TAKEN
PANCREAS (PA)	5.1480	.2003 %	.0846	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1550	.0060 %	.0025	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1410	.0055 %	.0023	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); LEFT CAUDAL LOBE TO DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT
-DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN AREAS, PINPOINT AND UP TO 0.5 X 0.3 CM

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
THYMUS (TH) :
-CYST,-PRESENT
-ATROPHY,-SLIGHT

3M_MN03279712

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05547 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2570.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5380 GRAMS BILE VOLUME IS 1.2000 ML	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	
THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: SPINAL CORD (SC)	

3M_MN03279713

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05550 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2820.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 6:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.4230	.0150 %	.0074	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2680	.0095 %	.0047	WEIGHT TAKEN
BRAIN (BR)	56.9130	2.0182 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	6.0900	.2160 %	.1070	WEIGHT TAKEN
RT KIDNEY (KD1)	6.1500	.2181 %	.1081	WEIGHT TAKEN
LIVER (LI)	54.4840	1.9321 %	.9573	WEIGHT TAKEN
LF OVARY (OV0)	.1270	.0045 %	.0022	WEIGHT TAKEN
RT OVARY (OV1)	.1270	.0045 %	.0022	WEIGHT TAKEN
PANCREAS (PA)	7.2830	.2583 %	.1280	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1670	.0059 %	.0029	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2290	.0081 %	.0040	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-VACUOLATION, HEPATOCELLULAR,-SLIGHT, MULTI-FOCAL
THYMUS (TH) :
-ATROPHY,-MINIMAL
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-SLIGHT

3M_MN03279714

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05550 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2820.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 6:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.6200 GRAMS BILE VOLUME IS 1.2000 ML	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	

3M_MN03279715

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05532 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2550.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 6:47 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3230	.0127 %	.0054	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2160	.0085 %	.0036	WEIGHT TAKEN
BRAIN (BR)	60.2360	2.3622 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.0310	.1973 %	.0835	WEIGHT TAKEN
RT KIDNEY (KD1)	4.9920	.1958 %	.0829	WEIGHT TAKEN
LIVER (LI)	58.3190	2.2870 %	.9682	WEIGHT TAKEN
LF OVARY (OV0)	.0630	.0025 %	.0010	WEIGHT TAKEN
RT OVARY (OV1)	.0870	.0034 %	.0014	WEIGHT TAKEN
PANCREAS (PA)	4.5080	.1768 %	.0748	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1150	.0045 %	.0019	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1020	.0040 %	.0017	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-RED FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK RED PINPOINT FOCI

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.4650 GRAMS BILE VOLUME IS 1.2000 ML

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

THYMUS (TH) :
-ATROPHY,-SEVERE
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-MODERATE

3M_MN03279716

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05532 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2550.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 6:47 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER (LI)

3M_MN03279717

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05538 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3200.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 10:25 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3850	.0120 %	.0069	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2630	.0082 %	.0047	WEIGHT TAKEN
BRAIN (BR)	55.6900	1.7403 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.8390	.1825 %	.1048	WEIGHT TAKEN
RT KIDNEY (KD1)	5.3480	.1671 %	.0960	WEIGHT TAKEN
LIVER (LI)	59.5780	1.8618 %	1.0698	WEIGHT TAKEN
LF OVARY (OV0)	.2420	.0076 %	.0043	WEIGHT TAKEN
RT OVARY (OV1)	.1690	.0053 %	.0030	WEIGHT TAKEN
PANCREAS (PA)	4.8070	.1502 %	.0863	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1350	.0042 %	.0024	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1480	.0046 %	.0027	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-DARK FOCUS(I)/AREA(S); ALL LOBES, DIFFUSE: MULTIPLE BLACK PINPOINT FOCI

SPLEEN (SP) :
-LIGHT FOCUS(I)/AREA(S); DIFFUSE: MULTIPLE GRAY AREAS, UP TO 1.2 X 0.7 CM

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
SPLEEN (SP) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

THYMUS (TH) :
-ATROPHY,-SLIGHT
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-MINIMAL
CECUM (CE) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

3M_MN03279718

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05538 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3200.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 10:25 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
CECUM (CE) : -RED FOCUS(I)/AREA(S); SEROSAL SURFACE: MULTIPLE DARK RED FOCI, UP TO 0.5 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5060 GRAMS BILE VOLUME IS 1.6000 ML	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	

3M_MN03279719

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05545 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2460.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.2640	.0107 %	.0047	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2060	.0084 %	.0037	WEIGHT TAKEN
BRAIN (BR)	55.6590	2.2626 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.4870	.2230 %	.0986	WEIGHT TAKEN
RT KIDNEY (KD1)	5.2040	.2115 %	.0935	WEIGHT TAKEN
LIVER (LI)	52.4930	2.1339 %	.9431	WEIGHT TAKEN
LF OVARY (OV0)	.2040	.0083 %	.0037	WEIGHT TAKEN
RT OVARY (OV1)	.1400	.0057 %	.0025	WEIGHT TAKEN
PANCREAS (PA)	4.1150	.1673 %	.0739	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2030	.0083 %	.0036	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1190	.0048 %	.0021	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-DEGENERATION/NECROSIS, HEPATOCELLULAR,-MINIMAL, MULTI-FOCAL
THYMUS (TH) :
-CYST,-PRESENT
-ATROPHY,-MINIMAL
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-MINIMAL

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
-NO MACROSCOPIC LESIONS

3M_MN03279720

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05545 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2460.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.7210 GRAMS BILE VOLUME IS 1.4000 ML	
THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)	

3M_MN03279721

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05548 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2865.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3880	.0135 %	.0063	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2850	.0099 %	.0046	WEIGHT TAKEN
BRAIN (BR)	61.9790	2.1633 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	6.0250	.2103 %	.0972	WEIGHT TAKEN
RT KIDNEY (KD1)	6.0670	.2118 %	.0979	WEIGHT TAKEN
LIVER (LI)	57.7670	2.0163 %	.9320	WEIGHT TAKEN
LF OVARY (OV0)	.2400	.0084 %	.0039	WEIGHT TAKEN
RT OVARY (OV1)	.1510	.0053 %	.0024	WEIGHT TAKEN
PANCREAS (PA)	5.0690	.1769 %	.0818	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1640	.0057 %	.0026	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1640	.0057 %	.0026	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-ADHESION(S); ADHERED TO PLEURA, DIAPHRAGM, PERICARDIUM, AND EACH OTHER: MULTIPLE GRAY, FIBROUS ADHESIONS; COLLECTED INTACT

CECUM (CE) :
-RED FOCUS(I)/AREA(S); DIFFUSE: MULTIPLE DARK RED FOCI, UP TO 0.5 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION

HISTOPATHOLOGY

LUNG (LU) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MODERATE, FOCAL
THYMUS (TH) :
-ATROPHY,-MODERATELY SEVERE
SPINAL CORD (SC) :
-PIGMENT, NEURONAL,-SLIGHT
CECUM (CE) :
>NOT REQUIRED TO BE EXAMINED FOR ANIMAL

3M_MN03279722

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05548 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2865.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY

GENERAL COMMENT (GC) :
-BONE MARROW SMEAR TAKEN
-EYES - DAVIDSONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.7810 GRAMS BILE VOLUME IS 2.6000 ML

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

3M_MN03279723

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2500.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3290	.0132 %	.0061	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2270	.0091 %	.0042	WEIGHT TAKEN
BRAIN (BR)	54.3510	2.1740 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	4.8280	.1931 %	.0888	WEIGHT TAKEN
RT KIDNEY (KD1)	4.9920	.1997 %	.0918	WEIGHT TAKEN
LIVER (LI)	75.5500	3.0220 %	1.3900	WEIGHT TAKEN
LF OVARY (OV0)	.1600	.0064 %	.0029	WEIGHT TAKEN
RT OVARY (OV1)	.1480	.0059 %	.0027	WEIGHT TAKEN
PANCREAS (PA)	4.4740	.1790 %	.0823	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1370	.0055 %	.0025	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1210	.0048 %	.0022	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN PINPOINT FOCI
-LIGHT FOCUS(I)/AREA(S); RIGHT AND LEFT CAUDAL LOBES: MULTIPLE TAN AREAS, UP TO 0.2 X 0.1 CM

HISTOPATHOLOGY

BONE, FEMUR (FE) :
-GROWTH PLATE OPEN,-MODERATE
KIDNEY (KD) :
-MINERALIZATION, MEDULLA,-MINIMAL
LUNG (LU) :
-HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,-MINIMAL
-INFILTRATE, MACROPHAGE, ALVEOLAR,-MINIMAL
LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE
-VACUOLATION, HEPATOCELLULAR,-SLIGHT, DIFFUSE

3M_MN03279724

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2500.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	THYMUS (TH) : -ATROPHY,-MODERATE
	TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN	ADRENAL, CORTEX (AC) : >UNREMARKABLE
	DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE
	JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
	ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
CECUM (CE) : -DARK FOCUS(I)/AREA(S); SEROSAL SURFACE AND LUMEN, DIFFUSE: MULTIPLE DARK BROWN, SLIGHTLY RAISED AREAS, UP TO 0.5 X 0.2 CM; COLLECTED ON ROUTINE SECTION	CECUM (CE) : -PARASITISM,-PRESENT
COLON (CO) : -DARK FOCUS(I)/AREA(S); SEROSAL SURFACE AND LUMEN, DIFFUSE: MULTIPLE DARK BROWN, SLIGHTLY RAISED FOCI, UP TO 0.3 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION	COLON (CO) : -PARASITISM, INTRAMUSCULAR,-PRESENT
	URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	OVARY (OV) : -MINERALIZATION,-MINIMAL
ADIPOSE TISSUE (AT) : -RAISED FOCUS(I)/AREA(S); MESENTERY, DIFFUSE: MULTIPLE TAN FOCI, UP TO 0.3 CM IN DIAMETER (CAP 29)	ADIPOSE TISSUE (AT) : -LYMPHOID TISSUE,-PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN	

3M_MN03279725

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2500.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

O B S E R V A T I O N S (CONTINUED)

NECROPSY

GENERAL COMMENT (GC) :
-EYES - DAVIDSONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.5260 GRAMS BILE VOLUME IS
2.0000 ML

THE POLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

HISTOPATHOLOGY

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), UTERUS (UT), VAGINA (VA), CERVIX (CV)

3M_MN03279726

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3290	.0103 %	.0056	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2360	.0074 %	.0040	WEIGHT TAKEN
BRAIN (BR)	58.3990	1.8336 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	6.9900	.2195 %	.1197	WEIGHT TAKEN
RT KIDNEY (KD1)	7.4110	.2327 %	.1269	WEIGHT TAKEN
LIVER (LI)	93.8600	2.9469 %	1.6072	WEIGHT TAKEN
LF OVARY (OV0)	.1010	.0032 %	.0017	WEIGHT TAKEN
RT OVARY (OV1)	.1360	.0043 %	.0023	WEIGHT TAKEN
PANCREAS (PA)	4.7900	.1504 %	.0820	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1910	.0060 %	.0033	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2400	.0075 %	.0041	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-DARK FOCUS(I)/AREA(S); ALL LOBES, DIFFUSE: MULTIPLE
PINPOINT BLACK FOCI
LIVER (LI) :
-MOTTLED; ALL LOBES: BROWN AND TAN

HISTOPATHOLOGY

MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL
LUNG (LU) :
>UNREMARKABLE

LIVER (LI) :
-HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-MODERATE
-VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATELY SEVERE
GALLBLADDER (GB) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL

3M_MN03279727

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	THYMUS (TH) : -CYST,-PRESENT -ATROPHY,-MODERATELY SEVERE
	TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT
	THYROID (TY) : -CYST, ULTIMOBRANCHIAL,-PRESENT
ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN	ADRENAL, CORTEX (AC) : -HYPERTROPHY, CORTICAL CELL,-MINIMAL -PIGMENT,-SLIGHT
	SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MODERATE
	DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
	JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
	ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
	CECUM (CE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
	UTERUS (UT) : -AMYLOID,-MODERATE
	OVARY (OV) : -AMYLOID,-MODERATE -ONE EXAMINED,-PRESENT
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN	

3M_MN03279728

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER

O B S E R V A T I O N S (CONTINUED)

NECROPSY

GENERAL COMMENT (GC) :
-EYES - DAVIDSONS
GENERAL INFORMATION (XX) :
>NOTE:>GALLBLADDER WEIGHT IS 0.6650 GRAMS BILE VOLUME IS 2.6000 ML

THE POLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

HISTOPATHOLOGY

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), HEART (HT), SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), VAGINA (VA), CERVIX (CV)

3M_MN03279729

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05540 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2700.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3440	.0127 %	.0061	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2550	.0094 %	.0045	WEIGHT TAKEN
BRAIN (BR)	56.3190	2.0859 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	5.2090	.1929 %	.0925	WEIGHT TAKEN
RT KIDNEY (KD1)	4.8440	.1794 %	.0860	WEIGHT TAKEN
LIVER (LI)	63.0760	2.3361 %	1.1200	WEIGHT TAKEN
LF OVARY (OV0)	.1400	.0052 %	.0025	WEIGHT TAKEN
RT OVARY (OV1)	.1410	.0052 %	.0025	WEIGHT TAKEN
PANCREAS (PA)	4.4510	.1649 %	.0790	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.2480	.0092 %	.0044	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.2540	.0094 %	.0045	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-RED FOCUS(I)/AREA(S); RIGHT CAUDAL AND APICAL LOBES:
MULTIPLE DARK RED INDISTINCT AREAS

HISTOPATHOLOGY

MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT
LUNG (LU) :
-HEMORRHAGE,-MODERATE

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-SLIGHT
THYMUS (TH) :
-CYST,-PRESENT
-ATROPHY,-SLIGHT

3M_MN03279730

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05540 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2700.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	THYROID (TY) : -CYST, ULTIMOBRANCHIAL,-PRESENT
	AORTA (AO) : -PROLIFERATION, INTIMAL,-MODERATE
	MUSCLE, SKELETAL (SM) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
SKIN (SK) : -ALOPECIA-FOCAL; RIGHT DORSAL THORACIC REGION: 0.3 X 2.5 CM (CAP 29)	SKIN (SK) : -HAIR FOLLICLES, DECREASED,-MODERATE
GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS	
GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5650 GRAMS BILE VOLUME IS 1.6000 ML	

3M_MN03279731

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05540 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2700.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 10:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), PITUITARY (PI), SALIV GL, MANDIB (SG), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV)

3M_MN03279732

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2230.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

ORGAN NAME	ABSOLUTE ORGAN WEIGHT (GRAMS)	ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%)	ORGAN TO BRAIN WEIGHT RATIO	O R G A N S T A T U S
LEFT ADRENAL (AD0)	.3850	.0173 %	.0065	WEIGHT TAKEN
RIGHT ADRENAL (AD1)	.2960	.0133 %	.0050	WEIGHT TAKEN
BRAIN (BR)	59.3140	2.6598 %	1.0000	WEIGHT TAKEN
LF KIDNEY (KD0)	6.0280	.2703 %	.1016	WEIGHT TAKEN
RT KIDNEY (KD1)	5.9040	.2648 %	.0995	WEIGHT TAKEN
LIVER (LI)	68.7130	3.0813 %	1.1585	WEIGHT TAKEN
LF OVARY (OV0)	.2350	.0105 %	.0040	WEIGHT TAKEN
RT OVARY (OV1)	.1740	.0078 %	.0029	WEIGHT TAKEN
PANCREAS (PA)	3.7750	.1693 %	.0636	WEIGHT TAKEN
LF THYROID/PARA (TT0)	.1730	.0078 %	.0029	WEIGHT TAKEN
RT THYROID/PARA (TT1)	.1630	.0073 %	.0027	WEIGHT TAKEN

O B S E R V A T I O N S

NECROPSY

LUNG (LU) :
-RED FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK RED FOCI, PINPOINT AND UP TO 1 MM IN DIAMETER

HISTOPATHOLOGY

MARROW, FEMUR (FM) :
>SECTION EXAMINED; TISSUE NOT PRESENT
BRAIN (BR) :
-INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL
KIDNEY (KD) :
-MINERALIZATION, MEDULLA,-MINIMAL
LUNG (LU) :
>UNREMARKABLE

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL
-HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-SLIGHT
GALLBLADDER (GB) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL

3M_MN03279733

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2230.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

O B S E R V A T I O N S (CONTINUED)

NECROPSY	HISTOPATHOLOGY
	TRACHEA (TR) :
	-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	THYROID (TY) :
	-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	SALIV GL, MANDIB (SG) :
	-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL
	MUSCLE, SKELETAL (SM) :
	-PARASITES, CYST,-PRESENT
	SPINAL CORD (SC) :
	-PIGMENT, NEURONAL,-MODERATE
	JEJUNUM (JE) :
	-INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT
SKIN (SK) :	SKIN (SK) :
-ALOPECIA-DIFFUSE; ALL FOUR LIMBS: HAIRCOAT THIN; COLLECTED	-HAIR FOLLICLES, DECREASED,-SLIGHT
GENERAL COMMENT (GC) :	
-BONE MARROW SMEAR TAKEN	
-EYES - DAVIDSONS	
GENERAL INFORMATION (XX) :	
>NOTE:>ANIMAL APPEARS TO BE IN ESTROUS GALLBLADDER WEIGHT IS 0.6040 GRAMS BILE VOLUME IS 1.8000 ML	

3M_MN03279734

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE
DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2230.0 GRAMS
DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
BONE, FEMUR (FE), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), HEART (HT), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), ESOPHAGUS (ES), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV)

3M_MN03279735

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05511 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 4240.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/00 7:56 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

*** ORGAN WEIGHTS WERE NOT RECORDED ***

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT

GENERAL COMMENT (GC) :
-NO MACROSCOPIC LESIONS

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), CAVITY, THORACIC (TA)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER, BIOPSY (LI0)

3M_MN03279736

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05522 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 4350.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/00 8:35 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

*** ORGAN WEIGHTS WERE NOT RECORDED ***

O B S E R V A T I O N S

NECROPSY	HISTOPATHOLOGY
	LIVER, BIOPSY (LI0) : -PIGMENT, HEPATOCELLULAR,-SLIGHT
	LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MODERATE -PIGMENT, HEPATOCELLULAR,-SLIGHT -HYPERPLASIA, BILE DUCT,-MODERATE -INFLAMMATION, EOSINOPHILIC, PERI-BILE DUCT,-MODERATE
LUNG (LU) : -ADHESION(S); ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE TAN FIBROUS ADHESIONS	LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL
CAVITY, THORACIC (TA) : -NODULE(S); WITHIN ADHESIONS: MULTIPLE TAN AND FIRM NODULES, UP TO 0.3 CM IN DIAMETER	

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), GENERAL COMMENT (GC)

3M_MN03279737

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05533 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 2535.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/00 8:58 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

*** ORGAN WEIGHTS WERE NOT RECORDED ***

O B S E R V A T I O N S

NECROPSY	HISTOPATHOLOGY
LIVER (LI) : -ADHESION(S); DIAPHRAGMATIC SURFACE OF RIGHT MEDIAN LOBE TO DIAPHRAGM: SINGLE TAN, FIBROUS LINEAR AREA, 2.0 CM IN LENGTH	LIVER (LI) : -FIBROSIS, CAPSULAR,-SLIGHT
GALLBLADDER (GB) : >NOTE:>NO BILE AVAILABLE FOR SPECIAL PROCEDURE	GALLBLADDER (GB) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), GENERAL COMMENT (GC), CAVITY, THORACIC (TA)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER, BIOPSY (LI0)

3M_MN03279738

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER: I05542 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC
DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 3705.0 GRAMS
DATE AND TIME OF NECROPSY: 02/25/00 9:23 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA
POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA

*** ORGAN WEIGHTS WERE NOT RECORDED ***

O B S E R V A T I O N S

NECROPSY

HISTOPATHOLOGY

LIVER (LI) :
-INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL

GENERAL COMMENT (GC) :
-NO MACROSCOPIC LESIONS

THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY:
LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), CAVITY, THORACIC (TA)

THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION:
LIVER, BIOPSY (LI0)

3M_MN03279739

APPENDIX 6

AniLytics Inc. Quality Assurance Statements
Summary and Individual Blood Hormone Determination

Note: This appendix contains information supplied and audited by AniLytics Inc.

3M_MN03279740

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Frank Newman
Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, E1, E2, E3, TSH TESTO3, T3, T4	9-6-98	9-9-98	98-681

MANAGEMENT 9/8/98

3M_MN03279741

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS INC STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, TEST, E1, E2 E3, T3, T4, TSH	11-29-98	11-30-98 Rewrite FDay 11/30/98	98-911

MANAGEMENT 11/30/98

3M_MN03279742

200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
TESTOS, CORT, E1, E2 E3, T3, TH, TSH	12-27-98	12-28-98	98-991

MANAGEMENT 12/28/98

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, TEST, E1, E2, E3 T3, TH, TSH	3-21-99	3-22-99	99-229

MANAGEMENT 3/22/99

3M_MN03279744

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with the EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Frank Newman
Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MGMT:	AUDIT #:
CORT, TESTOS, E1, E2, E3, T3, T4, TSH	4-25-99	4-26-99	99-336

MANAGEMENT 4/26/99

3M_MN03279745

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The reports listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS INC STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
CORTISOL, TESTOS, E1 E2, E3, T3, TH, TSH	7-4-99	7-5-99	99-564

MANAGEMENT 7/12/99

3M_MN03279746

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The report listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS INC STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
CORTISOL, TESTOS, E1 E2, E3, T3, T4, TSH, FT3, FT4	11-21-99	11-22-99	99-987

MANAGEMENT 11/22/99

3M_MN03279747

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The report listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS INC. STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
T3, T4, TSH, E1, E2, E3, CORT, TESTOS	4-2-00	4-3-00	00-229

MANAGEMENT 4/3/00

3M_MN03279748

ANALYTICS INCORPORATED
200 Girard Street, Suite 200, Gaithersburg, MD 20877
301-921-0168 800-237-2815

The report listed below was reviewed for compliance with the FDA Good Laboratory Practices and with EPA Good Laboratory Practices. The final report and all associated raw data were reviewed for accuracy and consistency and the findings were reported to management.

The methods used were the methods described and the report accurately reflects the data. Therefore, these studies were done in compliance with the FDA and EPA Good Laboratory Practices.

Franklin B. Newman
QA Auditor

SPONSOR: COVANCE LABS INC STUDY: 6329-223

REPORT TYPE:	AUDIT DATE:	REPORT TO MANAGEMENT:	AUDIT #:
FT3, FT4	4-16-00	4-17-00	00-299

MANAGEMENT 4/17/00

3M_MN03279749

Appendix 6

Summary and Individual Blood Hormone Determination
Day -50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	54.69	14.54	29.48	20.01	0.00	0.44	89.59	4.96
I05517	49.55	3.04	51.76	54.86	0.00	0.98	125.67	3.25
I05519	64.74	6.12	31.21	17.51	0.00	0.92	82.21	5.11
I05520	47.30	10.74	30.92	39.76	0.00	2.11	122.59	3.13
I05526	60.37	0.09	31.69	27.63	0.00	0.86	132.25	3.80
I05527	50.69	6.48	43.40	24.47	0.00	3.34	102.72	3.52
MEAN	54.56	6.84	36.41	30.71	0.00	1.44	109.17	3.96
S.D.	6.785	5.199	9.077	14.158	0.000	1.084	20.673	0.864
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	71.04	1.18	38.90	51.37	0.00	1.44	133.26	6.14
I05515	38.63	9.81	27.91	17.75	0.00	1.04	83.16	3.32
I05516	58.36	0.34	32.30	29.41	0.00	1.13	138.37	8.91
I05521	58.05	14.26	59.78	62.35	0.00	1.45	130.08	4.56
MEAN	56.52	6.40	39.72	40.22	0.00	1.27	121.22	5.73
S.D.	13.374	6.767	14.114	20.296	0.000	0.211	25.600	2.412
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	48.00	3.04	43.24	30.43	0.00	1.20	122.64	5.60
I05510	38.05	0.41	23.74	26.96	0.00	0.60	115.95	3.48
I05518	50.92	3.77	53.56	28.80	0.00	1.67	124.80	4.29
I05523	56.98	4.38	43.26	39.35	0.00	0.00	162.12	6.48
I05524	62.46	1.02	30.26	26.55	0.00	0.62	117.52	4.28
I05528	63.18	0.97	26.50	18.67	0.00	1.04	113.68	4.49
MEAN	53.27	2.27	36.76	28.46	0.00	0.86	126.12	4.77
S.D.	9.606	1.674	11.692	6.698	0.000	0.578	18.122	1.079
N	6	6	6	6	6	6	6	6

3M_MN03279750

Appendix 6

Summary and Individual Blood Hormone Determination
Day -50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05506	46.92	3.31	26.45	28.18	0.00	0.08	148.18	4.90
I05507	41.20	21.45	49.83	33.79	0.00	1.45	113.67	4.66
I05509	65.60	2.21	30.80	24.47	0.00	1.81	112.11	5.14
I05511	48.27	18.86	32.75	46.01	0.00	0.42	152.20	4.13
I05512	49.15	0.29	38.12	22.90	0.00	0.60	162.79	4.63
I05522	44.81	12.56	49.93	48.77	0.00	1.66	151.90	3.36
MEAN	49.33	9.78	37.98	34.19	0.00	1.00	140.14	4.47
S.D.	8.464	9.117	9.951	10.950	0.000	0.726	21.669	0.639
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	68.63	0.49	48.75	38.12	0.00	0.75	91.26	5.25
I05530	64.90	0.03	48.53	32.43	0.00	0.74	153.02	8.79
I05531	55.89	0.36	53.05	61.53	0.00	0.30	45.26	16.59
I05535	51.86	0.38	50.13	31.55	0.00	1.14	128.93	3.80
I05544	55.61	0.38	37.23	26.87	0.00	2.67	96.13	4.13
I05549	52.20	0.04	50.33	27.55	0.00	0.69	87.95	4.43
MEAN	58.18	0.28	48.0	36.34	0.00	1.05	100.43	7.17
S.D.	6.956	0.195	5.519	12.984	0.000	0.838	37.095	4.963
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05537	73.24	0.19	91.05	129.22	0.00	0.00	158.33	6.80
I05541	82.66	0.66	60.36	42.73	0.00	0.65	140.97	6.99
I05547	71.82	0.16	55.87	39.96	0.00	0.79	115.35	4.66
I05550	46.90	0.29	50.49	46.09	0.00	0.88	107.01	4.27
MEAN	68.66	0.33	64.44	64.50	0.00	0.58	130.42	5.68
S.D.	15.280	0.230	18.191	43.219	0.000	0.398	23.561	1.414
N	4	4	4	4	4	4	4	4

3M_MN03279751

Appendix 6

Summary and Individual Blood Hormone Determination
Day -50

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	56.59	0.13	51.67	35.53	0.00	4.46	64.50	5.49
I05538	51.32	0.23	52.69	35.81	0.00	0.00	137.04	3.21
I05539	66.59	0.34	129.12	82.62	0.00	1.48	117.92	5.68
I05545	63.69	0.25	176.45	132.50	0.00	0.67	135.57	5.05
I05548	65.26	0.45	63.53	47.80	0.00	0.00	104.23	4.24
I05552	49.09	0.33	23.32	15.96	0.00	1.52	71.94	6.35
MEAN	58.76	0.29	82.80	58.37	0.00	1.36	105.20	5.00
S.D.	7.502	0.110	57.794	42.484	0.000	1.663	31.182	1.123
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	58.99	0.35	96.99	64.39	0.00	2.10	101.63	4.25
I05534	59.49	0.05	42.90	34.98	0.00	0.98	97.38	4.94
I05536	51.68	0.29	47.76	46.31	0.00	0.17	124.27	5.78
I05540	46.17	0.15	54.58	88.38	0.00	1.51	126.16	5.23
I05542	87.39	0.63	39.07	31.81	0.00	0.32	109.29	6.44
I05551	67.04	0.38	86.86	107.99	0.00	0.21	95.16	5.78
MEAN	61.79	0.31	61.36	62.31	0.00	0.88	108.98	5.40
S.D.	14.438	0.201	24.447	30.672	0.000	0.795	13.480	0.766
N	6	6	6	6	6	6	6	6

3M_MN03279752

Appendix 6

Summary and Individual Blood Hormone Determination
Day -40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	57.43	3.30	23.93	11.61	0.00	0.26	113.08	4.24
I05517	43.65	2.35	42.46	29.34	0.00	0.50	104.32	2.99
I05519	71.52	0.37	32.19	19.63	0.00	0.56	122.61	5.26
I05520	52.42	11.10	46.29	35.48	0.00	0.34	137.32	3.54
I05526	84.79	0.21	26.36	20.87	0.00	1.13	154.19	3.86
I05527	79.36	5.72	33.96	34.93	0.00	0.95	99.03	4.72
MEAN	64.86	3.84	34.20	25.31	0.00	0.62	121.76	4.10
S.D.	16.197	4.098	8.780	9.507	0.000	0.345	20.932	0.819
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	79.55	1.10	35.50	4.64	0.00	1.16	140.65	6.28
I05515	67.38	5.86	21.00	28.82	0.00	0.21	97.32	4.57
I05516	87.16	0.19	23.13	23.58	0.00	0.94	127.13	5.92
I05521	62.83	9.82	63.80	49.29	0.00	1.12	120.13	6.34
MEAN	74.23	4.24	35.86	26.58	0.00	0.86	121.31	5.78
S.D.	11.141	4.473	19.695	18.359	0.000	0.442	18.118	0.826
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	50.93	4.07	45.97	18.34	0.00	0.85	130.66	6.01
I05510	77.83	0.53	31.51	17.29	0.00	0.69	104.25	3.94
I05518	67.52	0.93	45.46	25.93	0.00	1.87	145.93	4.76
I05523	61.48	1.81	34.64	27.49	0.00	0.00	136.56	5.13
I05524	63.60	0.68	31.45	16.37	0.00	0.75	107.44	4.14
I05528	72.30	6.04	28.17	13.10	0.00	0.00	111.71	3.63
MEAN	65.61	2.34	36.20	19.75	0.00	0.69	122.76	4.60
S.D.	9.320	2.235	7.651	5.688	0.000	0.689	17.258	0.881
N	6	6	6	6	6	6	6	6

3M_MN03279753

Appendix 6

Summary and Individual Blood Hormone Determination
Day -40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	49.42	1.27	28.98	21.20	0.00	0.82	157.93	5.12
I05507	44.53	7.01	32.46	30.79	0.00	1.92	88.90	6.69
I05509	82.95	1.03	27.21	14.40	0.00	0.57	116.45	4.44
I05511	75.12	16.78	37.12	42.06	0.00	0.59	188.61	4.90
I05512	81.05	0.14	37.24	21.98	0.00	0.25	169.66	3.80
I05522	58.08	10.11	52.20	49.26	0.00	1.54	158.85	3.42
MEAN	65.19	6.06	35.87	29.95	0.00	0.95	146.73	4.73
S.D.	16.683	6.565	8.991	13.432	0.000	0.643	36.914	1.157
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	81.80	0.41	42.94	31.46	0.00	0.00	75.62	4.60
I05530	70.50	0.01	90.55	65.47	0.00	0.00	128.68	5.65
I05531	85.44	0.25	52.80	91.87	0.00	0.11	73.71	4.93
I05535	85.08	0.37	79.48	52.46	0.00	0.73	125.42	4.02
I05544	89.58	0.44	72.70	46.44	0.00	2.16	106.71	3.73
I05549	66.75	0.15	50.29	34.57	0.00	0.69	76.27	4.49
MEAN	79.86	0.27	64.79	53.71	0.00	0.62	97.74	4.57
S.D.	9.123	0.168	18.833	22.407	0.000	0.827	25.813	0.680
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	79.24	0.17	59.21	48.11	0.00	0.01	131.29	6.03
I05541	108.45	0.77	116.25	90.73	0.00	0.26	132.70	6.63
I05547	67.50	0.19	40.43	67.42	0.00	1.14	86.87	4.59
I05550	89.13	0.23	62.40	61.31	0.00	0.93	88.98	2.99
MEAN	86.08	0.34	69.57	66.89	0.00	0.59	109.96	5.06
S.D.	17.337	0.288	32.593	17.818	0.000	0.536	25.465	1.624
N	4	4	4	4	4	4	4	4

3M_MN03279754

Appendix 6

Summary and Individual Blood Hormone Determination
Day -40

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	63.15	0.06	33.18	28.09	0.00	1.38	95.64	4.36
I05538	70.84	0.08	53.04	40.85	0.00	0.00	114.53	3.19
I05539	68.60	0.35	492.12	272.75	0.00	1.33	114.65	6.09
I05545	64.50	0.13	114.49	81.43	0.00	0.17	106.43	4.61
I05548	67.75	0.66	75.11	55.06	0.00	0.00	116.19	4.02
I05552	53.55	0.40	45.64	48.94	0.00	2.13	82.66	4.69
MEAN	64.73	0.28	135.60	88.02	0.00	0.84	105.02	4.49
S.D.	6.148	0.234	176.980	92.174	0.000	0.901	13.401	0.953
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	69.41	0.73	90.70	76.17	0.00	0.00	108.13	4.03
I05534	60.42	0.28	60.87	66.05	0.00	0.13	81.98	4.39
I05536	66.67	0.15	66.36	59.95	0.00	0.04	114.01	5.41
I05540	65.40	0.08	35.46	33.64	0.00	1.39	119.54	4.36
I05542	92.90	0.32	59.88	43.92	0.00	1.02	151.57	7.00
I05551	64.20	0.42	76.86	82.48	0.00	0.24	108.31	5.21
MEAN	69.83	0.33	65.02	60.37	0.00	0.47	113.92	5.07
S.D.	11.681	0.230	18.541	18.740	0.000	0.587	22.513	1.087
N	6	6	6	6	6	6	6	6

3M_MN03279755

Appendix 6

Summary and Individual Blood Hormone Determination
Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	59.85	2.60	18.82	27.46	0.00	0.00	101.15	3.82
I05517	50.40	2.25	35.11	41.06	0.00	0.00	112.05	3.11
I05519	74.30	0.40	25.09	31.24	0.00	0.00	112.26	4.39
I05520	55.75	3.11	29.31	51.38	0.00	0.00	115.75	2.89
I05526	72.92	0.48	22.23	21.97	0.00	0.00	127.37	2.83
I05527	67.71	2.43	29.56	26.74	0.00	0.00	92.95	3.90
MEAN	63.49	1.88	26.69	33.31	0.00	0.00	110.26	3.49
S.D.	9.676	1.151	5.838	10.926	0.000	0.000	11.939	0.637
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	81.35	1.41	31.71	43.75	0.00	0.00	120.88	5.30
I05515	77.44	1.40	26.17	32.63	0.00	0.00	126.21	2.51
I05516	50.15	0.31	29.91	35.52	0.00	0.00	97.87	5.85
I05521	61.80	3.03	40.47	57.63	0.00	0.00	105.02	4.16
MEAN	67.69	1.54	32.07	42.38	0.00	0.00	112.50	4.46
S.D.	14.422	1.121	6.060	11.204	0.000	0.000	13.269	1.475
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	58.10	5.40	30.42	27.04	0.00	0.00	117.98	5.76
I05510	68.33	0.38	25.88	22.77	0.00	0.00	114.00	3.90
I05518	54.45	1.06	26.53	39.19	0.00	0.32	149.51	4.50
I05523	66.60	2.36	25.62	37.12	0.00	0.00	140.05	6.33
I05524	91.70	1.11	23.61	32.22	0.00	0.00	86.43	3.74
I05528	69.75	0.74	22.60	21.66	0.00	0.00	100.82	3.55
MEAN	68.16	1.84	25.78	30.00	0.00	0.05	118.13	4.63
S.D.	13.025	1.867	2.718	7.358	0.000	0.131	23.608	1.155
N	6	6	6	6	6	6	6	6

3M_MN03279756

Appendix 6

Summary and Individual Blood Hormone Determination
Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	47.35	0.85	26.15	31.68	0.00	0.00	149.78	5.35
I05507	48.45	1.81	32.25	32.53	0.00	0.00	117.94	6.72
I05509	71.85	1.13	24.92	22.42	0.00	0.00	130.15	5.49
I05511	71.00	2.40	24.62	48.45	0.00	0.00	137.80	4.61
I05512	65.67	0.17	33.79	36.30	0.00	0.00	128.50	3.49
I05522	61.00	3.96	36.25	41.15	0.00	0.00	133.19	3.60
MEAN	60.89	1.72	29.66	35.42	0.00	0.00	132.89	4.88
S.D.	10.801	1.341	5.047	8.885	0.000	0.000	10.581	1.235
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	72.55	0.28	35.08	49.80	0.00	0.00	82.65	4.40
I05530	76.75	0.07	122.95	102.72	0.00	0.01	184.14	8.76
I05531	48.35	0.50	75.71	92.55	0.00	0.00	90.39	8.31
I05535	68.60	0.35	61.83	59.99	0.00	0.00	109.23	5.76
I05544	52.84	0.42	208.06	101.29	0.00	1.26	145.88	5.54
I05549	55.44	0.07	45.31	59.93	0.00	0.00	99.05	5.97
MEAN	62.42	0.28	91.49	77.71	0.00	0.21	118.56	6.46
S.D.	11.701	0.179	64.841	23.710	0.000	0.514	38.982	1.705
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	80.90	0.16	63.92	82.77	0.00	0.00	167.85	9.01
I05541	66.41	0.17	70.21	78.87	0.00	0.00	119.83	7.95
I05547	83.87	0.46	65.82	70.18	0.00	0.00	284.36	6.35
I05550	47.16	0.31	44.95	119.41	0.00	0.00	110.60	4.93
MEAN	69.59	0.28	61.23	87.81	0.00	0.00	170.66	7.06
S.D.	16.783	0.141	11.165	21.716	0.000	0.000	79.847	1.792
N	4	4	4	4	4	4	4	4

3M_MN03279757

Appendix 6

Summary and Individual Blood Hormone Determination
Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	57.80	0.18	73.31	64.68	0.00	1.98	221.66	8.42
I05538	87.05	0.09	34.86	46.45	0.00	0.00	133.62	6.15
I05539	50.45	0.08	45.40	87.24	0.00	0.00	122.82	8.69
I05545	57.66	0.03	97.36	92.73	0.00	0.00	126.61	7.04
I05548	56.95	0.59	80.60	76.53	0.00	0.00	125.43	5.95
I05552	62.72	0.54	35.64	71.52	0.00	0.08	99.82	6.53
MEAN	62.11	0.25	61.20	73.19	0.00	0.34	138.33	7.13
S.D.	12.832	0.248	26.181	16.617	0.000	0.802	42.411	1.168
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	80.05	0.55	197.69	243.31	0.00	0.04	298.47	7.38
I05534	71.00	0.19	75.81	98.79	0.00	0.00	161.23	6.76
I05536	48.50	0.16	51.69	75.52	0.00	0.00	130.92	6.89
I05540	68.05	0.05	27.69	27.51	0.00	0.00	94.60	4.96
I05542	82.95	0.37	53.10	54.14	0.00	0.00	124.93	8.88
I05551	63.39	0.18	133.61	259.85	0.00	0.00	119.61	7.73
MEAN	68.99	0.25	89.93	126.52	0.00	0.01	154.96	7.10
S.D.	12.436	0.179	63.894	99.828	0.000	0.016	73.494	1.295
N	6	6	6	6	6	6	6	6

3M_MN03279758

Appendix 6

Summary and Individual Blood Hormone Determination
Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	59.57	0.56	14.21	21.01	0.00	0.02	252.81	3.21
I05517	58.12	1.38	30.66	42.28	0.00	0.86	298.92	4.67
I05519	56.30	0.36	19.61	34.97	0.00	0.00	279.29	4.18
I05520	51.45	2.11	31.75	65.45	0.00	0.00	241.26	4.63
I05526	54.80	0.89	17.02	32.02	0.00	0.47	316.62	3.30
I05527	56.59	10.76	31.22	47.15	0.00	0.70	250.74	4.37
MEAN	56.14	2.68	24.08	40.48	0.00	0.34	273.27	4.06
S.D.	2.818	4.010	8.004	15.181	0.000	0.387	30.081	0.649
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	72.96	2.64	32.81	84.41	0.00	0.70	306.12	6.21
I05515	56.42	0.94	23.69	39.25	0.00	0.43	283.59	3.96
I05516	53.39	0.22	14.32	48.23	0.00	0.13	272.54	4.83
I05521	60.98	10.10	37.38	98.72	0.00	0.14	229.90	5.43
MEAN	60.94	3.48	27.05	67.65	0.00	0.35	273.04	5.11
S.D.	8.601	4.532	10.218	28.460	0.000	0.272	31.973	0.951
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	61.35	0.76	23.37	36.78	0.00	0.07	265.64	4.21
I05510	66.10	0.60	24.13	29.76	0.00	0.68	255.41	4.29
I05518	52.23	0.83	26.75	38.59	0.00	0.92	272.85	3.46
I05523	61.98	2.11	27.07	44.88	0.00	0.00	284.01	5.45
I05524	64.07	0.68	15.77	33.62	0.00	0.32	221.20	3.41
I05528	73.61	1.04	10.40	23.33	0.00	0.01	228.32	3.17
MEAN	63.22	1.00	21.25	34.49	0.00	0.33	254.57	4.00
S.D.	6.968	0.563	6.703	7.452	0.000	0.387	25.007	0.844
N	6	6	6	6	6	6	6	6

3M_MN03279759

Appendix 6

Summary and Individual Blood Hormone Determination
Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	60.57	1.13	24.16	182.56	0.00	0.00	229.83	3.61
I05507	69.37	14.80	51.78	91.86	0.00	0.36	199.81	3.33
I05509	86.47	1.24	17.49	35.79	0.00	0.66	259.19	4.31
I05511	75.68	1.50	6.35	35.89	0.00	0.14	230.58	4.22
I05512	64.22	0.25	21.10	39.97	0.00	0.04	246.92	2.99
I05522	53.06	37.59	69.66	162.36	0.00	0.03	270.21	3.18
MEAN	68.23	9.42	31.76	91.41	0.00	0.21	239.42	3.61
S.D.	11.785	14.866	23.908	66.580	0.000	0.259	25.037	0.549
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	58.61	0.31	42.85	72.21	0.00	0.18	256.85	5.54
I05530	77.09	0.08	39.24	74.66	0.00	0.69	189.21	8.01
I05531	60.99	0.20	88.53	208.96	0.00	0.27	211.24	6.09
I05535	61.72	0.25	40.91	63.01	0.00	0.40	267.83	5.64
I05544	62.18	0.46	75.30	65.02	0.00	2.61	216.47	4.38
I05549	56.68	0.18	65.95	56.58	0.00	0.21	236.08	5.23
MEAN	62.88	0.25	58.80	90.07	0.00	0.73	229.61	5.82
S.D.	7.266	0.130	20.805	58.605	0.000	0.941	29.621	1.217
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	76.40	0.23	64.21	177.41	0.00	0.00	279.90	6.02
I05541	81.53	0.31	61.86	127.77	0.00	0.01	240.82	6.09
I05547	63.15	0.39	45.86	76.97	0.00	0.68	223.65	4.37
I05550	64.55	0.27	55.39	143.29	0.00	0.27	232.10	3.75
MEAN	71.41	0.30	56.83	131.36	0.00	0.24	244.12	5.06
S.D.	8.993	0.068	8.209	41.770	0.000	0.319	24.864	1.180
N	4	4	4	4	4	4	4	4

3M_MN03279760

Appendix 6

Summary and Individual Blood Hormone Determination
Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	66.39	0.20	383.80	351.81	0.00	1.56	192.15	4.53
I05538	54.30	0.07	27.95	58.49	0.00	0.00	225.80	3.21
I05539	50.23	0.08	38.80	86.17	0.00	1.21	221.63	3.49
I05545	46.45	0.09	119.09	227.52	0.00	0.00	237.82	4.18
I05548	46.73	0.30	34.02	52.35	0.00	0.00	184.62	2.78
I05552	56.82	0.48	27.36	51.92	0.00	0.91	220.15	3.89
MEAN	53.49	0.20	105.17	138.04	0.00	0.61	213.70	3.68 *
S.D.	7.537	0.162	140.935	124.485	0.000	0.703	20.701	0.646
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	63.27	0.29	70.06	150.87	0.00	1.07	190.90	3.51
I05534	53.74	0.15	49.92	123.86	0.00	1.59	203.76	5.03
I05536	55.56	0.19	42.44	63.03	0.00	0.00	204.79	3.62
I05540	54.54	0.07	31.28	47.69	0.00	0.26	191.80	3.16
I05542	54.14	0.09	67.52	67.27	0.00	0.52	196.18	4.84
I05551	68.07	0.12	104.58	271.41	0.00	0.10	190.95	5.21
MEAN	58.22	0.15	60.97	120.69	0.00	0.59	196.40	4.23 *
S.D.	5.998	0.080	25.978	83.839	0.000	0.622	6.414	0.895
N	6	6	6	6	6	6	6	6

3M_MN03279761

Appendix 6

Summary and Individual Blood Hormone Determination
Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	64.62	0.50	17.70	28.21	0.00	0.25	119.34	2.89
I05517	57.71	1.30	35.89	51.07	0.00	1.72	163.61	2.79
I05519	60.20	0.39	27.43	24.22	0.00	0.00	145.97	2.77
I05520	50.13	2.28	27.41	69.97	0.00	0.00	164.61	3.81
I05526	63.25	0.65	15.13	34.66	0.00	0.00	139.41	1.73
I05527	43.13	1.40	38.03	42.05	0.00	1.42	135.30	2.55
MEAN	56.51	1.09	26.93	41.70	0.00	0.57	144.71	2.76
S.D.	8.318	0.719	9.256	16.877	0.000	0.790	17.407	0.667
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	86.10	2.10	29.19	71.76	0.00	0.54	147.03	4.36
I05515	59.33	0.67	27.02	53.19	0.00	0.11	143.03	3.15
I05516	49.45	0.27	17.22	77.85	0.00	0.47	118.77	4.47
I05521	62.77	3.13	44.97	95.20	0.00	0.57	148.62	3.64
MEAN	64.41	1.54	29.60	74.50 *	0.00	0.42	139.36	3.91 *
S.D.	15.522	1.318	11.494	17.333	0.000	0.213	13.928	0.624
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	70.82	1.07	34.40	36.91	0.00	1.22	131.32	3.22
I05510	58.68	0.51	25.73	26.22	0.00	1.53	117.68	2.56
I05518	60.80	0.77	31.30	30.11	0.00	2.85	167.15	2.73
I05523	76.60	2.83	35.79	62.53	0.00	0.00	166.99	4.44
I05524	62.76	0.94	21.61	31.79	0.00	0.00	135.36	2.60
I05528	63.38	0.77	14.54	33.29	0.00	0.29	131.96	2.90
MEAN	65.51	1.15	27.23	36.81	0.00	0.98	141.74	3.08
S.D.	6.813	0.845	8.199	13.086	0.000	1.118	20.528	0.711
N	6	6	6	6	6	6	6	6

3M_MN03279762

Appendix 6

Summary and Individual Blood Hormone Determination
Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	70.92	0.61	6.89	84.83	0.00	0.00	110.61	2.24
I05507	69.36	2.05	14.27	50.89	0.00	0.33	96.11	2.24
I05509	80.21	1.10	8.28	33.16	0.00	0.97	120.78	3.01
I05511	83.50	1.52	4.43	43.47	0.00	0.00	133.14	3.42
I05512	69.38	0.19	20.03	35.68	0.00	0.00	121.31	1.84
I05522	65.14	1.87	30.27	56.44	0.00	0.00	142.07	2.79
MEAN	73.09 *	1.22	14.03	50.75	0.00	0.22	120.67	2.59
S.D.	7.137	0.728	9.757	18.886	0.000	0.392	16.237	0.585
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	73.17	0.25	42.49	95.52	0.00	2.88	86.34	2.55
I05530	80.23	0.03	40.60	73.45	0.00	0.32	157.85	5.01
I05531	63.57	0.23	87.01	154.45	0.00	0.00	105.00	3.16
I05535	77.78	0.29	135.19	166.44	0.00	0.00	104.25	3.14
I05544	72.02	0.24	110.97	116.03	0.00	3.86	94.26	3.32
I05549	67.18	0.11	88.68	104.97	0.00	0.10	141.85	3.98
MEAN	72.33	0.19	84.16	118.48	0.00	1.19	114.93	3.53
S.D.	6.264	0.100	37.377	35.602	0.000	1.718	28.369	0.859
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	75.87	0.24	97.35	171.29	0.00	0.00	178.52	4.64
I05541	88.44	0.30	95.89	128.24	0.00	0.09	124.69	5.27
I05547	67.51	0.41	71.56	149.12	0.00	1.74	122.85	3.51
I05550	72.45	0.42	63.70	160.38	0.00	0.00	116.15	2.87
MEAN	76.07	0.34	82.13	152.26	0.00	0.46	135.55	4.07
S.D.	8.934	0.087	17.053	18.393	0.000	0.856	28.879	1.083
N	4	4	4	4	4	4	4	4

3M_MN03279763

Appendix 6

Summary and Individual Blood Hormone Determination
Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	63.46	0.05	196.89	162.41	0.00	3.00	100.87	4.30
I05538	62.14	0.06	40.91	57.31	0.00	0.00	122.69	1.97
I05539	65.91	0.00	50.54	122.72	0.00	1.30	109.98	3.15
I05545	60.86	0.05	142.62	226.73	0.00	0.00	147.17	2.68
I05548	48.14	0.36	60.76	96.83	0.00	0.48	99.01	1.94
I05552	61.25	0.44	60.28	85.06	0.00	0.13	102.13	2.55
MEAN	60.29	0.16	92.00	125.18	0.00	0.82	113.64	2.77
S.D.	6.228	0.189	63.048	61.195	0.000	1.176	18.596	0.880
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	68.36	1.04	539.64	637.44	0.00	1.64	92.49	2.41
I05534	67.55	0.05	21.16	92.30	0.00	1.91	104.34	3.70
I05536	73.98	0.12	53.49	103.29	0.00	0.17	101.67	2.53
I05540	73.87	0.09	47.69	87.57	0.00	0.00	102.37	1.65
I05542	66.81	0.40	414.10	248.93	0.00	0.69	84.83	3.75
I05551	113.15	0.10	98.43	208.43	0.00	0.00	85.64	4.45
MEAN	77.29	0.30	195.75	229.66	0.00	0.74	95.22	3.08
S.D.	17.850	0.384	222.733	210.776	0.000	0.849	8.753	1.049
N	6	6	6	6	6	6	6	6

3M_MN03279764

Appendix 6

Summary and Individual Blood Hormone Determination
Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	63.12	0.65	3.16	20.61	0.00	0.00	141.51	3.96
I05517	72.02	1.78	22.72	53.30	0.00	0.00	162.07	4.25
I05519	68.04	0.44	14.07	30.76	0.00	0.00	144.10	3.67
I05520	50.11	2.53	19.55	65.61	0.00	0.00	148.94	4.53
I05526	60.09	0.96	16.52	29.74	0.00	0.00	161.62	2.93
I05527	48.19	1.57	35.93	51.35	0.00	0.00	162.45	4.02
MEAN	60.26	1.32	18.66	41.90	0.00	0.00	153.45	3.89
S.D.	9.547	0.786	10.784	17.359	0.000	0.000	9.720	0.553
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	70.30	1.86	29.08	82.17	0.00	0.00	166.24	5.41
I05515	48.85	0.96	29.88	40.06	0.00	0.00	148.07	4.38
I05516	58.29	0.34	28.37	40.27	0.00	0.00	151.67	5.22
I05521	64.30	10.76	41.20	107.46	0.00	0.00	146.06	6.17
MEAN	60.44	3.48	32.13 *	67.49	0.00	0.00	153.01	5.30 *
S.D.	9.148	4.893	6.076	33.199	0.000	0.000	9.120	0.735
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	63.97	1.54	17.57	37.08	0.00	0.00	143.76	4.56
I05510	58.44	1.05	20.81	34.69	0.00	0.00	141.60	4.37
I05518	52.27	0.90	20.88	26.72	0.00	0.17	156.52	4.49
I05523	64.33	2.03	20.84	47.88	0.00	0.00	174.10	6.03
I05524	73.62	0.82	13.64	34.88	0.00	0.00	119.61	3.93
I05528	72.47	0.73	21.33	23.84	0.00	0.00	143.77	3.45
MEAN	64.18	1.18	19.18	34.18	0.00	0.03	146.56	4.47
S.D.	8.157	0.506	3.040	8.478	0.000	0.069	18.023	0.870
N	6	6	6	6	6	6	6	6

3M_MN03279765

Appendix 6

Summary and Individual Blood Hormone Determination
Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05506	73.97	0.48	2.29	48.87	0.00	0.00	107.40	4.98
I05507	49.60	2.71	22.58	40.22	0.00	0.00	89.57	4.45
I05509	86.62	1.73	4.65	34.03	0.00	0.00	127.61	4.61
I05511	60.08	1.70	3.05	38.67	0.00	0.00	144.57	5.46
I05512	64.66	0.26	13.32	33.13	0.00	0.00	102.29	3.78
I05522	67.73	1.87	19.66	57.55	0.00	0.00	136.40	4.38
MEAN	67.11	1.46	10.93	42.08	0.00	0.00	117.97 *	4.61
S.D.	12.571	0.923	8.875	9.438	0.000	0.000	21.468	0.570
N	6	6	6	6	6	6	6	6
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05529	74.49	0.55	59.28	96.58	0.00	0.00	95.65	3.94
I05530	69.78	0.06	30.39	37.67	0.00	0.00	200.64	6.12
I05531	50.36	0.30	76.52	104.81	0.00	0.00	117.41	4.52
I05535	62.89	0.29	126.05	94.80	0.00	0.00	144.43	4.54
I05544	70.71	1.05	218.24	115.65	0.00	0.00	160.65	4.46
I05549	65.26	0.32	85.32	88.15	0.00	0.00	139.16	5.01
MEAN	65.58	0.43	99.30	89.61	0.00	0.00	142.99	4.77
S.D.	8.513	0.342	66.222	27.146	0.000	0.000	36.187	0.746
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day								
I05537	75.93	0.30	276.11	579.38	0.00	0.00	161.68	5.86
I05541	89.16	0.37	88.60	143.46	0.00	0.00	144.58	6.55
I05547	68.87	0.38	48.03	87.11	0.00	0.00	121.55	5.03
I05550	61.58	0.28	34.29	106.94	0.00	0.00	160.17	6.54
MEAN	73.89	0.33	111.76	229.22	0.00	0.00	147.00	6.00
S.D.	11.748	0.050	111.968	234.602	0.000	0.000	18.641	0.720
N	4	4	4	4	4	4	4	4

3M_MN03279766

Appendix 6

Summary and Individual Blood Hormone Determination
Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	53.44	0.07	208.42	161.28	0.00	0.09	120.33	4.88
I05538	54.36	0.09	55.31	71.47	0.00	0.00	113.79	3.27
I05539	56.38	0.01	48.35	96.47	0.00	0.00	114.24	3.49
I05545	50.87	0.00	64.59	142.80	0.00	0.00	113.45	4.38
I05548	46.19	0.30	29.92	64.58	0.00	0.00	109.64	3.13
I05552	55.40	0.38	74.01	74.24	0.00	0.00	92.26	3.47
MEAN	52.77	0.14	80.10	101.81	0.00	0.02	110.62 *	3.77
S.D.	3.737	0.159	64.629	40.773	0.000	0.037	9.628	0.697
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	63.67	0.51	162.24	186.20	0.00	0.00	95.87	4.18
I05534	57.80	0.04	34.90	67.09	0.00	0.00	81.56	5.45
I05536	71.04	0.14	29.06	60.95	0.00	0.00	92.51	4.94
I05540	85.09	0.26	42.06	65.39	0.00	0.00	90.84	3.81
I05542	58.02	0.23	95.90	72.08	0.00	0.00	81.86	5.99
I05551	91.43	0.42	394.36	503.53	0.00	0.00	83.67	5.15
MEAN	71.18	0.27	126.42	159.21	0.00	0.00	87.72 *	4.92
S.D.	14.228	0.174	140.697	175.397	0.000	0.000	6.128	0.807
N	6	6	6	6	6	6	6	6

3M_MN03279767

Appendix 6

Summary and Individual Blood Hormone Determination
Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05508	49.36	0.80	11.03	16.55	0.00	0.01	153.39	4.94
I05517	44.88	0.89	26.64	34.19	0.00	1.43	155.85	4.14
I05519	54.72	0.41	21.40	24.00	0.00	0.48	152.78	4.19
I05520	37.96	3.20	19.07	35.67	0.00	0.35	168.82	4.97
I05526	60.22	0.91	15.79	22.56	0.00	0.30	162.99	3.38
I05527	39.62	2.05	43.81	46.79	0.00	0.02	164.16	4.68
MEAN	47.79	1.38	22.96	29.96	0.00	0.43	159.67	4.38
S.D.	8.681	1.049	11.485	10.990	0.000	0.524	6.579	0.608
N	6	6	6	6	6	6	6	6
Group: Male 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05514	57.72	1.43	29.26	65.16	0.00	0.76	148.24	5.02
I05515	41.90	0.44	9.14	29.60	0.00	0.32	133.97	3.70
I05516	43.62	0.31	16.57	29.96	0.00	0.11	77.19	5.04
I05521	53.31	8.03	41.46	70.45	0.00	0.15	117.72	5.13
MEAN	49.14	2.55	24.11	48.79	0.00	0.34	119.28 *	4.72
S.D.	7.613	3.686	14.242	22.060	0.000	0.298	30.705	0.683
N	4	4	4	4	4	4	4	4
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	42.54	0.25	28.98	21.56	0.00	1.10	134.08	4.41
I05510	39.10	2.63	25.43	19.76	0.00	0.51	110.87	3.40
I05518	46.25	0.70	28.63	25.41	0.00	2.09	136.26	4.42
I05523	57.87	2.06	26.43	39.59	0.00	0.18	144.20	4.67
I05524	51.67	0.73	20.26	20.89	0.00	0.09	114.48	3.94
I05528	52.89	0.42	9.63	13.61	0.00	0.46	107.88	3.12
MEAN	48.39	1.13	23.23	23.47	0.00	0.74	124.63 *	3.99
S.D.	7.014	0.973	7.363	8.774	0.000	0.751	15.365	0.621
N	6	6	6	6	6	6	6	6

3M_MN03279768

Appendix 6

Summary and Individual Blood Hormone Determination
Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05507	59.90	2.10	0.00	33.59	0.00	1.59	58.09	5.27
I05511	43.70	0.69	1.01	27.68	0.00	0.34	97.68	7.00
I05512	70.20	0.04	0.00	22.69	0.00	0.59	34.06	3.25
I05522	59.49	1.80	2.00	36.89	0.00	1.18	75.57	5.85
MEAN	58.32	1.16	0.75 *	30.21	0.00	0.93	66.35 *	5.34
S.D.	10.935	0.961	0.958	6.298	0.000	0.566	26.941	1.569
N	4	4	4	4	4	4	4	4
Group: Female 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	65.21	0.17	232.49	351.64	0.00	1.33	95.65	4.83
I05530	74.89	0.01	47.22	68.58	0.00	0.00	183.66	7.22
I05531	35.19	0.03	51.65	77.36	0.00	0.00	115.47	5.01
I05535	74.58	0.52	318.47	239.29	0.00	0.06	139.41	5.84
I05544	61.62	0.34	162.44	153.92	0.00	2.75	152.04	5.08
I05549	41.85	0.02	78.63	61.78	0.00	0.22	125.36	5.95
MEAN	58.89	0.18	148.48	158.76	0.00	0.73	135.27	5.66
S.D.	16.743	0.209	110.143	116.512	0.000	1.115	30.659	0.894
N	6	6	6	6	6	6	6	6
Group: Female 2 Dose Level: 0.03			Dosage Unit: mg/kg/day					
I05537	76.03	0.29	254.69	492.79	0.00	0.00	148.10	5.29
I05541	61.45	0.13	47.66	101.86	0.00	0.08	131.20	5.85
I05547	39.39	0.26	41.73	164.10	0.00	0.85	98.77	3.35
I05550	59.31	0.14	156.72	364.55	0.00	1.77	102.12	2.84
MEAN	59.05	0.21	125.20	280.83	0.00	0.68	120.05	4.33
S.D.	15.063	0.082	101.227	180.363	0.000	0.824	23.703	1.462
N	4	4	4	4	4	4	4	4

3M_MN03279769

Appendix 6

Summary and Individual Blood Hormone Determination
Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05532	47.71	0.01	197.86	141.98	0.00	4.33	90.44	4.36
I05538	36.38	0.04	45.10	64.69	0.00	0.25	100.45	2.83
I05539	42.82	0.00	52.30	100.79	0.00	0.89	106.11	3.63
I05545	48.24	0.04	52.62	74.46	0.00	0.62	86.22	4.00
I05548	32.13	0.03	39.61	51.74	0.00	0.98	103.15	4.03
I05552	48.26	0.16	36.02	60.51	0.65	0.57	93.10	4.59
MEAN	42.59	0.05	70.59	82.36	0.11	1.27	96.58 *	3.91 *
S.D.	6.904	0.058	62.705	33.716	0.265	1.520	7.824	0.622
N	6	6	6	6	6	6	6	6
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	63.42	0.17	36.11	55.31	0.00	2.31	83.76	5.31
I05534	66.38	0.05	9.45	37.27	0.00	1.10	81.38	6.31
I05536	51.73	0.09	0.00	53.37	0.00	0.62	76.41	5.96
I05540	60.27	0.15	47.41	60.05	0.00	0.21	71.65	3.74
I05542	56.03	0.19	93.61	115.82	0.00	0.55	92.22	5.83
I05551	96.30	0.07	52.80	99.85	0.00	0.22	104.92	6.49
MEAN	65.69	0.12	39.90	70.28	0.00	0.84	85.06 *	5.61
S.D.	15.876	0.058	33.589	30.505	0.000	0.793	11.963	1.002
N	6	6	6	6	6	6	6	6

3M_MN03279770

Appendix 6

Summary and Individual Blood Hormone Determination
Additional Collection - Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1	Dose Level: 0		Dosage Unit: mg/kg/day	
I05508	126.89	5.18	3.46	1.02
I05519	110.98	3.61	2.73	0.86
I05527	107.16	3.83	3.56	1.15
MEAN	115.01	4.21	3.25	1.01
S.D.	10.464	0.850	0.453	0.145
N	3	3	3	3
Group: Male 2	Dose Level: 0.03		Dosage Unit: mg/kg/day	
I05514	111.98	5.14	3.97	1.07
I05515	103.61	4.58	3.01	1.10
I05516	120.14	5.44	4.11	1.16
I05521	106.40	5.36	4.31	1.50
MEAN	110.53	5.13	3.85	1.21
S.D.	7.289	0.388	0.577	0.199
N	4	4	4	4
Group: Male 3	Dose Level: 0.15		Dosage Unit: mg/kg/day	
I05510	95.90	4.19	2.88	1.02
I05518	93.03	4.41	2.49	0.93
I05524	86.79	3.88	2.38	0.79
I05528	100.26	4.85	3.07	1.01
MEAN	94.00 *	4.33	2.71	0.94
S.D.	5.649	0.408	0.324	0.106
N	4	4	4	4

3M_MN03279771

Appendix 6

Summary and Individual Blood Hormone Determination
Additional Collection - Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 4	Dose Level: 0.75		Dosage Unit: mg/kg/day	
I05506	59.28	2.74	4.90	1.36
I05507	55.46	3.07	3.16	1.15
I05512	13.96	1.55	1.83	0.86
MEAN	42.90 *	2.45 *	3.30	1.12
S.D.	25.135	0.800	1.540	0.251
N	3	3	3	3
Group: Female 1	Dose Level: 0		Dosage Unit: mg/kg/day	
I05530	131.98	5.33	5.50	1.43
I05531	87.43	3.10	2.62	0.78
I05535	98.87	3.48	4.93	1.17
I05544	104.98	4.28	3.52	0.86
MEAN	105.82	4.05	4.14	1.06
S.D.	18.899	0.986	1.313	0.299
N	4	4	4	4
Group: Female 2	Dose Level: 0.03		Dosage Unit: mg/kg/day	
I05541	109.59	4.13	4.24	1.32
I05547	81.34	3.14	3.41	0.86
I05550	86.09	3.49	2.80	0.85
MEAN	92.34	3.59	3.48	1.01
S.D.	15.127	0.502	0.723	0.269
N	3	3	3	3

3M_MN03279772

Appendix 6

Summary and Individual Blood Hormone Determination
Additional Collection - Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day				
I05532	74.72	3.27	3.03	1.04
I05538	77.02	2.98	1.89	0.59
I05545	72.24	2.96	2.71	0.90
I05548	94.86	3.87	3.88	1.06
MEAN	79.71 *	3.27	2.88	0.90
S.D.	10.287	0.424	0.823	0.217
N	4	4	4	4
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day				
I05534	51.14	2.88	4.52	1.49
I05536	59.03	2.43	3.87	1.00
I05540	60.77	3.13	2.04	0.79
I05551	64.05	2.83	3.30	1.03
MEAN	58.75 *	2.82	3.43	1.08
S.D.	5.482	0.290	1.054	0.295
N	4	4	4	4

3M_MN03279773

Appendix 6

Summary and Individual Blood Hormone Determination
Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05520	38.18	2.66	17.90	64.49	0.00	1.61	159.60	3.75
I05526	44.16	2.51	10.98	25.43	0.00	2.12	183.22	2.87
MEAN	41.17	2.59	14.44	44.96	0.00	1.87	171.41	3.31
S.D.	4.228	0.106	4.893	27.620	0.000	0.361	16.702	0.622
N	2	2	2	2	2	2	2	2
Group: Male 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05505	27.26	0.99	17.56	32.66	0.00	1.21	154.43	3.28
I05523	52.61	3.84	21.73	59.98	0.00	0.97	164.81	4.20
MEAN	39.94	2.42	19.65	46.32	0.00	1.09	159.62	3.74
S.D.	17.925	2.015	2.949	19.318	0.000	0.170	7.340	0.651
N	2	2	2	2	2	2	2	2
Group: Male 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05511	51.54	4.72	0.00	37.83	0.00	1.67	165.18	4.74
I05522	44.31	5.36	27.09	70.81	0.00	1.05	129.72	2.51
MEAN	47.93	5.04	13.55	54.32	0.00	1.36	147.45	3.625
S.D.	5.112	0.453	19.156	23.320	0.000	0.438	25.074	1.577
N	2	2	2	2	2	2	2	2

3M_MN03279774

Appendix 6

Summary and Individual Blood Hormone Determination
Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	54.69	0.86	53.08	83.74	0.00	1.78	116.20	4.89
I05549	40.39	0.12	43.63	64.84	0.00	1.66	133.52	6.58
MEAN	47.54	0.49	48.36	74.29	0.00	1.72	124.86	5.74
S.D.	10.112	0.523	6.682	13.364	0.000	0.85	12.247	1.195
N	2	2	2	2	2	2	2	2
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05539	57.55	0.10	44.84	71.13	0.00	1.88	114.34	3.37
I05552	59.07	0.82	68.85	88.81	0.00	0.59	121.25	3.91
MEAN	58.31	0.46	56.85	79.97	0.00	1.24	117.80	3.64
S.D.	1.075	0.509	16.978	12.502	0.000	0.912	4.886	0.382
N	2	2	2	2	2	2	2	2
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	55.91	0.61	133.46	289.99	0.00	1.76	99.29	3.93
I05542	66.34	0.37	88.23	154.68	0.00	1.56	101.57	3.51
MEAN	61.13	0.49	110.85	222.34	0.00	1.66	100.43	3.72
S.D.	7.375	0.170	31.982	95.679	0.000	0.141	1.612	0.297
N	2	2	2	2	2	2	2	2

3M_MN03279775

Appendix 6

Summary and Individual Blood Hormone Determination
Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05520	52.17	2.83	40.85	78.85	0.00	0.25	171.00	4.18
I05526	44.90	1.40	16.61	31.48	0.00	0.00	133.39	1.74
MEAN	48.54	2.12	28.73	55.67	0.00	0.13	152.20	2.96
S.D.	5.141	1.011	17.140	34.203	0.000	0.177	26.594	1.725
N	2	2	2	2	2	2	2	2
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	46.88	0.50	23.84	43.65	0.00	0.10	154.84	3.79
I05523	54.44	7.18	25.40	58.41	0.00	0.00	151.74	3.37
MEAN	50.66	3.84	24.62	51.53	0.00	0.05	153.29	3.58
S.D.	5.346	4.723	1.103	11.144	0.000	0.071	2.192	0.297
N	2	2	2	2	2	2	2	2
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05511	37.08	1.55	17.87	53.06	0.00	0.67	170.42	4.18
I05522	25.17	2.99	26.57	77.43	0.00	0.33	137.27	2.45
MEAN	31.13	2.27	22.22	65.25	0.00	0.50	153.85	3.32
S.D.	8.422	1.018	6.152	17.232	0.000	0.240	23.441	1.223
N	2	2	2	2	2	2	2	2

3M_MN03279776

Appendix 6

Summary and Individual Blood Hormone Determination
Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	56.47	0.12	38.61	95.66	0.00	0.68	130.32	4.93
I05549	43.54	0.07	112.14	115.58	0.00	0.98	136.09	5.81
MEAN	50.01	0.10	75.38	105.62	0.00	0.83	133.21	5.37
S.D.	9.143	0.035	51.994	14.086	0.000	0.212	4.080	0.622
N	2	2	2	2	2	2	2	2
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05539	63.10	0.07	61.24	137.78	0.00	0.81	127.17	3.56
I05552	60.29	0.28	88.08	94.05	0.00	0.00	142.77	3.76
MEAN	61.70	0.18	74.66	115.92	0.00	0.41	134.97	3.66
S.D.	1.987	0.148	18.979	30.922	0.000	0.573	11.031	0.141
N	2	2	2	2	2	2	2	2
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	62.75	0.66	257.61	255.84	0.00	1.04	118.99	3.84
I05542	81.69	0.06	114.63	120.11	0.00	0.82	121.98	3.38
MEAN	72.22	0.36	186.12	187.98	0.00	0.93	120.49	3.61
S.D.	13.393	0.424	101.102	95.976	0.000	0.156	2.114	0.325
N	2	2	2	2	2	2	2	2

3M_MN03279777

Appendix 6

Summary and Individual Blood Hormone Determination
Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day								
I05520	34.89	1.76	17.17	62.84	0.00	0.00	134.97	5.56
I05526	45.23	1.40	14.11	34.27	0.00	0.02	167.54	2.40
MEAN	40.06	1.58	15.64	48.56	0.00	0.01	151.26	3.98
S.D.	7.311	0.255	2.164	20.202	0.000	0.014	23.030	2.234
N	2	2	2	2	2	2	2	2
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day								
I05505	42.85	3.64	25.06	39.86	0.00	0.25	146.70	2.43
I05523	61.34	2.55	25.26	63.44	0.00	0.00	161.73	3.31
MEAN	52.10	3.10	25.16	51.65	0.00	0.13	154.22	2.87
S.D.	13.074	0.771	0.141	16.674	0.000	0.177	10.628	0.622
N	2	2	2	2	2	2	2	2
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day								
I05511	59.62	2.36	6.94	51.42	0.00	0.24	163.13	4.19
I05522	26.17	4.12	30.46	83.94	0.00	0.09	163.73	2.36
MEAN	42.90	3.24	18.70	67.68	0.00	0.17	163.43	3.28
S.D.	23.653	1.245	16.631	22.995	0.000	0.106	0.424	1.294
N	2	2	2	2	2	2	2	2

3M_MN03279778

Appendix 6

Summary and Individual Blood Hormone Determination
Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	TOTAL THYROXIN µg/dL
Group: Female 1 Dose Level: 0			Dosage Unit: mg/kg/day					
I05529	64.71	0.44	43.91	115.88	0.00	0.00	91.10	4.88
I05549	47.01	0.02	42.07	57.38	0.00	0.68	130.21	4.88
MEAN	55.86	0.23	42.99	86.63	0.00	0.34	110.66	4.88
S.D.	12.516	0.297	1.301	41.366	0.000	0.481	27.655	0.000
N	2	2	2	2	2	2	2	2
Group: Female 3 Dose Level: 0.15			Dosage Unit: mg/kg/day					
I05539	45.77	0.04	48.03	127.24	0.00	0.29	114.25	3.00
I05552	44.48	0.18	114.70	124.21	0.00	0.00	103.46	2.98
MEAN	45.13	0.11	81.37	125.73	0.00	0.15	108.86	2.99
S.D.	0.912	0.099	47.143	2.143	0.000	0.205	7.630	0.014
N	2	2	2	2	2	2	2	2
Group: Female 4 Dose Level: 0.75			Dosage Unit: mg/kg/day					
I05533	49.13	0.49	109.08	153.99	0.00	0.64	115.88	2.59
I05542	63.28	0.40	108.09	128.04	0.00	0.01	85.17	3.22
MEAN	56.21	0.45	108.59	141.02	0.00	0.33	100.53	2.91
S.D.	10.006	0.064	0.700	18.349	0.000	0.445	21.715	0.445
N	2	2	2	2	2	2	2	2

3M_MN03279779

Appendix 6

Summary and Individual Blood Hormone Determination
Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1	Dose Level: 0			Dosage Unit: mg/kg/day						
I05520	48.93	1.68	22.29	66.72	0.00	0.00	113.68	4.34	3.20	1.27
I05526	54.85	1.47	12.73	34.79	0.00	0.08	167.98	6.23	3.35	1.26
MEAN	51.89	1.58	17.51	50.76	0.00	0.04	140.83	5.29	3.28	1.27
S.D.	4.186	0.148	6.760	22.578	0.000	0.057	38.396	1.336	0.106	0.007
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3	Dose Level: 0.15			Dosage Unit: mg/kg/day						
I05505	35.82	0.16	21.68	35.93	0.00	0.15	141.49	4.68	3.96	1.44
I05523	56.14	2.50	21.64	55.20	0.00	0.00	150.29	5.39	4.09	1.51
MEAN	45.98	1.33	21.66	45.57	0.00	0.08	145.89	5.04	4.03	1.48
S.D.	14.368	1.655	0.028	13.626	0.000	0.106	6.223	0.502	0.092	0.049
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4	Dose Level: 0.75			Dosage Unit: mg/kg/day						
I05511	52.62	1.59	0.00	43.71	0.00	0.01	145.00	4.78	4.61	1.17
I05522	27.46	1.66	14.90	66.78	0.00	0.05	116.61	4.24	2.84	0.95
MEAN	40.04	1.63	7.45	55.25	0.00	0.03	130.81	4.51	3.73	1.06
S.D.	17.791	0.049	10.536	16.313	0.000	0.028	20.075	0.382	1.252	0.156
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279780

Appendix 6

Summary and Individual Blood Hormone Determination
Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1	Dose Level: 0			Dosage Unit: mg/kg/day						
I05529	60.74	0.66	93.93	136.07	0.00	0.14	95.57	3.84	3.87	1.16
I05549	55.31	0.04	67.50	78.68	0.00	0.22	102.40	3.31	4.09	1.37
MEAN	58.03	0.35	80.72	107.38	0.00	0.18	98.99	3.58	3.98	1.27
S.D.	3.840	0.438	18.689	40.581	0.000	0.057	4.830	0.375	0.156	0.148
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3	Dose Level: 0.15			Dosage Unit: mg/kg/day						
I05539	54.81	0.00	46.03	127.28	0.00	0.00	102.53	2.30	3.24	0.99
I05552	61.78	0.15	78.67	179.51	0.00	0.33	86.79	2.66	3.34	1.04
MEAN	58.30	0.08	62.35	153.40	0.00	0.17	94.66	2.48	3.29	1.02
S.D.	4.929	0.106	23.080	36.932	0.000	0.233	11.130	0.255	0.071	0.035
N	2	2	2	2	2	2	2	2	2	2
Group: Female 4	Dose Level: 0.75			Dosage Unit: mg/kg/day						
I05533	40.44	0.02	95.89	182.57	0.00	0.85	127.50	4.40	4.41	1.38
I05542	66.14	0.03	95.19	116.98	0.00	0.00	94.51	2.64	4.04	1.08
MEAN	53.29	0.03	95.54	149.78	0.00	0.43	111.01	3.52	4.23	1.23
S.D.	18.173	0.007	0.495	46.379	0.000	0.601	23.327	1.245	0.262	0.212
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279781

Appendix 6

Summary and Individual Blood Hormone Determination
Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05520	56.87	2.87	31.48	71.33	0.00	0.00	142.33	4.92	3.54	1.36
I05526	50.92	2.98	22.18	39.48	0.00	0.01	173.51	5.87	3.31	1.43
MEAN	53.90	2.93	26.83	55.41	0.00	0.01	157.92	5.40	3.43	1.40
S.D.	4.207	0.078	6.576	22.521	0.000	0.007	22.048	0.672	0.163	0.049
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05505	35.11	5.86	27.97	33.61	0.00	0.15	141.33	4.17	3.71	1.35
I05523	69.91	3.19	21.80	59.64	0.00	0.00	136.42	4.73	3.76	1.21
MEAN	52.51	4.53	24.89	46.63	0.00	0.08	138.88	4.45	3.74	1.28
S.D.	24.607	1.888	4.363	18.406	0.000	0.106	3.472	0.396	0.035	0.099
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05511	53.56	2.07	12.59	50.72	0.00	0.00	189.73	6.84	3.92	1.07
I05522	42.27	1.98	22.13	61.86	0.00	0.00	142.92	6.13	3.06	1.07
MEAN	47.92	2.03	17.36	56.29	0.00	0.00	166.33	6.49	3.49	1.07
S.D.	7.983	0.064	6.746	7.877	0.000	0.000	33.100	0.502	0.608	0.000
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279782

Appendix 6

Summary and Individual Blood Hormone Determination
Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1	Dose Level: 0			Dosage Unit: mg/kg/day						
I05529	56.92	0.36	46.66	106.07	0.00	0.38	114.22	3.48	3.48	1.17
I05549	54.02	0.01	72.28	120.53	0.00	0.00	94.96	2.75	3.89	1.40
MEAN	55.47	0.19	59.47	113.30	0.00	0.19	104.59	3.12	3.69	1.29
S.D.	2.051	0.247	18.116	10.225	0.000	0.269	13.619	0.516	0.290	0.163
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3	Dose Level: 0.15			Dosage Unit: mg/kg/day						
I05539	48.00	0.01	53.88	120.92	0.00	0.12	113.58	2.73	3.40	1.10
I05552	74.04	0.13	25.95	71.07	0.00	0.39	89.22	3.99	3.06	1.03
MEAN	61.02	0.07	39.92	96.00	0.00	0.26	101.40	3.36	3.23	1.07
S.D.	18.413	0.085	19.749	35.249	0.000	0.191	17.225	0.891	0.240	0.049
N	2	2	2	2	2	2	2	2	2	2
Group: Female 4	Dose Level: 0.75			Dosage Unit: mg/kg/day						
I05533	61.92	0.13	166.75	352.52	0.00	0.28	108.62	3.84	3.20	1.15
I05542	89.59	0.07	164.57	175.61	0.00	0.00	105.87	3.34	3.31	1.07
MEAN	75.76	0.10	165.66	264.07	0.00	0.14	107.25	3.59	3.26	1.11
S.D.	19.566	0.042	1.541	125.094	0.000	0.198	1.945	0.354	0.078	0.057
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279783

Appendix 6

Summary and Individual Blood Hormone Determination
Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1	Dose Level: 0			Dosage Unit: mg/kg/day						
I05520	45.28	3.12	24.62	33.29	0.00	4.00	160.85	7.90	5.07	2.53
I05526	42.55	2.03	20.60	17.89	0.00	3.18	158.81	7.34	3.03	1.83
MEAN	43.92	2.58	22.61	25.59	0.00	3.59	159.83	7.62	4.05	2.18
S.D.	1.930	0.771	2.843	10.889	0.000	0.580	1.442	0.396	1.442	0.495
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3	Dose Level: 0.15			Dosage Unit: mg/kg/day						
I05505	35.05	5.77	33.45	15.52	0.00	3.02	156.75	5.12	4.10	1.85
I05523	58.45	4.15	34.94	31.76	0.00	2.40	189.99	8.58	4.63	2.07
MEAN	46.75	4.96	34.20	23.64	0.00	2.71	173.37	6.85	4.37	1.96
S.D.	16.546	1.146	1.054	11.483	0.000	0.438	23.504	2.447	0.375	0.156
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4	Dose Level: 0.75			Dosage Unit: mg/kg/day						
I05511	34.37	2.19	15.15	34.29	0.00	2.70	200.22	8.55	3.56	1.51
I05522	18.72	5.27	32.89	47.87	0.00	2.67	142.75	6.89	4.05	1.83
MEAN	26.55	3.73	24.02	41.08	0.00	2.69	171.49	7.72	3.81	1.67
S.D.	11.066	2.178	12.544	9.603	0.000	0.021	40.637	1.174	0.346	0.226
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279784

Appendix 6

Summary and Individual Blood Hormone Determination
Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1	Dose Level: 0			Dosage Unit: mg/kg/day						
I05529	61.24	0.75	60.82	62.11	0.00	3.41	131.39	6.12	4.81	2.15
I05549	45.43	0.16	58.64	17.39	0.00	2.27	127.08	5.03	4.72	2.27
MEAN	53.34	0.46	59.73	39.75	0.00	2.84	129.24	5.58	4.77	2.21
S.D.	11.179	0.417	1.541	31.622	0.000	0.806	3.048	0.771	0.064	0.085
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3	Dose Level: 0.15			Dosage Unit: mg/kg/day						
I05539	59.18	0.06	111.82	73.29	0.00	5.31	127.44	4.32	3.48	1.46
I05552	40.35	0.15	63.26	56.27	0.00	5.26	104.90	5.02	3.31	1.10
MEAN	49.77	0.11	87.54	64.78	0.00	5.29	116.17	4.67	3.40	1.28
S.D.	13.315	0.064	34.337	12.035	0.000	0.035	15.938	0.495	0.120	0.255
N	2	2	2	2	2	2	2	2	2	2
Group: Female 4	Dose Level: 0.75			Dosage Unit: mg/kg/day						
I05533	52.84	0.73	101.24	86.37	0.00	5.20	140.68	4.86	3.55	1.56
I05542	88.82	0.30	180.10	115.95	0.00	4.19	147.41	4.23	3.15	1.11
MEAN	70.83	0.52	140.67	101.16	0.00	4.70	144.05	4.55	3.35	1.34
S.D.	25.442	0.304	55.762	20.916	0.000	0.714	4.759	0.445	0.283	0.318
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279785

Appendix 6

Summary and Individual Blood Hormone Determination
Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Male 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05520	41.44	3.51	19.03	35.81	0.00	3.01	141.17	5.57	4.31	1.98
I05526	48.80	2.29	21.13	22.20	0.00	3.34	144.88	5.51	4.10	1.97
MEAN	45.12	2.90	20.08	29.01	0.00	3.18	143.03	5.54	4.21	1.98
S.D.	5.204	0.863	1.485	9.624	0.000	0.233	2.623	0.042	0.148	0.007
N	2	2	2	2	2	2	2	2	2	2
Group: Male 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05505	43.54	2.03	22.13	11.11	0.00	3.11	127.36	4.68	3.06	1.51
I05523	55.25	4.77	33.60	27.76	0.00	3.17	164.68	7.26	3.91	1.83
MEAN	49.40	3.40	27.87	19.44	0.00	3.14	146.02	5.97	3.49	1.67
S.D.	8.280	1.937	8.111	11.773	0.000	0.042	26.389	1.824	0.601	0.226
N	2	2	2	2	2	2	2	2	2	2
Group: Male 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05511	31.74	6.17	27.18	34.39	0.00	1.92	211.71	7.91	5.89	1.92
I05522	17.51	6.28	30.18	40.74	0.00	3.36	133.42	6.19	3.90	1.80
MEAN	24.63	6.23	28.68	37.57	0.00	2.64	172.57	7.05	4.90	1.86
S.D.	10.062	0.078	2.121	4.490	0.000	1.018	55.359	1.216	1.407	0.085
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279786

Appendix 6

Summary and Individual Blood Hormone Determination
Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	CORTISOL µg/dL	TESTOSTERONE ng/mL	ESTRADIOL pg/mL	ESTRONE pg/mL	ESTRIOL pg/mL	THYROID STIMULATING µU/mL	TOTAL TRIIODOTHYRONINE ng/dL	FREE TRIIODOTHYRONINE pg/mL	TOTAL THYROXIN µg/dL	FREE THYROXIN ng/dL
Group: Female 1	Dose Level: 0		Dosage Unit: mg/kg/day							
I05529	61.95	0.32	88.86	60.95	0.00	2.28	113.93	4.61	4.23	1.65
I05549	50.10	0.15	55.18	29.70	0.00	2.86	122.28	4.59	4.96	1.91
MEAN	56.03	0.24	72.02	45.33	0.00	2.57	118.11	4.60	4.60	1.78
S.D.	8.379	0.120	23.815	22.097	0.000	0.410	5.904	0.014	0.516	0.184
N	2	2	2	2	2	2	2	2	2	2
Group: Female 3	Dose Level: 0.15		Dosage Unit: mg/kg/day							
I05539	58.68	0.22	249.40	112.37	0.00	4.32	133.88	QNS	3.65	1.63
I05552	26.08	0.18	228.31	104.83	0.00	2.22	194.67	7.69	6.48	1.81
MEAN	42.38	0.20	238.86	108.60	0.00	3.27	164.28	7.69	5.07	1.72
S.D.	23.052	0.028	14.913	5.332	0.000	1.485	42.985	-	2.001	0.127
N	2	2	2	2	2	2	2	1	2	2
Group: Female 4	Dose Level: 0.75		Dosage Unit: mg/kg/day							
I05533	49.05	0.73	89.07	85.47	0.00	3.89	122.53	4.63	3.41	1.41
I05542	82.98	0.40	94.97	46.34	0.00	4.50	131.85	4.36	3.46	1.31
MEAN	66.02	0.57	92.02	65.91	0.00	4.20	127.19	4.50	3.44	1.36
S.D.	23.992	0.233	4.172	27.669	0.000	0.431	6.590	0.191	0.035	0.071
N	2	2	2	2	2	2	2	2	2	2

3M_MN03279787

Appendix 6

Summary and Individual E2, FSH, and LH
Additional Serum Analysis at Anilytics

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
Group: Male 1	Dose Level: 0	Dosage Unit: mg/kg/day	
I05508	0.00		
I05527	9.89		
MEAN	4.95		
S.D.	6.993		
N	2		
Group: Male 2	Dose Level: 0.03	Dosage Unit: mg/kg/day	
I05514	17.02		
I05515	0.49		
I05516	1.53		
I05521	47.01		
MEAN	16.51		
S.D.	21.691		
N	4		
Group: Male 3	Dose Level: 0.15	Dosage Unit: mg/kg/day	
I05510	6.62		
I05518	3.35		
I05524	0.76		
I05528	3.24		
MEAN	3.49		
S.D.	2.404		
N	4		

3M_MN03279788

Appendix 6

Summary and Individual E2, FSH, and LH
Additional Serum Analysis at Anilytics

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
Group: Male 4	Dose Level: 0.75	Dosage Unit: mg/kg/day	
I05506	0.00		
I05507	0.00		
I05512	0.00		
I05522a	18.68		
I05511a	12.85		
MEAN	6.31		
S.D.	8.877		
N	5		

a Recovery animal.

3M_MN03279789

Appendix 6

Summary and Individual E2, FSH, and LH
Additional Serum Analysis at Anilytics

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
Group: Female 1	Dose Level: 0	Dosage Unit: mg/kg/day	
I05530	27.79	3.46	0.75
I05531	132.76	1.61	0.81
I05535	27.20	1.21	2.93
I05544	85.52	0.36	1.95
MEAN	68.32	1.66	1.61
S.D.	50.931	1.308	1.039
N	4	4	4
Group: Female 2	Dose Level: 0.03	Dosage Unit: mg/kg/day	
I05541	76.34	2.24	2.25
I05547	88.20	2.83	0.83
I05550	33.55	0.51	1.85
MEAN	66.03	1.86	1.64
S.D.	28.747	1.206	0.732
N	3	3	3
Group: Female 3	Dose Level: 0.15	Dosage Unit: mg/kg/day	
I05532	40.88	2.03	2.79
I05538	87.24	1.80	2.19
I05545	42.82	0.38	2.17
I05548	33.03	0.42	1.86
MEAN	50.99	1.16	2.25
S.D.	24.533	0.88	0.389
N	4	4	4

3M_MN03279790

Appendix 6

Summary and Individual E2, FSH, and LH
Additional Serum Analysis at Anilytics

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	E2 pg/mL	FSH ng/mL	LH ng/mL
Group: Female 4	Dose Level: 0.75	Dosage Unit: mg/kg/day	
I05534	0.00	0.38	2.20
I05536	0.00	0.76	2.03
I05540	4.45	0.88	2.06
I05551	19.30	0.32	1.73
I05542a	159.41	1.37	2.55
I05533a	122.77	1.50	1.58
MEAN	50.99	0.87	2.03
S.D.	71.102	0.490	0.344
N	6	6	6

a Recovery animal.

3M_MN03279791

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol
Additional Serum Analysis at Mayo Clinic - Week 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05508	160	3	1.4	0.24	<35
I05527	132	3.5	1.5	0.86	<35
Mean	146.0	3.3	1.5	0.6	NA
SD	19.80	0.35	0.07	0.44	NA
N	2	2	2	2	NA
Group: Male 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05514	154	3.6	1.5	0.48	<35
I05515	135	3	1.4	0.49	<35
I05516	166	4	1.8	0.7	<35
I05521	126	4.1	1.4	0.55	<35
Mean	151.7	3.5	1.6	0.6	NA
SD	15.63	0.50	0.21	0.12	NA
N	3	3	3	3	NA
Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05510	123	3.2	1.3	1.5	<35
I05524	128	2.9	1.6	0.55	<35
I05528	133	2.8	NS	NS	<35
Mean	128.0	3.0	1.5	1.0	NA
SD	5.00	0.21	0.21	0.67	NA
N	3	3	2	2	NA

NS Test cancelled. Quantity not sufficient.

3M_MN03279792

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol
Additional Serum Analysis at Mayo Clinic - Week 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05506	94	5.6	1.6	1.7	<35
I05507	81	3.3	1.5	1.4	<35
I05512	53	2.4	1.4	1.2	<35
Mean	76.0	3.8	1.5	1.4	NA
SD	20.95	1.65	0.10	0.25	NA
N	3	3	3	3	NA
Group: Female 1 Dose Level: 0 Dosage Unit: mg/kg/day					
I05530	176	4.7	1.8	0.69	<35
I05531	128	2.9	1.4	0.27	146
I05535	134	4.7	1.7	NS	<35
I05544	154	2.8	1.2	2.1	83
Mean	148.0	3.8	1.5	1.0	114.5
SD	27.73	1.07	0.28	0.96	44.55
N	4	4	4	3	2
Group: Female 2 Dose Level: 0.03 Dosage Unit: mg/kg/day					
I05541	140	4.4	2	0.52	73
I05547	150	4.4	1.6	0.7	48
I05550	124	3.3	1.5	1.1	<35
Mean	138.0	4.0	1.7	0.8	60.5
SD	13.11	0.64	0.26	0.30	17.68
N	3	3	3	3	2

NS Test cancelled. Quantity not sufficient.

3M_MN03279793

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol
Additional Serum Analysis at Mayo Clinic - Week 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Female 3 Dose Level: 0.15 Dosage Unit: mg/kg/day					
I05532	100	3.5	1.4	3	<35
I05538	121	2.5	1.1	0.63	78
I05545	105	3.3	1.3	0.68	<35
I05548	137	3.6	1.6	0.99	<35
I05538	121	2.5	1.1	0.63	78
Mean	116.8	3.1	1.3	1.2	78.0
SD	14.70	0.54	0.21	1.03	0.00
N	5	5	5	5	2
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05534	79	4.2	1.9	3.3	<35
I05540	101	2.8	1.3	1.5	<35
I05551	120	4	1.6	0.88	<35
Mean	100.0	3.7	1.6	1.9	NA
SD	20.52	0.76	0.30	1.26	NA
N	3	3	3	3	NA

3M_MN03279794

Appendix 6

Summary and Individual T3, T4, Free T4, TSH, and Estradiol
Additional Serum Analysis at Mayo Clinic - Week 79

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

	T3 ng/dL	T4 ug/dL	Free T4 ng/dL	TSH mIU/L	Estradiol pg/mL
Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05522	132	3	1.2	0.49	<35
I05511	240	5.3	1.3	0.035	<35
Mean	186.0	4.2	1.3	0.3	NA
SD	76.37	1.63	0.07	0.32	NA
N	2	2	2	2	NA
Group: Female 4 Dose Level: 0.75 Dosage Unit: mg/kg/day					
I05542	134	3.3	1.4	0.79	152
I05533	134	3.5	1.4	1.4	53
Mean	134.0	3.4	1.4	1.1	102.5
SD	0.00	0.14	0.00	0.43	70.00
N	2	2	2	2	2

3M_MN03279795

APPENDIX 7

Cell Proliferation Report

Note: This appendix contains information supplied and audited by Pathology Associates International (PAI).

3M_MN03279796

PATHOLOGY ASSOCIATES
A CHARLES RIVER COMPANY

CELL PROLIFERATION REPORT

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS COVANCE STUDY NUMBER 6329-223

PREPARED FOR:

3M
TOXICOLOGY SERVICES
BUILDING 220-2E-02, 3M CENTER
ST. PAUL, MN 55144-1000

PREPARED BY:

PATHOLOGY ASSOCIATES - A CHARLES RIVER COMPANY
15 WORMAN'S MILL COURT, SUITE I
FREDERICK, MD 21701

TABLE OF CONTENTS

Contents	Section
Narrative	I
Table	II
Signature Page	III
Quality Assurance Statement	IV
Appendix	V

3M_MN03279798

I. CELL PROLIFERATION REPORT

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS COVANCE STUDY NUMBER 6329-223

PURPOSE

The purpose of the study was to assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks.

This report, submitted by Pathology Associates - A Charles River Company (PAI) to the study Sponsor, 3M, represents the cell proliferation findings and interpretation for Covance Study Number 6329-223 entitled "26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys". All aspects of the tasks associated with PAI's portion of this study were conducted in compliance with the Environmental Protection Agency Good Laboratory Practice (GLP) Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments.

MATERIALS AND METHODS

Tissue Collection for Cell Proliferation

Four animals per sex in groups 1 - 4 were sacrificed after 26 weeks on study. A representative sample of the liver, testes (males only) and pancreas from each animal was fixed in formalin, processed and embedded to paraffin block by Covance per protocol specifications. Tissue blocks were then shipped to PAI for sectioning and staining. From each block, a slide was prepared for H&E evaluation and immunohistochemical detection of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation.

Immunohistochemistry for Cell Proliferation

Sections of paraffin-embedded tissues were cut at 5 μm and placed on positively charged slides (Superfrost Plus, Fisher Scientific, Pittsburgh, PA) to ensure adhesion during processing for PCNA. Standard immunohistochemical methods were used to stain tissues for PCNA (PAI's Standard Operating Procedure for Immunohistochemical Staining (SOP #707). Briefly, tissue sections were incubated with a monoclonal antibody to PCNA and reagents required for the avidin-biotin peroxidase method for the detection of the antigen-antibody complex. PCNA expression in cells was localized by the chromagen 3,3'-diaminobenzidine (DAB). Tissue sections were counterstained with hematoxylin.

3M_MN03279799

1818.0966

Cell Proliferation Measurements

The percentage of hepatocytes in S-phase (labeling index, LI) was determined by scoring at least 3000 hepatocytes in 10 fields of liver. The LI in the testes (males only) was determined by scoring the number of PCNA-positive Leydig cells among at least 100 Leydig cells. The labeling index in the pancreas was scored subjectively with 4 being both acinar and islets stained heavily and 3 being predominant staining in the acinar region. A negative control slide was included in the staining run and consisted of study tissue that was not incubated with the primary antibody.

For cell proliferation evaluations, slides were first perused at low magnification (100X) to judge quality of staining, processing and sectioning, potential patterns of cellular proliferation, and histomorphologic changes. Cell proliferation was then quantified at higher magnification (200X for liver and pancreas, and 400X for testes) as described above. Histomorphology was further assessed by evaluating the H&E slide prepared from the same tissue block for each animal evaluated for cell proliferation.

Statistical Analysis

The Student's *t*-test (two-sided, unequal variance) was used to test for statistical significance in LI between control and treatment groups using Microsoft Excel version 5.0. A *P* value of 0.05 or less was judged to be statistically significant.

RESULTS

Cell Proliferation

Individual animal cell proliferation data are presented in Section II (Table II-1). Cell proliferation in the liver, testes and pancreas of control and test material-treated animals was similar.

Histopathology

Sections from the same tissue blocks used for preparation of PCNA-stained slides were stained with hematoxylin and eosin (H&E) for histopathologic evaluation to facilitate the interpretation of the immunostained slides. Individual animal findings are presented in Appendix I.

Single sections of liver, pancreas, and testes from 16 adult male monkeys and single sections of liver and pancreas from 16 adult female monkeys representing control, low-dose (0.03 mg/kg/day), mid-dose (0.15 mg/kg/day) and high-dose (0.75 mg/kg/day) treatment groups were evaluated histologically. Each tissue section was stained with hematoxylin and eosin. The purpose of this evaluation was to determine whether or not morphologic changes were occurring in these tissues which may alter or confound the specificity of the PCNA staining observed in these animals.

3M_MN03279800

1818.0967

The results showed that no significant changes were observed in either the liver, pancreas, or testicular tissues from male monkeys or the liver and pancreas tissues from female monkeys, which would alter the interpretation of the PCNA staining in this study.

DISCUSSION

In the present study, cell proliferation was measured within the liver, testes and pancreas of male monkeys, and the liver and pancreas of female monkeys from control (0 mg/kg/day), low dose (0.03 mg/kg/day), mid-dose (0.15 mg/kg/day) and high dose (0.75 mg/kg/day) groups after 26 weeks on study to assess the effect of the test material on critical enzyme levels, hormones, and other selected biological parameters, including cell proliferation.

There did not appear to be a cell proliferative response to the test material in the liver, testes or pancreas, as determined by labeling indices, which were similar in all animals.

SUMMARY

In the present study, cell proliferation, as determined by measuring the labeling index, was not increased in the liver, testes or pancreas of monkeys.

3M_MN03279801

1818.0968

II. TABLE

Legend

ND, not determined due to suboptimal staining
NP, slide not present
Liver labeling index: Percentage of hepatocytes in S-phase
Pancreas labeling index: Scored subjectively with 4 = islets and acinar staining heavily; 3 = staining more abundant in acinar cells than islets
Testes labeling index: Percentage of PCNA-positive Leydig cells

3M_MN03279802

1818.0969

COVANCE STUDY NO. 6329-223
Page II-1

TABLE II-1. CELL PROLIFERATION IN MONKEYS

Dose Group	Sex/Group	Animal Number	Labeling Index Liver	Labeling Index Pancreas	Labeling Index Testes
0 mg/kg/day (Control)	F/1	IO5530	0.000%	4	NP
0 mg/kg/day (Control)	F/1	IO5531	0.027%	3	NP
0 mg/kg/day (Control)	F/1	IO5535	0.000%	3	NP
0 mg/kg/day (Control)	F/1	IO5544	0.199%	4	NP
		Mean	**0.057%**	**3.5**	-
		SEM	**0.048%**	**0.3**	-
0.03 mg/kg/day (Low dose)	F/2	IO5537	0.113%	3	NP
0.03 mg/kg/day (Low dose)	F/2	IO5541	0.125%	4	NP
0.03 mg/kg/day (Low dose)	F/2	IO5547	0.000%	3	NP
0.03 mg/kg/day (Low dose)	F/2	IO5550	0.212%	3	NP
		Mean	**0.112%**	**3.3**	-
		SEM	**0.044%**	**0.3**	-
0.15 mg/kg/day (Mid dose)	F/3	IO5532	0.000%	3	NP
0.15 mg/kg/day (Mid dose)	F/3	IO5538	0.086%	3	NP
0.15 mg/kg/day (Mid dose)	F/3	IO5545	0.029%	3	NP
0.15 mg/kg/day (Mid dose)	F/3	IO5548	0.120%	4	NP
		Mean	**0.059%**	**3.3**	-
		SEM	**0.027%**	**0.3**	-
0.75 mg/kg/day (High dose)	F/4	IO5534	0.000%	3	NP
0.75 mg/kg/day (High dose)	F/4	IO5536	0.313%	3	NP
0.75 mg/kg/day (High dose)	F/4	IO5540	0.000%	3	NP
0.75 mg/kg/day (High dose)	F/4	IO5551	0.000%	3	NP
		Mean	**0.078%**	**3.0**	-
		SEM	**0.078%**	**0.0**	-
0 mg/kg/day (Control)	M/1	IO5508	0.100%	4	9.52%
0 mg/kg/day (Control)	M/1	IO5517	0.062%	3	9.00%
0 mg/kg/day (Control)	M/1	IO5519	0.108%	3	20.75%
0 mg/kg/day (Control)	M/1	IO5527	0.464%	4	19.23%
		Mean	**0.184%**	**3.5**	**14.63%**
		SEM	**0.094%**	**0.3**	**3.12%**
0.03 mg/kg/day (Low dose)	M/2	IO5514	0.095%	3	16.36%
0.03 mg/kg/day (Low dose)	M/2	IO5515	0.000%	3	18.52%
0.03 mg/kg/day (Low dose)	M/2	IO5516	0.000%	3	22.95%
0.03 mg/kg/day (Low dose)	M/2	IO5521	0.000%	4	12.38%
		Mean	**0.024%**	**3.3**	**17.55%**
		SEM	**0.024%**	**0.3**	**2.20%**
0.15 mg/kg/day (Mid dose)	M/3	IO5510	0.053%	3	9.17%
0.15 mg/kg/day (Mid dose)	M/3	IO5518	0.029%	4	17.14%
0.15 mg/kg/day (Mid dose)	M/3	IO5524	0.155%	3	14.42%
0.15 mg/kg/day (Mid dose)	M/3	IO5528	0.000%	4	10.71%
		Mean	**0.059%**	**3.5**	**12.86%**
		SEM	**0.034%**	**0.3**	**1.80%**
0.75 mg/kg/day (High dose)	M/4	IO5506	0.030%	3	7.69%
0.75 mg/kg/day (High dose)	M/4	IO5507	0.027%	3	19.61%
0.75 mg/kg/day (High dose)	M/4	IO5509	NP	NP	NP
0.75 mg/kg/day (High dose)	M/4	IO5512	0.000%	3	ND
		Mean	**0.019%**	**3.0**	**13.65%**
		SEM	**0.009%**	**0.0**	**5.96%**

ND, not determined due to suboptimal staining
NP, slide not present
Liver: Percentage of hepatocytes in S-phase
Pancreas: Scored subjectively with 4=islets and acinar stained heavily (>50% labeled); 3=acinar>>islets
Testes: Percentage of proliferating Leydig cells

3M_MN03279803

III. SIGNATURE PAGE

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys (Covance Study Number 6329-223)

Submitted by:

PAI Project Manager:

Sandra R. Eldridge, Ph.D. — Date: 1-2-02

PAI Project Pathologist:

Carolyn Moyer, D.V.M., Diplomate, A.C.V.P. — Date: 12/31/01

3M_MN03279804

1818.0971

IV. QUALITY ASSURANCE STATEMENT

3M_MN03279805

PATHOLOGY ASSOCIATES
A CHARLES RIVER COMPANY

Cell Proliferation Report

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Covance Study No.: 6329-223

QUALITY ASSURANCE STATEMENT

This cell proliferation project has been inspected and audited by the PAI Quality Assurance Unit (QAU) as required by the Good Laboratory Practice (GLP) regulations promulgated by the U.S. Environmental Protection Agency (TSCA). The cell proliferation report is an accurate reflection of the recorded data. The following table is a record of the inspections/audits performed and reported by the QAU.

Date of Inspection	Phase Inspected	Date Findings Reported to Project Manager/ PAI Management	Date Findings Reported to Study Director/Study Director Management
12/06/99	Primary Antibody Dilution	12/06/99	12/27/01
02/17/00	Study Data and Supporting Documentation	02/17/00	12/27/01
02/17/00	Draft Cell Proliferation Report	02/17/00	12/27/01
12/27/01	Final Cell Proliferation Report	12/27/01	12/27/01

Karen E. Butler
Quality Assurance Officer

12/27/01
Date

15 Worman's Mill Court, Suite I, Frederick, MD 21701 • 301.663.1644 • FAX: 301.663.8994 • www.paicriver.com

3M_MN03279806

APPENDIX I

3M_MN03279807

3MP #6329-223

Individual Animal Findings

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	SEX	DOSE GROUP	HISTOLOGIC FINDINGS
I05530	F	1	Liver - NSF Pancreas - NSF
I05531	F	1	Liver - NSF Pancreas - NSF
I05535	F	1	Liver - chronic inflammation, minimal Pancreas - NSF
I05544	F	1	Liver - NSF Pancreas - NSF
I05537	F	2	Liver - NSF Pancreas - NSF
I05541	F	2	Liver - chronic inflammation, minimal Pancreas - NSF
I05547	F	2	Liver - NSF Pancreas - NSF
I05550	F	2	Liver - NSF Pancreas - NSF
I05532	F	3	Liver - NSF Pancreas - NSF
I05538	F	3	Liver - chronic inflammation, minimal Pancreas - NSF
I05545	F	3	Liver - chronic inflammation, minimal Pancreas - NSF
I05548	F	3	Liver - chronic inflammation, minimal Pancreas - NSF
I05534	F	4	Liver - NSF Pancreas - NSF
I05536	F	4	Liver - fat infiltration, centrilobular, moderate Pancreas - NSF
I05540	F	4	Liver - NSF Pancreas - NSF
I05551	F	4	Liver - NSF Pancreas - NSF
I05508	M	1	Liver - chronic inflammation, minimal Pancreas - chronic inflammation, minimal Testes - NSF
I05517	M	1	Liver - NSF Pancreas - NSF Testes - crush artifact, focal
I05519	M	1	Liver - NSF Pancreas - NSF Testes - NSF
I05527	M	1	Liver - NSF Pancreas - NSF Testes - NSF
I05514	M	2	Liver - chronic inflammation, minimal Pancreas - chronic inflammation, minimal Testes - NSF
I05515	M	2	Liver - chronic inflammation, minimal Pancreas - NSF Testes - NSF
I05516	M	2	Liver - NSF Pancreas - NSF Testes - NSF
I05521	M	2	Liver - NSF Pancreas - NSF Testes - NSF
I05510	M	3	Liver - chronic inflammation, minimal Pancreas - NSF Testes - NSF

Legend: NSF = no significant findings

3M_MN03279808

3MP #6329-223

Individual Animal Findings

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	SEX	DOSE GROUP	HISTOLOGIC FINDINGS
I05518	M	3	Liver - NSF Pancreas - NSF Testes - NSF
I05524	M	3	Liver - NSF Pancreas - NSF Testes - NSF
I05528	M	3	Liver - NSF Pancreas - NSF Testes - NSF
I05507	M	4	Liver - fat infiltration, centrilobular, moderate Pancreas - NSF Testes - NSF
I05512	M	4	Liver - NSF Pancreas - NSF Testes - NSF
I05506	M	4	Liver - NSF Pancreas - NSF Testes - NSF
I05509	M	4	No microscopic slides available. (Inventory shows blocks submitted; STPR does not show blocks sectioned.)

Legend: NSF = no significant findings

3M_MN03279809

APPENDIX 8

Electron Microscopic Evaluation of Liver in Cynomolgus Monkeys

Note: This appendix contains information supplied and audited by Pathology Associates International (PAI).

3M_MN03279810

Pathology Associates International
A Company of Science Applications International Corporation
An Employee-Owned Company

PATHOLOGY REPORT
(ANCILLARY STUDY)

ELECTRON MICROSCOPIC EVALUATION OF LIVER IN CYNOMOLGUS MONKEYS (RECOVERY ANIMALS)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

CLIENT STUDY NUMBER 6329-223
PAI STUDY NUMBER EM 99.76

Prepared by:

James B. Nold, D.V.M., Ph.D., Diplomate, A.C.V.P.

Pathology Associates International
4915-D Prospectus Drive
Durham, NC 27713

September 1, 2000

PREPARED FOR 3M CORPORATE TOXICOLOGY,
3M CENTER, ST. PAUL, MN 55144-1000

4915 D Prospectus Drive • Durham, North Carolina 27713 • (919) 544-5257 • (919) 544-3278 FAX

3M_MN03279811

	Section
Pathology Narrative	I
Light Microscopy and Transmission Electron Micrograph Interpretation Forms	II
Transmission Electron Micrographs	III
Quality Assurance Statement	IV

3M_MN03279812

I. Pathology Narrative

3M_MN03279813

PATHOLOGY REPORT
(ANCILLARY STUDY)

ELECTRON MICROSCOPIC EVALUATION OF LIVER IN CYNOMOLGUS MONKEYS (RECOVERY ANIMALS)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

CLIENT STUDY NUMBER 6329-223
PAI STUDY NUMBER EM 99.76

SUMMMARY

Two male and two female cynomolgus monkeys treated for 26 weeks with 0.75 mg/kg PFOS were removed from treatment for up to 53 weeks. Liver samples obtained by biopsy at Week 57 and necropsy at Week 79 were examined for reversibility, persistence, or delayed occurrence of toxic effects. Light and electron microscopic evaluation of livers identified no pathological changes. The treatment-related changes of hepatocellular hypertrophy and vacuolation, noted at 26 weeks and characterized ultrastructurally by increased numbers of lipid droplets within hepatocytes, had completely disappeared during the recovery period.

PROCEDURES

The objective of this study was to examine by electron microscopy the livers from selected animals in a 26-week capsule toxicity study with PFOS in cynomolgus monkeys. In addition to a general qualitative evaluation for differences between control and treated animals, the ultrastructural endpoints included quantitation of peroxisomes within hepatocytes and membrane and mitochondrial changes in hepatocytes. Light microscopy of paraffin-embedded liver sections was also performed.

This report details the light and electron microscopy findings in the four high-dose male and female monkeys designated as recovery animals. A previous report (dated 6-24-1999) indicated that treatment of cynomolgus monkeys with 0.75 mg PFOS/kg/day for 26 weeks resulted in hepatocellular vacuolation and hypertrophy by light microscopy. Hepatocellular vacuolation and hypertrophy were primarily centrilobular in distribution and did vary in incidence and severity between individual animals. Ultrastructurally, there were increased lipid droplets within hepatocytes. Increased lipid droplets were

3M_MN03279814

1818.0981

present in both the high-dose males examined and in two of four high-dose females examined. Increased hepatocellular glycogen was present in the remaining two high-dose females. These ultrastructural changes correlated with hepatocellular hypertrophy and vacuolation noted by light microscopy and with increased liver weight parameters in the high-dose animals. The no-effect level for hepatocellular vacuolation (lipid droplet accumulation) was 0.15 mg/kg/day of PFOS (mid-dose group). Quantitation of peroxisomes within hepatocytes by electron microscopy indicated no remarkable differences between control livers and livers treated with 0.03, 0.15, or 0.75 mg PFOS/kg/day. Ultrastructural differences in cellular membranes or mitochondria were not discernible between control and treated animals in the samples examined. The recovery animals were examined to assess for reversibility or persistence of these hepatocellular changes, or for the delayed occurrence of additional PFOS-induced effects.

For the toxicity study, 22 male and 22 female cynomolgus monkeys were given the test article or the vehicle once daily for at least 26 weeks according to Text Table 1.

Text Table 1. Group Designations and Dosage Levels

Dosage Group	Dose Level (mg/kg/day)[a]	Total Material Dose Level (mg/kg/day)[b]	Number of Males	Number of Females
I	0[a]	30[a]	6[d]	6[d]
II	0.03	15[b]	4	4
III	0.15	6[c]	6[d]	6[d]
IV	0.75	30[c]	6[d]	6[d]

[a] Dose levels were provided. The control group (Group 1) received an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.
[b] The low-dose group (Group 2) received the test material diluted with lactose (1:499, w:w).
[c] The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w:w).
[d] Two animals in Groups 1, 3, and 4, designated as recovery animals, were treated for at least 26 weeks, then treatment was discontinued and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

During Week 57 (approximately 31 weeks into the recovery period), the 2 high-dose recovery males and 2 high-dose recovery females were anesthetized and liver biopsies were surgically obtained from each animal and chemically preserved and processed as described below.

During Week 79, the 4 high-dose recovery animals were necropsied and liver samples obtained as described below. The two control recovery animals were returned to the Covance stock animal colony, and the two Group III animals were transferred to a subsequent study (Covance 6329-268). Liver samples were not obtained and examined in the control recovery or Group III recovery animals.

Animals to be sacrificed at recovery sacrifice times were anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied. Multiple tissues were collected and preserved in 10% neutral-buffered formalin according to the protocol. Additionally,

3M_MN03279815

1818.0982

pieces of liver from each animal were thin-sliced and placed in ½ strength Karnovsky's fixative (2.0% paraformaldehyde/2.5% glutaraldehyde in 0.1M phosphate buffer) for subsequent ultrastructural examination. These livers were processed into Epon blocks and submitted to this laboratory for subsequent electron microscopy processing and evaluation. Hematoxylin and eosin (H&E) stained slide sections of formalin-fixed, paraffin-embedded livers were submitted for light microscopic examination.

The four high-dose recovery animals are listed in Text Table 2. For each animal, there was a 57-Week liver biopsy sample and a 79-Week terminal necropsy liver sample.

Text Table 2. Recovery Animals Examined by Light and Electron Microscopy

0.75 mg/kg/day PFOS (Group 4 High-Dose)	
Males	Females
I05511	I05533
I05522	I05542

Thin sections (approximately 90 nm) from the Epon-embedded livers were cut, mounted on 200-mesh copper grids, stained with 5% methanolic uranyl acetate and Reynold's lead citrate, and examined on a Zeiss 900 transmission electron microscope. Centrilobular hepatocytes, where clearly identifiable in liver sections, were preferentially examined. Representative electron photomicrographs of liver were taken and significant ultrastructural features were summarized for each photograph and animal on a designated transmission electron micrograph interpretation form. The number of peroxisomes in hepatocytes was manually counted for each center photographed hepatocyte and recorded. For light microscopy, the H&E slides from the same animals selected for electron microscopy were evaluated and significant features were summarized on a light microscopic evaluation form.

RESULTS AND DISCUSSION

Individual interpretations of light microscopy slides and electron micrographs for each animal are shown in Section II. Representative electron photomicrographs were selected as report figures, labeled, and are shown in Section III. All remaining electron micrographs are separately attached to this report.

Light Microscopy

A summary of the incidence and severity of light microscopic findings in the control and high-dose livers is shown in Text Table 3. There were no microscopic findings that appeared to be associated with test material administration. Hepatocellular hypertrophy and vacuolation, noted after 26 weeks of treatment in some high-dose animals, were not identified in recovery samples at either the 57-Week biopsy or 79-Week terminal necropsy samples, indicating complete reversal of the light microscopic liver changes.

3M_MN03279816

1818.0983

The liver findings noted in the recovery animals were considered normal background histopathology of cynomolgus monkeys.

Text Table 3. Incidence and Severity of Light Microscopic Liver Findings -- Recovery Animals

	0.75 mg/kg/day (High-Dose)	
	Males	Females
(number examined)	(2)	(2)
57-Week Biopsy		
Infiltrate, lymphohistiocytic, minimal	1	2
Terminal Necropsy		
Infiltrate, lymphohistiocytic, minimal	2	2
Hyperplasia, bile duct, slight	1	–
Inflammation, lymphohistiocytic, slight	1	–
Inflammation, eosinophilic, slight	1	–
Clearing, cytoplasmic, centrilobular, minimal	–	1

– Incidence of zero.

Electron Microscopy

Electron microscopic evaluation of the 57-week biopsy and 79-week necropsy liver samples identified no abnormal features, and all tissue samples were considered to be ultrastructurally normal (Text Table 4). The hepatocellular hypertrophy and vacuolation seen after 26 weeks of treatment, and characterized ultrastructurally by increased lipid droplets, were not seen in the recovery animal liver samples, indicating recovery of these test material related effects. The electron microscopic features described in these recovery samples were considered normal ultrastructural findings in hepatocytes. Figures 1-4 are representative electron micrographs from these samples and illustrate normal liver and hepatocellular features.

Text Table 4. Summary of Ultrastructural Findings – Recovery Animals

Treatment Group (mg/kg/day)/Sex	Animal No.	Comments
(0.75) Male, 57-week biopsy	I05511	Normal
(0.75) Male, 79- week necropsy	I05511	Normal
(0.75) Male, 57-week biopsy	I05522	Normal
(0.75) Male, 79-week necropsy	I05522	Normal
(0.75) Female, 57-week biopsy	I05533	Normal
(0.75) Female, 79-week necropsy	I05533	Normal
(0.75) Female, 57-week biopsy	I05542	Normal
(0.75) Female, 79-week necropsy	I05542	Normal

3M_MN03279817

Peroxisomes were identified and quantitated in representative hepatocytes (Text Table 5). Mean peroxisome numbers per hepatocyte were considered normal.

Text Table 5. Quantitation of Hepatocellular Peroxisomes

0.75 mg PFOS/kg/day (High-Dose) Recovery Animals

Male				Female			
57-week biopsy		79-week necropsy		57-week biopsy		79-week necropsy	
Animal Number	Number[1] of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes
I05511	18.5	I05511	19.2	I05533	29.8	I05533	20.8
I05522	19.4	I05522	25.8	I05542	23.0	I05542	15.2
Mean =	18.95	Mean =	22.5	Mean =	26.4	Mean =	18.0

[1] Average number of peroxisomes per hepatocyte for five hepatocytes counted per animal. For Animal No. I05511 (biopsy), peroxisomes were counted in only four hepatocytes

CONCLUSION

Light and electron microscopic evaluation of livers from cynomolgus monkeys treated with 0.75 mg PFOS/kg/day for 26 weeks and allowed to "recover" untreated for 31 and 53 weeks identified no pathological changes. The treatment-related changes of hepatocellular hypertrophy and vacuolation, characterized ultrastructurally by increased numbers of lipid droplets within hepatocytes at 26 weeks, had completely resolved during the recovery period.

SIGNATURE OF AUTHOR

James B. Nold

James B. Nold, D.V.M., Ph.D.,
Diplomate, A.C.V.P.

September 1, 2000
Date

3M_MN03279818

1818.0985

II. Light Microscopy and Transmission Electron Micrograph Interpretation Forms [1]

[1] Forms are exact copies of signed/dated raw data sheets maintained in archived study file.

3M_MN03279819

1818.0986

LIGHT MICROSCOPIC EVALUATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkeys

Animal No: see below Tissue: Liver

Sex: see below

Interpreting Pathologist (signature and date): April 7, 2000

Dose/Group	Animal Number	Microscopic Findings and Comments
0.75 mg/kg (High-dose) Recovery Males 57 wk biopsy	I05511	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05522	Normal
0.75 mg/kg (High-dose) Recovery Females 57 wk biopsy	I05533	1. Infiltrate, lymphohistiocytic, focal, minimal
	I05542	1. Infiltrate, lymphohistiocytic, multifocal, minimal
0.75 mg/kg (High-dose) Recovery Males 79 wk necropsy	I05511	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05522	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Hyperplasia, focal, slight, bile duct 3. Inflammation, lymphohistiocytic, multifocal, slight 4. Inflammation, eosinophilic, multifocal, slight
0.75 mg/kg (High-dose) Recovery Females 798 week necropsy	I05533	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05542	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal

3M_MN03279820

1818.0987

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)
Species/Strain: Cynomolgus Monkey

Animal No.: 10551;
57-week biopsy
Tissue: Liver - centrilobular

Treatment Group: .75 mg/kg (hi-dose)
Block No(s).: 99.76-31-1A
Z18823 -

Sex: Male
Photo/Negative No(s).: Z18827

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] May 26, 2000

Features: Z18823. Liver. Hepatocyte. 15,290X. This hepatocyte has a small round central nucleus. The surrounding cytoplasm contains numerous round to oval mitochondria and several small to large lipid droplets. The darker round organelles, mostly slightly smaller than the mitochondria, are peroxisomes. Twenty-four (24) peroxisomes counted. The intervening cytosol contains profiles of endoplasmic reticulum and some fine granules, which may be glycogen.
Z18824. Liver. 10,320X. Portions of three cells are present. The dorsal two hepatocytes exhibit a mixture of normal appearing cytoplasmic elements, including mitochondria, endoplasmic reticulum and scattered peroxisomes. The larger ventral cell's cytoplasm contains irregular clear spaces surrounded by membranous material. Only a couple of mitochondria are evident, and this cell is probably not a hepatocyte. Around the periphery are several large structures containing finely granular and reticular material. This may represent smooth endoplasmic reticulum intermixed with glycogen and/or ribosomes. It appears to be membrane bound, but this may be a pseudomembrane caused by compacting of the surrounding cytoplasm. Or, these structures may represent cytoplasmic invaginations of extracellular material such as plasma. The nuclear profiles in these cells appear normal. Peroxisomes were not counted in this electron micrograph because an individual hepatocyte showing most of its cytoplasm is not present.
Z18825. Liver. Hepatocyte. 10,320X. This hepatocyte is polygonal with a round central nucleus. Its surrounding cytoplasm contains numerous mitochondria and a few small lipid droplets. The intervening cytoplasm contains profiles of endoplasmic reticulum, scattered fine glycogen granules, and some dark round peroxisomes. Twenty-two (22) peroxisomes counted. Three adjacent hepatocytes appear essentially normal. At the bottom right of the photograph is a finely granular structure, which is outside of the centered hepatocyte and appears similar to that described in Z18224.
Z18826. Liver. Hepatocyte. 10,320X. This hepatocyte is bordered by an extracellular space along its right margin. The cell has a small nuclear profile and abundant cytoplasm containing numerous mitochondria and slightly dilated endoplasmic reticulum. Several lipid droplets are present. Seventeen (17) peroxisomes counted.

3M_MN03279821

I05511 Biopsy Continued.

Z18827 Liver. Hepatocyte. 10,320X. A large round nucleus is present in the centered hepatocyte. The surrounding cytoplasm contains numerous mitochondria and abundant endoplasmic reticulum. A few dark residual bodies are present. Eleven (11) peroxisomes counted. At the right dorsal margin of the photograph are an endothelial cell and a granular structure that appears to be an invagination of plasma.

Conclusions: Normal hepatocytes. Peroxisomes average 18.5 per hepatocyte.

3M_MN03279822

1818.0989

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)
Species/Strain: Cynomolgus Monkey

Animal No.: I05511
79-week necropsy
Tissue: Liver - centrilobular

Treatment Group: 75 mg/kg (hi-dose)
Block No(s).: 99.76-32-2A
Z18828

Sex: Male
Photo/Negative No(s).: Z18832

Significant Lesions (check one): ____ Yes X No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18828. Liver. Hepatocyte. 10,320X. This hepatocyte is somewhat oval in shape with a small round nucleus. Approximately 8-9 small to medium sized lipid droplets are present in the cytoplasm. The majority of the cytoplasm contains numerous round to rod-shaped mitochondria, intervening areas of smooth endoplasmic reticulum (SER) and "more clear" patches of glycogen. Some profiles of rough endoplasmic reticulum (RER) and round dark peroxisomes are also evident. Twenty-eight (28) peroxisomes counted. Bile canaliculi can be seen between the hepatocytes situated on the right and left with the central hepatocyte.
Z18829. Liver. Hepatocyte. 10,320X. The central vein and surrounding extracellular collagen are present at the top right margin of this electron micrograph. A sinusoid is also present at the lower left margin. The intervening hepatocyte has a round nucleus and surrounding cytoplasm containing numerous profiles of endoplasmic reticulum and dark mitochondria. There is mild dilatation of the endoplasmic reticulum and nuclear envelope, which is a fixation artifact. Several dark residual bodies and occasional small lipid droplets are also identified. Differentiation between peroxisomes and mitochondria is difficult. Eleven (11) peroxisomes counted.
Z18830. Liver. Hepatocyte. 10,320X. The cytoplasm of this hepatocyte contains abundant SER, although some profiles of RER are also evident, especially around some mitochondria. A nuclear profile is not evident in this plane of section of the centered hepatocyte. Approximately 20 lipid droplets are present. Twenty (20) peroxisomes counted. This hepatocyte's microvillous border is evident both dorsally and ventrally along sinusoids. The nucleus of an endothelial cell is present at the lower right. Adjacent hepatocytes are present to the left and right of the centered hepatocyte.
Z18831. Liver. Hepatocyte. 10,320X. The morphology of this hepatocyte is very similar to Z18828. The cytoplasm contains numerous mitochondria, endoplasmic reticulum and "more clear" patches of glycogen. Several lipid droplets are present. Nineteen (19) peroxisomes counted. The surrounding hepatocytes appear ultrastructurally similar.

3M_MN03279823

I05511 Necropsy Continued.

Z18832. Liver. Hepatocyte. 10,320X. This hepatocyte appears similar to Z18830. Its cytoplasm contains abundant SER. Other recognizable organelles include some RER, lipid droplets, mitochondria, peroxisomes and residual bodies. Eighteen (18) peroxisomes counted. At the lower right margin of the photograph is a sinusoid containing several erythrocytes. A prominent bile canaliculus is present at the right where three hepatocytes appear to meet. These hepatocytes are considered to be ultrastructurally normal.

Conclusions: Normal hepatocytes. Average 19.2 peroxisomes per hepatocyte.

3M_MN03279824

1818.0991

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)
Species/Strain: Cynomolgus Monkey

Animal No.: I05522
57-week biopsy
Tissue: Liver - centrilobular

Treatment Group: 75 mg/kg (hi-dose)
Block No(s).: 99.76-33-1A
Z18833 -

Sex: Male
Photo/Negative No(s).: Z18837

Significant Lesions (check one): ____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18833. Liver. Hepatocyte. 10,320X. A sinusoid containing finely granular plasma is along the right microvillous margin of this hepatocyte. The hepatocyte has an oval nucleus. In the surrounding cytoplasm are several very electron-dense residual bodies. There is mild dilatation of the nuclear envelope and endoplasmic reticulum, which is a fixation artifact. Eighteen (18) peroxisomes counted. Mitochondria are numerous and are variably shaped.

Z18834. Liver. Hepatocyte. 10,320X. This hepatocyte appears ultrastructurally similar to Z 18833. There is mild dilatation of the endoplasmic reticulum and nuclear envelope. The hepatocyte lines a sinusoid, which contains two erythrocytes and a granulated eosinophil. Eight (8) peroxisomes counted.

Z18835. Liver. Hepatocyte. 10,320X. Several small lipid droplets are present in the cytoplasm of this hepatocyte. It has a slightly oval nucleus and abundant cytoplasm which contains numerous mitochondria and profiles of endoplasmic reticulum. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. A distinct myelin figure is evident associated with a lipid droplet to the left of the nucleus. Twenty-two (22) peroxisomes counted.

Z18836. Liver. Hepatocyte. 10,320X. The hepatocyte has a large polygonal nucleus. The cytoplasm contains abundant SER and RER, which exhibit slight dilatation. Several small to large lipid droplets are present. Numerous round dark peroxisomes are evident. Thirty-five (35) peroxisomes counted. Mitochondria are numerous and variably shaped, but appear ultrastructurally normal.

Z18837. Liver. Hepatocyte. 10,320X. A sinusoid is present along the left and lower margins of this electron micrograph. The lighter-staining endothelial cell is present along the lower margin. The centered hepatocyte has an oval nucleus and numerous mitochondria and endoplasmic reticulum in its surrounding cytoplasm. There is mild dilatation of the endoplasmic reticulum and nuclear envelope. Several lipid droplets and residual bodies are also discernible. Fourteen (14) peroxisomes counted.

Conclusions: Normal hepatocytes. Peroxisomes average 19.4 per hepatocyte.

3M_MN03279825

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05522
79-week necropsy

Tissue: Liver - centrilobular

Treatment: Group: .75 mg/kg (lit-dose)

Block No(s).: 99.76-34-2A
Z18838 -

Sex: Male

Photo/Negative No(s).: Z18842

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18838. Liver. Hepatocyte. 10,320X. This hepatocyte has a large round nucleus. At the very top left margin of the electron micrograph is a segment of sinusoid along its microvillous border. A bile canaliculus is evident at the lower left margin of the photograph, where the centered hepatocyte meets an adjacent hepatocyte. The centered hepatocyte has abundant cytoplasm, which contains numerous profiles of RER and SER. There is slight dilatation of the endoplasmic reticulum. Mitochondria are numerous are round to oval in shape. Approximately twenty-three (23) peroxisomes counted.
Z18839. Liver. Hepatocyte. 10,320X. Two hepatocytes are clearly evident in this electron micrograph. They appear ultrastructurally similar. They exhibit mild dilatation of their endoplasmic reticulum and nuclear envelopes. They have numerous mitochondria and occasional lipid droplets and residual bodies. Peroxisomes are usually round and more electron-dense than the mitochondria. Seventeen (17) peroxisomes counted in the upper hepatocyte.
Z18840. Liver. Hepatocyte. 10,320X. This hepatocyte has a large round central nucleus. The surrounding cytoplasm has numerous mitochondria and many slightly dilated profiles of endoplasmic reticulum. Both the SER and RER appear slightly dilated. Approximately 15-16 small to medium sized lipid droplets are present, as are a few very electron dense residual bodies. Twenty-one (21) peroxisomes counted.
Z18841. Liver. Hepatocyte. 10,320X. This hepatocyte's nucleus is not evident in this plane of section. A sinusoid containing an erythrocyte is present along the very top margin of this electron micrograph. There is slight dilatation of the endoplasmic reticulum throughout the cytoplasm. Also, random small to medium sized lipid droplets are present. Numerous peroxisomes are evident. Forty (40) peroxisomes counted.
Z18842. Liver. Hepatocyte. 10,320X. This hepatocyte appears similar to Z18838, and is ultrastructurally normal. It has an oval nucleus and abundant surrounding cytoplasm containing numerous mitochondria and slightly dilated profiles of endoplasmic reticulum. Twenty-eight (28) peroxisomes counted. Sinusoids are evident at the upper left and lower right margins of the photograph.

Conclusions: Normal hepatocytes. Peroxisomes average 25.8 per hepatocyte.

3M_MN03279826

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)
Species/Strain: Cynomolgus Monkey

Animal No.: I05533
57-week biopsy
Tissue: Liver - centrilobular

Treatment Group: 75 mg/kg (hi-dose)
Block No(s).: 99.76-35-1A
Z18843 -

Sex: Female
Photo/Negative No(s).: Z18847

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18843. Liver. Hepatocyte. 10,320X. This hepatocyte has a small nuclear profile. A sinusoid lined by an endothelial cell is present along the upper right margin of the electron micrograph, and an adjacent hepatocyte is present at the lower left margin. A prominent bile canaliculus is present between the two hepatocytes. The cytoplasm of the centered hepatocyte is voluminous and contains numerous mitochondria and endoplasmic reticulum. The endoplasmic reticulum, nuclear envelope, and mitochondria appear to be slightly dilated. This dilatation is a fixation artifact. A few small to medium sized lipid droplets are present. Forty (40) peroxisomes counted.
Z18844. Liver. Hepatocyte. 10,320X. This somewhat triangular-shaped hepatocyte has a large oval nucleus. Its cytoplasm contains numerous mitochondria and slightly dilated profiles of RER. Some glycogen granules appear to be intermixed with the SER. Eighteen (18) peroxisomes counted.
Z18845. Liver. Hepatocyte. 10,320X. This electron micrograph appears similar to Z18844, although two nuclear profiles are present, which is probably a function of the plane of section although it may be binucleated. Thirty-four (34) peroxisomes counted.
Z18846. Liver. Hepatocyte. 10,320X. The centered hepatocyte contains a small round nucleus. The surrounding cytoplasm contains numerous mitochondria and slightly dilated profiles of endoplasmic reticulum, both SER and RER. One myelin figure and several lipid droplets are present. Thirty-three (33) peroxisomes counted. Some extracellular collagen and a sinusoid are present along the lower right margin of the photograph. The hepatocyte at the top right is more lightly staining than the centered hepatocyte, and its cytoplasm contain abundant SER. Some mitochondria and peroxisomes are also evident.
Z18847. Liver. Hepatocyte. 10,320X. This electron micrograph appears very similar to Z18844. Although there is slight dilatation of the endoplasmic reticulum, this hepatocyte appears ultrastructurally normal. Twenty-four (24) peroxisomes counted.

Conclusions: Normal hepatocytes. Peroxisomes average 29.8 per hepatocyte.

3M_MN03279827

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05533
79-week necropsy

Tissue: Liver - centrilobular

Treatment Group: 75 mg/kg (hi-dose)

Block No(s).: 99.76-36-2A
Z18848 -

Sex: Female

Photo/Negative No(s).: Z18852

Significant Lesions (check one): _____ Yes __X__ No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18848. Liver. Hepatocyte. 10,320X. This electron micrograph illustrates a hepatocyte with adjacent hepatocytes along either side. Sinusoids are present along the top right and bottom left margins. Along the sinusoids, the hepatocytes exhibit microvillous borders. Lightly staining endothelial cells line the sinusoids. The centered hepatocyte has a large oval nucleus and abundant surrounding cytoplasm. The cytoplasm contains large amounts of SER and numerous scattered mitochondria. A few lipid droplets and residual bodies are present. RER is evident as clusters, usually around mitochondria. Thirty-five (35) peroxisomes counted.
Z18849. Liver. Hepatocyte. 10,320X. This pentagonally-shaped hepatocyte has a somewhat "trapezoid" appearance and is bounded by hepatocytes on five sides. It has a round central nucleus and abundant surrounding cytoplasm. The cytoplasm contains numerous mitochondria and lots of SER. Some profiles of RER are present around the mitochondria. Twenty-four (24) peroxisomes counted.
Z18850. Liver. Hepatocyte. 10,320X. This hepatocyte is bordered by a sinusoid at its lower left margin. The sinusoid is lined by an endothelial cell and contains two profiles of erythrocytes. The hepatocyte has a small central nucleus. Its cytoplasm contains numerous areas of glycogen. These are lightly stained areas with fine granular material. Mitochondria, SER and RER appear ultrastructurally normal. Eight (8) peroxisomes counted.
Z18851. Liver. Hepatocyte. 10,320X. This electron micrograph appears essentially similar to Z18850. Near the top center there is a sinusoid lined by an endothelial cell and containing an erythrocyte. The hepatocyte's cytoplasm contains multiple patches of glycogen interspersed between SER and mitochondria. Eighteen (18) peroxisomes counted.
Z18852. Liver. Hepatocyte. 10,320X. This hepatocyte is round, with a round nucleus, and contains one medium sized lipid droplet in its cytoplasm. A sinusoid containing an erythrocyte is present along the lower right margin of the electron micrograph. Abundant SER, mitochondria, and some glycogen are present in the cytoplasm of the hepatocyte. Approximately nineteen (19) peroxisomes counted.

Conclusions: Normal hepatocytes. Peroxisomes average 20.8 per hepatocyte.

3M_MN03279828

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05542
57-week biopsy

Tissue: Liver - periportal

Treatment Group: .75 mg/kg/ (hi-dose)

Block No(s).: 99.76-37-1A
Z18853 -

Sex: Female

Photo/Negative No(s).: Z18857

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18853. Liver. Hepatocyte. 10,320X. This hepatocyte appears surrounded by adjacent hepatocytes on all sides. It has a large polygonal nucleus and abundant surrounding cytoplasm. Just to the lower left of its nucleus is a small segment of extracellular space containing some microvilli and collagen, probably next to a sinusoid. Several small lipid droplets are present in the cytoplasm of the centered hepatocyte. The endoplasmic reticulum is slightly dilated, and several residual bodies are present. Nineteen (19) peroxisomes counted.
Z18854. Liver. Hepatocyte. 10,320X. Similar to Z18853, the endoplasmic reticulum of this hepatocyte is slightly dilated, which along with the dilated nuclear envelope, is an artifact of fixation. The mitochondria appear to also exhibit some slight artifactual swelling. Multiple bile canaliculi are evident along the margins of this cell's contact with adjacent hepatocytes. Approximately thirteen (13) peroxisomes counted.
Z18855. Liver. Hepatocyte. 10,320X. This hepatocyte has a large round nucleus. It's surrounding cytoplasm contains numerous profiles of SER, which are minimally dilated. Approximately 20 small to medium sized lipid droplets are present in the cytoplasm. Fifty-one (51) peroxisomes counted.
Z18856. Liver. Hepatocyte. 10,320X. Extracellular space containing numerous collagen fibrils is present next to the centered hepatocyte. The hepatocyte has a large oval nucleus and abundant surrounding cytoplasm with numerous mitochondria and endoplasmic reticulum. A few small lipid droplets are present. Thirteen (13) peroxisomes counted.
Z18837. Liver. Hepatocyte. 10,320X. Smooth endoplasmic reticulum and mitochondria are abundant in the cytoplasm of this hepatocyte. The hepatocyte has a large round nucleus and several small to medium sized lipid droplets are present. Nineteen (19) peroxisomes counted.

Conclusions: Normal hepatocytes. Peroxisomes average 23.0 per hepatocyte.

3M_MN03279829

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05542
79-week necropsy

Tissue: Liver - centrilobular

Treatment Group: .75 mg/kg (hi-dose)

Block No(s).: 99.76-38-2A
Z18858 -

Sex: Female

Photo/Negative No(s).: Z18862

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] May 29, 2000

Features: Z18858. Liver. Hepatocyte. 10,320X. This hepatocyte has a round central nucleus. To the left of and beneath the nucleus are several medium sized lipid droplets. The remaining cytoplasm contains abundant SER, patches of glycogen, mitochondria, and some profiles of RER. Six (6) peroxisomes counted.
Z18859. Liver. Hepatocyte. 10,320X. The cytoplasm of this hepatocyte contains multiple areas of glycogen granule accumulation. These are lightly stained areas with numerous small electron dense granules. A few lipid droplets are also present in the cytoplasm. The darker and irregular cytoplasmic material is SER intermixed with glycogen. Five (5) peroxisomes counted.
Z18860. Liver. Hepatocyte. 10,320X. Thirty-two (32) peroxisomes are counted in this hepatocyte's cytoplasm. The cell has a large round nucleus. Most of the cytoplasm is occupied by SER, mitochondria, and occasional lipid droplets. Some profiles of RER are evident around mitochondria. A microvillous border and adjacent sinusoid are present along the right margin of this hepatocyte.
Z18861. Liver. Hepatocyte. 10,320X. For this hepatocyte, its nuclear profile is not present in this plane of section. A moderate number of medium sized lipid droplets are present. Several of these contain some membranous or myelin-like debris. Numerous profiles of SER and RER are present. There is slight dilatation of the endoplasmic reticulum. Numerous variably shaped mitochondria are present, but they appear ultrastructurally normal. Eleven (11) peroxisomes counted.
Z18862. Liver. Hepatocyte. 10,320X. This hepatocyte appears somewhat triangular shaped in this plane of section. It has a large round nucleus and abundant surrounding cytoplasm. Several small to medium sized lipid droplets are present. Abundant SER, some profiles of RER, mitochondria, and peroxisomes occupy the majority of the cytoplasm. Approximately twenty two (22) peroxisomes counted. A sinusoid with an endothelial cell and erythrocyte is present at the lower left margin of the photograph.

Conclusions: Normal hepatocytes. Peroxisomes average 15.2 per hepatocyte.

3M_MN03279830

III. Transmission Electron Micrographs

3M_MN03279831

Fig. 1



3M_MN03279832

Fig. 2



1000

Fig. 3



3M_MN03279834

Fig. 4



Electron Microscopy Report
Covance Study No. 6329-223
Recovery Sacrifice Animals

Figure Legends

Magnification. Print magnification is indicated on the back of each photograph. The measurement bar on each photomicrograph equals one micron (0.001mm).

Figure 1. Liver. Hepatocyte showing normal cytoplasmic organelles. Some peroxisomes and other normal organelles are identified. There is slight artifactual dilatation of the nuclear envelope and endoplasmic reticulum. Animal No. I05522, 0.75 mg/kg/day (high dose male), 57-week biopsy, 10,320X magnification.

Figure 2. Liver. Hepatocyte. Glycogen accumulations are shown. Glycogen are the small granules within the clear areas. Animal No. I05511, 0.75 mg/kg/day (high-dose male), 79-week necropsy, 10,320X magnification.

Figure 3. Liver. Hepatocyte showing normal cytoplasmic organelles. There is slight artifactual dilatation of the endoplasmic reticulum and nuclear envelope. Animal No. I05542, 0.75 mg/kg/day (high-dose female), 57-week biopsy, 10,320X magnification.

Figure 4. Liver. Hepatocyte showing normal cytoplasmic organelles. Animal No. I05533, 0.75 mg/kg/day (high dose female), 79-week necropsy, 10,320X magnification.

3M_MN03279836

Index of Labels for Ultrastructural Structures

Abbreviation	Structure
BC	Bile canaliculus
EV	Nuclear envelope
G	Glycogen
L	Lipid droplet
M	Mitochondria
N	Nucleus
P	Peroxisome
RB	Residual body
RER	Rough endoplasmic reticulum
SER	Smooth endoplasmic reticulum

3M_MN03279837

IV. Quality Assurance Statement

3M_MN03279838

QUALITY ASSURANCE STATEMENT

This electron microscopy study has been inspected and audited by the Quality Assurance Unit as required by the Good Laboratory Practices Regulations promulgated by the U.S. Food and Drug Administration. PAI has a functioning and responsive Quality Assurance Unit which reports directly to management. The following is a record of inspections/audits and their resulting reports:

Date of Inspection	Phase Inspected	Date Findings Reported to Management and Study Pathologist
4/1, 2/99	Data Audit	4/2/99
4/2/99	Draft Report Audit	4/2/99
7/13/99	Audit of Data from Additional Groups	7/13/99
7/13/99	Final Report Audit	7/13/99
5/25, 30/00	Data and Draft Report Audit Recovery Animals	5/30/00
9/1/00	Final Report Audit	9/1/00

Jeanne deWard, B.S., RQAP-GLP
Quality Assurance Specialist

9/1/00
Date

Sponsor: 3M Corporate Toxicology

Test Article: PFOS

Study Number: 6329-223, PAI Study EM-99.76

3M_MN03279839

Pathology Associates International
A Company of Science Applications International Corporation
An Employee-Owned Company

PATHOLOGY REPORT
(ANCILLARY STUDY)

ELECTRON MICROSCOPIC EVALUATION OF LIVER IN CYNOMOLGUS MONKEYS

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

CLIENT STUDY NUMBER 6329-223
PAI STUDY NUMBER EM 99.76

Prepared by:

James B. Nold, D.V.M., Ph.D., Diplomate, A.C.V.P.

Pathology Associates International
4915-D Prospectus Drive
Durham, NC 27713

July 13, 1999

PREPARED FOR 3M CORPORATE TOXICOLOGY,
3M CENTER, ST. PAUL, MN 55144-1000

4915 D Prospectus Drive • Durham, North Carolina 27713 • (919) 544-5257 • (919) 544-3218 FAX

3M_MN03279840

	Section
Pathology Narrative	I
Light Microscopy and Transmission Electron Micrograph Interpretation Forms	II
Transmission Electron Micrographs	III
Quality Assurance Statement	IV

3M_MN03279841

1818.1008

I. Pathology Narrative

3M_MN03279842

PATHOLOGY REPORT
(ANCILLARY STUDY)

ELECTRON MICROSCOPIC EVALUATION OF LIVER IN CYNOMOLGUS MONKEYS

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

CLIENT STUDY NUMBER 6329-223
PAI STUDY NUMBER EM 99.76

SUMMMARY

Treatment of cynomolgus monkeys with 0.75 mg PFOS/kg/day for 26 weeks resulted in hepatocellular vacuolation and hypertrophy by light microscopy. Hepatocellular vacuolation and hypertrophy were primarily centrilobular in distribution and did vary in incidence and severity between individual animals. Ultrastructurally, there were increased lipid droplets within hepatocytes. Increased lipid droplets were present in both the high-dose males examined and in two of four high-dose females examined. Increased hepatocellular glycogen was present in the remaining two high-dose females. These ultrastructural changes correlated with hepatocellular hypertrophy and vacuolation noted by light microscopy and with increased liver weight parameters in the high-dose animals. The no-effect level for hepatocellular vacuolation (lipid droplet accumulation) was 0.15 mg/kg/day of PFOS (mid-dose group).

Quantitation of peroxisomes within hepatocytes by electron microscopy indicated no remarkable differences between control livers and livers treated with 0.03, 0.15, or 0.75 mg PFOS/kg/day. Ultrastructural differences in cellular membranes or mitochondria were not discernible between control and treated animals in the samples examined.

PROCEDURES

The objective of this study was to examine by electron microscopy the livers from selected animals in a 26-week capsule toxicity study with PFOS in cynomolgus monkeys. In addition to a general qualitative evaluation for differences between control and treated animals, the ultrastructural endpoints included quantitation of peroxisomes within hepatocytes and membrane and mitochondrial changes in hepatocytes. Light microscopy of paraffin-embedded liver sections was also performed.

For the toxicity study, 22 male and 22 female cynomolgus monkeys were given the test article or the vehicle once daily for at least 26 weeks according to Text Table 1.

3M_MN03279843

Text Table 1. Group Designations and Dosage Levels

Dosage Group	Dose Level (mg/kg/day)[a]	Total Material Dose Level (mg/kg/day)[b]	Number of Males	Number of Females
I	0[a]	30[a]	6[d]	6[d]
II	0.03	15[b]	4	4
III	0.15	6[c]	6[d]	6[d]
IV	0.75	30[c]	6[d]	6[d]

[a] Dose levels were provided. The control group (Group 1) received an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.
[b] The low-dose group (Group 2) received the test material diluted with lactose (1:499, w:w).
[c] The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w:w).
[d] Two animals in Groups 1, 3, and 4, designated as recovery animals, were treated for at least 26 weeks, then treatment was discontinued and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 13 weeks posttreatment.

Animals to be sacrificed at scheduled terminal and recovery sacrifice times were anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied. Multiple tissues were collected and preserved in 10% neutral-buffered formalin according to the protocol. Additionally, pieces of liver from each animal were thin-sliced and placed in ½ strength Karnovsky's fixative (2.0% paraformaldehyde/2.5% glutaraldehyde in 0.1M phosphate buffer) for subsequent ultrastructural examination. These livers were processed into Epon blocks and submitted to this laboratory for subsequent electron microscopy processing and evaluation. Hematoxylin and eosin (H&E)-stained slide sections of formalin-fixed, paraffin-embedded livers were submitted for light microscopic examination.

Per sponsor request, tissue samples from terminal sacrifice control and high-dose males and females were initially processed and evaluated ultrastructurally (Text Table 2). Two high-dose males, Animals Nos. I05506 and I05509, died or were sacrificed in a moribund condition prior to scheduled terminal sacrifice. Ultrastructural examination of livers from these two unscheduled death animals was not performed. Following evaluation of the electron micrographs from the control and high-dose livers, the sponsor requested that electron microscopy be performed on the low- and mid-dose livers to evaluate whether increased lipid droplet accumulation was evident in these dose groups.

Text Table 2. Animals Selected for Electron Microscopy

0 mg/kg/day PFOS (Group 1 Control)		0.03 mg/kg/day PFOS (Group 2 low-dose)		0.15 mg/kg/day PFOS (Group 3 mid-dose)		0.75 mg/kg/day PFOS (Group 4 High-Dose)	
Males	Females	Males	Females	Males	Females	Males	Females
I05508	I05530	I05514	I05537	I05510	I05532	I05507	I05534
I05517	I05531	I05515	I05541	I05518	I05538	I05512	I05536
I05519	I05535	I05516	I05547	I05524	I05545		I05540
I05527	I05544	I05521	I05550	I05528	I05548		I05551

Thin sections (approximately 90 nm) from the Epon-embedded livers were cut, mounted on 200-mesh copper grids, stained with 5% methanolic uranyl acetate and Reynold's lead

3M_MN03279844

citrate, and examined on a Zeiss EM10C/CR, a Zeiss EM10, or a JEOL 100S transmission electron microscope. Centrilobular hepatocytes, where clearly identifiable in liver sections, were preferentially examined. Representative electron photomicrographs of liver were taken and significant ultrastructural features were summarized for each photograph and animal on a designated transmission electron micrograph interpretation form. The number of peroxisomes in hepatocytes was manually counted for each center photographed hepatocyte and recorded. For light microscopy, the H&E slides from the same animals selected for electron microscopy were evaluated and significant features were summarized on a light microscopic evaluation form.

RESULTS AND DISCUSSION

Individual interpretations of light microscopy slides and electron micrographs for each animal are shown in Section II. Representative electron photomicrographs were selected as report figures, labeled, and are shown in Section III. All remaining electron micrographs are maintained in the archived study file.

Light Microscopy

A summary of the incidence and severity of light microscopic findings in the control and high-dose livers is shown in Text Table 3. There was an increased incidence of vacuolation of the cytoplasm of hepatocytes in high-dose treated animals compared with control animals. The distribution of this vacuolation was predominantly centrilobular, but for one high-dose female, Animal No. I05534, there was diffuse slight hepatocellular vacuolation. Affected animals generally also had enlargement (hypertrophy) of centrilobular hepatocytes. This enlargement appeared to be related to the presence of the small to large vacuoles with the cytoplasm. Some sporadic vacuolation noted in low- and mid-dose animals did not appear to be treatment-related and was not clearly associated with hepatocellular hypertrophy.

Text Table 3. Incidence and Severity of Light Microscopic Liver Findings

Microscopic Finding	0 mg/kg/day (Control)		0.03 mg/kg (Low-Dose)		0.15 mg/kg (Mid-Dose)		0.75 mg/kg/day (High-Dose)	
	Males	Females	Males	Females	Males	Females	Males	Females
(number examined)	(4)	(4)	(4)	(4)	(4)	(4)	(2)	(4)
Vacuolation, hepatocellular, centrilobular								
minimal	-	-	1	-	-	-	-	2
slight	-	-	-	-	-	-	-	-
moderately-severe	-	-	-	-	-	-	1	1
Vacuolation, hepatocellular, diffuse								
slight	-	-	-	-	-	-	-	1
Vacuolation, hepatocellular, multifocal								
minimal	-	-	1	1	-	-	-	-

3M_MN03279845

Text Table 3 Continued. Incidence and Severity of Light Microscopic Liver Findings

Microscopic Finding	0 mg/kg/day (Control)		0.03 mg/kg (Low-Dose)		0.15 mg/kg (Mid-Dose)		0.75 mg/kg/day (High-Dose)	
	Males	Females	Males	Females	Males	Females	Males	Females
(number examined)	(4)	(4)	(4)	(4)	(4)	(4)	(2)	(4)
Hypertrophy, hepatocellular, centrilobular								
minimal	-	-	-	-	-	-	1	2
slight	-	-	-	-	-	-	-	-
moderate	-	-	-	-	-	-	1	1
Clearing, cytoplasmic, centrilobular								
minimal	1	2	-	2	1	-	-	-
slight	-	-	3	1	1	2	1	2
Clearing, cytoplasmic, diffuse								
minimal	-	-	-	-	1	-	-	-
slight	-	-	-	-	1	-	-	-
Infiltrate, lymphohistiocytic								
minimal	4	4	4	4	3	3	1	3
slight	-	-	-	-	-	1	-	-
Inflammation, eosinophilic-granulomatous								
minimal	-	-	1	-	-	-	-	-
slight	-	1	-	-	-	-	-	-
Pigment, hepatocellular, centrilobular								
slight	-	-	1	-	-	-	-	-
Ectasia, biliary								
minimal	-	-	-	1	-	-	-	-
Angiectasis								
minimal	1	-	-	-	-	-	-	-

Electron Microscopy

Control (0 mg/kg/day). Ultrastructural features of control hepatocytes are demonstrated in Figures 1 - 3. Hepatocytes characteristically contain numerous mitochondria and abundant endoplasmic reticulum. Peroxisomes are common organelles composed of a fine granular matrix surrounded by a membrane and normally vary in size from 0.1 - 1.5 microns in diameter. Hepatocytes exhibit a microvillous border which protrudes into the perisinusoidal space. Tight junctions border bile canaliculi between hepatocytes. Glycogen is common in the cytoplasm and may be in the form of small granules or slightly larger rosettes. Residual bodies are secondary lysosomes (phagolysosomes) containing electron dense degenerative cytoplasmic material. Lipid metabolism is a normal liver function, and it's normal to see random lipid droplets within hepatocytes.

There were no discernible differences between control males and females in this study, and all were considered normal. A summary of ultrastructural findings is shown in Text Table 4. One male, Animal No. I05527, appeared to have increased numbers of peroxisomes compared with the other control animals. However, because so few animals and individual hepatocytes were examined, this value may not be significantly increased.

3M_MN03279846

Text Table 4. Summary of Ultrastructural Findings

Treatment Group (mg/kg/day)/Sex	Animal No.	Comments
(0) Male	I05508	Normal
(0) Male	I05517	Normal
(0) Male	I05519	Normal
(0) Male	I05527	Normal. Increased peroxisomes
(0.03) Male	I05514	Mild increase in lipid droplets
(0.03) Male	I05515	Slight increase in lipid droplets
(0.03) Male	I05516	Normal
(0.03) Male	I05521	Normal
(0.15) Male	I05510	Normal
(0.15) Male	I05518	Normal
(0.15) Male	I05524	Normal, slight increase in peroxisomes
(0.15) Male	I05528	Normal
(0.75) Male	I05507	Lipid droplet accumulation, hepatocellular, moderately severe. Increased glycogen
(0.75) Male	I05512	Lipid droplet accumulation, moderate, hepatocellular. Increased peroxisomes
(0) Female	I05530	Normal
(0) Female	I05531	Normal
(0) Female	I05535	Normal
(0) Female	I05544	Normal
(0.03) Female	I05537	Normal
(0.03) Female	I05541	Normal
(0.03) Female	I05547	Normal
(0.03) Female	I05550	Normal
(0.15) Female	I05532	Normal
(0.15) Female	I05538	Increased glycogen
(0.15) Female	I05545	Normal
(0.15) Female	I05548	Normal
(0.75) Female	I05534	Increased glycogen
(0.75) Female	I05536	Lipid droplet accumulation, moderately severe
(0.75) Female	I05540	Lipid droplet accumulation, mild to moderate
(0.75) Female	I05551	Increased glycogen

Peroxisomes were identified and quantitated in representative hepatocytes. For the control livers, the average number of peroxisomes counted per hepatocyte photographed was 11.50 for control males and 10.94 peroxisomes per cell for control females. (Text Table 5). Depending upon fixation and staining, peroxisomes may be difficult to differentiate in routine electron photomicrographs from primary lysosomes or marginal cuts through the ends of mitochondria. Cytochemical and immunocytochemical methods are available for specifically identifying peroxisomes by light and electron microscopy, and utilization of these methods would provide a more specific and accurate method of peroxisome quantitation (Beier K, 1992; Reddy UN, 1988).

4915 D Prospectus Drive • Durham, North Carolina 27713 • (919) 544-5257 • (919) 544-3218 FAX

3M_MN03279847

Text Table 5 Quantitation of Hepatocellular Peroxisomes

0 mg PFOS/kg/day (Control)				0.03 mg PFOS/kg/day (Low-Dose)			
Male		Female		Male		Female	
Animal Number	Number[1] of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes
I05508	7.50	I05530	12.75	I05514	6.00	I05537	8.80
I05517	12.25	I05531	13.75	I05515	15.00	I05541	12.00
I05519	3.50	I05535	7.00	I05516	7.20	I05547	10.00
I05527	22.75	I05544	10.25	I05521	10.80	I05550	17.60
Mean =	11.50	Mean =	10.94	Mean =	9.75	Mean =	12.10
0.15 mg PFOS/kg/day (Mid-Dose)				0.75 mg PFOS/kg/day (High-Dose)			
Male		Female		Male		Female	
Animal Number	Number[1] of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes	Animal Number	Number of Peroxisomes
I05510	10.60	I05532	4.20	I05507	11.0	I05534	5.50
I05518	18.40	I05538	7.20	I05512	23.25	I05536	3.75
I05524	23.20	I05545	9.00			I05540	12.50
I05528	14.60	I05548	17.00			I05551	9.50
Mean =	16.70	Mean =	9.35	Mean =	17.12	Mean =	7.81

[1] Average number of peroxisomes per hepatocyte for four hepatocytes counted per animal for control and high-dose groups and five hepatocytes counted per animal for low- and mid-dose groups.

High-Dose (0.75 mg/kg/day). Lipid droplets were increased in animals given 0.75 mg PFOS/kg/day (Text Table 4). This increase was present in both high-dose males examined (Animal Nos. I05507 and I05512) and in two high-dose females (Animal Nos. I05536 and I05540). These are illustrated in Figures 4 - 7. Lipid droplets were randomly distributed in the cytosol and varied in size from less than .1 micron to greater than several microns in diameter. They generally were clear, but occasionally contained wispy lamellar material or faint smooth electron density. They were not membrane-bound, but appeared to form a defined margin with surrounding cytoplasm. These lipid droplets correlate with hepatocellular vacuolation described in these animals by light microscopy.

Increased cytoplasmic glycogen was evident in two high-dose females (Animal Nos. I05534 and I05551), and often formed distinct "pockets" of glycogen, resembling vacuoles or clear droplets, but containing glycogen particles (Figure 8). The accumulation of glycogen apparently correlates with the hepatocellular vacuolation described by light microscopy in these two animals. Lipid droplets did not appear increased in these two animals.

For high-dose animals, the average number of peroxisomes per hepatocyte was 17.12 for males and 7.81 for females (Text Table 5). One male (Animal No. I05512) averaged 23.25 peroxisomes per hepatocyte, however, this is not remarkably higher than that found in the control male Animal No. I05527. Animal No. I05507 averaged 11.0 peroxisomes per hepatocyte, similar to the average control value for males. Thus, administration of 0.75 mg/kg/day of PFOS to monkeys for 26 weeks did not appear to induce peroxisome proliferation in the liver.

3M_MN03279848

Differences in mitochondria and cellular membranes were not discernible between high-dose and control livers. Mitochondria from control and high-dose livers did not exhibit remarkable differences ultrastructurally (Figures 3, 9, 10).

Low-Dose (0.03 mg/kg/day). Electron microscopic examination of the livers from monkeys given 0.03 mg/kg/day of PFOS did not identify any atypical ultrastructural features compared with control sample. Lipid droplets were identified in some hepatocytes, and two low-dose males appeared to have slightly increased lipid droplet accumulation (Animal Nos. I05514 and I05515). However, increased lipid droplet accumulation was not seen in the low-dose females or in the mid-dose males and females, and this observation in the two low-dose males was believed to represent normal biological variance and sampling. As noted earlier, lipid metabolism is a normal liver function, and it's normal to see random lipid droplets within hepatocytes. Figure 11 illustrates a hepatocyte from the low-dose group.

For low-dose animals, the average number of peroxisomes per hepatocyte was 9.75 for males and 12.10 for females (Text Table 5).

Mid-Dose (0.15 mg/kg/day). There was no consistent ultrastructural evidence of increased lipid droplet accumulation in the livers of the mid-dose monkeys given 0.15 mg/kg/day of PFOS. This mid-dose level, 0.15 mg/kg/day, is the no-effect level for the PFOS-related effect of increased hepatocellular lipid accumulation (vacuolation) in monkeys given PFOS. One female, Animal No. I05538, had increased glycogen, but a marked increase in glycogen was not seen in any other mid-dose livers examined.

For mid-dose animals, the average number of peroxisomes per hepatocyte was 16.70 for males and 9.35 for females (Text Table 5). Figure 12 illustrates a hepatocyte from the mid-dose group.

CONCLUSION

Ultrastructural evaluation of livers from cynomolgus monkeys treated with 0.75 mg PFOS /kg/day for 26 weeks identified increased lipid droplets within hepatocytes. Increased lipid droplets were present in both treated males examined and in two of four treated females examined. Increased hepatocellular glycogen was present in the remaining two high-dose females. These ultrastructural changes correlated with hepatocellular hypertrophy and vacuolation noted by light microscopy and with increased liver weight parameters in the high-dose animals. The no-effect level for hepatocellular vacuolation (lipid droplet accumulation) was 0.15 mg/kg/day of PFOS (mid-dose group). Quantitation of peroxisomes within hepatocytes by electron microscopy indicated no remarkable differences between control livers and livers treated with 0.03, 0.15 or 0.75 mg/kg/day. Ultrastructural differences in cellular membranes or mitochondria were not discernible between control and treated animals in the samples examined.

3M_MN03279849

SIGNATURE OF AUTHOR

James B. Nold
James B. Nold, D.V.M., Ph.D.,
Diplomate, A.C.V.P.

July 13, 1999
Date

REFERENCES

Beier K: Light microscopic morphometric analysis of peroxisomes by automatic image analysis: advantages of immunostaining over the alkaline DAB method. *J. Histochem. Cytochem.*, 40(1):115-121, 1992.

Reddy, UN et. al: Tissue specificity and species differences in the distribution of urate oxidase in peroxisomes. *Lab. Invest.*, 58(1)100-111, 1988.

3M_MN03279850

II. Light Microscopy and Transmission Electron Micrograph Interpretation Forms [1]

[1] Forms are typographically corrected versions of signed/dated raw data sheets maintained in archived study file.

3M_MN03279851

LIGHT MICROSCOPIC EVALUATION

Study No.: 6329-223 (EM 99.76) Species/Strain: Cynomolgus Monkeys

Animal No: see below Tissue: Liver

Sex: see below

Interpreting Pathologist (signature and date): James B. Noel 6-24-99

Dose/Group	Animal Number	Microscopic Findings and Comments
0 mg/kg (Control) Males	I05508	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05517	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05519	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05527	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Angiectasis, focal, minimal
0 mg/kg (Control) Females	I05530	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05531	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05535	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
	I05544	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Inflammation, eosinophilic-granulomatous, focal, slight
0.75 mg/kg (High-dose) Males	I05507	1. Infiltrate, lymphohistiocytic, focal, minimal 2. Vacuolation, hepatocellular, centrilobular, moderately-severe 3. Hypertrophy, hepatocellular, centrilobular, moderate
	I05512	1. Clearing, cytoplasmic, centrilobular, slight 2. Hypertrophy, hepatocellular, centrilobular, minimal
0.75 mg/kg (High-dose) Females	I05534	1. Infiltrate, lymphohistiocytic, focal, minimal 2. Vacuolation, hepatocellular, diffuse, slight 3. Hypertrophy, hepatocellular, centrilobular, minimal
	I05536	1. Vacuolation, hepatocellular, centrilobular, moderately-severe 2. Hypertrophy, hepatocellular, centrilobular, moderate
	I05540	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Vacuolation, hepatocellular, centrilobular, minimal 3. Clearing, cytoplasmic, centrilobular, slight 4. Hypertrophy, hepatocellular, centrilobular, minimal
	I05551	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Vacuolation, hepatocellular, centrilobular, minimal 3. Clearing, cytoplasmic, centrilobular, slight

3M_MN03279852

Dose/Group	Animal Number	Microscopic Findings and Comments
0.03 mg/kg	I05514	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Inflammation, eosinophilic-granulomatous, focal, minimal 3. Pigment, hepatocellular, multifocal, centrilobular, minimal 4. Clearing, cytoplasmic, centrilobular, slight
(Low-dose)	I05515	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Vacuolation, hepatocellular, centrilobular, minimal
Males	I05516	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, slight
	I05521	1. Infiltrate, lymphohistiocytic, multifocal minimal 2. Pigment, hepatocellular, multifocal, centrilobular, slight 3. Vacuolation, hepatocellular, multifocal, minimal 4. Clearing, cytoplasmic, centrilobular, slight
0.03 mg/kg	I05537	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, slight
(Low-dose)	I05541	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
Females	I05547	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Ectasia, biliary, focal, minimal
	I05550	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal 3. Vacuolation, hepatocellular, multifocal, minimal
0.15 mg/kg	I05510	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, diffuse, minimal
(Mid-dose)	I05518	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, minimal
Males	I05524	1. Clearing, cytoplasmic, centrilobular, slight
	I05528	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, diffuse, slight
0.15 mg/kg	I05532	1. Infiltrate, lymphohistiocytic, multifocal, minimal
(Mid-dose)	I05538	1. Infiltrate, lymphohistiocytic, multifocal, minimal 2. Clearing, cytoplasmic, centrilobular, slight
Females	I05545	1. Infiltrate, lymphohistiocytic, multifocal, minimal
	I05548	1. Infiltrate, lymphohistiocytic, multifocal, slight 2. Clearing, cytoplasmic, centrilobular, slight

Interpreting Pathologist (signature and date): James B Arnold 6-14-99

3M_MN03279853

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: 105508

Tissue: Liver

Treatment Group: 0 mg/kg (Control)

Block No(s).: ~~99076-1~~ 99.76-1 JBr 4-5-99

Sex: Male

Photo/Negative No(s).: 43401 - 43405

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): MAR 3 1 1999

JBr 4-5-99

Features: 43402: Liver. Hepatocyte exhibiting large central nucleus. The cytoplasm contains many mitochondria and abundant endoplasmic reticulum. Bile canaliculi are evident at the lower right and left margins of this hepatocyte. A number (approximately 20-25) of small to medium-size clear lipid droplets are present, principally in the upper portion of the cell. Mitochondria appear normal; normal matrix granules are evident in most. Several lysosomes and peroxisomes are present. Five (5) peroxisomes counted.
43402: Liver. Hepatocyte is possibly bi-nucleate, but this may be function of cut through the nucleus. Some small to medium-sized clear lipid droplets present, similar to 43402. Microvillous border in space of Disse evident at top margin of cell. Several lamellar mylein-like bodies present within lysosomes. Five (5) peroxisomes counted. JBr 4-5-99
43403. Liver. Hepatocyte with bile canaliculus at lower right. Only a few small to medium-size clear lipid droplets are evident. Numerous mitochondria and abundant endoplasmic reticulum are evident. Clear structure at the bottom may be dilated Golgi, reticulum or artifact. Nine (9) peroxisomes counted.
43404: Liver. Hepatocyte with adjacent endothelial cell and sinusoid at the bottom of the photograph. Hepatocyte contains several small to medium-sized clear lipid droplets. One droplet contains some lamellar material. Eleven (11) peroxisomes counted.
43405: Liver. Hepatocyte with higher magnification of mitochondria. Seven mitochondria present with intervening rough endoplasmic reticulum and cytosol. Outer membrane, cristae, matrix and granules appear normal.

Conclusions: Normal hepatocyte. Average 7.5 peroxisomes counted per hepatocyte.

3M_MN03279854

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05517

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: 99.76-2

Sex: Male

Photo/Negative No(s).: 43406 - 43410

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): MAR 3 1 1999

Features: 43406: Liver. Hepatocyte surrounded by other hepatocytes with bile canaliculi in the lower right and upper left margins of the cell. There are numerous mitochondria and abundant endoplasmic reticulum. The ER and nuclear envelope appears slightly dilated. Only a couple small clear lipid droplets evident. Several small lysosomes or vacuoles with microvesicles in them are present. Five (5) peroxisomes counted.
43407: Liver. Hepatocyte with perisinusoidal microvillous border evident in lower right and upper left of photograph. A bile canaliculus is present on the right middle margin of the cell. Several small to medium-sized clear lipid droplets are evident. One larger one contains some lamellar profiles. Four (4) peroxisomes counted.
43408: Liver. Hepatocyte with sinusoid containing erythrocytes at the top. A lipid-containing perisinusoidal cell (Ito cell) is present at the top left and a bile canaliculus is present at the bottom. Random small clear lipid droplets are present in the hepatocellular cytoplasm and some of the ER appears mildly dilated. Eleven (11) peroxisomes counted.
43409: Liver. Hepatocyte contains numerous dense lysosomes and/or peroxisomes intermixed with mitochondria and abundant ER. Several small clear lipid droplets are evident. Twenty-nine (29) peroxisomes counted.
43410: Liver. Enlarged photograph of mitochondria. Ten mitochondria are clustered together in this photograph. Although the image is a little out of focus, these organelles appear essentially normal. There may be mild dilatation of the ER in the cytoplasm.

Conclusions: Normal hepatocyte. Average 12.25 peroxisomes per hepatocyte.

3M_MN03279855

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05519

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: 99.76-3

Sex: Male

Photo/Negative No(s).: 43421 - 43425, 43431

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: 43421: Liver. Hepatocyte. At lower left is a prominent perisinusoidal fat-storing cell (Ito cell) containing numerous large clear lipid droplets. The centered hepatocyte contains one large clear lipid droplet and several smaller ones. The nuclear envelope and ER is mildly dilated. Moderate numbers of glycogen granules present. Scattered residual bodies noted. Four (4) peroxisomes counted.
43422: Liver. Mitochondria and surrounding cytosol and ER. Membranes of ER are not very distinct. Glycogen in cytosol. Mitochondria appear essentially normal. Lamina of membranes and cristae appear parallel. Several normal granules in the matrix of the mitochondria.
43423: Liver. Mitochondria. Same view as 43422 but slightly less magnification. Some dilatation of ER. Mitochondria appear normal. A peroxisome is present in the lower left of the photograph.
43224: Liver. Hepatocyte with several medium-sized and one large clear lipid droplets. Small granules within cytosol and around ER appear to be glycogen particles or ribosomes and polyribosomes. Four (4) peroxisomes counted. Slightly out of focus.
43425: Liver. Hepatocyte surrounded by other hepatocytes and a sinusoid at lower right. Several bile canaliculi evident between hepatocytes. A single medium-sized clear lipid droplet is present in the hepatocyte. Four (4) peroxisomes counted. A couple of larger dense lysosomes also identified.
43431: Liver. The centered hepatocyte is oblong diagonally in the photograph, and doesn't contain any distinct lipid droplets. A few lipid droplets are present in adjacent hepatocytes. There is mild dilation of the ER and nuclear envelope. Only a few lysosomal structures noted. Two (2) peroxisomes counted.

Conclusions: Normal hepatocyte. Average 3.5 peroxisomes per hepatocyte.

3M_MN03279856

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05527

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: 99.76-4

Sex: Male

Photo/Negative No(s).: 43420 - 43426

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: 43426: Liver. Hepatocyte with several small to medium-sized lipid droplets (approximately 20). The adjacent lower left hepatocyte shows significant dilatation of its ER. At top left and right margin, the extracellular interstitium has some collagen fibers. Some residual bodies noted. Twenty-one (21) peroxisomes counted.
43427: Liver. Mitochondria. Membrane, cristae and matrix appear normal. Several normal granules present matrix. Some rough ER present adjacent to mitochondria. Lysosome present at left of center mitochondrion.
43428: Liver. Hepatocyte. There is mild dilation of the ER and nuclear envelope. Scattered small to medium-size clear lipid droplets (approximately 18). Scattered residual bodies noted. Twenty-five (25) peroxisomes counted.
43429: Liver. Hepatocyte. Bile canaliculi are evident at the lower right and top of the cell. The ER is mildly dilated. Scattered clear lipid droplets are evident. Abundant numbers of dense bodies (peroxisomes)/lysosomes and residual bodies are present. Thirty (30) peroxisomes counted.
43430: Liver. Hepatocyte appears similar to above described cells. There are some scattered small to medium-size clear lipid droplets. Some residual bodies are present. Fifteen (15) peroxisomes counted.

Conclusions: Normal hepatocyte. Appear to be increased numbers of peroxisomes compared with other control samples. Average 22.75 peroxisomes per hepatocyte.

3M_MN03279857

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05507

Tissue: Liver

Treatment Group: 0.75 mg/kg (hi-dose)

Block No(s).: 99.76-9

Sex: Male

Photo/Negative No(s).: 43411 - 43415

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

JBR 4-5-99

Features: 43411, 43412, 43413, 43414, 43415. Liver. Hepatocyte containing a single very large clear lipid droplet and many small to medium-size clear lipid droplets. There appears to be an increase in the amount of glycogen α-rosette granules. Several foci of ER appear irregularly dilated. A few scattered lysosomes and peroxisomes noted. Nine (9) peroxisomes counted.
43412: Liver. Hepatocyte contains a large number of small to medium-sized clear lipid droplets in the cytosol (approximately 125), most being very small. Abundant glycogen as α-rosettes is present in the cytoplasm. Twenty-six (26) peroxisomes counted.
43413: Liver. Hepatocyte containing several very large clear lipid droplets and many smaller droplets. Some interstitial tissue containing some collagen fibers is present at the lower left of the photograph. Some residual bodies present. Many glycogen rosettes present in cytoplasm. Three (3) peroxisomes counted.
43414: Liver. Several mitochondria are shown which appear essentially normal. Some normal dense granules are present in the matrix and the cristae and enveloping membrane appear normal. In the cytoplasm there are multiple small lipid droplets, usually surrounded by fine dense granules (glycogen or ribosomes).
43415: Liver. Hepatocyte with a bile canaliculus at the bottom margin and an interstitial fibroblastic cell at the upper right. The hepatocyte contains abundant small to medium-sized clear lipid droplets (>170). Random residual bodies are present. Six (6) peroxisomes counted.

JBR 4-5-99

Conclusions: Lipid accumulation, moderately-severe, hepatocellular. Increased glycogen. Average 11.0 peroxisomes per hepatocyte.

3M_MN03279858

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05512

Tissue: Liver

Treatment Group: 0.75 mg/kg (hi-dose)

Block No(s).: 99.76-10

Sex: Male

Photo/Negative No(s).: 43416 - 43420

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: 43416: Liver. Photographed hepatocyte is binucleated and contains many small clear lipid droplets. Most appear around 100 nm in diameter, although a few are larger and one is about 1.75 microns in diameter. They are too numerous to count. The droplets appear to be free within the cytosol and are not membrane-bound. Nine (9) peroxisomes counted.
43417: Liver. Hepatocyte contains multiple medium-sized clear lipid droplets (approximately 90). There are abundant numbers of dense primary lysosomes or peroxisomes. Forty-five (45) peroxisomes counted.
43418: Liver. Hepatocyte containing numerous small to medium-sized clear lipid droplets within the cytosol. They are too numerous to count. Twelve (12) peroxisomes counted.
43419: Liver. Hepatocyte adjacent to a central vein. Microvillous border in the perisinusoidal space and endothelium and erythrocytes are evident. Cell contains small lipid droplets too numerous to count. A moderate number of primary lysosomes and/or peroxisomes are evident. Twenty-five (25) peroxisomes counted.
43420. Liver. Mitochondria. Mitochondria appear essentially normal. Numerous small lipid droplets are present in the surrounding cytosol.

Conclusions: Lipid accumulation, moderate, hepatocellular. Numbers of peroxisomes ~~and lysosomes~~ appear increased, average ~~23.25~~ 22.75 peroxisomes per hepatocyte.

4/5/99

3M_MN03279859

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05530

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: 99.76-5

Sex: Female

Photo/Negative No(s).: L4756 - L4760

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: L4756: Liver. Hepatocyte contains three small lipid droplets. There are bile canaliculi at the top right at top left, and a perisinusoidal microvillous border at the bottom. The nuclear envelope and ER shows some mild artifactual (fixation) dilation. Numerous mitochondria are present. Five (5) peroxisomes counted.
L4757: Liver. Mitochondria. Higher magnification of five mitochondria. Matrix and dense granules appear normal. ER between mitochondria is slightly dilated.
L4758: Liver. Hepatocyte. A sinusoid is present at the top of the photograph, lined by an endothelial cell. Four (4) medium-sized lipid droplets are present in this cell. The nuclear envelope and ER shows some mild artifactual (fixation) dilation. Numerous mitochondria are present. Four (4) peroxisomes counted.
L4759: Liver: Hepatocyte containing scattered small to medium-sized lipid droplets (approximately 14). Scattered primary lysosomes and/or peroxisomes present. There is a perisinusoidal microvillous border at the top beneath an endothelial cell and sinusoid. Twenty-five (25) peroxisomes counted.
L4760: Liver. Hepatocyte containing approximately nine (9) small to medium-sized lipid droplets. Seventeen (17) peroxisomes counted.

Conclusions: Normal hepatocyte. Average 12.75 peroxisomes per hepatocyte.

3M_MN03279860

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: 105531

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: ~~99.76-5~~ 99.76-6 L4761 -

Sex: Female

Photo/Negative No(s).: L4765

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): MAR 3 1 1999

Features: L4761: Liver. Hepatocyte with large central nucleus. Two margins are straight-edged by the grid bar. A few small to medium-sized clear to slightly shaded lipid droplets are present (approximately 32). ER profiles and glycogen granules are scattered throughout the cytosol. A moderate number of primary lysosomes and/or peroxisomes noted. Nine (9) peroxisomes counted.
L4762: Liver. Mitochondria. One oval and one club-shaped mitochondria present. Both appear normal with cristae, membranes, and matrix. The club-shaped one contains several normal dense granules and some slightly dilated cristae, probably fixation artifact. Some RER and smooth ER (SER) are evident in the cytosol.
L4763: Liver. Hepatocyte surrounded by interstitium containing some collagen fibers. Cell has slightly dilated ER and nuclear envelope. A single small lipid droplet is present in this cell. Four (4) peroxisomes counted.
L4764: Liver. This hepatocyte shows some dilation of ER and several lamellar residual bodies in the cytoplasm. Four (4) small lipid droplets are evident. Numerous scattered glycogen granules are present. Eight (8) peroxisomes counted.
L4765: Liver. Hepatocyte containing 5 small to medium-sized clear lipid droplets. Bile canaliculi are evident at the lower left and top right of the cell margins. A cluster of RER is present in the lower left side of the nucleus. Some larger dark lysosomes/peroxisomes are present among some of the mitochondria. Thirty-four (34) peroxisomes counted.

Conclusions: Normal hepatocyte. Average 13.75 peroxisomes per hepatocyte.

3M_MN03279861

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05535

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: 99.76-7

Sex: Female

Photo/Negative No(s).: L4766 - L4770

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: L4766: Liver. Hepatocyte contains some mild dilatation of the nuclear envelope and ER (fixation artifact). On the left and right sides are bile canaliculi, and ventrally is the sinusoidal margin showing the perisinusoidal microvillous border. Several dense residual bodies are present in the cytoplasm. Three small lipid droplets, one containing a lamellar body, are evident. One (1) peroxisome counted.
L4767: Liver. Mitochondria. Higher magnification of four mitochondria show normal morphology. Membranes, cristae and matrix appear normal. Scattered dense granules are present. The ER in the cytosol is mildly dilated.
L4768: Liver. Hepatocyte. There is moderate dilatation of the ER and nuclear envelope. Several scattered small to medium-sized clear lipid droplets are evident, as are some scattered residual bodies. Sinusoids are present at the bottom right and upper left of the photograph, and a bile canaliculus is present on the right margin of this centered hepatocyte with its neighbor hepatocyte. Two (2) peroxisomes counted.
L4769: Liver. Hepatocyte with sinusoid in upper right corner and canaliculi prominent along ~~to~~ the bottom border. The cell exhibits dilated ER and nuclear envelope like the previously described cells for this animal – indicating suboptimal fixation. Multiple residual bodies are present. Nineteen (19) peroxisomes counted.
L4770: Liver. Hepatocyte with similar overall morphology as L4769. Six (6) peroxisomes counted.

[signature] 4-5-99

Conclusions: Normal hepatocyte. Suboptimal fixation. Average 7.0 peroxisomes per hepatocyte.

3M_MN03279862

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05544

Tissue: Liver

Treatment Group: 0 mg/kg (control)

Block No(s).: 99.76-8
L4771 -

Sex: Female

Photo/Negative No(s).: L4775

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999
are JBm 4-5-99

Features: L4771: Liver. Along left margin of hepatocyte ~~is~~ some interstitium and collagen fibers. Hepatocyte contains approximately 17 small to medium-sized clear lipid droplets. A few residual bodies are evident. There is some minimal to mild dilatation of ER. Eight (8) peroxisomes counted.
L4772: Liver. Enlarged photograph of three mitochondria. No abnormalities noted.
L4773: Liver. Hepatocyte with one large and several small to medium-sized lipid droplets in the cytoplasm. Eight (8) peroxisomes counted.
L4774: Liver. Hepatocyte with prominent microvillous border along bottom sinusoid. An endothelial cell nucleus is evident along this border. In the hepatocyte are several medium-sized clear lipid droplets. The ER does show some mild dilatation and there are abundant glycogen granules in the cytoplasm. Several dark residual bodies are present. Eight (8) peroxisomes counted.
L4775: Liver. Hepatocyte with sinusoid on the right and prominent canaliculus on top and left margins. No lipid droplets present in centered hepatocyte, although one medium-sized lipid droplet is present in top adjacent hepatocyte. Cytoplasm contains some RER but not much SER, possibly a periportal hepatocyte. Random peroxisomes and/or primary lysosomes noted. Seventeen (17) peroxisomes counted.

Conclusions: Normal hepatocyte. Average 10.25 peroxisomes per hepatocyte.

3M_MN03279863

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05534

Tissue: Liver

Treatment Group: .75 mg/kg (hi-dose)

Block No(s).: 99.76-11

Sex: Female

Photo/Negative No(s).: L4798 - L4802

Significant Lesions (check one): X Yes ____ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: L4798: Liver. Hepatocyte surrounded by adjacent hepatocytes. It contains abundant numbers of mitochondria and ER. There is mild dilatation of the nuclear envelope and of some ER. Scattered residual bodies are present. Just one distinct lipid droplet is evident. Four (4) peroxisomes counted.
L4799: Liver. Enlarged view of five mitochondria. Mitochondria appear essentially normal. Several dense granules are present in the matrix. The cristae and limiting membranes appear normal. At the ~~ride~~ right side is the mildly dilated nuclear envelope and the nucleus. JBR 4.5.99
L4800: Liver. Hepatocyte. A few small clear lipid droplets are present in the cytoplasm There are also abundant glycogen granules in the cytoplasm. A number of "clear areas" in the cytoplasm appear to contain glycogen granules without a distinct lipid droplet margin. Two (2) peroxisomes counted.
L4801. Liver. Hepatocyte. There are numerous small to medium-sized rarefied JBR 4.5.99 "pockets" in the cytoplasm (approximately 57). Some contain some whispy lamellar material, and some glycogen granules appear to be in these spaces. The margins of these JBR 4.5.99 droplets are not as sharply defined as clear round lipid droplets usually are. Four (4) peroxisomes counted.
L4802: Liver. Hepatocyte appears similar to L4801 with some small to medium-sized lipid droplets and other rarefied areas with glycogen in the cytoplasm (approximately 29). JBR 4.5.99 Some contain some whispy lamellar material. There are also abundant glycogen granules throughout the cytoplasm. Twelve (12)peroxisomes counted.

Conclusions: Increased glycogen in this animal. Increased number of glycogen granules. Average ~~4.75~~ 5.5 peroxisomes per hepatocyte.

JBR 4.5.99

3M_MN03279864

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05536

Tissue: Liver

Treatment Group: .75 mg/kg (hi-dose)

Block No(s).: 99.76-12

Sex: Female

Photo/Negative No(s).: L4804 - L4808

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): MAR 31 1999

Features: L4804. Liver. Hepatocyte. Only a small segment of the nucleus is evident. There are multiple large clear lipid droplets in the cytoplasm. Numerous smaller droplets appear as less distinct dilatations in the cytosol. There are abundant glycogen granules in the cytoplasm. Three (3) peroxisomes counted.
L4805: Liver. Hepatocyte. Multiple small to large clear lipid droplets in cytoplasm. Four (4) peroxisomes counted.
L4806: Liver. Enlarged magnification of a cluster of mitochondria. Cristae are not well defined in this photograph, but matrix, granules and outer limiting membrane appear normal.
L4507: Liver. Hepatocyte. Multiple small to large clear lipid droplets in cytoplasm (approximately 123). There are abundant glycogen granules in the cytoplasm. Three (3) peroxisomes counted.
L4808: Liver. Hepatocyte contains multiple small to large lipid droplets. Droplets are too numerous to count. Several dense residual bodies present. Five (5) peroxisomes counted.

Conclusions: Moderately-severe lipid accumulation in hepatocytes. Membranes and mitochondria appear essentially similar to controls. Average 3.75 peroxisomes per hepatocyte.

3M_MN03279865

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05540

Tissue: Liver

Treatment Group: .75 mg/kg (hi-dose)

Block No(s).: 99.76-13

Sex: Female

Photo/Negative No(s).: L4809 - L4813

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): [signature] MAR 31 1999

Features: L4809: Liver. Hepatocyte. Only a small segment of nucleus is present in this photograph. Abundant ER and glycogen granules are present. There are scattered small to large lipid droplets, but not too many in this hepatocyte (approximately 15). A few dark residual bodies are evident. Fifteen (15) peroxisomes counted.
L4810: Liver. Enlarged photograph of several mitochondria. No abnormalities noted. Cytoplasm contains some ER and scattered glycogen granules.
L4811: Liver. Hepatocyte contains multiple medium to large clear lipid droplets (approximately 41). There is abundant glycogen in the cytoplasm. Five (5) peroxisomes counted.
L4812: Liver. Hepatocyte. Similar to L4811. Hepatocyte contains multiple small to large clear lipid droplets, too numerous to count. There is abundant glycogen in the cytoplasm. Twenty-eight (28) peroxisomes counted.
L4813: Liver. Hepatocyte contains abundant mitochondria and ER. Only a few clear lipid droplets are present. An endothelial cell is present at the top of the photograph. There is minimal to mild dilatation of the ER and nuclear envelope. Scattered residual bodies are present. Two (2) peroxisomes clearly identified.

Conclusions: Mild to moderate increase in cytoplasmic lipid droplets. Increased glycogen in most hepatocytes. Average 12.5 peroxisomes per hepatocyte.

3M_MN03279866

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05551

Tissue: Liver

Treatment Group: .75 mg/kg (hi-dose)

Block No(s).: 99.76-14

Sex: Female

Photo/Negative No(s).: L4814 - L4818

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): MAR 3 1 1999

Features: L4814. Liver. Hepatocyte. There is a dilated canaliculus at the top right of the hepatocyte. In the cytoplasm there are multiple rarefied areas that mostly appear to contain glycogen granules. However, a few have some lamellar material in them. There is slight dilatation of the nuclear envelope and ER. Some residual bodies are present. No distinct lipid droplets are present in this hepatocyte, however, there are several lipid droplets in the perisinusoidal fat-storing cell (Ito cell) at the top left. Nine (9) peroxisomes counted.
L4815: Liver. Enlargement of a cluster of mitochondria. These organelles appear essentially normal.
L4816: Liver. Hepatocyte contains a single medium-sized clear lipid droplet. The cytoplasm contains abundant glycogen granules. Several residual bodies present. Four (4) peroxisomes clearly identified. Several small dark bodies appear to be tips of mitochondria.
L4817: Liver. Hepatocyte appears similar to L4814. There is abundant glycogen in the cytoplasm, often making clear areas containing just glycogen granules. Several clusters of RER present. One small lipid droplet present. Fourteen (14) peroxisomes counted.
L4818: Liver. Hepatocyte contains multiple rarefied "pockets" of glycogen granules. No lipid droplets present. Eleven (11) peroxisomes counted.

Conclusions: Increased glycogen. Average 9.5 peroxisomes per hepatocyte.

3M_MN03279867

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05514

Tissue: Liver

Treatment Group: .03 mg/kg (low-dose)

Block No(s).: 99.76-15

Sex: Male

Photo/Negative No(s).: Z16232 - Z16236

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16232. Liver. Hepatocyte. Hepatocyte contains multiple small to medium-sized lipid droplets scattered throughout its cytoplasm. At the top margin is a microvillous border and some collagen fibers in the space of Disse. Smooth endoplasmic reticulum (SER) and rough endoplasmic reticulum (RER) are present throughout the cytoplasm with many mitochondria also throughout. Mitochondria are well-preserved and cristae, granules and matrix are clearly evident. Several irregular dark staining residual bodies are present. One (1) peroxisome counted.
Z16233. Liver. Hepatocyte. A moderate number of small to medium-sized lipid droplets are present in the cytoplasm, as well as several prominent residual bodies. The upper left and lower left borders show microvilli and collagen fibers adjacent to a sinusoid or central vein. The RER forms a distinct palisade a the bottom of the cell. Nine (9) peroxisomes counted.
Z16234. Liver. Hepatocyte. Centered hepatocyte shows minimal fixation artifact with some slight dilatation of SER and the nuclear envelope. There are a few small to medium-sized lipid droplets present. Four (4) peroxisomes counted.
Z16235. Liver. Hepatocyte. Cell appears similar to those described above. There are random lipid droplets and multiple residual bodies. Five (5) peroxisomes counted.
Z16236. Liver. Hepatocyte. Multiple small to medium-sized lipid droplets present in the cytoplasm. Only a small nuclear profile is evident in this cell. Eleven (11) probable peroxisomes counted.

Conclusions: Tissue appears well-fixed for ultrastructural examination. There appears to be a mild increase in numbers of lipid droplets. Average 6.0 peroxisomes per hepatocyte.

3M_MN03279868

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05515

Tissue: Liver

Treatment Group: .03 mg/kg (low-dose)

Block No(s).: 99.76-16

Sex: Male

Photo/Negative No(s).: Z16237 - Z16241

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16237. Liver. Hepatocyte. A central vein is present at the top margin and contains a large amount of collagen extracellularly. A bile canaliculus is present on the left between three hepatocytes. the endoplasmic reticulum and nuclear envelope are slightly dilated – this is a fixation artifact. Several lipid droplets are present. Prominent glycogen granules are present throughout the cytoplasm. Twenty-two (22) peroxisomes.
Z16238. Liver. Hepatocyte. A bile canaliculus is present at the top border with another hepatocyte. One large and several smaller lipid droplets are present. Mitochondria appear normal and have fine cristae, matrix, and granules. Twenty-one (21) peroxisomes.
Z16239. Liver. Hepatocyte. Large central nucleus is adjacent to a large lipid droplet. A few smaller lipid droplets are present. There is artifactual dilatation of the RER and the nuclear envelope. Several residual bodies are present. Fourteen (14) peroxisomes counted.
Z16240. Liver. Hepatocyte. The centered hepatocyte contains several medium-sized lipid droplets. There is marked dilatation of the RER and the nuclear envelope. A bile canaliculus is present on the left margin of this cell and extracellular collagen is evident in the upper right. Ten (10) peroxisomes counted.
Z16241. Liver. Hepatocyte. Hepatocyte contains two larger lipid droplets and several smaller ones. The RER and nuclear envelope are dilated. The ventral margin shows a microvillous border next to an endothelial cell at the bottom. A prominent bile canaliculus is present on the left, surrounded by dark desmosomes. Eight (8) peroxisomes counted.

Conclusions: Slight (equivocal) increase in lipid droplets. Average 15.0 peroxisomes per hepatocyte.

3M_MN03279869

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05516

Tissue: Liver

Treatment Group: .03 mg/kg (low-dose)

Block No(s).: 97.76-17

Sex: Male

Photo/Negative No(s).: Z16242 - Z16246

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16242. Liver. Hepatocyte. Hepatocyte is adjacent to a cell containing a large lipid droplet, probably a perisinusoidal fat-storing cell (Ito cell). The hepatocyte contains numerous normal-appearing mitochondria and scattered dark irregular residual bodies. Smooth and RER are present throughout the cytoplasm. One (1) probable peroxisome counted.
Z16243. Liver. Hepatocyte. Hepatocyte has a bile canaliculus present along its right margin with an adjacent hepatocyte. The cytosol contains abundant smooth and RER and numerous mitochondria. A few residual bodies are present. Two (2) peroxisomes seen.
Z16244. Liver. Hepatocyte. Hepatocyte exhibits very slight dilatation of the endoplasmic reticulum and nuclear envelope. Glycogen granules are present throughout the cytoplasm, and scattered residual bodies are present. Two (2) probable peroxisomes identified.
Z16245. Liver. Hepatocyte. A clear vacuole with a central round density is present to the left of the nucleus of the hepatocyte. This appears to be a cytoplasmic invagination from the plasma membrane. Normal-appearing mitochondria are present throughout the cytoplasm. A few residual bodies are present. Fifteen (15) peroxisomes counted.
Z16246. Liver. Hepatocyte. The centered hepatocyte appears essentially similar to above-described cells. There are glycogen granules throughout the cytoplasm. Sixteen (16) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Average 7.2 peroxisomes per hepatocyte.

3M_MN03279870

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05521

Tissue: Liver

Treatment Group: 0.03 mg/kg (low-dose)

Block No(s).: 99.76-18

Sex: Male

Photo/Negative No(s).: Z16247 - Z16251

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16247. Liver. Hepatocyte. Several large irregular electron-dense residual bodies are present in the centered hepatocyte and the subjacent hepatocyte. The SER and nuclear envelope are slightly dilated. Also, the mitochondria appears slightly swollen, although this appears to be artifactual along with the dilated SER. A few small lipid droplets are present. Fourteen (14) peroxisomes counted.
Z16248. Liver. Hepatocyte. Clusters of fine granules, probably glycogen, are present in the cytoplasm. The mitochondria appears slightly dilated, as does the SER in an adjacent hepatocyte to the top left. The smooth ER is poorly defined. Several small lipid droplets are present. Two erythrocytes are present at the lower right of the photograph. Eleven (11) peroxisomes counted.
Z16249. Liver. Hepatocyte. The RER, nuclear envelope, and SER in the hepatocyte are slightly dilated, consistent with some fixation artifact. Several small lipid droplets and residual bodies are present. A small segment of a perisinusoidal fat-storing cell is present at the lower right, adjacent to an endothelial cell. Sixteen (16) peroxisomes identified.
Z16250. Liver. Hepatocyte. Several small lipid droplets are present in the hepatocyte. Multiple dark and irregular residual bodies are also present. The ER is slightly dilated throughout. Three (3) probable peroxisomes counted.
Z16251. Liver. Hepatocyte. There is mild dilatation of the nuclear envelope and the endoplasmic reticulum throughout. Mitochondria have a paler matrix and may be slightly enlarged. On the left is the hepatocyte's microvillous border, with an adjacent endothelial cell and erythrocyte in the sinusoid. A bile canaliculus is present in the lower right. Ten (10) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Some minimal to slight fixation artifacts. Average 10.8 peroxisomes per hepatocyte.

3M_MN03279871

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05537

Tissue: Liver

Treatment Group: .03 mg/kg (low-dose)

Block No(s).: 99.76-19

Sex: Female

Photo/Negative No(s).: Z16252 - Z16256

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): James B Nold MAY 20 1999

Features: Z16252. Liver. Hepatocyte. Fixation appears good. Dorsal to the hepatocyte is a central vein or sinusoid area. Several medium-sized lipid droplets are present in the cytoplasm. Fine glycogen granules are scattered throughout the cytoplasm. A desmosome is present at the lower left margin with an adjacent hepatocyte. Ten (10) peroxisomes counted.
Z16253. Liver. Hepatocyte. Hepatocyte shows very slight dilatation of endoplasmic reticulum. There is one large lipid droplet and several small droplets within the cytoplasm. A bile canaliculus is present at the top right margin of the cell. Five (5) peroxisomes counted.
Z16254. Liver. Hepatocyte. This cell appears essentially similar to Z16253, although there are lesser numbers of lipid droplets. Two irregular dark-staining residual bodies are present on the left and right side of the nucleus. The one on the right is somewhat vacuolated. Eleven (11) peroxisomes counted.
Z16255. Liver. Hepatocyte. A medium-sized lipid droplet containing some lamellar material is present to the right of the nucleus. Just a few smaller lipid droplets are present elsewhere in the cytoplasm. The endoplasmic reticulum is slightly dilated. At the bottom is the microvillous border extending into the space of Disse. A few small residual bodies are present. Six (6) probable peroxisomes counted.
Z16256. Liver. Hepatocyte. In this hepatocyte two mitochondria appear paler and somewhat swollen. The rest appear normal. Twelve (12) probable peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Quantity of lipid appears within normal expectations. Average 8.8 peroxisomes per hepatocyte.

3M_MN03279872

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05541

Tissue: Liver

Treatment Group: .03 mg/kg (low-dose)

Block No(s).: 99.76-20

Sex: Female

Photo/Negative No(s).: Z16257 - Z16261

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16257. Liver. Hepatocyte. Microvillar borders are present along the lower left and upper right margins of this hepatocyte. A bile canaliculus is present at the lower right. Lamellar material within a lipid droplet is present to the lower right of the central nucleus. There is abundant SER throughout the cell, and the RER appears slightly dilated. Seven (7) probable peroxisomes counted.
Z16258. Liver. Hepatocyte. Several medium-size lipid droplets are present, as well as approximately eight residual bodies, in the cytoplasm. The lower left margin is a microvillous border, and a bile canaliculus is present in the mid and upper right margins of this hepatocyte. Eight (8) peroxisomes counted.
Z16259. Liver. Hepatocyte. This cell is surrounded by several other hepatocytes, and contains approximately ten medium-sized lipid droplets in its cytoplasm. Several very dark round to oval residual bodies are present at the top of the cell. Several dark mitochondria noted; these are often difficult to differentiate from lysosomes or peroxisomes. Fourteen (14) peroxisomes counted.
Z16260. Liver. Hepatocyte. Hepatocyte appears essentially similar to those described above. Two lipid droplets noted. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Twenty-three (23) peroxisomes counted.
Z16261. Liver. Hepatocyte. Cell contains approximately 5 small to medium-sized lipid droplets. At the bottom is a sinusoid containing a platelet or segment of a granulocyte in the circulation. Another sinusoidal margin and microvillous border is present at the top. There is slight dilatation of the endoplasmic reticulum. Eight (8) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Some lipid droplets noted, but within normal expectations for hepatocytes. Average 12.0 peroxisomes per hepatocyte.

3M_MN03279873

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05547

Tissue: Liver

Treatment Group: 0.3 mg/kg (low-dose)

Block No(s).: 99.76-21

Sex: Females

Photo/Negative No(s).: Z16262 - Z16266

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16262. Liver. Hepatocyte. Photograph shows a hepatocyte with just a small nuclear profile. A microvillous border is present at the top right. Some artifactual knife marks are present. Several dark residual bodies are present, and only about six small lipid droplets are evident in the cytoplasm. Abundant SER and RER are throughout the cytoplasm intermixed with numerous mitochondria. Four (4) peroxisomes identified. Z16263. Liver. Hepatocyte. Numerous collagen fibers are present along the dorsal extracellular margin. At the lower left this hepatocyte's microvillous border extends in the space of Disse. There is slight dilatation of the nuclear envelope and endoplasmic reticulum. Several residual bodies and lipid droplets are present. Fine glycogen granules are randomly scattered throughout the cytoplasm. Six (6) peroxisomes clearly identified. Z16264. Liver. Hepatocyte. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. A bile canaliculus is present at the dorsal right margin of the cell, and another hepatocyte is present along the ventral margin. The general morphology is similar to the above described cells. Only one lipid droplet is evident in this cell. Several residual bodies are evident. Fourteen (14) probable peroxisomes identified. Z16265. Liver. Hepatocyte. A central vein and sinusoid surround this hepatocyte on the lower and upper left margins. Erythrocytes are present in the vascular lumens. Within the hepatocyte there is slight dilatation of the endoplasmic reticulum and nuclear envelope. Two small lipid droplets are present. Nine (9) peroxisomes counted. Z16266. Liver. Hepatocyte. Hepatocyte appears essentially similar to cells described above. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. A large irregularly-shaped residual body is present to the lower left of the nucleus. Seventeen (17) probable peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Average 10.0 peroxisomes per hepatocyte.

3M_MN03279874

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: 105550

Tissue: Liver

Treatment Group: .03 mg/kg (low-dose)

Block No(s).: 99.76-22

Sex: Female

Photo/Negative No(s).: Z16267 - Z16272

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16267. Liver. Hepatocyte. Abundant numbers of glycogen granules are present throughout the cytoplasm of this hepatocyte. Bile canaliculi are evident on the right, left and lower left margins. A large dark residual body is present in an adjacent hepatocyte at the top left. Several smaller residual bodies are present in the cytoplasm of the centered hepatocyte. Mitochondria appear normal, having cristae, sporadic granules and a fine grainy matrix. Five (5) probable peroxisomes counted.
Z16268. Liver. Hepatocyte. Cytoplasm has a somewhat light appearance due to slight dilatation of the endoplasmic reticulum. The nuclear envelope is also slightly dilated. These are artifactual fixation-related changes. Prominent bile canaliculi are present on the left and lower right cellular margins. No lipid droplets evident. Fifteen (15) peroxisomes counted.
Z16269. Liver. Hepatocyte. Cell appears similar to Z16267 described above. There appears to be abundant glycogen granules in the cytosol. A microvillous border is present at the upper right extending in to the space of Disse, while bile canaliculi are evident along the lower left and upper left margins. There are many dark mitochondria which are difficult to differentiate from peroxisomes. Twenty-seven (27) probable peroxisomes counted.
Z16270. Liver. Hepatocyte. This hepatocyte appears to be binucleate. An endothelial cell is present lining the sinusoid ventrally and two erythrocytes are present dorsal to this cell. The endoplasmic reticulum and nuclear envelope is slightly dilated. Twenty (20) peroxisomes seen.
Z16272. Liver. Hepatocyte. Two large and multiple smaller lipid droplets are present in this hepatocyte. Dorsally, the microvillous border extends into the space of Disse and is adjacent to an endothelial cell. Ventrally are a small segment of a lipid-containing cell, probably a perisinusoidal fat-storing cell and an adjacent hepatocyte. Twenty-one (21) probable peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Although one cell (Z16272) had a lot of lipid droplets, the overall impression is that lipid content in this liver was within expected normal limits. Average 17.6 peroxisomes per hepatocyte.

3M_MN03279875

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05510

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-23

Sex: Male

Photo/Negative No(s).: Z16273 - Z16277

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): MAY 20 1999

Features: Z16273. Liver. Hepatocyte. Numerous glycogen granules are present randomly throughout the SER and cytosol. Fixation appears good. One swollen "barbell-shaped" mitochondria is present, but all other mitochondria appear normal. Scattered dark residual bodies are present. Thirteen (13) peroxisomes counted.
Z16274. Liver. Hepatocyte. Several small to medium-sized lipid droplets are present in the cytoplasm of the hepatocyte. Along its right margin its microvillous border faces another hepatocyte. A poorly-defined bile canaliculus is present at the lower left. The cytoplasm is filled with SER, RER, mitochondria and glycogen granules throughout. Some peroxisomes are noted. Scattered dark residual bodies are present. Ten (10) peroxisomes counted.
Z16275. Liver. Hepatocyte. Centered hepatocyte has only a small nuclear profile. At the bottom is a central vein surrounded by an endothelial cell and a moderate number of extracellular collagen fibers. An endothelial cell is the lighter shaded cell at the top right. Three lipid droplets present in the cytoplasm. Thirteen (13) peroxisomes counted.
Z16276. Liver. Hepatocyte. This cell appears similar to Z16273. Approximately 10 small to medium-sized lipid droplets are present in the cytoplasm. Numerous glycogen granules are evident in the cytosol. A lamellar body is present at the bottom margin of the cell. Fourteen (14) peroxisomes counted.
Z16277. Liver. Hepatocyte. Approximately a dozen small to medium-sized lipid droplets are present in the cytoplasm. The cluster of 5 droplets at the far right are in another cell. The cytoplasm contains abundant fine glycogen granules. Several residual bodies are noted. Three (3) probable peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Moderate amount of glycogen in several cells. Number of lipid droplets appears normal. Average ~~8.6~~ 10.6 peroxisomes per hepatocyte. 5-13-99

3M_MN03279876

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05518

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose

Block No(s).: 99.76-24

Sex: Male

Photo/Negative No(s).: Z16278 - Z16282

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): MAY 20 1999

Features: Z16278. Liver. Hepatocyte. At the top right this hepatocyte is bordered by a perisinusoidal fat-storing cell containing several prominent lipid droplets. Four small lipid droplets are present in the hepatocyte. A bile canaliculus, adjacent to a large residual body, is present on the left margin of the cell. There is slight dilatation of the nuclear envelope and endoplasmic reticulum. Multiple irregular residual bodies are evident. Thirteen (13) peroxisomes clearly identified.
Z16279. Liver. Hepatocyte. The centered hepatocyte is bordered by a darker hepatocyte on the right. On its left is a band of interstitial collagen. The nuclear envelope and endoplasmic reticulum are slightly dilated. Several endocytotic vesicles are present along the right cellular membrane. Sixteen (16) probable peroxisomes counted.
Z16280. Liver. Hepatocyte. Hepatocyte has prominent bile canaliculi along its right and left margins with the adjacent hepatocytes. One small lipid droplet noted. Mitochondria stain somewhat more pale in this cell and contrast with darker peroxisomes. Multiple clusters of RER evident. Twelve (12) peroxisomes counted.
Z16281. Liver. Hepatocyte. This hepatocyte appears to be binucleate. At the top left is an erythrocyte within the central vein or sinusoid. Several small lipid droplets are present in the cytoplasm. There is slight to moderate dilatation of the endoplasmic reticulum and nuclear envelope. Some shrunken mitochondria are difficult to differentiate from lysosomes or peroxisomes. Thirty-two (32) probable peroxisomes counted.
Z16282. Liver. Hepatocyte. General cellular morphology is similar to cell described above. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Nineteen (19) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Only small numbers of lipid droplets seen. Average 18.4 peroxisomes per hepatocyte.

3M_MN03279877

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05524

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-25

Sex: Male

Photo/Negative No(s).: Z16283 - Z16287

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): MAY 20 1999

Features: Z16283. Liver. Hepatocyte. Hepatocyte contains two medium-sized lipid droplets. The nuclear envelope and endoplasmic reticulum are slightly dilated. At the top right is a bile canaliculus between this cell and an adjacent hepatocyte. Desmosomes are present around the canaliculus. Thirty-one (31) peroxisomes counted.
Z16284. Liver. Hepatocyte. This centered hepatocyte is surrounded by other hepatocytes on all margins in this photograph. Bile canaliculi are evident at the top left and bottom left margins. No lipid droplets are evident in this cell. Mitochondria, RER and SER appear normal. Twenty-nine (29) probable peroxisomes counted.
Z16285. Liver. Hepatocyte. Two erythrocytes are present in the sinusoid adjacent to the left of this hepatocyte. Collagen fibers are present in the space of Disse. Along the right margin of this cell is a prominent bile canaliculus . A single medium-sized lipid droplet is present in this cell. Twenty-seven (27) peroxisomes counted.
Z16286. Liver. Hepatocyte. Cell appears essentially similar to cells described above. At top left and bottom right are erythrocytes within sinusoids. No distinct lipid droplets are present in this cell. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Several dark residual bodies are present. Twenty-one (21) peroxisomes counted.
Z16287. Liver. Hepatocyte. Cell has two large and several smaller lipid droplets present in its cytoplasm. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Several dark residual bodies are present. Glycogen granules are present throughout the cytoplasm. Eight (8) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Slight increase in average number of peroxisomes. No increase in lipid noted. Average 23.2 peroxisomes per hepatocyte.

3M_MN03279878

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05528

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-26

Sex: Male

Photo/Negative No(s).: Z16288 - Z16292

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16288. Liver. Hepatocyte. This hepatocyte contains about five medium-sized and approximately fifteen small lipid droplets in its cytoplasm. Microvillous border beneath endothelial cells are evident at the upper right and lower left margins. A bile canaliculus surrounded by desmosomes is present at the lower right margin. Scattered dark-staining residual bodies are present in the cytoplasm. There is slight dilatation of the endoplasmic reticulum and the nuclear envelope. Five (5) peroxisomes clearly identified.
Z16289. Liver. Hepatocyte. This hepatocyte's microvillous border extends into the space of Disse at the upper left margin of the photograph. At the lower left is a perisinusoidal fat-storing cell (Ito cell). There is slight dilatation of the endoplasmic reticulum and the nuclear envelope. Two small lipid droplets are evident. Sixteen (16) peroxisomes counted.
Z16290. Liver. Hepatocyte. This cell is a little darker staining than previous cells. At lower left a granulocyte is present in the sinusoid or central vein. At the top right a perisinusoidal fat-storing cell (Ito cell) is present. Several small lipid droplets are present in the hepatocyte and a few residual bodies are evident. There is slight dilatation of the endoplasmic reticulum and the nuclear envelope. Nineteen (19) peroxisomes counted.
Z16291. Liver. Hepatocyte. Much of the cytoplasm has a dense granular appearance, composed of SER, glycogen granules, and probable cytoskeletal components. Approximately eighteen small to medium-sized lipid droplets are present. Nineteen (19) probable peroxisomes counted.
Z16292. Liver. Hepatocyte. Hepatocyte appears similar to Z16291. There are several lipid droplets present in the cytoplasm. Fourteen probable (14) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Lipid droplet numbers within normal expectations. Average 14.6 peroxisomes per hepatocyte.

3M_MN03279879

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05532

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-27

Sex: Female

Photo/Negative No(s).: Z16293 - Z16297

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16293. Liver. Hepatocyte. This photograph has a centered hepatocyte. At the top are multiple lipid droplets which are in an adjacent perisinusoidal fat-storing cell (Ito cell), not in this hepatocyte. There are numerous glycogen granules in the cytosol intermixed with the endoplasmic reticulum. Two very small lipid droplets are present. Mitochondria appear normal. They show fine cristae, some granules and finely grainy matrix. Four (4) peroxisomes clearly identified.
Z16294. Liver. Hepatocyte. A single large lipid droplet is present in the cytoplasm beneath the nucleus. Similar to Z16293, there are many fine granules in the cytoplasm which appear to be glycogen granules. Three (3) peroxisomes identified in this hepatocyte.
Z16295. Liver. Hepatocyte. Several medium-sized lipid droplets are present in this hepatocyte. At the upper right is a "P"-shaped extracellular area containing collagen fibers. Moderate amounts of glycogen are present in the cytoplasm of the hepatocyte. Several residual bodies are also present. Five (5) probable peroxisomes counted.
Z16296. Liver. Hepatocyte. Centered hepatocyte appears similar to those described above. Three lipid droplets are evident in its cytoplasm. At the bottom is a longitudinal profile of a bile canaliculus and a cross-section of a canaliculus at the top margin. Fine glycogen granules are present throughout. Six (6) peroxisomes counted.
Z16297. Liver. Hepatocyte.. Centered hepatocyte appears similar to those described above. Two medium-sized and several small lipid droplets present. To the right is an area of interstitium containing some collagen fibers. The nucleus probably belongs to an endothelial cell. Three (3) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. Moderate amounts of glycogen present in most cells. Lipid droplet numbers appear normal. Average 4.2 peroxisomes per hepatocyte.

3M_MN03279880

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05538

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-28

Sex: Female

Photo/Negative No(s).: Z16298 - Z16302

Significant Lesions (check one): X Yes _____ No

Interpreting Pathologist (signature and date): James B. Nold MAY 20 1999

Features: Z16298. Liver. Hepatocyte. Section has a prominent single knife mark transecting the cell beneath the nucleus. Numerous glycogen granules are present in the cytoplasm. A single small lipid droplet is present. Mitochondria and other organelles appear normal. Five (5) peroxisomes counted.
Z16299. Liver. Hepatocyte. Hepatocyte has a single large and several small lipid droplets. A sinusoid is present at the upper left margin where the microvillous border extends into the space of Disse. There are abundant glycogen granules in the cytoplasm. Some mitochondria are lighter staining than the majority of darker one. These light mitochondria are somewhat difficult to differentiate from lysosomes or peroxisomes. Eighteen (18) probable peroxisomes counted.
Z16300. Liver. Hepatocyte. Cell contains abundant glycogen often in irregular clear spaces or pockets in the cytosol. A single lipid droplet is present. Three (3) peroxisomes identified.
Z16301. Liver. Hepatocyte. This centered hepatocyte has adjacent hepatocyte dorsally and ventrally and a microvillous-sinusoidal border at the top right. Its cytoplasm contains multiple irregular pockets of glycogen granules. Other organelles appear somewhat clumped between the glycogen pockets. Nine (9) peroxisomes counted.
Z16302. Liver. Hepatocyte. This cell appears similar to Z16301, although it has more pockets of glycogen granules and has an overall light appearance. Other organelles appear clumped between the glycogen granules. One (1) peroxisome clearly identified.

Conclusions: Essentially normal hepatocytes. There is increased glycogen in some of these hepatocytes. Average 7.2 peroxisomes per hepatocyte.

3M_MN03279881

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05545

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-29

Sex: Female

Photo/Negative No(s).: Z16303 - Z16307

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16303. Liver. Hepatocyte. This cell is bordered by hepatocytes on the top right and bottom right and by an interstitial margin on the left. Prominent bile canaliculi are evident between adjacent hepatocytes. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. No lipid droplets are evident. Several dark irregular residual bodes are present. Six (6) probable peroxisomes counted.
Z16304. Liver. Hepatocyte. Centered hepatocyte is surrounded by hepatocytes on all margins. Bile canaliculi are evident at the right and bottom margins. Its endoplasmic reticulum and nuclear envelope are slightly dilated. Several residual bodies are present. No lipid droplets are present. Fourteen (14) probable peroxisome counted.
Z16305. Liver. Hepatocyte. Hepatocyte appears similar to Z16303 above. At top left is a central vein, lined by an endothelial cell and containing a segment of an erythrocyte. No lipid droplets are evident in this hepatocyte. Seven (7) peroxisomes clearly identified.
Z16306. Liver. Hepatocyte. This cell is somewhat lighter staining than previous hepatocytes, although the mitochondria still are staining fairly darkly. Cell on the far right may be an endothelial cell. Twelve (12) probable peroxisomes counted.
Z16307. Liver. Hepatocyte. All mitochondria in this cell are darkly staining. There is slight dilatation of the endoplasmic reticulum. Six (6) peroxisomes identified.

Conclusions: Essentially normal hepatocytes. No evidence of increased lipid droplets. Average 9.0 peroxisomes per hepatocyte.

3M_MN03279882

TRANSMISSION ELECTRON MICROGRAPH INTERPRETATION

Study No.: 6329-223 (EM 99.76)

Species/Strain: Cynomolgus Monkey

Animal No.: I05548

Tissue: Liver

Treatment Group: .15 mg/kg (mid-dose)

Block No(s).: 99.76-30
Z16308 - Z16309

Sex: Female

Photo/Negative No(s).: Z16311-
Z16313

Significant Lesions (check one): _____ Yes ___X___ No

Interpreting Pathologist (signature and date): [signature] MAY 20 1999

Features: Z16308. Liver. Hepatocyte. The centered hepatocyte is bordered by adjacent hepatocytes on its left and right margins. On the right is a prominent bile canaliculus. A microvillous border is evident at the top right. Fixation appears good and cytoplasmic organelles appear normal. No lipid droplets are present in the cytoplasm. Abundant SER is present in the cytoplasm. There are a number of shrunken dark, variably-sized mitochondria, which are difficult to clearly differentiate from possible lysosomes or peroxisomes. One large lysosome is present at about "4:40 o'clock" from the nucleus, and contains some linear debris. Twenty-nine (29) peroxisomes identified.
Z16309. Liver. Hepatocyte. This hepatocyte exhibits slight dilatation of the endoplasmic reticulum and nuclear envelope. Three small to medium-sized lipid droplets are present. An erythrocyte is evident in a sinusoid at the bottom left of the photograph. Random dark and irregular residual bodies are present. Seventeen (17) peroxisomes clearly identified.
Z16310. Liver. Hepatocyte. Crystalloid inclusions in some mitochondria, an occasional finding in mitochondria. Peroxisomes not counted in this hepatocyte.
Z16311. Liver. Hepatocyte. One large and several smaller lipid droplets are present in the cytoplasm. There is slight dilatation of the endoplasmic reticulum and nuclear envelope. Prominent bile canaliculi are present on the left and right margins with adjacent hepatocytes. Sixteen (16) probable peroxisome counted.
Z16312. Liver. Hepatocyte. This hepatocyte is bordered by adjacent hepatocyte on all margins. Several small lipid droplets are present in the cytoplasm. There is slight dilatation of the nuclear envelope and endoplasmic reticulum. Nine (9) probable peroxisomes counted.
Z16313. Liver. Hepatocyte. Two medium-sized and several smaller lipid droplets are evident in the cytoplasm. At the bottom left of the photograph are some interstitial collagen fibers. A bile canaliculus is present at the top right margin of the cell. There is slight dilatation of the endoplasmic reticulum, especially the RER, and the nuclear envelope. A large lysosome is present in close proximity to the noted bile canaliculus; it contains some electron-dense material. Fourteen (14) peroxisomes counted.

Conclusions: Essentially normal hepatocytes. No substantial increase in lipid droplets noted. Average 17.0 peroxisomes per hepatocyte.

3M_MN03279883

III. Transmission Electron Micrographs

3M_MN03279884

Figure Legends

Magnification. Print magnification is indicated on the back of each photograph. The measurement bar on each photomicrograph equals one micron (0.001 mm).

Figure 1. Liver. Hepatocyte showing normal cytoplasmic organelles. Some peroxisomes are identified and other normal organelles. Ventrally the microvillous border extends into the perisinusoidal space. Animal No. I05517, 0 mg/kg/day (control male), 10,920X magnification.

Figure 2. Liver. Hepatocyte. Several lipid droplets are present. There is slight artifactual dilatation of some rough endoplasmic reticulum. Some extracellular collagen is present in the interstitium in the upper right corner. An endothelial cell nucleus is present lining the sinusoid in the lower right corner of the photograph. Animal No. I05544, 0 mg/kg/day (control female), 11,200X magnification.

Figure 3. Liver. Hepatocyte. Mitochondria showing outer membrane, cristae, matrix and granules. These granules within the mitochondrial matrix are normal and are sites of calcium accumulation. Animal No. I05519, 0 mg/kg/day (control male), 112,000X magnification.

Figure 4. Liver. Hepatocyte showing increased lipid droplet accumulation. Lipid droplets vary from small to very large. Several residual bodies are present. Peroxisomes are scare. Animal No. I05507, 0.75 mg/kg/day (high-dose male), 10,920X magnification.

Figure 5. Liver. Hepatocyte showing numerous lipid droplets and peroxisomes. Several peroxisomes are labeled. Animal No.I05512, 0.75 mg/kg/day (high-dose male), 10,920X magnification.

Figure 6. Liver. Hepatocyte with many small to large lipid droplets. Representative peroxisomes are labeled. Desmosomes and a bile canaliculus is evident at the right. Animal No.I05536, 0.75 mg/kg/day (high-dose female), 11,200X magnification.

Figure 7. Liver. Hepatocyte with multiple lipid droplets and abundant glycogen granules in the cytoplasm. Animal No. I05540, 0.75 mg/kg/day (high-dose female), 11,200X magnification.

Figure 8. Liver. Hepatocyte containing numerous "pockets" of glycogen. Animal No. I05551, 0.75 mg/kg/day (high-dose female), 11,200X magnification.

3M_MN03279885

Figure 9. Liver. Hepatocyte. Mitochondria showing outer membrane, cristae and matrix. Small lipid droplets are present in the surrounding cytosol. Animal No. I05512, 0.75 mg/kg/day (high-dose male), 112,000X magnification.

Figure 10. Liver. Hepatocyte. Mitochondria showing outer membrane, cristae, matrix, and granules. The nucleus is present on the right. Animal No. I05534, 0.75 mg/kg/day (high-dose female), 95,200X magnification.

Figure 11. Liver. Hepatocyte. There is moderate accumulation of small to medium-sized lipid droplets in this hepatocyte. Only a small nuclear profile is evident in this cell. The endoplasmic reticulum is slightly dilated. Animal No. I05514, 0.03 mg/kg/day (low-dose male), 11,200X magnification.

Figure 12. Liver. Hepatocyte. Mitochondria, endoplasmic reticulum and some residual bodies make up the majority of this hepatocyte's cytoplasm. A few small dark mitochondria are present, but no clearly identifiable peroxisomes are present. No lipid droplets are present in this cell, although a single lipid droplet is present in the subjacent cell at the bottom of the photograph. Animal No. I05545, 0.15 mg/kg/day (mid-dose female), 11,200X magnification

3M_MN03279886

Index of Labels for Ultrastructural Structures

Abbreviation	Structure
BC	Bile canaliculus
CO	Collagen
CR	Cristae
D	Desmosome
EC	Endothelial cell
G	Glycogen
GR	Granules
LD	Lipid droplet
M	Mitochondria
MV	Microvilli
MX	Matrix
N	Nucleus
OM	Outer membrane
P	Peroxisome
RB	Residual body
RER	Rough endoplasmic reticulum
SER	Smooth endoplasmic reticulum

3M_MN03279887



3M_MN03279888



3M_MN03279889



3M_MN03279890



3M_MN03279891



3M_MN03279892



3M_MN03279893



3M_MN03279894



3M_MN03279895

3M_MN03279896



3M_MN03279897


M
LD
P
P
RER
N
RB
M
LD
M
LD
RB
P


BC
EC
SER
M
P
N
M
RB
RER
M
RB
P
LD

IV. Quality Assurance Statement

3M_MN03279900

Pathology Associates International
A Company of Science Applications International Corporation
An Employee-Owned Company

QUALITY ASSURANCE STATEMENT

This electron microscopy study has been inspected and audited by the Quality Assurance Unit as required by the Good Laboratory Practices Regulations promulgated by the U.S. Food and Drug Administration. PAI has a functioning and responsive Quality Assurance Unit which reports directly to management. The following is a record of inspections/audits and their resulting reports:

Date of Inspection	Phase Inspected	Date Findings Reported to Management and Study Director
4/1, 2/99	Data Audit	4/2/99
4/2/99	Draft Report Audit	4/2/99
7/13/99	Audit of Data from Additional Groups	7/13/99
7/13/99	Final Report Audit	7/13/99

Jeanne deWard, B.S., RQAP-GLP
Quality Assurance Specialist

7/13/99
Date

Sponsor: 3M Corporate Toxicology

Test Article: PFOS

Study Number: 6329-223, PAI Study EM-99.76

4915 D Prospectus Drive • Durham, North Carolina 27713 • (919) 544-5257 • (919) 544-3218 FAX

APPENDIX 9

Urobilinogen Analysis Report

Note: The report in this appendix was supplied by the Sponsor, based on data supplied by the Mayo Clinic. The analysis at the Mayo Clinic was not done in compliance with Good Laboratory Practice Regulations and was not audited by a Quality Assurance Unit.

3M_MN03279902

Urobilinogen Analysis Report for Study title: 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (PFOS) in Cynomolgus Monkeys Covance 6329-223, (3M Medical Dept number: T- 6295.7).

Author: Andrew M. Seacat

Final Report Date: 3/1/01

Introduction

In an effort to understand the lowering of bilirubin in the blood of the PFOS high dose (0.75 mg/kg/day) Cynomolgus monkeys, the potential excretion of urobilinogen was evaluated. The hypothesis being tested is that increased fecal urobilinogen excretion is responsible for the observed lowering of bilirubin in the blood in the high dose animals. The null hypothesis would state that the is no significant difference between the control and high dose fecal urobilinogen values.

Method summary

Six-hour fecal samples were collected from the cages of the control and high dose male and female monkeys and were sent to Dr. Joe McConnell at Mayo Clinic for fecal urobilinogen analysis (1).

Results

The urobilinogen values obtained from the six hour fecal samples collected were not significantly different between the control and high dose groups of male and female Cynomolgus monkeys (Table 1). Therefore the null hypothesis cannot be rejected. The urobilinogen values were within the assay detection limits, but were very low compared to the typical human range of urobilinogen values. This could be due to a true physiological species difference or possibly due to analytical difficulties encountered with a new matrix.

Reference:

1. Urobilinogen (UB) Analysis Results from Dr Joseph P. McConnell., Porphyrins and nutritional Biochemistry lab, Dept of Laboratory Medicine and Pathology. Mayo Clinic, Rochester MN.

3M_MN03279903

Covance: 6329-223
3M T-6295.7

Urobilinogen Report

Table 1 Urobilinogen results:

Animal #	Dose level	Sex	mg UB/g feces	mg UB/24 hours	Dunnett's T-Test	Dunnett's T-Test
					Female control Vs Female high dose PFOS, mg UB/g Feces	Female control Vs female high dose PFOS, mg UB/24 hour Feces
105532	0 mg/kg/d	F	0.142	5.68	0.68	0.77
105533	0 mg/kg/d	F	0.245	7.84		
105531	0 mg/kg/d	F	0.156	5.62		
105535	0 mg/kg/d	F	0.277	5.42		
105544	0 mg/kg/d	F	0.133	4.25		
105549	0 mg/kg/d	F	0.227	5.44		
	Avg		0.197	5.542		
	SD		0.061	1.434		
105533	0.75 mg/kg/d	F	0.288	14.996		
105534	0.75 mg/kg/d	F	0.175	6.308		
105526	0.75 mg/kg/d	F	0.425	29.86		
105540	0.75 mg/kg/d	F	0.188	7.52		
105542	0.75 mg/kg/c	F	0.123	2.94		
105551	0.75 mg/kg/d	F	0.155	2.70		
	Avg		0.224	9.221		
	SD		0.128	7.452		
					Male Contro. Vs male high dose PFOS, mg UB/g Feces	Male Control Vs male high dose PFOS, mg UB/24 hour Feces
105508	0 mg/kg/d	M	0.413	9.92	0.41	0.17
105517	0 mg/kg/c	M	0.150	6.00		
105519	0 mg/kg/d	M	0.216	6.91		
105520	0 mg/kg/d	M	0.214	8.56		
105525	0 mg/kg/d	M	0.165	4.62		
105527	0 mg/kg/d	M	0.151	4.82		
	Avg		0.218	6.805		
	SD		0.033	1.521		
105506	0.75 mg/kg/d	M	0.212	6.77		
105507	0.75 mg/kg/d	M	0.156	1.87		
105511	0.75 mg/kg/d	M	0.183	7.32		
105512	0.75 mg/kg/d	M	0.168	3.36		
105522	0.75 mg/kg/d	M	0.175	4.90		
	Avg		0.179	4.844		
	SD		0.021	2.285		

UB = urobilinogen
Normal values, human adults 50- 300 mg UB/24 hours

2

3M_MN03279904

APPENDIX 10

Dose Confirmation Analysis Report
Compound Stability Report
Analytical Laboratory Report
Certificate of Analysis
Quality Assurance Statement

Note: This appendix contains information supplied and audited by the Sponsor.

Dose Confirmation Analysis Report for Study title: 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (PFOS) in Cynomolgus Monkeys Covance 6329-223, (3M Medical Dept number: T- 6295.7).

Author: Andrew M. Seacat

Final Report Date: 3/1/01

Introduction

Dose confirmation analysis were performed on samples of perfluorooctanesulfonic acid potassium salt (KPFOS) triturated in lactose at dilutions of 1:499 and 1:39 w:w. The low dose group (0.03 mg/kg/day of PFOS) received 15 mg/kg/d of the 1:499 w:w dilution in gelatin capsules. The mid-dose (0.25 mg/kg/day PFOS) and the high-dose (0.75 mg/kg/day) groups received 6 and 30 mg/kg/day respectively of the 1:39 w:w dilution in gelatin capsule. Samples from the top, middle and bottom of each mixture were collected on day –15 prior to the in-life phase of the study for homogeneity analysis and sent to 3M Environmental lab. Samples collected from the middle of the preparations were collected prestudy and at the end of the treatment phase for material content analysis to assess compound stability in the dosing vehicle.

Method summary

The dose confirmation data were collected according to a method described fully in the Analytical Laboratory Report (1). Briefly, dose confirmation was performed by diluting the lactose dose samples 1000-fold with Milli-Q water, which were then extracted using the ion-pair reagent tetrabutylammonium hydrogen sulfate according to the procedure (1). The extracts from the 1:499 and the 1:39 dilutions were then diluted 1:5 and 1:50, respectively, to bring the PFOS levels in the linear range of the instrument. For each sample, (top, middle and bottom), the average PFOS spiked matrix extract value was used as correction factor for calculating the percent recovery. In all cases, samples were analyzed versus an unextracted curve using HPLC-ESMS/MS.

Results

The results indicated that the 1:499 dilution used for the 0.03 mg/kg/day dose group was 86± 4 % of the target concentration, and that the 1:39 dilution used for the 0.75 and 0.15 mg/kg/day dose groups were 113 ± 31 % of the target concentration (Table 1)

The stability samples were obtained from the middle of each mixture and were received on 5-07-99. The stability sample for the 1:499 was 100 ± 4 % of the target concentration, and the stability sample for the 1:39 was 69 ± 0 % of the target concentration (Table 2).

3M_MN03279906

Reference:

1. Hansen K. J. Analytical Laboratory Report from the 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (PFOS) in Cynomolgus Monkeys on the Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples. Project Identification: Covance 6329-222, 6329-223, 3M Medical Dept number: T- 6295.7, Analytical study: FACT TOX030, 3M Laboratory request No. U2279. 214 pp, 2000.

Covance: 6329-223
3M T-6295.7

Dose Analysis Report

Appendix

Table 1. Dose sample analysis

6329-223 Lactose Dose Verification

8/21/05 Analysis

1:39 Dose (25000 ppm PFOS)	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g	MS Average Recovery Corrected Conc. ug/g	Corrected % Recovery for ug/g
Top	580	479	83	25000	20647	83	23618	94
Middle	500	556	130	25000	32537	130	37210	149
Bottom	500	422	84	25000	21108	84	24145	97
Avg							28328	113
SD							7705	31

1:499 Dose (2000 ppm PFOS)	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g	MS Average Recovery Corrected Conc. ug/g	Corrected % Recovery for ug/g
Top	410	305	74	2000	1490	74	1795	90
Middle	404	287	71	2000	1425	71	1716	86
Bottom	400	272	68	2000	1361	68	1639	82
Avg							1717	86
SD							78	4

Actual Matrix Spike (MS) Conc. - Actual Background Conc. divided by Expectec times 100
Spiked too low which accounts for the wide differences in recovery

1:39 Dose (25000 ppm PFOS) Matrix Spike (MS)	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Calculated Conc. ug/g	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g
Top	604	567	94	21658	10.8	12.1	112
Middle	524	465	92	24252	12.5	-82.8	-864*
Bottom	524	438	83	21888	12.5	7.82	65
Avg							87

* an outlier, not used in any calculations

Actual Matrix Spike Conc. - Actual Background Conc. divided by Expected times 100

1:499 Dose (2000 ppm PFOS) MS	Expected Conc. ng/mL	Actual Conc. ng/mL	% Recovery for ng/mL	Calculated Conc. ug/g	Expected Conc. ug/g	Actual Calculated Conc. ug/g	% Recovery for ug/g
Top	606	475	78	2320	9.77	8.30	85
Middle	590	447	75	2217	9.92	7.92	80
Bottom	596	440	74	2202	10.0	8.41	84
Avg							83

PFOS = Perfluorooctanesulfonate

3

3M_MN03279908

Covance: 6329-223
3M T-6295.7

Dose Analysis Report

Table 2 . Stability Sample analysis

Group Dose	Sample #	Expected Conc. PFOS ng/mL	PFOS-Bckgrnd Conc. ng/mL	PFOS % Recovery Accuracy
Method Blk	Lact091800-WBlk-1	0.00	NA	NA
	Lact091800-WBlk-2	0.00	NA	NA
QC	Lact091800-(1:39)-MS1	25	6.21	25%
	Lact091800-(1:39)-MSD1	25	-17.89	-71%
	Lact091800-(1:499)-MS1	200	236.6	118%
	Lact091800-(1:499)-MSD1	200	177.4	89%
Dose	Lact091800-(1:39)-1	515	NA	69%
	Lact091800-(1:39)-2	515	NA	69%
	Avg			69%
	Lact091800-(1:499)-1	414	NA	103%
	Lact091800-(1:499)-2	414	NA	98%
	Avg			100%

3M_MN03279909

 Dose Analysis Report

Example calculations

Calculating conc. (Top 1:39) ug/g: $\frac{(479.02\ ng/mL \times 100\ mL \times 1\ mL)}{(0.02\ mL \times 0.116\ g \times 1000\ ng/ug)}$ = 20647 ug/g

Expected concentration (Top 1:39) ug/g: $\frac{(50\ ug/mL \times 0.025\ mL)}{0.1160\ g}$ = 10.8 ug/g

Actual Calculated Conc. (Top 1:39) ug/g:

$$\frac{\frac{(507\ ng/mL \times 100\ mL \times 1\ mL)}{(0.02\ mL \times 0.116\ g \times 1000\ ng/ug)} - \frac{(479.02\ ng/mL \times 100\ mL \times 1\ mL)}{(0.02\ mL \times 0.116\ g \times 1000\ ng/ug)}}{100} = 12.1\ ug/g$$

The number is divided by 100 since the sample was
diluted 1:100, 1.0 mL of diluted sample removed, then spiked with standard.

3M_MN03279910

Corporate Health Physics
Corporate Occupational Medicine
Corporate Product Responsibility
Corporate Toxicology
3M Medical Department

3M Center, 220-2E-02
PO Box 33220
St. Paul, MN 55133-3220
651 733 1110

September 6, 2000

3M

Peter J. Thomford, Ph.D.
Study Director, Toxicology
Covance Laboratories Inc.
3301 Kinsman Blvd.
Madison WI 53704

Re. Covance 6329-222 (T-6295.6), 6329-223 (T-6295.7). Perfluorooctanesulfonate Compound Stability Report

Peter:

The perfluorooctanesulfonic acid potassium salt (PFOS, FC-95 Lot 217) used in Covance 6329-222, 6329-223, has remained stable for the entire duration of the study. A Certificate of Analysis (C of A) dated March 9, 2000 (1), identified the compound as being 90.49% C8F17SO3-K+ by a combination of LC/MS, ^{1}H-NMR, ^{19}F-NMR, and elemental analysis techniques. Previously, on December 1st 1997, ^{19}F-NMR was used to characterize FC-95 lot 217 and showed that the isomer distribution was identical to the C of A sent to you earlier this year (2). Additionally, ^{19}F-NMR and 1H NMR conducted on August 24th 2000 (3) were compared to the ^{19}F-NMR completed on December 1st 1997 and indicated that there was no significant differences in the composition of this lot of PFOS over intervening 3 and a half year time period. Thus, PFOS, FC-95 Lot 217 used was stable for greater the time period during which these studies were conducted.

Sincerely,

Andrew M. Seacat

Andrew M. Seacat Ph.D.
Toxicology Specialist

References:

1. Payfer R.M. Certificate Of Analysis FC-95, Lot 217. 3M Specialty Chemicals Division. March 9, 2000

2. Kestner T. Fluorochemical Isomer Distribution by ^{19}F-NMR Spectroscopy. FC-95, lot 217 Analytical Request 53030 . SA&C Analytical Lab. December 1, 1997

3. Kestner T. Chemical Characterization of PFOS (FC-95, lot 217) by ^{1}H-NMR & ^{19}F-NMR Spectroscopy. Comparison to FC-95/217 analysis from Req.#53030-Request No. 61886. 3M SA&C Analytical Lab - 236-2B-11. August 24, 2000.

ANALYTICAL LABORATORY REPORT

FROM THE

26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (T-6295) in Cynomolgus Monkeys

ON THE

Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples

Project Identification

3M Medical Department Study: T-6295.7
Covance In-Life Study: #6329-223

Analytical Study: FACT TOX-030
3M Laboratory Request No. U2279

Study Completion Date

At signing

Total Number of Pages

233

3M Medical Department Study: T-6295.7
Report No. FACT TOX-030
Laboratory Request Number-U2279

GLP COMPLIANCE STATEMENT

Study Title: Analytical Laboratory Report from the 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (T-6295) in Cynomolgus Monkeys on the Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples

Study Identification Number: FACT TOX-030, T-6295.7, Covance #6329-223

This study was conducted in compliance with United States Environmental Protection Agency Good Laboratory Practice (GLP) Standards 40 CFR Part 792, with the exceptions in the bulleted list below. All raw data and samples for this study are retained in archives at the 3M Lab and will be retained for a period of at least ten years. The analytical phase completed at the 3M Lab was performed in accordance with 3M ET&SS Standard Operating Procedures.

Exceptions to GLP compliance:

- There were two study directors in this study. This study was designed as two separate studies. The in-life phase study was considered to end at the generation and shipment of specimens. The analytical study was considered to start at the receipt of these specimens for analysis. This resulted in having two separate study directors, one for each phase of the same study. However, since the technical performance of each phase was entirely separate, no effect is expected from this exception.
- On a few occasions, data were not recorded or corrected exactly as required by the GLPs.
- The 3M TOX 030 protocol states in the Regulatory Compliance section that "This study will be conducted in accordance with the United States Environmental Protection Agency Good Laboratory Practices Standards, 40 CFR 792, with the exception that analysis of the test material mixture for concentration, solubility, homogeneity, and stability will not be conducted, and is the responsibility of the Sponsor." Analyses were, however, completed on the concentration and homogeneity of the test material mixture, according to non-GLP validated methods, and are included in this report. As per the protocol, solubility and stability determinations were not conducted.

Andrew M. Seacat 9/19/00
Study Director Date

John L. Butenhoff 19 SEPT 2000
Study Sponsor Date

3M Environmental Laboratory Page 2

3M_MN03279914

3m Medical Department Study: T-6295.7

Report No. FACT TOX-030
laboratory Request Number-U2279

3M Medical Department Study: T-6295.7

Report No. FACT TOX-030
Laboratory Request Number-U2279

GLP Study—Quality Assurance Statement

Study Title: Analytical Laboratory Report from the 26-Week Capsule Toxicity Study with Perfluorooctanesulfonic Acid Potassium Salt (T-6295) in Cynomolgus Monkeys on the Determination of the Presence and Concentration of Perfluorooctanesulfonate (PFOS) in Liver and Serum Samples

Study Identification Number: FACT TOX-030, T-6295.7, Covance #6329-223

The analytical phase of this study has been inspected by the 3M Lab Quality Assurance Unit (QAU) as indicated in the following table. The findings were reported to the study director and management.

[illegible]	[illegible]	Date Reported to [illegible]	[illegible]
December 01/98	Sample receipt	1/17/00	1/17/00
March 19,22,23/99	Analysis	3/25/99	3/25/99
October 14/99	Extraction	10/20/99	10/20/99
May 3,8–12,15–19,22–26,29–31/00, June 1,2,5,7,8/00	Data	6/14/00	6/14/00
June 1,5,7,12–16/00	Draft report	6/16/00	6/16/00
September 14/00	Draft report	9/14/00	9/14/00

QAU Representative 9/22/00 Date

3M Environmental Laboratory Page 3

INTERIM CERTIFICATE OF ANALYSIS

Revision 1(9/7/00)

Centre Analytical Laboratories COA Reference #: 023-018A

3M Product: PFOS, Lot 217

Reference #: SD-018

Purity: 86.9%

Test Name	Specifications	Result
Purity[1]		**86.9%**
Appearance	White Crystalline Powder	Conforms
Identification NMR		Positive
Metals (ICP/MS) 1. Calcium 2. Magnesium 3. Sodium 4. Potassium[2] 5. Nickel 6. Iron 7. Manganese		 1. 0.005 wt./wt.% 2. 0.001 wt./wt.% 3. 1.439 wt./wt.% 4. 6.849 wt./wt.% 5. <0.001 wt./wt.% 6. 0.005 wt./wt.% 7. <0.001 wt./wt.%
Total % Impurity (NMR)		1.93 wt./wt.%
Total % Impurity (LC/MS)		8.41 wt./wt.%
Total % Impurity (GC/MS)		None Detected
Related Compounds – POAA		0.33 wt./wt.%
Residual Solvents (TGA)		None Detected
Purity by DSC		Not Applicable[3]
Inorganic Anions (IC) 1. Chloride 2. Fluoride 3. Bromide 4. Nitrate 5. Nitrite 6. Phosphate 7. Sulfate[4]		 1. <0.015 wt./wt.% 2. 0.59 wt./wt.% 3. <0.040 wt./wt.% 4. <0.009 wt./wt.% 5. <0.006 wt./wt.% 6. <0.007 wt./wt.% 7. 8.76 wt./wt.%
Organic Acids [5] (IC) 1. TFA 2. PFPA 3. HFBA 4. NFPA		 1. <0.1 wt./wt.% 2. <0.1 wt./wt.% 3. 0.10 wt./wt.% 4. 0.28 wt./wt.%
Elemental Analysis[6]: 1. Carbon 2. Hydrogen 3. Nitrogen 4. Sulfur 5. Fluorine	 1. Theoretical Value = 17.8% 2. Theoretical Value = 0% 3. Theoretical Value = 0% 4. Theoretical Value = 5.95% 5. Theoretical Value = 60%	 1. 12.48 wt./wt.% 2. 0.244 wt./wt.% 3. 1.74 wt./wt.% 4. 8.84 wt./wt.% 5. 54.1 wt./wt.%

INTERIM CERTIFICATE OF ANALYSIS

Centre Analytical Laboratories COA Reference #: 023-018A

Date of Last Analysis: 08/31/00

Expiration Date: 08/31/01

Storage Conditions: Frozen ≤-10°C

Re-assessment Date: 08/31/01

[1]Purity = 100% - (sum of metal impurities, 1.45% +LC/MS impurities, 8.41%+Inorganic Fluoride, 0.59%+NMR impurities, 1.93%+organic acid impurities, 0.38%+POAA, 0.33%)

Total impurity from all tests = 13.09%
Purity = 100% - 13.09% = 86.9%

[2]Potassium is expected in this salt form and is therefore not considered an impurity.

[3]Purity by DSC is generally not applicable to materials of low purity. No endotherm was observed for this sample.

[4]Sulfur in the sample appears to be converted to SO_4 and hence detected using the inorganic anion method conditions. The anion result agrees well with the sulfur determination in the elemental analysis, lending confidence to this interpretation. Based on the results, the SO_4 is not considered an impurity.

[5]TFA	Trifluoroacetic acid
HFBA	Heptafluorobutyric acid
NFPA	Nonofluoropentanoic acid
PFPA	Pentafluoropropanoic acid

[6]Theoretical value calculations based on the empirical formula, $C_8F_{17}SO_3^-K^+$ (MW=538)

This work was conducted under EPA Good Laboratory Practice Standards (40 CFR 160).

INTERIM CERTIFICATE OF ANALYSIS

Centre Analytical Laboratories COA Reference #: 023-018A

LC/MS Purity Profile:

Impurity	wt./wt. %
C4	1.22
C5	1.33
C6	4.72
C7	1.14
Total	**8.41**

Note: The C4 and C6 values were calculated using the C4 and C6 standard calibration curves, respectively. The C5 value was calculated using the average response factors from the C4 and C6 standard curves. Likewise, the C7 value was calculated using the average response factors from the C6 and C8 standard curves.

Prepared By: _____ _____
David S. Bell Date
Scientist, Centre Analytical Laboratories

Reviewed By: _____ _____
John Flaherty Date
Laboratory Manager, Centre Analytical Laboratories

Sponsor Protocol No.: FACT-TCR001
Centre Study No.: 023-018

QUALITY ASSURANCE STATEMENT

Centre Study Number 023-018, entitled, "Characterization Study of PFOS, Lot 217 and Lot 171" was reviewed by Centre Analytical Laboratories' Quality Assurance Unit. All reviewed phases were reviewed for conduct according to Centre Analytical Laboratories' Standard Operating Procedures, the Study Protocol, and all applicable Good Laboratory Practice Standards. All findings were reported to the Study Director and to management.

Phase	Date Inspected	Date Reported to Study Director and Centre Management	Date Reported to Sponsor Management
1. Protocol Review	5/19/00	5/19/00	7/14/00
2. Label Checks (solubility)	7/14/00	7/17/00	Pending
3. Standard Solution Preparation and analysis by instrumentation	6/20,21/00 6/22/00	6/22/00 6/22/00	7/14/00 7/14/00
4. Raw Data Review (NMR)	7/11-13/00	7/15/00	Pending
5. Standard Solution Preparation (Solubility)	7/14/00	7/20/00	Pending
6. Standard Solution Preparation	6/29, 30/00 7/26/00	6/30/00 7/27/00	7/14/00 Pending
7. Report Review (DSC/TGA)	8/8/00	8/8/00	Pending
8. Data Review and Interim Report Review	8/8,9/00	8/9/00	Pending

Lisa Manning
Quality Assurance Officer

8-9-00
Date

"THIS IS AN EXACT COPY OF THE ORIGINAL DOCUMENT"

BY CS DATE 12/4/01